<SEC-DOCUMENT>0001683168-23-008557.txt : 20231130 <SEC-HEADER>0001683168-23-008557.hdr.sgml : 20231130 <ACCEPTANCE-DATETIME>20231129213537 ACCESSION NUMBER: 0001683168-23-008557 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 70 CONFORMED PERIOD OF REPORT: 20230831 FILED AS OF DATE: 20231130 DATE AS OF CHANGE: 20231129 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CNBX Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001343009 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 203373669 STATE OF INCORPORATION: NV FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-52403 FILM NUMBER: 231453820 BUSINESS ADDRESS: STREET 1: #3 BETHESDA METRO CENTER STREET 2: SUITE 700 CITY: BETHESDA STATE: MD ZIP: 20814 BUSINESS PHONE: 877-424-2429 MAIL ADDRESS: STREET 1: #3 BETHESDA METRO CENTER STREET 2: SUITE 700 CITY: BETHESDA STATE: MD ZIP: 20814 FORMER COMPANY: FORMER CONFORMED NAME: Cannabics Pharmaceuticals Inc. DATE OF NAME CHANGE: 20140620 FORMER COMPANY: FORMER CONFORMED NAME: American Mining Corp DATE OF NAME CHANGE: 20110510 FORMER COMPANY: FORMER CONFORMED NAME: Thrust Energy Corp. DATE OF NAME CHANGE: 20051031 </SEC-HEADER> <DOCUMENT> <TYPE>10-K <SEQUENCE>1 <FILENAME>cnbx_i10k-083123.htm <DESCRIPTION>FORM 10-K FOR AUG 2023 <TEXT> <XBRL> <?xml version="1.0" encoding="utf-8"?> <html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:CNBX="http://cnbxpharma.com/20230831"> <head> <title></title> <meta http-equiv="Content-Type" content="text/html" /> </head> <!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 --> <!-- Field: Set; Name: xdx; ID: xdx_03C_CNBX_cnbxpharma.com_20230831 --> <!-- Field: Set; Name: xdx; ID: xdx_047_20220901_20230831 --> <!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false --> <!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DDocumentFiscalYearFocus_2023 --> <!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY --> <!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DEntityCentralIndexKey_0001343009 --> <!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD --> <!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares --> <!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares --> <!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure --> <body style="font: 10pt Times New Roman, Times, Serif"> <div style="display: none"> <ix:header> <ix:hidden> <ix:nonNumeric contextRef="From2022-09-01to2023-08-31" name="dei:AmendmentFlag">false</ix:nonNumeric> <ix:nonNumeric contextRef="From2022-09-01to2023-08-31" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric> <ix:nonNumeric contextRef="From2022-09-01to2023-08-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric> <ix:nonNumeric contextRef="From2022-09-01to2023-08-31" name="dei:EntityCentralIndexKey">0001343009</ix:nonNumeric> <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-09-012022-08-31_us-gaap_CommonStockMember" id="xdx2ixbrl0285" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-09-012022-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0287" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-09-012022-08-31_custom_WarrantsMember" id="xdx2ixbrl0288" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-09-012022-08-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-09-012022-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-09-012022-08-31_custom_WarrantsMember" id="xdx2ixbrl0295" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-09-012022-08-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="CNBX:PostsplitAdjustment" contextRef="From2021-09-012022-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0303" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="CNBX:PostsplitAdjustment" contextRef="From2021-09-012022-08-31_custom_WarrantsMember" id="xdx2ixbrl0304" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="CNBX:PostsplitAdjustment" contextRef="From2021-09-012022-08-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0305" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="CNBX:PostsplitAdjustment" contextRef="From2021-09-012022-08-31" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2021-09-012022-08-31_us-gaap_CommonStockMember" id="xdx2ixbrl0310" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2021-09-012022-08-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2021-09-012022-08-31_custom_WarrantsMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2021-09-012022-08-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-09-012022-08-31_us-gaap_CommonStockMember" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-09-012022-08-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-09-012022-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-09-012022-08-31_custom_WarrantsMember" id="xdx2ixbrl0320" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-09-012023-08-31_us-gaap_CommonStockMember" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-09-012023-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0335" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-09-012023-08-31_custom_WarrantsMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-09-012023-08-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-09-012023-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-09-012023-08-31_custom_WarrantsMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-09-012023-08-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0344" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="CNBX:ExpirationOfWarrants" contextRef="From2022-09-012023-08-31_us-gaap_CommonStockMember" id="xdx2ixbrl0349" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="CNBX:ExpirationOfWarrants" contextRef="From2022-09-012023-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="CNBX:ExpirationOfWarrants" contextRef="From2022-09-012023-08-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="CNBX:ExpirationOfWarrants" contextRef="From2022-09-01to2023-08-31" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2022-09-012023-08-31_us-gaap_CommonStockMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2022-09-012023-08-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2022-09-012023-08-31_custom_WarrantsMember" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2022-09-012023-08-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0360" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-09-012023-08-31_us-gaap_CommonStockMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-09-012023-08-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-09-012023-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-09-012023-08-31_custom_WarrantsMember" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"></ix:nonFraction> <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-08-31_custom_WarrantsMember" id="xdx2ixbrl0373" unitRef="USD" xs:nil="true"></ix:nonFraction> </ix:hidden> <ix:references> <link:schemaRef xlink:href="cnbx-20230831.xsd" xlink:type="simple" /> </ix:references> <ix:resources> <xbrli:context id="From2022-09-01to2023-08-31"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-01</xbrli:startDate> <xbrli:endDate>2023-08-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2023-08-31"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2023-11-29"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-29</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2022-08-31"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="From2021-09-012022-08-31"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-09-01</xbrli:startDate> <xbrli:endDate>2022-08-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2021-08-31"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2021-08-31_us-gaap_CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2021-08-31_us-gaap_AdditionalPaidInCapitalMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2021-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2021-08-31_custom_WarrantsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CNBX:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2021-08-31_us-gaap_RetainedEarningsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2022-08-31_us-gaap_CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2022-08-31_us-gaap_AdditionalPaidInCapitalMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2022-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2022-08-31_custom_WarrantsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CNBX:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2022-08-31_us-gaap_RetainedEarningsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="From2021-09-012022-08-31_us-gaap_CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-09-01</xbrli:startDate> <xbrli:endDate>2022-08-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="From2021-09-012022-08-31_us-gaap_AdditionalPaidInCapitalMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-09-01</xbrli:startDate> <xbrli:endDate>2022-08-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="From2021-09-012022-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-09-01</xbrli:startDate> <xbrli:endDate>2022-08-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="From2021-09-012022-08-31_custom_WarrantsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CNBX:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-09-01</xbrli:startDate> <xbrli:endDate>2022-08-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="From2021-09-012022-08-31_us-gaap_RetainedEarningsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-09-01</xbrli:startDate> <xbrli:endDate>2022-08-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="From2022-09-012023-08-31_us-gaap_CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-01</xbrli:startDate> <xbrli:endDate>2023-08-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="From2022-09-012023-08-31_us-gaap_AdditionalPaidInCapitalMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-01</xbrli:startDate> <xbrli:endDate>2023-08-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="From2022-09-012023-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-01</xbrli:startDate> <xbrli:endDate>2023-08-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="From2022-09-012023-08-31_custom_WarrantsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CNBX:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-01</xbrli:startDate> <xbrli:endDate>2023-08-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="From2022-09-012023-08-31_us-gaap_RetainedEarningsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-01</xbrli:startDate> <xbrli:endDate>2023-08-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2023-08-31_us-gaap_CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2023-08-31_us-gaap_AdditionalPaidInCapitalMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2023-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2023-08-31_custom_WarrantsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CNBX:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2023-08-31_us-gaap_RetainedEarningsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2023-08-31_us-gaap_FairValueInputsLevel1Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2023-08-31_us-gaap_FairValueInputsLevel3Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="From2022-09-012023-08-31_custom_CEOAndChairmanMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CNBX:CEOAndChairmanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-01</xbrli:startDate> <xbrli:endDate>2023-08-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="From2021-09-012022-08-31_custom_CEOAndChairmanMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CNBX:CEOAndChairmanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-09-01</xbrli:startDate> <xbrli:endDate>2022-08-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2023-08-31_custom_CEOAndChairmanMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CNBX:CEOAndChairmanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2022-08-31_custom_CEOAndChairmanMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CNBX:CEOAndChairmanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="From2022-09-012023-08-31_srt_ChiefFinancialOfficerMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-01</xbrli:startDate> <xbrli:endDate>2023-08-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="From2021-09-012022-08-31_srt_ChiefFinancialOfficerMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-09-01</xbrli:startDate> <xbrli:endDate>2022-08-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2023-08-31_custom_ThreeDirectorsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CNBX:ThreeDirectorsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2022-08-31_custom_ThreeDirectorsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CNBX:ThreeDirectorsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2023-08-31_custom_CannabicsIncMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CNBX:CannabicsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2022-08-31_custom_CannabicsIncMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CNBX:CannabicsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="From2022-09-012023-08-31_custom_ShareBasedPaymentMember_custom_ChairmanAndBoardMembersMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">CNBX:ShareBasedPaymentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CNBX:ChairmanAndBoardMembersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-01</xbrli:startDate> <xbrli:endDate>2023-08-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="From2021-09-012022-08-31_custom_ShareBasedPaymentMember_custom_ChairmanAndBoardMembersMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">CNBX:ShareBasedPaymentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CNBX:ChairmanAndBoardMembersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-09-01</xbrli:startDate> <xbrli:endDate>2022-08-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="From2022-05-112022-05-12"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-11</xbrli:startDate> <xbrli:endDate>2022-05-12</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="From2022-09-012023-08-31_us-gaap_InvestorMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-01</xbrli:startDate> <xbrli:endDate>2023-08-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="From2020-12-152020-12-16_custom_SecuritiesPurchaseAgreementMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CNBX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-15</xbrli:startDate> <xbrli:endDate>2020-12-16</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="From2020-12-202020-12-21_custom_InitialNoteMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CNBX:InitialNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-20</xbrli:startDate> <xbrli:endDate>2020-12-21</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="From2021-02-212021-02-22_custom_SecondNoteMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CNBX:SecondNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-21</xbrli:startDate> <xbrli:endDate>2021-02-22</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="From2021-04-222021-04-23_custom_NoteMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CNBX:NoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-22</xbrli:startDate> <xbrli:endDate>2021-04-23</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2020-12-21_custom_InitialNoteMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CNBX:InitialNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-21</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2021-02-22_custom_SecondNoteMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CNBX:SecondNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-22</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2021-04-23_custom_NoteMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CNBX:NoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-04-23</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="From2022-09-012023-08-31_us-gaap_InvestorMember_us-gaap_CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-01</xbrli:startDate> <xbrli:endDate>2023-08-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2021-04-23_custom_SeniorSecuredNoteMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">CNBX:SeniorSecuredNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-04-23</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="From2021-04-222021-04-23_custom_SeniorSecuredNoteMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">CNBX:SeniorSecuredNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-22</xbrli:startDate> <xbrli:endDate>2021-04-23</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2022-03-16_custom_DemandNoteMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">CNBX:DemandNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-16</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="From2022-03-152022-03-16_custom_DemandNoteMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">CNBX:DemandNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-03-15</xbrli:startDate> <xbrli:endDate>2022-03-16</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2022-06-15_custom_SecuritiesPurchaseAgreementMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CNBX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-15</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="From2022-06-142022-06-15_custom_SecuritiesPurchaseAgreementMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CNBX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-06-14</xbrli:startDate> <xbrli:endDate>2022-06-15</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2023-03-31_custom_SecuritiesPurchaseAgreementMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CNBX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="From2023-01-012023-03-31_custom_SecuritiesPurchaseAgreementMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CNBX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2023-06-12_custom_SecuritiesPurchaseAgreementMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CNBX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-12</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="From2023-06-112023-06-12_custom_SecuritiesPurchaseAgreementMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CNBX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-11</xbrli:startDate> <xbrli:endDate>2023-06-12</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2018-09-24_custom_Warrant1Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CNBX:Warrant1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-09-24</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2020-12-16_custom_Warrant2Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CNBX:Warrant2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-16</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="From2022-09-012023-08-31_custom_Warrant1Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CNBX:Warrant1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-01</xbrli:startDate> <xbrli:endDate>2023-08-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="From2022-09-012023-08-31_custom_Warrant2Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CNBX:Warrant2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-01</xbrli:startDate> <xbrli:endDate>2023-08-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="From2018-09-232018-09-24_custom_Warrant1Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CNBX:Warrant1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-09-23</xbrli:startDate> <xbrli:endDate>2018-09-24</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="From2020-12-152020-12-16_custom_Warrant2Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CNBX:Warrant2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-15</xbrli:startDate> <xbrli:endDate>2020-12-16</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2022-08-31_custom_WarrantsMember882227078"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CNBX:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2021-08-31_custom_WarrantsMember882227078"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CNBX:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2020-08-31_custom_WarrantsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CNBX:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="From2022-09-012023-08-31_custom_WarrantsMember882227093"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CNBX:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-01</xbrli:startDate> <xbrli:endDate>2023-08-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="From2021-09-012022-08-31_custom_WarrantsMember882227093"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CNBX:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-09-01</xbrli:startDate> <xbrli:endDate>2022-08-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="From2020-09-012021-08-31_custom_WarrantsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CNBX:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-09-01</xbrli:startDate> <xbrli:endDate>2021-08-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2023-08-31_custom_WarrantsMember882227109"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CNBX:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="From2022-09-012023-08-31_us-gaap_DomesticCountryMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-01</xbrli:startDate> <xbrli:endDate>2023-08-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2023-08-31_custom_UnitedStates1Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">CNBX:UnitedStates1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2022-08-31_custom_UnitedStates1Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">CNBX:UnitedStates1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="From2022-09-012023-08-31_us-gaap_IsraelTaxAuthorityMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-01</xbrli:startDate> <xbrli:endDate>2023-08-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2023-08-31_us-gaap_IsraelTaxAuthorityMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2022-08-31_us-gaap_IsraelTaxAuthorityMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2023-08-31_us-gaap_DomesticCountryMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2022-08-31_us-gaap_DomesticCountryMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2023-08-31_us-gaap_ForeignCountryMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="AsOf2022-08-31_us-gaap_ForeignCountryMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-08-31</xbrli:instant> </xbrli:period> </xbrli:context> <xbrli:context id="From2022-12-082022-12-09"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001343009</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-08</xbrli:startDate> <xbrli:endDate>2022-12-09</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:unit id="USD"> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit> <xbrli:unit id="Shares"> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit> <xbrli:unit id="USDPShares"> <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit> <xbrli:unit id="Pure"> <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit> </ix:resources> </ix:header> </div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt"><a href="#toc">Table of Contents</a></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>FORM <span id="xdx_906_edei--DocumentType_c20220901__20230831_zff9LipRpDpj"><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_900_edei--DocumentAnnualReport_c20220901__20230831_zlmuN8cAQR7b"><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport">☒</ix:nonNumeric></span> <b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the fiscal year ended <span id="xdx_905_edei--DocumentPeriodEndDate_c20220901__20230831_zIcSZbXcAy"><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><span id="xdx_905_edei--CurrentFiscalYearEndDate_c20220901__20230831" title="Current Fiscal Year End Date"><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate">August 31</ix:nonNumeric></span>, 2023</ix:nonNumeric></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">or</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_90C_edei--DocumentTransitionReport_c20220901__20230831_zTtHGWfrhyMc"><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">☐</ix:nonNumeric></span> <b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the transition period from ______ to ______.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Commission File Number:</b> <span id="xdx_90D_edei--EntityFileNumber_c20220901__20230831_zmhsGFVKkHHe"><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" name="dei:EntityFileNumber">000-52403</ix:nonNumeric></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">___________________________________________________</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b><span id="xdx_903_edei--EntityRegistrantName_c20220901__20230831_zlihaesW8Ry5"><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" name="dei:EntityRegistrantName">CNBX PHARMACEUTICALS INC.</ix:nonNumeric></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">___________________________________________________</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="border-bottom: black 1pt solid; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityIncorporationStateCountryCode_c20220901__20230831_zj55Vd0SI3N2"><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td> <td style="width: 2%; text-align: center"> </td> <td style="border-bottom: black 1pt solid; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityTaxIdentificationNumber_c20220901__20230831_z80AaA4q6pok"><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" name="dei:EntityTaxIdentificationNumber">20-3373669</ix:nonNumeric></span></b></span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State of Incorporation)</span></td> <td style="text-align: center"> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer Identification No.)</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="text-align: center"> </td></tr> <tr> <td style="border-bottom: black 1pt solid; vertical-align: top"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.75pt 0pt 0; text-align: center"><b><span id="xdx_90E_edei--EntityAddressAddressLine1_c20220901__20230831_zkSHqphxegf1"><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" name="dei:EntityAddressAddressLine1">#3 Bethesda Metro Center</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressAddressLine2_c20220901__20230831_zYLPXeV69rNe"><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" name="dei:EntityAddressAddressLine2">Suite 700</ix:nonNumeric></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.75pt 0pt 0; text-align: center"><b><span id="xdx_90D_edei--EntityAddressCityOrTown_c20220901__20230831_z1rsvzuZHISc"><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" name="dei:EntityAddressCityOrTown">Bethesda</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressStateOrProvince_c20220901__20230831_z5izbIMWe5Ca"><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" name="dei:EntityAddressStateOrProvince">MD</ix:nonNumeric></span></b></p></td> <td style="vertical-align: top; text-align: center"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityAddressPostalZipCode_c20220901__20230831_zAruUSJpOX2i"><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" name="dei:EntityAddressPostalZipCode">20814</ix:nonNumeric></span></b></span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</span></td> <td style="text-align: center"> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant's telephone number, including area code: <span id="xdx_90D_edei--CityAreaCode_c20220901__20230831_z8UEgfjVhCDc"><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" name="dei:CityAreaCode">877</ix:nonNumeric></span> <span id="xdx_904_edei--LocalPhoneNumber_c20220901__20230831_zQdTsy3t4sYj"><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" name="dei:LocalPhoneNumber">424-2429</ix:nonNumeric></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">___________________________________________________</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities registered under Section 12(b) of the Act:</b></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of each class</span></td> <td style="width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of each exchange on which registered</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered under Section 12(g) of the Act:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_906_edei--Security12bTitle_c20220901__20230831_zE2cmDrng3Bd"><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" name="dei:Security12bTitle">Common Stock, $.0001 Par Value</ix:nonNumeric></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Title of class)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">___________________________________________________</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. ☐ Yes ☒ <span id="xdx_901_edei--EntityWellKnownSeasonedIssuer_c20220901__20230831_zBpj72icEama"><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. ☐ Yes ☒ <span id="xdx_902_edei--EntityVoluntaryFilers_c20220901__20230831_zL5lPXEJFjoj"><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ <span id="xdx_908_edei--EntityCurrentReportingStatus_c20220901__20230831_zsaIhOXHkRPi"><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> ☐ No</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ <span id="xdx_90D_edei--EntityInteractiveDataCurrent_c20220901__20230831_zgyH8HCc04ih"><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> ☐ No</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☒</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 20%"> </td> <td style="width: 42%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer ☐</span></td> <td style="width: 38%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer ☐</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--EntityFilerCategory_c20220901__20230831_zoGn7Qmesiol"><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span> ☒</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company <span id="xdx_90B_edei--EntitySmallBusiness_c20220901__20230831_zgQOGBi4DKT1"><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">☒</ix:nonNumeric></span></span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company <span id="xdx_902_edei--EntityEmergingGrowthCompany_c20220901__20230831_zeFAfOtNYfm6"><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">☐</ix:nonNumeric></span></span></td> <td style="text-align: justify"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <span id="xdx_902_edei--IcfrAuditorAttestationFlag_c20220901__20230831_zSRX4Lyluevg"><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" format="ixt:booleanfalse" name="dei:IcfrAuditorAttestationFlag">☐</ix:nonNumeric></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the fi ling reflect the correction of an error to previously issued financial statements. <span id="xdx_909_edei--DocumentFinStmtErrorCorrectionFlag_c20220901__20230831_zsF1gFmrFpY"><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" format="ixt:booleanfalse" name="dei:DocumentFinStmtErrorCorrectionFlag">☐</ix:nonNumeric></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes ☒ <span id="xdx_90A_edei--EntityShellCompany_c20220901__20230831_zxhBmeAdNkO4"><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 31st, 2023, the last business day of the registrant’s most recently completed fourth quarter, the aggregate market value of the Common Stock held by non-affiliates of the registrant was $<span id="xdx_90B_edei--EntityPublicFloat_iI_pp0p0_c20230831_zaVwew4d2gH6" title="Entity Public Float"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2023-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">437,714</ix:nonFraction></span>, based upon the closing price on that date of the Common Stock of the registrant on the OTC Bulletin Board system of $0.02. For purposes of this response, the registrant has assumed that its directors, executive officers and beneficial owners of 5% or more of its Common Stock are deemed affiliates of the registrant.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of November 29, 2023, the registrant had <span id="xdx_903_edei--EntityCommonStockSharesOutstanding_iI_c20231129_zTzhYpPIMXw9" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-11-29" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,311,352</ix:nonFraction></span> shares of its Common Stock, $0.0001 par value, outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 1 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden --> <!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="toc"></span>Table of Contents</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td colspan="2" style="text-align: center"><a href="#k2022_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART I</b></span></a></td></tr> <tr style="vertical-align: top"> <td style="width: 92%; text-align: center"> </td> <td style="width: 8%"> </td></tr> <tr style="vertical-align: top"> <td><a href="#k2022_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1. Description of Business</span></a></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr> <tr style="vertical-align: top"> <td><a href="#k2022_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A. Risk Factors</span></a></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</span></td></tr> <tr style="vertical-align: top"> <td><a href="#k2022_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1B. Unresolved Staff Comments</span></a></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td></tr> <tr style="vertical-align: top"> <td><a href="#k2022_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2. Properties</span></a></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td></tr> <tr style="vertical-align: top"> <td><a href="#k2022_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3. Legal Proceedings</span></a></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td></tr> <tr style="vertical-align: top"> <td><a href="#k2022_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4. Mine Safety Disclosures</span></a></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td colspan="2" style="text-align: center"><a href="#k2022_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART II</b></span></a></td></tr> <tr style="vertical-align: top"> <td colspan="2" style="text-align: center"> </td></tr> <tr style="vertical-align: top"> <td><a href="#k2022_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5. Market For Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td></tr> <tr style="vertical-align: top"> <td><a href="#k2022_031"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6. Selected Financial Data</span></a></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td></tr> <tr style="vertical-align: top"> <td><a href="#k2022_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations</span></a></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td></tr> <tr style="vertical-align: top"> <td><a href="#k2022_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7A. Quantitative and Qualitative Disclosures About Market Risk.</span></a></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td></tr> <tr style="vertical-align: top"> <td><a href="#k2022_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 8. Financial Statements and Supplementary Data.</span></a></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr> <tr style="vertical-align: top"> <td><a href="#k2022_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr> <tr style="vertical-align: top"> <td><a href="#k2022_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9A. Controls and Procedures</span></a></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr> <tr style="vertical-align: top"> <td><a href="#k2022_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9B. Other Information</span></a></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td colspan="2" style="text-align: center"><a href="#k2022_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART III</b></span></a></td></tr> <tr style="vertical-align: top"> <td colspan="2" style="text-align: center"> </td></tr> <tr style="vertical-align: top"> <td><a href="#k2022_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 10. Directors, Executive Officers, Promoters and Control Persons; Compliance With Section 16(A) of the Exchange Act</span></a></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr> <tr style="vertical-align: top"> <td><a href="#k2022_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 11. Executive Compensation</span></a></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr> <tr style="vertical-align: top"> <td><a href="#k2022_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 12. Security Ownership of Certain Beneficial Owners and Management Related Stockholder Matters.</span></a></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr> <tr style="vertical-align: top"> <td><a href="#k2022_026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></a></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr> <tr style="vertical-align: top"> <td><a href="#k2022_027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 14. Principal Accounting Fees and Services</span></a></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td colspan="2" style="text-align: center"><a href="#k2022_028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART IV</b></span></a></td></tr> <tr style="vertical-align: top"> <td><a href="#k2022_029"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 15. Exhibits</span></a></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k2022_030">Signatures</a></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 2 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Value: 1; Name: PageNo -->i<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORWARD LOOKING STATEMENTS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain statements made in this Annual Report are “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995) regarding the plans and objectives of management for future operations. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements made in this Report are based on current expectations that involve numerous risks and uncertainties. The Company’s plans and objectives are based, in part, on assumptions involving the growth and expansion of business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Although the Company believes that its assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance that the forward-looking statements made in this Report will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements made in this Report, the inclusion of such information should not be regarded as a representation by the Company or any other person that the objectives and plans of the Company will be achieved.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As used in this Annual Report, the terms “we”, “us”, “our”, “Company”, and “CNBX” means CNBX Pharmaceuticals Inc., unless otherwise indicated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 3 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="k2022_001"></span>PART I</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="k2022_002"></span><b>Item 1. Description of Business</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CNBX PHARMACEUTICALS, INC. is based in Bethesda, Maryland, is a clinical stage company dedicated to discovery, development and commercialization of novel cannabinoid-based products and innovative technologies for the treatment of cancer. Our first lead product candidate is a Cannabics SR, the oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS). Our leading anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) is RCC-33.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Historically we were previously an exploration stage mining company which transitioned into a bio-tech company in 2014.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our corporate address is #3 Bethesda Metro Center, Suite 700, Bethesda, Maryland, 20814; Telephone (877) 424-2429.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company was previously engaged in the oil and gas exploration business. On April 29th, 2014, the Company began a new direction and the majority of the Shareholders of the Company elected the Board of Directors and renamed the Company CNBX Pharmaceuticals Inc. The Company’s R&D is conducted in a Government licensed lab facility in Israel with the focus of development of cannabinoid-based therapies, medications and administration routes for treatment of cancer. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">History:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CNBX Pharmaceuticals Inc. was incorporated on September 15, 2004, under the laws of the State of Nevada, as Thrust Energy Corp., for the purpose of acquiring undivided working interests in small oil and gas exploration properties and non-operating interests in both producing and exploration projects throughout the United States and Canada.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2010, we increased our authorized capital to 900 million shares of common stock (par value $0.0001) and 100 million shares of preferred stock (par value $0.0001) and effected a 20-for-1 reverse split of our issued and outstanding common stock. As a result of the reverse split, our issued and outstanding common stock was reduced from 13,604,000 shares to 680,202 shares and 5,000,000 preferred shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to our inability to earn any meaningful revenue from oil and gas exploration, our management determined in April 2011 that we should change our business plan to include toll milling and refining.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 5, 2011, we effected a change of name to American Mining Corp. by completing a short form merger with a wholly-owned subsidiary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 25, 2014, Cannabics Inc., a Delaware Corporation, purchased 20,500,000 shares of restricted stock of the Company, thus acquiring control of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 3, 2014, the Company's Board of Directors declared a two-to-one forward stock split of all outstanding shares of common stock. The stock split was approved by FINRA on June 19th, 2014. The effect of the stock split increased the number of shares of common stock outstanding from 40,880,203 to 81,760,406. All common share and per common share data in these financial statements and related notes hereto have been retroactively adjusted to account for the effect of the stock split for all periods presented prior to June 3rd, 2014. The total number of authorized common shares and the par value thereof was not changed by the split.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 4 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 19, 2014, FINRA granted final approval of Change of Name & Ticker Symbol of the Corporation from American Mining Corporation to CNBX PHARMACEUTICALS INC., with the new Ticker Symbol of “CNBX”. Said approval was predicated upon CNBX Pharmaceuticals Inc.’s filing of Articles of Merger with American Mining Corporation with the Nevada Secretary of State on May 21st, 2014. Under the laws of the State of Nevada, CNBX Pharmaceuticals Inc. was merged with and into the Registrant, with the Registrant being the surviving entity. The Merger was completed under Section 92A.180 of the Nevada Revised Statutes, Chapter 92A, as amended, and as such, does not require the approval of the stockholders of either the Registrant or CNBX Pharmaceuticals Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 24, 2014, the Company executed a Collaboration Agreement with Cannabics Inc. (“Cannabics”), a Delaware corporation and largest shareholder of the Company. Per the terms of the Agreement, the Company issued 18,239,594 shares of its common stock to acquire the entire institutional knowledge of Cannabics, Inc., which primarily consists of in-process Research & Development technology, the cumulative result of its years of scientific institutional knowledge in the fields of Molecular Biology, Cancer and Pharmacology research. Additionally, Cannabics tendered $150,000 to the Company specifically earmarked as working funds towards prospective projects of the Company. Per the Agreement, from that day forth they have carried forward their research and development as part of, and for the exclusive benefit of the Company, which initial findings have now branched out into new and divergent discoveries.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 25, 2014, CNBX Pharmaceuticals Inc. incorporated a wholly owned subsidiary in Israel, named “G.R.I.N Ultra Ltd”, dedicated to advanced research and development.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 3, 2018, the Company announced the conclusion of its Clinical Trial of Cannabics SR 5mg drug for Cancer Anorexia Cachexia Syndrome, as noted on the press release of that date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 16<sup>th</sup>, 2020, the Company announced its appointment of Dr. Erez Scapa, MD, to its Scientific Board of Advisors. Dr. Scapa is an Expert in Invasive Gastroenterology in the Sourasky Medical Center in Tel-Aviv, Israel, where he is head of the Endoscopic Submucosal Dissection (ESD) program.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 5<sup>th</sup>, 2020, the Company announced its appointment of Dr. Dana Ben-Ami Shor to its Scientific Board of Advisors, where she will help lead the design and implementation of the company's clinical validation plan of its novel drug candidates for the treatment of colorectal cancer.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 20<sup>th</sup>, 2020, the Company announced the creation of a new Division for its Anti-Tumor drug candidate RCC-33, for the treatment of colorectal cancer. The emanates from the Company’s focus on a clinical validation path, including <i>in-vivo</i> experiments, collaborations with key medical centers, and the preparation of a product dossier with which the company plans to schedule a Pre IND-Meeting with the U.S. Food and Drug Administration (the “FDA”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 18<sup>th</sup>, 2021, the Company filed 2 new Provisional Patent applications on Compositions and Methods for treating cancer, including colorectal cancer and early intervention therapy for colorectal cancer patients.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 10, 2022, the Company changed its name from “Cannabics Pharmaceuticals Inc.” to the current CNBX Pharmaceuticals Inc.; effectuated a one-for-one hundred twenty (1:120) reverse split of the issued and outstanding shares of common stock of the Company and decreased its authorized shares of preferred stock from 100,000,000 to 5,000,000 as noted in the 8K of May 13<sup>th</sup>, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 20<sup>th</sup>, 2022, Dr. Eyal Ballan resigned his position as Chief Technical Officer, and was replaced by Dr. Sanja Goldberg as noted in the 8K of July 24<sup>th</sup>, 2022. Sanja is no longer with the company but could be called back.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 5 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Our Business:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Company Overview</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a clinical-stage company specializing in the discovery, development and commercialization of novel cannabinoid-based products and innovative technologies for the treatment of cancer.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our first lead product candidate is Cannabics SR the oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS), showed promising results in a peer-reviewed clinical study that concluded the results justify a larger clinical study. For oncology, we intend to pursue a broad strategy of combining our technology platforms with conventional oncology therapies, based on their mechanisms of action, safety profiles and versatility. Our leading anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) is RCC-33, a first-in-class therapy being developed primarily in two settings: one to reduce tumor cell activity in CRC patients as a standalone in neoadjuvant treatment or “window of opportunity” at the time after colonoscopy, prior to cancer staging; and another for patients with refractory to therapy and adjuvant to surgery also at the time after colonoscopy. Neoadjuvant treatment is the administration of antitumor therapy as a first step to shrink a cancerous tumor prior to surgical intervention. We intend to initiate Phase I/II clinical trials for both candidates in 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.55pt; text-align: justify"><b>1. General:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CNBX Pharmaceuticals Inc. is a clinical stage pharmaceutical company primarily focused on the development of novel cannabinoid-based products and innovative technologies for the treatment of cancer.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The company is currently preparing to launch Phase I/II (a) clinical study in 2023, for the evaluation of its lead drug candidates Cannabics SR for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS) and RCC-33 for the treatment of colorectal cancer. The company’s activities are centered around the company’s biological laboratory facilities located in Rehovot Israel, where our scientific team leads the company’s research and development efforts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our company’s core activities consist of:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%; text-align: right"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 1%"> </td> <td style="width: 94%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug Discovery: development of novel molecular formulations and drug candidates;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: right"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual Property: filing of corresponding IP to protect our products; and</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: right"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory Affairs: initiation of the regulatory pathway for each drug candidate in our development pipeline</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our current business model is to undertake an FDA regulatory pathway for each of the new drug candidates under IND (Investigational New Drug) classification and complete a successful Phase I/II(a) clinical study (toxicity and proof of concept in humans). In reaching this milestone, where an initial feasibility in humans was demonstrated, the company will have gained several commercial opportunities for capitalizing on each such product candidate, including entering into commercial agreements with larger pharma corporations. Accordingly, our company does not engage in any manufacturing, distribution, or sales of products, nor is it foreseeable to expect that we will in the near future.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <!-- Field: Page; Sequence: 6; Value: 52 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.55pt; text-align: justify"><b>2. Development pipeline:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>2.1. Cannabics SR for Cancer Anorexia-Cachexia Syndrome</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.55pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Overview</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are developing Cannabics SR as a product candidate for the treatment of CACS. Cannabics SR is a sustained-release oral capsule containing a standardized compound of cannabinoids that has demonstrated a clinically significant weight increase in CACS patients in a peer-reviewed pilot study conducted by Dr. Gil Bar-Sela of the Rambam Hospital Health Care Campus, Division of Oncology, in Haifa, Israel. Our patent-pending technology provides for a convenient, once or twice daily administration, with rapid onset and a steady state of therapeutic effect for a 6 to 8-hour duration.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cancer Anorexia-Cachexia Syndrome</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CACS is a common complication of cancer associated with high morbidity and mortality. It is a complex metabolic syndrome in which a persistently elevated basal metabolic rate is not compensated for by adequate calorie or protein intake, causing involuntary and progressive weight loss leading to increasing functional impairment in cancer patients, especially in advanced stages of the disease. Once established, CACS cannot presently be reversed using available pharmacological or nutritional support techniques.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unlike starvation, body-weight loss in CACS patients arises mainly from loss of muscle mass, characterized by increased catabolism of skeletal muscle and decreased protein synthesis. This weight loss is associated with important clinical outcomes such as increased morbidity, diminished effectiveness of chemotherapy, muscle wasting, inflammation, fatigue, and reduced survival expectations. The impact of CACS on the patient is not, however, limited to the effect of weight loss. Quality of life, functional abilities, symptoms, psychological outcomes, and social aspects are all affected by CACS.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the National Cancer Institute, nearly one-third of cancer deaths can be attributed to the severe weight loss and “metabolic mutiny” associated with CACS, and more than 50% of patients with cancer die with cachexia being present. The overall prevalence of CACS is currently estimated to range from 40% at cancer diagnosis to 70-80% in advanced phases of the disease (<i>Source: Critical Reviews in Oncology/Hematology, 2013;88(3):625-636</i>), while the overall prevalence of weight loss in cancer patients may be as high as 86% in the last 1-2 weeks of life (<i>Source: Journal of Pain and Symptom Management 2007;34:94–104</i>).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The cause and subsequent development of CACS is still poorly understood, but several factors and biological pathways are known to be involved, including inflammation, decreased secretion of anabolic hormones, and altered metabolic response. While there have been important advances in the study of CACS over the past decade, including progress in understanding its mechanisms and the development of promising pharmacologic and supportive care interventions, there is presently no effective pharmacologic therapy for CACS.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Current treatments for CACS are generally based on nutritional support and CACS pathophysiology-modulating drugs, with the most common being the progestogens, megestrol and medroxyprogesterone, and corticosteroids. Progestogens appear to stimulate appetite and improvements in body weight by increasing adipose tissue, but have not been confirmed to augment lean body mass. Megestrol also carries an increased risk of mortality and thromboembolism. Nonetheless, megestrol is the only FDA approved treatment option for CACS and no drug to date has been shown to be superior to it in efficacy and tolerability. Corticosteroids are also considered effective in stimulating appetite and reducing fatigue but should only be used for short periods and in selected cases because of side effects from longer term use, such as insulin resistance, fluid retention, steroidal myopathy, skin fragility, adrenal insufficiency, and sleep and cognitive disorders. Other drugs are being investigated or are in development. Given the dearth of approved therapies, we believe that CACS remains a significant area of unmet medical need.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 7; Value: 52 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cannabinoid Therapies for CACS</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cannabis has long been suggested as a well-tolerated, safe, and effective option to help patients cope with cancer related symptoms with fewer serious side effects than most prescription drugs currently used as anti-emetics, analgesics, and the like. As such, cannabinoids are finding application in palliative care for reducing nausea and vomiting, alleviating cancer pain, and stimulating appetite, as well as improving quality of life in cancer patients. Dronabinol (Marinol®) and nabilone (Cesamet®), two drugs based on synthetic cannabinoids, have each been approved by the FDA for the treatment of chemotherapy-related nausea in patients who do not respond to conventional antiemetic therapy. Another drug, nabiximols (Sativex®), a specific cannabis extract, is approved in Canada and the United Kingdom for symptomatic relief of pain in advanced cancer patients.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Despite interest in cannabinoid-based therapies as a treatment for CACS, their use has been limited by impediments beyond the legal status of cannabis. The most significant obstacle is the lack of clinical research demonstrating their efficacy. While there is evidence that cannabinoids improve appetite, body weight, body fat level, caloric intake, mood, and quality of life in cancer patients, the few studies on these effects have yielded mixed and inconclusive findings. In addition, some of these studies have suffered from methodological constraints that limit any ability to draw firm conclusions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The therapeutic use of cannabinoids has also been inhibited by limitations associated with traditional administration routes that reduce their effectiveness. Smoking and ingestion of cannabis suffer from wide variability in potency due to a lack of standardized and reproducible formulations. The ingestion of unformulated cannabis has also been associated with poor absorption and low bioavailability versus other administration routes, requiring higher doses and a greater risk of negative side effects. Additionally, the lack of available information on cannabinoid strains has made it difficult for healthcare providers to establish dosing rates. In our experience, however, the principal concern of patients with respect to medical cannabis lies in the undesirable side effects, such as disorientation and dizziness, which result from significant variability in peak blood levels of active cannabinoids soon after administration. We further believe that these side effects, which are common among immediate release methods, are a significant factor in the failure of patients to adhere to recommended treatment regimens and are therefore a pervasive threat to their health and wellbeing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cannabics SR</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cannabics SR is an oral composition in the form of a hydroxypropylmethylcellulose (HPMC) capsule containing a patent-pending formulation of cannabinoid extracts suspended in a lipid emulsion. It provides a relatively rapid onset of action, typically within 30-40 minutes, followed by a gradual and sustained release of active cannabinoids, resulting in a steady state level of beneficial effects for up to 6 to 8 hours with each capsule. Cannabics SR provides a consistent, predictable concentration of cannabinoids with an absorption profile and bioavailability of active ingredients that we believe to be superior to other oral cannabinoid administrations. We believe that the multifactorial benefits of the active pharmaceutical ingredients in Cannabics SR address an unmet medical need for a safe and effective treatment of CACS, leading to improved patient adherence and better health outcomes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cannabics SR capsules contain only food grade materials without any artificial additives. The active ingredients of each capsule are standardized in composition, formulation, and dose, and are comprised of only pure, natural extracts of active cannabinoids from selected strains of medical cannabis. All excipients are recognized by the FDA as Generally Regarded as Safe.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the therapeutic potential of Cannabics SR as a treatment for CACS, we believe that our SR technology may be formulated to serve the unique needs of patients suffering from other indications for which a sustained release of a cannabinoid formulation may be beneficial.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Clinical Development</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2016, we commenced a two-year pilot study to evaluate the influence of Cannabics SR capsules on CACS, and, in particular, on weight loss in advanced cancer patients. The study was led by Professor Gil Bar-Sela, the former Deputy Director of the Division of Oncology at Rambam Health Care Campus, Head of the Palliative and Supportive Oncology Unit, and Head of Service for Melanoma and Sarcoma Patients.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 8; Value: 52 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patients were administered 2 × 10 mg of Cannabics SR per 24 hours for six months. During the study, after some patients reported several psychoactive side effects, the dosage of each capsule was reduced to 5 mg. Almost no side effects were reported with the 5 mg dosage. Participants were weighed at each physician visit. The primary objective of the study was a weight gain of ≥10% from baseline. Of 24 patients who agreed to participate in the study, 17 started the Cannabics SR treatment, but only 11 received the capsules for more than two weeks. Three of six patients who completed the study period met the primary end-point. The remaining three patients had stable weights. In quality-of-life questionnaires patients reported less appetite loss after the Cannabics SR treatment (p=0.05). According to patients’ self-reports, improvement in appetite and mood as well as a reduction in pain and fatigue was demonstrated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Despite various limitations, the preliminary study demonstrated a weight increase of ≥10% in 3 out of 17 (17.6%) of patients with doses of 5 mg × 1 or 5 mg × 2 capsules daily, without significant side effects. The remaining patients had stable weights. Also, all patients who remained in the study for at least 4.5 months reported an increase in appetite, as did 83% of the patients who completed the study. For 50% of the patients who completed the study, there were reports of pain reduction and sleep improvement. Additional results showed a significant decrease of appetite loss complaints among 83% of the patients who completed the study. (See <i>Bar-Sela, Gil et al. “The Effects of Dosage-Controlled Cannabis Capsules on Cancer-Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients: Pilot Study.” Integrative Cancer Therapies vol. 18 (2019): 1534735419881498. doi:10.1177/1534735419881498</i>.)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Figure 1</i></b><i>: Appetite loss among the six patients who completed Cannabics SR treatment, as reported on European Organization of Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLC-C30</i>)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><img src="image_001.jpg" alt="" style="height: 316px; width: 500px" /> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <!-- Field: Page; Sequence: 9; Value: 52 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Commercialization</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The results of our planned pilot studies may permit us to commercialize Cannabics SR in Israel under license by the Israeli Ministry of Health. If we are granted such a permit, we intend to engage a GMP manufacturer in Israel to produce Cannabics SR capsules for national distribution.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 13, 2020, the Israeli Ministry of Economy signed a Free Export Order, authorizing the export of GMP certified medical cannabis products from Israel. We are currently evaluating our export opportunities and optimal commercialization path for Cannabics SR across all available international markets, particularly with regard to the European Union, Canada, and Australia. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cancer and Cancer Anorexia Cachexia Syndrome (CACS) Market Analysis</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The dynamics of the cancer cachexia market are expected to shift in the coming years as a result of the positive outcomes of some of the rare candidates during the development stage by key players that are in the early stages of clinical development have the potential to create a significant positive shift. The emerging therapies are projected to be launched during the forecast period. In addition, the dearth of effective therapies for this condition presents a great opportunity for pharma companies to create novel drugs because there is less competition in the cancer cachexia market. Moreover, the rising awareness about the condition is also impacting the growth of the cancer cachexia market positively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Global Cancer Cachexia Market Size is projected to reach USD 2.93 billion by 2027, exhibiting a CAGR of 4.8% during the forecast period [2020-2027].</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><img src="image_002.jpg" alt="" style="height: 249px; width: 500px" /> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">https://www.fortunebusinessinsights.com/cancer-cachexia-market-103262</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">North America region holds the largest market share of the global Cancer Anorexia-Cachexia Syndrome Drug North America is expected to hold a large market share in the global Cancer Anorexia-Cachexia Syndrome Drug Market due to the growing incidence of cancer cases. The International Agency for Research on Cancer (IARC) claims 13 million new cancer cases worldwide. The World Cancer Report provides that the incidence rate of new cancer cases is increased by 50% to 15 million in 2020. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel products, the total availability of advanced technological tools, FDA approval of new drugs and many companies are developing oncology products (https://www.datamintelligence.com/research-report/ cancer-anorexia-cachexia-syndrome-drug-market)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 10; Value: 52 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.65pt; text-align: justify">2.2 <i>RCC-33: colorectal cancer treatment drug candidate:</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our anti-neoplastic flagship product under development, RCC-33, is an antitumor drug candidate for the treatment of colorectal cancer, which is the 3<sup>rd</sup> most diagnosed and 2<sup>nd</sup> most lethal of all cancers, with approximately 2M new cases being diagnosed annually worldwide and a current market estimated at $12B, and which is expected to reach $17B by 2027.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The RCC-33 proprietary formula consists of a specific synthetic cannabinoid molecular composition that has demonstrated the potential to reduce colorectal cancer tumor volume by over 30% in repeated in-vivo studies performed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-align: justify"><b>Cancer and Cannabinoids</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cancer is a general term used to describe a group of more than 100 related diseases characterized by uncontrolled growth and spread of abnormal cells, leading to the development of a mass commonly known as a tumor, followed by invasion of the surrounding tissues and subsequent spread, or metastasis, to other parts of the body. Despite enormous investment in research and the introduction of new treatments, cancer remains a critical area of unmet medical need. According to the World Health Organization, cancer is the second leading cause of mortality worldwide, responsible for an estimated nearly 10 million deaths in 2021. As of January 1, 2019, there were more than 16.9 million people with a history of cancer living in the United States, with 1.9 million new cases and 609,360 cancer deaths expected in 2022 (<i>Source: American Cancer Society. Cancer Facts & Figures 2022).</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Over the past decade, there has been growing interest in the therapeutic value of cannabinoid compounds in oncology. Cannabis has long been suggested as a well-tolerated, safe, and effective option to help patients cope with cancer related symptoms by reducing nausea and vomiting, alleviating cancer pain, stimulating appetite, and improving quality of life. Beyond their palliative benefits, however, cannabinoids have also been receiving increased attention for their anti-cancer potential, which we believe may one day revolutionize cancer therapy.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cannabinoids are a diverse class of chemical compounds that occur naturally within cannabis plants and are pharmacologically similar to cannabinoids produced by the human body, known as endocannabinoids. Endocannabinoids form part of the human endocannabinoid system (ECS), a complex biological network that also includes cannabinoid receptors and enzymes involved in cannabinoid formation, transport, and degradation. The ECS is regarded as an important endogenous system implicated in regulation of the most vital biological processes to maintain homeostasis, assisting the body to remain stable and balanced despite external, or environmental, fluctuations <i>(Source: Current Pharmaceutical Design, 2016;22(12):1756-1766)</i>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dysregulation of the ECS owing to variation in the expression and function of cannabinoid receptors or enzymes or the concentration of endocannabinoids has been associated with several diseases, including cancer (<i>Source: International Journal of Molecular Sciences, 2020;21(3):747</i>). Indeed, the mechanisms involved in the regulation of the ECS as well as the processes that it regulates include practically every pathway important in cancer biology. Expression of the ECS is altered in numerous types of tumors, compared to healthy tissue, and this aberrant expression has been related to cancer prognosis and disease outcome, depending on the origin of the cancer (<i>Source: British Journal of Pharmacology, 2018;175(13):2566-2580</i>). Recent studies suggest that endocannabinoids contribute to maintaining balance in cell proliferation and that targeting the ECS can affect cancer growth (<i>Source: Canadian Urological Association Journal, 2017;11(3-4):E138-E142</i>).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cannabinoids can interact with the cannabinoid receptors in the ECS, sometimes with a higher affinity than endocannabinoids. As a consequence, all the processes regulated by endocannabinoids are susceptible to interference by cannabinoids. The ability to use cannabinoids to modulate the ECS encompasses several attractive pharmacotherapeutic targets for systemic anti-cancer treatment and has sparked considerable research examining cannabinoid action on cancer cells (<i>Source: Pharmacological Reviews, 2006;58(3):389-462</i>).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 11; Value: 52 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cannabinoids have demonstrated selective anti-tumor properties in preclinical studies, exerting anti-proliferative, proapoptotic, anti-angiogenic, and anti-metastatic and anti-inflammatory effects depending on tumor type and specific setting (<i>Source: Cancer Medicine, 2018:7(3):765-775</i>). These effects appear to be more pronounced when cannabinoids are used together versus being administered separately, a mechanism known as the <i>entourage effect</i>. We believe, therefore, that cannabinoid combinations may hold promise for an improved anti-proliferative strategy for cancer management.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to their potential role as anti-cancer agents, cannabinoids have been observed to act synergistically with some conventional antineoplastic drugs, such as chemotherapeutic agents, enhancing their effectiveness (<i>Source: Cancer Medicine, 2018;7(3)765-775</i>). This raises the potential for combinational therapies that may increase the range of chemotherapeutic options available to patients and enable targeting of tumor progression at different levels while also permitting dosages of cytotoxic drugs to be dramatically reduced without compromising efficacy.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Figure 2</i></b><i>: Synergistic effects of cannabis extracts and chemotherapies on cancer biopsy after treatment with the same extract and three different chemotherapy combinations</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><img src="image_015.jpg" alt="" style="height: 257px; width: 575px" /> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this filing, we are not aware of any cannabinoid-based therapies approved for the anti-cancer treatment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our lead product candidate is RCC-33, which we are developing as a treatment for CRC. RCC-33 is an oral capsule containing a proprietary formulation of cannabinoids that have demonstrated synergistic efficacy in reducing the viability of human colon cancer cell lines in preclinical studies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Colorectal Cancer</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CRC is one of the more common forms of cancer worldwide, representing a significant challenge to the global healthcare system. According to the World Health Organization, CRC is the third most diagnosed cancer in the world and the second-leading cause of cancer-related mortality. In the United States, there were approximately 1,369,005 people living with CRC in 2019(<i>Source: National Cancer Institute. “Cancer Stat Facts: Colorectal Cancer”</i>). In 2022, an estimated 151,030 cases of colon cancer and 44,850 cases of rectal cancer will be diagnosed in the US, and a total of 52,580 people will die from these cancers (<i>Source: American Cancer Society. “Cancer Facts & Figures 2022”</i>).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 12; Value: 52 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Most CRCs begin as a noncancerous growth called a polyp that develops on the inner lining of the colon or rectum. The most common kind of polyp is called an adenomatous polyp or adenoma. According to the American Cancer Society, an estimated one-third to one-half of all individuals will eventually develop one or more adenomas. Although all adenomas have the capacity to become cancerous, fewer than 10% are estimated to progress to invasive cancer. The likelihood that an adenoma will evolve into cancer increases as it becomes larger or when it acquires certain histopathological characteristics. Adenomas that become cancerous, called adenocarcinomas, comprise nearly 96% of all CRCs (<i>Source: American Cancer Society. “Colorectal Cancer Facts & Figures 2020-2022”</i>). Adenocarcinomas may grow into blood vessels or lymph vessels, increasing the chance of metastasis to other anatomical sites.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CRC usually develops slowly, over a period of 10 to 20 years. The complex sequence of events occurring during initiation, development and propagation of adenocarcinomas is likely the result of a lifelong accumulation of mutations caused by both genetic and environmental factors known as the adenoma to carcinoma sequence. While the specific cause of any particular case of CRC is often unknown, more than one-half of all cases and deaths are attributable to lifestyle and environmental factors, such as smoking, unhealthy diet, high alcohol consumption, physical inactivity, and excess body weight (<i>Source: American Cancer Society. “Cancer Facts & Figures 2020”</i>).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CRC does not usually cause symptoms until the disease is advanced, therefore early detection of adenomas by screening is vital. If not treated or removed, an adenoma can become a potentially life-threatening cancer.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Current Standard of Care</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Treatment options for CRC patients depend on several factors, including the type and stage of cancer, possible side effects, and the patient’s preferences and overall health. Surgical removal of the tumor is the most common form of treatment, particularly in the early stages of malignancy. Patients with more advanced stages of CRC may be given adjuvant chemotherapy to kill any cancer cells remaining after surgery, though standard chemotherapy is associated with severe side effects and provides marginal benefit to the majority of patients. While radiation therapy is often used to treat rectal cancer, it is not generally recommended for colon cancer patients except in the later stages of the disease (<i>Source: American Cancer Society. “Treating Colorectal Cancer”)</i>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CRC is a heterogeneous disease with distinct clinical, molecular, and pathophysiological characteristics. As a result, the response to treatment is variable between patients, even when they are diagnosed at the same clinical stage. Such heterogeneity remains an obstacle to the optimization of treatment for each individual. Researchers are continuing to investigate new treatment options, such as immunotherapy and targeted therapy, that focus upon the genes, proteins, and other factors in a particular tumor (<i>Source: American Cancer Society. “Advances in Colorectal Research”</i>).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immunotherapy uses the body’s own immune system to kill cancer cells. There are already several FDA-approved immunotherapy options for CRC, such as pembrolizumab (Keytruda®), nivolumab (Opdivo®), and ipilimumab (Yervoy®). Many immunotherapies that have shown promise in addressing other types of cancer are also being tested for CRC. While immunotherapy has had some encouraging results, significant limitations remain. Its efficacy is often unpredictable, and the treatment can lead to the body becoming resistant or result in off-target toxicities where the body’s immune system attacks healthy tissue. Immunotherapy may take longer than other protocols and it is substantially more expensive than classical treatments (<i>Source: Pharmacy & Therapeutics, 2017;42(8):514-521</i>).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Targeted therapy uses drugs to target specific molecules inside cancer cells or on their surface to slow the growth of cancer, destroy cancer cells, and relieve cancer symptoms. There are different types of targeted therapy drugs, each working differently depending on what molecule the drug is targeting. A treatment is chosen based on the types of molecules expressed on the patient’s tumor cells, which allows doctors to tailor cancer treatment for each person. Several targeted therapy drugs, such as bevacizumab (Avasin®) and cetuximab (Erbitux®), are already used to treat advanced CRC. Despite showing clinical promise, targeted therapy has challenges, such as tumor heterogeneity, off-target toxicity, and acquired resistance (<i>Source: Medical Research Journal, 2019;4(2):99-105</i>). The lack of biomarkers by which to identify patients having a high probability of response is also a particularly significant obstacle. As with immunotherapy, the cost of targeted therapy is substantially higher than classical treatments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 13; Value: 52 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that there is no “magic bullet” to cure cancer and that a personalized combination of cancer treatments may be the best course for long term survival benefits in each case. To that end, the development of more prevention strategies and novel agents will be essential.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cannabinoids and Colorectal Cancer</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One area of increasing interest in the treatment of CRC lies in the development and use of cannabinoid therapeutics. The ECS is regarded as an important regulatory system in the gastrointestinal tract, being involved in several important functions such as motility, secretion, sensation, inflammation, and carcinogenesis. Recent studies advocate that the ECS plays a critical role in the development of CRC and should therefore be considered as an appropriate target for CRC inhibition (<i>Source: Frontiers in Pharmacology, 2016;7:361</i>). The expression of ECS components in CRC has been found to be increased and associated with poorer prognosis and advanced stages of disease (<i>Source: Cannabis and Cannabinoid Research, 2018, 3(1):272-281</i>). For example, cannabinoid receptors have been found to be overexpressed in tumor cells of the colon and this up-regulation has been postulated to be an indicator of cancer outcome (<i>Source: British Journal of Pharmacology, 2018; 175(13): 2566-2580</i>).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research on the effects of cannabinoid compounds on CRC has demonstrated an ability to reduce the viability of CRC cell lines <i>in vitro</i> (<i>Source: Cancer Medicine, 2018;7(3):765-775</i>), while there is also convincing scientific evidence that cannabinoids are able to prevent or reduce carcinogenesis in different animal models of colon cancer (<i>Source: Expert Review of Gastroenterology & Hepatology, 11:10, 871-873</i>).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that cannabinoids are a promising therapeutic agent for the treatment of CRC. We have conducted several <i>in vitro</i> unpublished studies using our bioinformatics platform to confirm that cannabinoids cause necrosis in colon cancer cells. While many cannabinoids demonstrate levels of toxicity on cancer cells, we have found that certain cannabinoid extracts and combinations show increased levels of toxicity relative to other isolated or combined cannabinoids. These findings have spurred the development of RCC-33, our product candidate for the treatment of CRC.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Figure 3</i></b><i>: Synergistic effects of different cannabinoid combinations on viability of a colon cancer cell line</i>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img src="image_016.jpg" alt="" style="height: 248px; width: 400px" /></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></p> <!-- Field: Page; Sequence: 14 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>RCC-33</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are developing RCC-33 as an oral capsule or solution containing high concentrations of the cannabinoids CBDV and CBGA in a novel formulation, which we believe may be effective in the treatment of adenocarcinomas of the colon. The cannabinoids in RCC-33 have demonstrated complex synergistic anti-tumor effects in combination, with no psychoactive effect. In our preclinical <i>in vitro</i> studies evaluating the influence of 15 different cannabinoids on human colon cancer cell lines (RKO, HCT116), alone and in combination, RCC-33 demonstrated clear efficacy in reducing the viability of colon cancer cells versus alternative cannabinoid combinations. Importantly, we could detect significant reduction effect on tumour development in mice inoculated with human colorectal cancer cells.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><img src="image_017.jpg" alt="" style="height: 502px; width: 625px" /> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p> <!-- Field: Page; Sequence: 15 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Development Plan</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The company is currently preparing to launch Phase I/II (a) clinical study in 2023, for the evaluation of its lead drug candidates Cannabics SR for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS) and RCC-33 for the treatment of colorectal cancer. We plan to conduct further preclinical studies to establish the safety and efficacy before proceeding with first-in-human clinical testing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Preclinical Studies</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to conduct non-clinical safety studies following Good Laboratory Practice (GLP) to evaluate the systemic and local toxicity of escalating doses of RCC-33 and establish dosing parameters. The results of these preclinical studies, which are expected in 2024, will guide our planned Phase I/II(a) clinical trial. The non-clinical requirements to support the development program will be verified with the FDA at a pre-IND meeting. Such studies may include repeated dose toxicity studies, male and female fertility studies, embryofetal development studies, animal abuse related studies, pharmacokinetics studies, drug-drug interaction studies, and others.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Clinical Trials</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to evaluate the safety, tolerability, and pharmacokinetic properties of Cannabis SR and RCC-33 in a Phase I/II(a) ascending dose clinical trial in CRC patients, commencing in the first quarter 2025. The clinical trial will examine the tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of RCC-33 in CRC patients. We are currently identifying potential contract research organizations and clinical trial centers to conduct the Phase I/II(a) human proof of concept study, which is estimated to cost $6,500,000. As of the date of this filing, however, the Company does not have sufficient funds to complete the Phase I/II(a) study.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the results from our Phase I trials, we plan to submit an IND to the FDA for RCC-33 with the clinical protocol for a Phase II double-blind placebo controlled clinical trial evaluating RCC-33 in patients with CRC at various dosing levels versus placebo. The outcomes from the planned Phase II human proof of concept trial will inform our decision regarding further steps in the clinical development of RCC-33.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Pipeline:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to <b>RCC-33</b>, our colorectal cancer treatment drug candidate, the company has several other drug candidates under development, including <b>PLP-33</b> for the local treatment of Lateral Spreading, or Sessile, colorectal polyps during colonoscopy, <b>BRST-33</b> for the treatment of breast cancer, <b>MLN-33</b> for the treatment of Melanoma and <b>PRST-33</b> for the treatment of prostate cancer. These additional drug candidates are in the early stage of development and the company expects to complete the in-vivo research for each product by end of 2025. (see Fig. 4).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 16; Value: 52 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Fig. 4- Edit Graph to reflect delay until 2025</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b><img src="image_018.jpg" alt="" style="height: 430px; width: 450px" /></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-align: justify; text-indent: -14.6pt"><b>2.3 Product lines currently not actively developed:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The company has several product lines that are currently not being actively developed following company’s decision to focus its resources and attention exclusively on the development of its FDA route drug candidates, and SR Capsule described above. The product lines not actively developed include:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cannabics CDx (<i>evaluate</i>) Drug Sensitivity Test</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cannabics CDx is an ex-vivo drug sensitivity test under development to provide healthcare providers with clinical decision support data from which they can identify, for a particular cancer patient undergoing cannabinoid therapy, which cannabinoids or cannabinoid combinations may have the most beneficial anti-cancer effects, and which cannabinoids may be contraindicated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 17; Value: 52 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Company may revisit this decision at a later stage after launching the <i>first in human</i> clinical studies for the validation of its colorectal cancer treatment drug candidate RCC-33.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-align: justify; text-indent: -14.6pt"><b>3. Market opportunity for cancer treatment drug candidates:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-align: justify; text-indent: -14.6pt"><b>3.1. Neoadjuvant therapy:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the National Cancer Institute, Neoadjuvant Therapy is a "treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery”.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><img src="image_019.jpg" alt="" style="height: 360px; width: 625px" /></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Limitations:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%; text-align: right"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 1%"> </td> <td style="width: 94%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mild to severe side effects</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: right"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suppressed immune system</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: right"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential resistance of tumor residues to postoperative chemotherapy *</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-indent: -14.6pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* “nCRT increases ITGH and may result in the expansion of resistant tumor cell populations in residual tumors”.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Frontiers in Oncology. 2019</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>The Effects of Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer—The Impact in Intratumoral Heterogeneity.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p> <!-- Field: Page; Sequence: 18 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.3pt; text-indent: -29.2pt"><b>3.1.1 Neoadjuvant therapy in rectal cancer</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.4pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neoadjuvant chemoradiotherapy has become the standard treatment for locally advanced rectal cancer. Neoadjuvant chemoradiotherapy not only can reduce tumor size and recurrence, but also increase the tumor resection rate and anus retention rate with very slight side effect. Comparing with preoperative chemotherapy, preoperative chemoradiotherapy can further reduce the local recurrence rate and downstage. Middle and low rectal cancers can benefit more from neoadjuvant chemoradiotherapy than high rectal cancer.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.3pt"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><img src="image_019.gif" alt="" style="height: 289px; width: 425px" /> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><img src="image_009.jpg" alt="" style="height: 37px; width: 295px" /></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.3pt; text-indent: -29.2pt"><b>3.1.2 Neoadjuvant therapy in breast cancer</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In early breast cancer, surgery is the mainstay of curative treatment. Complementary local radiotherapy and systemic - adjuvant endocrine therapy or chemotherapy treatments are associated with the aim of reducing the risk of relapse according to the clinicopathological characteristics of the tumor. However, the possibility of administering these therapies prior to surgery in neoadjuvant setting offers several advantages:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%; text-align: right"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 1%"> </td> <td style="width: 94%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduction in tumor size to improve respectability,</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: right"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased rate of conservative surgery improving esthetic results,</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: right"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduction in the extent of axillary surgery,</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: right"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">early treatment of micrometastatic disease</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <!-- Field: Page; Sequence: 19 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">Fig5. Asco Guidelines for neoadjuvant therapy in breast cancer</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><img src="image_010.jpg" alt="" style="height: 338px; width: 500px" /></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><img src="image_011.jpg" alt="" style="height: 37px; width: 500px" /> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to ASCO guidelines most of the patients are eligible for neoadjuvant chemotherapy and are the end consumers of BRST-33, while the current treatment regimen negates severe side effects.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt"><b>Side effects and risks of standard of care:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt"><b> </b></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 8%; text-align: right"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 1%"> </td> <td style="width: 91%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">nausea or vomiting</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: right"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hair loss</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: right"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">nail or skin changes</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: right"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appetite loss</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: right"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">weight changes</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: right"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diarrhea or constipation</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: right"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">mouth sores</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: right"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fatigue</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-align: justify"><b></b></p> <!-- Field: Page; Sequence: 20 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-align: justify; text-indent: -14.6pt"><b>3.2. Cannabinoid Neoadjuvant Therapy</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For some time now, the FDA has promoted clinical studies on Cannabinoids as a growing range of stakeholders has expressed interest in development of drugs that contain cannabis and compounds found in cannabis. Recent legislative changes have also opened new opportunities for medical cannabis clinical research. As this body of research progresses and grows, the FDA is working to support drug development in this emerging scientific arena.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>RCC-33 & BRST-33 – Potential safe drugs improving rectal and breast cancer neoadjuvant standard of care</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 57.4pt; text-align: justify; text-indent: -51.75pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-align: justify"><b>RCC-33 & BRST-33</b> anticipated advantage over standard of care:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 8%; text-align: right"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 1%"> </td> <td style="width: 91%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Suppressed immune system</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: right"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential low toxicity which is even more important in neoadjuvant treatment since patients will suffer less side effects. Since the two drug candidates are based on two natural molecules (cannabinoids) found in the Cannabis plant, the safety of the molecules in the short and long run is potentially lower. Not like in a new drug entity in which toxicity could not be predicted.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: right"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overcoming Potential resistance of tumor residues to postoperative chemotherapy</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 25.5pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-align: justify; text-indent: -14.6pt"><b> 4. Outsourced GMP manufacturing and commercial operation:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-align: justify; text-indent: -14.6pt"><b>4.1. Outsourced GMP manufacturing</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-align: justify; text-indent: -14.6pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our current position is that all of our Chemistry Manufacturing and Controls (CMC) required for the approval process of our drug candidates is to be outsourced. The RCC-33 formulation, as well as all additional drug candidates in our pipeline, while inspired by natural molecules, could consist only of formulations made from <span style="text-decoration: underline">chemically synthesized molecules, or APIs (Active Pharmaceutical Ingredients)</span>. Our Company is not engaged in the development of any botanical or botanically based product/s. Additionally, in view of our upcoming submission of a pre-IND meeting request with the FDA, the Company may enter an new agreement with Purisys, a supplier of GMP (Good Manufacturing Practice) grade APIs suited for Clinical Stage Products. Purisys is a large and long-established US corporation with a long track record of working with the FDA. Accordingly, under said agreement, we will request that Purisys will also support CNBX throughout an IND filing process, including providing all necessary and related information concerning CMC in the form of a comprehensive technical package to be presented to the FDA. APIs supplied under said agreement will be used by Company in Phase I/II (a) clinical studies that it is planning to launch in 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-align: justify; text-indent: -14.6pt"><b>4.2. Commercial Operations</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-align: justify; text-indent: -14.6pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not established a sales, marketing, or product distribution infrastructure. We plan to commercialize any drugs we develop through licensing arrangements and strategic partnerships with established companies in the pharmaceutical industry having strong marketing capabilities and distribution networks. We generally intend to advance our drug candidates through Phase I and Phase II clinical trials as appropriate in order to establish their clinical and commercial potential before negotiating the terms of any licensing or collaboration. We believe that this approach will achieve the fullest marketing and distribution potential of any drugs or other products that we may develop in the short term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-align: justify; text-indent: -14.6pt"><b>5. Core activities:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-align: justify; text-indent: -14.6pt"><b>5.1. Drug Discovery</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-align: justify; text-indent: -14.6pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Conduct all screening and pre-clinical research at in-house state of the art laboratory facilities</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 21 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Research and Development:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To address these problems and improve clinical outcomes, CNBX Pharmaceuticals focuses on the development of diagnostics that monitor cancer progression and cannabinoid-cancer sensitivity tests to tailor treatment of cancer with cannabinoid medicine. Utilizing novel High-Throughput Screening (HTS) methods to perform studies on cancer cell lines and on circulating tumor cells (CTC) derived from cannabis medicated patients.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We aim to treat a wide scope of cancers both as the main treatment and as a conjugate to conventional chemotherapy. We believe a significant need remains for novel drugs for patients who do not respond to existing therapies or for whom these therapies bear undesirable side effects. We recognize the potential therapeutic applications of the synergistic effects of these active compounds thus building the methodology and procedures that decipher specific ratios of active compounds in regard to their antitumor activity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our government licensed laboratory operates a unique, custom designed and built research and development laboratory which combines high throughput screening, (HTS) capabilities with the most advanced data tools allowing us to enable miniaturization and automation of a variety of biological assays. The automated system is comprised of:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1%; text-align: justify"> </td> <td style="width: 4%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">High Content Screening (HCS) Platform, which is an automated cellular imaging and analysis platform designed for quantitative microscopy.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1%; text-align: justify"> </td> <td style="width: 4%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Flow Cytometry, which enables multi-parametric single cell analysis.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1%; text-align: justify"> </td> <td style="width: 4%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Automated workstation, for liquid handling for dispensing accurate and reproducible volumes of liquids and compounds.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1%; text-align: justify"> </td> <td style="width: 4%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Multimode microplate reader, designed for fast measurements of numerous biological reactions/processes.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The integration of these instruments is enabled via a robotic arm, which allows a continuous process which utilizes all instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Readouts generated from these instruments provide us with insights to the effect of our cannabinoid library on parameters such as, proliferation inhibition, apoptosis induction, angiogenesis prevention and toxicity on cancerous cells.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These experiments will produce multiplexed data composed of images of cells, cell specific markers and the extent/signal of the biological response. The biological response will be measured using different concentration of cannabinoids and their combinations, thus determining the most effective cannabinoid treatment for a specific cancer type.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>In vitro Studies – Drug Screening</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have a proprietary procedure of high throughput screening (HTS) and high content screening (HCS) for the detection of correlations between cannabinoid ratios, dosages and anti-tumor activity using a growing library of human cancer cell lines and creating an enlarged variety of Cannabis-based compounds. We examine the biological activity of these compounds on tumor cell lines of distinct tissue lineage and creating a highly valuable therapeutic data. We Screen for the most potent cannabinoid/natural extracts. Our goal in the invitro studies is to build a library of both purified and natural cannabinoid extracts and to reveal their biological impact on a library of cancer cell lines. The HTS technology enables us to gain this data base in a faster manner and to reveal more mechanisms of action that are related to the genetics of the cancer. We are now in the process of merging our data with sophisticated data mining to help find meaningful insights of both treatment and outcome.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our core technology is a continuously evolving bioinformatics platform that utilizes high-throughput screening technology, advanced data analytics, and proprietary methodologies to rapidly examine the physiologic effect of multiple cannabinoid compounds on tumor cells. This technology enables us to screen thousands of cannabinoid combinations, generating multiple datasets on the anti-tumor properties of different cannabinoid formulations and ratios. We conduct a broad range of preclinical research on cannabinoids through our bioinformatics platform, which informs the development of our product drug candidates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p> <!-- Field: Page; Sequence: 22 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <img src="image_012.jpg" alt="" style="height: 388px; width: 685px" /></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><img src="image_013.jpg" alt="" style="height: 29px; width: 180px" /> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have developed a continuously evolving preclinical bioinformatics platform that enables us to evaluate and classify the physiological impact of multiple cannabinoid compounds on various cancer cells. Utilizing state-of-the-art high-throughput screening and flow cytometry, our platform is capable of testing thousands of compounds weekly, allowing us to rapidly and effectively examine their interactions with a growing library of human cancer cell lines and biopsies. Through the large body of data generated by our platform, we are accumulating in-depth knowledge of the various therapeutic effects of cannabinoids and patterns of cannabinoid ratios that demonstrate meaningful physiologic impact on cancer.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our bioinformatics platform includes the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%"> </td> <td style="width: 3%"><span style="font-family: Wingdings; font-size: 10pt">Ø</span></td> <td style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">high-throughput screening, high content screening, flow cytometry, machine learning, robotics, and proprietary methodologies;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%"> </td> <td style="width: 3%"><span style="font-family: Wingdings; font-size: 10pt">Ø</span></td> <td style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a library of human cancer cell lines and thousands of different combinations and ratios of cannabinoid compounds in a costumed matrix;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%"> </td> <td style="width: 3%"><span style="font-family: Wingdings; font-size: 10pt">Ø</span></td> <td style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a growing database of biological response data;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%"> </td> <td style="width: 3%"><span style="font-family: Wingdings; font-size: 10pt">Ø</span></td> <td style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in-house extraction, processing methodologies, and analytical techniques that yield well-characterized and standardized extracts;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <!-- Field: Page; Sequence: 23 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%"> </td> <td style="width: 3%"><span style="font-family: Wingdings; font-size: 10pt">Ø</span></td> <td style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborations with regulated cannabis producers that may expand our cannabinoid compound library and provide us with access for future proprietary cultivars;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%"> </td> <td style="width: 3%"><span style="font-family: Wingdings; font-size: 10pt">Ø</span></td> <td style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fully integrated in-house research and development; and</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%"> </td> <td style="width: 3%"><span style="font-family: Wingdings; font-size: 10pt">Ø</span></td> <td style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory expertise.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Once a series of potentially active cannabinoids is identified for a specific cancer type, we then test and confirm their activity through <i>in vitro</i> and <i>ex-vivo</i> evaluation studies to determine their potential activity. Through this process, we are able to assess their therapeutic potential. The results of our pre-clinical experiments provide starting points for our clinical development programs.<b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-indent: -14.6pt"><b>5.2. Intellectual Property</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-indent: -14.6pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Expand and protect the technology, inventions, and trade secrets that are critical for business development.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-indent: -14.6pt"><b>6. Competition</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We believe that our scientific knowledge, experience, technology and development capabilities provide us with competitive advantages, but we face competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. Many of our current and potential competitors have longer operating histories and substantially greater financial, scientific, technical, intellectual property, regulatory and human resources than we have, as well as greater experience in developing and commercializing products, including obtaining FDA and other regulatory approvals.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As the medical use of cannabis increasingly receives government approval worldwide, we face growing competition from many new and existing companies seeking to develop cannabinoid-based therapies. Companies currently known to be developing cannabinoid-based human therapeutics include GW Pharmaceuticals PLC, Cannabis Science Inc., InMed Pharmaceuticals Inc., Emerald Bioscience Inc., Corbus Pharmaceuticals Holdings Inc., Zynerba Pharmaceuticals Inc., PharmaCyte Biotech, Inc., Tetra Bio-Pharma Inc. and Cure Pharmaceutical Holding Corp.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many of our competitors are conducting research targeting the same technologies, applications, and markets as we are. Consequently, they may develop products for the same indications we are pursuing or may pursue in the future that are more effective, better tolerated, more widely-prescribed or accepted, more useful, and less costly. Any products that we successfully develop and commercialize will compete with existing products, as well as those currently in development or that may become available in the future.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to competing for market position, we will also compete in terms of recruiting and retaining qualified personnel, acquiring intellectual property, establishing clinical trial sites, and enrolling patients for clinical trials and in obtaining funding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Given the rapid changes affecting the global, national, and regional economies in general and cannabis-related medical research and development in particular, we may not be able to create and maintain a competitive advantage in the marketplace. Time-to-market is a critical factor in our industry and our success will depend on our ability to timely develop innovative technologies that will be accepted by patients. Our competitors may be better able to react to market changes, respond more rapidly to new regulations, or allocate greater resources to the development of their products than we can, which may result in our technologies and products becoming obsolete before we are able to enter the market, recover the expenses incurred to develop them, or generate significant revenue. Our success will depend, in part, upon our ability to develop our product candidates in a timely manner, keep our future products current with advancing technologies, achieve market acceptance of our future products, gain name recognition and a positive reputation in the healthcare industry, and establish successful marketing, sales, and distribution efforts. We cannot be certain that we will be able to compete against current or future competitors or that competitive pressure will not seriously harm our business prospects.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <!-- Field: Page; Sequence: 24 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-indent: -14.6pt"><b>7. Competitive Factors</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Pharmaceutical industry is highly competitive and we will be competing with many other and better financed companies. We are a clinical stage and early stage-biotech pharmaceutical company, with relatively deminimis cash flow. We compete with other early-stage bio-tech and pharmaceutical companies for financing from a limited number of investors that are prepared to make investments in early-stage development companies. The presence of competing early-stage pharmaceutical companies may impact on our ability to raise additional capital in order to fund our research and development if investors are of the view that investments in competitors are more attractive based on their subjective analysis of our company, the general market conditions and the price of the investment offered to investors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-indent: -14.6pt"><b>8. Regulations</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CNBX Pharmaceuticals Inc. is purely a Bio-Technology Pharmaceutical company which licenses use of its Intellectual Property, it does not produce, manufacture or provide any product in any location. We are duly licensed by the Israeli Health Ministry for our research in Israel. Beyond the Israeli Health Ministry and the FDA regulatory pathway for our drug candidates as described above, we are not under the aegis of any Federal or State regulatory scheme as we have no manufacturing activity. Any licensee whom we engage must be duly licensed and certified according to all pertinent local government regulations in their jurisdiction. The Company is exploring drug development within approved laboratory clinical trial settings conducted within approved regulatory frameworks. Should any prescription drug product be developed by the Company, such drug product will not be commercialized prior to receipt of applicable regulatory approval, which will only be granted if clinical evidence of safety and efficacy for the intended use(s) is successfully developed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>United States</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the U.S., the FDA and other federal, state, local and foreign regulatory agencies impose substantial requirements upon the clinical development, approval, labeling, manufacture, marketing and distribution of drug products. These agencies regulate, among other things, research and development activities and the testing, approval, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, advertising and promotion of any prescription drug product candidates or commercial products. The regulatory approval process is generally lengthy and expensive, with no guarantee of a positive result. Moreover, failure to comply with applicable FDA or other requirements may result in civil or criminal penalties, recall or seizure of products, injunctive relief including partial or total suspension of production, or withdrawal of a product from the market.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cannabis (other than hemp) is strictly controlled under the <i>Controlled Substances Act</i> (21 U.S.C. § 811) (the “CSA”) as a Schedule I substance. Schedule I substances by definition have no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse. Schedule I and II drugs are subject to the strictest controls under the CSA, including manufacturing and procurement quotas, security requirements and criteria for importation. Anyone wishing to conduct research on substances listed in Schedule I under the CSA must register with the U.S. Drug Enforcement Administration (the “DEA”), and obtain DEA approval of the research proposal. For any product containing cannabis to be available for commercial marketing in the United States, cannabis must be rescheduled, or the product itself must be scheduled, by the DEA to Schedule II, III, IV or V. Scheduling determinations by the DEA are dependent on FDA approval of a substance or a specific formulation of a substance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The process required before a prescription drug product candidate may be marketed in the United States generally involves:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%"> </td> <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="text-align: justify; width: 96%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion of extensive non-clinical laboratory tests, animal studies and formulation studies, all performed in accordance with the FDA’s Good Laboratory, Good Clinical and/or Manufacturing Practice regulations;</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval by an institutional review board or independent ethics committee at each clinical trial site before each trial may be initiated;</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for some products, performance of adequate and well-controlled human clinical trials in accordance with the FDA’s regulations, including Good Clinical Practices, to establish the safety and efficacy of the prescription drug product candidate for each proposed indication;</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission to the FDA of a New Drug Application (“NDA”);</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Satisfactory completion of one or more FDA pre-approval inspections of the manufacturing facility or facilities where the drug will be produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug’s identity, strength, quality, and purity; and</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA review and approval of the NDA prior to any commercial marketing, sale or shipment of the drug.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 25 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The testing and approval process requires substantial time, effort and financial resources, and the Company cannot be certain that any approvals for its prescription drug product candidates will be granted on a timely basis, if at all.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Non-clinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate toxicity in animals and other animal studies. The results of non-clinical tests, together with manufacturing information and analytical data, are submitted as part of an IND to the FDA. Some non-clinical testing may continue even after an IND is submitted. The IND also includes one or more protocols for the initial clinical trial or trials and an investigator’s brochure. An IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions relating to the proposed clinical trials as outlined in the IND and places the clinical trial on a clinical hold. In such cases, the IND sponsor and the FDA must resolve any outstanding concerns or questions before any clinical trials can begin. Clinical trial holds also may be imposed at any time before or during studies due to safety concerns or non-compliance with regulatory requirements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An independent institutional review board, at each of the clinical centers proposing to conduct the clinical trial, must review and approve the plan for any clinical trial before it commences at that center. An independent institutional review board considers, among other things, whether the risks to individuals participating in the trials are minimized and are reasonable in relation to anticipated benefits. The independent institutional review board also approves the consent form signed by the trial participants and must monitor the study until completed. The FDA, the independent institutional review board, or the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trials to public registries.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical trials to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap. In general in Phase 1, the initial introduction of the drug into healthy human subjects or patients, the drug is tested to assess metabolism, pharmacokinetics, pharmacological actions, side effects associated with increasing doses and, if possible, early evidence on effectiveness. Phase 2 usually involves trials in a limited patient population to determine the effectiveness of the drug for a particular indication, dosage tolerance and optimum dosage, and to identify common adverse effects and safety risks. If a compound demonstrates evidence of effectiveness and an acceptable safety profile in Phase 2 evaluations, Phase 3 trials are undertaken to obtain the additional information about clinical efficacy and safety in a larger number of patients, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the drug and to provide adequate information for the labeling of the drug. In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the drug. The FDA may, however, determine that a drug is effective based on one clinical study plus confirmatory evidence. Only a small percentage of investigational drugs complete all three phases and obtain marketing approval. In some cases, the FDA may require post-market studies, known as Phase 4 studies, to be conducted as a condition of approval in order to gather additional information on the drug’s effect in various populations and any side effects associated with long-term use. Depending on the risks posed by the drugs, other post-market requirements may be imposed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After completion of the required clinical testing, an NDA is prepared and submitted to the FDA. The FDA approval of the NDA is required before marketing of the product may begin in the U.S. The NDA must include the results of all pre-clinical, clinical, and other testing and a compilation of data relating to the product’s pharmacology, chemistry, manufacture, and controls. The cost of preparing and submitting an NDA is substantial.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA has 60 days from its receipt of an NDA to determine whether the application will be accepted for filing based on the agency’s threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. Under the statute and implementing regulations, the FDA has 180 days (the initial review cycle) from the date of filing to issue either an approval letter or a complete response letter, unless the review period is adjusted by mutual agreement between the FDA and the applicant or as a result of the applicant submitting a major amendment. In practice, the performance goals established pursuant to the Prescription Drug User Fee Act have effectively extended the initial review cycle beyond 180 days. The FDA’s current performance goals call for the FDA to complete review of 90 percent of standard (non-priority) NDAs within 10 months of receipt and within six months for priority NDAs, but two additional months are added to standard and priority NDAs for a new molecular entity, or NME.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 26 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA may also refer applications for novel drug products, or drug products that present difficult questions of safety or efficacy, to an advisory committee, which is typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the drug is manufactured. The FDA will not approve the product unless compliance with current GMP is satisfactory and the NDA contains data that provide substantial evidence that the drug is safe and effective in the indication studied.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After the FDA evaluates the NDA and the manufacturing facilities, it issues either a n approval letter or a complete response letter. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the FDA’s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing 90 percent of resubmissions within two to six months depending on the type of information included.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. As a condition of NDA approval, the FDA may require a risk evaluation and mitigation strategy, or REMS, to help ensure that the benefits of the drug outweigh the potential risks. REMS can include medication guides, communication plans for health care professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the drug. Moreover, product approval may require substantial post-approval testing and surveillance to monitor the drug’s safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA offers a number of regulatory mechanisms that provide expedited or accelerated approval procedures for selected drugs and indications which are designed to address unmet medical needs in the treatment of serious or life-threatening diseases or conditions. These include programs such as Breakthrough Therapy designations, Fast Track designations, Priority Review and Accelerated Approval, which the Company may need to rely upon in order to receive timely approval or to be competitive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company may plan to seek orphan drug designation for certain indications qualified for such designation. Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a “rare disease or condition,” which, in the U.S., is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or 200,000 or more individuals in the United States and for which there is no reasonable expectation that the cost of developing and making a drug available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan drug designation must be requested before submitting an NDA. If a product that has an orphan drug designation subsequently receives the first regulatory approval for the indication for which it has such designation, the product is entitled to orphan exclusivity, meaning that the applicable regulatory authority may not approve any other applications to market the same drug for the same indication, except in very limited circumstances, for a period of seven years in the U.S. Orphan drug designation does not prevent competitors from developing or marketing different drugs for the same indication or the same drug for different indications. After orphan drug designation is granted, the identity of the therapeutic agent and its potential orphan use are publicly disclosed. Orphan drug designation does not convey an advantage in, or shorten the duration of, the development, review and approval process. However, this designation provides an exemption from marketing and authorization fees.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Drugs manufactured or distributed pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, reporting of adverse experiences with the product, and complying with promotion and advertising requirements. The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-market testing, including phase IV clinical trials, and surveillance to further assess and monitor the product’s safety and effectiveness after commercialization. In addition, drug manufacturers and their subcontractors involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including current Good Manufacturing Practices, which impose certain procedural and documentation requirements. Failure to comply with statutory and regulatory requirements may subject a manufacturer to legal or regulatory action, such as warning letters, suspension of manufacturing, product seizures, injunctions, civil penalties or criminal prosecution. There is also a continuing, annual prescription drug product program user fee.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 27 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, requirements for post-market studies or clinical trials to assess new safety risks, or imposition of distribution or other restrictions under a risk evaluation and mitigation strategy.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Controlled Substances</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The CSA and its implementing regulations establish a “closed system” of regulations for controlled substances. The CSA imposes registration, security, recordkeeping and reporting, storage, manufacturing, distribution, importation and other requirements under the oversight of the DEA. The DEA is responsible for regulating controlled substances, and requires those individuals or entities that manufacture, import, export, distribute, research, or dispense controlled substances to comply with the regulatory requirements in order to prevent the diversion of controlled substances to illicit channels of commerce.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Facilities that manufacture, distribute, import or export any controlled substance must register annually with the DEA. The DEA registration is specific to the particular location, activity(ies) and controlled substance schedule(s). For example, separate registrations are needed for import and manufacturing, and each registration will specify which schedules of controlled substances are authorized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The DEA inspects all manufacturing facilities to review security, recordkeeping, reporting and handling prior to issuing a controlled substance registration. The specific security requirements vary by the type of business activity and the schedule and quantity of controlled substances handled. The most stringent requirements apply to manufacturers of Schedule I and Schedule II substances. Required security measures commonly include background checks on employees and physical control of controlled substances through storage in approved vaults, safes and cages, and through use of alarm systems and surveillance cameras. Once registered, manufacturing facilities must maintain records documenting the manufacture, receipt and distribution of all controlled substances. Manufacturers must submit periodic reports to the DEA of the distribution of Schedule I and II controlled substances, Schedule III narcotic substances, and other designated substances. Registrants must also report any controlled substance thefts or significant losses, and must obtain authorization to destroy or dispose of controlled substances. Imports of Schedule I and II controlled substances for commercial purposes are generally restricted to substances not already available from a domestic supplier or where there is not adequate competition among domestic suppliers. In addition to an importer or exporter registration, importers and exporters must obtain a permit for every import or export of a Schedule I and II substance or Schedule III, IV and V narcotic, and submit import or export declarations for Schedule III, IV and V non-narcotics.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For drugs manufactured in the United States, the DEA establishes annually an aggregate quota for the number of substances within Schedules I and II that may be manufactured or produced in the United States based on the DEA’s estimate of the quantity needed to meet legitimate medical, scientific, research and industrial needs. The quotas apply equally to the manufacturing of the active pharmaceutical ingredient and production of dosage forms. The DEA may adjust aggregate production quotas a few times per year, and individual manufacturing or procurement quotas from time to time during the year, although the DEA has substantial discretion in whether or not to make such adjustments for individual companies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Individual U.S. states also establish and maintain separate controlled substance laws and regulations, including licensing, recordkeeping, security, distribution, and dispensing requirements. State authorities, including boards of pharmacy, regulate use of controlled substances in each state. Failure to maintain compliance with applicable requirements, particularly as manifested in the loss or diversion of controlled substances, can result in enforcement action that could have a material adverse effect on the Company’s business, operations and financial condition. The DEA may seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to revoke those registrations. In certain circumstances, violations could lead to criminal prosecution.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 28 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.15pt; text-indent: -14.6pt"><b>9. Employees</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of August 31, 2023, the Company had 2 employees, our Directors Gabriel Yariv and Eyal Barad, Aside from counsel, all employees reside in Israel.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Israeli labor laws principally govern the length of the workday, minimum wages for employees, procedures for hiring and dismissing employees, determination of severance pay, annual leave, sick days, advance notice of termination of employment, equal opportunity and anti-discrimination laws and other conditions of employment. Subject to certain exceptions, Israeli law generally requires severance pay upon the retirement, death or dismissal of an employee, and requires us and our employees to make payments to the National Insurance Institute, which is similar to the U.S. Social Security Administration. Our employees have defined benefit pension plans that comply with applicable Israeli legal requirements, which also include the mandatory pension payments required by applicable law and allocations for severance pay.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="k2022_003"></span><b>Item 1A. Risk Factors</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Risk Factors</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>You should consider carefully the risks and uncertainties described below, together with all of the other information in this Annual Report on Form 10-K. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. The risks described below are not the only risks facing the Company. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, results of operations and prospects.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Risks Related to Our Company and Business</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Our independent auditors have expressed substantial doubt about our ability to continue operating as a going concern, which could prevent us from obtaining new financing on reasonable terms or at all.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our independent registered public accountants have expressed substantial doubt about our ability to continue as a going concern. This opinion could materially limit our ability to raise additional funds by issuing new debt or equity securities or otherwise. If we fail to raise sufficient capital when needed, we will not be able to complete our proposed business. As a result, we may have to liquidate our business and investors may lose their investments. Our ability to continue as a going concern is dependent upon our ability to successfully accomplish our plan of operations described in this filing, obtain financing and eventually attain profitable operations. Investors should consider our independent registered public accountant’s comments when deciding whether to invest in the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We have not generated any significant revenue since our inception and we may never achieve profitability.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an early-stage biotechnology company and have not generated any significant revenue since we commenced our present operations in April 2014. At the present time, Cannabics SR is the only product that we have commercialized. To date, we have financed our operations primarily through private placements of common stock, warrants, and direct equity investments. As we continue our research and development of cannabinoid-based diagnostics, our expenses are expected to increase significantly. Accordingly, we will need to generate significant revenue to achieve profitability. Even as we begin to commercialize our technologies, we expect our losses to continue as a result of ongoing research and development expenses. These losses, among other things, have had and will continue to have an adverse effect on our working capital, total assets and stockholders’ equity. Because of the numerous risks and uncertainties associated with product development and commercialization efforts, we are unable to predict at what stage the Company will become profitable. We may never become profitable. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we are unable to achieve and then maintain profitability, our business, financial condition and results of operations will be negatively affected, and the market value of our common stock will decline.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 29 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Since we have a limited operating history in our business, it is difficult for potential investors to evaluate our business.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We commenced operations as a biotechnology company in April 2014, and therefore have a relatively short operating history upon which an evaluation of our future success or failure can objectively be made. Our business is a highly speculative undertaking and involves a substantial degree of risk. We have not demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by early-stage companies in new and rapidly evolving competitive fields, including under-capitalization, cash shortages, limitations with respect to personnel, financial, and other resources and lack of revenue. The likelihood of our success must be considered in light of the early stage of our operations. There is no assurance that our business will ever be successful or that we will be able to attain profitability. Any failure by the Company to report profits may adversely affect the price of our common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We will need to raise additional capital to meet our business requirements in the future, which may be costly or difficult to obtain and could dilute our stockholders’ ownership interests.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has not yet generated significant revenue and will require additional capital to continue its research and development activities, conduct clinical trials, commercialize its products and otherwise fund its operations. Our ability to secure required financing will depend in part upon investor perception of our ability to create a successful business. Capital market conditions and other factors beyond our control may also play important roles in our ability to raise capital. There can be no assurance that debt or equity financing will be available or sufficient for our requirements or for other corporate purposes, or if debt or equity financing is available, that it will be on terms acceptable to us. Moreover, future activities may require us to alter our capitalization significantly. Our inability to access sufficient capital for our operations could have a material adverse effect on our financial condition, results of operations and prospects. If we are unable to obtain additional funding as needed, we may be required to reduce the scope of our research and development activities, which could harm our business plan, financial condition and operating results, or we may be required to cease our operations entirely, in which case, our investors will lose all of their investment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any additional capital raised through the sale of equity or equity-backed securities may dilute our stockholders’ ownership percentages and could also result in a decrease in the market value of our equity securities. The terms of any securities issued by us in future capital transactions may be more favorable to new investors, and may include preferences, superior voting rights and the issuance of warrants or other derivative securities, which may have a further dilutive effect on the holders of our securities then outstanding. Any debt financing secured in the future could involve restrictive covenants relating to capital raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we may incur substantial costs in pursuing future capital financing, including investment banking fees, legal fees, accounting fees, securities law compliance fees, printing and distribution expenses and other costs. We may also be required to recognize non-cash expenses in connection with certain securities we issue, such as convertible notes and warrants, which may have an adverse impact on our financial condition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We are highly dependent on the success of cannabinoid technology, and we may not be able to develop the technology, successfully obtain regulatory or marketing approval for, or successfully commercialize, our products or product candidates.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business is focused entirely upon the research, development and commercialization of cannabinoid-based technologies for the detection and treatment of cancer. Our success is dependent upon the viability of this technology and the development of cancer diagnostics and therapies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not received regulatory approval from the FDA to market any diagnostics or therapeutics based on botanical cannabinoids. The FDA has approved Epidiolex (CBD) oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. This is the first FDA-approved drug that contains a purified drug substance derived from cannabis. The FDA has also approved two drugs that contain a synthetic substance that acts similarly to cannabis compounds but is not present in the cannabis plant.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 30 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The scientific evidence underlying the feasibility of developing cannabinoid-based technologies for the detection and treatment of cancer is both preliminary and limited. In 2017, an <i>ad hoc</i> committee of the National Academies of Sciences, Engineering, and Medicine determined that while there is conclusive or substantial evidence that oral cannabinoids are effective antiemetics in the treatment of chemotherapy-induced nausea and vomiting, there was insufficient evidence to make any statement about the efficacy of cannabinoids as a treatment for cancer. The <i>ad hoc</i> committee went on to state that further clinical research into the anti-cancer effects of cannabinoids needs to be conducted.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If our cannabinoid technology is found to be ineffective or unsafe in humans, or if it never receives regulatory approval for commercialization, we may never be able bring our product candidates to market and may never become profitable. Further, our current business strategy, including all of our research and development, is focused on utilizing cannabinoid technology to detect and treat cancer. This lack of diversification increases the risk associated with the ownership of our common stock. If we are unsuccessful in developing and commercializing our cannabinoid-based technology and its application to the detection and treatment of cancer, we may be required to alter our scope and direction and steer away from the intellectual property we have developed as well as the core capabilities of our management team and advisory board. Without successful commercialization of our products and product candidates, we may never become profitable, which would have a material adverse effect on our business, results of operations and financial condition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Our success depends upon our ability to retain our senior management and our ability to attract, retain and motivate other qualified personnel.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an early-stage biotechnology company. As of August 30, 2020, we had five employees and several key consultants. Our success materially depends upon the efforts of our management and other key personnel, including but not limited to Dr Sanja Goldberg, our Chief Technology Officer. If we lose the services of Dr. Goldberg’s or any other executive officers or significant employees, our business would likely be materially and adversely affected. At this time, we do not currently have “key man” life insurance for or any other executive officer.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because of the specialized scientific and managerial nature of our business, we rely heavily on our ability to attract and retain qualified scientific, technical and managerial personnel. The competition for qualified personnel in the biotechnology industry is intense. Due to this intense competition, we may be unable to continue to attract and retain qualified personnel necessary for the development of our business or to recruit suitable replacement personnel. Any difficulties in obtaining and retaining qualified officers, employees and consultants could have a material adverse effect on our operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The relative lack of public company experience by our management team may put us at a competitive disadvantage.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a company with a class of securities registered under the United States Securities Exchange Act of 1934, as amended (the “Exchange Act”), we are subject to reporting and other legal, accounting, corporate governance, and regulatory requirements imposed by the Exchange Act and rules and regulations promulgated under the Exchange Act. With the exception of our CFO, Uri Ben-Or, our management team lacks significant public company experience, which could impair our ability to comply with these legal, accounting, and regulatory requirements. Such responsibilities include complying with securities laws and making required disclosures on a timely basis. Our senior management may not be able to implement and effect programs and policies in an effective and timely manner that adequately respond to such increased legal and regulatory compliance and reporting requirements. Our failure to do so could lead to the imposition of fines and penalties and further result in the deterioration of our business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>If we are unable to enter into acceptable sales, marketing and distribution arrangements with third parties or establish sales, marketing and distribution capabilities, we may not be successful in commercializing any product candidate that we develop if and when a product candidate is approved.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not have any sales, marketing or distribution infrastructure and have no experience in the commercialization of biotechnology. To achieve commercial success for any product, we must develop a sales and marketing organization, outsource these functions to third parties or license our products to others.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States, we intend to only commercialize our products by licensing them to organizations having greater resources and experience than we do. While we have already licensed our Cannabics SR medical cannabis capsules in Colorado to Mountain High Products LLC, and in states outside of Colorado to the Cima Group LLC, there can be no assurance that such licensing efforts will be successful, or that we will be able to license any future products on satisfactory terms, or at all. We do not presently have any other agreement or arrangement for the commercialization of our products in the United States or elsewhere.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 31 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While we generally intend to adopt a licensing model for the commercialization of our products, we may also seek one or more strategic partners for commercialization of our products outside the United States. As a result of entering into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or the profitability of our product revenue may be lower, perhaps substantially lower, than if we were to directly market and sell products in those markets. Furthermore, we may be unsuccessful in entering into the necessary arrangements with third parties or may be unable to do so on terms that are favorable to us. In addition, we may have little or no control over such third parties and any of them may fail to devote the necessary resources and attention to sell and market our product candidates effectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we do not license our products or outsource our commercialization efforts, we will be required to develop our own sales, marketing and distribution capabilities, which will require substantial resources and will be time-consuming, and could delay any product launch. Moreover, we may not be able to hire or retain a sales force that is sufficient in size or has adequate expertise in the consumer health markets that we plan to target. If we are unable to establish or retain a sales force and marketing and distribution capabilities, our operating results may be adversely affected.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we do not successfully license our products or establish sales and marketing capabilities, either on our own or in collaboration with third parties, it is likely that we will be unable to commercialize any of our products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We face intense competition, often from companies with greater resources and experience than we have, which may result in others developing or commercializing competing products before us or more successfully.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The market for cancer diagnostics and therapies is intensely competitive, subject to rapid change and significantly affected by new product introductions and other market activities of industry participants. Our competitors include large multinational corporations and their operating units, including Abbott Laboratories Inc., Cepheid Inc., Philips, GE Healthcare, Siemens, Gen-Probe Incorporated, MDxHealth SA, EpiGenomics AG, Roche Diagnostics, Exact Sciences Corporation, Sequenom, Inc. and several others. We also compete against pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide, as well as smaller and other early-stage companies. Other potential competitors include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many of our competitors and potential competitors have or will have substantially greater financial, technological, managerial and research and development resources and experience than we have, and many have been engaged in the biotechnology industry for a much longer time than we have. Many of our competitors spend significantly more funds on research, development, promotion and sale of new and existing products than we do, and may therefore be able to react more quickly to new or emerging technologies, shifting market conditions and regulatory changes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There can be no assurance that any of our current or future products and technologies will have a competitive advantage in the marketplace, or that they will remain competitive following the introduction of competing products or technologies. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, more convenient or less expensive. There can be no assurance that we will be successful in the face of increasing competition from new technologies or products introduced by existing companies in the industry or by new companies entering the market.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>If we are unable to compete successfully, there may be a material and adverse effect on our business, financial condition and results of operations.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the marketplace does not accept the products in our development pipeline or any other diagnostic products we might develop, we may be unable to generate sufficient revenue to sustain and grow our business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 32 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if we are able to successfully develop and obtain regulatory approval of a product candidate, our ability to generate significant revenue will depend on the acceptance of our products by physicians and patients. Physicians, hospitals, clinical laboratories, researchers or others in the healthcare industry may not use our current or future diagnostic product candidates unless they are determined to be an effective and cost-efficient means of detecting and diagnosing cancer. Market acceptance of our current or future therapeutic products will depend on a number of factors, including the indication statement and warnings approved by regulatory authorities in the product label, continued demonstration of efficacy and safety in commercial use, physicians’ willingness to prescribe the product, reimbursement from third-party payers such as government healthcare systems and insurance companies, the price of the product, the nature of any post-approval risk management plans mandated by regulatory authorities, competition, marketing and distribution support. In addition, we will need to expend a significant amount of resources on marketing and educational efforts to create awareness of our products and to encourage their acceptance and adoption. If the market for our products does not develop sufficiently or the products are not accepted, our revenue potential will be harmed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We are exposed to potential product liability risks that are inherent in the testing, manufacturing and marketing of cancer diagnostics, pharmaceuticals and dietary supplements.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While we do not presently carry any product liability insurance coverage, we intend to obtain such insurance in amounts we believe to be commercially reasonable for our current level of activity and exposure. There is no assurance, however, that we will be able to obtain or maintain insurance coverage that will be adequate to cover our potential liabilities, or that premiums will be commercially justifiable. Furthermore, insurance that might otherwise be readily available, may be more difficult for us to find and more expensive because we work with medicinal cannabis. If we are the subject of a successful product liability claim that exceeds the limits of, or is not otherwise covered by our insurance, or if we incur such liability at a time when we are not able to obtain liability insurance, we may incur substantial charges that adversely affect our earnings and require the commitment of capital resources that might otherwise be available for the development and commercial launch of our product programs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>If we fail to protect our intellectual property rights, our ability to pursue the development of our technologies and products would be negatively affected.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our success will depend in part on our ability to protect our intellectual property. This is done, in part, by obtaining patents and trademarks and then maintaining adequate protection of our technologies, tradenames and products. If we do not adequately protect our intellectual property, competitors may be able to use our technologies to produce and market products in direct competition with us and erode our competitive advantage. Some foreign countries lack rules and methods for defending intellectual property rights and do not protect proprietary rights to the same extent as the United States. Many companies have had difficulty protecting their proprietary rights in these foreign countries. We may not be able to prevent misappropriation of our proprietary rights.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are currently seeking patent protection for several processes and finished products. However, the patent process is subject to numerous risks and uncertainties, and there can be no assurance that we will be successful in protecting our products by obtaining and defending patents. These risks and uncertainties include the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patents that may be issued or licensed may be challenged, invalidated, or circumvented, or otherwise may not provide any competitive advantage;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our competitors, many of which have substantially greater resources than us and many of which have made significant investments in competing technologies, may seek, or may already have obtained, patents that will limit, interfere with, or eliminate our ability to make, use, and sell our products and product candidates either in the United States or in international markets;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">there may be significant pressure on the United States government and other international governmental bodies to limit the scope of patent protection both inside and outside the United States for treatments that prove successful as a matter of public policy regarding worldwide health concerns;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">countries other than the United States may have less restrictive patent laws than those upheld by United States courts, allowing foreign competitors the ability to exploit these laws to create, develop, and market competing products.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 33 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any patents issued to us may not provide us with meaningful protection, and third parties may challenge, circumvent or narrow them. Third parties may also independently develop products similar to our products or product candidates, duplicate our unpatented product or product candidates, and design around any patents on product candidates we may develop.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, extensive time is required for development, testing and regulatory review of product candidates. While extension of a patent term due to regulatory delays may be available, it is possible that before any of our product candidates can be commercialized, any related patent, even with an extension, may expire or remain in force for only a short period following commercialization, thereby reducing any advantages of the patent.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the United States Patent and Trademark Office (the “USPTO”), and patent offices in other jurisdictions have often required that patent applications concerning biotechnology-related inventions be limited or narrowed substantially to cover only the specific innovations exemplified in the patent application, thereby limiting the scope of protection against competitive challenges. Thus, even if we or our licensors are able to obtain patents, the patents may be substantially narrower than anticipated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to patents, we rely on a combination of trade secrets, confidentiality, nondisclosure and other contractual provisions, and security measures to protect our confidential and proprietary information. These measures may not adequately protect our trade secrets or other proprietary information. If they do not adequately protect our rights, third parties could use our technology, and we could lose any competitive advantage we may have. In addition, others may independently develop similar proprietary information or techniques or otherwise gain access to our trade secrets, which could impair any competitive advantage we may have.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Costly litigation may be necessary to protect our intellectual property rights and we may be subject to claims alleging the violation of the intellectual property rights of others.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may face significant expense and liability as a result of litigation or other proceedings relating to patents and other intellectual property rights of others. If another party has also filed a patent application or been issued a patent relating to an invention or technology claimed by us in pending applications, we may be required to participate in an interference proceeding declared by the USPTO to determine priority of invention, which could result in substantial uncertainties and costs, even if the eventual outcome were favorable to us. We could also be required to participate in interference proceedings involving issued patents and pending applications of another entity. An adverse outcome in an interference proceeding could require us to cease using the technology or to license rights from prevailing third parties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The cost to us of any patent litigation or other proceeding relating to our patents or patent applications, even if resolved in our favor, could be substantial. Our ability to enforce our patent protection could be limited by our financial resources, and may be subject to lengthy delays.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A third party might claim that we are using inventions claimed by their patents and might go to court to stop us from engaging in our normal operations and activities, such as research, development and the sale of any future products. Such lawsuits are expensive and would consume time and other resources. There is a risk that the court will decide that we are infringing the third party’s patents and will order us to stop the activities claimed by the patents, redesign our products or processes to avoid infringement or obtain licenses (which may not be available on commercially reasonable terms). In addition, there is a risk that a court will order us to pay the other party damages for having infringed their patents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no guarantee that any prevailing patent owner would offer us a license so that we could continue to engage in activities claimed by the patent, or that such a license, if made available to us, could be acquired on commercially acceptable terms. In addition, third parties may, in the future, assert other intellectual property infringement claims against us with respect to our products, technologies or other matters.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 34 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Failure in our information technology or storage systems could significantly disrupt our operations and our research and development efforts, which could adversely impact our revenues, as well as our research, development and commercialization efforts.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our ability to execute our business strategy depends, in part, on the continued and uninterrupted performance of our information technology (“IT”), systems, which support our operations and our research and development efforts, as well as our storage systems. Due to the sophisticated nature of the technology we use in our products and service offerings, we are substantially dependent on our IT systems. IT systems are vulnerable to damage from a variety of sources, including telecommunications or network failures, malicious human acts and natural disasters. Moreover, despite network security and back-up measures, some of our servers are potentially vulnerable to physical or electronic break-ins, computer viruses and similar disruptive problems. Despite the precautionary measures we have taken to prevent unanticipated problems that could affect our IT systems, sustained or repeated system failures that interrupt our ability to generate and maintain data, could adversely affect our ability to operate our business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We will need to grow the size of our organization, and we may experience difficulties in managing any growth we may achieve.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this filing, we have two full-time employees. As our development and commercialization plans and strategies progress, we expect to need additional research, development, managerial, operational, sales, marketing, financial, accounting, legal and other resources. Future growth would impose significant added responsibilities on our management, which may not be able to accommodate those added responsibilities. If we fail to effectively manage our future growth, it could delay the execution of our business plan and disrupt our operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We are subject to financial reporting and other requirements that place significant demands on our resources.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to reporting and other obligations under the Securities Exchange Act of 1934, as amended, including the requirements of Section 404 of the Sarbanes-Oxley Act of 2002. Section 404 requires us to conduct an annual management assessment of the effectiveness of our internal controls over financial reporting. These reporting and other obligations place significant demands on our management, administrative, operational, internal audit and accounting resources. The costs of preparing and filing annual and quarterly reports, proxy statements and other information with the SEC and furnishing audit reports to stockholders causes our expenses to be higher than they would be if we remained a privately-held company. The increased costs associated with operating as a public company may decrease our net income or increase our net loss, and may cause us to reduce costs in other areas of our business or increase the prices of our product to offset the effect of such increased costs. Additionally, if these requirements divert our management’s attention from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management assessed the effectiveness of the Company’s internal controls over financial reporting as of August 31, 2023, based on the framework in Internal Control—Integrated Framework (COSO 2013) issued by the Committee of Sponsoring Organization of the Treadway Commission. On the basis of that assessment, management determined that our internal controls over financial reporting were effective as of that date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective internal controls are necessary for us to provide reasonable assurance with respect to our financial reports and to effectively prevent fraud. If we cannot provide reasonable assurance with respect to our financial reports and effectively prevent fraud, our reputation and operating results could be harmed. Pursuant to the Sarbanes-Oxley Act of 2002, we are required to furnish a report by management on internal control over financial reporting, including management’s assessment of the effectiveness of such control. Internal control over financial reporting may not prevent or detect misstatements because of its inherent limitations, including the possibility of human error, the circumvention or overriding of controls, or fraud. Therefore, even effective internal controls can provide only reasonable assurance with respect to the preparation and fair presentation of financial statements. In addition, projections of any evaluation of effectiveness of internal control over financial reporting to future periods are subject to the risk that the control may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. If we fail to maintain the adequacy of our internal controls, including any failure to implement required new or improved controls, or if we experience difficulties in their implementation, our business and operating results could be adversely impacted, we could fail to meet our reporting obligations, and our business and stock price could be adversely affected.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 35 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At August 31, 2023, our Chief Executive Officer and Chief Financial Officer evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) and concluded that, subject to the inherent limitations identified in Item 9A of Part II of our Annual Report on Form 10-K for the fiscal year ended August 31, 2023, our disclosure controls and procedures were effective as of that date. Our independent auditors issued an adverse attestation report regarding the effectiveness of our internal control over financial reporting as of August 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since that time, we have implemented a remediation plan to address the previously reported material weakness in internal control over financial reporting, described in Part II, Item 9A, "Controls and Procedures" in our Annual Report on Form 10-K for the fiscal year ended August 31, 2023. Remediation measures include adding additional resources in our finance function, addition of qualified financial professionals and formation of our Audit Committee. The material weakness will not be considered remediated, until the applicable controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively. We expect that the remediation of this material weakness will be completed prior to the end of fiscal year 2022. Notwithstanding the material weakness, we believe the financial statements in this report fairly present, in all material respects, our financial position, results of operations, and cash flows for the periods presented in conformity with U.S. GAAP.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Risks Related to Cannabis</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Our failure to comply with controlled substance legislation could restrict or harm our ability to develop and commercialize our products.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business is, and will be, subject to wide-ranging laws and regulations of Israel, the United States (federal and state), the European Community and other governments in each of the countries where we may develop and market our products. We must comply with all regulatory requirements if we expect to be successful.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Most countries are parties to the Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol, which governs international trade and domestic control of narcotic substances, including cannabis extracts. Countries may interpret and implement their treaty obligations in a way that creates a legal obstacle to us obtaining marketing approval in those countries for any cannabinoid-based products we develop. These countries may not be willing or able to amend or otherwise modify their laws and regulations to permit our products to be marketed, or achieving such amendments to the laws and regulations may take a prolonged period of time. In the case of countries with similar obstacles, we would be unable to market our product candidates in countries in the near future or perhaps at all if the laws and regulations in those countries do not change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any cannabinoid-based product candidate that we may develop for use in the United States, will be subject to U.S. controlled substance laws and regulations that will require us, along with our collaborators and licensees, to expend time, money and effort in all areas of regulatory compliance, including, if applicable, manufacturing, production, quality control and assurance and clinical trials. Any failure to comply with these laws and regulations, or the cost of compliance with these laws and regulations, could adversely affect the results of our business operations and our financial condition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The constant evolution of laws and regulations affecting the research and development of cannabis-based diagnostics and therapies could detrimentally affect our business. Laws and regulations related to the therapeutic uses of cannabis are subject to changing interpretations. These changes may require us to incur substantial costs associated with legal and compliance fees and ultimately require us to alter our business plan. Furthermore, violations or alleged violation of these laws could disrupt our business and result in a material adverse effect on our operations, including our ability to conduct clinical trials that are prerequisite to our ability to commercialize our cannabis-based medical products and therapies. We cannot predict the nature of any future laws, regulations, interpretations or applications of laws and regulations and it is possible that new laws and regulations may be enacted in the future that will be directly applicable to our business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Cannabis remains illegal under U.S. federal law, and any change in the enforcement priorities of the federal government could render our current and planned future operations unprofitable or even prohibit such operations.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a biotechnology company focused on the research and development of cannabinoid-based diagnostics, anti-cancer pharmaceuticals and palliative therapies. The commercial viability of our products and technologies in the United States depends, in part, on state laws and regulations; however, Cannabis remains illegal under US federal law.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 36 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The United States federal government regulates drugs through the Controlled Substances Act of 1970 (the “CSA”), which places controlled substances, including cannabis, on one of five schedules. Cannabis is currently classified as a Schedule I controlled substance, which is viewed as having a high potential for abuse and no currently accepted medical use in treatment in the United States. No prescriptions may be written for Schedule I substances, and such substances are subject to production quotas, security requirements and criteria for importation imposed by the United States Drug Enforcement Administration (the “DEA”). Because of this, doctors may not prescribe cannabis for medical use under federal law, although they can recommend its use under the First Amendment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, thirty-seven U.S. states and the District of Columbia allow the use of medical cannabis. Eighteen states and the District of Columbia also allow its recreational use. Because cannabis is a Schedule I controlled substance, however, the development of a legal cannabis industry under the laws of these states is in conflict with the Federal Controlled Substances Act, which makes cannabis use and possession illegal on a national level. The United States Supreme Court has confirmed that the federal government has the right to regulate and criminalize cannabis, including for medical purposes, and that federal law criminalizing the use of cannabis pre-empts state laws that legalize its use.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2014, the United States House of Representatives passed an amendment (the “Rohrabacher-Farr Amendment”) to the Commerce, Justice, Science, and Related Agencies Appropriations Bill, which funds the United States Department of Justice (the “DOJ”). The Rohrabacher-Farr Amendment prohibits the DOJ from using funds to prevent states with medical cannabis laws from implementing such laws. In August 2016, a Ninth Circuit federal appeals court ruled in <i>United States v. McIntosh</i> that the Rohrabacher-Farr Amendment bars the DOJ from spending funds on the prosecution of conduct that is allowed by state medical cannabis laws, provided that such conduct is in strict compliance with applicable state law. While the Rohrabacher-Farr Amendment has been included as a rider to the Consolidated Appropriations Acts every year since 2014, there can be no assurances that the Rohrabacher-Farr Amendment will be included in future appropriations bills or budget resolutions. The federal government could at any time change its enforcement priorities against the cannabis industry. We do not grow or distribute cannabis, but our current and planned business operations may involve licensing cannabinoid-based products and technology. Any change in enforcement priorities could render such operations unprofitable or even prohibit such operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Our ability to earn revenue through licensing our product in the United States is dependent on additional states legalizing medical marijuana.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are engaged in the business developing and commercializing cannabinoid-based products for the detection and treatment of cancer. Our ability to commercialize our products in the United States is dependent upon the continued progress of legislative authorization of cannabis at the state level for medical purposes and, in certain states, based on the specifics of the legislation passed in that state. Any number of factors could slow or halt the progress. Furthermore, progress, while encouraging, is not assured. The legislative process normally encounters set-backs before achieving success. While there may be ample public support for legislative proposals, there must be political will in the legislative committee or a bill may never advance to a vote. Numerous factors impact the legislative process. Any one of these factors could slow or halt the progress and adoption of cannabis for medical purposes, which would limit the market for our products and negatively impact our business and revenues.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Changes in consumer preferences and acceptance of medical cannabis, or any negative trends, will adversely affect our business.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business is substantially dependent on market acceptance of medical cannabis. Market perception of medical cannabis can be significantly influenced by a number of social, political and economic factors that are beyond our control, including scientific research or findings, regulatory investigations, litigation, media attention and other publicity regarding such products and treatments. There can be no assurance that future scientific research, findings, regulatory proceedings, litigation, media attention or other research findings or publicity will be favorable to the market for any of our current or future cannabinoid-based diagnostics or therapies. Future research reports, findings, regulatory proceedings, litigation, media attention or other publicity that are perceived as less favorable than, or that question, earlier research reports, findings or publicity could have a material adverse effect on the demand for our products, as well as our business, results of operations, financial condition and cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 37 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that as cannabis-based biotechnology becomes more widely accepted by the U.S. medical community and the public at large, the stigma associated with medical cannabis will moderate and, as a result, consumer demand will likely continue to grow. There is, however, no assurance that such increase in demand will occur, that we will benefit from any demand increase or that our business will ever become profitable. We cannot predict the future growth rate and size of the market, assuming that the regulatory climate permits, of which there can be no assurance. Any negative outlook on medical cannabis will adversely affect our business prospects.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also believe that large, well-funded pharmaceutical and other related businesses and industries may have economic reasons to oppose cannabinoid-based therapies. The pharmaceutical industry is well-funded with a strong and experienced lobby presence at both the federal and state levels, as well as internationally, that surpasses financial resources of the current group of medical cannabis research and development companies. Any effort by the pharmaceutical lobby to halt or delay cannabinoid-based medical products and therapies could have a detrimental impact on our business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Risks Related to Product Development</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>If we fail to successfully develop and commercialize diagnostics, pharmaceutical or therapies, we may be unable to execute our plan of operations.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our current business strategy focuses on discovering, developing and commercializing cannabinoid-based diagnostics, anti-cancer pharmaceuticals and palliative therapies. To date, we have only commercialized Cannabics SR, our non-pharmaceutical extended release capsules for palliative therapy. The success of our business will depend upon our ability to fully develop and commercialize the diagnostics and therapeutic product candidates in our current development pipeline as well as to continue the discovery and development of other products and technology.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to commercializing our product candidates, we will be required to undertake time-consuming and costly development activities with uncertain outcomes, including conducting clinical studies and obtaining regulatory clearance or approval in Israel, the United States, the European Union and other countries where we may develop and market our product candidates. Delays in obtaining approvals and clearances could have material adverse effects on us and our ability to fully carry out our plan of operations. We have limited experience in taking products through these processes and there are considerable risks involved in these activities. The science and methods that we are employing are innovative and complex, and it is possible that our development programs will ultimately not yield products suitable for commercialization or government approval. Product candidates that appear promising in early development may fail to be validated in subsequent studies, and even if we achieve positive results, we may still fail to obtain the necessary regulatory clearances or approvals. Few research and development projects result in commercial products, and perceived viability in early clinical studies often is not replicated in later studies. At any point, we may abandon development of a product candidate, or we may be required to expend considerable resources obtaining additional clinical and nonclinical data, which would adversely impact the timing for generating potential revenue from those products. Further, our ability to develop and launch product candidates is dependent on our receipt of substantial additional funding. If our discovery and development programs yield fewer commercial product candidates than we expect, we may be unable to execute our business plan, and our business, financial condition and results of operations may be adversely affected.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we fail to maintain or establish satisfactory arrangements for the supply of raw materials or the manufacture of our product candidates for preclinical or clinical trials, or if we experience an interruption of supply, we might not have sufficient quantities of our product candidates at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not produce medical cannabis, and therefore our ability to research, develop and commercialize our cannabinoid-based diagnostics and therapeutic product candidates is dependent upon a sufficient supply of medical cannabis strains. Any significant interruption or negative change in the availability or economics of the supply chain for medical cannabis could materially impact our business, financial condition and operating results. Some strains of medical cannabis may only be available from a single supplier or a limited group of suppliers. If a sole source supplier were to go out of business, we might be unable to find a replacement source in a timely manner or at all. If a sole source supplier were to be acquired by a competitor, that competitor might elect not to supply us. Any inability to secure required supplies of medical cannabis or to do so on appropriate terms could have a materially adverse impact on our business, financial condition and operating results.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 38 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Our clinical diagnostics may never be validated.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA regulates the sale and distribution, in interstate commerce, of <i>in vitro</i> diagnostic test kits, reagents and instruments used to perform diagnostic testing. To the extent that any diagnostic test we develop is regarded as an <i>in vitro</i> diagnostic test rather than as a Laboratory Developed Test (“LDT”), we will be subject to increased FDA regulation that will delay and add to the cost of commercialization of our diagnostic product candidates, which will have a material adverse effect on our business, results of operations and financial condition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are also subject to the United States Clinical Laboratory Improvement Amendments of 1988 (“CLIA”), federal regulatory standards that apply to all clinical laboratories that perform testing on specimens derived from humans in the United States for the purpose of providing information for the diagnosis, prevention or treatment of disease. CLIA is intended to ensure the quality and reliability of clinical laboratories in the United States by mandating specific standards in the areas of personnel qualifications, administration, and participation in proficiency testing, patient test management, quality control, quality assurance and inspections. Accreditation by the College of American Pathologists (“CAP”), one of six CLIA-approved accreditation organizations, is sufficient to satisfy the requirements of CLIA.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The validation for CLIA or CAP is a two-step process. The first step is optimization of all of the steps of the test protocol to show that the test is able to produce repeatable and consistent results. The second step is the clinical validation, in which statistically significant sensitivity and specificity of the test on the appropriate human samples are determined. Overall, the purpose of the validation process is to determine the accuracy, precision, sensitivity and specificity of the test. The time and cost to complete the validation process can vary widely, and it is possible that we would be unable to complete the validation process along the timeline and within the budget as planned.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this filing, our clinical diagnostics have not yet been validated for commercialization in a CLIA or CAP laboratory, and we have not yet begun the validation process. We may be unable to enter into an agreement with a CLIA or CAP laboratory on favorable terms, or at all. Although we may be able to validate the tests, they might have sensitivity and specificity that is insufficient to bring the product to market. Any delays or incurrence of greater costs than budgeted in validating these tests may have a material adverse effect on our business, results of operations and financial condition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The Federal Food and Drug Administration may impose additional regulatory obligations and costs upon the development of our diagnostics.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 3, 2014, the FDA issued draft guidance regarding oversight of LDTs, titled “Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs).” According to this guidance, the FDA plans to take a phased-in risk-based approach to regulating LDTs. The FDA plans to phase in enforcement of LTD premarket review, quality system oversight and adverse event reporting over a number of years. The FDA would require that laboratories providing LDTs, subject to certain limited exemptions, within six months after the guidance documents are finalized to comply with (i) either a new notification procedure in which the laboratory must provide the FDA with certain basic information about each LDT offered by their laboratory or the FDA’s device registration and listing requirements, and (ii) the medical device reporting, or MDR, requirements for LDTs offered by that laboratory. Under this new risk-based approach, it is possible that some level of pre-market review may be required for our LDTs, which may require us to obtain additional clinical data.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA draft guidance was subject to public comment until February 2, 2015. On January 13, 2017, the FDA issued a discussion paper on LDTs that does not represent the formal position of FDA and is not enforceable, but is intended to advance public discussion on future LDT oversight. At the present time, we cannot assess what the additional costs and regulatory burdens of any FDA final guidance or FDA enforcement will be, or the impact it may have on our business and operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the FDA requires us to seek clearance or approval for any of our diagnostic products (as opposed to simply licensing our technology to a CLIA lab), we may not be able to obtain such approvals on a timely basis, or at all. The cost of conducting clinical trials and otherwise developing data and information to support any applications may be significant. Failure to comply with applicable regulatory requirements of the FDA could result in enforcement action, including receiving untitled or warning letters, fines, injunctions, or civil or criminal penalties. In addition, we could be subject to a recall or seizure of products, operating restrictions, partial suspension or total shutdown of production. Any such enforcement action would have a material adverse effect on our business, financial condition and operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 39 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Changes in laws and regulations concerning clinical diagnostic tests may adversely affect our business, financial condition and results of operations.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The clinical laboratory testing industry is highly regulated, and failure to comply with applicable regulatory, supervisory or licensing requirements may adversely affect our business, financial condition and results of operations. In particular, the laws and regulations governing the marketing and research of clinical diagnostic testing are extremely complex and in many instances there are no clear regulatory or judicial interpretations of these laws and regulations, which increase the risk that we may be found to be in violation of these laws.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> The regulatory environment in which we operate may change significantly and adversely in the future. The molecular diagnostics industry as a whole is a growing industry and regulatory agencies such as the FDA may also apply heightened scrutiny to new developments in the field of molecular diagnostics. Should we be deemed to not be in compliance with regulatory requirements or any changes thereto, we may be subject to sanctions which could include required changes to our operations, adverse publicity, substantial financial penalties and criminal proceedings. Any change in the laws and the regulations relating to our business, whether in the form of new or amended laws or regulations or regulatory policies, or the application of any of the above, may adversely affect our business, financial condition and results of operations by increasing our costs to comply with the new laws or constraining our ability to develop, market and commercialize our diagnostic tests.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For example, a development affecting our industry is the increased enforcement of the federal False Claims Act and, in particular, actions brought pursuant to the False Claims Act's "whistleblower" or " <i>qui tam</i> " provisions. The False Claims Act imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal governmental payer program. The <i>qui tam</i> provisions of the False Claims Act allow a private individual to bring civil actions on behalf of the federal government for violations of the False Claims Act and permit such individuals to share in any amounts paid by the defendant to the government in fines or settlement. When an entity is determined to have violated the False Claims Act, it is subject to mandatory damages of three times the actual damages sustained by the government, plus mandatory civil penalties ranging from $5,500 to $11,000 for each false claim. In addition, various states have enacted false claim laws analogous to the federal False Claims Act, and in some cases go even further because many of these state laws apply where a claim is submitted to any third-party payer and not merely a governmental payer program.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, there has been a recent trend of increased U.S. federal and state regulation of payments made to physicians, which are governed by laws and regulations including the Stark Law. Among other requirements, the Stark Law requires laboratories to track, and places a cap on, non-monetary compensation provided to referring physicians. While we have a compliance plan to address compliance with applicable fraud and abuse laws and regulations, the evolving commercial compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and reporting requirements increases the possibility that we could violate one or more of these requirements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of our diagnostics and therapeutic product candidates are in clinical and preclinical development, the validation of which may not be successful and may be subject to delays, which would have a material adverse effect on our business, results of operation and financial condition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, we have devoted our resources towards developing the technology upon which we are building our clinical diagnostics and therapeutic product candidates. Our clinical diagnostic product candidates have yet to be validated and our clinical therapeutic product candidates are currently in a preclinical development phase. As of the date of this filing, only Cannabics SR, our non-pharmaceutical palliative therapy, has been commercialized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may be unable to successfully complete the clinical validation process for our diagnostic product candidates due to several factors, including our ability to acquire enough samples for full validation and the procurement of materials necessary to conduct testing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may not be able to successfully complete the preclinical testing necessary to advance our therapeutic product candidates into clinical development, including animal pharmacology and toxicity studies. The results of any preclinical work may indicate that our therapeutic product candidates do not have the safety or efficacy necessary to file an Investigational New Drug (“IND”) with the FDA in order to move our product on to the clinical development process.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 40 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Once we initiate the clinical development of our product candidates, it may be difficult to identify and qualify patients to participate in future clinical trials for our product candidates, and the timing of our clinical trials depends on the speed at which we can recruit patients to participate in testing as well as completion of required follow-up periods. If patients are unwilling to participate in our clinical trials due to concerns over the safety of the product candidate or for other reasons, the timeline for conducting the trials and obtaining regulatory approval may be delayed. Furthermore, we may also compete for patients with other companies conducting similar clinical trials. Any delays in our future clinical trials could result in increased costs, delays in product development or termination of the clinical trials altogether.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any of these events could have a material adverse effect on our business, results of operations and financial condition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We may fail to demonstrate the safety and efficacy of our therapeutic product candidates in accordance with regulatory standards and may incur delays and substantial costs in our clinical trials.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to commercialize our therapeutic product candidates, we must conduct extensive clinical trials demonstrating the safety and efficacy of our product candidates in humans. The clinical testing process is expensive, difficult to design and implement, takes many years to complete and is unpredictable in both its duration and outcome. A failure of one or more clinical trials can occur at any stage of testing. There is a high failure rate for drugs and biological products proceeding through clinical trials. The research, testing, manufacturing, labeling, packaging, storage, approval, sale, marketing, advertising and promotion, pricing, export, import and distribution of drug products are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, which regulations differ from country to country. We are not permitted to market our therapeutic product candidates as a prescription pharmaceutical product in the United States until we receive approval of a New Drug Application (“NDA”), from the FDA, or in any foreign countries until we receive the requisite approval from such countries. In the United States, the FDA generally requires the completion of pre-clinical testing and clinical trials of each drug to establish its safety and efficacy and extensive pharmaceutical development to ensure its quality before an NDA is approved. Regulatory authorities in other jurisdictions impose similar requirements. Of the large number of drugs in development, only a small percentage result in the submission of an NDA to the FDA and even fewer are eventually approved for commercialization. We have not submitted an NDA to the FDA or comparable applications to other regulatory authorities. Preclinical and clinical data is often susceptible to varying interpretations and types of analyses and regulatory authorities may fail to approve our product. In addition, even if we successfully complete early clinical trials, such results may not be indicative of the success or results of our later clinical trials.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our successful completion of clinical trials may be materially adversely affected by many factors, including:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ineffective trial design and disagreement with the FDA on final trial design;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition of a clinical hold following an inspection of our clinical trial operations by the FDA or other regulatory authorities;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties or delays in reaching an agreement with a contract research organization, and clinical trial sites;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in obtaining required institutional review board approval for each trial site;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">data collected from clinical trials may not be sufficient to support the submission of a NDA or other submission or to obtain regulatory approval in the United States or elsewhere;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays or difficulties in recruiting suitable patients to participate in clinical trials;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in manufacturing or delivering products and materials to clinical trial sites;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 41 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays or difficulties caused by lack of patient adherence to treatment or post-treatment follow-up;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays caused by patients dropping out of a trial and the need for recruiting additional patients; and</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays caused by clinical sites dropping out of the trial and the time required to recruit a new site.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any of these delays or difficulties could cause us to be delayed in obtaining marketing approval from regulatory authorities, if at all, or allow us to obtain approval for specific indications or patient populations that are not as broad as currently targeted. In addition, such delays or difficulties may cause our development costs or our time to bring our product candidates to market to increase, may weaken our competitive positioning in the market and may have a material adverse effect on our business, results of operations and financial condition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We cannot predict if or when we will receive regulatory approval to commercialize a therapeutic product candidate.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot commercialize a therapeutic product candidate until the appropriate regulatory authorities, such as the FDA or a state regulating authority, have reviewed and approved the product candidate. Even if our therapeutic product candidates demonstrate safety and efficacy in clinical trials, regulatory agencies may not complete their review processes in a timely manner, and we may not be able to obtain timely regulatory approval. We may never be able to receive regulatory approval for our therapeutic product candidates at all. Additional delays may result if an FDA advisory committee or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical trials and the review process. Regulatory agencies may also approve a product candidate for fewer or more limited indications than requested or may grant approval subject to the performance of post-marketing studies. In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates. Delays or failure to obtain necessary regulatory approvals could have a material adverse effect on our business, results of operations and financial condition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Even if we obtain regulatory approval for a therapeutic product candidate, we will remain subject to extensive regulatory scrutiny.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if we obtain regulatory approval in the United States for our therapeutic product candidates, the FDA and other appropriate regulatory agencies may still impose significant restrictions or delays, including restriction of patient population or indications or additional costly studies. Any changes to the approved product or its labeling or manufacturing process would require FDA approval. Any advertisements or promotions must comply with FDA regulations and are subject to FDA review as well as state and federal laws. Drug product manufacturers are subject to continual review and inspection by the FDA and other regulatory authorities to comply with Current Good Manufacturing Practice standards. If the FDA or other regulatory authority finds previously undiscovered compliance issues with products, such as unanticipated adverse effects or issues with the manufacturing facility, the FDA or other regulatory authority may:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue a warning letter asserting that we are in violation of law;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek an injunction;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impose civil or criminal penalties or monetary fines;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend or withdraw regulatory approval;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend currently ongoing clinical trials;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse any pending applications;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 42 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seize product; or</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prohibit us from entering into beneficial or necessary contracts such as supply or government contracts.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any government investigation of alleged violations of law could require us to expend significant time and resources in response, could result in litigation and litigation-related expense and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our therapeutic product candidates and generate revenue, which would have a material adverse effect on our business, results of operations and financial condition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, even if we obtain regulatory approvals, the timing or scope of any approvals may prohibit or reduce our ability to commercialize our therapeutic product candidates successfully. For example, if the approval process takes too long, we may miss market opportunities and give other companies the ability to develop competing products or establish market dominance. Any regulatory approval that we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render our products not commercially viable. For example, regulatory authorities may approve our therapeutic product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our therapeutic product candidates, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve our therapeutic product candidates with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that indication. Further, the FDA may place conditions on approvals including potential requirements or risk management plans and the requirement for a Risk Evaluation and Mitigation Strategy (“REMS”) to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS; the FDA will not approve the NDA without an approved REMS, if required. A REMS could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of our therapeutic product candidates. Moreover, product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following the initial marketing of the product. Any of the foregoing scenarios could materially harm the commercial success of our product candidates and have a material adverse effect on our business, results of operations and financial condition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We may fail to obtain orphan drug status for our therapeutic product candidates.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to seek orphan drug status from the FDA for those anti-cancer therapeutic product candidates we are presently developing to the extent such product candidates are eligible for orphan drug status under the Orphan Drug Act of 1983. The orphan drug status gives the manufacturer specific financial incentives to develop a pharmacological agent. If a product that has an orphan drug designation receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same medication for the same indication, except in very limited circumstances, for seven years. Failure to obtain an orphan drug designation for our product candidates may have a material adverse effect on our business, results of operations and financial condition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Any of our therapeutic product candidates may cause adverse effects or have properties that could delay or prevent their regulatory approval or limit the scope of any specific indications or market acceptance.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adverse events caused by our therapeutic product candidates could cause interruptions, delays or the halting of our clinical trials. If adverse effects are observed in any clinical trials for our therapeutic product candidates, we may be unable to obtain timely, or any, regulatory approval of our therapeutic product candidates. Adverse effects caused by our therapeutic product candidates could also subject us to litigation and liability, which could have a material adverse effect on our business, results of operations and financial condition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, if any of our therapeutic product candidates are approved for commercialization and are found to cause serious or unpredicted side effects, serious consequences may result, including but not limited to, the withdrawal of marketing approval by regulatory authorities, restrictions on distribution by regulatory authorities, the need to conduct additional clinical trials, litigation and potential liability for personal injury to patients and damage to our reputation. Furthermore, our ability to achieve and maintain profitability may be permanently impaired. Any of these events could have a material adverse effect on our business, results of operations and financial condition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 43 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Our dietary supplements are subject to government regulation, both in the United States and internationally, which could increase our costs significantly and limit or prevent the sale of our dietary supplements.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The manufacture, packaging, labeling, advertising, promotion, distribution and sale of Cannabics SR, and any other dietary supplements that we may develop and commercialize, is subject to regulation by numerous national and local governmental agencies in the United States and other countries, including the FDA and Federal Trade Commission in the United States, and the Ministry of Health in Israel. Failure to comply with these regulatory requirements may result in various types of penalties or fines. These include injunctions, product withdrawals, recalls, product seizures, fines and criminal prosecutions. Individual states also regulate dietary supplements. A U.S. state may interpret claims or products presumptively valid under federal law as illegal under that state’s regulations. In markets outside the United States, we will likely be required to obtain approvals, licenses, or certifications from a country’s ministry of health or comparable agency, as well as labeling and packaging regulations, all of which vary from country to country. Approvals or licensing may be conditioned on reformulation of products or may be unavailable with respect to certain products or product ingredients. Any of these government agencies, as well as legislative bodies, can change existing regulations, or impose new ones, or could take aggressive measures, causing or contributing to a variety of negative consequences, including:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements for the reformulation of certain or all products to meet new standards;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the recall or discontinuance of certain or all products;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional record keeping;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expanded documentation of the properties of certain or all products;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expanded or different labeling;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse event tracking and reporting; and</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional scientific substantiation.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any or all of these requirements could have a material adverse effect on us. There can be no assurance that the regulatory environment in which we operate will not change or that such regulatory environment, or any specific action taken against us, will not result in a material adverse effect on us.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Changes in legislation or regulation in the health care systems in the United States and foreign jurisdictions may affect us.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our ability to successfully commercialize our cannabinoid-based products may depend on how the healthcare systems of the United States, the European Union and other governments provide coverage or reimbursement. Reimbursement and healthcare payment systems in international markets vary significantly by country, and include both government sponsored healthcare and private insurance. To obtain reimbursement or pricing approval in some countries, we may be required to produce clinical data, which may involve one or more clinical trials, that compares the cost-effectiveness of our products to other available therapies. We may not obtain international reimbursement or pricing approvals in a timely manner, if at all. Our failure to receive international reimbursement or pricing approvals would negatively impact market acceptance of our products in the international markets in which those approvals are sought.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that future reimbursement may be subject to increased restrictions in the United States, the European Union and in other international markets. There is increasing pressure by governments worldwide to contain health care costs by limiting both the coverage and the level of reimbursement for therapeutic products and by refusing, in some cases, to provide any coverage for products that have not been approved by the relevant regulatory agency. Future legislation, regulation or reimbursement policies of third-party payers may adversely affect the demand for our product candidates currently under development and limit our ability to sell our product candidates on a profitable basis. In addition, third party payers continually attempt to contain or reduce the costs of healthcare by challenging the prices charged for healthcare products and services. If reimbursement for our products is unavailable or limited in scope or amount or if pricing is set at unsatisfactory levels, market acceptance of our products candidates will be impaired and future revenues, if any, will be adversely affected.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 44 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Risks Related to Our Dependence on Third Parties</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We rely and expect to continue to rely heavily on third parties to conduct our preclinical studies and clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such studies and trials.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not have in-house research facilities and, as a consequence, we must currently rely on third parties to conduct our clinical trials. We expect to continue to rely heavily on third parties, such as contract research organizations, clinical data management organizations, medical institutions, clinical investigators and others to conduct our clinical trials. Our agreements with these third parties generally allow the third party to terminate our agreement with them at any time. If we are required to enter into alternative arrangements because of any such termination, the introduction of our product candidates to market could be delayed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our reliance on third parties for research and development will reduce our control over such activities but will not relieve us of our responsibilities. Likewise, our reliance on third parties whom we do not control does not relieve us of our responsibility to comply with regulatory requirements to use Current Good Clinical Practice standards when conducting, recording and reporting the results of clinical trials in order to ensure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We are also required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database of regulatory agencies within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The third parties on whom we rely may also have relationships with other entities, some of whom may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with the requirements of a regulatory agency or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Collaboration agreements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our diagnostics and therapeutic product candidates.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may enter into collaboration agreements with pharmaceutical companies and biotechnology institutions for the development or commercialization of our cannabinoid-based diagnostics and therapeutic product candidates, which agreements may contain provisions based upon, among other things, the merits of retaining certain rights. We will face significant competition in seeking appropriate collaborators and in negotiating agreements at acceptable terms, if at all. We may not be successful in our efforts to enter, implement and maintain collaboration agreements. Disagreements stemming from collaboration agreements concerning development, intellectual property, regulatory or commercialization matters can lead to delays and, in some cases, termination of our collaboration agreements or otherwise result in the potentially significant costs and fees in seeking to enforce or protect our rights, if any. Any such disagreements can be difficult if, in fact, neither of the parties has final decision-making authority. The resulting outcome of any disputes or disagreements would in all likelihood adversely affect our business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Data provided by collaborators and others upon which we rely that has not been independently verified could turn out to be false, misleading, or incomplete.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely on third-party vendors, scientists, and collaborators to provide us with significant data and other information related to our projects, clinical trials, and our business. If such third parties provide inaccurate, misleading, or incomplete data, our business, prospects, and results of operations could be materially adversely affected.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 45 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Our business model is substantially dependent on third party licensees to market and sell our products, which will subject us to a number of risks.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We depend on third party licensees to sell, market, and service our products and current and future products in our intended markets. We are subject to a number of risks associated with reliance upon third party licensees, including:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack of day-to-day control over the activities of licensees;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third party licensees may not commit the necessary resources to market and sell our current and future products to our level of expectations;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third party licensees may terminate their arrangements with us on limited or no notice or may change the terms of these arrangements in a manner unfavorable to us; and</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disagreements with our future licensees could result in costly and time-consuming litigation or arbitration which we could be required to conduct in jurisdictions with which we are not familiar.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we fail to establish and maintain satisfactory relationships with our future third party licensees, our revenue and market share may not grow as anticipated, and we could be subject to unexpected costs which could harm our results of operations and financial condition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Risks Related To Operating In Israel</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Failure to secure the necessary Israeli licenses to use cannabis for medical research could limit our ability to execute our research and development activities, delay the launch of our products and adversely affect the results of our business operations.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, we have only conducted our research in Israel and, in fact, have limited our operations to Israel. The biotechnologies that we are developing contain cannabis, a “controlled substance” as defined in the Israeli Dangerous Drugs Ordinance [New Version], 5733 - 1973. In Israel, licenses to cultivate, possess and to use cannabis for medical research are granted by the Ministry of Health, Israel Medical Cannabis Unit (“IMCU”), on an <i>ad hoc</i> basis. We have obtained all IMCU licenses that are necessary for us to carry out our research. Even though we have an established track record of successfully obtaining the requisite licenses as required, there can be no assurance that we will continue to be able to secure licenses in the future. If we fail to comply with Israeli rules and regulations related to the licensing of cannabis, we may not be able to research and develop our product candidates as we intend or at all.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We may become subject to claims for remuneration or royalties for assigned service invention rights by our employees, which could result in litigation and adversely affect our business.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A significant portion of our intellectual property has been developed by our Israeli employees in the course of their employment for us. Under the Israeli Patent Law, 5727-1967 (the “Israeli Patent Law”), inventions conceived of by an employee during the term and as part of the scope of his or her employment with a company are regarded as “service inventions,” which belong to the employer, absent a specific agreement between the employee and employer giving the employee service invention rights. The Israeli Patent Law also provides that if there is no such agreement between an employer and an employee, the Israeli Compensation and Royalties Committee (the “C&R Committee”), a body constituted under the Israeli Patent Law, shall determine whether the employee is entitled to remuneration for his or her inventions. The C&R Committee (decisions of which have been upheld by the Israeli Supreme Court) has held that employees may be entitled to remuneration for their service inventions despite having specifically waived any such rights. Further, the C&R Committee has not yet set specific guidelines regarding the method for calculating this remuneration or the criteria or circumstances under which an employee’s waiver of his or her right to remuneration will be disregarded. We generally enter into intellectual property assignment agreements with our employees pursuant to which such employees assign to us all rights to any inventions created in the scope of their employment or engagement with us. Although our employees have agreed to assign to us service invention rights and have specifically waived their right to receive any special remuneration for such assignment beyond their regular salary and benefits, we may face claims demanding remuneration in consideration for assigned inventions. As a consequence of such claims, we could be required to pay additional remuneration or royalties to our current or former employees, or be forced to litigate such claims, which could negatively affect our business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 46 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We expect that our results of operations will be subject to fluctuations in currency exchange rates because a substantial portion of our anticipated revenue will be generated in U.S. dollars and Euros while a significant portion of our expenses will be incurred in New Israeli Shekels.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect a substantial portion of our revenue will be generated in U.S. dollars and Euros, while a significant portion of our expenses, principally salaries and related personnel expenses, is paid in New Israeli Shekels, or NIS. As a result, we are exposed to the risk that the rate of inflation in Israel will exceed the rate of devaluation of the NIS in relation to the Euro or the U.S. dollar, or that the timing of this devaluation will lag behind inflation in Israel. Because inflation has the effect of increasing the U.S. dollar and Euro costs of our operations, it would therefore have an adverse effect on our dollar-measured results of operations. The value of the NIS, against the Euro, the U.S. dollar, and other currencies may fluctuate and is affected by, among other things, changes in Israel’s political and economic conditions. Any significant revaluation of the NIS may materially and adversely affect our cash flows, revenues and financial condition. Fluctuations in the NIS exchange rate, or even the appearance of instability in such exchange rate, could adversely affect our ability to operate our business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We may not be able to enforce covenants not-to-compete under current Israeli law.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have non-competition agreements with most of our employees, all of which are governed by Israeli law. These agreements generally prohibit our employees from competing with us or working for our competitors for a specified period following termination of their employment. However, Israeli courts are reluctant to enforce non-compete undertakings of former employees and tend, if at all, to enforce those provisions for relatively brief periods of time in restricted geographical areas and only when the employee has unique value specific to that employer’s business and not just regarding the professional development of the employee. Any such inability to enforce non-compete covenants may cause us to lose any competitive advantage arising from confidential information known to such former employees.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>It may be difficult for investors in the United States to enforce any judgments obtained against us or some of our directors or officers.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">   </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The majority of our assets are located outside the United States. In addition, certain of our officers are nationals or residents of countries other than the United States, and all or a substantial portion of such persons’ assets are located outside the United States. As a result, it may be difficult for investors to enforce within the United States any judgments obtained against us or any of our non-U.S. officers, including judgments predicated upon the civil liability provisions of the securities laws of the United States or any state thereof. It may also be difficult to assert claims under United States securities law in actions originally instituted outside of the United States. Moreover, Israeli courts may refuse to hear a United States securities law claim because Israeli courts may not be the most appropriate forums in which to bring such a claim. Even if an Israeli court agrees to hear a claim, it may determine that Israeli law, and not U.S. law, is applicable to the claim. Further, if U.S. law is found to be applicable, certain content of applicable U.S. law must be proved as a fact, which can be a time-consuming and costly process, and certain matters of procedure would still be governed by Israeli law. Consequently, our investors may be effectively prevented from pursuing remedies under U.S. federal and state securities laws against us or any of our non-U.S. directors or officers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>If there are significant shifts in the political, economic and military conditions in Israel and its neighbors, it could have a material adverse effect on our business relationships and profitability.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of our research facilities and certain of our key personnel are located in Israel. Our business is directly affected by the political, economic and military conditions in Israel and its neighbors. Since the establishment of the State of Israel in 1948, a number of armed conflicts have occurred between Israel and its Arab neighbors. A state of hostility, varying in degree and intensity, has caused security and economic problems in Israel. Although Israel has entered into peace treaties with Egypt and Jordan, and various agreements with the Palestinian Authority, there has been a marked increase in violence, civil unrest and hostility, including armed clashes, between the State of Israel and the Palestinians since September 2000. The establishment in 2006 of a government in the Gaza Strip by representatives of the Hamas militant group has created heightened unrest and uncertainty in the region. In mid-2006, Israel engaged in an armed conflict with Hezbollah, a Shiite Islamist militia group based in Lebanon, and in June 2007, there was an escalation in violence in the Gaza Strip. From December 2008 through January 2009 and again in November and December 2012, Israel engaged in an armed conflict with Hamas, which involved missile strikes against civilian targets in various parts of Israel and negatively affected business conditions in Israel. In July 2014, Israel launched an additional operation against Hamas operatives in the Gaza strip in response to Palestinian groups launching rockets at Israel. Recent political uprisings and social unrest in Syria are affecting its political stability, which has led to the deterioration of the political relationship between Syria and Israel and have raised new concerns regarding security in the region and the potential for armed conflict. Similar civil unrest and political turbulence is currently ongoing in many countries in the region. The continued political instability and hostilities between Israel and its neighbors and any future armed conflict, terrorist activity or political instability in the region could adversely affect our operations in Israel and adversely affect the market price of our shares of common stock. In addition, several countries restrict doing business with Israel and Israeli companies have been and are today subjected to economic boycotts. The interruption or curtailment of trade between Israel and its present trading partners could adversely affect our business, financial condition and results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 47 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Risks Related to Our Stock</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>There can be no assurance of an active, liquid and orderly trading market for our common stock or that investors will be able to sell their shares of common stock.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At present, our common stock is quoted on the OTCQB tier of the marketplace maintained by OTC Markets Group Inc., under the symbol “CNBX.” There is only a limited, liquid public trading market for our common stock. There can be no assurance that a liquid market for our common stock will continue. Market liquidity will depend on the perception of our business and any steps that our management might take to bring public awareness of our business to the investing public within the parameters of the federal securities laws. There is no assurance that any such awareness will be generated or sustained. Therefore, investors may not be able to liquidate their investment or liquidate it at a price paid by investors equal to or greater than their initial investment in our common stock. Moreover, holders of our common stock may not find purchasers for their shares should they to decide to sell the common stock held by them at any particular time if ever. Our common stock should be purchased only by investors who have no immediate need for liquidity in their investment and who can hold our common stock, possibly for a prolonged period of time.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The price of our common stock is volatile, and the value of your investment could decline.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The market price of our common stock has been highly volatile. Between September 1<sup>st</sup>, 2022, and August 31<sup>st</sup>, 2023, the sales price of our stock on the OTCQB ranged from a low of $0.03 per share to a high of $3.96 per share. Accordingly, it is difficult to forecast the future performance of our common stock. The market price of our common stock may be higher or lower than the price you pay, depending on many factors, some of which are beyond our control and may not be related to our operating performance. These fluctuations could cause you to lose all or part of your investment in our common stock. Factors that could cause fluctuations in the trading price of our common stock include the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">technological innovations or new products and services by us or our competitors;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory developments at the federal, state or local level;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions or departures of key personnel;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to execute our business plan;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating results that fall below expectations;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss of any strategic relationship;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">industry developments;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic, political and other external factors; and</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"> </td> <td style="width: 2%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">period-to-period fluctuations in our financial results.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The stock market generally and in particular, the market for stocks of biotechnology companies with lower market capitalizations, like us, have from time to time experienced, and likely will again experience significant price and volume fluctuations that are unrelated to the operating performance of a particular company. The trading price of our common stock might decline in reaction to events that affect other companies in our industry, even if these events do not directly affect us.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 48 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Periods of volatility in the market price of a company’s securities have often been followed by securities class action litigation against that company. If our stock price continues to be volatile, we may become the target of securities litigation, which could result in substantial costs and divert our management’s attention and resources from our business. This could have a material adverse effect on our business, operating results and financial condition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We may never pay any dividends to our shareholders.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently intend to retain any future earnings for use in the operation and expansion of our business. Accordingly, we do not expect to pay any dividends in the foreseeable future, but will review this policy as circumstances dictate. The declaration and payment of all future dividends, if any, will be at the sole discretion of our board of directors, which retains the right to change our dividend policy at any time. Consequently, our stockholders must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any future gains on their investment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of August 31, 2023, Cannabics Inc., a Delaware corporation owns 21.5% of our common stock. Our two Directors are also holders of shares in Cannabics Inc., and therefore have substantial influence over it. Accordingly, the Company (and our management) may be able to control the outcome of stockholder votes, including votes concerning the election of directors, amendment of our organizational documents, approval of mergers, sales of assets and other significant corporate transactions. This concentration of ownership in Cannabics Inc. (and our management) may have the effect of delaying or preventing a change in our management and voting control of Cannabics Inc., including preventing or discouraging unsolicited acquisition proposals or offers for our common stock that some of our stockholders may believe is in their best interest.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We may issue shares of preferred stock with greater rights than our common stock, which may entrench management and result in dilution of our stockholders' investment.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Articles of Incorporation authorize the issuance of up to 100 million shares of preferred stock, par value $0.0001 per share. The authorized but unissued preferred stock may be issued by our board of directors from time to time on any number of occasions, without stockholder approval, as one or more separate series of shares comprised of any number of the authorized but unissued shares of preferred stock, designated by resolution of our board of directors stating the name and number of shares of each series and setting forth separately for such series the relative rights, privileges and preferences thereof, including, if any, the: (i) rate of dividends payable thereon; (ii) price, terms and conditions of redemption; (iii) voluntary and involuntary liquidation preferences; (iv) provisions of a sinking fund for redemption or repurchase; (v) terms of conversion to common stock, including conversion price, and (vi) voting rights. Such preferred stock may enable our board of directors to hinder or discourage any attempt to gain control of the Company by a merger, tender offer at a control premium price, proxy contest or otherwise. Consequently, the preferred stock could entrench our management. The market price of our common stock could be depressed by the existence of the preferred stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Nevada law and certain provisions of our Articles of Incorporation and bylaws may discourage mergers and other transactions.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions of Nevada law, such as its business combination statute, and certain provisions of our Articles of Incorporation and by-laws could make it more difficult for someone to acquire control of the Company and limit the price that certain investors might be willing to pay for shares of our common stock. These provisions may make it more difficult for stockholders to take certain corporate actions and could delay or prevent someone from acquiring our business. The provisions could be beneficial to our management and the board of directors in a hostile tender offer, and could have an adverse impact on stockholders who might want to participate in such tender offer, or who might want to replace some or all of the members of the board of directors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 49 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Our common stock may be subject to penny stock rules, which may make it more difficult for our investors to sell their common stock.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is presently considered to be a "penny stock" and is subject to SEC rules and regulations that impose limitations upon the manner in which such shares may be publicly traded, and regulate broker-dealer practices in connection with transactions in "penny stocks." Penny stocks generally are equity securities with a price of less than $5.00 (other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system). The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document that provides information about penny stocks and the risks in the penny stock market. The broker-dealer must also provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction, and monthly account statements showing the market value of each penny stock held in the customer's account. In addition, the penny stock rules generally require that prior to a transaction in a penny stock, the broker-dealer make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's written agreement to the transaction. These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for a stock that becomes subject to the penny stock rules which may increase the difficulty investors may experience in attempting to liquidate such securities. These requirements could also hamper our ability to raise funds in the primary market for our shares of common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="k2022_004"></span>Item 1B. Unresolved Staff Comments</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="k2022_005"></span><b>Item 2. Properties</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our executive offices and laboratory are located in Eli Horovitz Street, 12 Rehovot Israel. We lease the property of our laboratory in Rehovot, Israel, the monthly lease is $6,500 per month. Our current lease terminates at the end of February 2024, although we have the option to renew for two additional years, it is more unlikely than likely that we will exercise the two-year option</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As security for its obligation under a property lease agreement, credit cards, the Company’s subsidiary provided a bank guarantee in the amount of $5,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="k2022_006"></span><b>Item 3. Legal Proceedings</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="k2022_007"></span><b>Item 4. Mine Safety Disclosures</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <!-- Field: Page; Sequence: 50 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="k2022_008"></span><b>PART II</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="k2022_009"></span><b>Item 5. Market For Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Market Information.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have one class of securities, Common Voting Equity Shares ("Common Stock"). The holders of our common stock have equal ratable rights to dividends from funds legally available if and when declared by our Board of Directors and are entitled to share pro-rata in all of our available assets for distribution to holders of common stock upon liquidation, dissolution or winding up of our affairs; there are no preemptive, subscription or conversion rights and there are no redemption or sinking fund provisions or rights.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is quoted on the OTC Bulletin Board (“OTCQB”) under the symbol "CNBX". As of November 29, 2022, the Company’s common stock was held by 58 shareholders of record, which does not include shares that are held in street or nominee name.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Shareholders</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our shares of common stock are issued in registered form. The registrar and transfer agent for our shares of common stock is ClearTrust LLC, 16540 Pointe Village Dr. Suite 210, Lutz, FL 33558; (813) 235-4490.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 14th, 2023, the shareholders' list of our shares of common stock showed 57 registered holders of our shares of common stock and 28,311,352 shares of common stock outstanding. The number of record holders was determined from the records of our transfer agent and does not include beneficial owners of shares of common stock whose shares are held in the names of various security brokers, dealers, and registered clearing agencies, which as of last quarter was in excess of 35,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Issuer Purchases of Equity Securities</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended August 31, 2023, and August 31, 2022, there were no repurchases of the Company’s common stock by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividend Policy</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors may declare and pay dividends on outstanding shares of common stock out of funds legally available there for in our sole discretion; however, to date no dividends have been declared or paid on common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Indemnification of Directors and Officers</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nevada Corporation Law allows for the indemnification of officers, directors, and any corporate agents in terms sufficiently broad to indemnify such persons under certain circumstances for liabilities, including reimbursement for expenses, incurred arising under the 1933 Act. The Bylaws of the Company provide that the Company will indemnify its directors and officers to the fullest extent authorized or permitted by law and such right to indemnification will continue as to a person who has ceased to be a director or officer of the Company and will inure to the benefit of his or her heirs, executors and Consultants; provided, however, that, except for proceedings to enforce rights to indemnification, the Company will not be obligated to indemnify any director or officer in connection with a proceeding (or part thereof) initiated by such person unless such proceeding (or part thereof) was authorized by the Board of Directors. The right to indemnification conferred will include the right to be paid by the Company the expenses (including attorney’s fees) incurred in defending any such proceeding in advance of its final disposition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 51 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company may, to the extent authorized from time to time by the Board of Directors, provide rights to indemnification and to the advancement of expenses to employees and agents of the Company similar to those conferred to directors and officers of the Company. The rights to indemnification and to the advancement of expenses are subject to the requirements of the 1940 Act to the extent applicable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, the Company may maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of the Company or another company against any expense, liability or loss, whether or not the Company would have the power to indemnify such person against such expense, liability or loss under the Nevada General Corporation Law.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Anti-Takeover Provisions Under the Nevada Revised Statutes</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain provisions of Nevada law, and our Articles of Incorporation and our Bylaws, each as amended and subject, where applicable as described below, our opting out of certain provisions of Nevada law, contain provisions that could make the following transactions more difficult: acquisition of us by means of a tender offer; acquisition of us by means of a proxy contest or otherwise; or removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions that might result in a premium over the market price for our shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.2pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Recent Sales of Unregistered Securities</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Penny Stock Regulation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our shares must comply with the Penny Stock Reform Act of 1990, which may potentially decrease our shareholders’ ability to easily transfer their shares. Broker-dealer practices in connection with transactions in "penny stocks" are regulated. Penny stocks generally are equity securities with a price of less than $5.00. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document that provides information about penny stocks and the risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction, and monthly account statements showing the market value of each penny stock held in the customer's account. In addition, the penny stock rules generally require that prior to a transaction in a penny stock, the broker-dealer make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's written agreement to the transaction. These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for a stock that must comply with the penny stock rules. Since our shares must comply with such penny stock rules, our shareholders will in all likelihood find it more difficult to sell their securities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="k2022_031"></span>Item 6. Selected Financial Data</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 52 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="k2022_010"></span><b>Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THE FOLLOWING DISCUSSION SHOULD BE READ IN CONJUNCTION WITH OUR AUDITED FINANCIAL STATEMENTS AND THE RELATED NOTES THAT APPEAR ELSEWHERE IN THIS ANNUAL REPORT. THE FOLLOWING DISCUSSION CONTAINS FORWARD-LOOKING STATEMENTS THAT REFLECT OUR PLANS, ESTIMATES AND BELIEFS. OUR ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THOSE DISCUSSED IN THE FORWARD-LOOKING STATEMENTS. FACTORS THAT COULD CAUSE OR CONTRIBUTE TO SUCH DIFFERENCES INCLUDE THOSE DISCUSSED BELOW AND ELSEWHERE IN THIS ANNUAL REPORT.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>FORWARD-LOOKING STATEMENTS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain statements made in this report may constitute “forward-looking statements on our current expectations and projections about future events”. These forward-looking statements involve known or unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases you can identify forward-looking statements by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These statements are based on our current beliefs, expectations, and assumptions and are subject to a number of risks and uncertainties. Although we believe that the expectations reflected-in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. These forward-looking statements are made as of the date of this report, and we assume no obligation to update these forward-looking statements whether as a result of new information, future events, or otherwise, other than as required by law. In light of these assumptions, risks, and uncertainties, the forward-looking events discussed in this report might not occur and actual results and events may vary significantly from those discussed in the forward-looking statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <b>Overview</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company was incorporated in the State of Nevada, on September 15, 2004, as Thrust Energy Corp. On May 5, 2011, the Company changed its name to American Mining Company. Our principal offices are in Bethesda, Maryland. On May 21st, 2014 the Company changed its name to its current CNBX Pharmaceuticals Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company was originally engaged in the exploration, development and production of oil and gas projects within North America, but was unable to operate profitably. In May 2011, the Company suspended its oil and gas operations and changed its business to toll milling and refining and mine development. As of April 2014, the Company has changed its course of business to Biotechnology Pharmaceutical development. As such, the Company has divested itself of its former mining properties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Financing</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will require additional financing to implement our business plan, which may include joint venture projects and debt or equity financings. The nature of this enterprise and lack of positive cash flow places debt financing beyond the credit-worthiness required by most banks or typical investors of corporate debt until such time as an economically viable profits and losses can be demonstrated. Therefore any debt financing of our activities may be costly and result in substantial dilution to our stockholders.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Future financing through equity investments is likely to be dilutive to existing stockholders. Also, the terms of securities we may issue in future capital transactions may be more favorable for our new investors. Newly issued securities may include preferences, superior voting rights, and the issuance of warrants or other derivative securities, which may have additional dilutive effects. Further, we may incur substantial costs in pursuing future capital and financing, including investment banking fees, legal fees, accounting fees, and other costs. We may also be required to recognize non-cash expenses in connection with certain securities we may issue, such as convertible notes and warrants, which will adversely impact our financial condition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 53 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our ability to obtain needed financing may be impaired by such factors as the capital markets, both generally and specifically in the bio-pharma industry, and the fact that we have not been profitable to date, which could impact the availability or cost of future financings. If the amount of capital we are able to raise from financing activities, together with our revenue from operations, is not sufficient to satisfy our capital needs, even to the extent that we reduce our operations accordingly, we may be required to cease operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no assurance that we will be able to obtain financing on terms satisfactory to us, or at all. We do not have any arrangements in place for any future financing. If we are unable to secure additional funding, we may cease or suspend operations. We have no plans, arrangements or contingencies in place in the event that we cease operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Results of Operations</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Year ended August 31, 2023 compared to the year ended August 31, 2022</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Revenues</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended August 31, 2023, our total revenues were 410,165, compared to $29,958 for year August 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The company revenues were generated from laboratory services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Operating and Other Expenses</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended August 31, 2023, our total operating expenses were $1,341,545 compared to $2,983,928 for the year ended August 31, 2022. The decrease is attributable mainly to general and administrative of $890,667 and decrease in research and development expenditures of $751,716. The decrease in the general and administrative expenses attributed mainly to Share based payment expenses of $547,800, Insurance of $29,917 and Legal and professional fees of $270,390.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We realized financial loss of $52,623 for year August 31, 2023, compared to financial loss of $769,280 for year August 31, 2022. The decrease in financial expense was mainly attributable to a convertible loan valuation expense of $708,270.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We realized a capital loss of $2,726,231 compared to a capital gain loss of $12,800 for year August 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result, the net loss was $3,710,234 for the year August 31, 2023, compared to a net loss of $3,723,250 for year August 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The net loss for the year ended August 31, 2023, was $3,710,234 compared to net Income of $3,723,250 for the year ended August 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity and Capital Resources</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Overview</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended August 31, 2023, as well as August 31, 2022, we funded our operations through issuance of common stock and advances from our majority shareholder. Our principal use of funds during the year ended August 31, 2023, has been for laboratory and clinical research relating to our proprietary materials normative corporate operating expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt"></p> <!-- Field: Page; Sequence: 54 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Liquidity and Capital Resources during the year ended August 31, 2023 compared to the year ended August 31, 2022</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of August 31, 2023, we had $129,696 cash compared to $117,515 as of August 31, 2022. The Company used cash in operations of $112,521 for the year ended August 31, 2023, compared to cash used in operations of 1,679,192 for the year ended August 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended August 31, 2023, the Company's investing earned totaled $24,702. This compares to net cash flow for investing activities in the year ended August 31, 2022, in the amount of $25,229.  The difference reflects primarily of realized held for trading investments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended August 31, 2023, the company had net cash earned from financing activities of $100,000. This compares to $389,858in the year ended August 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Year ended August 31, 2022 compared to the year ended August 31, 2021</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Revenues</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The revenues for the year ended August 31, 2022, totaled to $29,958 compared to $7,157 for the year ended August 31, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Operating and Other Expenses</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">For the year ended August 31, 2022, our total operating expenses were $2,983,928 compared to $2,600,177 for the year ended August 31, 2021. The increase is attributable mainly to general and administrative of $976,271 and decrease in research and development expenditures of $588,252. The increase in the general and administrative expenses attributed mainly to Share based payment expenses of $695,103, Salary expenses of $236,933, Insurance of $36,045, other expenses of $21,735 and decrease in Legal and professional fees of $43,503.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We realized financial loss of $769,280 for year August 31, 2022, compared to financial loss of $594,270 for year August 31, 2021. The increase in financial expense was mainly attributable to exchange differences in total of$36,586 and a convertible loan valuation expense of $15,374 and decrease in capital gain of $183,168 and other expenses of $59,000. Asa result, the net loss was $3,723,250 for the year August 31, 2022, compared to a net loss of $3,194,447 for year August 31, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The net loss for the year ended August 31, 2022, was $3,723, 250 compared to net Income of $3,194, 447 for the year ended August 31, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Liquidity and Capital Resources during the year ended August 31, 2022 compared to the year ended August 31, 2021</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of August 31, 2022, we had $117,515 in cash compared to $777,611 as of August 31, 2021. The Company used cash in operations of $1,679,192 for the year ended August 31, 2022, compared to cash used in operations of $2,774,954 for the year ended August 31, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended August 31, 2022, the Company's investing earned totaled $25,229. This compares to net cash used for investing activities in the year ended August 31, 2021, in the amount of $3,286,584. The difference reflects primarily of realized held for trading investments and purchase of fixed assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended August 31, 2022, the Company's net cash earned from financing activities of $389,858. This compares non in the year ended August 31, 2021</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 55 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Going Concern</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our independent auditors included an explanatory paragraph in their report on the accompanying consolidated financial statements regarding concerns about our ability to continue as a going concern. Our financial statements contain additional note disclosures describing the circumstances that lead to this disclosure by our independent auditors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our financial statements have been prepared on a going concern basis, which assumes the realization of assets and settlement of liabilities in the normal course of business. Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and/or to obtain the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they become due. The outcome of these matters cannot be predicted with any certainty at this time and raise substantial doubt that we will be able to continue as a going concern. Our financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no assurance that our operations will be profitable. The Company has conducted private placements of its common stock, which have generated funds to satisfy the initial cash requirements of its planned Nevada exploration ventures. Our continued existence and plans for future growth depend on our ability to obtain the additional capital necessary to operate either through the generation of revenue or the issuance of additional debt or equity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Off-Balance Sheet Arrangements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently have no off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="k2022_011"></span>Item 7A. Quantitative and Qualitative Disclosures About Market Risk.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 56; Value: 52 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="k2022_012"></span><b>Item 8. Financial Statements and Supplementary Data.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Index</b></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Page</span></b></span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><a href="#k2022_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report of Independent Registered Public Accounting Firm – Weinstein International CPA</span></a> <span style="color: Black">(PCAOB #<span id="xdx_908_edei--AuditorFirmId_c20220901__20230831_zUXdfL8zl7Bf"><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" name="dei:AuditorFirmId">6629</ix:nonNumeric></span>)</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Financial Statements</span></td> <td> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: top"> <td style="padding-left: 10pt; width: 93%"><a href="#k2022_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets as of August 31, 2023 and 2022</span></a></td> <td style="width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: top"> <td style="padding-left: 10pt"><a href="#k2022_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Operations for the Years Ended August 31, 2023 and 2022</span></a></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: top"> <td style="padding-left: 10pt"><a href="#k2022_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows for the Years Ended August 31, 2023 and 2022</span></a></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: top"> <td style="padding-left: 10pt"><a href="#k2022_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Stockholders' Equity (Deficit) for the Years Ended August 31, 2023 and 2022</span></a></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: top"> <td><a href="#k2022_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Consolidated Financial Statements</span></a></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt"></p> <!-- Field: Page; Sequence: 57 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="image_014.jpg" alt="" style="height: 90px; width: 200px" /></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="k2022_013"></span><b><span style="text-decoration: underline">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Shareholders and the Board of Directors of CNBX Pharmaceuticals Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Opinion on the Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated balance sheets of CNBX Pharmaceuticals Inc. (“the Company”) as of August 31, 2023, and 2022 and the related statements of operations, changes in stockholders' deficit and cash flows, for each of the years ended August 31, 2023 and 2022, and the related notes and schedules (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of August 31, 2023, and 2022, and the results of its operations and its cash flows for each of the periods ended August 31, 2023 and 2022, in conformity with generally accepted accounting principles in the United States of America.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Basis for Opinion</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Going Concern</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have been prepared assuming the Company will continue as a going concern. As more fully described in Note 1, the Company has incurred significant losses and needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 58; Options: NewSection; Value: 1 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Critical Audit Matters</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or are required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Going concern- refer to note 1 of the financial statements </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Critical audit matter description</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company raised a substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time. The financial statements for the years under audit have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. See the explanatory paragraph of the opinion paragraph.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">How the Critical Audit Matter was addressed in the Audit</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="width: 4%; text-align: justify"> </td> <td style="vertical-align: top; width: 4%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="vertical-align: top; width: 92%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We evaluated whether there is substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time.</span></td></tr> <tr> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr> <td style="text-align: justify"> </td> <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We obtained information about management's plans that are intended to mitigate the effect of such conditions or events, and assess the likelihood that such plans can be effectively implemented.</span></td></tr> <tr> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr> <td style="text-align: justify"> </td> <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We added explanatory paragraph to the audit report.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Convertible Loan-refer to note 6 of the financial Statements</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Critical audit matter description</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to raise funds, the company entered into a Securities Purchase Agreement (“SPA”) with an institutional investor for a private placement of senior secured convertible notes totaling up to an aggregate of $2,750,000 in 2020. As of the balance sheet date, the balance of the convertible loan is $1,343,584.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At this time a portion of the loan has been converted to common shares. While the loan is presented on the books as a liability, the company expects that the entire amount will be converted to share capital. If the lender were to request payment in kind the company would possibly not have sufficient to repay the loan, therefore we consider this a critical audit matter.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">How the Critical Audit Matter was addressed in the Audit</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="width: 3%; text-align: justify"> </td> <td style="vertical-align: top; width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="vertical-align: top; width: 94%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We evaluated whether it is reasonable to expect the loan to be converted to share capital or if the company will be required to pay cash</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/<span style="text-decoration: underline">s/ <span id="xdx_906_edei--AuditorName_c20220901__20230831_zXZJSugLNmmk"><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" name="dei:AuditorName">Weinstein International. C.P.A.</ix:nonNumeric></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company's auditor since 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_90B_edei--AuditorLocation_c20220901__20230831_za2Hu9rqMv35"><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" name="dei:AuditorLocation">Tel - Aviv, Israel</ix:nonNumeric></span><br /> November 30, 2023</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <!-- Field: Page; Sequence: 59; Value: 1 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CNBX PHARMACEUTICALS INC.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="k2022_014"></span><b>Audited Consolidated Balance Sheets</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_30C_111_zXzg6caqNXGa" summary="xdx: Statement - Audited Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20230831" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_493_20220831" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">August 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">August 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--AssetsAbstract_iB_zMYsdAxbRI7g" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>ASSETS</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AssetsCurrentAbstract_iB_zZQSkKgYVogb" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Current assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_maCzB0C_zXxz6UUVrBi1" style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left; text-indent: -10pt; padding-left: 20pt">Cash and cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,696</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">117,515</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_maCzB0C_zEev7Fhf8wze" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Prepaid expenses and other receivables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,612</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,772</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AssetsCurrent_iTI_mtCzB0C_maCzFxE_zzYAmmqJlgke" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 30pt">Total current assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">224,308</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">198,287</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--Investments_iI_d0_maCzFxE_zJdJz1NkMq2a" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Available for sale Investment</td><td style="color: red"> </td> <td style="color: red; text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2023-08-31" format="ixt:zerodash" decimals="0" unitRef="USD">–</ix:nonFraction></td><td style="color: red; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">176,087</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_iI_maCzFxE_zPP6hY6XbhWj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Equipment, net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">274,731</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">436,792</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--Assets_iTI_mtCzFxE_zcaHsDElNgh2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">499,039</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">811,166</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zJH9SilWM0yg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">LIABILITIES AND STOCKHOLDERS' EQUITY</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LiabilitiesCurrentAbstract_iB_zMamlf7zG7T8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Current liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_maCzrZN_zPBRUM6JZp47" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Accounts payable and accrued liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">335,915</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">461,128</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ConvertibleDebtCurrent_iI_maCzrZN_zC2qk3qffrv5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Convertible loan</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleDebtCurrent" contextRef="AsOf2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,343,584</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleDebtCurrent" contextRef="AsOf2022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,758,702</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--DueToRelatedParty_iI_maCzrZN_z9tLU3UPKUYa" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Due to a related party</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="CNBX:DueToRelatedParty" contextRef="AsOf2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">836,829</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="CNBX:DueToRelatedParty" contextRef="AsOf2022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">223,645</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LiabilitiesCurrent_iTI_mtCzrZN_maLASEz29v_zDd7jLOHKFU5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 30pt">Total current liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,516,328</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,443,475</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--StockholdersEquityAbstract_iB_z4eNQfpTfiTc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stockholders' equity (deficit):</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--PreferredStockValue_iI_d0_maSEzLO3_zrV4iULjda23" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Preferred stock, $<span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_c20230831_pdd" title="Preferred stock, par value"><span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_c20220831_pdd" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-08-31" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-08-31" decimals="INF" unitRef="USDPShares">.0001</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_c20230831_pdd" title="Preferred stock, shares authorized"><span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_c20220831_pdd" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-08-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-08-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized <span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_do_c20230831_zjVcOHTa5Z4j" title="Preferred stock, shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230831_zZY3QDWhdMbj" title="Preferred stock, shares outstanding"><span id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_do_c20220831_zGLla1tuhsvb" title="Preferred stock, shares issued"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20220831_zzSVApaSOj74" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-08-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-08-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-08-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-08-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-08-31" format="ixt:zerodash" decimals="0" unitRef="USD">–</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-08-31" format="ixt:zerodash" decimals="0" unitRef="USD">–</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--CommonStockValue_iI_pp0p0_maSEzLO3_zHe1yGSn7g7l" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Common stock, $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_c20230831_pdd" title="Common stock, par value"><span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_c20220831_pdd" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-08-31" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-08-31" decimals="INF" unitRef="USDPShares">.0001</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_c20230831_pdd" title="Common stock, shares authorized"><span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_c20220831_pdd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-08-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-08-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">900,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_909_eus-gaap--CommonStockSharesIssued_c20230831_pdd" title="Common stock, shares issued"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_c20230831_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-08-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-08-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,611,352</ix:nonFraction></ix:nonFraction></span></span>and <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_c20220831_pdd" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_c20220831_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-08-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-08-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,238,659</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding at August 31, 2023 and August 31, 2022 respectively.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,261</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">124</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AdditionalPaidInCapital_iI_maSEzLO3_zXfYLjHVDrB" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Additional paid-in capital</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,239,652</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,031,869</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherAdditionalCapital_iI_d0_maSEzLO3_z2SipZzUIL7f" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Issuance of warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAdditionalCapital" contextRef="AsOf2023-08-31" format="ixt:zerodash" decimals="0" unitRef="USD">–</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAdditionalCapital" contextRef="AsOf2022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,459,510</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iI_d0_maSEzLO3_z2JuRiUHHKVd" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Other comprehensive loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2023-08-31" format="ixt:zerodash" decimals="0" unitRef="USD">–</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2022-08-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,574,846</ix:nonFraction></td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_maSEzLO3_zu6XCGCFsTm9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Accumulated deficit</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-08-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,259,202</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-08-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,548,968</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--StockholdersEquity_iTI_pp0p0_mtSEzLO3_maLASEz29v_zVTNNWEPIJS9" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 30pt">Total stockholders' equity (deficit)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,017,289</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,632,311</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtLASEz29v_z3rggys8EFd" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders' equity</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">499,039</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">811,166</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of the financial statements</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p> <!-- Field: Page; Sequence: 60; Value: 1 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CNBX PHARMACEUTICALS INC.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="k2022_015"></span><b>Audited Consolidated Statements of Operations</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_304_113_zbRoLAimDfEi" summary="xdx: Statement - Audited Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-left: 20pt"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20220901_20230831" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20210901_20220831" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the Year Ended August 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_40D_eus-gaap--Revenues_maOILzHn7_z0AQiLssTHSk" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Revenues</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">410,165</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,958</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingExpensesAbstract_iB_zQdSO8iRQYu5" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Operating expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_maOEzkpU_zNoAuMkLMwCh" style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left; text-indent: -10pt; padding-left: 20pt">Research and development expense</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">431,565</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,183,281</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_maOEzkpU_zJlcBmnfkmT" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">General and administrative expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">909,980</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,800,647</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingExpenses_iT_mtOEzkpU_msOILzHn7_zTSjgVPTiuxc" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,341,545</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,983,928</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingIncomeLoss_iT_mtOILzHn7_maNILzPJI_zsqsiuSfm90d" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Loss from operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">931,380</ix:nonFraction></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,953,970</ix:nonFraction></td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--OtherIncomeAbstract_iB_zi1AdQGJetD8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Other income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--CapitalGainLoss_maNILzPJI_z0yTti9vW4l7" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">Capital Gain (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(<ix:nonFraction name="CNBX:CapitalGainLoss" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,726,231</ix:nonFraction></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="CNBX:CapitalGainLoss" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,800</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--FinancialLossNet_maNILzPJI_zwN4bBb8qMBa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 30pt">Financial loss, net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="CNBX:FinancialLossNet" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">52,623</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="CNBX:FinancialLossNet" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">782,080</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--NetIncomeLoss_iT_pp0p0_mtNILzPJI_maCINOTzcAM_z5MPtU1EL7Ek" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 30pt">Net (loss) income</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,710,234</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,723,250</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d0_maCINOTzcAM_zbPTQILpWg6c" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 30pt">(Loss) Profit from available for sale assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="From2022-09-01to2023-08-31" format="ixt:zerodash" decimals="0" unitRef="USD">–</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">669,131</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ComprehensiveIncomeNetOfTax_iT_pp0p0_mtCINOTzcAM_zU90lSH9DL2b" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 30pt">Total comprehensive (loss) income</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,710,234</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">4,392,381</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net (loss) per share - basic and diluted:</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20220901__20230831_ziEzo4BaWmed" title="Net (loss) per share - basic"><span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_c20220901__20230831_z55YdcaoLBv3" title="Net (loss) per share - diluted">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.42</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareBasic_c20210901__20220831_zZ5Kv77oJPJg" title="Net (loss) per share - basic"><span id="xdx_901_eus-gaap--EarningsPerShareDiluted_c20210901__20220831_zM7eJi3evpI2" title="Net (loss) per share - diluted">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">3.59</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Weighted average number of shares outstanding - Basic and Diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220901__20230831_z8ZTdcfq2IZd" title="Weighted average number of shares outstanding - Basic"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220901__20230831_zog2RQVxj7Uf" title="Weighted average number of shares outstanding - Diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,824,636</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20210901__20220831_zPqyPCADGAFg" title="Weighted average number of shares outstanding - Basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20210901__20220831_z3YburKWl152" title="Weighted average number of shares outstanding - Diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,222,641</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* In the year ended August 31, 2022 revenues of $29,958 was presented under General and administrative expenses, was allocated to Revenues under previous year results.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying notes are an integral part of the financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><br /> </p> <!-- Field: Page; Sequence: 61; Value: 1 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CNBX PHARMACEUTICALS INC.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="k2022_016"></span><b>Audited Consolidated Statements of Cash Flows</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" id="xdx_30F_112_zS38dhNo0AZc" summary="xdx: Statement - Audited Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-left: 20pt"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20220901__20230831_zgQYyFvGJSnb" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_493_20210901__20220831_zii0fEHxVFxl" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the year Ended August 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zQOWil8PSN7l" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Cash flows from operating activities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--NetIncomeLoss_maCz1xP_ze885rnmd0Hk" style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left">Net (Loss) Profit</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,710,234</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,723,250</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_iB_zpB1mYr3XUTg" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Adjustments required to reconcile net loss to net cash used in operating activities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--Depreciation_maCz1xP_zYHlx1j3Oc2a" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Depreciation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,061</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">198,527</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ShareBasedCompensation_maCz1xP_zI3LgO1sX3v8" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Share based payment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,480</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">728,869</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--InterestOnConvertibleLoan_maCz1xP_z1VhosMLBS23" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Interest on Convertible loan</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="CNBX:InterestOnConvertibleLoan" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,811</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="CNBX:InterestOnConvertibleLoan" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">722,236</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--CapitalLossGain_iN_di_msCz1xP_zAcBHyXvvwib" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Capital loss (Gain)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="CNBX:CapitalLossGain" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,726,232</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(<ix:nonFraction name="CNBX:CapitalLossGain" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,800</ix:nonFraction></td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInOtherOperatingAssetsAbstract_iB_z84J6MAIujNi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Changes in operating assets and liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInPrepaidExpensesOther_iN_pp0p0_di_msCz1xP_zhkewRDixwO8" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">Accounts Receivable and prepaid expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,840</ix:nonFraction></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">123,603</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_maCz1xP_zyALhQQHYKu2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 30pt">Accounts payable and accrued liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">487,969</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">283,623</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtCz1xP_maCz7Oh_z7YsSqJHRKVk" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 40pt">Net cash used in operating activities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">112,521</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,679,192</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zZTi2Rt8b9a1" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Cash flows from investing activities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ProceedsFromSaleOfPropertyPlantAndEquipment_d0_maNCPBUzYJG_zAaqWfFP6QC7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Sale of equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2022-09-01to2023-08-31" format="ixt:zerodash" decimals="0" unitRef="USD">–</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,885</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ProceedsFromSaleOfEquitySecuritiesFvNi_d0_maNCPBUzYJG_z7PbKzYllMJ8" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Realization of Held for trading investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,702</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi" contextRef="From2021-09-012022-08-31" format="ixt:zerodash" decimals="0" unitRef="USD">–</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--PaymentsToAcquireMachineryAndEquipment_iN_di0_msNCPBUzYJG_zh13GySWAVvf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Acquisition of equipment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireMachineryAndEquipment" contextRef="From2022-09-01to2023-08-31" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">–</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMachineryAndEquipment" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,656</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iT_pp0p0_mtNCPBUzYJG_maCz7Oh_z6cL1rulUvFl" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 30pt">Net cash used in investing activities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,702</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,229</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zd5sRUD3xXMf" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Cash flows from financing activities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ProceedsFromConvertibleDebt_maCztRM_z53rWWUfCct2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Proceeds from issuance of a Convertible loan</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">389,858</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_mtCztRM_maCz7Oh_zdhDk3JLcWUh" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 30pt">Net cash provided by financing activities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">389,858</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_pp0p0_mtCz7Oh_z9OmII36rjwe" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Net increase (decrease) in cash</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,181</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,264,105</ix:nonFraction></td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d0_zV950aBAIgJ6" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Effect of exchange rate fluctuations on cash</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="From2022-09-01to2023-08-31" format="ixt:zerodash" decimals="0" unitRef="USD">–</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,853</ix:nonFraction></td><td style="text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Cash and cash equivalents at beginning of year</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">117,515</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,386,473</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents at end of the year</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">129,696</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">117,515</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zGsub6kaBtOg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Significant non-cash transactions:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--ExerciseOfConvertibleLoanToSharesOfCommonStock._i01_z7MbtxUV2v41" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 20pt">Exercise of a Convertible loan to shares of common stock.</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CNBX:ExerciseOfConvertibleLoanToSharesOfCommonStock." contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">569,930</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CNBX:ExerciseOfConvertibleLoanToSharesOfCommonStock." contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225,286</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of the financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p> <!-- Field: Page; Sequence: 62; Value: 1 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CNBX PHARMACEUTICALS INC.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="k2022_017"></span><b>Audited Consolidated Statements of Stockholders' Equity (Deficit)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_309_114_ztu3WGFd520e" summary="xdx: Statement - Audited Consolidated Statements of Stockholders' Equity (Deficit)" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zMt0rZKSr7f" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zVooVu9rxb74" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zyUertPk125c" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_custom--WarrantsMember_zs1qaTmQYx9" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zv6Ej70952H7" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_4B3_z655c7GqVXx1" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Common stock</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; text-align: center">Additional<br /> paid in</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; text-align: center">Other comprehensive</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; text-align: center">Accumulated</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; text-align: center">Total stockholders’ equity</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Amount</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">capital</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Loss</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Warrants</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">deficit</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">(deficit)</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_43C_c20210901__20220831_eus-gaap--StockholdersEquity_iS_zdHjn8YLsOp4" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 23%; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Balance, August 31, 2021</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_c20210901__20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAUUFXitKzxj" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-08-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,206,230</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-08-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,475</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-08-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,063,363</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,905,715</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-08-31_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,459,510</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-08-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,825,718</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,805,915</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zJcmnhMcpQG5" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Share based Payment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0285">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-09-012022-08-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">728,869</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0287">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0288">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0289">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">728,869</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zvzkb3nfiV2g" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Exercise of a Convertible loan to shares of common stock.</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210901__20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGkA1UXSDGJ6" title="Exercise of a Convertible loan to shares of common stock, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2021-09-012022-08-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,027</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-09-012022-08-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-09-012022-08-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225,284</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0294">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0295">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0296">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225,286</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--PostsplitAdjustment_zgbjzOpqKlg7" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Post-split adjustment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--PostsplitAdjustmentShares_c20210901__20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWszTfNNSY0h" title="Post-split adjustment, shares" style="text-align: right"><ix:nonFraction name="CNBX:PostsplitAdjustmentShares" contextRef="From2021-09-012022-08-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,402</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(<ix:nonFraction name="CNBX:PostsplitAdjustment" contextRef="From2021-09-012022-08-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,353</ix:nonFraction></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="CNBX:PostsplitAdjustment" contextRef="From2021-09-012022-08-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,353</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0303">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0304">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0305">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0306">–</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_zkhLKVPLQZI5" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Other comprehensive loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0310">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0311">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2021-09-012022-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">669,131</ix:nonFraction></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0313">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0314">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">669,131</ix:nonFraction></td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zPIhBhOwEcr5" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Net loss for the year ended August 31, 2022</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0317">–</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0318">–</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0319">–</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0320">–</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-09-012022-08-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,723,250</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,723,250</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_431_c20220901__20230831_eus-gaap--StockholdersEquity_iS_z5djekqBXL94" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Balance, August 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_c20220901__20230831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrksIykIGfCa" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-08-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,238,659</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-08-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">124</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-08-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,031,869</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,574,846</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-08-31_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,459,510</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-08-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,548,968</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-08-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,632,311</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zdOBtCOHGpg9" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Share based Payment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0333">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-09-012023-08-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,480</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0335">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0336">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,480</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zsfO5ztcKwC9" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Exercise of a Convertible loan to shares of common stock.</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220901__20230831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSCUW83V6Sg8" title="Exercise of a Convertible loan to shares of common stock, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2022-09-012023-08-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,372,693</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-09-012023-08-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,137</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-09-012023-08-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">567,793</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0342">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0343">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0344">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">569,930</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--ExpirationOfWarrants_iP3us-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_zvfsrgWxkjY1" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Expiration of warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0349">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="CNBX:ExpirationOfWarrants" contextRef="From2022-09-012023-08-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,459,510</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0351">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(<ix:nonFraction name="CNBX:ExpirationOfWarrants" contextRef="From2022-09-012023-08-31_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,459,510</ix:nonFraction></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0353">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0354">–</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_zgExkFI5uYY7" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Other comprehensive loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0357">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2022-09-012023-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,574,846</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0359">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0360">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,574,846</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLoss_zkqtB20XYJJ1" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Net loss for the year ended August 31, 2023</td><td style="color: red; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; color: red; text-align: left"> </td><td style="color: red; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0363">–</span></td><td style="padding-bottom: 1pt; color: red; text-align: left"> </td><td style="color: red; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0364">–</span></td><td style="padding-bottom: 1pt; color: red; text-align: left"> </td><td style="color: red; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0365">–</span></td><td style="padding-bottom: 1pt; color: red; text-align: left"> </td><td style="color: red; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0366">–</span></td><td style="padding-bottom: 1pt; color: red; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-09-012023-08-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,710,234</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,710,234</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_433_c20220901__20230831_eus-gaap--StockholdersEquity_iE_znnFZAbyytd6" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Balance, August 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_c20220901__20230831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3Hj5xi98z9d" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-08-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,611,352</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-08-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,261</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-08-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,239,652</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0372">–</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0373">–</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-08-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,259,202</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-08-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,017,289</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of the financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <!-- Field: Page; Sequence: 63; Value: 1 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CNBX PHARMACEUTICALS INC.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="k2022_018"></span><b>Notes to Consolidated Financial Statements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>As of August 31, 2023</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b> </b></p> <ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zUgHR0qPoya3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 – <span id="xdx_825_zmPn1m0VPhs2">Nature of Business, Presentation and Going Concern</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Organization</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CNBX Pharmaceuticals Inc. (the "Company"), was incorporated in the State of Nevada, on September 15, 2004, under the name of Thrust Energy Corp. The Company was originally engaged in the exploration, exploitation, development and production of oil and gas projects within North America, but was unable to operate profitably.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2011, the Company changed its name to American Mining Corporation, suspending its oil and gas operations and changing its business to toll milling and refining, mineral exploration and mine development.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 25, 2014, the Company experienced a change in control. Cannabics, Inc. (“Cannabics”) acquired a majority of the issued and outstanding common stock of the Company in accordance with stock purchase agreements by and between Cannabics and Thomas Mills (“Mills”). On the closing date, April 25, 2014, pursuant to the terms of the Stock Purchase Agreement, Cannabics purchased from Mills 41,000,000 shares of the Company’s outstanding restricted common stock for $198,000, representing 51%.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 21, 2014, the Company changed its name, via merger in the state of Nevada, to CNBX Pharmaceuticals Inc. The Company’s principal offices are in Bethesda, Maryland. As of May 21, 2014, the Company has changed its course of business to laboratory research and development.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 25, 2014, the Company organized G.R.I.N. Ultra Ltd. (“GRIN”), an Israeli corporation, as a wholly-owned subsidiary. GRIN will provide research and development activities for the Company’s products in Israel.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock Split</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 3, 2014, the Company’s Board of Directors declared a two-to-one forward stock split of all outstanding shares of common stock. The stock split was approved by FINRA on June 25, 2014. The effect of the stock split increased the number of shares of common stock outstanding from 40,880,203 to 81,760,406. All common share and per common share data in these financial statements and related notes hereto have been retroactively adjusted to account for the effect of the stock split for all periods presented prior to June 3, 2014. The total number of authorized common shares and the par value thereof was not changed by the split. Additionally, on May 12, 2022, the Company effected a reverse-split of its common stock on a 1:120 basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basis of Presentation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the Securities and Exchange Commission (“SEC”). </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Going Concern</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred a net loss of $<span id="xdx_90D_eus-gaap--NetIncomeLoss_iN_di_c20220901__20230831_zoL9JYAMpCB2" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,710,234</ix:nonFraction></span> for the year ended August 31, 2023 and has incurred cumulative losses since inception of $<span id="xdx_904_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20230831_z4qFAplZC3I3" title="Cumulative losses"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-08-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,259,202</ix:nonFraction></span>. These conditions raise substantial doubt about the ability of the Company to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <ix:exclude><p id="xdx_239_z7ZFxSDHsXca" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p></ix:exclude> <ix:exclude><p id="xdx_23B_zdi3cbLvsft8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p></ix:exclude> <ix:exclude><p id="xdx_23A_zenqMKKXvJDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude> <ix:exclude><!-- Field: Page; Sequence: 64; Value: 1 --> <div id="xdx_231_zn60798vxYzk" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div id="xdx_237_zRhwvaGxpE28" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --></ix:exclude> <ix:exclude><p id="xdx_235_zvumzKOEQNSc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p></ix:exclude> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s continuation as a going concern is dependent upon its ability to generate revenues, its ability to continue to raise investment capital, and implementing its business plan. No assurance can be given that the Company will be successful in these efforts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern. No assurance can be given that the Company will be successful in these efforts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> </ix:nonNumeric><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_801_eus-gaap--SignificantAccountingPoliciesTextBlock_zxzFvLnukb3i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2 – <span id="xdx_821_zqZd5fOxFT61">Summary of Significant Accounting Policies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_84F_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zasdwoFqnSzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_862_zHpXURhREUQb">Functional currency</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The currency of the primary economic environment in which the operations of the Company and its Subsidiary are conducted is the U.S. dollar (“$” or “dollar”). Therefore, the functional currency of the Company and its Subsidiary is the dollar.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Transactions and balances denominated in dollars are presented at their original amounts. Non-dollar transactions and balances have been re-measured to dollars in accordance with the provisions of ASC 830-10 (formerly Statement of Financial Accounting Standard 52), "Foreign Currency Translation". All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> </ix:nonNumeric><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_848_eus-gaap--UseOfEstimates_zdGpwSbTPWNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86C_zBdGvHpwOwnc">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates in the accompanying financial statements include the amortization period for intangible assets, impairment valuation of intangible assets, valuation of share-based payments and the valuation allowance on deferred tax assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> </ix:nonNumeric><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zoWydCZHRYT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_863_ze39WOn0Kvtd">Principles of Consolidation</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements include the accounts of Cannabics Pharmaceutical Inc. and its wholly-owned subsidiary, G.R.I.N. Ultra Ltd. All significant inter-company balances and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> </ix:nonNumeric><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zSjJfU0091U1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_866_zV0TnliunyC3">Cash and Cash Equivalents</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. At August 31, 2023 and 2022, cash equivalents consisted of bank accounts held at financial institutions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> </ix:nonNumeric><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zAVF42egYI56" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_z7MsdL5Qgk93">Concentration of Credit Risk</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company places its cash and cash equivalents with high credit quality financial institutions. There is Federal Deposit Insurance on the Company’s U.S. bank accounts for up to $<span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_c20230831_zsXZ4YmmMrXh" title="Federal deposit insurance"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <ix:exclude><p id="xdx_237_zcsNmani5Qve" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p></ix:exclude> <ix:exclude><p id="xdx_23F_zD9YUXIlGbN6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p></ix:exclude> <ix:exclude><p id="xdx_239_zQhTEj3WelMj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude> <ix:exclude><!-- Field: Page; Sequence: 65; Value: 1 --> <div id="xdx_236_zxIOrzpDgVd6" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div id="xdx_236_z0JUaWsnDYB8" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --></ix:exclude> <ix:exclude><p id="xdx_232_zAstGGT3cTHi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p></ix:exclude> </ix:nonNumeric><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zKdVb9dYFvu8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_861_zM3nN5mFmew2">Equipment, net</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equipment at August 31, 2023 consists of computer equipment, office equipment and cars recorded at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation of property and equipment is computed by the straight-line method (after taking into account their respective estimated residual values) over the assets estimated useful lives of 3 years for computer equipment, 14 years for office equipment and 7 years for cars. Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in the consolidated statements of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expense was $<span id="xdx_909_eus-gaap--Depreciation_pp0p0_c20220901__20230831_zxPka4lcudAd" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">162,061</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--Depreciation_pp0p0_c20210901__20220831_zjNy6luMvZag" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">198,527</ix:nonFraction></span> for the years ended August 31, 2023, and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> </ix:nonNumeric><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_84A_eus-gaap--RevenueRecognitionPolicyTextBlock_zH9eTZ69Sl2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_864_zVkMFXRjFV5a">Revenue recognition</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue is recognized when delivery has occurred, evidence of an arrangement exists, title and risks and rewards for the products are transferred to the customer, collection is reasonably assured and product returns can be reliably estimated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue from license agreements is recognized over the periods from which the Company is entitled to the respective payments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> </ix:nonNumeric><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z7cPcYYiIODh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86F_zzQygxnq2Cn4">Impairment or Disposal of Long-Lived Assets</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for the impairment or disposal of long-lived assets according to the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) 360 “Property, Plant and Equipment”. ASC 360 clarifies the accounting for the impairment of long-lived assets and for long-lived assets to be disposed of, including the disposal of business segments and major lines of business. Long-lived assets are reviewed when facts and circumstances indicate that the carrying value of the asset may not be recoverable. When necessary, impaired assets are written down to estimated fair value based on the best information available. Estimated fair value is generally based on either appraised value or measured by discounting estimated future cash flows. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i> </b></p> </ix:nonNumeric><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zLUS1qmp63W4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_zMPjBNjTXWak">Fair Value of Financial Instruments</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following provides an analysis of financial instruments that are measured subsequent to initial recognition at fair value, grouped into Levels 1 to 3 based on the degree to which fair value is observable:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1 - fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical assets or liabilities;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2 - fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 - fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of August 31, 2023 and 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <ix:exclude><p id="xdx_23E_zErjEJeSHsQj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p></ix:exclude> <ix:exclude><p id="xdx_23A_zKUZSP8dbhVg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p></ix:exclude> <ix:exclude><p id="xdx_23B_zyk4hUWlhNSk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude> <ix:exclude><!-- Field: Page; Sequence: 66; Value: 1 --> <div id="xdx_23B_zw2tcC0bJSzd" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div id="xdx_236_zPZfBYSPPbKi" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --></ix:exclude> <ix:exclude><p id="xdx_231_zircqaQWW9G7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p></ix:exclude> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company applied ASC 820 for all non-financial assets and liabilities measured at fair value on a non-recurring basis. The adoption of ASC 820 for non-financial assets and liabilities did not have a significant impact on the Company’s financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of August 31, 2023, the company had <span id="xdx_90C_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_pp0p0_do_c20230831__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zwmD6vnxaVY4" title="Fair value of financial instruments"><ix:nonFraction name="us-gaap:FinancialInstrumentsOwnedAtFairValue" contextRef="AsOf2023-08-31_us-gaap_FairValueInputsLevel1Member" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></span> level 1 fair values financial instruments assets, and had financial instruments liabilities of $<span id="xdx_904_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_pp0p0_c20230831__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zk7UI53qLko4" title="Fair value of financial instruments"><ix:nonFraction name="us-gaap:FinancialInstrumentsOwnedAtFairValue" contextRef="AsOf2023-08-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,343,584</ix:nonFraction></span> at level 3.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of August 31, 2023, the fair values of the Company’s financial instruments approximate their historical carrying amount.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> </ix:nonNumeric><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zd4GJkrTJvI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_867_zfa6qvHm7Nnb">Research and development, net</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, employee benefits, the cost of supplies, the cost of services provided by outside contractors, including services related to the Company’s clinical trials, clinical trial expenses and the full cost of manufacturing product for use in research and preclinical development. All costs associated with research and developments are expensed as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources a substantial portion of its clinical trial activities, utilizing external entities such as Contract Research Organizations, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical studies. For each clinical trial that the Company conducts, clinical trial costs are expensed immediately.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> </ix:nonNumeric><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_845_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zw0IQJyuYpSi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_867_zj8xAVbxwC1g">Stock Based Compensation</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for Stock-Based Compensation under ASC 718 “Compensation – Stock Compensation”, which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 requires measurement of the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees. Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Any stock options or warrants issued to non-employees are recorded in expense and additional paid-in capital in shareholders' deficit over the applicable service periods using variable accounting through the vesting dates based on the fair value of the options or warrants at the end of each period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issues stock to consultants for various services. The costs for these transactions are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The value of the common stock is measured at the earlier of (i) the date at which a firm commitment for performance by the counterparty to earn the equity instruments is reached or (ii) the date at which the counterparty's performance is complete. The Company recognized consulting expense and a corresponding increase to additional paid-in-capital related to stock issued for services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <ix:exclude><p id="xdx_230_zZf63SskKjf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p></ix:exclude> <ix:exclude><p id="xdx_23B_zV8PosS99sAd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p></ix:exclude> <ix:exclude><p id="xdx_23D_z1Bw5dgYOGZ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude> <ix:exclude><!-- Field: Page; Sequence: 67; Value: 1 --> <div id="xdx_233_zKJlaxFl5zOi" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div id="xdx_231_zDEjmlrdb5Ef" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --></ix:exclude> <ix:exclude><p id="xdx_23D_zjuV59AO1Y15" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p></ix:exclude> </ix:nonNumeric><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zUkROnVPmps" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_868_zUXl2xHYlfsf">Income Taxes</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Income taxes are accounted for under the liability method of accounting for income taxes. Under the liability method, future tax liabilities and assets are recognized for the estimated future tax consequences attributable to differences between the amounts reported in the financial statement carrying amounts of assets and liabilities and their respective tax bases. Future tax assets and liabilities are measured using enacted or substantially enacted income tax rates expected to apply when the asset is realized or the liability settled. The effect of a change in income tax rates on future income tax liabilities and assets is recognized in income in the period that the change occurs. Future income tax assets are recognized to the extent that they are considered more likely than not to be realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FASB has issued ASC 740 “Income Taxes”. ASC 740 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. This standard requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the implementation of this standard, the Company performed a review of its material tax positions in accordance with recognition and measurement standards established by ASC 740 and concluded that the tax position of the Company has not met the more-likely-than-not threshold as of August 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> </ix:nonNumeric><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p id="xdx_84F_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zSnHwkCGDCU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_863_zAGkIY4cCnHg">Comprehensive Income</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company adopted ASC 220, <i>Comprehensive Income</i> which establishes standards for reporting and display of comprehensive income, its components and accumulated balances. The Company is disclosing this information on its Statement of Stockholders' Equity. Comprehensive income comprises equity except those resulting from investments by owners and distributions to owners. The Company has no elements of “other comprehensive income” for the years ended August 31, 2023, and 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> </ix:nonNumeric><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_zAoLYEHBGOJf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_860_zwYQG4hFDs02">Basic and Diluted Loss per Share</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company computes income (loss) per share in accordance with ASC 260, “Earnings per Share”, which requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the statement of operations. Basic EPS is computed by dividing income (loss) available to common shareholders by the weighted average number of shares outstanding during the period. Diluted EPS gives effect to all dilutive potential shares of common stock outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. As of August 31, 2023, and 2022, the potentially dilutive shares were anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> </ix:nonNumeric><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_znBnyLGreJAe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_861_zB3T8mebmmhd">Segment Information</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the provisions of ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, the Company is required to report financial and descriptive information about its reportable operating segments. The Company does not consider itself to have any operating segments as of August 31, 2023, and 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> </ix:nonNumeric><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription"><p id="xdx_848_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zVNcwYGTkZXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_864_z3ConaoVnQr4">Reclassification</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <ix:exclude><p id="xdx_23C_zSO9ZSaD7QD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p></ix:exclude> <ix:exclude><p id="xdx_231_zaTQ8p1IwS6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p></ix:exclude> <ix:exclude><p id="xdx_23C_ziqpDkcUWBG8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude> <ix:exclude><!-- Field: Page; Sequence: 68; Value: 1 --> <div id="xdx_236_z6gdVfPge023" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div id="xdx_230_z6CpbwBW8076" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --></ix:exclude> <ix:exclude><p id="xdx_233_ziu1F3f8at2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p></ix:exclude> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> </ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"><p id="xdx_804_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zA1Tut4YNa4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 3 – <span id="xdx_82F_zlOfAqKbIydf">Recent Accounting Pronouncements</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2015, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis”, which provides guidance in evaluating entities for inclusion in consolidations. ASU 2015-02 is effective for fiscal years beginning after December 15, 2015. The Company does not believe the adoption of ASU 2015-02 will have a material effect on its consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-10 (“ASU 2014-10”), <i>Development Stage Entities (Topic 915), Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation.</i> The objective of the amendments in this Update is to improve financial reporting by reducing the cost and complexity associated with incremental reporting requirements for development stage entities. The amendments in this Update also eliminate an exception provided to development stage entities in Topic 810, Consolidation, for determining whether an entity is a variable interest entity on the basis of the amount of investment equity at risk. The amendments related to the elimination of inception-to-date information and the other remaining disclosure requirements of Topic 915 should be applied retrospectively except for the clarification to Topic 275, which shall be applied prospectively. These amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amendment eliminating the exception to the sufficiency-of-equity-at-risk criterion for development stage entities in paragraph 810-10-15-16 should be applied retrospectively for annual reporting periods beginning after December 15, 2015 and interim periods therein. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued. The Company has adopted ASU 2014-10 in the fourth quarter of 2014 and does not expect this adoption to have a material impact on its consolidated financial condition, results of operations or cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2014, the FASB issued ASU No. 2014-15, <i>Presentation of Financial Statements-Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.</i> The objective of the amendments in this Update is to provide guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if “conditions or events raise substantial doubt about the entity’s ability to continue as a going concern.” The ASU applies to all entities and is effective for annual periods ending after December 15, 2017, and interim periods thereafter, with early adoption permitted. The Company is evaluating the impact of ASU 2014-15 on its consolidated financial condition, results of operations and cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2015-16 (ASU 2015-16) "Simplifying the Accounting for Measurement Period Adjustments". ASU 2015-16 require that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The amendments in ASU 2015-16 require that the acquirer record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. The amendments in ASU 2015-16 require an entity to present separately on the face of the income statement or disclose in the notes the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. For public business entities, the amendments in ASU 2015-16 are effective for fiscal years beginning after December 15, 2015, including interim periods within those fiscal years. The amendments in ASU 2015-16 should be applied prospectively to adjustments to provisional amounts that occur after the effective date of this update with earlier application permitted for financial statements that have not been issued. For all other entities, the amendments in ASU 2015-16 are effective for fiscal years beginning after December 15, 2017, and interim periods within fiscal years beginning after December 15, 2017. The amendments in ASU 2015-16 should be applied prospectively to adjustments to provisional amounts that occur after the effective date of this update with earlier application permitted for financial statements that have not yet been made available for issuance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <ix:exclude><p id="xdx_232_z0pJglGqVZ2a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p></ix:exclude> <ix:exclude><p id="xdx_238_z3x116iKD42i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p></ix:exclude> <ix:exclude><p id="xdx_23C_z0uTP1XNSWz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude> <ix:exclude><!-- Field: Page; Sequence: 69; Value: 1 --> <div id="xdx_23A_zceiY70nFYn2" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div id="xdx_231_z8jZFJSGbBo2" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --></ix:exclude> <ix:exclude><p id="xdx_23A_zfhcNTjTTg01" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p></ix:exclude> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p> </ix:nonNumeric><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_801_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zOtjZrQ2oLXb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 4 – <span id="xdx_824_zoQatmsGZYv2">Related Party Transactions</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended August 31, 2023, and August 31, 2022, the Company paid approximately of $<span id="xdx_904_eus-gaap--OfficersCompensation_pp0p0_c20220901__20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndChairmanMember_zzDYIor6CfOk" title="Compensation paid"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2022-09-012023-08-31_custom_CEOAndChairmanMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">79,100</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--OfficersCompensation_pp0p0_c20210901__20220831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndChairmanMember_zQ6ssdpTfoV1" title="Compensation paid"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2021-09-012022-08-31_custom_CEOAndChairmanMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">334,395</ix:nonFraction></span> as compensation to our CEO and chairman.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended August 31, 2023 the Company accrued additional $<span id="xdx_907_eus-gaap--AccruedSalariesCurrentAndNoncurrent_iI_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndChairmanMember_zaFIKrNa7BO1" title="Accrued salaries"><ix:nonFraction name="us-gaap:AccruedSalariesCurrentAndNoncurrent" contextRef="AsOf2023-08-31_custom_CEOAndChairmanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">416,497</ix:nonFraction></span> in salaries, including socials benefits, to our CEO and chairman. compared to $<span id="xdx_90F_eus-gaap--AccruedSalariesCurrentAndNoncurrent_iI_c20220831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndChairmanMember_zCmQNQs4Jvm2" title="Accrued salaries"><ix:nonFraction name="us-gaap:AccruedSalariesCurrentAndNoncurrent" contextRef="AsOf2022-08-31_custom_CEOAndChairmanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">196,687</ix:nonFraction></span> for the year ended August 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of August 31, 2023, the Company had a balance outstanding payable to our CEO and chairman: Gabriel Yariv and Eyal Barad in the total of $<span id="xdx_90B_eus-gaap--NotesPayableCurrent_iI_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndChairmanMember_zqx8rKkos1J4" title="Outstanding payable"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2023-08-31_custom_CEOAndChairmanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">613,184</ix:nonFraction></span> under related parties compared to $<span id="xdx_90B_eus-gaap--NotesPayableCurrent_iI_c20220831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndChairmanMember_zehIJaPykONe" title="Outstanding payable"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2022-08-31_custom_CEOAndChairmanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">196,687</ix:nonFraction></span> for the year ended August 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended August 31, 2023, and August 31, 2022, the Company paid approximately of $<span id="xdx_903_eus-gaap--OfficersCompensation_pp0p0_c20220901__20230831__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_z4WgbAZa4ce6" title="Compensation paid"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2022-09-012023-08-31_srt_ChiefFinancialOfficerMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,321</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--OfficersCompensation_pp0p0_c20210901__20220831__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_z0kMEv2vSnK" title="Compensation paid"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2021-09-012022-08-31_srt_ChiefFinancialOfficerMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">75,318</ix:nonFraction></span> as compensation to our CFO</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended August 31, 2023 the Company accrued $<span id="xdx_904_eus-gaap--AccruedSalariesCurrentAndNoncurrent_iI_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThreeDirectorsMember_zexPZ54imLj4" title="Accrued salaries"><ix:nonFraction name="us-gaap:AccruedSalariesCurrentAndNoncurrent" contextRef="AsOf2023-08-31_custom_ThreeDirectorsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,000</ix:nonFraction></span> in salaries to three directors compared to $<span id="xdx_90F_eus-gaap--AccruedSalariesCurrentAndNoncurrent_iI_c20220831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThreeDirectorsMember_zPxSjVLo2pl4" title="Accrued salaries"><ix:nonFraction name="us-gaap:AccruedSalariesCurrentAndNoncurrent" contextRef="AsOf2022-08-31_custom_ThreeDirectorsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,000</ix:nonFraction></span> for the year ended August 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cannabics Inc. (the parent company) balance as of August 31, 2023, and on August 31, 2022 was $<span id="xdx_90C_ecustom--DueToRelatedPartiesCurrent1_iI_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CannabicsIncMember_zM2GcEfYdVQf" title="Due to related parties"><span id="xdx_905_ecustom--DueToRelatedPartiesCurrent1_iI_c20220831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CannabicsIncMember_zU99ZllDso17" title="Due to related parties"><ix:nonFraction name="CNBX:DueToRelatedPartiesCurrent1" contextRef="AsOf2023-08-31_custom_CannabicsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="CNBX:DueToRelatedPartiesCurrent1" contextRef="AsOf2022-08-31_custom_CannabicsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">223,645</ix:nonFraction></ix:nonFraction></span></span>. The advance is due on demand and bears no interest.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended August 31, 2023, the Company recorded a non cash expense of $<span id="xdx_90E_eus-gaap--OtherNoncashExpense_c20220901__20230831__us-gaap--NonmonetaryTransactionTypeAxis__custom--ShareBasedPaymentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChairmanAndBoardMembersMember_zjr6PraKzgHf" title="Non cash expense"><ix:nonFraction name="us-gaap:OtherNoncashExpense" contextRef="From2022-09-012023-08-31_custom_ShareBasedPaymentMember_custom_ChairmanAndBoardMembersMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,551</ix:nonFraction></span> as share based payment, to the company chairman and board members, compared to $<span id="xdx_905_eus-gaap--OtherNoncashExpense_c20210901__20220831__us-gaap--NonmonetaryTransactionTypeAxis__custom--ShareBasedPaymentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChairmanAndBoardMembersMember_z0LMpBvonJhh" title="Non cash expense"><ix:nonFraction name="us-gaap:OtherNoncashExpense" contextRef="From2021-09-012022-08-31_custom_ShareBasedPaymentMember_custom_ChairmanAndBoardMembersMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">670,850</ix:nonFraction></span> for the year ended August 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> </ix:nonNumeric><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z3kHD7j9uta1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 5 – <span id="xdx_82E_ziZ88Wu6bLQa">Commitments and Contingencies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As security for its obligation under a property lease agreement, cars lease and credit cards of the Company’s subsidiary provided a bank guarantee in the amount of $<span id="xdx_900_eus-gaap--BankAcceptancesExecuted_iI_pp0p0_c20230831_zAvFvkfyLf7c" title="Bank guarantee"><ix:nonFraction name="us-gaap:BankAcceptancesExecuted" contextRef="AsOf2023-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000</ix:nonFraction></span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> </ix:nonNumeric><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z3g3uDVdRAMk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 6 – <span id="xdx_820_zr2rYOmYpUgk">Stockholders’ Equity (Deficit)</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Authorized Shares</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is authorized to issue up to <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20230831_zcSC7Ij68Wig" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-08-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">900,000,000</ix:nonFraction></span> shares of common stock par value $0<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230831_zl4VRxR25Yf2" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-08-31" decimals="INF" unitRef="USDPShares">.0001</ix:nonFraction></span> per share. Each outstanding share of common stock entitles the holder to one vote per share on all matters submitted to a stockholder vote. All shares of common stock are non-assessable and non-cumulative, with no pre-emptive rights. The Company’s initial Articles authorized <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20230831_zQkar9JR7Mnj" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-08-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></span> preferred shares at <span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230831_zXhvGdakyud6" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-08-31" decimals="INF" unitRef="USDPShares">.0001</ix:nonFraction></span> par value, no other attributes have been assigned and no such shares have ever been issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Common Stock</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 12, 2022, the Company effected a reverse-split of its common stock on a <span id="xdx_90B_eus-gaap--StockholdersEquityReverseStockSplit_c20220511__20220512_z14s04EETD9a" title="Stock split"><ix:nonNumeric contextRef="From2022-05-112022-05-12" name="us-gaap:StockholdersEquityReverseStockSplit">1:120</ix:nonNumeric></span> basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended August 31, 2023, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220901__20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z8JPRd14xF85" title="Stock issued for exercise of convertible debt, shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2022-09-012023-08-31_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,372,693</ix:nonFraction></span> shares of its common stock to an investors as a result of a convertible loan exercise in the sum of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pp0p0_c20220901__20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zJHxP2ewukx3" title="Stock issued for exercise of convertible debt, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-09-012023-08-31_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">569,930</ix:nonFraction></span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <ix:exclude><p id="xdx_236_zrvbpULwdnT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p></ix:exclude> <ix:exclude><p id="xdx_23D_zXV39sS4WKX3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p></ix:exclude> <ix:exclude><p id="xdx_239_zMCR7jkDGmsd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i></i></b></p></ix:exclude> <ix:exclude><!-- Field: Page; Sequence: 70; Value: 1 --> <div id="xdx_23F_zBEjWbJfBTvf" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div id="xdx_23F_zcdsaWQnrlNg" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --></ix:exclude> <ix:exclude><p id="xdx_237_z50pNwF76c82" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p></ix:exclude> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock Based Compensation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 6, 2021, the Compensation Committee adopted, and the Board ratified the Company’s Equity Incentive Plan. The Plan is intended to secure for the Company the benefits arising from ownership of the Company’s common stock by the employees, officers, directors and consultants of the Company, all of whom are, and will be, responsible for the Company’s future growth. The Plan is designed to help attract and retain for the Company, qualified personnel for positions of exceptional responsibility, to reward employees, officers, directors and consultants for their services to the Company and to motivate such individuals through added incentives to further contribute to the success of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Plan provides an opportunity for an employee, officer, director or consultant of the Company, subject to certain national securities and taxation laws, to receive (i) incentive stock options, (ii) nonqualified stock options; (iii) restricted stock; (iv) stock awards; (v) shares in performance of services; or (vi) any combination of the foregoing. Incentive stock options granted under the Plan are intended to qualify as “<span style="text-decoration: underline">incentive stock options</span>” within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the “<span style="text-decoration: underline">Code</span>”). Nonqualified (non-statutory stock options) granted under the Plan are not intended to qualify as incentive stock options under the Code. The Plan is administered by the Altshuler Shaham Benefits Firm, a licensed fiduciary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 2, 2022, the Compensation Committee approved amending the Plan to increase the number of shares reserved for issuance under the Plan to 15% of the common stock outstanding immediately following consummation of this offering.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Private Placement of Notes and Warrant</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 16, 2020, we entered into a Securities Purchase Agreement (“SPA”) with an institutional investor for a private placement of senior secured convertible notes totaling up to an aggregate of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfSeniorLongTermDebt_pp0p0_c20201215__20201216__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zk1bwJMLs0nc" title="Senior convertible notes issued"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" contextRef="From2020-12-152020-12-16_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,750,000</ix:nonFraction></span> to be issued in three tranches subject to the achievement of certain milestones. The convertible notes include a conversion right, at the Investor’s option, to convert the convertible notes into shares of our Common Stock at a conversion price equal to the lower of (i) $<span id="xdx_90E_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20201215__20201216__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zOnfx4Qw2mV6" title="Conversion price"><ix:nonFraction name="us-gaap:CommonStockConvertibleConversionPriceIncrease" contextRef="From2020-12-152020-12-16_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">42</ix:nonFraction></span> per share or (ii) eighty percent (80%) of the average of the two lowest daily volume-weighted average price for the Company’s Common Stock during the ten (10) consecutive trading days preceding the conversion date (the “notes”). The investor has the right to have the conversion price reduced if we issue Common Stock or convertible notes at a lower conversion price than $<span id="xdx_90A_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20201215__20201216__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z2jUUxfFyUuk" title="Lower conversion price"><ix:nonFraction name="us-gaap:CommonStockConvertibleConversionPriceDecrease" contextRef="From2020-12-152020-12-16_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">42</ix:nonFraction></span> during the period that the notes are outstanding. The notes are due one year from issuance. The notes will be interest free, but in the event of a default, they will bear annual interest at a rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20201215__20201216__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zKgTRMPKmjBa" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2020-12-152020-12-16_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">18.00</ix:nonFraction></span>%. The SPA and the notes contain events of default, including, among other things, failure to repay the notes by the maturity date, and bankruptcy and insolvency events, that would result in the imposition of the default interest rate.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 21, 2020, we closed the first tranche and issued a note in the amount of $<span id="xdx_90F_eus-gaap--ProceedsFromNotesPayable_pp0p0_c20201220__20201221__us-gaap--DebtInstrumentAxis__custom--InitialNoteMember_zdqkQGqtXS27" title="Notes payable"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2020-12-202020-12-21_custom_InitialNoteMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">825,000</ix:nonFraction></span> (the “Initial Note”). On February 22, 2021, we closed the second tranche and issued a second note in the amount of $<span id="xdx_906_eus-gaap--ProceedsFromNotesPayable_pp0p0_c20210221__20210222__us-gaap--DebtInstrumentAxis__custom--SecondNoteMember_zXO2H5cmHXXd" title="Notes payable"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2021-02-212021-02-22_custom_SecondNoteMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">550,000</ix:nonFraction></span> (the “Second Note”). On April 23, 2021, we closed the third tranche and issued a third note in the amount of $<span id="xdx_906_eus-gaap--ProceedsFromNotesPayable_pp0p0_c20210422__20210423__us-gaap--DebtInstrumentAxis__custom--NoteMember_zoOezx6QHnwi" title="Notes payable"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2021-04-222021-04-23_custom_NoteMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,375,000</ix:nonFraction></span> (the “Note”). The Initial Note was issued at a discount of $<span id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20201221__us-gaap--DebtInstrumentAxis__custom--InitialNoteMember_ztOhqMrdg4x1" title="Unamortized Discount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2020-12-21_custom_InitialNoteMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">75,000</ix:nonFraction></span>; the Second Note was issued at a discount of $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20210222__us-gaap--DebtInstrumentAxis__custom--SecondNoteMember_ztfJSHYMovW" title="Unamortized Discount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2021-02-22_custom_SecondNoteMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></span>; and the Note was issued at a discount of $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20210423__us-gaap--DebtInstrumentAxis__custom--NoteMember_zjVD2KhK89Bl" title="Unamortized Discount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2021-04-23_custom_NoteMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">125,000</ix:nonFraction></span>. In addition, we issued to the Investor <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220901__20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z9MaZauuZ4G2" title="Convertible shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2022-09-012023-08-31_us-gaap_InvestorMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">32,614</ix:nonFraction></span> shares of Common Stock as pre-delivery shares in accordance with the terms of the SPA, which shares will be deducted from the total number of shares to be issued to the Investor upon conversion of the Initial Note.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 23, 2021, we entered into a senior secured promissory note (the “Senior Secured Note”) for $<span id="xdx_903_eus-gaap--SeniorNotesCurrent_iI_pp0p0_c20210423__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNoteMember_zQyCa2JUTnWc" title="Senior secured note"><ix:nonFraction name="us-gaap:SeniorNotesCurrent" contextRef="AsOf2021-04-23_custom_SeniorSecuredNoteMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,375,000</ix:nonFraction></span> with the institutional investor. This follows the SPA, a restated securities purchase agreement dated as of February 22, 2021, as well as accompanying documents for an aggregate principal amount of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210423__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNoteMember_zIcUp6BkM1f4" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-04-23_custom_SeniorSecuredNoteMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,750,000</ix:nonFraction></span> having an aggregate original issue discount of <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20210423__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNoteMember_zOQ8UQOZidle" title="Original issue discount percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2021-04-23_custom_SeniorSecuredNoteMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>%, and ranking senior to all outstanding and future indebtedness of the Company. In addition, the SPA granted the investor a right to receive 100% warrant coverage, and we issued a warrant to the investor for up to <span id="xdx_904_ecustom--WarrantsIssued_c20210422__20210423__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNoteMember_zYxRMBTU8Rok" title="Warrants issued"><ix:nonFraction name="CNBX:WarrantsIssued" contextRef="From2021-04-222021-04-23_custom_SeniorSecuredNoteMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,833</ix:nonFraction></span> shares of our Common Stock, which expires three years from the issuance date of the warrant, with an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210423__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNoteMember_zoc83BqupLwk" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-04-23_custom_SeniorSecuredNoteMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">60</ix:nonFraction></span> per share. The warrant may be exercised and converted to Common Stock at the investor’s option at any time until the expiration date. These securities were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act, and Regulation D promulgated thereunder, as these securities were sold to “accredited investors” within the meaning of Regulation D.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <ix:exclude><p id="xdx_234_zy86d8HQHFae" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p></ix:exclude> <ix:exclude><p id="xdx_23C_zzS5Qr9RdKBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p></ix:exclude> <ix:exclude><p id="xdx_23E_zDNxSRo0gua1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude> <ix:exclude><!-- Field: Page; Sequence: 71; Value: 1 --> <div id="xdx_238_zuCwAHsgnPX4" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div id="xdx_234_za7s5IOVajs7" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --></ix:exclude> <ix:exclude><p id="xdx_23B_zExlr5qmhpD1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p></ix:exclude> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 15, 2022, we entered into a forbearance agreements with the institutional investor relating to that certain Senior Secured Note. Pursuant to the forbearance agreement, the investor, through March 7, 2022, agreed to forbear from exercising any rights and remedies against the Company related to the outstanding payments and to waive certain other defaults under the Senior Secured Note and related rights pursuant to the registration rights agreement entered into in December 2020 between the Company and the investor.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 28, 2022, we entered into a forbearance agreements with the institutional investor relating to that certain Senior Secured Note. Pursuant to the forbearance agreement, the investor, through December 12, 2022, agreed to forbear from exercising any rights and remedies against the Company related to the outstanding payments and to waive certain other defaults under the Senior Secured Note and related rights pursuant to the registration rights agreement entered into in December 2020 between the Company and the investor.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 16, 2022, we issued to the investor a demand promissory note (the “Demand Note”) in the principal amount of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220316__us-gaap--LongtermDebtTypeAxis__custom--DemandNoteMember_z1r7BHLwqZX" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2022-03-16_custom_DemandNoteMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">280,000</ix:nonFraction></span> (the “Principal”) with an original issue discount of $<span id="xdx_902_ecustom--OriginalIssueDiscount_pp0p0_c20220315__20220316__us-gaap--LongtermDebtTypeAxis__custom--DemandNoteMember_zYH3mYZktDZa" title="Original issue discount"><ix:nonFraction name="CNBX:OriginalIssueDiscount" contextRef="From2022-03-152022-03-16_custom_DemandNoteMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,000</ix:nonFraction></span>. The Demand Note is payable on demand at any time after the earlier to occur of (i) May 16, 2022, and (ii) the public or private offering of any securities by the Company (the “Next Subsequent Placement”). Any amount of Principal due under the Demand Note which is not paid when due shall result in a late charge being incurred and payable by the Company in an amount equal to interest on such amount at the rate of fifteen percent (15%) per annum from the date such amount was due until the same is paid in full (the “Late Charges”). With the agreement, the Principal and accrued and unpaid Late Charges under the Demand Note and amounts owed under the Senior Secured Note may be applied to all, or any part, of the purchase price of securities to be issued upon the consummation of an offering of securities by the Company to the investor. So long as any amounts remain outstanding under the Demand Note or the Senior Secured Note, all cash proceeds received by the Company on or after issuance of the Demand Note from the Next Subsequent Placement or any other sales of any securities of the Company shall be used to (x) first, repay the Demand Note and (y) second, repay the Senior Secured Note.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 28, 2022, we entered into a forbearance agreements with the institutional investor relating to that certain Senior Secured Note. Pursuant to the forbearance agreement, the investor, through December 12, 2022, agreed to forbear from exercising any rights and remedies against the Company related to the outstanding payments and to waive certain other defaults under the Senior Secured Note and related rights pursuant to the registration rights agreement entered into in May 16, 2022 between the Company and the investor.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 15, 2022, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220615__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zkN1XDryNNtk" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2022-06-15_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">154,250</ix:nonFraction></span>.00. ($<span id="xdx_905_eus-gaap--InterestExpenseOtherLongTermDebt_pp0p0_c20220614__20220615__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zgheLxOCvI43" title="Net of issuance expenses"><ix:nonFraction name="us-gaap:InterestExpenseOtherLongTermDebt" contextRef="From2022-06-142022-06-15_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">154,000</ix:nonFraction></span> net of issuance expenses). The Convertible Promissory Note carry interest of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220614__20220615__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zbvqBdt1hZh9" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2022-06-142022-06-15_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9</ix:nonFraction></span>% and due on June 15<sup>th</sup> 2023<span style="color: red">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the period of January through March , 2023, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zqN0c5VPYHWd" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-03-31_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">35,000</ix:nonFraction></span>.00. ($<span id="xdx_902_eus-gaap--InterestExpenseOtherLongTermDebt_pp0p0_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zK6YLaXASyfi" title="Net of issuance expenses"><ix:nonFraction name="us-gaap:InterestExpenseOtherLongTermDebt" contextRef="From2023-01-012023-03-31_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">35,000</ix:nonFraction></span> net of issuance expenses). The Convertible Promissory Note carry interest of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zPj9HYsjnbvd" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2023-01-012023-03-31_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% and due on June 15<sup>th</sup> 2023</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 12, 2023, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230612__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z7JAkqQtRzXf" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-06-12_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">65,000</ix:nonFraction></span>.00. ($<span id="xdx_901_eus-gaap--InterestExpenseOtherLongTermDebt_pp0p0_c20230611__20230612__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zgZY5ZFjPn3f" title="Net of issuance expenses"><ix:nonFraction name="us-gaap:InterestExpenseOtherLongTermDebt" contextRef="From2023-06-112023-06-12_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">65,000</ix:nonFraction></span> net of issuance expenses). The Convertible Promissory Note carry interest of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20230611__20230612__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zI32sSvd2mka" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2023-06-112023-06-12_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% and due on August 85<sup>th</sup> 2023</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <ix:exclude><p id="xdx_234_z6TaFpEhj995" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.55pt"> </p></ix:exclude> <ix:exclude><p id="xdx_23C_zfOMrkLzneB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.55pt"> </p></ix:exclude> <ix:exclude><p id="xdx_236_zlqrO9mbgCai" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.55pt"></p></ix:exclude> <ix:exclude><!-- Field: Page; Sequence: 72; Value: 52 --> <div id="xdx_23A_zHaFrj2vrYf6" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div id="xdx_231_zQAPWKiBk8sc" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --></ix:exclude> <ix:exclude><p id="xdx_23D_zbrIUuI8rp69" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p></ix:exclude> </ix:nonNumeric><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="CNBX:WarrantDisclosureTextBlock"><p id="xdx_80C_ecustom--WarrantDisclosureTextBlock_zIBYLKFNNOAd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 7 – <span id="xdx_820_zZbl1RNUJYfi">Warrants</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%"> </td> <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 24, 2018, as part of a securities purchase agreement the company issued <span id="xdx_90A_ecustom--WarrantsIssuedShares_iI_c20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zN5No6biie1j" title="Warrants issued, shares"><ix:nonFraction name="CNBX:WarrantsIssuedShares" contextRef="AsOf2018-09-24_custom_Warrant1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">41,667</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants, to purchase common shares of the Company at $1.00 per share; said Warrants are valid for five years, expiring on <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zUC8E42d8e1l" title="Expiry date"><ix:nonNumeric contextRef="AsOf2018-09-24_custom_Warrant1Member" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">August 24<sup>th</sup>, 2023</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of each warrant is approximately $66 and the total value of the 41,667 warrants is $<span id="xdx_906_ecustom--FairValueOfWarrantsIssued_iI_pp0p0_c20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zXDplwKeIdZb" title="Fair value of warrants issued"><ix:nonFraction name="CNBX:FairValueOfWarrantsIssued" contextRef="AsOf2018-09-24_custom_Warrant1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,784,387</ix:nonFraction></span></span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the warrants are estimated using the Black Scholes option-pricing model with the following assumptions:</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <ix:nonNumeric contextRef="From2022-09-012023-08-31_custom_Warrant1Member" escape="true" name="CNBX:ScheduleOfAssumptionsUsedWarrantsTableTextBlock"><table cellspacing="0" cellpadding="0" id="xdx_895_ecustom--ScheduleOfAssumptionsUsedWarrantsTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zVElxf5u2a8b" summary="xdx: Disclosure - Warrants (Details - Fair value)" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td><span id="xdx_8BA_zJm3qkZpcmnd" style="display: none">Schedule of assumptions</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 4%"> </td> <td style="width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PV of exercise Share price</span></td> <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_909_eus-gaap--SharePrice_iI_c20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_z1BT0cHaYSe" title="PV of exercise Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2018-09-24_custom_Warrant1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1</ix:nonFraction></span></span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Volatility</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20180923__20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zeTBcoOuuMM3" title="Expected Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2018-09-232018-09-24_custom_Warrant1Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">102.0</ix:nonFraction></span>%</span></td></tr> <tr style="vertical-align: bottom"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Free Interest Rate</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20180923__20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zdNvz4JpueA9" title="Risk Free Interest Rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2018-09-232018-09-24_custom_Warrant1Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.58</ix:nonFraction></span>%</span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Term (years)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180923__20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zFtOmMqNY6ni" title="Expected Term (years)"><ix:nonNumeric contextRef="From2018-09-232018-09-24_custom_Warrant1Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5</ix:nonNumeric></span></span></td></tr> <tr style="vertical-align: bottom"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Dividend Yield</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20180923__20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zrFEQSaMlp2f" title="Expected Dividend Yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2018-09-232018-09-24_custom_Warrant1Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span>%</span></td></tr> </table> </ix:nonNumeric><p id="xdx_8A5_zjfuPdWMVrp2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.55pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: justify">The said warrants expired on August 24, 2023</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.55pt"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%"> </td> <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 16, 2020, as part of a convertible loan agreement the company issued <span id="xdx_90F_ecustom--WarrantsIssuedShares_iI_c20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zbWV2H4HvBId" title="Warrants issued, shares"><ix:nonFraction name="CNBX:WarrantsIssuedShares" contextRef="AsOf2020-12-16_custom_Warrant2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,667</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants, to purchase common shares of the Company at $0.50 per share; said Warrants are valid for three years, expiring on <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zfC8VHQycqT7" title="Expiry date"><ix:nonNumeric contextRef="AsOf2020-12-16_custom_Warrant2Member" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">August 24<sup>th</sup>, 2023</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The first trench was received on December 22, 2020, the second trench was received on February 2,2021 and the third trench was received on April 23, 2021, in the total sum of $2,456,750 net of issuance expenses.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: justify">The fair value of the first, second and third trenches are approximately $10.8, $10.8 and $12 respectively and the total value of the 45,667 warrants is $<span id="xdx_90A_ecustom--FairValueOfWarrantsIssued_iI_pp0p0_c20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zWpAFglpSLy2" title="Fair value of warrants issued"><ix:nonFraction name="CNBX:FairValueOfWarrantsIssued" contextRef="AsOf2020-12-16_custom_Warrant2Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">515,818</ix:nonFraction></span></p></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the warrants are estimated using the Black Scholes option-pricing model with the following assumptions:</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <ix:nonNumeric contextRef="From2022-09-012023-08-31_custom_Warrant2Member" escape="true" name="CNBX:ScheduleOfAssumptionsUsedWarrantsTableTextBlock"><table cellspacing="0" cellpadding="0" id="xdx_891_ecustom--ScheduleOfAssumptionsUsedWarrantsTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zVngV2lP0uHc" summary="xdx: Disclosure - Warrants (Details - Fair Value)" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td><span id="xdx_8B4_zxXZSpwzzkcb" style="display: none">Schedule of assumptions</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 4%"> </td> <td style="width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PV of exercise Share price</span></td> <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_902_eus-gaap--SharePrice_iI_c20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zNnoDkT6AMg6" title="PV of exercise Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2020-12-16_custom_Warrant2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.50</ix:nonFraction></span></span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Volatility</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20201215__20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_z9rpupLhw5Pi" title="Expected Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-12-152020-12-16_custom_Warrant2Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">117.0</ix:nonFraction></span>%</span></td></tr> <tr style="vertical-align: bottom"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Free Interest Rate</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20201215__20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zFW1J9F73Pai" title="Risk Free Interest Rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-12-152020-12-16_custom_Warrant2Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.3</ix:nonFraction></span>%</span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Term (years)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201215__20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zWx6JIt6RCIk" title="Expected Term (years)"><ix:nonNumeric contextRef="From2020-12-152020-12-16_custom_Warrant2Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">3</ix:nonNumeric></span></span></td></tr> <tr style="vertical-align: bottom"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Dividend Yield</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20201215__20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_z1t4FU9U4YTg" title="Expected Dividend Yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-12-152020-12-16_custom_Warrant2Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span>%</span></td></tr> </table> </ix:nonNumeric><p id="xdx_8A5_z1W67LP466G5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.55pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The said warrants expired on <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zd7iWix5XxC1" title="Expiry date"><ix:nonNumeric contextRef="AsOf2020-12-16_custom_Warrant2Member" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">August 24, 2023</ix:nonNumeric></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.55pt"> </p> <ix:exclude><p id="xdx_230_zkakjzK0wMCd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.55pt"> </p></ix:exclude> <ix:exclude><p id="xdx_233_z2LE7bNK6f9c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.55pt"> </p></ix:exclude> <ix:exclude><p id="xdx_23A_zRTltuZFjQK9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.55pt"></p></ix:exclude> <ix:exclude><!-- Field: Page; Sequence: 73; Value: 1 --> <div id="xdx_235_znAQHgA4lpX5" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div id="xdx_233_zjDVfj8S7a5i" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --></ix:exclude> <ix:exclude><p id="xdx_23F_z619r2dR3Fu9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.55pt"> </p></ix:exclude> <ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zERxgiZX0yd8" summary="xdx: Disclosure - Warrants (Details - Warrant activity)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span id="xdx_8BB_ztOw1gBNt206" style="display: none">Schedule of warrant activity</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Weighted Average Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Weighted Average Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Weighted Average Exercise</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 28%; text-indent: -8.1pt; padding-left: 8.1pt">Warrants outstanding as of September 1</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zgWrZ1o57Ct3" title="Warrants outstanding, beginning balance" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-08-31_custom_WarrantsMember882227078" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">87,500</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zgvVr5xXzDUj" title="Weighted average exercise price, warrants outstanding, beginning balance" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-08-31_custom_WarrantsMember882227078" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">88.6</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z5foQcP6gjNb" title="Warrants outstanding, beginning balance" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2021-08-31_custom_WarrantsMember882227078" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">87,500</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zIRlhE1ltJD" title="Weighted average exercise price, warrants outstanding, beginning balance" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-08-31_custom_WarrantsMember882227078" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">88.6</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zNG7yT6CJkq6" title="Warrants outstanding, beginning balance" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2020-08-31_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">41,667</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z4EfRS3SYc7j" title="Weighted average exercise price, warrants outstanding, beginning balance" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-08-31_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">120</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--WarrantsIssued_d0_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zK64zLnL95yb" title="Warrants issued" style="text-align: right"><ix:nonFraction name="CNBX:WarrantsIssued" contextRef="From2022-09-012023-08-31_custom_WarrantsMember882227093" format="ixt:zerodash" decimals="INF" unitRef="Shares">–</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_ecustom--WeightedAverageExercisePriceWarrantsIssued_d0_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z7vqhXQ16R2e" title="Weighted average exercise price, warrants issued" style="text-align: right"><ix:nonFraction name="CNBX:WeightedAverageExercisePriceWarrantsIssued" contextRef="From2022-09-012023-08-31_custom_WarrantsMember882227093" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">–</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--WarrantsIssued_d0_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zi2frAR9Toce" title="Warrants issued" style="text-align: right"><ix:nonFraction name="CNBX:WarrantsIssued" contextRef="From2021-09-012022-08-31_custom_WarrantsMember882227093" format="ixt:zerodash" decimals="INF" unitRef="Shares">–</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_ecustom--WeightedAverageExercisePriceWarrantsIssued_d0_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_ztYq09v4YV18" title="Weighted average exercise price, warrants issued" style="text-align: right"><ix:nonFraction name="CNBX:WeightedAverageExercisePriceWarrantsIssued" contextRef="From2021-09-012022-08-31_custom_WarrantsMember882227093" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">–</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--WarrantsIssued_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zYvUnGuitYh2" title="Warrants issued" style="text-align: right"><ix:nonFraction name="CNBX:WarrantsIssued" contextRef="From2020-09-012021-08-31_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,667</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_ecustom--WeightedAverageExercisePriceWarrantsIssued_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zh5bN0Ls9Q0h" title="Weighted average exercise price, warrants issued" style="text-align: right"><ix:nonFraction name="CNBX:WeightedAverageExercisePriceWarrantsIssued" contextRef="From2020-09-012021-08-31_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">60</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_d0_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zFORyrQsEHh3" title="Warrants exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-09-012023-08-31_custom_WarrantsMember882227093" format="ixt:zerodash" decimals="INF" unitRef="Shares">–</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_ecustom--WeightedAverageExercisePriceWarrantsExercised_d0_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zrTkVciJK45h" title="Weighted average exercise price, warrants exercised" style="text-align: right"><ix:nonFraction name="CNBX:WeightedAverageExercisePriceWarrantsExercised" contextRef="From2022-09-012023-08-31_custom_WarrantsMember882227093" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">–</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_d0_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zLaPhjRgS6lc" title="Warrants exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2021-09-012022-08-31_custom_WarrantsMember882227093" format="ixt:zerodash" decimals="INF" unitRef="Shares">–</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_ecustom--WeightedAverageExercisePriceWarrantsExercised_d0_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zL50dXEitBJa" title="Weighted average exercise price, warrants exercised" style="text-align: right"><ix:nonFraction name="CNBX:WeightedAverageExercisePriceWarrantsExercised" contextRef="From2021-09-012022-08-31_custom_WarrantsMember882227093" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">–</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_d0_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_ztSvWZlzcKR3" title="Warrants exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2020-09-012021-08-31_custom_WarrantsMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">–</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_ecustom--WeightedAverageExercisePriceWarrantsExercised_d0_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zOz7RF1oXiYb" title="Weighted average exercise price, warrants exercised" style="text-align: right"><ix:nonFraction name="CNBX:WeightedAverageExercisePriceWarrantsExercised" contextRef="From2020-09-012021-08-31_custom_WarrantsMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">–</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zoq1gLO5YWM4" title="Warrants expired" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2022-09-012023-08-31_custom_WarrantsMember882227093" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">87,500</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_ecustom--WeightedAverageExercisePriceWarrantsExpired_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zmTxZ6yTyGQh" title="Weighted average exercise price, warrants expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="CNBX:WeightedAverageExercisePriceWarrantsExpired" contextRef="From2022-09-012023-08-31_custom_WarrantsMember882227093" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">88.6</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di0_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z7MHQglGENQ3" title="Warrants expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2021-09-012022-08-31_custom_WarrantsMember882227093" format="ixt:zerodash" decimals="INF" sign="-" unitRef="Shares">–</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_ecustom--WeightedAverageExercisePriceWarrantsExpired_d0_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zCw0QQ3P4pNb" title="Weighted average exercise price, warrants expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="CNBX:WeightedAverageExercisePriceWarrantsExpired" contextRef="From2021-09-012022-08-31_custom_WarrantsMember882227093" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">–</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di0_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z4uHcKnaBAD3" title="Warrants expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2020-09-012021-08-31_custom_WarrantsMember" format="ixt:zerodash" decimals="INF" sign="-" unitRef="Shares">–</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_ecustom--WeightedAverageExercisePriceWarrantsExpired_d0_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zxwCmQKkAzF3" title="Weighted average exercise price, warrants expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="CNBX:WeightedAverageExercisePriceWarrantsExpired" contextRef="From2020-09-012021-08-31_custom_WarrantsMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">–</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt; text-indent: -8.1pt; padding-left: 8.1pt">Warrants outstanding as of August 31</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_d0_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zCfIPlGsIcLl" title="Warrants outstanding, ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-08-31_custom_WarrantsMember882227109" format="ixt:zerodash" decimals="INF" unitRef="Shares">–</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_d0_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zfaJlc2tU8jg" title="Weighted average exercise price, warrants outstanding, ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-08-31_custom_WarrantsMember882227109" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">–</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z5eiwsHAgBoh" title="Warrants outstanding, ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-08-31_custom_WarrantsMember882227078" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">87,500</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z2KaL2aRhJ9e" title="Weighted average exercise price, warrants outstanding, ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-08-31_custom_WarrantsMember882227078" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">88.6</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_ziC9jWbqiksg" title="Warrants outstanding, ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2021-08-31_custom_WarrantsMember882227078" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">87,500</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zbI297c0Ydyf" title="Weighted average exercise price, warrants outstanding, ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-08-31_custom_WarrantsMember882227078" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">88.6</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt; text-indent: -8.1pt; padding-left: 8.1pt">Warrants exercisable as of August 31</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_d0_c20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zJpk2wG0d7u8" title="Warrants exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CNBX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" contextRef="AsOf2023-08-31_custom_WarrantsMember882227109" format="ixt:zerodash" decimals="INF" unitRef="Shares">–</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--WeightedAverageExercisePriceWarrantsExercisable_iI_d0_c20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zXSu0jo1Ulu9" title="Weighted average exercise price, warrants exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CNBX:WeightedAverageExercisePriceWarrantsExercisable" contextRef="AsOf2023-08-31_custom_WarrantsMember882227109" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">–</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zodeKPStZEDf" title="Warrants exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CNBX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" contextRef="AsOf2022-08-31_custom_WarrantsMember882227078" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">87,500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--WeightedAverageExercisePriceWarrantsExercisable_iI_c20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zSlPEJMqXZZ4" title="Weighted average exercise price, warrants exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CNBX:WeightedAverageExercisePriceWarrantsExercisable" contextRef="AsOf2022-08-31_custom_WarrantsMember882227078" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">88.6</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zRv5ZXdapHNi" title="Warrants exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CNBX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" contextRef="AsOf2021-08-31_custom_WarrantsMember882227078" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">87,500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--WeightedAverageExercisePriceWarrantsExercisable_iI_c20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z3qpfUHjwVp5" title="Weighted average exercise price, warrants exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CNBX:WeightedAverageExercisePriceWarrantsExercisable" contextRef="AsOf2021-08-31_custom_WarrantsMember882227078" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">88.6</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> </ix:nonNumeric><p id="xdx_8A8_zbng7zRCLFw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.55pt"> </p> </ix:nonNumeric><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80D_eus-gaap--IncomeTaxDisclosureTextBlock_zSFWPq0H72U6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 8 – <span id="xdx_82D_z9gFqvDOD0mf">Income Taxes</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Taxes on income included in the consolidated statements of operations represent current taxes due to taxable income of the Company and its Subsidiary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.2pt; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.2pt; text-align: justify"><b>Corporate taxation in the U.S.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.2pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The applicable corporate tax rate for the Company is <span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20220901__20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zOSHUdodBFA6" title="Effective tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-09-012023-08-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></span>%.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No provision for income tax was made for the period from September 15, 2004 (Inception) to August 31, 2023, as the Company had cumulative operating losses. For the years ended August 31, 2023, and 2022, the Company incurred net losses for tax purposes of $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20230831__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStates1Member_zvU7aXAxsxrk" title="Net operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-08-31_custom_UnitedStates1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,848,572</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20220831__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStates1Member_zqT751q6i348" title="Net operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-08-31_custom_UnitedStates1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">903,813</ix:nonFraction></span>, respectively. Under U.S. tax laws, subject to certain limitations, carry forward tax losses expire 20 years after the year in which incurred. In the case of the Company, subject to potential limitations in accordance with the relevant law, the net loss carry forward will expire in the years 2032 through 2036.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">   </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.2pt; text-align: justify"><b>Corporate taxation in Israel:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.2pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Subsidiary is taxed in accordance with Israeli tax laws. The corporate tax rate applicable is <span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_dp_c20220901__20230831__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--IsraelTaxAuthorityMember_z5WOPRTWF70d" title="Effective tax rate, Israel"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="From2022-09-012023-08-31_us-gaap_IsraelTaxAuthorityMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">23</ix:nonFraction></span>%.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of August 31, 2023, the Subsidiary has an accumulated tax loss carry forward of approximately $<span id="xdx_907_eus-gaap--OperatingLossCarryforwards_pp0p0_c20230831__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--IsraelTaxAuthorityMember_zZk9ZH4tyiuj" title="Net operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-08-31_us-gaap_IsraelTaxAuthorityMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,593,815</ix:nonFraction></span> (as of August 31, 2022, approximately $<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_pp0p0_c20220831__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--IsraelTaxAuthorityMember_zRjbSXjIRc81" title="Net operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-08-31_us-gaap_IsraelTaxAuthorityMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,373,689</ix:nonFraction></span>). Under the Israeli tax laws, carry forward tax losses have no expiration date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The income tax expense (benefit) differs from the amount computed by applying the United States Statutory corporate income tax rate as follows: </p> <ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zgJhIPUIx80h" summary="xdx: Disclosure - Income Taxes (Details - rate)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span id="xdx_8B3_zIUTlIVUkQld" style="display: none">Schedule of effective income tax rate</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the Year Ended August 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">United States statutory corporate income tax rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20220901__20230831_zgUCWK1I3kf3" title="United States statutory corporate income tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></span>%</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20210901__20220831_zcgx2Vc0gNNg" title="United States statutory corporate income tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></span>%</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance on deferred tax assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_dpi_c20220901__20230831_zkaxt4a8l7n8" title="Change in valuation allowance on deferred tax assets">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></span>%</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_dpi_c20210901__20220831_z5CA2HrvbqT2" title="Change in valuation allowance on deferred tax assets">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></span>%</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Provision for income tax</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_c20220901__20230831_zxxUW2CdrBk9" title="Provision for income tax"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2022-09-01to2023-08-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">–</ix:nonFraction></span>%</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_c20210901__20220831_zHpoAhLh1rGe" title="Provision for income tax"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2021-09-012022-08-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">–</ix:nonFraction></span>%</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> </ix:nonNumeric><p id="xdx_8A9_zQwQjAucNFD5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <ix:exclude><p id="xdx_23F_zLHIYhm11L6g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p></ix:exclude> <ix:exclude><p id="xdx_235_zoKbddVLV2S2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p></ix:exclude> <ix:exclude><p id="xdx_232_zDCCfBHdRxBb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude> <ix:exclude><!-- Field: Page; Sequence: 74; Value: 1 --> <div id="xdx_23F_z7XN8Ev1l1sg" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div id="xdx_239_zl9Rle9wL4S6" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --></ix:exclude> <ix:exclude><p id="xdx_236_zmxvL4tUvv6c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p></ix:exclude> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred income taxes reflect the tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for tax purposes. The components of the net deferred income tax assets are approximately as follows: </p> <ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z1ZUhSk2ZSCa" summary="xdx: Disclosure - Income Taxes (Details - Deferred tax assets)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt"><span id="xdx_8B4_zPcrQ0cK8JN" style="display: none">Schedule of deferred income tax assets</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">August 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">US Deferred income tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left; text-indent: -10pt; padding-left: 20pt">Net operating loss carry forwards benefit</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zL2THumqnoB8" title="Net operating loss carry forwards benefit" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-08-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,035,360</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20220831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zsvNG3u0AbS8" title="Net operating loss carry forwards benefit" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-08-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,576,499</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_z2l0hHKoX0m7" title="Valuation allowance" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-08-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,035,360</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20220831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_ze0UGwNCVW1l" title="Valuation allowance" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-08-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,576,499</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred income tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zbfmrgAccXf7" title="Net deferred income tax assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-08-31_us-gaap_DomesticCountryMember" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">–</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20220831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zmd25C1Dq17h" title="Net deferred income tax assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2022-08-31_us-gaap_DomesticCountryMember" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">–</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Outside US Deferred income tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Net operating loss carry forwards benefit</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zfbtDPbtDuhc" title="Net operating loss carry forwards benefit" style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-08-31_us-gaap_ForeignCountryMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,949,564</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20220831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zeRbYqhNeJ5a" title="Net operating loss carry forwards benefit" style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-08-31_us-gaap_ForeignCountryMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,804,533</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_z5Yaff7ccvAa" title="Valuation allowance" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-08-31_us-gaap_ForeignCountryMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,949,564</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20220831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zotbNCzvpek5" title="Valuation allowance" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-08-31_us-gaap_ForeignCountryMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,804,533</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_ze0pP0JQLpR2" title="Net deferred income tax assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-08-31_us-gaap_ForeignCountryMember" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">–</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20220831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_z9yT8Dxhjv27" title="Net deferred income tax assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2022-08-31_us-gaap_ForeignCountryMember" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">–</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">August 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Consolidated Deferred income tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left; text-indent: -10pt; padding-left: 20pt">Net operating loss carry forwards benefit</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20230831_zNA5yXQdBTR5" title="Net operating loss carry forwards benefit" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,984,924</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20220831_z9pIXewBhq1b" title="Net operating loss carry forwards benefit" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,381,031</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20230831_zFnddgNEVW1" title="Valuation allowance" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,984,924</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20220831_z0c7kaHproCf" title="Valuation allowance" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,381,031</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred income tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20230831_zLiITVuvgLsj" title="Net deferred income tax assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-08-31" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">–</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20220831_zD5iUELuuZO4" title="Net deferred income tax assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2022-08-31" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">–</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> </ix:nonNumeric><p id="xdx_8AF_zuXgA7rzIm2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amount taken into income as deferred income tax assets must reflect that portion of the income tax loss carry forwards that is more likely than not to be realized from future operations. The Company has established a full valuation allowance on its net deferred tax assets because of a lack of sufficient positive evidence to support its realization. The valuation allowance increased by $<span id="xdx_90D_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pp0p0_c20220901__20230831_zp19Dr9w6C7f" title="Increase (decrease) in valuation allowance"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">603,893</ix:nonFraction></span> and decreased $<span id="xdx_901_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pp0p0_c20210901__20220831_zyjRC6S5L0C" title="Increase (decrease) in valuation allowance"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,055,107</ix:nonFraction></span> for the years ended August 31, 2023, and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No provision for income taxes has been provided in these financial statements due to the net loss for the years ended August 31, 2023 and 2021. At August 31, 2023, the Company has net operating loss carry forwards of approximately $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_pp0p0_c20230831_zafcw4QF61Gk" title="Net operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,259,202</ix:nonFraction></span> which expire commencing 2032. The potential tax benefit of these losses may be limited due to certain change in ownership provisions under Section 382 of the Internal Revenue Code (“IRS”) and similar state provisions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IRS Section 382 places limitations (the “Section 382 Limitation”) on the amount of taxable income which can be offset by net operating loss carry forwards after a change in control (generally greater than 50% change in ownership) of a loss corporation. Generally, after a change in control, a loss corporation cannot deduct operating loss carry forwards in excess of the Section 382 Limitation. Due to these “change in ownership” provisions, utilization of the net operating loss and tax credit carry forwards may be subject to an annual limitation regarding their utilization against taxable income in future periods. The Company has not concluded its analysis of Section 382 through August 31, 2023, but believes the provisions will not limit the availability of losses to offset future income.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is subject to income taxes in the U.S. federal jurisdiction and is subject to examination for a period of three years for current filings and indefinitely for any delinquent filings. The tax regulations within each jurisdiction are subject to interpretation of related tax laws and regulations and require significant judgment to apply. The Company estimates that the amount of penalties, if any, will not have a material effect on the results of operations, cash flows or financial position. No provisions have been made in the financial statements for such penalties, if any.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <ix:exclude><p id="xdx_234_zUmSDL2iuWTa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p></ix:exclude> <ix:exclude><p id="xdx_238_z6P6MAB5gZn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p></ix:exclude> <ix:exclude><p id="xdx_23D_z8KIeGeEI98e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></ix:exclude> <ix:exclude><!-- Field: Page; Sequence: 75; Value: 1 --> <div id="xdx_23E_zbYqIAh40xw8" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div id="xdx_239_zgxGjzXuapvd" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --></ix:exclude> <ix:exclude><p id="xdx_23D_zALk6KyroC87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p></ix:exclude> </ix:nonNumeric><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="CNBX:CapitalLossDisclosureTextBlock"><p id="xdx_808_ecustom--CapitalLossDisclosureTextBlock_zRxjLd7DC78l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 9 – <span id="xdx_82C_z7tXlZQK8gAa">Capital loss</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 9th, 2022, the Company sold her holdings in Sativusin in consideration of $<span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20221208__20221209_zLw9Iok06LMa" title="Sale consideration"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2022-12-082022-12-09" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,200</ix:nonFraction></span>, as a result the company recorded a capital loss of $<span id="xdx_909_ecustom--CapitalLoss_c20221208__20221209_zsnZLjuW35cg" title="Capital loss"><ix:nonFraction name="CNBX:CapitalLoss" contextRef="From2022-12-082022-12-09" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,726,231</ix:nonFraction></span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> </ix:nonNumeric><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock"><p id="xdx_80B_eus-gaap--OtherNonoperatingIncomeAndExpenseTextBlock_zUGX1LeFBZa1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 10</b> – <span id="xdx_820_z3GNDRXzrkg"><b>General & administrate expenses </b></span></p> <ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_z7aDLip9uSh7" summary="xdx: Disclosure - General and administrative expenses (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B7_zkRRd1cSq0M4" style="display: none">Schedule of general and administrative expenses</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20220901__20230831_zxT46YnSOUdl" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20210901__20220831_zf7V85Xymjh3" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">For the year Ended<br /> August 31,<br /> 2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">For the year Ended<br /> August 31,<br /> 2022</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40C_eus-gaap--LaborAndRelatedExpense_maGAAEzYXX_z4LoQHdGhQd7" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Salaries and related expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:LaborAndRelatedExpense" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">461,375</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:LaborAndRelatedExpense" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">379,618</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_maGAAEzYXX_zCiYWpWnW9Ha" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Share based payment to related parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,480</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">728,870</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LegalFees_maGAAEzYXX_zjhvfrsiVoFl" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Legal and professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,108</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">443,851</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--GeneralInsuranceExpense_maGAAEzYXX_zowgSWKhZyul" style="vertical-align: bottom; background-color: White"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralInsuranceExpense" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,278</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralInsuranceExpense" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,192</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--MarketingExpense_maGAAEzYXX_zDUSeKr4zPYc" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Marketing expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketingExpense" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,223</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketingExpense" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,977</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OtherGeneralExpense_maGAAEzYXX_zKsXhX5atAyh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Other expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralExpense" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,516</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralExpense" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,139</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--GeneralAndAdministrativeExpense_iT_pp0p0_mtGAAEzYXX_zOpDmNcV0xQb" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"><b style="display: none">Total general and administrative expenses</b></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">909,980</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,800,647</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">*</td></tr> </table></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* In the year ended August 31, 2022 revenues of $29,958 was presented under General and administrative expenses, was allocated to Revenues under previous year results.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> </ix:nonNumeric><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock"><p id="xdx_806_eus-gaap--OtherIncomeAndOtherExpenseDisclosureTextBlock_z1x55BcGsgec" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 11</b> – <span id="xdx_825_zMwkgPw0ZgRa"><b>Financial (Income) expenses </b></span></p> <ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="CNBX:ScheduleOfFinancialIncomeExpensesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--ScheduleOfFinancialIncomeExpensesTableTextBlock_zGwZfD6rIcA4" summary="xdx: Disclosure - Financial (Income) expenses (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span id="xdx_8B9_znjXAsjDcYD4" style="display: none">Schedule of financial income expenses</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_492_20220901__20230831_zUcrKjMH1kEc" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_498_20210901__20220831_zGuGRyJHAW3g" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">For the year<br /> Ended<br /> August 31, 2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">For the year<br /> Ended<br /> August 31, 2022</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_eus-gaap--InterestExpenseBorrowings_i_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Interest and bank charges</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:InterestExpenseBorrowings" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,174</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:InterestExpenseBorrowings" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,273</ix:nonFraction></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--LossGainFromConvertibleLoanValuation_zuBlVcyCiO82" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Loss (Gain) from convertible loan valuation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="CNBX:LossGainFromConvertibleLoanValuation" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,810</ix:nonFraction></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><ix:nonFraction name="CNBX:LossGainFromConvertibleLoanValuation" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">722,236</ix:nonFraction></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt; text-align: left">Currency exchange differences loss (profit)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,361</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,571</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OtherNonoperatingIncomeExpense_pp0p0_zSZgT9dfWBe5" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><b style="display: none">Total other income expenses</b></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2022-09-01to2023-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">52,623</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2021-09-012022-08-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">782,080</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> </ix:nonNumeric><ix:nonNumeric contextRef="From2022-09-01to2023-08-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_801_eus-gaap--SubsequentEventsTextBlock_zRa01Zm0aKKe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 11 – <span id="xdx_826_zWabb91Dk7Vk">Subsequent Events</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 13, 2023, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $25,000.00. ($25,000 net of issuance expenses). The Convertible Promissory Note carry interest of 5% and due on January 1st 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the period September through October, 2023, the company issued 5,700,000 shares as a result of a convertible of a loan at the total of $65,908.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> </ix:nonNumeric><p id="xdx_817_zCEFvETGYd5f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 76; Value: 1 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="k2022_019"></span><b>Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="k2022_020"></span><b>Item 9A. Controls and Procedures</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Evaluation of Disclosure Controls and Procedures</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Disclosure Controls and Procedures</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains a set of disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and is accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In accordance with Rule 13a-15(b) of the Exchange Act, as of the end of the period covered by this Annual Report on Form 10-K, an evaluation was carried out under the supervision and with the participation of the Company’s management, including its Chief Executive Officer, Chief Financial Officer and the Audit Committee, of the effectiveness of its disclosure controls and procedures. The Audit Committee assessed, reviewed and determined that the Company’s disclosure controls and procedures were effective as to this annual filing. Based on that evaluation, The Board accepted and ratified the findings of the Audit Committee that the Company’s disclosure controls and procedures, as of August 31, 2023, the end of the period covered by this Annual Report on Form 10-K, were effective to provide reasonable assurance that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and is accumulated and communicated to the Company’s management, including the Chief Executive Officer, Chief Financial Officer, and Audit Committee as appropriate to allow timely decisions regarding required disclosure.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Management’s Report on Internal Control over Financial Reporting</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act). Internal control over financial reporting is a process designed by, or under the supervision of, the issuer’s principal executive and principal financial officers, or persons performing similar functions, and effected by the issuer’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that our degree of compliance with the policies or procedures may deteriorate.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management assessed the effectiveness of the Company’s internal controls over financial reporting as of August 1, 2022, based on the framework in Internal Control—Integrated Framework (COSO 2013) issued by the Committee of Sponsoring Organization of the Treadway Commission. On the basis of that assessment, management determined that our internal controls over financial reporting were effective as of that date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i></i></b> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 77; Options: NewSection; Value: 52 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 55; Name: PageNo -->55<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Changes in Internal Control Over Financial Reporting</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since our previous annual report, the Company has created an Audit Committee to better review our internal financial reporting. There were no other changes in our internal control over financial reporting during the year ended August 31, 2023, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Limitations on the Effectiveness of Controls</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.2pt">Our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives as specified above. Management does not expect, however, that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and fraud. Any control system, no matter how well designed and operated, is based upon certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error will not occur or that all control issues and instances of inaccurate entries, if any, within the Company have been detected.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="k2022_021"></span>Item 9B. Other Information</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 78; Value: 52 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="k2022_022"></span><b>PART III</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="k2022_023"></span><b>Item 10. Directors, Executive Officers, Promoters and Control Persons; Compliance With Section 16(A) of the Exchange Act</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following individuals serves as Directors and Executive Officers of the Company as of the date of this Annual Report. Directors of the Company hold office until the next annual meeting of our shareholders or until their successors have been elected and qualified. Executive officers of the Company are appointed by our board of directors and hold office until their death, resignation or removal from office.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Director Independence</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors annually determines the independence of each director and nominee for election as a director. The Board makes these determinations in accordance with The NASDAQ Capital Market’s (“<span style="text-decoration: underline">NASDAQ’s</span>”) listing standards for the independence of Directors and the SEC’s rules.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.2pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In assessing director independence, the Board considers, among other matters, the nature and extent of any business relationships, including transactions conducted, between the Company and each director and between the Company and any organization for which one of our Directors is a Director or executive officer or with which one of our directors is otherwise affiliated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board has affirmatively determined that Mr. Shaul Yemal, Mr. Gil Feiler, and Inbar Maymon are independent.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.2pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with NASDAQ requirements, our Board is comprised of a majority of independent Directors and the Compensation and Audit Committees are comprised entirely of independent Directors. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">  </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; width: 23%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td> <td style="width: 1%"> </td> <td style="border-bottom: black 1pt solid; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td> <td style="width: 1%"> </td> <td style="border-bottom: black 1pt solid; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td> <td style="width: 1%"> </td> <td style="border-bottom: black 1pt solid; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Held Position Since</b></span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanja Goldberg</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CTO</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 24, 2022</span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uri Ben-Or</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CFO</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 05, 2016</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inbar Maymon</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resigned January 31<sup>st</sup>, 2023</span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gil Feiler</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resigned January 31<sup>st</sup>, 2023</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shaul Yemal</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resigned December 22<sup>nd</sup>, 2022</span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eyal Barad</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director, CEO</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 13, 2018</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gabriel Yariv</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director, Chair of Board</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2, 2019</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Officer Qualifications:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Sanja Goldberg has held several Senior Researcher positions at Israel’s largest hospital, Sheba Medical Center’s Cancer Research Lab and Regenerative Research Lab. Additionally she has had several Executive positions, including at Compugen and at TaGeza Biopharma where she was VP of Research and Development. Dr. Goldberg obtained her Ph.D. in Cell Biology from the Department of Cell Biology and Genetics, Erasmus MC, Rotterdam, the Netherlands, in 2009, and has since led cutting edge science in her positions related to cancer and early-stage drug discovery activities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Uri Ben-Or, is our CFO. Mr. Ben-Or is a licensed CPA, MBA and has More than 15 years of experience as CFO of public and private companies in the life science and Medical Device Industry. Uri has significant expertise in public Life Science companies traded on the TASE. In addition, Uri has strong finance, operation, and business development background in both startups and public global companies in the US, Europe, and Israel including developing strategic policy and guidance with respect to corporate structure and fundraising.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 79; Value: 52 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Eyal Barad, is a co-founder, and our Director and CEO. Mr. Barad brings over 20 years of executive managerial experience in successful technology ventures and was a pioneer in the digital publishing industry in NYC. He has a BA in Economics & International Relations from the Hebrew University in Jerusalem, and an MBA with Honors from Haifa University.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Gabriel Yariv is our Chair and brings over 20 years of successful executive experience in the medical industry. Mr. Yariv was part of the founding group of BreathID, an Oridion Medical business unit (now Medtronic) and its subsequent spinoff company, Exalenz Bioscience, which develops and manufactures advanced non-invasive diagnostic medical devices for gastrointestinal and liver conditions. Mr. Yariv also co-founded SimuTec, a medical simulation and training company in Brazil that develops and commercializes advanced personalized Virtual Reality training programs for physicians. Mr. Yariv is actively engaged in non-profit and philanthropic activities including ongoing business mentoring of entrepreneurs, founder of the Yariv Foundation for Leadership, and current member of the Friends of the Israel Museum society. Mr. Yariv holds a BA (Cum Laude) in History, Philosophy & Political science from Boston University.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All directors serve for terms of one year each and are subject to re-election at Annual Meeting of Shareholders, unless they earlier resign.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no material proceedings to which any of our directors, officers or affiliates, any owner of record or beneficially of more than five percent of any class of our voting securities, or any associate of any such director, officer, affiliate, or security holder is a party adverse to us or any of our subsidiaries or has a material interest adverse to us or any of our subsidiaries.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have attempted and will continue to attempt to ensure that any transactions between we and our officers, directors, principal shareholders, or other affiliates have been and will be on terms no less favorable to us than could be obtained from unaffiliated third parties on an arm’s length basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Involvement in Certain Legal Proceedings</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as noted herein or below, during the last ten (10) years none of our directors or officers have:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) had any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) been convicted in a criminal proceeding or subject to a pending criminal proceeding;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) been subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities; or</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) been found by a court of competent jurisdiction in a civil action, the Commission or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of these filing requirements were satisfied by the Company’s officers, directors, and ten-percent holders.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 80; Value: 52 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In making these statements, we have relied on the written representation of our Directors and Officers or copies of the reports that they have filed with the Commission.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Code of Ethics</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has adopted a Code of Ethics for Senior Financial Officers that is applicable to our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Indemnification</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under our Articles of Incorporation and Bylaws of the corporation, we may indemnify an officer or director who is made a party to any proceeding, including a law suit, because of his position, if he acted in good faith and in a manner he reasonably believed to be in our best interest. We may advance expenses incurred in defending a proceeding. To the extent that the officer or director is successful on the merits in a proceeding as to which he is to be indemnified, we must indemnify him against all expenses incurred, including attorney's fees. With respect to a derivative action, indemnity may be made only for expenses actually and reasonably incurred in defending the proceeding, and if the officer or director is judged liable, only by a court order. The indemnification is intended to be to the fullest extent permitted by the laws of the State of Nevada.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regarding indemnification for liabilities arising under the Securities Act of 1933, which may be permitted to directors or officers under Nevada law, we have been advised that, in the opinion of the Securities and Exchange Commission, indemnification is against public policy, as expressed in the Act and is, therefore, unenforceable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="k2022_024"></span><b>Item 11. Executive Compensation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We recorded consulting expenses fees to three of our Directors, CFO and salary to three officers. For the current year ending August 31, 2023, our Directors and officers received a yearly salary of $119,421.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Summary Compensation Table</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Executive Officer Compensation Schedules – See Section D of Main Questionnaire</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Schedule D.I</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary Compensation Table in For Fiscal 2023</b></span></p> <p style="margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Name</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Salary ($)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Consulting fees ($)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Bonus ($)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock awards</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option awards</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cars Expenses</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nonqualified deferred compensation earnings ($)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nonqualified deferred compensation earnings ($)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total ($)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 19%; text-align: left">Eyal Barad</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 6%; text-align: right">226,672</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 6%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 6%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 6%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 6%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 6%; text-align: right">27,257</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 6%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 6%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 6%; text-align: right">253,929</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Gabriel Yariv</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">214,754</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">139,900</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26,913</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">381,567</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Dr. Inbar</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dr. Gil Feiler</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">36,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,846</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,846</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Shaul Yemal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,805</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,805</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Uri Ben-Or</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">40,321</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">40,321</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">441,427</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">83,321</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">168,551</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">54,170</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">747,469</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <!-- Field: Page; Sequence: 81; Value: 52 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth, as of August 31, 2023, information concerning ownership of our securities by (i) each director, (ii) each executive officer, (iii) all directors and executive officers as a group; and (iv) each person known to us to be the beneficial owner of more than five percent of each class:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number and percentage of shares beneficially owned includes any shares as to which the named person has sole or shared voting power or investment power and any shares that the named person has the right to acquire within 60 days.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Beneficial Ownership</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Name of Beneficial Owner</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Common Shares</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Percentage of class</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Cannabics Inc. *</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 13%; font-weight: bold; text-align: right">724,499</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 13%; font-weight: bold; text-align: right">3.2%</td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">____________________</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">*Our 2 Directors Eyal Barad and Gabriel Yariv are also holders of Cannabics, Inc. The mailing address for all directors, executive officers and beneficial owners of Cannabics Inc. is #3 Bethesda Metro Center, Suite 700, Bethesda, Maryland, 20814.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">*The Directors of the Company hold positions in Cannabics, Inc., the majority holder. The relative positions of Cannabics, Inc. are listed below :</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: center">Shareholder</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">% Issued</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Eyal Barad, Director, CEO</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">316</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">26.25%</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Eyal Ballan, past Director, CTO</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">141</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11.71%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Gabriel Yariv, Director COO</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.33%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Shay Avraham Sarid</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">223</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18.52%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Itamar Borochov</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">222</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18.44%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Seach Sarid Ltd.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.32%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Ariel Kirtchuk</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.08%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">J Reiger Ltd</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">128</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10.63%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Cannis Group</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">68</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.64%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Gil Feiler</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">37</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3.07%</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,204</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">100.00%</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise noted, we believe that all persons or entities named in the table have sole voting and investment power with respect to all shares of common stock beneficially owned by them. For purposes hereof, a person is considered to be the beneficial owner of securities that can be acquired by such person within 60 days from the date hereof.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Compensation Plan Information</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 6<sup>th</sup>, 2021, the Compensation Committee adopted, and the Board ratified the Company’s Equity Incentive Plan. The Plan is intended to secure for the Company the benefits arising from ownership of the Company’s common stock by the employees, officers, directors and consultants of the Company, all of whom are, and will be, responsible for the Company’s future growth. The Plan is designed to help attract and retain for the Company, qualified personnel for positions of exceptional responsibility, to reward employees, officers, directors and consultants for their services to the Company and to motivate such individuals through added incentives to further contribute to the success of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <!-- Field: Page; Sequence: 82; Value: 52 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Plan provides an opportunity for an employee, officer, director or consultant of the Company, subject to certain national securities and taxation laws, to receive (i) incentive stock options, (ii) nonqualified stock options; (iii) restricted stock; (iv) stock awards; (v) shares in performance of services; or (vi) any combination of the foregoing. Incentive stock options granted under the Plan are intended to qualify as “<span style="text-decoration: underline">incentive stock options</span>” within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the “<span style="text-decoration: underline">Code</span>”). Nonqualified (non-statutory stock options) granted under the Plan are not intended to qualify as incentive stock options under the Code. The Plan is administered by the Altshuler Shaham Benefits Firm, a licensed fiduciary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="k2022_025"></span>Item 12. Security Ownership of Certain Beneficial Owners and Management Related Stockholder Matters.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="k2022_026"></span><b>Item 13. Certain Relationships and Related Transactions, and Director Independence</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="k2022_027"></span><b>Item 14. Principal Accounting Fees and Services</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Audit Fees</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate fees billed by Weinstein International CPA for professional services rendered for the audit of our annual financial statements included in this Annual Report on Form 10-K for the fiscal year ended August 31, 2023, were $10,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>All Other Fees</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the fiscal years ended August 31, 2023, and 2022, the Company did not pay any other fees.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective May 6, 2003, the Securities and Exchange Commission adopted rules that require that before Weinstein International CPA is engaged by us or our subsidiaries to render any auditing or permitted non-audit related service, the engagement be:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%"> </td> <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="width: 96%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approved by our audit committee; or</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">entered into pursuant to pre-approval policies and procedures established by the audit committee, provided the policies and procedures are detailed as to the particular service, the audit committee is informed of each service, and such policies and procedures do not include delegation of the audit committee's responsibilities to management.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not have an audit committee. Our Board of Directors pre-approves all services provided by our independent auditors. All of the above services and fees were reviewed and approved by our Board of Directors before the respective services were rendered.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <!-- Field: Page; Sequence: 83; Value: 52 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="k2022_028"></span><b>PART IV</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="k2022_029"></span><b>Item 15. Exhibits</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 11%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit 3.1</b></span></td> <td style="width: 89%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1343009/000130368110000147/tegc8k_30sep10ex31.txt">Amended Articles of Incorporation, Cannabics Pharmaceuticals Inc., Incorporated by reference.</a></span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit 3.2</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1343009/000101968715003780/cnbx_10ka-ex0302.htm">Bylaws of Cannabics Pharmaceuticals, Incorporated by reference.</a></span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit 3.3</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1343009/000101968715003780/cnbx_10ka-ex0303.htm">Subsidiary – G.R.I.N. Ultra Ltd – Board Resolution Authorizing Creation, Incorporated by reference.</a></span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit 3.4</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1343009/000101968715003780/cnbx_10ka-ex0304.htm">Subsidiary – G.R.I.N. Ultra Ltd – Official Companies Listing (Israel) Incorporated by reference.</a></span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit 3.5</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1343009/000101968714002800/cannabics_8k-ex1001.htm">Material Contract – Collaboration & Exclusivity Agreement with Cannabics, Inc., incorporated by reference from Form 8K filed July 25th, 2014.</a></span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit 3.6</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1343009/000101968715003653/cannibics_8k-ex9901.htm">Intellectual Property & Subsidiary Assignment of October 7th, 2015, Incorporated by reference from form 8K of October 8th, 2015.</a></span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit 3.7</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1343009/000101968715003653/cannibics_8k-ex9902.htm">Assignment & Assumption of Debt & Liabilities Agreement of October 7th, 2015, Incorporated by reference from form 8K of October 8th, 2015.</a></span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit 3.8</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1343009/000101968715003653/cannibics_8k-ex9903.htm">Debt Cancellation Agreement of October 7th, 2015, Incorporated by reference from form 8K of October 8th, 2015.</a></span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit 3.9</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1343009/000101968716004971/cannabics_ex1001.htm">IP Licensing Agreement with The CIMA Group LLC, December 17th, 2015.</a></span></td></tr> <tr style="vertical-align: top"> <td style="width: 10%"> </td> <td style="text-align: justify; width: 90%"> </td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit 31.1</b></span></td> <td style="text-align: justify"><a href="cnbx_ex3101.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification by the Principal Executive Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)).</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit 31.2</b></span></td> <td style="text-align: justify"><a href="cnbx_ex3102.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification by the Principal Financial Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)).</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit 32.1</b></span></td> <td style="text-align: justify"><a href="cnbx_ex3201.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification by the Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit 32.2</b></span></td> <td style="text-align: justify"><a href="cnbx_ex3202.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification by the Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. *</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit 99.1</b></span></td> <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1343009/000168316822008095/cnbx_ex9901.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Audit Committee Charter</span></a></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit 99.2</b></span></td> <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1343009/000168316822008095/cnbx_ex9902.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Compensation Committee Charter</span></a></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the inline XBRL document.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">   Filed herewith.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <!-- Field: Page; Sequence: 84; Value: 52 --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="k2022_030"></span><b>SIGNATURES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 54%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November 29th, 2023</span></td> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td> <td style="border-bottom: black 1pt solid; width: 43%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Eyal Barad</i></span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.45pt 0pt 0">Eyal Barad, Director</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.45pt 0pt 0">Chief Executive Officer</p></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Uri Ben-Or</i></span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.45pt 0pt 0">Uri Ben-Or, Chief Financial Officer</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.45pt 0pt 0">Principal Accounting Officer</p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <!-- Field: Page; Sequence: 85; Options: Last --> <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"> </td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right"> </td></tr></table></div> <!-- Field: /Page --> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> </body> </html> <!-- Field: Set; Name: xdx; ID: xdx_08B_extensions --> <!-- 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 --> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-31.1 <SEQUENCE>2 <FILENAME>cnbx_ex3101.htm <DESCRIPTION>CERTIFICATION <TEXT> <HTML> <HEAD> <TITLE></TITLE> </HEAD> <BODY STYLE="font: 10pt Times New Roman, Times, Serif"> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exhibit 31.1</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Eyal Barad, certify that:</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 2%"> </TD> <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD> <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this Form 10-K of CNBX PHARMACEUTICALS INC.;</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 2%"> </TD> <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD> <TD STYLE="width: 95%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 2%"> </TD> <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD> <TD STYLE="width: 95%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report;</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 2%"> </TD> <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD> <TD STYLE="width: 95%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 5%"> </TD> <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD> <TD STYLE="width: 92%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 5%"> </TD> <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD> <TD STYLE="width: 92%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 5%"> </TD> <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD> <TD STYLE="width: 92%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 5%"> </TD> <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD> <TD STYLE="width: 92%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 2%"> </TD> <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD> <TD STYLE="width: 95%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 5%"> </TD> <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD> <TD STYLE="width: 92%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 5%"> </TD> <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD> <TD STYLE="width: 92%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant’s internal control over financial reporting.</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 54%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November 29th, 2023</FONT></TD> <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD> <TD STYLE="border-bottom: black 1pt solid; width: 41%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Eyal Barad</I></FONT></TD></TR> <TR STYLE="vertical-align: top"> <TD> </TD> <TD> </TD> <TD> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.75pt 0pt 0">Eyal Barad</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.75pt 0pt 0">Director, Chief Executive Officer</P></TD></TR> <TR STYLE="vertical-align: top"> <TD> </TD> <TD> </TD> <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CNBX PHARMACEUTICALS INC.</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> </BODY> </HTML> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-31.2 <SEQUENCE>3 <FILENAME>cnbx_ex3102.htm <DESCRIPTION>CERTIFICATION <TEXT> <HTML> <HEAD> <TITLE></TITLE> </HEAD> <BODY STYLE="font: 10pt Times New Roman, Times, Serif"> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exhibit 31.2</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Uri Ben-Or, certify that:</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 2%"> </TD> <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD> <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this Form 10-K of CNBX PHARMACEUTICALS INC.;</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 2%"> </TD> <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD> <TD STYLE="width: 95%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 2%"> </TD> <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD> <TD STYLE="width: 95%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report;</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 2%"> </TD> <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD> <TD STYLE="width: 95%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 5%"> </TD> <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD> <TD STYLE="width: 92%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 5%"> </TD> <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD> <TD STYLE="width: 92%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 5%"> </TD> <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD> <TD STYLE="width: 92%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 5%"> </TD> <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD> <TD STYLE="width: 92%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 2%"> </TD> <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD> <TD STYLE="width: 95%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 5%"> </TD> <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD> <TD STYLE="width: 92%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 5%"> </TD> <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD> <TD STYLE="width: 92%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant’s internal control over financial reporting.</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 54%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November 29th, 2023</FONT></TD> <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD> <TD STYLE="border-bottom: black 1pt solid; width: 41%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Uri Ben-Or</I></FONT></TD></TR> <TR STYLE="vertical-align: top"> <TD> </TD> <TD> </TD> <TD> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.75pt 0pt 0">Uri Ben-Or</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.75pt 0pt 0">Chief Financial Officer</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.75pt 0pt 0">Principal Accounting Officer</P></TD></TR> <TR STYLE="vertical-align: top"> <TD> </TD> <TD> </TD> <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CNBX PHARMACEUTICALS INC.</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> </BODY> </HTML> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-32.1 <SEQUENCE>4 <FILENAME>cnbx_ex3201.htm <DESCRIPTION>CERTIFICATION <TEXT> <HTML> <HEAD> <TITLE></TITLE> </HEAD> <BODY STYLE="font: 10pt Times New Roman, Times, Serif"> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exhibit 32.1</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO 18 U.S.C. SECTION 1350,</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with this Annual Report of CNBX PHARMACEUTICALS INC. (the “Company”) on Form 10-K for the year ending August 31, 2023, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Eyal Barad, Chief Executive Officer (Principal Executive Officer) of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 2%"> </TD> <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD> <TD STYLE="width: 96%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such Annual Report on Form 10-K for the year ending August 31, 2023, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 2%"> </TD> <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD> <TD STYLE="width: 96%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The information contained in such Annual Report on Form 10-K for the year ending August 31, 2023, fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 54%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November 29th, 2023</FONT></TD> <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD> <TD STYLE="border-bottom: black 1pt solid; width: 41%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Eyal Barad</I></FONT></TD></TR> <TR STYLE="vertical-align: top"> <TD> </TD> <TD> </TD> <TD> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.75pt 0pt 0">Eyal Barad</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.75pt 0pt 0">Director, Chief Executive Officer</P></TD></TR> <TR STYLE="vertical-align: top"> <TD> </TD> <TD> </TD> <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CNBX PHARMACEUTICALS INC.</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> </BODY> </HTML> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-32.2 <SEQUENCE>5 <FILENAME>cnbx_ex3202.htm <DESCRIPTION>CERTIFICATION <TEXT> <HTML> <HEAD> <TITLE></TITLE> </HEAD> <BODY STYLE="font: 10pt Times New Roman, Times, Serif"> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exhibit 32.2</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO 18 U.S.C. SECTION 1350,</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B> </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with this Annual Report of CNBX PHARMACEUTICALS INC. (the “Company”) on Form 10-K for the year ending August 31, 2023, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Uri Ben-Or, Chief Financial Officer (Principal Financial Officer) of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 2%"> </TD> <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD> <TD STYLE="width: 96%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such Annual Report on Form 10-K for the year ending August 31, 2023, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 2%"> </TD> <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD> <TD STYLE="width: 96%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The information contained in such Annual Report on Form 10-K for the year ending August 31, 2023, fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <TR STYLE="vertical-align: top"> <TD STYLE="width: 54%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November 29th, 2023</FONT></TD> <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD> <TD STYLE="border-bottom: black 1pt solid; width: 41%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Uri Ben-Or</I></FONT></TD></TR> <TR STYLE="vertical-align: top"> <TD> </TD> <TD> </TD> <TD> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.75pt 0pt 0">Uri Ben-Or</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.75pt 0pt 0">Chief Financial Officer</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.75pt 0pt 0">Principal Accounting Officer</P></TD></TR> <TR STYLE="vertical-align: top"> <TD> </TD> <TD> </TD> <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CNBX PHARMACEUTICALS INC.</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </P> </BODY> </HTML> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>6 <FILENAME>image_001.jpg <DESCRIPTION>GRAPHIC <TEXT> begin 644 image_001.jpg M_]C_X 02D9)1@ ! 0$ > !X #_VP!# ," @," @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_ MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%!3_P 1" %9 B(# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]4Z**;0 Z MBF9HS0 ^BF9HS0 ^BF9HS0 ^BF9HS0 ^BF9HS0 ^BF9HS0 ^BF9HS0 ^BF9H MS0 ^BF9HS0 ^BF9HS0 ^BF9HS0 ^BF9HS0 ^BF9HS0 ^BF9HS0 ^BF9HS0 ^ MBF9HS0 ^BF9HS0 ^BF9HS0 ^BF9HS0 ^BF9HS0 ^BF9HS0 ^BF9HS0 ^BF9H MS0 ^BF9HS0 ^BF9HS0 ^BF9HS0 ^BF9HS0 ^BF9HS0 ^BF9HS0 ^BF9HS0 ^ MBF9HS0 ^BF9HS0 ^BF;]O!ZT^@ HHHH *QO%7B"+PKX?U#6+A6>"Q@:=XUZL M!V%;-<9\8%V?"_Q2P//V"7^5 '$Z3\>/$&N:;;W]G\/=7DM;A \;X'*GOUJT M?C)XI_Z)SJ__ 'R/\:[+X4D_\*W\-\YQ8QC_ ,=%=8OUH \@_P"%R>*O^B<Z MO_WR/\:/^%R>*O\ HG.K_P#?(_QKU^B@#R#_ (7)XJ_Z)SJ__?(_QH_X7)XJ M_P"B<ZO_ -\C_&O7Z* /(/\ A<GBK_HG.K_]\C_&C_A<GBK_ *)SJ_\ WR/\ M:]?HH \@_P"%R>*O^B<ZO_WR/\:/^%R>*O\ HG.K_P#?(_QKU^B@#R#_ (7) MXJ_Z)SJ__?(_QH_X7)XJ_P"B<ZO_ -\C_&O7Z* /(/\ A<GBK_HG.K_]\C_& MC_A<GBK_ *)SJ_\ WR/\:]?HH \@_P"%R>*O^B<ZO_WR/\:/^%R>*O\ HG.K M_P#?(_QKU^B@#R#_ (7)XJ_Z)SJ__?(_QH_X7)XJ_P"B<ZO_ -\C_&O7Z* / M(/\ A<GBK_HG.K_]\C_&C_A<GBK_ *)SJ_\ WR/\:]?HH \@_P"%R>*O^B<Z MO_WR/\:/^%R>*O\ HG.K_P#?(_QKU^B@#R#_ (7)XJ_Z)SJ__?(_QH_X7)XJ M_P"B<ZO_ -\C_&O7Z* /(/\ A<GBK_HG.K_]\C_&C_A<GBK_ *)SJ_\ WR/\ M:]?HH \B_P"%Q^*?^B=:O_WR/\:/^%Q^*?\ HG6K_P#?(_QKUK<V>XY].M)O M;=@<^OM0!Y-_PN/Q3_T3K5_^^1_C1_PN/Q3_ -$ZU?\ [Y'^->LHY;/S9(H9 MRO.?EQR: /)O^%Q^*?\ HG6K_P#?(_QH_P"%Q^*?^B=:O_WR/\:]95V9B#Q@ M _6GC/K0!Y'_ ,+C\4_]$ZU?_OD?XT?\+C\4_P#1.M7_ .^1_C7K;,5[T9/& M#^= 'DG_ N/Q3_T3K5_^^1_C1_PN/Q3_P!$ZU?_ +Y'^->L^8QX'WCT!HWM MOQVQD4 >3?\ "X_%/_1.M7_[Y'^-(?C)XI_Z)SJ__?(_QKUDR,JG/5<9XJ1< M]Z /(?\ A<GBK_HG.K_]\C_&C_A<GBK_ *)SJ_\ WR/\:]?HH \@_P"%R>*O M^B<ZO_WR/\:/^%R>*O\ HG.K_P#?(_QKU^B@#R#_ (7)XJ_Z)SJ__?(_QH_X M7)XJ_P"B<ZO_ -\C_&O7Z* /(/\ A<GBK_HG.K_]\C_&C_A<GBK_ *)SJ_\ MWR/\:]?HH \@_P"%R>*O^B<ZO_WR/\:/^%R>*O\ HG.K_P#?(_QKU^B@#R#_ M (7)XJ_Z)SJ__?(_QH_X7)XJ_P"B<ZO_ -\C_&O7Z* /(/\ A<GBK_HG.K_] M\C_&C_A<GBK_ *)SJ_\ WR/\:]?HH \@_P"%R>*O^B<ZO_WR/\:/^%R>*O\ MHG.K_P#?(_QKU^B@#R#_ (7)XJ_Z)SJ__?(_QH_X7)XJ_P"B<ZO_ -\C_&O7 MZ* /(/\ A<GBK_HG.K_]\C_&C_A<GBK_ *)SJ_\ WR/\:]?HH \@_P"%R>*O M^B<ZO_WR/\:/^%R>*O\ HG.K_P#?(_QKU^B@#R#_ (7)XJ_Z)SJ__?(_QH_X M7)XJ_P"B<ZO_ -\C_&O7Z* /(/\ A<GBK_HG.K_]\C_&@?&/Q7G_ ))UJP'3 MH.?UKU^D(]_>@#SKX;?%I?B!K&JZ5=:+>:'J6F[3)#= LI[BO0XRW1OK^M> M._#_ "?CWXZYQF"+^=>R+W/O0 ZBBB@ KC?C'_R2SQ3_ ->$O\J[*N-^,?\ MR2SQ3_UX2_RH D^%/_)-_#G_ %Y1_P JZU:Y+X4_\DW\.?\ 7E'_ "KK5H 6 MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *; MNIU,H ^-OVXOV\F_9GUC3_"WA_2UU7Q+>1_:)/-)"P1]B?K1^S!^W5)^T5\, M_&%RVG1Z/XQ\/V;S-!]Z-P!D-2?MP?L'3?M+:Q8>*/#NK1Z3XDM8_(D%QDQS MQCH#@=JM_LF_L'K\ ?A]XJLM5U8:AXE\26[6UQ=P+A(4(P H]J .H^"G[97A MWQ5X5M4\3M<Z3KL=F]W,UU 8HYU5B"8B?O'BL;XH_MQ:-_PJG7-7\#PW5SX@ MM6BCCMY;<ED$APKD=ZATC]AF\U+3TTWQ?XOFUC3;"S>TTQ(8@CV^XD[B>_6M M7PW^R%>VO@&\\/W^KVZW9>'R=1@C_>,D9X#\<\4 ;.C_ +66@^&]-T73_$<E MYJ.K?9X6U:^M+0^19/)C:)"/N\FN@N/VM/ T&MZ_IZO>2)H:*UY>B'_1U+#* MJ'[D\5Q_B;]DS5-2\0:L-*\4-IOAKQ +?^W+ P@M<&+&-I[9Q6G_ ,,BZ;)X M#\=>$WU*3[!XBGCGBD4?O("@&W)^H% '>_"'X^>%_C4-170)I/M6GLHN;>9" MK*#T(]17(_MF?&37?@3\#]1\3^'A VK)*D,1N!N4%C@<5K?L^_!:\^$>GWD. MI3V]]>RJL7VJ"/:61>FX]S63^V=\'M>^.'P-U/PWX:>&/5Y)8YX1/PNY3F@# MY*\8?M&?M3_#WX?V'C;5WT%]"D>%Y-D8#;'(XS^-?7>H?M1:-X)\,^#KWQ3; M7,#ZU:PS2W4,>88FD QD_4U\>^,OV>_VI?B5X LO!&M0:"NBQM"CLK$-M0CG MI[5]!^//V.=:^($'AY9_$TEK;V>G6UI<676,/%CE1T[4 <EXY_;DUKP9\4?% M)71;S4/"FDB&"*WCMR3.\@&'W=NO2O:=8_;"\$>&]0TG3]3^UVM[>10R3QM$ M?]%\P#;O]*R/$G[)\FL:1XPM(-<>WFUI+4P3; 3#)"H"D^QQ6-=_LA:C+X\T M_P 4MK45]>S6T-OJ\5VFZ.X\OIM&* /4O!O[1GA?Q]\1-1\'Z+'>WE[8#=/= M+"?LZ@C(^?WKU'?T]^G->6_![X*)\)]2\3W27GVM=:N?M&S8%\KT4'TKTY4. MX'V_+Z4 34M)Z4M !1110 4444 %%%% !1110 4444 %%%% !1129H 6BDW4 M9H 6BBB@ HHHH *3O2TG>@#QKX??\E[\<_\ 7"+^=>R)T_&O&_A]_P E[\<_ M]<(OYU[(G3\: '4444 %<;\8_P#DEGBG_KPE_E795QOQC_Y)9XI_Z\)?Y4 2 M?"G_ ))OX<_Z\H_Y5UJUR7PI_P"2;^'/^O*/^5=:M !F@L!575-2M='LY;V^ MGCM;2%2\DTIPJ*.Y/85S4WQ8\(0^$6\4OX@L?^$?4G&HB4&(XZX8=: .NW@T MNX>M<%>?&WP-8^&;+Q)/XFT^'1;T[;:\,HQ(?2NOTO5;+7-/@O[&X2ZM9P&C MFB.0P/>@"]D4M1Y&[&>?2I* "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH *;M-.HH :/IS2*I7C@"GT4 (:._2EHH 3FBEHH 3%)MW')'3I3J* M(V0]L<]<]Z<J\>E.HH 3FBEHH 3;1BEHH **** "BBB@ HHHH **** "BBB@ M HHHH **** $S368 \G'UI3UJ*XF2WADDDD6*-%+LS=% Y)H >6 .#]:%<?T MK\Z_V@/^"KD'A/Q=>>'OA[H2:TME(8IM3N&_=EQP0H[BNW_90_X*3Z3\;O$D M'A+Q7I"^&O$=SE;9HI-T5P1Z>A]J!GV^K!NAS3JB4D-@]<XX'6I:!!29%+3, M]* 'TG>C-'>@#QKX??\ )>_'/_7"+^=>R)T_&O&_A]_R7OQS_P!<(OYU[(G3 M\: '4444 %<;\8_^26>*?^O"7^5=E7&_&/\ Y)9XI_Z\)?Y4 2?"G_DF_AS_ M *\H_P"5=:M<E\*?^2;^'/\ KRC_ )5UJT <?\6WTB/X>ZXVO1-/I2VLAEC0 M%F?C@ #KUKX.\&ZC9#]G_P ",-)OCX<\/^)Y;G6+&2!@HMF+8)0CD8_G7Z.7 M$*7$?ER(LB'JCC(-54TVR6)K<64(C8?-&(QM/U&* /S4L=/CT'Q<?%NO^'KN M?X5:E<WATFRD@9XX]Z$(0G;)/'O7V7^R%H.J^'?@;HUKJT,MK+))++#;S AH MX6;* Y]J]@?3;::W%O);1-;I]R%HAL7Z5:A7:@7CCHN, 4 <)\2-2\3:':RZ MAI=Q:K:1@ QN.:C@L_'DMK')_:-GE@#T]:T/BS_R)5U_UTC_ )UU.G_\@^V_ MZXK_ "H XO\ LWQY_P!!&S_*C^S?'?\ T$;/\J] HH \_P#[-\=_]!&S_*C^ MS?'?_01L_P J] HH \__ +-\=_\ 01L_RH_LWQW_ -!&S_*O0** //\ ^S?' M?_01L_RH_LWQW_T$;/\ *O0** //_P"S?'?_ $$;/\J/[-\=_P#01L_RKT"B M@#S_ /LWQW_T$;/\J/[-\=_]!&S_ "KT"B@#S_\ LWQW_P!!&S_*C^S?'?\ MT$;/\J] HH \_P#[-\=_]!&S_*C^S?'?_01L_P J] HH \__ +-\=_\ 01L_ MRH_LWQW_ -!&S_*O0** //\ ^S?'?_01L_RH_LWQW_T$;/\ *O0** //_P"S M?'?_ $$;/\J/[-\=_P#01L_RKT"B@#S_ /LWQW_T$;/\J/[-\=_]!&S_ "KT M"B@#S_\ LWQW_P!!&S_*C^S?'?\ T$;/\J] HH \_P#[-\=_]!&S_*C^S?'? M_01L_P J] HH \__ +-\=_\ 01L_RH_LWQW_ -!&S_*O0** //\ ^S?'?_01 ML_RH_LWQW_T$;/\ *O0** //_P"S?'?_ $$;/\J/[-\=_P#01L_RKT"B@#S_ M /LWQW_T$;/\J/[-\=_]!&S_ "KT"B@#S_\ LWQW_P!!&S_*C^S?'?\ T$;/ M\J] HH \_P#[-\=_]!&S_*C^S?'?_01L_P J] HH \__ +-\=_\ 01L_RH_L MWQW_ -!&S_*O0** //\ ^S?'?_01L_RH_LWQW_T$;/\ *O0** //_P"S?'?_ M $$;/\J/[-\=_P#01L_RKT"B@#S_ /LWQW_T$;/\JY#XPZ+\0KKX5^*XK:^A MEN&T^4+' ,.WRG(4]C7MQZ57FPRLIV[6&,,,J?4&@#^;*%)(Y)8IPRWL4DB3 MJWWE?<<@^]=;\([/4]2^+W@VST0EM9;4(_(\OAE.>I]J_4O]H#_@E[X(^+GB M6X\0Z#J%QX5U"Z?S+FWMS^YD;^\!V-=E^S#_ ,$__!'[.NK2:Z9I?$GB0C"W MEV/]5G&0OY4#N>SV>F>/5L[=7U"S1UB0,",G<!SFI?[-\=_]!&S_ "KO%7YR M00<GFI*!'G_]F^._^@C9_E6YX7MM>MOM']M744^X_NO+'2NDHH 9]*6G4G>@ M#QKX??\ )>_'/_7"+^=>R)T_&O&_A]_R7OQS_P!<(OYU[(G3\: '4444 %<; M\8_^26>*?^O"7^5=E7&_&/\ Y)9XI_Z\)?Y4 2?"G_DF_AS_ *\H_P"5=:M< ME\*?^2;^'/\ KRC_ )5UJT ,E) X.*\(_:RU[Q=H/A'2H_"[75K8W=X$U2_L MEWSVMO@Y=1['%>\R#(YZ5R/Q&^'\7Q%\//IDU_=:=&[9:6U<J^"""/I0!\1^ M&?CEX[^*5MIW@>S\3R:2D4ERZ:Y,A2>ZCB0LN[TSBOJO]E_XA:G\2?A+I^IZ MO)Y^H0R26DMRO_+4HV-V/>LK7OV1O!.N>$=$T2$76G?V6Q*7UNY6>3/WMS9R M<C/YUZIX+\%Z3X \,V.AZ-;_ &6PM%VQJ"<DGJ3ZDT <C\9?%=K8Z%-I\L5P MTKNN&2/*]:O67Q7TQ+&V L]1/R ?\>Y]*M_%E5'@V=BH+>8G)'/6NHT^%!I] MM\B_ZI3T'I0!R/\ PM_3/^?+4O\ P'-'_"X-,_Y\M2_\!S7<_9XO^>:?]\BC M[/%_SS3_ +Y% '#?\+@TS_GRU+_P'-'_ N#3/\ GRU+_P !S7<_9XO^>:?] M\BC[/%_SS3_OD4 <-_PN#3/^?+4O_ <T?\+@TS_GRU+_ ,!S7<_9XO\ GFG_ M 'R*/L\7_/-/^^10!PW_ N#3/\ GRU+_P !S1_PN#3/^?+4O_ <UW/V>+_G MFG_?(H^SQ?\ /-/^^10!PW_"X-,_Y\M2_P# <T?\+@TS_GRU+_P'-=S]GB_Y MYI_WR*/L\7_/-/\ OD4 <-_PN#3/^?+4O_ <T?\ "X-,_P"?+4O_ '-=S]G MB_YYI_WR*/L\7_/-/^^10!PW_"X-,_Y\M2_\!S1_PN#3/^?+4O\ P'-=S]GB M_P">:?\ ?(H^SQ?\\T_[Y% '#?\ "X-,_P"?+4O_ '-'_"X-,_Y\M2_\!S7 M<_9XO^>:?]\BC[/%_P \T_[Y% '#?\+@TS_GRU+_ ,!S1_PN#3/^?+4O_ <U MW/V>+_GFG_?(H^SQ?\\T_P"^10!PW_"X-,_Y\M2_\!S1_P +@TS_ )\M2_\ M <UW/V>+_GFG_?(H^SQ?\\T_[Y% '#?\+@TS_GRU+_P'-'_"X-,_Y\M2_P# M<UW/V>+_ )YI_P!\BC[/%_SS3_OD4 <-_P +@TS_ )\M2_\ <T?\+@TS_GR MU+_P'-=S]GB_YYI_WR*/L\7_ #S3_OD4 <-_PN#3/^?+4O\ P'-'_"X-,_Y\ MM2_\!S7<_9XO^>:?]\BC[/%_SS3_ +Y% '#?\+@TS_GRU+_P'-'_ N#3/\ MGRU+_P !S7<_9XO^>:?]\BC[/%_SS3_OD4 <-_PN#3/^?+4O_ <T?\+@TS_G MRU+_ ,!S7<_9XO\ GFG_ 'R*/L\7_/-/^^10!PW_ N#3/\ GRU+_P !S1_P MN#3/^?+4O_ <UW/V>+_GFG_?(H^SQ?\ /-/^^10!PW_"X-,_Y\M2_P# <T?\ M+@TS_GRU+_P'-=S]GB_YYI_WR*/L\7_/-/\ OD4 <-_PN#3/^?+4O_ <T?\ M"X-,_P"?+4O_ '-=S]GB_YYI_WR*/L\7_/-/^^10!PW_"X-,_Y\M2_\!S1_ MPN#3/^?+4O\ P'-=S]GB_P">:?\ ?(H^SQ?\\T_[Y% '#?\ "X-,_P"?+4O_ M '-'_"X-,_Y\M2_\!S7<_9XO^>:?]\BC[/%_P \T_[Y% '#?\+@TS_GRU+_ M ,!S1_PN#3/^?+4O_ <UW/V>+_GFG_?(H^SQ?\\T_P"^10!PW_"X-,_Y\M2_ M\!S1_P +@TS_ )\M2_\ <UW/V>+_GFG_?(H^SQ?\\T_[Y% '#?\+@TS_GRU M+_P'-'_"X-,_Y\M2_P# <UW/V>+_ )YI_P!\BC[/%_SS3_OD4 <+_P +>TO_ M )\M2_\ <TG_"W-+_Y\M2_\!S7=^1'_ ,\U_P"^11Y$?_/-?^^10!PG_"W- M+_Y\M2_\!S2_\+>TO_GRU+_P'-=UY$?_ #S7_OD4>1'_ ,\U_P"^10!PO_"W M]+_Y\M2_\!S2_P#"X-,_Y\M2_P# <UW/V>+_ )YI_P!\BC[/%_SS3_OD4 <- M_P +@TS_ )\M2_\ <UM^&_&%MXJ$RVL=U T?7SX]M;WV>+_ )YI_P!\BD\M M!G"A<]=HQ0 Y6W $4M)2T >-_#[_ )+WXY_ZX1?SKV1.GXUXW\/O^2]^.?\ MKA%_.O9$Z?C0 ZBBB@ KC?C'_P DL\4_]>$O\J[*N-^,?_)+/%/_ %X2_P J M )/A3_R3?PY_UY1_RKK5KDOA3_R3?PY_UY1_RKK5H 9,.AYX["O-_C?\9K;X M*^&(=5N+)]2EN)_L\$*/Y:ER,C<QX XZUZ1(O<'!Q7AO[6'POU_XK>#=+L-& MMX+^UANQ->:?,VS[1'@@J'ZJ<D=!0!S4G[:EA-X6L+O3?"][J'B*ZD:-]'C? M[BHI9I ^,,N!VKV;X5_$JP^*W@O3_$NFJ\-M= J8''S1R+PRD^QKY0T/]F3X MH> [/1-;T6.QNM0L?/M(=%FE^2WMI%(_UF/F(SZ5]*_L[_"^X^$OPPT[0KR4 M2WV][BXQ]U9';<0/I0!L?%ID/@^=&<(?,0X)Y/-=/I]Q#]@M@9H_]6H^\/2O M/_C-X1LK_09M2EDN//1TPJRD+R<=*OV7PET5K&V/GWX_=AO^/D]Q0!W7VR#_ M )[Q_P#?0H^V0?\ />/_ +Z%<;_PI_1.\]__ .!)H_X4_HG_ #WO_P#P)- ' M9?;(/^>\?_?0H^V0?\]X_P#OH5QO_"G]$_Y[W_\ X$FC_A3^B?\ />__ / D MT =E]L@_Y[Q_]]"C[9!_SWC_ .^A7&_\*?T3_GO?_P#@2:/^%/Z)_P ][_\ M\"30!V7VR#_GO'_WT*/MD'_/>/\ [Z%<;_PI_1/^>]__ .!)H_X4_HG_ #WO M_P#P)- '9?;(/^>\?_?0H^V0?\]X_P#OH5QO_"G]$_Y[W_\ X$FC_A3^B?\ M/>__ / DT =E]L@_Y[Q_]]"C[9!_SWC_ .^A7&_\*?T3_GO?_P#@2:/^%/Z) M_P ][_\ \"30!V7VR#_GO'_WT*/MD'_/>/\ [Z%<;_PI_1/^>]__ .!)H_X4 M_HG_ #WO_P#P)- '9?;(/^>\?_?0H^V0?\]X_P#OH5QO_"G]$_Y[W_\ X$FC M_A3^B?\ />__ / DT =E]L@_Y[Q_]]"C[9!_SWC_ .^A7&_\*?T3_GO?_P#@ M2:/^%/Z)_P ][_\ \"30!V7VR#_GO'_WT*/MD'_/>/\ [Z%<;_PI_1/^>]__ M .!)H_X4_HG_ #WO_P#P)- '9?;(/^>\?_?0H^V0?\]X_P#OH5QO_"G]$_Y[ MW_\ X$FC_A3^B?\ />__ / DT =E]L@_Y[Q_]]"C[9!_SWC_ .^A7&_\*?T3 M_GO?_P#@2:/^%/Z)_P ][_\ \"30!V7VR#_GO'_WT*/MD'_/>/\ [Z%<;_PI M_1/^>]__ .!)H_X4_HG_ #WO_P#P)- '9?;(/^>\?_?0H^V0?\]X_P#OH5QO M_"G]$_Y[W_\ X$FC_A3^B?\ />__ / DT =E]L@_Y[Q_]]"C[9!_SWC_ .^A M7&_\*?T3_GO?_P#@2:/^%/Z)_P ][_\ \"30!V7VR#_GO'_WT*/MD'_/>/\ M[Z%<;_PI_1/^>]__ .!)H_X4_HG_ #WO_P#P)- '9?;(/^>\?_?0H^V0?\]X M_P#OH5QO_"G]$_Y[W_\ X$FC_A3^B?\ />__ / DT =E]L@_Y[Q_]]"C[9!_ MSWC_ .^A7&_\*?T3_GO?_P#@2:/^%/Z)_P ][_\ \"30!V7VR#_GO'_WT*/M MD'_/>/\ [Z%<;_PI_1/^>]__ .!)H_X4_HG_ #WO_P#P)- '9?;(/^>\?_?0 MH^V0?\]X_P#OH5QO_"G]$_Y[W_\ X$FC_A3^B?\ />__ / DT =E]L@_Y[Q_ M]]"C[9!_SWC_ .^A7&_\*?T3_GO?_P#@2:/^%/Z)_P ][_\ \"30!V7VR#_G MO'_WT*/MD'_/>/\ [Z%<;_PI_1/^>]__ .!)H_X4_HG_ #WO_P#P)- '9?;( M/^>\?_?0H^V0?\]X_P#OH5QO_"G]$_Y[W_\ X$FC_A3^B?\ />__ / DT =E M]L@_Y[Q_]]"C[9!_SWC_ .^A7&_\*?T3_GO?_P#@2:/^%/Z)_P ][_\ \"30 M!V7VR#_GO'_WT*/MD'_/>/\ [Z%<;_PI_1/^>]__ .!)H_X4_HG_ #WO_P#P M)- '9?;(/^>\?_?0H^V0?\]X_P#OH5QO_"G]$_Y[W_\ X$FC_A3^B?\ />__ M / DT =E]L@_Y[Q_]]"D2=)%9D=7 _N'.*X[_A3^B?\ />__ / DUM>&O!EC MX5\W[')<-YG7SI"U &V#D YS3J N** /&_A]_P E[\<_]<(OYU[(G3\:\;^' MW_)>_'/_ %PB_G7LB=/QH =1110 5QOQC_Y)9XI_Z\)?Y5V5<;\8_P#DEGBG M_KPE_E0!)\*?^2;^'/\ KRC_ )5UJUR7PI_Y)OX<_P"O*/\ E76K0 UP<@@X MQZUC^)?%FC^#[,7>LZC#IMLS!0]PVU23T%;+#=QVKR3]IVZT#2?A!K6I>(=' M37%M8C]FM&4DO,WRI@#N,Y_"@#KYOBAX3M]%76I/$%@NE,^P7GGC87_NUT5E M?0:A:PW5LZ36TX#I-&V58'H0?2OSIO?AKI7PFT7X=67C2SG'A;4+&XO;NVR[ M+'<NC-&#COTKZM_8ZM=6LO@3H\>JK,7,TK6RS9#>06^0<]@* /0/BQEO!ETH MY/F)WQT-=1IIW:?;?]<E'7VKSOXS-K_]AS+:+:OIS.NXR?>'/%7;.X\=BSMM ML.G;/+!Z'ICB@#T/<*0N!7!_:?'XZ0:;CZFC[1X_/_+'3OPS0!W?F#_)H\P? MY-<'Y_C_ /YXZ=^1H\_Q_P#\\=._(T =YY@_R:/,'^37!^?X_P#^>.G?D:// M\?\ _/'3OR- '>>8/\FCS!_DUP?G^/\ _GCIWY&CS_'_ /SQT[\C0!WGF#_) MH\P?Y-<'Y_C_ /YXZ=^1H\_Q_P#\\=._(T =YY@_R:/,'^37!^?X_P#^>.G? MD://\?\ _/'3OR- '>>8/\FCS!_DUP?G^/\ _GCIWY&CS_'_ /SQT[\C0!WG MF#_)H\P?Y-<'Y_C_ /YXZ=^1H\_Q_P#\\=._(T =YY@_R:/,'^37!^?X_P#^ M>.G?D://\?\ _/'3OR- '>>8/\FCS!_DUP?G^/\ _GCIWY&C[1X_'_+'3OR- M '>>8.2> .M+N''<'O7SS^T!\?\ 7?V=_AO?>+/$$-E*D?[NWMHN&FE(X7Z5 M^;.N?\%-/CCK'B#^T[2^L=+M0VY-/6([-O93WZ=Z /VLWC.*-PKXP_8[_;4\ M1_M/Z7>6+6%CIOB;35!N+=C\LB_WQ7TI]H\>G($.G9QGO0!W7F#_ ":/,'^3 M7!^?X_\ ^>.G?D://\?_ //'3OR- '>>8/\ )H\P?Y-<'Y_C_P#YXZ=^1H\_ MQ_\ \\=._(T =YY@_P FCS/E)'/MFN$\[Q__ ,\=._(URGQ1^*WB/X/^ ]9\ M6>($TY=.TZ'S&7."Q[ >M 'LY;IP3GTHWBOQ>\<_\%/OC-XLUTWV@SV/A[2U M;]U:[-VY?5C[BOJO]C']O;Q-^T%J$W@_5[&QL?%,$?FPS'B.X0=3CUH ^]]P MIOF#_)KA&N/'O:'3OR-)Y_C_ /YXZ=^1H [SS!_DT>8/\FN#\_Q__P \=._( MT>?X_P#^>.G?D: .\\P?Y-'F#_)K@_/\?_\ /'3OR-+YWC__ )XZ=^1H [OS M!D#J:7<.E>6>*O&/BOP1X<U3Q!K']G0:=IUNT\S@?,0.PK\P?BI_P5"^+'B[ M7IV\)O9^'='B<K"NS<\B@XW,?Z4 ?LCNZ\4;^<'TS7YR?L@?\%$/%WQ8\66W M@/Q/:V*:W*O^C7IX6?';T!/O7V^;CQ[N<"'3\ \9H [OS!_DT>8/\FN#\_Q_ M_P \=._(T>?X_P#^>.G?D: .\\P?Y-'F#_)K@_/\?_\ /'3OR-'G^/\ _GCI MWY&@#O/,'^31Y@_R:X/S_'__ #QT[\C1Y_C_ /YXZ=^1H [SS!_DT>8/\FN# M\_Q__P \=._(T>?X_P#^>.G?D: .\\P?Y-'F#_)K@_/\?_\ /'3OR-'G^/\ M_GCIWY&@#O/,'^32ALUP7G^/_P#GCIWY&MWPU)XAD\[^VDMHN?W?D<T =#NI M*2EH \;^'W_)>_'/_7"+^=>R)T_&O&_A]_R7OQS_ -<(OYU[(G3\: '4444 M%<;\8_\ DEGBG_KPE_E795QOQC_Y)9XI_P"O"7^5 $GPI_Y)OX<_Z\H_Y5UJ MUR7PI_Y)OX<_Z\H_Y5UJT !..3Q5+4]/L]4B$%[;17<((81RJ&7<.AJXYP5] MSBO"/VK_ (R:M\)_!6E#0T8ZOK%ZME',L>]H0>K@=R!0![%K'AW2_$5G%;ZC MI]K?6ZD,L5Q&'"XZ8]*O6]O%;0QQ0HL4<8VHH 4>@':OC.Z^.GBGQ9'X>\% M^"_%S2:TZ37&I:K=6^V1#&A;9CMR,5[W^S3\2=1^*WPKL-<U5(TU!7DM)Y8_ M^6CQMM+8]Z .D^*W_(FW/M)'_.NJL.=/M\'/[I?Y5Y]\9/%FG6.ARZ=-(RW3 M.NU=I(/XUI67Q8\.1V=L/M3_ ' /]6?2@#NN?7]*/Q_2N*_X6YX<_P"?J3_O MV?\ "C_A;GAS_GZD_P"_9_PH [7\?TH_']*XK_A;GAS_ )^I/^_9_P */^%N M>'/^?J3_ +]G_"@#M?Q_2C\?TKBO^%N>'/\ GZD_[]G_ H_X6YX<_Y^I/\ MOV?\* .U_']*/Q_2N*_X6YX<_P"?J3_OV?\ "C_A;GAS_GZD_P"_9_PH [7\ M?TH_']*XK_A;GAS_ )^I/^_9_P */^%N>'/^?J3_ +]G_"@#M?Q_2C\?TKBO M^%N>'/\ GZD_[]G_ H_X6YX<_Y^I/\ OV?\* .U_']*/Q_2N*_X6YX<_P"? MJ3_OV?\ "C_A;GAS_GZD_P"_9_PH [7\?TH_']*XK_A;GAS_ )^I/^_9_P * M/^%N>'/^?J3_ +]G_"@#M?Q_2C\?TKBO^%N>'/\ GZD_[]G_ H_X6YX<_Y^ MI/\ OV?\* .U_']*1L^I_*N+_P"%N>'/^?J3_OV?\*/^%N>'/^?J3_OV?\* M/E+_ (*Q>!]9\5? ;3]1TR&2ZATF]\^ZA12?D(^]@>E?D9'=QW"QLCB1<?>S M\P]?RK^A?4OB1X3UJQGLKU_M%I<(8Y(982RR ]5(Q7RKXF_8;_9N\1>(I=6^ MRWEE%(_F2V=IN$3-G)'3B@#YX_X)(^#M6U3XQ:]XL@CE70;>R-LUQM.R5SC@ M'H>E?K;][U'?I7DOP\O_ (;_ J\.6^A>%;6/2=.B'$-O"06]V..373?\+<\ M.@X-S-^,9H [;\?TH_']*XK_ (6YX<_Y^I/^_9_PH_X6YX<_Y^I/^_9_PH [ M7\?TH_']*XK_ (6YX<_Y^I/^_9_PH_X6YX<_Y^I/^_9_PH [7\:^7/\ @HUX M'U?QY^S'XAM]%B:[N;/;=26Z@DO&#SP.N*]O_P"%N>'#_P O3_\ ?!J*Z^*' MAFYA:.2=I8W!5HWB)1@>S>U '\\-I,NU(P Q4C<C\8(&"IKZE_X)I^!]7\6? MM-Z=JVF)(^FZ-$SWEX =J_\ 3//2OM+Q_P#L9?L[?$#Q-/K4MI=:;-<2&2>W MLU98W8]3CL*]P^$>G_"SX'^'%T3P?9)I=DOWW6(F28^K-C)H ]N&3STIWX_I M7%?\+=\.=/M3_P#?LT?\+<\.?\_4G_?L_P"% ':_C^E'X_I7%?\ "W/#G_/U M)_W[/^%'_"W/#G_/U)_W[/\ A0!VOX_I17%?\+<\.?\ /U)_W[/^%'_"W/#G M_/S)_P!\&@#C/VPO!^I^//V=?&FCZ1O-])9ET5 =S!>2H_*OP.@4VZRP2HT$ MUM)Y<T<@QL8'&WGO7]$3?%GPY)\OVB1@?X1&3GV/M7S1\6OV3_V>_C#K\NNW MUG+I6IRONEEL4*>8W^Z!UH&?G)^Q1X-U?QQ^TYX-CT:.1UTJY^UW=Q&"42,= M0Q'3J*_>5<AL9SP :\#^"O@GX0_L]Z5)8^#]/6Q>;FXNFC+32'U)Q7I7_"V_ M#N>+J1A_>\LT#.V_']*/Q_2N*_X6YX<_Y^I/^_9_PH_X6YX<_P"?J3_OV?\ M"@D[7\?TH_']*XK_ (6YX<_Y^I/^_9_PH_X6YX<_Y^I/^_9_PH [7\?TH_'] M*XK_ (6YX<_Y^I/^_9_PH_X6YX<_Y^I/^_9_PH [7\?TH_']*XK_ (6YX<_Y M^I/^_9_PH_X6YX<_Y^I/^_9_PH [7\?TH_']*XK_ (6YX<_Y^I/^_9_PH_X6 MYX<_Y^I/^_9_PH [7\?TI#D\=*XO_A;GAS_GZD_[]G_"MGP[XNT[Q,LXT^5I MO)^]N4B@#:P:6E7ITQ1WH \:^'W_ "7OQS_UPB_G7LB=/QKQOX??\E[\<_\ M7"+^=>R)T_&@!U%%% !7&_&/_DEGBG_KPE_E795QOQC_ .26>*?^O"7^5 $G MPI_Y)OX<_P"O*/\ E76K7)?"G_DF_AS_ *\H_P"5=:M #9/E!;/;&*\^^,7P MAT_XO>&[>PO;N;3[VUE6YM+^V.'@D7.&'X$UZ#)CY0?6O//C-\9-&^"?A>VU MG6(+BZBN+@6L,%JNZ1Y&S@ ?G0!YA>_L5>'9]!M(++7-2TW7XY6FN==@;$]U MO!#AO8@D?C7M7PZ\ Z7\,_"=GX>T>/RK:V7[S\F1N['WS7FOBK]J+2/!?A71 MM2U'0]435-6#?9])CCW7)C49+D#L!S7I?P]\=Z3\4/"NG^(M$F,EC<C*[AAE M(X96'J* */Q8MX6\'W#,D9D\R/YMOO726.GV?V&W_P!&B_U*_P ]*Y_XL8; MP7<J0"WF1X7=C^*NHL&"V-MEO^68[CTH 7^S[/\ Y](O^_8H_L^S_P"?2+_O MVM6-R^H_2C*^H_2@"O\ V?9_\^D7_?M:/[/L_P#GTB_[]K5C*^H_2C*^H_2@ M"O\ V?9_\^D7_?M:/[/L_P#GTB_[]K5C*^H_2C*^H_2@"O\ V?9_\^D7_?M: M/[/L_P#GTB_[]K5C*^H_2C*^H_2@"O\ V?9_\^D7_?M:/[/L_P#GTB_[]K5C M*^H_2C*^H_2@"O\ V?9_\^D7_?M:/[/L_P#GTB_[]K5C*^H_2C*^H_2@"O\ MV?9_\^D7_?M:/[/L_P#GTB_[]K5C*^H_2C*^H_2@"O\ V?9_\^D7_?M:/[/L M_P#GTB_[]K5C*^H_2C*^H_2@"O\ V?9_\^D7_?M:/[/L_P#GTB_[]K5C*^H_ M2C*^H_2@"O\ V?9_\^D7_?M:/[/L_P#GTB_[]K5C*^H_2C*^H_2@"O\ V?9_ M\^D7_?M:/[/L_P#GTB_[]K5C*^H_2C*^H_2@"O\ V?:?\^D7_?L4?8+3_GTB M_P"_8JQE?4?I1N7^]_*@"O\ V?9_\^D7_?M:/[/L_P#GTB_[]K5C*^H_2C*^ MH_2@"O\ V?9_\^D7_?M:/[/L_P#GTB_[]K5C*^H_2C*^H_2@"O\ V?9_\^D7 M_?M:/[/L_P#GTB_[]K5C*^H_2C*^H_2@"O\ V?9_\^D7_?M:/[/L_P#GTB_[ M]K5C*^H_2C*^H_2@"O\ V?9_\^D7_?M:/[/L_P#GTB_[]K5C*^H_2C*^H_2@ M"O\ V?9_\^D7_?M:/[/L_P#GTB_[]K5C*^H_2C*^H_2@"O\ V?9_\^D7_?M: M/[/L_P#GTB_[]K5C*^H_2C*^H_2@"O\ V?9_\^D7_?M:/[/L_P#GTB_[]K5C M*^H_2C*^H_2@"O\ V?9_\^D7_?M:/[/L_P#GTB_[]K5C*^H_2C*^H_2@"O\ MV?9_\^D7_?M:/[/L_P#GTB_[]K5C*^H_2C*^H_2@"O\ V?9_\^D7_?M:/[/L M_P#GTB_[]K5C*^H_2C*^H_2@"O\ V?9_\^D7_?M:/[/L_P#GTB_[]K5C*^H_ M2C*^H_2@"O\ V?9_\^D7_?M:/[/L_P#GTB_[]K5C*^H_2C*^H_2@"O\ V?9_ M\^D7_?M:/[/L_P#GTB_[]K5C*^H_2C*^H_2@"O\ V?9_\^D7_?M:?%;00?ZN M..,_[*XJ7*^H_2FQL&8@8)_V30!(.GK1WH!R,T=Z /&OA]_R7OQS_P!<(OYU M[(G3\:\;^'W_ "7OQS_UPB_G7LB=/QH =1110 5QOQC_ .26>*?^O"7^5=E7 M&_&/_DEGBG_KPE_E0!)\*?\ DF_AS_KRC_E76K7)?"G_ ))OX<_Z\H_Y5UJT M -?)Z<<'FO(OVD_#L7B+P&+:?PI<>+E5]R6UI(4DCDP=L@((Q@XKUYZKR2+% M&[.V$7DEFV@>Y/:@#X6TWX-_%_P/IOAOQ?/8GQ-J\"SVG]DRREI;2"1"%^8] M2,C/TKZ9_9I^'-_\+_A?8Z/J;*+^2:2\EA7_ )9F0YV_A7HD^O:;9V/VZXU* MTCLV/RS/.JQ^G#9Y-78)$FC65'22.0;PZG(*]L&@#S?XS>%EU#0I[YKZ>/8\ M?[M#QUJU9_"A)+.V/]MW_P!P'_6'TK2^+!QX+N"&/^LC^[]:ZK3\#3[8Y'^J M4_I0!Q/_ J=?^@YJ'_?PT?\*G7_ *#FH?\ ?PUW^!1M% ' ?\*G7_H.:A_W M\-'_ J=?^@YJ'_?PUW^T4;10!P'_"IU_P"@YJ'_ '\-'_"IU_Z#FH?]_#7? M[11M% ' ?\*G7_H.:A_W\-'_ J=?^@YJ'_?PUW^T4;10!P'_"IU_P"@YJ'_ M '\-'_"IU_Z#FH?]_#7?[11M% ' ?\*G7_H.:A_W\-'_ J=?^@YJ'_?PUW^ MT4;10!P'_"IU_P"@YJ'_ '\-'_"IU_Z#FH?]_#7?[11M% ' ?\*G7_H.:A_W M\-'_ J=?^@YJ'_?PUW^T4;10!P'_"IU_P"@YJ'_ '\-'_"IU_Z#FH?]_#7? M[11M% ' ?\*G7_H.:A_W\-'_ J=?^@YJ'_?PUW^T4;10!P'_"IU_P"@YJ'_ M '\-'_"IU_Z#FH?]_#7?[11M% ' ?\*G7_H.:A_W\-'_ J=?^@YJ'_?PUW^ MT4;10!P'_"IU_P"@YJ'_ '\-'_"IU_Z#FH?]_#7?[11M% ' ?\*G7_H.:A_W M\-'_ J=?^@YJ'_?PUW^T4;10!P'_"IU_P"@YJ'_ '\-'_"IU_Z#FH?]_#7? M[11M% ' ?\*G7_H.:A_W\-'_ J=?^@YJ'_?PUW^T4;10!P'_"IU_P"@YJ'_ M '\-'_"IU_Z#FH?]_#7?[11M% ' ?\*G7_H.:A_W\-'_ J=?^@YJ'_?PUW^ MT4;10!P'_"IU_P"@YJ'_ '\-'_"IU_Z#FH?]_#7?[11M% ' ?\*G7_H.:A_W M\-'_ J=?^@YJ'_?PUW^T4;10!P'_"IU_P"@YJ'_ '\-'_"IU_Z#FH?]_#7? M[11M% ' ?\*G7_H.:A_W\-'_ J=?^@YJ'_?PUW^T4;10!P'_"IU_P"@YJ'_ M '\-'_"IU_Z#FH?]_#7?[11M% ' ?\*G7_H.:A_W\-'_ J=?^@YJ'_?PUW^ MT4;10!P'_"IU_P"@YJ'_ '\-'_"IU_Z#FH?]_#7?[11M% ' ?\*G7_H.:A_W M\-'_ J=?^@YJ'_?PUW^T4;10!P'_"IU_P"@YJ'_ '\-;OA7PHOAKS=M[->; MN\QS71;10,-P* &HQVC/6G4E+0!XW\/O^2]^.?\ KA%_.O9$Z?C7C?P^_P"2 M]^.?^N$7\Z]D3I^- #J*** "N-^,?_)+/%/_ %X2_P J[*N-^,?_ "2SQ3_U MX2_RH D^%/\ R3?PY_UY1_RKK5KDOA3_ ,DW\.?]>4?\JZU: $?T'7'%> _M MA^)M;TOX:-I&D:=J%U'K!:WO+K35+26\.T[F'^->^OGC'KS431AXRC*I3!!5 MAG@T ?E_X'UW1]=\%> M \2W>I6/@:TBO5$^H.Z^=.JMM);N=V#@]Q7VI^QQ M=:K=? W2I-5DFD)GE6U:XR6: -A#S[5Z/JWPW\+ZYH\>D7V@6%QIR.9([9H5 MVJQ.=P]"36_:6,.GVT%M;01P00J$CA0;1&H& !B@#SOXS:GK5OHLL%MIRR61 MD3,^_D8/I6E9Z_XQ%C;@>'X#^[ _UWMUJU\5L_\ "%W1_P"FB=_4UU6G?\>% ML<_\LU/3VH Y#_A(O&G_ $+L'_?^C_A(O&G_ $+L'_?^NXP?\BDP?\B@#B/^ M$B\:?]"[!_W_ */^$B\:?]"[!_W_ *[?!_R*,'_(H XC_A(O&G_0NP?]_P"C M_A(O&G_0NP?]_P"NWP?\BC!_R* .(_X2+QI_T+L'_?\ H_X2+QI_T+L'_?\ MKM\'_(HP?\B@#B/^$B\:?]"[!_W_ */^$B\:?]"[!_W_ *[?!_R*,'_(H XC M_A(O&G_0NP?]_P"D_P"$C\9[L'P[#^$]=QSZ_I7RW^WS^U=<?LR_#6V;1527 MQ1K,AM;/>,^5_MX]J /;QKWC7:<^'K?/J+D8_P ::WB+QH.GAV _]MZ_)R#P MO^UIJB)XZ3Q5?[VM_MRS++B/R^N-F<8K[G_X)^_M97O[2/@G4-.\2",>+-!D M^SW3H,"8#C?B@#WP>(O&A_YER$?]MZ/^$B\:?]"[!_W_ *[C;UXI,'_(H XC M_A(O&G_0NP?]_P"C_A(O&G_0NP?]_P"NWP?\BC!_R* .(_X2+QI_T+L'_?\ MH_X2+QI_T+L'_?\ KM\'_(HP?7]* .'_ .$D\:;L?\(W#TX/G\4?\))XSR,> M'8?^_P!2_&OQU/\ #'X6^(O%%M$ES<:;:M/'')]TL!WKX@\%_M;?M1?$+PO9 M^)M%\":+)I5Y&TL)9R"5&?\ "@#[>_X23QIG'_".0_\ ?_BE_P"$B\:?]"[! M_P!_Z\G_ &)/VBO$?[1/@O6]0\4Z=!IFL:7>FREAM_N@C.?Y5]'X/^10!Q'_ M D7C3_H78/^_P#1_P )%XT_Z%V#_O\ UV^#_D48/^10!Q'_ D7C3_H78/^ M_P#1_P )%XT_Z%V#_O\ UV^#_D48/^10!Q'_ D7C3_H78/^_P#1_P )%XT_ MZ%V#_O\ UV^#_D48/^10!Q'_ D7C3_H78/^_P#1_P )%XT_Z%V#_O\ UV^# M_D48/^10!Q'_ D7C3_H78/^_P#1_P )%XT_Z%V#_O\ UV^#_D48/^10!Q'_ M D7C3_H78/^_P#1_P )%XT_Z%V#_O\ UV^#_D48/^10!Q'_ D7C3_H78/^ M_P#1_P )%XT_Z%V#_O\ UV^#_D48/^10!Q'_ D7C3_H78/^_P#1_P )%XT_ MZ%V#_O\ UV^#_D48/^10!Q'_ D7C3_H78/^_P#1_P )%XT_Z%V#_O\ UV^# M_D48/^10!Q'_ D7C3_H78/^_P#1_P )%XT_Z%V#_O\ UV^#_D48/^10!Q'_ M D7C3_H78/^_P#1_P )%XT_Z%V#_O\ UV^#_D48/^10!Q'_ D7C3_H78/^ M_P#1_P )%XS[^'8,=\3\UV^#_D4A#%@ WU&.M '$?\))XTQD^'(=O_7?FC_A M)/&>X >'8>1WGKXSU[]LCXX^*OC!XS\+_#WPEI6HV/AVY\AYKARK/@UU/P#_ M &M_BOX@_:%@^&GQ'\-:=I4US9M=(]HV<8Z#^= 'U*WB+QFK8_X1V$GU\_BD M_P"$B\:?]"[!_P!_Z[;8%^5> #FEP?\ (H XC_A(O&G_ $+L'_?^MOPWJFLZ MAYW]JZ<ECL^[Y;[MU;F#_D4OL>10 4M)2T >-_#[_DO?CG_KA%_.O9$Z?C7C M?P^_Y+WXY_ZX1?SKV1.GXT .HHHH *XWXQ_\DL\4_P#7A+_*NRKC?C'_ ,DL M\4_]>$O\J )/A3_R3?PY_P!>4?\ *NM6N2^%/_)-_#G_ %Y1_P JZU: &R,5 M7CK7GGQU\1ZQX8^'M_JNC:A#I4UNC2-<SPM+@!2<!1SDD 5Z')GT!KA_BOX+ MUCQUX;:PT76ET.Y8[7DEA$JE"""I7_/2@#YDT']J3XA^/O!W@VPT6+3;3Q;K M%O/=R74JYB\J$$X*_P );'?UKZ'_ &??B=<_%WX8Z?K]] MO>>:]O.H^Z9$; M:2OMFO(D_8<M=%\,:3:^'?%=WI?B.SDE>;5V&XRK*"'0+_"N"<5[O\*?AQIW MPI\$V/AW3C)+!;C+S2?>DD)R7Q[F@#+^,GB;3+'PU/8SW*K=.Z8CP3T-:UC\ M2/#D=C;*=33/E ?=/I5'XO:/8S>%KFYELXY)O,7]X1SUKH=/\*Z,]C;,=,M< M^6#_ *L>E %;_A9WAO\ Z"2?D:/^%G>&_P#H))^1K1_X1/1_^@7:_P#?H4?\ M(GH__0+M?^_0H SO^%G>&_\ H))^1H_X6=X;_P"@DGY&M'_A$]'_ .@7:_\ M?H4?\(GH_P#T"[7_ +]"@#._X6=X;_Z"2?D:/^%G>&_^@DGY&M'_ (1/1_\ MH%VO_?H4?\(GH_\ T"[7_OT* ,[_ (6=X;_Z"2?D:/\ A9WAO_H))^1K1_X1 M/1_^@7:_]^A1_P (GH__ $"[7_OT* ,[_A9WAO\ Z"2?D:/^%G>&_P#H))^1 MK1_X1/1_^@7:_P#?H4?\(GH__0+M?^_0H S?^%F>&\Y_M)/R-?!'_!53P8/B M)X0\.>+O#<YU.71+@_:;6-"S>7UW 5^A/_")Z/\ ] NU_P"_0IK>$=%DCDC? M2;5TD7:ZF(%6'H10!^4V@_\ !1;P7I7PJM_"CZ)?-=QZ4; Y<A@Q&,XKT'_@ ME7X0/@RW\7^.O$4YTN/5I?+L[69"K-&3G<1^%?:$O[)'PEF\0'6G\#:6;YCD M_N1MSGKBO1XO!^APQ1PQZ3:1Q0KLCC6$!5'H!0!1_P"%F^&_^@E'^1H_X6=X M;_Z"2?D:T?\ A$]'_P"@7:_]^A1_PB>C_P#0+M?^_0H SO\ A9WAO_H))^1H M_P"%G>&_^@DGY&M'_A$]'_Z!=K_WZ%'_ B>C_\ 0+M?^_0H SO^%G>&_P#H M))^1II^)OAK_ *"<?Y&M/_A$]'_Z!=K_ -^A2?\ "(Z/_P! NT_[]B@#Q[]I MWQ=I/B/X ^-K'3KL75U/I\D:11H2S$C@ 5\(_ _]L ?#/X0Z-X1OOAWXBN+R MSMG@DDBB?&3GD<5^I_\ PB6CJV?[,M1](QS[4[_A$]%SN.D66[U^SK_A0!\1 M_P#!,_Q)%H/@#QC>:[!<:*^HZP]S%!>1LK["3C.:^RO^%G>&_P#H))^1K2;P MIHY_YA=H!Z"( ?D*3_A$]'_Z!=K_ -^A0!G?\+.\-_\ 023\C1_PL[PW_P!! M)/R-:/\ PB>C_P#0+M?^_0H_X1/1_P#H%VO_ 'Z% &=_PL[PW_T$D_(T?\+. M\-_]!)/R-:/_ B>C_\ 0+M?^_0H_P"$3T?_ *!=K_WZ% &=_P +.\-_]!)/ MR-'_ L[PW_T$D_(UH_\(GH__0+M?^_0H_X1/1_^@7:_]^A0!G?\+.\-_P#0 M23\C1_PL[PW_ -!)/R-:/_")Z/\ ] NU_P"_0H_X1/1_^@7:_P#?H4 9W_"S MO#?_ $$D_(T?\+.\-_\ 023\C6C_ ,(GH_\ T"[7_OT*/^$3T?\ Z!=K_P!^ MA0!G?\+.\-_]!)/R-'_"SO#?_023\C6C_P (GH__ $"[7_OT*/\ A$]'_P"@ M7:_]^A0!G?\ "SO#?_023\C1_P +.\-_]!)/R-:/_")Z/_T"[7_OT*/^$3T? M_H%VO_?H4 9W_"SO#?\ T$D_(T?\+.\-_P#023\C6C_PB>C_ /0+M?\ OT*/ M^$3T?_H%VO\ WZ% &=_PL[PW_P!!)/R-'_"SO#?_ $$D_(UH_P#")Z/_ - N MU_[]"C_A$]'_ .@7:_\ ?H4 9W_"SO#?_023\C1_PL[PW_T$D_(UH_\ ")Z/ M_P! NU_[]"C_ (1/1_\ H%VO_?H4 9W_ L[PW_T$D_(T?\ "SO#?_023\C6 MC_PB>C_] NU_[]"C_A$]'_Z!=K_WZ% &;_PL[PW_ -!)/R-'_"R?#DK(!J,9 M);CJ*T?^$1T?_H%VG_?L4'PGH^-O]F6OJ,1CK0!^5NC_ !RD^ ?[1GQ:O;WP MAK6NV>M7OFVMQ8P,$89SUQ73? OXL_\ "U/VV=,\:R:!JGA_1[?3'MV:_A8? M-GIFOTO/AC26P#I5F1W)@4_TI%\+:0G*Z5:+GKB%?\* ,QOB9X;20@ZG'G.. MAI?^%G>&_P#H))^1K0'A'1P,?V9:E<[N8QG-+_PB>C_] NU_[]"@#._X6=X; M_P"@DGY&M'1/%&F>(EE.GW2W'EG#8!%'_")Z/_T"[7_OT*LV6BV6F[_LEI%; M[^OEKB@"Y2TG-+0!XW\/O^2]^.?^N$7\Z]D3I^->-_#[_DO?CG_KA%_.O9$Z M?C0 ZBBB@ KC?C'_ ,DL\4_]>$O\J[*N-^,?_)+/%/\ UX2_RH D^%/_ "3? MPY_UY1_RKK5KDOA3_P DW\.?]>4?\JZU: &R9*X'7K7'?%+XG:;\)O#+ZWJL M-Q<6RG!6V0LW0GIZ8%=A(VWGOCI7CO[4GB7QCX?^%UW%X'\._P#"0ZU>8M@& M (@1^&DQWP/YT 9NH?M@_#VW\!Z3XKAO)[^UU!]L%K;H3.K#[V1[#/Y5ZOX) M\9:5\0/#EEK^B7*W.GWB[DE'4>JGWKXEM?AUJ_PYTGP1XAT'P)>W]A86]Q:: MAITR@R_:I4(,X_V-S5]-?LN?#[4_AO\ "'3M-U>,0W\DDER]MGY8M[;@/K0! MUOQ8S_PA-UQ_RTC_ )UU.G@_V?;\?\L5_E7G/QF\/W=YH<UU'JTUO LB[K<? M=-7K'X?ZFUE;$>*;_P"X.C>U 'H=%<%_PKW5O^AJO_\ OJC_ (5[JW_0U7W_ M 'U0!WM%<%_PKW5O^AJOO^^J/^%>ZM_T-5]_WU0!WM%<%_PKW5O^AJOO^^J/ M^%>ZM_T-5]_WU0!WM%<%_P *]U;_ *&J^_[ZH_X5[JW_ $-5]_WU0!WM%<%_ MPKW5O^AJOO\ OJC_ (5[JW_0U7W_ 'U0!WM%<%_PKW5O^AJOO^^J/^%>ZM_T M-5]_WU0!WM%<%_PKW5O^AJOO^^J/^%>ZM_T-5]_WU0!WM%<%_P *]U;_ *&J M^_[ZH_X5[JW_ $-5]_WU0!WM%<%_PKW5O^AJOO\ OJC_ (5[JW_0U7W_ 'U0 M!WM%<%_PKW5O^AJOO^^J/^%>ZM_T-5]_WU0!WM%<%_PKW5O^AJOO^^J/^%>Z MM_T-5]_WU0!WM%<%_P *]U;_ *&J^_[ZH_X5[JW_ $-5]_WU0!WM%<%_PKW5 MO^AJOO\ OJC_ (5[JW_0U7W_ 'U0!WM%<%_PKW5O^AJOO^^J/^%>ZM_T-5]_ MWU0!WM%<%_PKW5O^AJOO^^J/^%>ZM_T-5]_WU0!WM%<%_P *]U;_ *&J^_[Z MH_X5[JW_ $-5]_WU0!WM%<%_PKW5O^AJOO\ OJC_ (5[JW_0U7W_ 'U0!WM% M<%_PKW5O^AJOO^^J/^%>ZM_T-5]_WU0!WM%<%_PKW5O^AJOO^^J/^%>ZM_T- M5]_WU0!WM%<%_P *]U;_ *&J^_[ZH_X5[JW_ $-5]_WU0!WM%<%_PKW5O^AJ MOO\ OJC_ (5[JW_0U7W_ 'U0!WM%<%_PKW5O^AJOO^^J/^%>ZM_T-5]_WU0! MWM%<%_PKW5O^AJOO^^J/^%>ZM_T-5]_WU0!WM%<%_P *]U;_ *&J^_[ZH_X5 M[JW_ $-5]_WU0!WM%<%_PKW5O^AJOO\ OJC_ (5[JW_0U7W_ 'U0!WM%<%_P MKW5O^AJOO^^J/^%>ZM_T-5]_WU0!WM%<%_PKW5O^AJOO^^JV?#6@7>@B<W.J MSZH6Z+-_#0!T='>F1Y'7K[4_O0!XU\/O^2]^.?\ KA%_.O9$Z?C7C?P^_P"2 M]^.?^N$7\Z]D3I^- #J*** "N-^,?_)+/%/_ %X2_P J[*N-^,?_ "2SQ3_U MX2_RH D^%/\ R3?PY_UY1_RKK5KDOA3_ ,DW\.?]>4?\JZU: $<>U1-(L8)= MPB#J6.!4DF<9 S7D'[5VFI?_ +\3,VNS: (;<S"YA?8=PZ+GWH ]8::&)0[ M.B*1@;F &/8T]2K*"#O!^Z<YS[U\ :QXF'C7PO\ ![0M<\17%MX6FT.>XN]1 MAN#&9;A%)5"^>HP#^%?2G['^M:OX@^!^CW&K2RSRI--##<2\F2%6PCGU)% ' M>?%CGP5/GG]Y'_.NJT__ )!]M_UR7^5><?&;7=1M=%EM(=*>XM3(N9U[<U>M M?'6O1V-L%\+W)&P#KVQ0!Z'29K@AX\\1'_F5;C_OJC_A._$7_0JS_P#?5 '> MYHS7!?\ "=^(O^A5G_[ZH_X3SQ#W\*W'_?5 '>YHS7!?\)YX@_Z%6X_.C_A/ M/$';PK<?]]4 =[FC-<%_PG?B+_H59_\ OJC_ (3OQ%_T*L__ 'U0!WN:,UP7 M_"=^(O\ H59_^^J/^$[\1?\ 0JS_ /?5 '>YHS7!?\)WXB_Z%6?_ +ZH_P"$ M[\1?]"K/_P!]4 =[FC-<%_PG?B+_ *%6?_OJC_A._$7_ $*L_P#WU0!WN:,U MP7_"=^(O^A5G_P"^J/\ A._$7_0JS_\ ?5 '>YHS7!?\)WXB_P"A5G_[ZH_X M3OQ%_P!"K/\ ]]4 =[FC-<%_PG?B+_H59_\ OJC_ (3OQ%_T*L__ 'U0!WN: M,UP7_"=^(O\ H59_^^J/^$[\1?\ 0JS_ /?5 '>YHS7!?\)WXB_Z%6?_ +ZH M_P"$[\1?]"K/_P!]4 =[FC-<%_PG?B+_ *%6?_OJC_A._$7_ $*L_P#WU0!W MN:,UP7_"=^(O^A5G_P"^J/\ A._$7_0JS_\ ?5 '>YHS7!?\)WXB_P"A5G_[ MZH_X3SQ#W\*W'_?5 '>YHS7!?\)YXA[>%;C_ +ZH_P"$[\1?]"K/_P!]4 =[ MFC-<%_PG?B+_ *%6?_OJC_A._$7_ $*L_P#WU0!WN:,UP7_"=^(O^A5G_P"^ MJ/\ A._$7_0JS_\ ?5 '>YHS7!?\)WXB_P"A5G_[ZH_X3OQ%_P!"K/\ ]]4 M=[FC-<%_PG?B+_H59_\ OJC_ (3SQ#W\*W'_ 'U0!WN:,UP7_">>(>WA6X_[ MZH_X3OQ%_P!"K/\ ]]4 =[FC-<%_PG?B+_H59_\ OJC_ (3OQ%_T*L__ 'U0 M!WN:,UP7_"=^(O\ H59_^^J/^$[\1?\ 0JS_ /?5 '>YHS7!?\)WXB_Z%6?_ M +ZH_P"$[\1?]"K/_P!]4 =[FC-<%_PG?B+_ *%6?_OJC_A._$7_ $*L_P#W MU0!WN:,UP7_"=^(O^A5G_P"^J/\ A._$7_0JS_\ ?5 '>YHK@O\ A._$7_0J MS_\ ?5;GA;Q!J.M"9K_2I-,V\*)#F@#H:6D'3KFEH \;^'W_ "7OQS_UPB_G M7LB=/QKQOX??\E[\<_\ 7"+^=>R)T_&@!U%%% !7&_&/_DEGBG_KPE_E795Q MOQC_ .26>*?^O"7^5 $GPI_Y)OX<_P"O*/\ E76K7)?"G_DF_AS_ *\H_P"5 M=:M "-VK \9>!M$^(6COI/B"QCU+39&#/:RYV/CUQ70$9I&7@\X]Z /-[W]G MGX=7GAFW\/3^%[-]'MG\V"UPVV,GK@YX'M7=Z/I-GH>FV]AI]M%96-N@CA@A M&%11T KQ/X^_&GQ'X-\2Z1X1\%V$-]X@O()+UVNFVHL4:ECSZD BNU^!?Q3_ M .%N_#G3O$<EH=/N92T,\.<J)%.&Q[4 :7Q89E\%W15BIWIT^M=3I['^S[<Y MR?*4_I7$?%[6["U\*W%M->0Q3,\9$;'YCR.@K>LO&.AQZ?;YU6U'[I?^6@]* M .CV^YI",=S^=8W_ FNA?\ 05M?^_@I#XTT,Y_XFMKC_KH* -=I N23P.O/ M3WK+A\6:-<WQLH=8L9+OIY*7"L^?3&:^#?\ @I7^U5K7A,Z!\._ NK"ROM<. M+O4;5LO$A.,9KYCUC]B/XF> ?"5QXZM_B%<B>TM_MX,=VQD8X# DY_2@#]HA M(<@'(/<>E/ SW-?'_P#P3U_:JG^.'P@>/Q;?QKXCT606UQ-,=OGKV?WZ5]3+ MXVT+_H*VO_?P4 ;>WW-&WW-8O_";:%_T%;;_ +^"F_\ "<:%_P!!2V'U?B@# M<V^YHV^YK#;QQH*XSJUJ<],2"E_X3;0A_P Q6U_[^"@#;V^YHV^YK%'C;0O^ M@K:_]_!1_P )KH7_ $%;7_OX* -K;[FC;[FL7_A-="_Z"MK_ -_!1_PFNA?] M!6U_[^"@#:V^YHV^YK%_X370O^@K:_\ ?P4?\)MH7_05M?\ OX* -K;[FC;[ MFL3_ (3;0NO]JVN.Y\P4@\<:$6VC5+8MUX?(H W-ON:-ON:Q1XVT(@'^U;;_ M +^"C_A-="_Z"MK_ -_!0!M;?<T;?<UB_P#":Z%_T%;7_OX*/^$UT+_H*VO_ M '\% &UM]S1M]S6+_P )KH7_ $%;7_OX*/\ A-="_P"@K:_]_!0!M;?<T;?< MUB_\)KH7_05M?^_@I/\ A-M"_P"@K:X_ZZ"@#;V^YHV^YK#;QMH:_P#,4ML^ MSYYH_P"$VT/_ *"MK_W\% &WCW/YTS<0W/0\#GO61_PFNA$?\A6U_P"_@K&\ M9?$+2M(\)ZSJ%KJEL;FUM)98_F!PP4D?K0!V6&QR>:3<=P!R,]*_,'X2>,?V MG?CMX?NO$>D?$/3=/L)+^2.*VEB&553QSFO9/V%_CQXU\0>,OB+X4^)?B*VU M&\T.X5(I\! 1WQ0!]MBG;?<UB?\ "::"K8_M:US_ -=!2_\ ":Z%_P!!6U_[ M^"@#:V^YHV^YK%_X370O^@K:_P#?P4S_ (3G0B<+JMJ3V&^@#=V^YIIK%_X3 M;0_^@K:_]_!1_P )MH7_ $%;7_OX* -DGD#./J:3YNF"/>N?O/&^BQVL\D>J M6I>.)G&7R,@=Z_.3P%\2/VC_ (]^(O&-[X8\>6&D:-I^J26T4,T0)V@X&/:@ M#].RQ^7J">U/Q[G\Z^#_ -D7XV_$RU_:$\7_ \^*/B:UU:.PLQ<Q3JFP!CC M _G7VL/&NA<?\36U_P"_@H V]ON:-ON:Q?\ A-="_P"@K:_]_!1_PFNA?]!6 MU_[^"@#:V^YHV^YK#/CC05&?[5M<?]=!D4[_ (370O\ H*VO_?P4 ;6WW-&W MW-8O_":Z%_T%;7_OX*/^$UT+_H*VO_?P4 ;6WW-&WW-8O_":Z%_T%;7_ +^" MC_A-="_Z"MK_ -_!0!M;?<T;?<UB_P#":Z%_T%;7_OX*/^$UT+_H*VO_ '\% M &UM]S1BL7_A-="_Z"MK_P!_!5G3?$&GZNT@L[N*Y,9^81MG% &CMI* W'(H MH \;^'W_ "7OQS_UPB_G7LB=/QKQOX??\E[\<_\ 7"+^=>R)T_&@!U%%% !7 M&_&/_DEGBG_KPE_E795QOQC_ .26>*?^O"7^5 $GPI_Y)OX<_P"O*/\ E76K M7)?"G_DF_AS_ *\H_P"5=:M "TC*&4@]*:YQBFA^2.IQF@#P[X\? 36?B%XD MT7Q3X8UI-$\0:?#):,\B%TDA<$,,>N":[GX-_"^'X1^ ;#PY#<F[:(M+-.PP M7D8Y8X]*[C^[DMCTQ2+U(PJMW^E 'G/QI\,V.I>%)[N2W1KM'C"S,.5Y[5OZ M?X!\/MIUONTNW/[E<_+[56^*P+>"[E0"Q:2/&/K74Z?_ ,>-NN"#Y2J?8X'! MH RO^%?^'1_S"K?_ +YI/^%?^'MO_(*M\=?N]ZZ!3NYSD4YNE 'YV_\ !2[] ME75_$$GA_P"(W@;23>7.C./MVGVP^:2,'.0*^=M<_;H\:>.O!MUX'M?AQ.ES M=VHT]!';.'#8V@<CN:_91TW-@KE6X;(R"/2O&_!OQ+^'GBCXP:WX3T?1(8?$ M>EJ'GN)+((#DGE3CGIUH \B_X)Y?LHW/P9^$,L_C+3T_X2#6I!<2VLPRULN. M$_6OJ8?#_P .C/\ Q*K?_OFMV-MV>#P<<G)I] '/_P#"O_#O_0*M_P#OFN>\ M?>!=%M_!NJFWL(HY-F0W<5Z#7/?$'_D3]4_ZYT 8W@WP'H<GA73GFTVWD<QA MBQ7DUL_\*]\/=]*M\_[E3>"_F\)Z;CO"*W,&@#GO^%?^'?\ H%6__?-'_" ^ M'?\ H$V^/7;704UFPRC(!/YT 8'_ @/AW_H$P?]\4O_ @'AW_H$V^/]VO, M-<_:J\.>%?BQ8^"=6T_4+&2^E^SVVHS1D12R'HH->V8/'.2O% &%_P *_P## MO_0*M_\ OFC_ (5_X=/']E6__?-="/NX[T8- '(ZQX#T"+1[YH]+MU81L0=O MH*Q?AIX+T6^\%Z?+-81O(P8ECU/)KN=<_P"0+J'_ %R?^1K!^%/_ "(NF?1O MYF@"X/A_X=Q_R"K?_OFC_A7_ (=_Z!5O_P!\UT '%+B@#GO^$ \.C_F%6_\ MWS1_P@/AW_H$P?\ ?%;K=]O#D8W8Z5Y!\3?VDM"^%'BO3=,UJPOEL[N:.U&J M*A,2R.<*#^- 'H7_ K_ ,/?] FW_P"^:7_A7_AW_H%6_P#WS6W&ZR*LBG>K M#(;V-2K0!@?\*^\/?] JW_[YJ&;X?^'DMY?^)5;],_=KIZANO^/>7_=H \L^ M%/@W1[S2;]KBR2<K>. 9.> >E=HOP]\/;1G2K?/^[6-\(?\ D#:C_P!?LG\Z M[S!H Y[_ (5_X=_Z!5O_ -\UD>,?AKI&H>$=;L['2X?M5S92PQJ!CYBI _6N MWIK8],L.?>@#\N_@KI_[1GP'\.77AFQ^%$>K6<-_+)'>2,/G5CQ7L?["_P $ M_&EGXX^(WBSXE^$UT6?6[A7M[:7!P/PKZ2^.G[0GA;X :/97_B.>9FNYU@AM M[<%G9B0,X';D5Z+I>H1ZI8VMW&&$=Q$LR!NNU@"/T- &6?A]X=8Y_LJW_P"^ M:/\ A7_AW_H%6_\ WS70_P -�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end </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>7 <FILENAME>image_002.jpg <DESCRIPTION>GRAPHIC <TEXT> begin 644 image_002.jpg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end </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>8 <FILENAME>image_009.jpg <DESCRIPTION>GRAPHIC <TEXT> begin 644 image_009.jpg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end </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>9 <FILENAME>image_010.jpg <DESCRIPTION>GRAPHIC <TEXT> begin 644 image_010.jpg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end </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>10 <FILENAME>image_011.jpg <DESCRIPTION>GRAPHIC <TEXT> begin 644 image_011.jpg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end </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>11 <FILENAME>image_012.jpg <DESCRIPTION>GRAPHIC <TEXT> begin 644 image_012.jpg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end </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>12 <FILENAME>image_013.jpg <DESCRIPTION>GRAPHIC <TEXT> begin 644 image_013.jpg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end </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>13 <FILENAME>image_014.jpg <DESCRIPTION>GRAPHIC <TEXT> begin 644 image_014.jpg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end </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>14 <FILENAME>image_015.jpg <DESCRIPTION>GRAPHIC <TEXT> begin 644 image_015.jpg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ⅅ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end </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>15 <FILENAME>image_016.jpg <DESCRIPTION>GRAPHIC <TEXT> begin 644 image_016.jpg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end </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>16 <FILENAME>image_017.jpg <DESCRIPTION>GRAPHIC <TEXT> begin 644 image_017.jpg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end </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>17 <FILENAME>image_018.jpg <DESCRIPTION>GRAPHIC <TEXT> begin 644 image_018.jpg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�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end </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>18 <FILENAME>image_019.jpg <DESCRIPTION>GRAPHIC <TEXT> begin 644 image_019.jpg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end </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>19 <FILENAME>image_019.gif <DESCRIPTION>GRAPHIC <TEXT> begin 644 image_019.gif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end </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.SCH <SEQUENCE>20 <FILENAME>cnbx-20230831.xsd <DESCRIPTION>XBRL SCHEMA FILE <TEXT> <XBRL> <?xml version="1.0" encoding="US-ASCII" ?> <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20b --> <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com --> <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 --> <!-- Field: Doc-Info; Name: Misc; Value: +Kopo7xRiXgen8uEbXpMOaCIuaPty552OYkxvmR3fWn67ywlinaSRSOC6XOWIaEH --> <schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:CNBX="http://cnbxpharma.com/20230831" elementFormDefault="qualified" targetNamespace="http://cnbxpharma.com/20230831"> <annotation> <appinfo> <link:roleType roleURI="http://cnbxpharma.com/role/Cover" id="Cover"> <link:definition>00000001 - Document - Cover</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets" id="AuditedConsolidatedBalanceSheets"> <link:definition>00000002 - Statement - Audited Consolidated Balance Sheets</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheetsParenthetical" id="AuditedConsolidatedBalanceSheetsParenthetical"> <link:definition>00000003 - Statement - Audited Consolidated Balance Sheets (Parenthetical)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations" id="AuditedConsolidatedStatementsOfOperations"> <link:definition>00000004 - Statement - Audited Consolidated Statements of Operations</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperationsParenthetical" id="AuditedConsolidatedStatementsOfOperationsParenthetical"> <link:definition>00000005 - Statement - Audited Consolidated Statements of Operations (Parenthetical)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows" id="AuditedConsolidatedStatementsOfCashFlows"> <link:definition>00000006 - Statement - Audited Consolidated Statements of Cash Flows</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfStockholdersEquityDeficit" id="AuditedConsolidatedStatementsOfStockholdersEquityDeficit"> <link:definition>00000007 - Statement - Audited Consolidated Statements of Stockholders' Equity (Deficit)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcern" id="NatureOfBusinessPresentationAndGoingConcern"> <link:definition>00000008 - Disclosure - Nature of Business, Presentation and Going Concern</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies"> <link:definition>00000009 - Disclosure - Summary of Significant Accounting Policies</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/RecentAccountingPronouncements" id="RecentAccountingPronouncements"> <link:definition>00000010 - Disclosure - Recent Accounting Pronouncements</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions"> <link:definition>00000011 - Disclosure - Related Party Transactions</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies"> <link:definition>00000012 - Disclosure - Commitments and Contingencies</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/StockholdersEquityDeficit" id="StockholdersEquityDeficit"> <link:definition>00000013 - Disclosure - Stockholders’ Equity (Deficit)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/Warrants" id="Warrants"> <link:definition>00000014 - Disclosure - Warrants</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/IncomeTaxes" id="IncomeTaxes"> <link:definition>00000015 - Disclosure - Income Taxes</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/CapitalLoss" id="CapitalLoss"> <link:definition>00000016 - Disclosure - Capital loss</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/GeneralAdministrateExpenses" id="GeneralAdministrateExpenses"> <link:definition>00000017 - Disclosure - General & administrate expenses</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/FinancialIncomeExpenses" id="FinancialIncomeExpenses"> <link:definition>00000018 - Disclosure - Financial (Income) expenses</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/SubsequentEvents" id="SubsequentEvents"> <link:definition>00000019 - Disclosure - Subsequent Events</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies"> <link:definition>00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/WarrantsTables" id="WarrantsTables"> <link:definition>00000021 - Disclosure - Warrants (Tables)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/IncomeTaxesTables" id="IncomeTaxesTables"> <link:definition>00000022 - Disclosure - Income Taxes (Tables)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/GeneralAdministrateExpensesTables" id="GeneralAdministrateExpensesTables"> <link:definition>00000023 - Disclosure - General & administrate expenses (Tables)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/FinancialIncomeExpensesTables" id="FinancialIncomeExpensesTables"> <link:definition>00000024 - Disclosure - Financial (Income) expenses (Tables)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcernDetailsNarrative" id="NatureOfBusinessPresentationAndGoingConcernDetailsNarrative"> <link:definition>00000025 - Disclosure - Nature of Business, Presentation and Going Concern (Details Narrative)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative"> <link:definition>00000026 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative"> <link:definition>00000027 - Disclosure - Related Party Transactions (Details Narrative)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative"> <link:definition>00000028 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" id="StockholdersEquityDeficitDetailsNarrative"> <link:definition>00000029 - Disclosure - Stockholders’ Equity (Deficit) (Details Narrative)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/WarrantsDetails-FairValue" id="WarrantsDetails-FairValue"> <link:definition>00000030 - Disclosure - Warrants (Details - Fair value)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/WarrantsDetails-FairValueDisclosure" id="WarrantsDetails-FairValueDisclosure"> <link:definition>00000031 - Disclosure - Warrants (Details - Fair Value)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/WarrantsDetails-WarrantActivity" id="WarrantsDetails-WarrantActivity"> <link:definition>00000032 - Disclosure - Warrants (Details - Warrant activity)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/WarrantsDetailsNarrative" id="WarrantsDetailsNarrative"> <link:definition>00000033 - Disclosure - Warrants (Details Narrative)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/IncomeTaxesDetails-Rate" id="IncomeTaxesDetails-Rate"> <link:definition>00000034 - Disclosure - Income Taxes (Details - rate)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/IncomeTaxesDetails-DeferredTaxAssets" id="IncomeTaxesDetails-DeferredTaxAssets"> <link:definition>00000035 - Disclosure - Income Taxes (Details - Deferred tax assets)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative"> <link:definition>00000036 - Disclosure - Income Taxes (Details Narrative)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/CapitalLossDetailsNarrative" id="CapitalLossDetailsNarrative"> <link:definition>00000037 - Disclosure - Capital loss (Details Narrative)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/GeneralAndAdministrativeExpensesDetails" id="GeneralAndAdministrativeExpensesDetails"> <link:definition>00000038 - Disclosure - General and administrative expenses (Details)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://cnbxpharma.com/role/FinancialIncomeExpensesDetails" id="FinancialIncomeExpensesDetails"> <link:definition>00000039 - Disclosure - Financial (Income) expenses (Details)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:linkbaseRef xlink:type="simple" xlink:href="cnbx-20230831_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" /> <link:linkbaseRef xlink:type="simple" xlink:href="cnbx-20230831_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" /> <link:linkbaseRef xlink:type="simple" xlink:href="cnbx-20230831_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" /> <link:linkbaseRef xlink:type="simple" xlink:href="cnbx-20230831_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" /> </appinfo> </annotation> <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" /> <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" /> <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" /> <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" /> <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" /> <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" /> <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" /> <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" /> <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" /> <element id="CNBX_WarrantsMember" name="WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_CEOAndChairmanMember" name="CEOAndChairmanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_ThreeDirectorsMember" name="ThreeDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_CannabicsIncMember" name="CannabicsIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_ShareBasedPaymentMember" name="ShareBasedPaymentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_ChairmanAndBoardMembersMember" name="ChairmanAndBoardMembersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_InitialNoteMember" name="InitialNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_SecondNoteMember" name="SecondNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_NoteMember" name="NoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_SeniorSecuredNoteMember" name="SeniorSecuredNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_DemandNoteMember" name="DemandNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_Warrant1Member" name="Warrant1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_Warrant2Member" name="Warrant2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_UnitedStates1Member" name="UnitedStates1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_DueToRelatedParty" name="DueToRelatedParty" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_CapitalGainLoss" name="CapitalGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_FinancialLossNet" name="FinancialLossNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_InterestOnConvertibleLoan" name="InterestOnConvertibleLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_CapitalLossGain" name="CapitalLossGain" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_ExerciseOfConvertibleLoanToSharesOfCommonStock." name="ExerciseOfConvertibleLoanToSharesOfCommonStock." nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_ExpirationOfWarrants" name="ExpirationOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_PostsplitAdjustment" name="PostsplitAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_PostsplitAdjustmentShares" name="PostsplitAdjustmentShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_DisclosureWarrantsAbstract" name="DisclosureWarrantsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_WarrantDisclosureTextBlock" name="WarrantDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_DisclosureCapitalLossAbstract" name="DisclosureCapitalLossAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_CapitalLossDisclosureTextBlock" name="CapitalLossDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_ScheduleOfAssumptionsUsedWarrantsTableTextBlock" name="ScheduleOfAssumptionsUsedWarrantsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_ScheduleOfFinancialIncomeExpensesTableTextBlock" name="ScheduleOfFinancialIncomeExpensesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_DueToRelatedPartiesCurrent1" name="DueToRelatedPartiesCurrent1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_WarrantsIssued" name="WarrantsIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_OriginalIssueDiscount" name="OriginalIssueDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_WeightedAverageExercisePriceWarrantsIssued" name="WeightedAverageExercisePriceWarrantsIssued" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_WeightedAverageExercisePriceWarrantsExercised" name="WeightedAverageExercisePriceWarrantsExercised" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_WeightedAverageExercisePriceWarrantsExpired" name="WeightedAverageExercisePriceWarrantsExpired" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_WeightedAverageExercisePriceWarrantsExercisable" name="WeightedAverageExercisePriceWarrantsExercisable" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_WarrantsIssuedShares" name="WarrantsIssuedShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_FairValueOfWarrantsIssued" name="FairValueOfWarrantsIssued" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_CapitalLoss" name="CapitalLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="CNBX_LossGainFromConvertibleLoanValuation" name="LossGainFromConvertibleLoanValuation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> </schema> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.CAL <SEQUENCE>21 <FILENAME>cnbx-20230831_cal.xml <DESCRIPTION>XBRL CALCULATION FILE <TEXT> <XBRL> <?xml version="1.0" encoding="US-ASCII" standalone="no"?> <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20b --> <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com --> <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 --> <link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"> <link:roleRef roleURI="http://cnbxpharma.com/role/Cover" xlink:href="cnbx-20230831.xsd#Cover" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets" xlink:href="cnbx-20230831.xsd#AuditedConsolidatedBalanceSheets" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheetsParenthetical" xlink:href="cnbx-20230831.xsd#AuditedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations" xlink:href="cnbx-20230831.xsd#AuditedConsolidatedStatementsOfOperations" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperationsParenthetical" xlink:href="cnbx-20230831.xsd#AuditedConsolidatedStatementsOfOperationsParenthetical" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows" xlink:href="cnbx-20230831.xsd#AuditedConsolidatedStatementsOfCashFlows" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfStockholdersEquityDeficit" xlink:href="cnbx-20230831.xsd#AuditedConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcern" xlink:href="cnbx-20230831.xsd#NatureOfBusinessPresentationAndGoingConcern" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="cnbx-20230831.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/RecentAccountingPronouncements" xlink:href="cnbx-20230831.xsd#RecentAccountingPronouncements" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/RelatedPartyTransactions" xlink:href="cnbx-20230831.xsd#RelatedPartyTransactions" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/CommitmentsAndContingencies" xlink:href="cnbx-20230831.xsd#CommitmentsAndContingencies" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/StockholdersEquityDeficit" xlink:href="cnbx-20230831.xsd#StockholdersEquityDeficit" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/Warrants" xlink:href="cnbx-20230831.xsd#Warrants" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/IncomeTaxes" xlink:href="cnbx-20230831.xsd#IncomeTaxes" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/CapitalLoss" xlink:href="cnbx-20230831.xsd#CapitalLoss" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/GeneralAdministrateExpenses" xlink:href="cnbx-20230831.xsd#GeneralAdministrateExpenses" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/FinancialIncomeExpenses" xlink:href="cnbx-20230831.xsd#FinancialIncomeExpenses" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/SubsequentEvents" xlink:href="cnbx-20230831.xsd#SubsequentEvents" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cnbx-20230831.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/WarrantsTables" xlink:href="cnbx-20230831.xsd#WarrantsTables" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/IncomeTaxesTables" xlink:href="cnbx-20230831.xsd#IncomeTaxesTables" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/GeneralAdministrateExpensesTables" xlink:href="cnbx-20230831.xsd#GeneralAdministrateExpensesTables" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/FinancialIncomeExpensesTables" xlink:href="cnbx-20230831.xsd#FinancialIncomeExpensesTables" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcernDetailsNarrative" xlink:href="cnbx-20230831.xsd#NatureOfBusinessPresentationAndGoingConcernDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="cnbx-20230831.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cnbx-20230831.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cnbx-20230831.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:href="cnbx-20230831.xsd#StockholdersEquityDeficitDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/WarrantsDetails-FairValue" xlink:href="cnbx-20230831.xsd#WarrantsDetails-FairValue" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/WarrantsDetails-FairValueDisclosure" xlink:href="cnbx-20230831.xsd#WarrantsDetails-FairValueDisclosure" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/WarrantsDetails-WarrantActivity" xlink:href="cnbx-20230831.xsd#WarrantsDetails-WarrantActivity" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/WarrantsDetailsNarrative" xlink:href="cnbx-20230831.xsd#WarrantsDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/IncomeTaxesDetails-Rate" xlink:href="cnbx-20230831.xsd#IncomeTaxesDetails-Rate" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/IncomeTaxesDetails-DeferredTaxAssets" xlink:href="cnbx-20230831.xsd#IncomeTaxesDetails-DeferredTaxAssets" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="cnbx-20230831.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/CapitalLossDetailsNarrative" xlink:href="cnbx-20230831.xsd#CapitalLossDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/GeneralAndAdministrativeExpensesDetails" xlink:href="cnbx-20230831.xsd#GeneralAndAdministrativeExpensesDetails" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/FinancialIncomeExpensesDetails" xlink:href="cnbx-20230831.xsd#FinancialIncomeExpensesDetails" xlink:type="simple" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/Cover" xlink:title="00000001 - Document - Cover" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - Audited Consolidated Balance Sheets"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" /> <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" /> <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" /> <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments" /> <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapInvestments" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" /> <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" /> <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaapConvertibleDebtCurrent" /> <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleDebtCurrent" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_DueToRelatedParty" xlink:label="loc_CNBXDueToRelatedParty" /> <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_CNBXDueToRelatedParty" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" /> <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" /> <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" /> <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAdditionalCapital" xlink:label="loc_us-gaapOtherAdditionalCapital" /> <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapOtherAdditionalCapital" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" /> <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" /> <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" /> <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" /> <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" /> </link:calculationLink> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - Audited Consolidated Balance Sheets (Parenthetical)" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - Audited Consolidated Statements of Operations"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" /> <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" /> <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" /> <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" /> <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" /> <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_CapitalGainLoss" xlink:label="loc_CNBXCapitalGainLoss" /> <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_CNBXCapitalGainLoss" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_FinancialLossNet" xlink:label="loc_CNBXFinancialLossNet" /> <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_CNBXFinancialLossNet" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" /> <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" /> <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" weight="1" /> </link:calculationLink> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Audited Consolidated Statements of Operations (Parenthetical)" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - Audited Consolidated Statements of Cash Flows"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" /> <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" /> <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" /> <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_InterestOnConvertibleLoan" xlink:label="loc_CNBXInterestOnConvertibleLoan" /> <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CNBXInterestOnConvertibleLoan" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_CapitalLossGain" xlink:label="loc_CNBXCapitalLossGain" /> <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CNBXCapitalLossGain" xlink:type="arc" weight="-1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" /> <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" weight="-1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" /> <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" /> <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:label="loc_us-gaapProceedsFromSaleOfEquitySecuritiesFvNi" /> <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfEquitySecuritiesFvNi" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquireMachineryAndEquipment" /> <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireMachineryAndEquipment" xlink:type="arc" weight="-1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" /> <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" /> <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" /> <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" /> <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" /> </link:calculationLink> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfStockholdersEquityDeficit" xlink:title="00000007 - Statement - Audited Consolidated Statements of Stockholders' Equity (Deficit)" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcern" xlink:title="00000008 - Disclosure - Nature of Business, Presentation and Going Concern" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/RecentAccountingPronouncements" xlink:title="00000010 - Disclosure - Recent Accounting Pronouncements" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/RelatedPartyTransactions" xlink:title="00000011 - Disclosure - Related Party Transactions" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/CommitmentsAndContingencies" xlink:title="00000012 - Disclosure - Commitments and Contingencies" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/StockholdersEquityDeficit" xlink:title="00000013 - Disclosure - Stockholders’ Equity (Deficit)" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/Warrants" xlink:title="00000014 - Disclosure - Warrants" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - Income Taxes" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/CapitalLoss" xlink:title="00000016 - Disclosure - Capital loss" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/GeneralAdministrateExpenses" xlink:title="00000017 - Disclosure - General & administrate expenses" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/FinancialIncomeExpenses" xlink:title="00000018 - Disclosure - Financial (Income) expenses" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/SubsequentEvents" xlink:title="00000019 - Disclosure - Subsequent Events" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/WarrantsTables" xlink:title="00000021 - Disclosure - Warrants (Tables)" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/IncomeTaxesTables" xlink:title="00000022 - Disclosure - Income Taxes (Tables)" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/GeneralAdministrateExpensesTables" xlink:title="00000023 - Disclosure - General & administrate expenses (Tables)" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/FinancialIncomeExpensesTables" xlink:title="00000024 - Disclosure - Financial (Income) expenses (Tables)" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcernDetailsNarrative" xlink:title="00000025 - Disclosure - Nature of Business, Presentation and Going Concern (Details Narrative)" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000026 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000027 - Disclosure - Related Party Transactions (Details Narrative)" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000028 - Disclosure - Commitments and Contingencies (Details Narrative)" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:title="00000029 - Disclosure - Stockholders’ Equity (Deficit) (Details Narrative)" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/WarrantsDetails-FairValue" xlink:title="00000030 - Disclosure - Warrants (Details - Fair value)" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/WarrantsDetails-FairValueDisclosure" xlink:title="00000031 - Disclosure - Warrants (Details - Fair Value)" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/WarrantsDetails-WarrantActivity" xlink:title="00000032 - Disclosure - Warrants (Details - Warrant activity)" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/WarrantsDetailsNarrative" xlink:title="00000033 - Disclosure - Warrants (Details Narrative)" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/IncomeTaxesDetails-Rate" xlink:title="00000034 - Disclosure - Income Taxes (Details - rate)" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/IncomeTaxesDetails-DeferredTaxAssets" xlink:title="00000035 - Disclosure - Income Taxes (Details - Deferred tax assets)" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000036 - Disclosure - Income Taxes (Details Narrative)" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/CapitalLossDetailsNarrative" xlink:title="00000037 - Disclosure - Capital loss (Details Narrative)" /> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/GeneralAndAdministrativeExpensesDetails" xlink:title="00000038 - Disclosure - General and administrative expenses (Details)"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" /> <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" /> <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" /> <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="loc_us-gaapGeneralInsuranceExpense" /> <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapGeneralInsuranceExpense" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaapMarketingExpense" /> <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapMarketingExpense" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralExpense" xlink:label="loc_us-gaapOtherGeneralExpense" /> <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapOtherGeneralExpense" xlink:type="arc" weight="1" /> </link:calculationLink> <link:calculationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/FinancialIncomeExpensesDetails" xlink:title="00000039 - Disclosure - Financial (Income) expenses (Details)" /> </link:linkbase> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.DEF <SEQUENCE>22 <FILENAME>cnbx-20230831_def.xml <DESCRIPTION>XBRL DEFINITION FILE <TEXT> <XBRL> <?xml version="1.0" encoding="US-ASCII" standalone="no"?> <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20b --> <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com --> <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 --> <link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"> <link:roleRef roleURI="http://cnbxpharma.com/role/Cover" xlink:href="cnbx-20230831.xsd#Cover" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets" xlink:href="cnbx-20230831.xsd#AuditedConsolidatedBalanceSheets" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheetsParenthetical" xlink:href="cnbx-20230831.xsd#AuditedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations" xlink:href="cnbx-20230831.xsd#AuditedConsolidatedStatementsOfOperations" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperationsParenthetical" xlink:href="cnbx-20230831.xsd#AuditedConsolidatedStatementsOfOperationsParenthetical" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows" xlink:href="cnbx-20230831.xsd#AuditedConsolidatedStatementsOfCashFlows" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfStockholdersEquityDeficit" xlink:href="cnbx-20230831.xsd#AuditedConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcern" xlink:href="cnbx-20230831.xsd#NatureOfBusinessPresentationAndGoingConcern" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="cnbx-20230831.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/RecentAccountingPronouncements" xlink:href="cnbx-20230831.xsd#RecentAccountingPronouncements" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/RelatedPartyTransactions" xlink:href="cnbx-20230831.xsd#RelatedPartyTransactions" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/CommitmentsAndContingencies" xlink:href="cnbx-20230831.xsd#CommitmentsAndContingencies" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/StockholdersEquityDeficit" xlink:href="cnbx-20230831.xsd#StockholdersEquityDeficit" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/Warrants" xlink:href="cnbx-20230831.xsd#Warrants" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/IncomeTaxes" xlink:href="cnbx-20230831.xsd#IncomeTaxes" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/CapitalLoss" xlink:href="cnbx-20230831.xsd#CapitalLoss" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/GeneralAdministrateExpenses" xlink:href="cnbx-20230831.xsd#GeneralAdministrateExpenses" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/FinancialIncomeExpenses" xlink:href="cnbx-20230831.xsd#FinancialIncomeExpenses" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/SubsequentEvents" xlink:href="cnbx-20230831.xsd#SubsequentEvents" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cnbx-20230831.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/WarrantsTables" xlink:href="cnbx-20230831.xsd#WarrantsTables" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/IncomeTaxesTables" xlink:href="cnbx-20230831.xsd#IncomeTaxesTables" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/GeneralAdministrateExpensesTables" xlink:href="cnbx-20230831.xsd#GeneralAdministrateExpensesTables" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/FinancialIncomeExpensesTables" xlink:href="cnbx-20230831.xsd#FinancialIncomeExpensesTables" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcernDetailsNarrative" xlink:href="cnbx-20230831.xsd#NatureOfBusinessPresentationAndGoingConcernDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="cnbx-20230831.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cnbx-20230831.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cnbx-20230831.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:href="cnbx-20230831.xsd#StockholdersEquityDeficitDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/WarrantsDetails-FairValue" xlink:href="cnbx-20230831.xsd#WarrantsDetails-FairValue" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/WarrantsDetails-FairValueDisclosure" xlink:href="cnbx-20230831.xsd#WarrantsDetails-FairValueDisclosure" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/WarrantsDetails-WarrantActivity" xlink:href="cnbx-20230831.xsd#WarrantsDetails-WarrantActivity" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/WarrantsDetailsNarrative" xlink:href="cnbx-20230831.xsd#WarrantsDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/IncomeTaxesDetails-Rate" xlink:href="cnbx-20230831.xsd#IncomeTaxesDetails-Rate" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/IncomeTaxesDetails-DeferredTaxAssets" xlink:href="cnbx-20230831.xsd#IncomeTaxesDetails-DeferredTaxAssets" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="cnbx-20230831.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/CapitalLossDetailsNarrative" xlink:href="cnbx-20230831.xsd#CapitalLossDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/GeneralAndAdministrativeExpensesDetails" xlink:href="cnbx-20230831.xsd#GeneralAndAdministrativeExpensesDetails" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/FinancialIncomeExpensesDetails" xlink:href="cnbx-20230831.xsd#FinancialIncomeExpensesDetails" xlink:type="simple" /> <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" /> <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" /> <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" /> <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" /> <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" /> <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" /> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/Cover" xlink:title="00000001 - Document - Cover" /> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - Audited Consolidated Balance Sheets" /> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - Audited Consolidated Balance Sheets (Parenthetical)" /> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - Audited Consolidated Statements of Operations" /> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Audited Consolidated Statements of Operations (Parenthetical)" /> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - Audited Consolidated Statements of Cash Flows" /> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfStockholdersEquityDeficit" xlink:title="00000007 - Statement - Audited Consolidated Statements of Stockholders' Equity (Deficit)"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_20" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_20" xlink:type="arc" order="21" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_WarrantsMember" xlink:label="loc_CNBXWarrantsMember_30" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CNBXWarrantsMember_30" xlink:type="arc" order="31" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_40" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_40" xlink:type="arc" order="41" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" xlink:type="arc" order="3" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" xlink:type="arc" order="4" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" xlink:type="arc" order="5" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_ExpirationOfWarrants" xlink:label="loc_CNBXExpirationOfWarrants_70" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CNBXExpirationOfWarrants_70" xlink:type="arc" order="6" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_PostsplitAdjustment" xlink:label="loc_CNBXPostsplitAdjustment_70" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CNBXPostsplitAdjustment_70" xlink:type="arc" order="7" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_PostsplitAdjustmentShares" xlink:label="loc_CNBXPostsplitAdjustmentShares_70" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CNBXPostsplitAdjustmentShares_70" xlink:type="arc" order="8" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax_70" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax_70" xlink:type="arc" order="9" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="10" /> </link:definitionLink> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcern" xlink:title="00000008 - Disclosure - Nature of Business, Presentation and Going Concern" /> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies" /> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/RecentAccountingPronouncements" xlink:title="00000010 - Disclosure - Recent Accounting Pronouncements" /> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/RelatedPartyTransactions" xlink:title="00000011 - Disclosure - Related Party Transactions" /> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/CommitmentsAndContingencies" xlink:title="00000012 - Disclosure - Commitments and Contingencies" /> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/StockholdersEquityDeficit" xlink:title="00000013 - Disclosure - Stockholders’ Equity (Deficit)" /> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/Warrants" xlink:title="00000014 - Disclosure - Warrants" /> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - Income Taxes" /> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/CapitalLoss" xlink:title="00000016 - Disclosure - Capital loss" /> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/GeneralAdministrateExpenses" xlink:title="00000017 - Disclosure - General & administrate expenses" /> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/FinancialIncomeExpenses" xlink:title="00000018 - Disclosure - Financial (Income) expenses" /> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/SubsequentEvents" xlink:title="00000019 - Disclosure - Subsequent Events" /> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)" /> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/WarrantsTables" xlink:title="00000021 - Disclosure - Warrants (Tables)"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_Warrant1Member" xlink:label="loc_CNBXWarrant1Member_10" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CNBXWarrant1Member_10" xlink:type="arc" order="11" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_Warrant2Member" xlink:label="loc_CNBXWarrant2Member_20" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CNBXWarrant2Member_20" xlink:type="arc" order="21" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_ScheduleOfAssumptionsUsedWarrantsTableTextBlock" xlink:label="loc_CNBXScheduleOfAssumptionsUsedWarrantsTableTextBlock_40" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CNBXScheduleOfAssumptionsUsedWarrantsTableTextBlock_40" xlink:type="arc" order="0" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_40" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_40" xlink:type="arc" order="1" /> </link:definitionLink> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/IncomeTaxesTables" xlink:title="00000022 - Disclosure - Income Taxes (Tables)" /> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/GeneralAdministrateExpensesTables" xlink:title="00000023 - Disclosure - General & administrate expenses (Tables)" /> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/FinancialIncomeExpensesTables" xlink:title="00000024 - Disclosure - Financial (Income) expenses (Tables)" /> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcernDetailsNarrative" xlink:title="00000025 - Disclosure - Nature of Business, Presentation and Going Concern (Details Narrative)" /> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000026 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_30" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_30" xlink:type="arc" order="31" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_40" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_40" xlink:type="arc" order="41" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_60" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_60" xlink:type="arc" order="0" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_60" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDepreciation_60" xlink:type="arc" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsOwnedAtFairValue" xlink:label="loc_us-gaapFinancialInstrumentsOwnedAtFairValue_60" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFinancialInstrumentsOwnedAtFairValue_60" xlink:type="arc" order="2" /> </link:definitionLink> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000027 - Disclosure - Related Party Transactions (Details Narrative)"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_CEOAndChairmanMember" xlink:label="loc_CNBXCEOAndChairmanMember_0" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CNBXCEOAndChairmanMember_0" xlink:type="arc" order="1" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_ThreeDirectorsMember" xlink:label="loc_CNBXThreeDirectorsMember_60" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CNBXThreeDirectorsMember_60" xlink:type="arc" order="61" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_CannabicsIncMember" xlink:label="loc_CNBXCannabicsIncMember_80" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CNBXCannabicsIncMember_80" xlink:type="arc" order="81" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_ChairmanAndBoardMembersMember" xlink:label="loc_CNBXChairmanAndBoardMembersMember_100" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CNBXChairmanAndBoardMembersMember_100" xlink:type="arc" order="102" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srtChiefFinancialOfficerMember_40" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefFinancialOfficerMember_40" xlink:type="arc" order="41" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="loc_us-gaapNonmonetaryTransactionTypeAxis" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapNonmonetaryTransactionTypeAxis" xlink:type="arc" order="3" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="loc_us-gaapNonmonetaryTransactionTypeDomain" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapNonmonetaryTransactionTypeAxis" xlink:to="loc_us-gaapNonmonetaryTransactionTypeDomain" xlink:type="arc" order="20" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="loc_us-gaapNonmonetaryTransactionTypeDomain_10" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapNonmonetaryTransactionTypeAxis" xlink:to="loc_us-gaapNonmonetaryTransactionTypeDomain_10" xlink:type="arc" order="30" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_ShareBasedPaymentMember" xlink:label="loc_CNBXShareBasedPaymentMember_100" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonmonetaryTransactionTypeDomain" xlink:to="loc_CNBXShareBasedPaymentMember_100" xlink:type="arc" order="101" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation_130" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOfficersCompensation_130" xlink:type="arc" order="0" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedSalariesCurrentAndNoncurrent_130" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccruedSalariesCurrentAndNoncurrent_130" xlink:type="arc" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent_130" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNotesPayableCurrent_130" xlink:type="arc" order="2" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_DueToRelatedPartiesCurrent1" xlink:label="loc_CNBXDueToRelatedPartiesCurrent1_130" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CNBXDueToRelatedPartiesCurrent1_130" xlink:type="arc" order="3" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense_130" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherNoncashExpense_130" xlink:type="arc" order="4" /> </link:definitionLink> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000028 - Disclosure - Commitments and Contingencies (Details Narrative)" /> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:title="00000029 - Disclosure - Stockholders’ Equity (Deficit) (Details Narrative)"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_20" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember_20" xlink:type="arc" order="21" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_SecuritiesPurchaseAgreementMember" xlink:label="loc_CNBXSecuritiesPurchaseAgreementMember_30" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CNBXSecuritiesPurchaseAgreementMember_30" xlink:type="arc" order="31" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="3" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_InitialNoteMember" xlink:label="loc_CNBXInitialNoteMember_40" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CNBXInitialNoteMember_40" xlink:type="arc" order="41" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_SecondNoteMember" xlink:label="loc_CNBXSecondNoteMember_50" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CNBXSecondNoteMember_50" xlink:type="arc" order="51" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_NoteMember" xlink:label="loc_CNBXNoteMember_60" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CNBXNoteMember_60" xlink:type="arc" order="61" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="4" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_100" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_100" xlink:type="arc" order="102" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="5" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_SeniorSecuredNoteMember" xlink:label="loc_CNBXSeniorSecuredNoteMember_110" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_CNBXSeniorSecuredNoteMember_110" xlink:type="arc" order="111" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_DemandNoteMember" xlink:label="loc_CNBXDemandNoteMember_130" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_CNBXDemandNoteMember_130" xlink:type="arc" order="131" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_220" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_220" xlink:type="arc" order="0" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_220" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_220" xlink:type="arc" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_220" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_220" xlink:type="arc" order="2" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_220" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_220" xlink:type="arc" order="3" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_220" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_220" xlink:type="arc" order="4" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_220" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_220" xlink:type="arc" order="5" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_220" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_220" xlink:type="arc" order="6" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfSeniorLongTermDebt_220" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfSeniorLongTermDebt_220" xlink:type="arc" order="7" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:label="loc_us-gaapCommonStockConvertibleConversionPriceIncrease_220" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockConvertibleConversionPriceIncrease_220" xlink:type="arc" order="8" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:label="loc_us-gaapCommonStockConvertibleConversionPriceDecrease_220" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockConvertibleConversionPriceDecrease_220" xlink:type="arc" order="9" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_220" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_220" xlink:type="arc" order="10" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable_220" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromNotesPayable_220" xlink:type="arc" order="11" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_220" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_220" xlink:type="arc" order="12" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesCurrent" xlink:label="loc_us-gaapSeniorNotesCurrent_220" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSeniorNotesCurrent_220" xlink:type="arc" order="13" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_220" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_220" xlink:type="arc" order="14" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_220" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_220" xlink:type="arc" order="15" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_WarrantsIssued" xlink:label="loc_CNBXWarrantsIssued_220" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CNBXWarrantsIssued_220" xlink:type="arc" order="16" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_220" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_220" xlink:type="arc" order="17" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_OriginalIssueDiscount" xlink:label="loc_CNBXOriginalIssueDiscount_220" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CNBXOriginalIssueDiscount_220" xlink:type="arc" order="18" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseOtherLongTermDebt" xlink:label="loc_us-gaapInterestExpenseOtherLongTermDebt_220" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapInterestExpenseOtherLongTermDebt_220" xlink:type="arc" order="19" /> </link:definitionLink> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/WarrantsDetails-FairValue" xlink:title="00000030 - Disclosure - Warrants (Details - Fair value)"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_Warrant1Member" xlink:label="loc_CNBXWarrant1Member_0" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CNBXWarrant1Member_0" xlink:type="arc" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_30" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharePrice_30" xlink:type="arc" order="0" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_30" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_30" xlink:type="arc" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30" xlink:type="arc" order="2" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_30" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_30" xlink:type="arc" order="3" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30" xlink:type="arc" order="4" /> </link:definitionLink> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/WarrantsDetails-FairValueDisclosure" xlink:title="00000031 - Disclosure - Warrants (Details - Fair Value)"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_Warrant2Member" xlink:label="loc_CNBXWarrant2Member_0" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CNBXWarrant2Member_0" xlink:type="arc" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_30" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharePrice_30" xlink:type="arc" order="0" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_30" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_30" xlink:type="arc" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30" xlink:type="arc" order="2" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_30" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_30" xlink:type="arc" order="3" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30" xlink:type="arc" order="4" /> </link:definitionLink> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/WarrantsDetails-WarrantActivity" xlink:title="00000032 - Disclosure - Warrants (Details - Warrant activity)"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_WarrantsMember" xlink:label="loc_CNBXWarrantsMember_0" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CNBXWarrantsMember_0" xlink:type="arc" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_80" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_80" xlink:type="arc" order="0" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_80" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_80" xlink:type="arc" order="1" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_WarrantsIssued" xlink:label="loc_CNBXWarrantsIssued_80" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CNBXWarrantsIssued_80" xlink:type="arc" order="2" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_WeightedAverageExercisePriceWarrantsIssued" xlink:label="loc_CNBXWeightedAverageExercisePriceWarrantsIssued_80" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CNBXWeightedAverageExercisePriceWarrantsIssued_80" xlink:type="arc" order="3" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_80" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_80" xlink:type="arc" order="4" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_WeightedAverageExercisePriceWarrantsExercised" xlink:label="loc_CNBXWeightedAverageExercisePriceWarrantsExercised_80" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CNBXWeightedAverageExercisePriceWarrantsExercised_80" xlink:type="arc" order="5" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_80" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_80" xlink:type="arc" order="6" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_WeightedAverageExercisePriceWarrantsExpired" xlink:label="loc_CNBXWeightedAverageExercisePriceWarrantsExpired_80" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CNBXWeightedAverageExercisePriceWarrantsExpired_80" xlink:type="arc" order="7" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" xlink:label="loc_CNBXShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_80" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CNBXShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_80" xlink:type="arc" order="10" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_WeightedAverageExercisePriceWarrantsExercisable" xlink:label="loc_CNBXWeightedAverageExercisePriceWarrantsExercisable_80" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CNBXWeightedAverageExercisePriceWarrantsExercisable_80" xlink:type="arc" order="11" /> </link:definitionLink> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/WarrantsDetailsNarrative" xlink:title="00000033 - Disclosure - Warrants (Details Narrative)"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_Warrant1Member" xlink:label="loc_CNBXWarrant1Member_0" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CNBXWarrant1Member_0" xlink:type="arc" order="1" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_Warrant2Member" xlink:label="loc_CNBXWarrant2Member_10" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CNBXWarrant2Member_10" xlink:type="arc" order="11" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_WarrantsIssuedShares" xlink:label="loc_CNBXWarrantsIssuedShares_30" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CNBXWarrantsIssuedShares_30" xlink:type="arc" order="0" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_30" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_30" xlink:type="arc" order="1" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_FairValueOfWarrantsIssued" xlink:label="loc_CNBXFairValueOfWarrantsIssued_30" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CNBXFairValueOfWarrantsIssued_30" xlink:type="arc" order="2" /> </link:definitionLink> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/IncomeTaxesDetails-Rate" xlink:title="00000034 - Disclosure - Income Taxes (Details - rate)" /> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/IncomeTaxesDetails-DeferredTaxAssets" xlink:title="00000035 - Disclosure - Income Taxes (Details - Deferred tax assets)"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_0" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_0" xlink:type="arc" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember_20" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember_20" xlink:type="arc" order="21" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_70" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_70" xlink:type="arc" order="0" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_70" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_70" xlink:type="arc" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet_70" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsNet_70" xlink:type="arc" order="2" /> </link:definitionLink> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000036 - Disclosure - Income Taxes (Details Narrative)"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_0" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_0" xlink:type="arc" order="1" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_UnitedStates1Member" xlink:label="loc_CNBXUnitedStates1Member_10" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_CNBXUnitedStates1Member_10" xlink:type="arc" order="11" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:type="arc" order="2" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:type="arc" order="20" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain_10" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain_10" xlink:type="arc" order="30" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IsraelTaxAuthorityMember" xlink:label="loc_us-gaapIsraelTaxAuthorityMember_30" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapIsraelTaxAuthorityMember_30" xlink:type="arc" order="31" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_100" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_100" xlink:type="arc" order="0" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_100" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_100" xlink:type="arc" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_100" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_100" xlink:type="arc" order="2" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_100" /> <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_100" xlink:type="arc" order="3" /> </link:definitionLink> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/CapitalLossDetailsNarrative" xlink:title="00000037 - Disclosure - Capital loss (Details Narrative)" /> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/GeneralAndAdministrativeExpensesDetails" xlink:title="00000038 - Disclosure - General and administrative expenses (Details)" /> <link:definitionLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/FinancialIncomeExpensesDetails" xlink:title="00000039 - Disclosure - Financial (Income) expenses (Details)" /> </link:linkbase> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.LAB <SEQUENCE>23 <FILENAME>cnbx-20230831_lab.xml <DESCRIPTION>XBRL LABEL FILE <TEXT> <XBRL> <?xml version="1.0" encoding="US-ASCII" standalone="no"?> <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20b --> <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com --> <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 --> <link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"> <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" /> <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" /> <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" /> <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" /> <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" /> <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" /> <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" /> <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_WarrantsMember" xlink:label="CNBX_WarrantsMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_WarrantsMember" xlink:to="CNBX_WarrantsMember_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_WarrantsMember_lbl" xml:lang="en-US">Warrants [Member]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party, Type [Axis]</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_CEOAndChairmanMember" xlink:label="CNBX_CEOAndChairmanMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_CEOAndChairmanMember" xlink:to="CNBX_CEOAndChairmanMember_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_CEOAndChairmanMember_lbl" xml:lang="en-US">C E O And Chairman [Member]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US">Chief Financial Officer [Member]</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_ThreeDirectorsMember" xlink:label="CNBX_ThreeDirectorsMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_ThreeDirectorsMember" xlink:to="CNBX_ThreeDirectorsMember_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_ThreeDirectorsMember_lbl" xml:lang="en-US">Three Directors [Member]</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_CannabicsIncMember" xlink:label="CNBX_CannabicsIncMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_CannabicsIncMember" xlink:to="CNBX_CannabicsIncMember_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_CannabicsIncMember_lbl" xml:lang="en-US">Cannabics Inc [Member]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis_lbl" xml:lang="en-US">Nonmonetary Transaction Type [Axis]</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_ShareBasedPaymentMember" xlink:label="CNBX_ShareBasedPaymentMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_ShareBasedPaymentMember" xlink:to="CNBX_ShareBasedPaymentMember_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_ShareBasedPaymentMember_lbl" xml:lang="en-US">Share Based Payment [Member]</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_ChairmanAndBoardMembersMember" xlink:label="CNBX_ChairmanAndBoardMembersMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_ChairmanAndBoardMembersMember" xlink:to="CNBX_ChairmanAndBoardMembersMember_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_ChairmanAndBoardMembersMember_lbl" xml:lang="en-US">Chairman And Board Members [Member]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_SecuritiesPurchaseAgreementMember" xlink:label="CNBX_SecuritiesPurchaseAgreementMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_SecuritiesPurchaseAgreementMember" xlink:to="CNBX_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_InitialNoteMember" xlink:label="CNBX_InitialNoteMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_InitialNoteMember" xlink:to="CNBX_InitialNoteMember_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_InitialNoteMember_lbl" xml:lang="en-US">Initial Note [Member]</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_SecondNoteMember" xlink:label="CNBX_SecondNoteMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_SecondNoteMember" xlink:to="CNBX_SecondNoteMember_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_SecondNoteMember_lbl" xml:lang="en-US">Second Note [Member]</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_NoteMember" xlink:label="CNBX_NoteMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_NoteMember" xlink:to="CNBX_NoteMember_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_NoteMember_lbl" xml:lang="en-US">Note [Member]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_SeniorSecuredNoteMember" xlink:label="CNBX_SeniorSecuredNoteMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_SeniorSecuredNoteMember" xlink:to="CNBX_SeniorSecuredNoteMember_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_SeniorSecuredNoteMember_lbl" xml:lang="en-US">Senior Secured Note [Member]</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_DemandNoteMember" xlink:label="CNBX_DemandNoteMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_DemandNoteMember" xlink:to="CNBX_DemandNoteMember_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_DemandNoteMember_lbl" xml:lang="en-US">Demand Note [Member]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_Warrant1Member" xlink:label="CNBX_Warrant1Member" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_Warrant1Member" xlink:to="CNBX_Warrant1Member_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_Warrant1Member_lbl" xml:lang="en-US">Warrant 1 [Member]</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_Warrant2Member" xlink:label="CNBX_Warrant2Member" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_Warrant2Member" xlink:to="CNBX_Warrant2Member_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_Warrant2Member_lbl" xml:lang="en-US">Warrant 2 [Member]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Authority [Member]</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_UnitedStates1Member" xlink:label="CNBX_UnitedStates1Member" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_UnitedStates1Member" xlink:to="CNBX_UnitedStates1Member_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_UnitedStates1Member_lbl" xml:lang="en-US">United States [Member]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IsraelTaxAuthorityMember" xlink:label="us-gaap_IsraelTaxAuthorityMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IsraelTaxAuthorityMember" xlink:to="us-gaap_IsraelTaxAuthorityMember_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IsraelTaxAuthorityMember_lbl" xml:lang="en-US">Israel Tax Authority [Member]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US">Foreign Tax Authority [Member]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other receivables</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments" xlink:label="us-gaap_Investments" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Investments" xlink:to="us-gaap_Investments_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Investments_lbl" xml:lang="en-US">Available for sale Investment</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Equipment, net</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">Convertible loan</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_DueToRelatedParty" xlink:label="CNBX_DueToRelatedParty" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_DueToRelatedParty" xlink:to="CNBX_DueToRelatedParty_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_DueToRelatedParty_lbl" xml:lang="en-US">Due to a related party</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' equity (deficit):</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $.0001 par value, 5,000,000 shares authorized no shares issued and outstanding.</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $.0001 par value, 900,000,000 shares authorized, 22,611,352and 1,238,659 shares issued and outstanding at August 31, 2023 and August 31, 2022 respectively.</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAdditionalCapital" xlink:label="us-gaap_OtherAdditionalCapital" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAdditionalCapital" xlink:to="us-gaap_OtherAdditionalCapital_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAdditionalCapital_lbl" xml:lang="en-US">Issuance of warrants</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Other comprehensive loss</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity (deficit)</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expense</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAbstract" xlink:label="us-gaap_OtherIncomeAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="us-gaap_OtherIncomeAbstract_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAbstract_lbl" xml:lang="en-US">Other income</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_CapitalGainLoss" xlink:label="CNBX_CapitalGainLoss" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_CapitalGainLoss" xlink:to="CNBX_CapitalGainLoss_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_CapitalGainLoss_lbl" xml:lang="en-US">Capital Gain (loss)</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_FinancialLossNet" xlink:label="CNBX_FinancialLossNet" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_FinancialLossNet" xlink:to="CNBX_FinancialLossNet_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_FinancialLossNet_lbl" xml:lang="en-US">Financial loss, net</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net (loss) income</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US">(Loss) Profit from available for sale assets</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Total comprehensive (loss) income</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net (loss) per share - basic</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net (loss) per share - diluted</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of shares outstanding - Basic</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of shares outstanding - Diluted</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net (Loss) Profit</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share based payment</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_InterestOnConvertibleLoan" xlink:label="CNBX_InterestOnConvertibleLoan" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_InterestOnConvertibleLoan" xlink:to="CNBX_InterestOnConvertibleLoan_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_InterestOnConvertibleLoan_lbl" xml:lang="en-US">Interest on Convertible loan</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_CapitalLossGain" xlink:label="CNBX_CapitalLossGain" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_CapitalLossGain" xlink:to="CNBX_CapitalLossGain_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CNBX_CapitalLossGain_lbl" xml:lang="en-US">Capital loss (Gain)</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAbstract_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xml:lang="en-US">Accounts Receivable and prepaid expenses</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Sale of equipment</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:label="us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:to="us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_lbl" xml:lang="en-US">Realization of Held for trading investments</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:to="us-gaap_PaymentsToAcquireMachineryAndEquipment_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_lbl" xml:lang="en-US">Acquisition of equipment</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from issuance of a Convertible loan</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate fluctuations on cash</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and cash equivalents at end of the year</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Significant non-cash transactions:</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_ExerciseOfConvertibleLoanToSharesOfCommonStock." xlink:label="CNBX_ExerciseOfConvertibleLoanToSharesOfCommonStock." /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_ExerciseOfConvertibleLoanToSharesOfCommonStock." xlink:to="CNBX_ExerciseOfConvertibleLoanToSharesOfCommonStock._lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_ExerciseOfConvertibleLoanToSharesOfCommonStock._lbl" xml:lang="en-US">Exercise of a Convertible loan to shares of common stock.</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share based Payment</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Exercise of a Convertible loan to shares of common stock.</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Exercise of a Convertible loan to shares of common stock, shares</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_ExpirationOfWarrants" xlink:label="CNBX_ExpirationOfWarrants" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_ExpirationOfWarrants" xlink:to="CNBX_ExpirationOfWarrants_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_ExpirationOfWarrants_lbl" xml:lang="en-US">Expiration of warrants</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_PostsplitAdjustment" xlink:label="CNBX_PostsplitAdjustment" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_PostsplitAdjustment" xlink:to="CNBX_PostsplitAdjustment_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_PostsplitAdjustment_lbl" xml:lang="en-US">Post-split adjustment</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_PostsplitAdjustmentShares" xlink:label="CNBX_PostsplitAdjustmentShares" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_PostsplitAdjustmentShares" xlink:to="CNBX_PostsplitAdjustmentShares_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_PostsplitAdjustmentShares_lbl" xml:lang="en-US">Post-split adjustment, shares</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Other comprehensive loss</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net loss</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Nature of Business, Presentation and Going Concern</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders’ Equity (Deficit)</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_DisclosureWarrantsAbstract" xlink:label="CNBX_DisclosureWarrantsAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_DisclosureWarrantsAbstract" xlink:to="CNBX_DisclosureWarrantsAbstract_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_DisclosureWarrantsAbstract_lbl" xml:lang="en-US">Warrants</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_WarrantDisclosureTextBlock" xlink:label="CNBX_WarrantDisclosureTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_WarrantDisclosureTextBlock" xlink:to="CNBX_WarrantDisclosureTextBlock_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CNBX_WarrantDisclosureTextBlock_lbl" xml:lang="en-US">Warrants</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_DisclosureCapitalLossAbstract" xlink:label="CNBX_DisclosureCapitalLossAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_DisclosureCapitalLossAbstract" xlink:to="CNBX_DisclosureCapitalLossAbstract_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_DisclosureCapitalLossAbstract_lbl" xml:lang="en-US">Capital Loss</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_CapitalLossDisclosureTextBlock" xlink:label="CNBX_CapitalLossDisclosureTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_CapitalLossDisclosureTextBlock" xlink:to="CNBX_CapitalLossDisclosureTextBlock_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_CapitalLossDisclosureTextBlock_lbl" xml:lang="en-US">Capital loss</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl" xml:lang="en-US">General & administrate expenses</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_lbl" xml:lang="en-US">Financial (Income) expenses</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Functional currency</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Equipment, net</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development, net</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock Based Compensation</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Income</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Loss per Share</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassification</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_ScheduleOfAssumptionsUsedWarrantsTableTextBlock" xlink:label="CNBX_ScheduleOfAssumptionsUsedWarrantsTableTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_ScheduleOfAssumptionsUsedWarrantsTableTextBlock" xlink:to="CNBX_ScheduleOfAssumptionsUsedWarrantsTableTextBlock_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_ScheduleOfAssumptionsUsedWarrantsTableTextBlock_lbl" xml:lang="en-US">Schedule of assumptions</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of warrant activity</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of effective income tax rate</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred income tax assets</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of general and administrative expenses</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_ScheduleOfFinancialIncomeExpensesTableTextBlock" xlink:label="CNBX_ScheduleOfFinancialIncomeExpensesTableTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_ScheduleOfFinancialIncomeExpensesTableTextBlock" xlink:to="CNBX_ScheduleOfFinancialIncomeExpensesTableTextBlock_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_ScheduleOfFinancialIncomeExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of financial income expenses</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net loss</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Cumulative losses</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="srt_PlatformOperatorCryptoAssetTable" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetTable" xlink:to="srt_PlatformOperatorCryptoAssetTable_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetTable_lbl" xml:lang="en-US">Platform Operator, Crypto-Asset [Table]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="srt_PlatformOperatorCryptoAssetLineItems" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetLineItems" xlink:to="srt_PlatformOperatorCryptoAssetLineItems_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetLineItems_lbl" xml:lang="en-US">Platform Operator, Crypto-Asset [Line Items]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Federal deposit insurance</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_2_lbl" xml:lang="en-US">Depreciation expense</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsOwnedAtFairValue" xlink:label="us-gaap_FinancialInstrumentsOwnedAtFairValue" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsOwnedAtFairValue" xlink:to="us-gaap_FinancialInstrumentsOwnedAtFairValue_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsOwnedAtFairValue_lbl" xml:lang="en-US">Fair value of financial instruments</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="us-gaap_OfficersCompensation" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficersCompensation_lbl" xml:lang="en-US">Compensation paid</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedSalariesCurrentAndNoncurrent" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedSalariesCurrentAndNoncurrent_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued salaries</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Outstanding payable</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_DueToRelatedPartiesCurrent1" xlink:label="CNBX_DueToRelatedPartiesCurrent1" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_DueToRelatedPartiesCurrent1" xlink:to="CNBX_DueToRelatedPartiesCurrent1_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_DueToRelatedPartiesCurrent1_lbl" xml:lang="en-US">Due to related parties</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US">Non cash expense</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BankAcceptancesExecuted" xlink:label="us-gaap_BankAcceptancesExecuted" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BankAcceptancesExecuted" xlink:to="us-gaap_BankAcceptancesExecuted_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BankAcceptancesExecuted_lbl" xml:lang="en-US">Bank guarantee</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Stock split</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xml:lang="en-US">Convertible shares</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2_lbl" xml:lang="en-US">Stock issued for exercise of convertible debt, value</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_lbl" xml:lang="en-US">Senior convertible notes issued</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:to="us-gaap_CommonStockConvertibleConversionPriceIncrease_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease_lbl" xml:lang="en-US">Conversion price</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:label="us-gaap_CommonStockConvertibleConversionPriceDecrease" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:to="us-gaap_CommonStockConvertibleConversionPriceDecrease_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockConvertibleConversionPriceDecrease_lbl" xml:lang="en-US">Lower conversion price</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Interest rate</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Notes payable</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Unamortized Discount</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesCurrent" xlink:label="us-gaap_SeniorNotesCurrent" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeniorNotesCurrent" xlink:to="us-gaap_SeniorNotesCurrent_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeniorNotesCurrent_lbl" xml:lang="en-US">Senior secured note</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Original issue discount percentage</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_WarrantsIssued" xlink:label="CNBX_WarrantsIssued" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_WarrantsIssued" xlink:to="CNBX_WarrantsIssued_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_WarrantsIssued_lbl" xml:lang="en-US">Warrants issued</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrants exercise price</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_OriginalIssueDiscount" xlink:label="CNBX_OriginalIssueDiscount" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_OriginalIssueDiscount" xlink:to="CNBX_OriginalIssueDiscount_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_OriginalIssueDiscount_lbl" xml:lang="en-US">Original issue discount</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseOtherLongTermDebt" xlink:label="us-gaap_InterestExpenseOtherLongTermDebt" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOtherLongTermDebt" xlink:to="us-gaap_InterestExpenseOtherLongTermDebt_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseOtherLongTermDebt_lbl" xml:lang="en-US">Net of issuance expenses</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">PV of exercise Share price</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected Volatility</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk Free Interest Rate</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected Term (years)</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected Dividend Yield</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding, beginning balance</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Weighted average exercise price, warrants outstanding, beginning balance</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_WeightedAverageExercisePriceWarrantsIssued" xlink:label="CNBX_WeightedAverageExercisePriceWarrantsIssued" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_WeightedAverageExercisePriceWarrantsIssued" xlink:to="CNBX_WeightedAverageExercisePriceWarrantsIssued_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_WeightedAverageExercisePriceWarrantsIssued_lbl" xml:lang="en-US">Weighted average exercise price, warrants issued</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Warrants exercised</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_WeightedAverageExercisePriceWarrantsExercised" xlink:label="CNBX_WeightedAverageExercisePriceWarrantsExercised" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_WeightedAverageExercisePriceWarrantsExercised" xlink:to="CNBX_WeightedAverageExercisePriceWarrantsExercised_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_WeightedAverageExercisePriceWarrantsExercised_lbl" xml:lang="en-US">Weighted average exercise price, warrants exercised</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Warrants expired</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_WeightedAverageExercisePriceWarrantsExpired" xlink:label="CNBX_WeightedAverageExercisePriceWarrantsExpired" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_WeightedAverageExercisePriceWarrantsExpired" xlink:to="CNBX_WeightedAverageExercisePriceWarrantsExpired_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_WeightedAverageExercisePriceWarrantsExpired_lbl" xml:lang="en-US">Weighted average exercise price, warrants expired</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Warrants outstanding, ending balance</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Weighted average exercise price, warrants outstanding, ending balance</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" xlink:label="CNBX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" xlink:to="CNBX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_lbl" xml:lang="en-US">Warrants exercisable</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_WeightedAverageExercisePriceWarrantsExercisable" xlink:label="CNBX_WeightedAverageExercisePriceWarrantsExercisable" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_WeightedAverageExercisePriceWarrantsExercisable" xlink:to="CNBX_WeightedAverageExercisePriceWarrantsExercisable_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_WeightedAverageExercisePriceWarrantsExercisable_lbl" xml:lang="en-US">Weighted average exercise price, warrants exercisable</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_WarrantsIssuedShares" xlink:label="CNBX_WarrantsIssuedShares" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_WarrantsIssuedShares" xlink:to="CNBX_WarrantsIssuedShares_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_WarrantsIssuedShares_lbl" xml:lang="en-US">Warrants issued, shares</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Expiry date</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_FairValueOfWarrantsIssued" xlink:label="CNBX_FairValueOfWarrantsIssued" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_FairValueOfWarrantsIssued" xlink:to="CNBX_FairValueOfWarrantsIssued_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_FairValueOfWarrantsIssued_lbl" xml:lang="en-US">Fair value of warrants issued</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">United States statutory corporate income tax rate</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance on deferred tax assets</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Provision for income tax</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forwards benefit</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred income tax assets</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">Effective tax rate</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Effective tax rate, Israel</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Increase (decrease) in valuation allowance</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Sale consideration</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_CapitalLoss" xlink:label="CNBX_CapitalLoss" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_CapitalLoss" xlink:to="CNBX_CapitalLoss_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CNBX_CapitalLoss_lbl" xml:lang="en-US">Capital loss</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US">Salaries and related expenses</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share based payment to related parties</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal and professional fees</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="us-gaap_GeneralInsuranceExpense" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralInsuranceExpense" xlink:to="us-gaap_GeneralInsuranceExpense_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralInsuranceExpense_lbl" xml:lang="en-US">Insurance</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketingExpense" xlink:label="us-gaap_MarketingExpense" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketingExpense" xlink:to="us-gaap_MarketingExpense_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketingExpense_lbl" xml:lang="en-US">Marketing expenses</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralExpense" xlink:label="us-gaap_OtherGeneralExpense" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralExpense" xlink:to="us-gaap_OtherGeneralExpense_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralExpense_lbl" xml:lang="en-US">Other expenses</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">Total general and administrative expenses</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="us-gaap_InterestExpenseBorrowings" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseBorrowings" xlink:to="us-gaap_InterestExpenseBorrowings_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseBorrowings_lbl" xml:lang="en-US">Interest and bank charges</link:label> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_LossGainFromConvertibleLoanValuation" xlink:label="CNBX_LossGainFromConvertibleLoanValuation" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_LossGainFromConvertibleLoanValuation" xlink:to="CNBX_LossGainFromConvertibleLoanValuation_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_LossGainFromConvertibleLoanValuation_lbl" xml:lang="en-US">Loss (Gain) from convertible loan valuation</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Currency exchange differences loss (profit)</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income expenses</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_UnitedStates1Member" xlink:to="CNBX_UnitedStates1Member_doc" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CNBX_UnitedStates1Member_doc" xml:lang="en-US">United States [Member]</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_CapitalLossGain" xlink:to="CNBX_CapitalLossGain_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_CapitalLossGain_2_lbl" xml:lang="en-US">CapitalLossGain</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:to="us-gaap_PaymentsToAcquireMachineryAndEquipment_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Machinery and Equipment</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_2_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_WarrantDisclosureTextBlock" xlink:to="CNBX_WarrantDisclosureTextBlock_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_WarrantDisclosureTextBlock_2_lbl" xml:lang="en-US">WarrantDisclosureTextBlock</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CNBX_CapitalLoss" xlink:to="CNBX_CapitalLoss_2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CNBX_CapitalLoss_2_lbl" xml:lang="en-US">CapitalLoss</link:label> </link:labelLink> </link:linkbase> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.PRE <SEQUENCE>24 <FILENAME>cnbx-20230831_pre.xml <DESCRIPTION>XBRL PRESENTATION FILE <TEXT> <XBRL> <?xml version="1.0" encoding="US-ASCII" standalone="no"?> <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20b --> <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com --> <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 --> <link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"> <link:roleRef roleURI="http://cnbxpharma.com/role/Cover" xlink:href="cnbx-20230831.xsd#Cover" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets" xlink:href="cnbx-20230831.xsd#AuditedConsolidatedBalanceSheets" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheetsParenthetical" xlink:href="cnbx-20230831.xsd#AuditedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations" xlink:href="cnbx-20230831.xsd#AuditedConsolidatedStatementsOfOperations" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperationsParenthetical" xlink:href="cnbx-20230831.xsd#AuditedConsolidatedStatementsOfOperationsParenthetical" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows" xlink:href="cnbx-20230831.xsd#AuditedConsolidatedStatementsOfCashFlows" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfStockholdersEquityDeficit" xlink:href="cnbx-20230831.xsd#AuditedConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcern" xlink:href="cnbx-20230831.xsd#NatureOfBusinessPresentationAndGoingConcern" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="cnbx-20230831.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/RecentAccountingPronouncements" xlink:href="cnbx-20230831.xsd#RecentAccountingPronouncements" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/RelatedPartyTransactions" xlink:href="cnbx-20230831.xsd#RelatedPartyTransactions" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/CommitmentsAndContingencies" xlink:href="cnbx-20230831.xsd#CommitmentsAndContingencies" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/StockholdersEquityDeficit" xlink:href="cnbx-20230831.xsd#StockholdersEquityDeficit" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/Warrants" xlink:href="cnbx-20230831.xsd#Warrants" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/IncomeTaxes" xlink:href="cnbx-20230831.xsd#IncomeTaxes" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/CapitalLoss" xlink:href="cnbx-20230831.xsd#CapitalLoss" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/GeneralAdministrateExpenses" xlink:href="cnbx-20230831.xsd#GeneralAdministrateExpenses" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/FinancialIncomeExpenses" xlink:href="cnbx-20230831.xsd#FinancialIncomeExpenses" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/SubsequentEvents" xlink:href="cnbx-20230831.xsd#SubsequentEvents" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cnbx-20230831.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/WarrantsTables" xlink:href="cnbx-20230831.xsd#WarrantsTables" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/IncomeTaxesTables" xlink:href="cnbx-20230831.xsd#IncomeTaxesTables" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/GeneralAdministrateExpensesTables" xlink:href="cnbx-20230831.xsd#GeneralAdministrateExpensesTables" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/FinancialIncomeExpensesTables" xlink:href="cnbx-20230831.xsd#FinancialIncomeExpensesTables" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcernDetailsNarrative" xlink:href="cnbx-20230831.xsd#NatureOfBusinessPresentationAndGoingConcernDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="cnbx-20230831.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cnbx-20230831.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cnbx-20230831.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:href="cnbx-20230831.xsd#StockholdersEquityDeficitDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/WarrantsDetails-FairValue" xlink:href="cnbx-20230831.xsd#WarrantsDetails-FairValue" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/WarrantsDetails-FairValueDisclosure" xlink:href="cnbx-20230831.xsd#WarrantsDetails-FairValueDisclosure" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/WarrantsDetails-WarrantActivity" xlink:href="cnbx-20230831.xsd#WarrantsDetails-WarrantActivity" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/WarrantsDetailsNarrative" xlink:href="cnbx-20230831.xsd#WarrantsDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/IncomeTaxesDetails-Rate" xlink:href="cnbx-20230831.xsd#IncomeTaxesDetails-Rate" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/IncomeTaxesDetails-DeferredTaxAssets" xlink:href="cnbx-20230831.xsd#IncomeTaxesDetails-DeferredTaxAssets" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="cnbx-20230831.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/CapitalLossDetailsNarrative" xlink:href="cnbx-20230831.xsd#CapitalLossDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/GeneralAndAdministrativeExpensesDetails" xlink:href="cnbx-20230831.xsd#GeneralAndAdministrativeExpensesDetails" xlink:type="simple" /> <link:roleRef roleURI="http://cnbxpharma.com/role/FinancialIncomeExpensesDetails" xlink:href="cnbx-20230831.xsd#FinancialIncomeExpensesDetails" xlink:type="simple" /> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/Cover" xlink:title="00000001 - Document - Cover"> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" /> <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" /> <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" /> <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" /> <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" /> <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" /> <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" /> <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" /> <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" /> <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" /> <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" /> <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" /> <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" /> <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" /> <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" /> <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" /> <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" /> <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" /> <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" /> <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" /> <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" /> <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" /> <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" /> <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" /> <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" /> <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" /> <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" /> <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" /> <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" /> <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" /> <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" /> <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" /> <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" /> <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" /> <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" /> <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" /> <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" /> <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" /> <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" /> <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" /> <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" /> <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" /> <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" /> <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" /> <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" /> <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" /> <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" /> <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" /> <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" /> <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" /> <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" /> <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" /> <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" /> <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" /> <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" /> <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" /> <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" /> <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" /> <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" /> <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" /> <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" /> <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - Audited Consolidated Balance Sheets"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" /> <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" /> <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" /> <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments" /> <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapInvestments" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" /> <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" /> <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" /> <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" /> <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" /> <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaapConvertibleDebtCurrent" /> <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapConvertibleDebtCurrent" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_DueToRelatedParty" xlink:label="loc_CNBXDueToRelatedParty" /> <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_CNBXDueToRelatedParty" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" /> <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" /> <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" /> <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" /> <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" /> <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAdditionalCapital" xlink:label="loc_us-gaapOtherAdditionalCapital" /> <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapOtherAdditionalCapital" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" /> <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" /> <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" /> <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" /> <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - Audited Consolidated Balance Sheets (Parenthetical)"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" /> <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" /> <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" /> <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" /> <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" /> <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" /> <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - Audited Consolidated Statements of Operations"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" /> <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" /> <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" /> <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" /> <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAbstract" xlink:label="loc_us-gaapOtherIncomeAbstract" /> <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherIncomeAbstract" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_CapitalGainLoss" xlink:label="loc_CNBXCapitalGainLoss" /> <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_CNBXCapitalGainLoss" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_FinancialLossNet" xlink:label="loc_CNBXFinancialLossNet" /> <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_CNBXFinancialLossNet" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" /> <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" /> <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" /> <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Audited Consolidated Statements of Operations (Parenthetical)"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" /> <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" /> <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - Audited Consolidated Statements of Cash Flows"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" /> <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" /> <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" /> <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_InterestOnConvertibleLoan" xlink:label="loc_CNBXInterestOnConvertibleLoan" /> <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_CNBXInterestOnConvertibleLoan" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_CapitalLossGain" xlink:label="loc_CNBXCapitalLossGain" /> <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_CNBXCapitalLossGain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAbstract" /> <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAbstract" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" /> <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" /> <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" /> <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" /> <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" /> <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:label="loc_us-gaapProceedsFromSaleOfEquitySecuritiesFvNi" /> <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapProceedsFromSaleOfEquitySecuritiesFvNi" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquireMachineryAndEquipment" /> <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapPaymentsToAcquireMachineryAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" /> <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" /> <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" /> <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" /> <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" /> <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" /> <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" /> <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" /> <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" /> <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_ExerciseOfConvertibleLoanToSharesOfCommonStock." xlink:label="loc_CNBXExerciseOfConvertibleLoanToSharesOfCommonStock." /> <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_CNBXExerciseOfConvertibleLoanToSharesOfCommonStock." xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfStockholdersEquityDeficit" xlink:title="00000007 - Statement - Audited Consolidated Statements of Stockholders' Equity (Deficit)"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" /> <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" /> <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_WarrantsMember" xlink:label="loc_CNBXWarrantsMember" /> <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_CNBXWarrantsMember" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" /> <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" /> <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" /> <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" /> <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" /> <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_ExpirationOfWarrants" xlink:label="loc_CNBXExpirationOfWarrants" /> <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CNBXExpirationOfWarrants" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_PostsplitAdjustment" xlink:label="loc_CNBXPostsplitAdjustment" /> <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CNBXPostsplitAdjustment" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_PostsplitAdjustmentShares" xlink:label="loc_CNBXPostsplitAdjustmentShares" /> <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CNBXPostsplitAdjustmentShares" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" /> <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" /> <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" /> <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" /> <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcern" xlink:title="00000008 - Disclosure - Nature of Business, Presentation and Going Concern"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/RecentAccountingPronouncements" xlink:title="00000010 - Disclosure - Recent Accounting Pronouncements"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/RelatedPartyTransactions" xlink:title="00000011 - Disclosure - Related Party Transactions"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/CommitmentsAndContingencies" xlink:title="00000012 - Disclosure - Commitments and Contingencies"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/StockholdersEquityDeficit" xlink:title="00000013 - Disclosure - Stockholders’ Equity (Deficit)"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/Warrants" xlink:title="00000014 - Disclosure - Warrants"> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_DisclosureWarrantsAbstract" xlink:label="loc_CNBXDisclosureWarrantsAbstract" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_WarrantDisclosureTextBlock" xlink:label="loc_CNBXWarrantDisclosureTextBlock" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CNBXDisclosureWarrantsAbstract" xlink:to="loc_CNBXWarrantDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - Income Taxes"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/CapitalLoss" xlink:title="00000016 - Disclosure - Capital loss"> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_DisclosureCapitalLossAbstract" xlink:label="loc_CNBXDisclosureCapitalLossAbstract" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_CapitalLossDisclosureTextBlock" xlink:label="loc_CNBXCapitalLossDisclosureTextBlock" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CNBXDisclosureCapitalLossAbstract" xlink:to="loc_CNBXCapitalLossDisclosureTextBlock" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/GeneralAdministrateExpenses" xlink:title="00000017 - Disclosure - General & administrate expenses"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaapOtherIncomeAndExpensesAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:label="loc_us-gaapOtherNonoperatingIncomeAndExpenseTextBlock" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeAndExpenseTextBlock" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/FinancialIncomeExpenses" xlink:title="00000018 - Disclosure - Financial (Income) expenses"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaapOtherIncomeAndExpensesAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaapOtherIncomeAndOtherExpenseDisclosureTextBlock" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapOtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/SubsequentEvents" xlink:title="00000019 - Disclosure - Subsequent Events"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" /> <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" /> <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" /> <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" /> <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" /> <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" /> <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" /> <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" /> <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" /> <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" /> <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" /> <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" /> <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" /> <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" /> <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/WarrantsTables" xlink:title="00000021 - Disclosure - Warrants (Tables)"> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_DisclosureWarrantsAbstract" xlink:label="loc_CNBXDisclosureWarrantsAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CNBXDisclosureWarrantsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_Warrant1Member" xlink:label="loc_CNBXWarrant1Member" /> <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CNBXWarrant1Member" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_Warrant2Member" xlink:label="loc_CNBXWarrant2Member" /> <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CNBXWarrant2Member" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_ScheduleOfAssumptionsUsedWarrantsTableTextBlock" xlink:label="loc_CNBXScheduleOfAssumptionsUsedWarrantsTableTextBlock" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CNBXScheduleOfAssumptionsUsedWarrantsTableTextBlock" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/IncomeTaxesTables" xlink:title="00000022 - Disclosure - Income Taxes (Tables)"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/GeneralAdministrateExpensesTables" xlink:title="00000023 - Disclosure - General & administrate expenses (Tables)"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaapOtherIncomeAndExpensesAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/FinancialIncomeExpensesTables" xlink:title="00000024 - Disclosure - Financial (Income) expenses (Tables)"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaapOtherIncomeAndExpensesAbstract" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_ScheduleOfFinancialIncomeExpensesTableTextBlock" xlink:label="loc_CNBXScheduleOfFinancialIncomeExpensesTableTextBlock" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_CNBXScheduleOfFinancialIncomeExpensesTableTextBlock" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcernDetailsNarrative" xlink:title="00000025 - Disclosure - Nature of Business, Presentation and Going Concern (Details Narrative)"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000026 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" /> <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" /> <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsOwnedAtFairValue" xlink:label="loc_us-gaapFinancialInstrumentsOwnedAtFairValue" /> <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFinancialInstrumentsOwnedAtFairValue" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000027 - Disclosure - Related Party Transactions (Details Narrative)"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_CEOAndChairmanMember" xlink:label="loc_CNBXCEOAndChairmanMember" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CNBXCEOAndChairmanMember" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_ThreeDirectorsMember" xlink:label="loc_CNBXThreeDirectorsMember" /> <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CNBXThreeDirectorsMember" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_CannabicsIncMember" xlink:label="loc_CNBXCannabicsIncMember" /> <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CNBXCannabicsIncMember" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_ChairmanAndBoardMembersMember" xlink:label="loc_CNBXChairmanAndBoardMembersMember" /> <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CNBXChairmanAndBoardMembersMember" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srtChiefFinancialOfficerMember" /> <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefFinancialOfficerMember" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="loc_us-gaapNonmonetaryTransactionTypeAxis" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapNonmonetaryTransactionTypeAxis" order="30" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="loc_us-gaapNonmonetaryTransactionTypeDomain" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonmonetaryTransactionTypeAxis" xlink:to="loc_us-gaapNonmonetaryTransactionTypeDomain" order="0" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_ShareBasedPaymentMember" xlink:label="loc_CNBXShareBasedPaymentMember" /> <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonmonetaryTransactionTypeDomain" xlink:to="loc_CNBXShareBasedPaymentMember" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOfficersCompensation" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedSalariesCurrentAndNoncurrent" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccruedSalariesCurrentAndNoncurrent" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" /> <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_DueToRelatedPartiesCurrent1" xlink:label="loc_CNBXDueToRelatedPartiesCurrent1" /> <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CNBXDueToRelatedPartiesCurrent1" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense" /> <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherNoncashExpense" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000028 - Disclosure - Commitments and Contingencies (Details Narrative)"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BankAcceptancesExecuted" xlink:label="loc_us-gaapBankAcceptancesExecuted" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapBankAcceptancesExecuted" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:title="00000029 - Disclosure - Stockholders’ Equity (Deficit) (Details Narrative)"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" /> <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_SecuritiesPurchaseAgreementMember" xlink:label="loc_CNBXSecuritiesPurchaseAgreementMember" /> <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CNBXSecuritiesPurchaseAgreementMember" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="30" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_InitialNoteMember" xlink:label="loc_CNBXInitialNoteMember" /> <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CNBXInitialNoteMember" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_SecondNoteMember" xlink:label="loc_CNBXSecondNoteMember" /> <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CNBXSecondNoteMember" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_NoteMember" xlink:label="loc_CNBXNoteMember" /> <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CNBXNoteMember" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="40" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" /> <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="50" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_SeniorSecuredNoteMember" xlink:label="loc_CNBXSeniorSecuredNoteMember" /> <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_CNBXSeniorSecuredNoteMember" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_DemandNoteMember" xlink:label="loc_CNBXDemandNoteMember" /> <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_CNBXDemandNoteMember" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" /> <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" /> <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" /> <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" /> <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" /> <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfSeniorLongTermDebt" /> <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfSeniorLongTermDebt" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:label="loc_us-gaapCommonStockConvertibleConversionPriceIncrease" /> <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockConvertibleConversionPriceIncrease" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:label="loc_us-gaapCommonStockConvertibleConversionPriceDecrease" /> <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockConvertibleConversionPriceDecrease" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" /> <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" /> <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" /> <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesCurrent" xlink:label="loc_us-gaapSeniorNotesCurrent" /> <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSeniorNotesCurrent" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" /> <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" /> <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_WarrantsIssued" xlink:label="loc_CNBXWarrantsIssued" /> <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CNBXWarrantsIssued" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" /> <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_OriginalIssueDiscount" xlink:label="loc_CNBXOriginalIssueDiscount" /> <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CNBXOriginalIssueDiscount" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseOtherLongTermDebt" xlink:label="loc_us-gaapInterestExpenseOtherLongTermDebt" /> <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapInterestExpenseOtherLongTermDebt" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/WarrantsDetails-FairValue" xlink:title="00000030 - Disclosure - Warrants (Details - Fair value)"> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_DisclosureWarrantsAbstract" xlink:label="loc_CNBXDisclosureWarrantsAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CNBXDisclosureWarrantsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_Warrant1Member" xlink:label="loc_CNBXWarrant1Member" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CNBXWarrant1Member" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" /> <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" /> <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" /> <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/WarrantsDetails-FairValueDisclosure" xlink:title="00000031 - Disclosure - Warrants (Details - Fair Value)"> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_DisclosureWarrantsAbstract" xlink:label="loc_CNBXDisclosureWarrantsAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CNBXDisclosureWarrantsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_Warrant2Member" xlink:label="loc_CNBXWarrant2Member" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CNBXWarrant2Member" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" /> <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" /> <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" /> <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/WarrantsDetails-WarrantActivity" xlink:title="00000032 - Disclosure - Warrants (Details - Warrant activity)"> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_DisclosureWarrantsAbstract" xlink:label="loc_CNBXDisclosureWarrantsAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CNBXDisclosureWarrantsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_WarrantsMember" xlink:label="loc_CNBXWarrantsMember" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CNBXWarrantsMember" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_WarrantsIssued" xlink:label="loc_CNBXWarrantsIssued" /> <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CNBXWarrantsIssued" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_WeightedAverageExercisePriceWarrantsIssued" xlink:label="loc_CNBXWeightedAverageExercisePriceWarrantsIssued" /> <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CNBXWeightedAverageExercisePriceWarrantsIssued" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" /> <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_WeightedAverageExercisePriceWarrantsExercised" xlink:label="loc_CNBXWeightedAverageExercisePriceWarrantsExercised" /> <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CNBXWeightedAverageExercisePriceWarrantsExercised" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" /> <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_WeightedAverageExercisePriceWarrantsExpired" xlink:label="loc_CNBXWeightedAverageExercisePriceWarrantsExpired" /> <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CNBXWeightedAverageExercisePriceWarrantsExpired" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_2" /> <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" /> <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" xlink:label="loc_CNBXShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" /> <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CNBXShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_WeightedAverageExercisePriceWarrantsExercisable" xlink:label="loc_CNBXWeightedAverageExercisePriceWarrantsExercisable" /> <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CNBXWeightedAverageExercisePriceWarrantsExercisable" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/WarrantsDetailsNarrative" xlink:title="00000033 - Disclosure - Warrants (Details Narrative)"> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_DisclosureWarrantsAbstract" xlink:label="loc_CNBXDisclosureWarrantsAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CNBXDisclosureWarrantsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_Warrant1Member" xlink:label="loc_CNBXWarrant1Member" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CNBXWarrant1Member" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_Warrant2Member" xlink:label="loc_CNBXWarrant2Member" /> <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CNBXWarrant2Member" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_WarrantsIssuedShares" xlink:label="loc_CNBXWarrantsIssuedShares" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CNBXWarrantsIssuedShares" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_FairValueOfWarrantsIssued" xlink:label="loc_CNBXFairValueOfWarrantsIssued" /> <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CNBXFairValueOfWarrantsIssued" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/IncomeTaxesDetails-Rate" xlink:title="00000034 - Disclosure - Income Taxes (Details - rate)"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" /> <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/IncomeTaxesDetails-DeferredTaxAssets" xlink:title="00000035 - Disclosure - Income Taxes (Details - Deferred tax assets)"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember" /> <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" /> <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000036 - Disclosure - Income Taxes (Details Narrative)"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_UnitedStates1Member" xlink:label="loc_CNBXUnitedStates1Member" /> <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_CNBXUnitedStates1Member" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" order="20" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" order="0" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IsraelTaxAuthorityMember" xlink:label="loc_us-gaapIsraelTaxAuthorityMember" /> <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapIsraelTaxAuthorityMember" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" /> <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" /> <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/CapitalLossDetailsNarrative" xlink:title="00000037 - Disclosure - Capital loss (Details Narrative)"> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_DisclosureCapitalLossAbstract" xlink:label="loc_CNBXDisclosureCapitalLossAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CNBXDisclosureCapitalLossAbstract" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_CapitalLoss" xlink:label="loc_CNBXCapitalLoss" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CNBXDisclosureCapitalLossAbstract" xlink:to="loc_CNBXCapitalLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/GeneralAndAdministrativeExpensesDetails" xlink:title="00000038 - Disclosure - General and administrative expenses (Details)"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaapOtherIncomeAndExpensesAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" /> <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="loc_us-gaapGeneralInsuranceExpense" /> <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapGeneralInsuranceExpense" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaapMarketingExpense" /> <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapMarketingExpense" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralExpense" xlink:label="loc_us-gaapOtherGeneralExpense" /> <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapOtherGeneralExpense" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" /> <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://cnbxpharma.com/role/FinancialIncomeExpensesDetails" xlink:title="00000039 - Disclosure - Financial (Income) expenses (Details)"> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaapOtherIncomeAndExpensesAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="loc_us-gaapInterestExpenseBorrowings" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapInterestExpenseBorrowings" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="cnbx-20230831.xsd#CNBX_LossGainFromConvertibleLoanValuation" xlink:label="loc_CNBXLossGainFromConvertibleLoanValuation" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_CNBXLossGainFromConvertibleLoanValuation" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" /> <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" /> <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" /> </link:presentationLink> </link:linkbase> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>25 <FILENAME>R1.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164536601856"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th> <th class="th" colspan="1">12 Months Ended</th> <th class="th" colspan="1"></th> </tr> <tr> <th class="th"><div>Aug. 31, 2023</div></th> <th class="th"><div>Nov. 29, 2023</div></th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td> <td class="text">10-K<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td> <td class="text">false<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td> <td class="text">true<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td> <td class="text">false<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td> <td class="text">Aug. 31, 2023<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td> <td class="text">FY<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td> <td class="text">2023<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td> <td class="text">--08-31<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td> <td class="text">000-52403<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td> <td class="text">CNBX PHARMACEUTICALS INC.<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td> <td class="text">0001343009<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td> <td class="text">20-3373669<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td> <td class="text">NV<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td> <td class="text">#3 Bethesda Metro Center<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td> <td class="text">Suite 700<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td> <td class="text">Bethesda<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td> <td class="text">MD<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td> <td class="text">20814<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td> <td class="text">877<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td> <td class="text">424-2429<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td> <td class="text">Common Stock, $.0001 Par Value<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td> <td class="text">No<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td> <td class="text">No<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td> <td class="text">Yes<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td> <td class="text">Yes<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td> <td class="text">Non-accelerated Filer<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td> <td class="text">true<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td> <td class="text">false<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td> <td class="text">false<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td> <td class="nump">$ 437,714<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td> <td class="text"> <span></span> </td> <td class="nump">28,311,352<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td> <td class="text">false<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td> <td class="text">false<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td> <td class="text">6629<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td> <td class="text">Weinstein International. C.P.A.<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td> <td class="text">Tel - Aviv, Israel<span></span> </td> <td class="text"> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_AmendmentFlag</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_AuditorFirmId</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:nonemptySequenceNumberItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_AuditorLocation</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:internationalNameItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_AuditorName</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:internationalNameItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_CityAreaCode</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_CoverAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:gMonthDayItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentAnnualReport</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:fiscalPeriodItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:gYearItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:dateItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentTransitionReport</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentType</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:submissionTypeItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:stateOrProvinceItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityCentralIndexKey</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:centralIndexKeyItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:yesNoItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityFileNumber</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:fileNumberItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityFilerCategory</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:filerCategoryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:edgarStateCountryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:yesNoItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityPublicFloat</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityRegistrantName</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityShellCompany</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntitySmallBusiness</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:employerIdItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:yesNoItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:yesNoItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_LocalPhoneNumber</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_Security12bTitle</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:securityTitleItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>26 <FILENAME>R2.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164534982128"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Audited Consolidated Balance Sheets - USD ($)<br></strong></div></th> <th class="th"><div>Aug. 31, 2023</div></th> <th class="th"><div>Aug. 31, 2022</div></th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td> <td class="nump">$ 129,696<span></span> </td> <td class="nump">$ 117,515<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other receivables</a></td> <td class="nump">94,612<span></span> </td> <td class="nump">80,772<span></span> </td> </tr> <tr class="rou"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td> <td class="nump">224,308<span></span> </td> <td class="nump">198,287<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Available for sale Investment</a></td> <td class="nump">0<span></span> </td> <td class="nump">176,087<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Equipment, net</a></td> <td class="nump">274,731<span></span> </td> <td class="nump">436,792<span></span> </td> </tr> <tr class="reu"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td> <td class="nump">499,039<span></span> </td> <td class="nump">811,166<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td> <td class="nump">335,915<span></span> </td> <td class="nump">461,128<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible loan</a></td> <td class="nump">1,343,584<span></span> </td> <td class="nump">1,758,702<span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_DueToRelatedParty', window );">Due to a related party</a></td> <td class="nump">836,829<span></span> </td> <td class="nump">223,645<span></span> </td> </tr> <tr class="rou"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td> <td class="nump">2,516,328<span></span> </td> <td class="nump">2,443,475<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.0001 par value, 5,000,000 shares authorized no shares issued and outstanding.</a></td> <td class="nump">0<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.0001 par value, 900,000,000 shares authorized, 22,611,352and 1,238,659 shares issued and outstanding at August 31, 2023 and August 31, 2022 respectively.</a></td> <td class="nump">2,261<span></span> </td> <td class="nump">124<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td> <td class="nump">22,239,652<span></span> </td> <td class="nump">18,031,869<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAdditionalCapital', window );">Issuance of warrants</a></td> <td class="nump">0<span></span> </td> <td class="nump">3,459,510<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td> <td class="nump">0<span></span> </td> <td class="num">(2,574,846)<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td> <td class="num">(24,259,202)<span></span> </td> <td class="num">(20,548,968)<span></span> </td> </tr> <tr class="rou"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td> <td class="num">(2,017,289)<span></span> </td> <td class="num">(1,632,311)<span></span> </td> </tr> <tr class="reu"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td> <td class="nump">$ 499,039<span></span> </td> <td class="nump">$ 811,166<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CNBX_DueToRelatedParty"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">CNBX_DueToRelatedParty</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>CNBX_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_Assets</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AssetsCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_Investments</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAdditionalCapital"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of additional paid-in capital (APIC) classified as other.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherAdditionalCapital</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PreferredStockValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>27 <FILENAME>R3.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164536557008"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Audited Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th> <th class="th"><div>Aug. 31, 2023</div></th> <th class="th"><div>Aug. 31, 2022</div></th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td> <td class="nump">$ 0.0001<span></span> </td> <td class="nump">$ 0.0001<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td> <td class="nump">5,000,000<span></span> </td> <td class="nump">5,000,000<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td> <td class="nump">0<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td> <td class="nump">0<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td> <td class="nump">$ 0.0001<span></span> </td> <td class="nump">$ 0.0001<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td> <td class="nump">900,000,000<span></span> </td> <td class="nump">900,000,000<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td> <td class="nump">22,611,352<span></span> </td> <td class="nump">1,238,659<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td> <td class="nump">22,611,352<span></span> </td> <td class="nump">1,238,659<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>28 <FILENAME>R4.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164536510688"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audited Consolidated Statements of Operations - USD ($)<br></strong></div></th> <th class="th" colspan="2">12 Months Ended</th> </tr> <tr> <th class="th"><div>Aug. 31, 2023</div></th> <th class="th"><div>Aug. 31, 2022</div></th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td> <td class="nump">$ 410,165<span></span> </td> <td class="nump">$ 29,958<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td> <td class="nump">431,565<span></span> </td> <td class="nump">1,183,281<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td> <td class="nump">909,980<span></span> </td> <td class="nump">1,800,647<span></span> </td> </tr> <tr class="rou"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td> <td class="nump">1,341,545<span></span> </td> <td class="nump">2,983,928<span></span> </td> </tr> <tr class="reu"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td> <td class="num">(931,380)<span></span> </td> <td class="num">(2,953,970)<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAbstract', window );"><strong>Other income</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_CapitalGainLoss', window );">Capital Gain (loss)</a></td> <td class="num">(2,726,231)<span></span> </td> <td class="nump">12,800<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_FinancialLossNet', window );">Financial loss, net</a></td> <td class="num">(52,623)<span></span> </td> <td class="num">(782,080)<span></span> </td> </tr> <tr class="reu"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td> <td class="num">(3,710,234)<span></span> </td> <td class="num">(3,723,250)<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">(Loss) Profit from available for sale assets</a></td> <td class="nump">0<span></span> </td> <td class="num">(669,131)<span></span> </td> </tr> <tr class="reu"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive (loss) income</a></td> <td class="num">$ (3,710,234)<span></span> </td> <td class="num">$ (4,392,381)<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CNBX_CapitalGainLoss"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">CNBX_CapitalGainLoss</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>CNBX_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CNBX_FinancialLossNet"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">CNBX_FinancialLossNet</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>CNBX_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingExpenses</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherIncomeAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_Revenues</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>29 <FILENAME>R5.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164539405632"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audited Consolidated Statements of Operations (Parenthetical) - $ / shares<br></strong></div></th> <th class="th" colspan="2">12 Months Ended</th> </tr> <tr> <th class="th"><div>Aug. 31, 2023</div></th> <th class="th"><div>Aug. 31, 2022</div></th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (loss) per share - basic</a></td> <td class="num">$ (0.42)<span></span> </td> <td class="num">$ (3.59)<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net (loss) per share - diluted</a></td> <td class="num">$ (0.42)<span></span> </td> <td class="num">$ (3.59)<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding - Basic</a></td> <td class="nump">8,824,636<span></span> </td> <td class="nump">1,222,641<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding - Diluted</a></td> <td class="nump">8,824,636<span></span> </td> <td class="nump">1,222,641<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>30 <FILENAME>R6.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164534647008"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audited Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th> <th class="th" colspan="2">12 Months Ended</th> </tr> <tr> <th class="th"><div>Aug. 31, 2023</div></th> <th class="th"><div>Aug. 31, 2022</div></th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (Loss) Profit</a></td> <td class="num">$ (3,710,234)<span></span> </td> <td class="num">$ (3,723,250)<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td> <td class="nump">162,061<span></span> </td> <td class="nump">198,527<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based payment</a></td> <td class="nump">180,480<span></span> </td> <td class="nump">728,869<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_InterestOnConvertibleLoan', window );">Interest on Convertible loan</a></td> <td class="nump">54,811<span></span> </td> <td class="nump">722,236<span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_CapitalLossGain', window );">Capital loss (Gain)</a></td> <td class="nump">2,726,232<span></span> </td> <td class="num">(12,800)<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Accounts Receivable and prepaid expenses</a></td> <td class="num">(13,840)<span></span> </td> <td class="nump">123,603<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td> <td class="nump">487,969<span></span> </td> <td class="nump">283,623<span></span> </td> </tr> <tr class="reu"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td> <td class="num">(112,521)<span></span> </td> <td class="num">(1,679,192)<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Sale of equipment</a></td> <td class="nump">0<span></span> </td> <td class="nump">26,885<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi', window );">Realization of Held for trading investments</a></td> <td class="nump">24,702<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMachineryAndEquipment', window );">Acquisition of equipment</a></td> <td class="nump">0<span></span> </td> <td class="num">(1,656)<span></span> </td> </tr> <tr class="rou"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td> <td class="nump">24,702<span></span> </td> <td class="nump">25,229<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of a Convertible loan</a></td> <td class="nump">100,000<span></span> </td> <td class="nump">389,858<span></span> </td> </tr> <tr class="reu"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td> <td class="nump">100,000<span></span> </td> <td class="nump">389,858<span></span> </td> </tr> <tr class="rou"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash</a></td> <td class="nump">12,181<span></span> </td> <td class="num">(1,264,105)<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate fluctuations on cash</a></td> <td class="nump">0<span></span> </td> <td class="num">(4,853)<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td> <td class="nump">117,515<span></span> </td> <td class="nump">1,386,473<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of the year</a></td> <td class="nump">129,696<span></span> </td> <td class="nump">117,515<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Significant non-cash transactions:</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_ExerciseOfConvertibleLoanToSharesOfCommonStock.', window );">Exercise of a Convertible loan to shares of common stock.</a></td> <td class="nump">$ 569,930<span></span> </td> <td class="nump">$ 225,286<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CNBX_CapitalLossGain"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">CNBX_CapitalLossGain</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>CNBX_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CNBX_ExerciseOfConvertibleLoanToSharesOfCommonStock."> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">CNBX_ExerciseOfConvertibleLoanToSharesOfCommonStock.</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>CNBX_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CNBX_InterestOnConvertibleLoan"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">CNBX_InterestOnConvertibleLoan</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>CNBX_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_Depreciation</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssetsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMachineryAndEquipment"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of machinery and equipment.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMachineryAndEquipment</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479567/321-10-45-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>31 <FILENAME>R7.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164539309952"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Audited Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)<br></strong></div></th> <th class="th"><div>Common Stock [Member]</div></th> <th class="th"><div>Additional Paid-in Capital [Member]</div></th> <th class="th"><div>AOCI Attributable to Parent [Member]</div></th> <th class="th"><div>Warrants [Member]</div></th> <th class="th"><div>Retained Earnings [Member]</div></th> <th class="th"><div>Total</div></th> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Aug. 31, 2021</a></td> <td class="nump">$ 14,475<span></span> </td> <td class="nump">$ 17,063,363<span></span> </td> <td class="num">$ (1,905,715)<span></span> </td> <td class="nump">$ 3,459,510<span></span> </td> <td class="num">$ (16,825,718)<span></span> </td> <td class="nump">$ 1,805,915<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Aug. 31, 2021</a></td> <td class="nump">1,206,230<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based Payment</a></td> <td class="text"> <span></span> </td> <td class="nump">728,869<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">728,869<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Exercise of a Convertible loan to shares of common stock.</a></td> <td class="nump">$ 2<span></span> </td> <td class="nump">225,284<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">225,286<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Exercise of a Convertible loan to shares of common stock, shares</a></td> <td class="nump">20,027<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_PostsplitAdjustment', window );">Post-split adjustment</a></td> <td class="num">$ (14,353)<span></span> </td> <td class="nump">14,353<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_PostsplitAdjustmentShares', window );">Post-split adjustment, shares</a></td> <td class="nump">12,402<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(669,131)<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(669,131)<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(3,723,250)<span></span> </td> <td class="num">(3,723,250)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Aug. 31, 2022</a></td> <td class="nump">$ 124<span></span> </td> <td class="nump">18,031,869<span></span> </td> <td class="num">(2,574,846)<span></span> </td> <td class="nump">3,459,510<span></span> </td> <td class="num">(20,548,968)<span></span> </td> <td class="num">(1,632,311)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Aug. 31, 2022</a></td> <td class="nump">1,238,659<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based Payment</a></td> <td class="text"> <span></span> </td> <td class="nump">180,480<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">180,480<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Exercise of a Convertible loan to shares of common stock.</a></td> <td class="nump">$ 2,137<span></span> </td> <td class="nump">567,793<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">569,930<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Exercise of a Convertible loan to shares of common stock, shares</a></td> <td class="nump">21,372,693<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_ExpirationOfWarrants', window );">Expiration of warrants</a></td> <td class="text"> <span></span> </td> <td class="nump">3,459,510<span></span> </td> <td class="text"> <span></span> </td> <td class="num">(3,459,510)<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">2,574,846<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">2,574,846<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(3,710,234)<span></span> </td> <td class="num">(3,710,234)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Aug. 31, 2023</a></td> <td class="nump">$ 2,261<span></span> </td> <td class="nump">$ 22,239,652<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">$ (24,259,202)<span></span> </td> <td class="num">$ (2,017,289)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Aug. 31, 2023</a></td> <td class="nump">22,611,352<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CNBX_ExpirationOfWarrants"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">CNBX_ExpirationOfWarrants</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>CNBX_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CNBX_PostsplitAdjustment"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">CNBX_PostsplitAdjustment</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>CNBX_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CNBX_PostsplitAdjustmentShares"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">CNBX_PostsplitAdjustmentShares</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>CNBX_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SharesOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>32 <FILENAME>R8.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164538418672"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business, Presentation and Going Concern<br></strong></div></th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr><th class="th"><div>Aug. 31, 2023</div></th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of Business, Presentation and Going Concern</a></td> <td class="text"><p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zUgHR0qPoya3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 – <span id="xdx_825_zmPn1m0VPhs2">Nature of Business, Presentation and Going Concern</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Organization</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CNBX Pharmaceuticals Inc. (the "Company"), was incorporated in the State of Nevada, on September 15, 2004, under the name of Thrust Energy Corp. The Company was originally engaged in the exploration, exploitation, development and production of oil and gas projects within North America, but was unable to operate profitably.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2011, the Company changed its name to American Mining Corporation, suspending its oil and gas operations and changing its business to toll milling and refining, mineral exploration and mine development.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 25, 2014, the Company experienced a change in control. Cannabics, Inc. (“Cannabics”) acquired a majority of the issued and outstanding common stock of the Company in accordance with stock purchase agreements by and between Cannabics and Thomas Mills (“Mills”). On the closing date, April 25, 2014, pursuant to the terms of the Stock Purchase Agreement, Cannabics purchased from Mills 41,000,000 shares of the Company’s outstanding restricted common stock for $198,000, representing 51%.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 21, 2014, the Company changed its name, via merger in the state of Nevada, to CNBX Pharmaceuticals Inc. The Company’s principal offices are in Bethesda, Maryland. As of May 21, 2014, the Company has changed its course of business to laboratory research and development.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 25, 2014, the Company organized G.R.I.N. Ultra Ltd. (“GRIN”), an Israeli corporation, as a wholly-owned subsidiary. GRIN will provide research and development activities for the Company’s products in Israel.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock Split</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 3, 2014, the Company’s Board of Directors declared a two-to-one forward stock split of all outstanding shares of common stock. The stock split was approved by FINRA on June 25, 2014. The effect of the stock split increased the number of shares of common stock outstanding from 40,880,203 to 81,760,406. All common share and per common share data in these financial statements and related notes hereto have been retroactively adjusted to account for the effect of the stock split for all periods presented prior to June 3, 2014. The total number of authorized common shares and the par value thereof was not changed by the split. Additionally, on May 12, 2022, the Company effected a reverse-split of its common stock on a 1:120 basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basis of Presentation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the Securities and Exchange Commission (“SEC”). </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Going Concern</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred a net loss of $<span id="xdx_90D_eus-gaap--NetIncomeLoss_iN_di_c20220901__20230831_zoL9JYAMpCB2" title="Net loss">3,710,234</span> for the year ended August 31, 2023 and has incurred cumulative losses since inception of $<span id="xdx_904_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20230831_z4qFAplZC3I3" title="Cumulative losses">24,259,202</span>. These conditions raise substantial doubt about the ability of the Company to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s continuation as a going concern is dependent upon its ability to generate revenues, its ability to continue to raise investment capital, and implementing its business plan. No assurance can be given that the Company will be successful in these efforts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern. No assurance can be given that the Company will be successful in these efforts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>33 <FILENAME>R9.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164538173744"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr><th class="th"><div>Aug. 31, 2023</div></th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td> <td class="text"><p id="xdx_801_eus-gaap--SignificantAccountingPoliciesTextBlock_zxzFvLnukb3i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2 – <span id="xdx_821_zqZd5fOxFT61">Summary of Significant Accounting Policies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84F_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zasdwoFqnSzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_862_zHpXURhREUQb">Functional currency</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The currency of the primary economic environment in which the operations of the Company and its Subsidiary are conducted is the U.S. dollar (“$” or “dollar”). Therefore, the functional currency of the Company and its Subsidiary is the dollar.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Transactions and balances denominated in dollars are presented at their original amounts. Non-dollar transactions and balances have been re-measured to dollars in accordance with the provisions of ASC 830-10 (formerly Statement of Financial Accounting Standard 52), "Foreign Currency Translation". All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_848_eus-gaap--UseOfEstimates_zdGpwSbTPWNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86C_zBdGvHpwOwnc">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates in the accompanying financial statements include the amortization period for intangible assets, impairment valuation of intangible assets, valuation of share-based payments and the valuation allowance on deferred tax assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zoWydCZHRYT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_863_ze39WOn0Kvtd">Principles of Consolidation</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements include the accounts of Cannabics Pharmaceutical Inc. and its wholly-owned subsidiary, G.R.I.N. Ultra Ltd. All significant inter-company balances and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zSjJfU0091U1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_866_zV0TnliunyC3">Cash and Cash Equivalents</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. At August 31, 2023 and 2022, cash equivalents consisted of bank accounts held at financial institutions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zAVF42egYI56" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_z7MsdL5Qgk93">Concentration of Credit Risk</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company places its cash and cash equivalents with high credit quality financial institutions. There is Federal Deposit Insurance on the Company’s U.S. bank accounts for up to $<span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_c20230831_zsXZ4YmmMrXh" title="Federal deposit insurance">250,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zKdVb9dYFvu8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_861_zM3nN5mFmew2">Equipment, net</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equipment at August 31, 2023 consists of computer equipment, office equipment and cars recorded at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation of property and equipment is computed by the straight-line method (after taking into account their respective estimated residual values) over the assets estimated useful lives of 3 years for computer equipment, 14 years for office equipment and 7 years for cars. Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in the consolidated statements of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expense was $<span id="xdx_909_eus-gaap--Depreciation_pp0p0_c20220901__20230831_zxPka4lcudAd" title="Depreciation expense">162,061</span> and $<span id="xdx_906_eus-gaap--Depreciation_pp0p0_c20210901__20220831_zjNy6luMvZag" title="Depreciation expense">198,527</span> for the years ended August 31, 2023, and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p id="xdx_84A_eus-gaap--RevenueRecognitionPolicyTextBlock_zH9eTZ69Sl2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_864_zVkMFXRjFV5a">Revenue recognition</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue is recognized when delivery has occurred, evidence of an arrangement exists, title and risks and rewards for the products are transferred to the customer, collection is reasonably assured and product returns can be reliably estimated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue from license agreements is recognized over the periods from which the Company is entitled to the respective payments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z7cPcYYiIODh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86F_zzQygxnq2Cn4">Impairment or Disposal of Long-Lived Assets</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for the impairment or disposal of long-lived assets according to the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) 360 “Property, Plant and Equipment”. ASC 360 clarifies the accounting for the impairment of long-lived assets and for long-lived assets to be disposed of, including the disposal of business segments and major lines of business. Long-lived assets are reviewed when facts and circumstances indicate that the carrying value of the asset may not be recoverable. When necessary, impaired assets are written down to estimated fair value based on the best information available. Estimated fair value is generally based on either appraised value or measured by discounting estimated future cash flows. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i> </b></p> <p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zLUS1qmp63W4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_zMPjBNjTXWak">Fair Value of Financial Instruments</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following provides an analysis of financial instruments that are measured subsequent to initial recognition at fair value, grouped into Levels 1 to 3 based on the degree to which fair value is observable:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1 - fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical assets or liabilities;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2 - fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 - fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of August 31, 2023 and 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company applied ASC 820 for all non-financial assets and liabilities measured at fair value on a non-recurring basis. The adoption of ASC 820 for non-financial assets and liabilities did not have a significant impact on the Company’s financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of August 31, 2023, the company had <span id="xdx_90C_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_pp0p0_do_c20230831__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zwmD6vnxaVY4" title="Fair value of financial instruments">no</span> level 1 fair values financial instruments assets, and had financial instruments liabilities of $<span id="xdx_904_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_pp0p0_c20230831__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zk7UI53qLko4" title="Fair value of financial instruments">1,343,584</span> at level 3.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of August 31, 2023, the fair values of the Company’s financial instruments approximate their historical carrying amount.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zd4GJkrTJvI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_867_zfa6qvHm7Nnb">Research and development, net</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, employee benefits, the cost of supplies, the cost of services provided by outside contractors, including services related to the Company’s clinical trials, clinical trial expenses and the full cost of manufacturing product for use in research and preclinical development. All costs associated with research and developments are expensed as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources a substantial portion of its clinical trial activities, utilizing external entities such as Contract Research Organizations, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical studies. For each clinical trial that the Company conducts, clinical trial costs are expensed immediately.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_845_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zw0IQJyuYpSi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_867_zj8xAVbxwC1g">Stock Based Compensation</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for Stock-Based Compensation under ASC 718 “Compensation – Stock Compensation”, which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 requires measurement of the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees. Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Any stock options or warrants issued to non-employees are recorded in expense and additional paid-in capital in shareholders' deficit over the applicable service periods using variable accounting through the vesting dates based on the fair value of the options or warrants at the end of each period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issues stock to consultants for various services. The costs for these transactions are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The value of the common stock is measured at the earlier of (i) the date at which a firm commitment for performance by the counterparty to earn the equity instruments is reached or (ii) the date at which the counterparty's performance is complete. The Company recognized consulting expense and a corresponding increase to additional paid-in-capital related to stock issued for services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zUkROnVPmps" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_868_zUXl2xHYlfsf">Income Taxes</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Income taxes are accounted for under the liability method of accounting for income taxes. Under the liability method, future tax liabilities and assets are recognized for the estimated future tax consequences attributable to differences between the amounts reported in the financial statement carrying amounts of assets and liabilities and their respective tax bases. Future tax assets and liabilities are measured using enacted or substantially enacted income tax rates expected to apply when the asset is realized or the liability settled. The effect of a change in income tax rates on future income tax liabilities and assets is recognized in income in the period that the change occurs. Future income tax assets are recognized to the extent that they are considered more likely than not to be realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FASB has issued ASC 740 “Income Taxes”. ASC 740 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. This standard requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the implementation of this standard, the Company performed a review of its material tax positions in accordance with recognition and measurement standards established by ASC 740 and concluded that the tax position of the Company has not met the more-likely-than-not threshold as of August 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84F_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zSnHwkCGDCU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_863_zAGkIY4cCnHg">Comprehensive Income</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company adopted ASC 220, <i>Comprehensive Income</i> which establishes standards for reporting and display of comprehensive income, its components and accumulated balances. The Company is disclosing this information on its Statement of Stockholders' Equity. Comprehensive income comprises equity except those resulting from investments by owners and distributions to owners. The Company has no elements of “other comprehensive income” for the years ended August 31, 2023, and 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_zAoLYEHBGOJf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_860_zwYQG4hFDs02">Basic and Diluted Loss per Share</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company computes income (loss) per share in accordance with ASC 260, “Earnings per Share”, which requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the statement of operations. Basic EPS is computed by dividing income (loss) available to common shareholders by the weighted average number of shares outstanding during the period. Diluted EPS gives effect to all dilutive potential shares of common stock outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. As of August 31, 2023, and 2022, the potentially dilutive shares were anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_znBnyLGreJAe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_861_zB3T8mebmmhd">Segment Information</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the provisions of ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, the Company is required to report financial and descriptive information about its reportable operating segments. The Company does not consider itself to have any operating segments as of August 31, 2023, and 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_848_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zVNcwYGTkZXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_864_z3ConaoVnQr4">Reclassification</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>34 <FILENAME>R10.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164539365024"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements<br></strong></div></th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr><th class="th"><div>Aug. 31, 2023</div></th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recent Accounting Pronouncements</a></td> <td class="text"><p id="xdx_804_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zA1Tut4YNa4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 3 – <span id="xdx_82F_zlOfAqKbIydf">Recent Accounting Pronouncements</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2015, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis”, which provides guidance in evaluating entities for inclusion in consolidations. ASU 2015-02 is effective for fiscal years beginning after December 15, 2015. The Company does not believe the adoption of ASU 2015-02 will have a material effect on its consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-10 (“ASU 2014-10”), <i>Development Stage Entities (Topic 915), Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation.</i> The objective of the amendments in this Update is to improve financial reporting by reducing the cost and complexity associated with incremental reporting requirements for development stage entities. The amendments in this Update also eliminate an exception provided to development stage entities in Topic 810, Consolidation, for determining whether an entity is a variable interest entity on the basis of the amount of investment equity at risk. The amendments related to the elimination of inception-to-date information and the other remaining disclosure requirements of Topic 915 should be applied retrospectively except for the clarification to Topic 275, which shall be applied prospectively. These amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amendment eliminating the exception to the sufficiency-of-equity-at-risk criterion for development stage entities in paragraph 810-10-15-16 should be applied retrospectively for annual reporting periods beginning after December 15, 2015 and interim periods therein. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued. The Company has adopted ASU 2014-10 in the fourth quarter of 2014 and does not expect this adoption to have a material impact on its consolidated financial condition, results of operations or cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2014, the FASB issued ASU No. 2014-15, <i>Presentation of Financial Statements-Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.</i> The objective of the amendments in this Update is to provide guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if “conditions or events raise substantial doubt about the entity’s ability to continue as a going concern.” The ASU applies to all entities and is effective for annual periods ending after December 15, 2017, and interim periods thereafter, with early adoption permitted. The Company is evaluating the impact of ASU 2014-15 on its consolidated financial condition, results of operations and cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2015-16 (ASU 2015-16) "Simplifying the Accounting for Measurement Period Adjustments". ASU 2015-16 require that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The amendments in ASU 2015-16 require that the acquirer record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. The amendments in ASU 2015-16 require an entity to present separately on the face of the income statement or disclose in the notes the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. For public business entities, the amendments in ASU 2015-16 are effective for fiscal years beginning after December 15, 2015, including interim periods within those fiscal years. The amendments in ASU 2015-16 should be applied prospectively to adjustments to provisional amounts that occur after the effective date of this update with earlier application permitted for financial statements that have not been issued. For all other entities, the amendments in ASU 2015-16 are effective for fiscal years beginning after December 15, 2017, and interim periods within fiscal years beginning after December 15, 2017. The amendments in ASU 2015-16 should be applied prospectively to adjustments to provisional amounts that occur after the effective date of this update with earlier application permitted for financial statements that have not yet been made available for issuance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org//250/tableOfContent<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>35 <FILENAME>R11.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164535810080"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr><th class="th"><div>Aug. 31, 2023</div></th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td> <td class="text"><p id="xdx_801_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zOtjZrQ2oLXb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 4 – <span id="xdx_824_zoQatmsGZYv2">Related Party Transactions</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended August 31, 2023, and August 31, 2022, the Company paid approximately of $<span id="xdx_904_eus-gaap--OfficersCompensation_pp0p0_c20220901__20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndChairmanMember_zzDYIor6CfOk" title="Compensation paid">79,100</span> and $<span id="xdx_90C_eus-gaap--OfficersCompensation_pp0p0_c20210901__20220831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndChairmanMember_zQ6ssdpTfoV1" title="Compensation paid">334,395</span> as compensation to our CEO and chairman.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended August 31, 2023 the Company accrued additional $<span id="xdx_907_eus-gaap--AccruedSalariesCurrentAndNoncurrent_iI_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndChairmanMember_zaFIKrNa7BO1" title="Accrued salaries">416,497</span> in salaries, including socials benefits, to our CEO and chairman. compared to $<span id="xdx_90F_eus-gaap--AccruedSalariesCurrentAndNoncurrent_iI_c20220831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndChairmanMember_zCmQNQs4Jvm2" title="Accrued salaries">196,687</span> for the year ended August 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of August 31, 2023, the Company had a balance outstanding payable to our CEO and chairman: Gabriel Yariv and Eyal Barad in the total of $<span id="xdx_90B_eus-gaap--NotesPayableCurrent_iI_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndChairmanMember_zqx8rKkos1J4" title="Outstanding payable">613,184</span> under related parties compared to $<span id="xdx_90B_eus-gaap--NotesPayableCurrent_iI_c20220831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndChairmanMember_zehIJaPykONe" title="Outstanding payable">196,687</span> for the year ended August 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended August 31, 2023, and August 31, 2022, the Company paid approximately of $<span id="xdx_903_eus-gaap--OfficersCompensation_pp0p0_c20220901__20230831__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_z4WgbAZa4ce6" title="Compensation paid">40,321</span> and $<span id="xdx_90B_eus-gaap--OfficersCompensation_pp0p0_c20210901__20220831__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_z0kMEv2vSnK" title="Compensation paid">75,318</span> as compensation to our CFO</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended August 31, 2023 the Company accrued $<span id="xdx_904_eus-gaap--AccruedSalariesCurrentAndNoncurrent_iI_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThreeDirectorsMember_zexPZ54imLj4" title="Accrued salaries">43,000</span> in salaries to three directors compared to $<span id="xdx_90F_eus-gaap--AccruedSalariesCurrentAndNoncurrent_iI_c20220831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThreeDirectorsMember_zPxSjVLo2pl4" title="Accrued salaries">36,000</span> for the year ended August 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cannabics Inc. (the parent company) balance as of August 31, 2023, and on August 31, 2022 was $<span id="xdx_90C_ecustom--DueToRelatedPartiesCurrent1_iI_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CannabicsIncMember_zM2GcEfYdVQf" title="Due to related parties"><span id="xdx_905_ecustom--DueToRelatedPartiesCurrent1_iI_c20220831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CannabicsIncMember_zU99ZllDso17" title="Due to related parties">223,645</span></span>. The advance is due on demand and bears no interest.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended August 31, 2023, the Company recorded a non cash expense of $<span id="xdx_90E_eus-gaap--OtherNoncashExpense_c20220901__20230831__us-gaap--NonmonetaryTransactionTypeAxis__custom--ShareBasedPaymentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChairmanAndBoardMembersMember_zjr6PraKzgHf" title="Non cash expense">168,551</span> as share based payment, to the company chairman and board members, compared to $<span id="xdx_905_eus-gaap--OtherNoncashExpense_c20210901__20220831__us-gaap--NonmonetaryTransactionTypeAxis__custom--ShareBasedPaymentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChairmanAndBoardMembersMember_z0LMpBvonJhh" title="Non cash expense">670,850</span> for the year ended August 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>36 <FILENAME>R12.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164538764320"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr><th class="th"><div>Aug. 31, 2023</div></th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td> <td class="text"><p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z3kHD7j9uta1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 5 – <span id="xdx_82E_ziZ88Wu6bLQa">Commitments and Contingencies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As security for its obligation under a property lease agreement, cars lease and credit cards of the Company’s subsidiary provided a bank guarantee in the amount of $<span id="xdx_900_eus-gaap--BankAcceptancesExecuted_iI_pp0p0_c20230831_zAvFvkfyLf7c" title="Bank guarantee">5,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>37 <FILENAME>R13.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164541453968"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders’ Equity (Deficit)<br></strong></div></th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr><th class="th"><div>Aug. 31, 2023</div></th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders’ Equity (Deficit)</a></td> <td class="text"><p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z3g3uDVdRAMk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 6 – <span id="xdx_820_zr2rYOmYpUgk">Stockholders’ Equity (Deficit)</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Authorized Shares</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is authorized to issue up to <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20230831_zcSC7Ij68Wig" title="Common stock, shares authorized">900,000,000</span> shares of common stock par value $0<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230831_zl4VRxR25Yf2" title="Common stock, par value">.0001</span> per share. Each outstanding share of common stock entitles the holder to one vote per share on all matters submitted to a stockholder vote. All shares of common stock are non-assessable and non-cumulative, with no pre-emptive rights. The Company’s initial Articles authorized <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20230831_zQkar9JR7Mnj" title="Preferred stock, shares authorized">5,000,000</span> preferred shares at <span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230831_zXhvGdakyud6" title="Preferred stock, par value">.0001</span> par value, no other attributes have been assigned and no such shares have ever been issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Common Stock</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 12, 2022, the Company effected a reverse-split of its common stock on a <span id="xdx_90B_eus-gaap--StockholdersEquityReverseStockSplit_c20220511__20220512_z14s04EETD9a" title="Stock split">1:120</span> basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended August 31, 2023, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220901__20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z8JPRd14xF85" title="Stock issued for exercise of convertible debt, shares issued">21,372,693</span> shares of its common stock to an investors as a result of a convertible loan exercise in the sum of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pp0p0_c20220901__20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zJHxP2ewukx3" title="Stock issued for exercise of convertible debt, value">569,930</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock Based Compensation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 6, 2021, the Compensation Committee adopted, and the Board ratified the Company’s Equity Incentive Plan. The Plan is intended to secure for the Company the benefits arising from ownership of the Company’s common stock by the employees, officers, directors and consultants of the Company, all of whom are, and will be, responsible for the Company’s future growth. The Plan is designed to help attract and retain for the Company, qualified personnel for positions of exceptional responsibility, to reward employees, officers, directors and consultants for their services to the Company and to motivate such individuals through added incentives to further contribute to the success of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Plan provides an opportunity for an employee, officer, director or consultant of the Company, subject to certain national securities and taxation laws, to receive (i) incentive stock options, (ii) nonqualified stock options; (iii) restricted stock; (iv) stock awards; (v) shares in performance of services; or (vi) any combination of the foregoing. Incentive stock options granted under the Plan are intended to qualify as “<span style="text-decoration: underline">incentive stock options</span>” within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the “<span style="text-decoration: underline">Code</span>”). Nonqualified (non-statutory stock options) granted under the Plan are not intended to qualify as incentive stock options under the Code. The Plan is administered by the Altshuler Shaham Benefits Firm, a licensed fiduciary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 2, 2022, the Compensation Committee approved amending the Plan to increase the number of shares reserved for issuance under the Plan to 15% of the common stock outstanding immediately following consummation of this offering.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Private Placement of Notes and Warrant</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 16, 2020, we entered into a Securities Purchase Agreement (“SPA”) with an institutional investor for a private placement of senior secured convertible notes totaling up to an aggregate of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfSeniorLongTermDebt_pp0p0_c20201215__20201216__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zk1bwJMLs0nc" title="Senior convertible notes issued">2,750,000</span> to be issued in three tranches subject to the achievement of certain milestones. The convertible notes include a conversion right, at the Investor’s option, to convert the convertible notes into shares of our Common Stock at a conversion price equal to the lower of (i) $<span id="xdx_90E_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20201215__20201216__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zOnfx4Qw2mV6" title="Conversion price">42</span> per share or (ii) eighty percent (80%) of the average of the two lowest daily volume-weighted average price for the Company’s Common Stock during the ten (10) consecutive trading days preceding the conversion date (the “notes”). The investor has the right to have the conversion price reduced if we issue Common Stock or convertible notes at a lower conversion price than $<span id="xdx_90A_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20201215__20201216__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z2jUUxfFyUuk" title="Lower conversion price">42</span> during the period that the notes are outstanding. The notes are due one year from issuance. The notes will be interest free, but in the event of a default, they will bear annual interest at a rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20201215__20201216__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zKgTRMPKmjBa" title="Interest rate">18.00</span>%. The SPA and the notes contain events of default, including, among other things, failure to repay the notes by the maturity date, and bankruptcy and insolvency events, that would result in the imposition of the default interest rate.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 21, 2020, we closed the first tranche and issued a note in the amount of $<span id="xdx_90F_eus-gaap--ProceedsFromNotesPayable_pp0p0_c20201220__20201221__us-gaap--DebtInstrumentAxis__custom--InitialNoteMember_zdqkQGqtXS27" title="Notes payable">825,000</span> (the “Initial Note”). On February 22, 2021, we closed the second tranche and issued a second note in the amount of $<span id="xdx_906_eus-gaap--ProceedsFromNotesPayable_pp0p0_c20210221__20210222__us-gaap--DebtInstrumentAxis__custom--SecondNoteMember_zXO2H5cmHXXd" title="Notes payable">550,000</span> (the “Second Note”). On April 23, 2021, we closed the third tranche and issued a third note in the amount of $<span id="xdx_906_eus-gaap--ProceedsFromNotesPayable_pp0p0_c20210422__20210423__us-gaap--DebtInstrumentAxis__custom--NoteMember_zoOezx6QHnwi" title="Notes payable">1,375,000</span> (the “Note”). The Initial Note was issued at a discount of $<span id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20201221__us-gaap--DebtInstrumentAxis__custom--InitialNoteMember_ztOhqMrdg4x1" title="Unamortized Discount">75,000</span>; the Second Note was issued at a discount of $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20210222__us-gaap--DebtInstrumentAxis__custom--SecondNoteMember_ztfJSHYMovW" title="Unamortized Discount">50,000</span>; and the Note was issued at a discount of $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20210423__us-gaap--DebtInstrumentAxis__custom--NoteMember_zjVD2KhK89Bl" title="Unamortized Discount">125,000</span>. In addition, we issued to the Investor <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220901__20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z9MaZauuZ4G2" title="Convertible shares">32,614</span> shares of Common Stock as pre-delivery shares in accordance with the terms of the SPA, which shares will be deducted from the total number of shares to be issued to the Investor upon conversion of the Initial Note.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 23, 2021, we entered into a senior secured promissory note (the “Senior Secured Note”) for $<span id="xdx_903_eus-gaap--SeniorNotesCurrent_iI_pp0p0_c20210423__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNoteMember_zQyCa2JUTnWc" title="Senior secured note">1,375,000</span> with the institutional investor. This follows the SPA, a restated securities purchase agreement dated as of February 22, 2021, as well as accompanying documents for an aggregate principal amount of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210423__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNoteMember_zIcUp6BkM1f4" title="Principal amount">2,750,000</span> having an aggregate original issue discount of <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20210423__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNoteMember_zOQ8UQOZidle" title="Original issue discount percentage">10</span>%, and ranking senior to all outstanding and future indebtedness of the Company. In addition, the SPA granted the investor a right to receive 100% warrant coverage, and we issued a warrant to the investor for up to <span id="xdx_904_ecustom--WarrantsIssued_c20210422__20210423__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNoteMember_zYxRMBTU8Rok" title="Warrants issued">45,833</span> shares of our Common Stock, which expires three years from the issuance date of the warrant, with an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210423__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNoteMember_zoc83BqupLwk" title="Warrants exercise price">60</span> per share. The warrant may be exercised and converted to Common Stock at the investor’s option at any time until the expiration date. These securities were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act, and Regulation D promulgated thereunder, as these securities were sold to “accredited investors” within the meaning of Regulation D.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 15, 2022, we entered into a forbearance agreements with the institutional investor relating to that certain Senior Secured Note. Pursuant to the forbearance agreement, the investor, through March 7, 2022, agreed to forbear from exercising any rights and remedies against the Company related to the outstanding payments and to waive certain other defaults under the Senior Secured Note and related rights pursuant to the registration rights agreement entered into in December 2020 between the Company and the investor.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 28, 2022, we entered into a forbearance agreements with the institutional investor relating to that certain Senior Secured Note. Pursuant to the forbearance agreement, the investor, through December 12, 2022, agreed to forbear from exercising any rights and remedies against the Company related to the outstanding payments and to waive certain other defaults under the Senior Secured Note and related rights pursuant to the registration rights agreement entered into in December 2020 between the Company and the investor.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 16, 2022, we issued to the investor a demand promissory note (the “Demand Note”) in the principal amount of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220316__us-gaap--LongtermDebtTypeAxis__custom--DemandNoteMember_z1r7BHLwqZX" title="Principal amount">280,000</span> (the “Principal”) with an original issue discount of $<span id="xdx_902_ecustom--OriginalIssueDiscount_pp0p0_c20220315__20220316__us-gaap--LongtermDebtTypeAxis__custom--DemandNoteMember_zYH3mYZktDZa" title="Original issue discount">40,000</span>. The Demand Note is payable on demand at any time after the earlier to occur of (i) May 16, 2022, and (ii) the public or private offering of any securities by the Company (the “Next Subsequent Placement”). Any amount of Principal due under the Demand Note which is not paid when due shall result in a late charge being incurred and payable by the Company in an amount equal to interest on such amount at the rate of fifteen percent (15%) per annum from the date such amount was due until the same is paid in full (the “Late Charges”). With the agreement, the Principal and accrued and unpaid Late Charges under the Demand Note and amounts owed under the Senior Secured Note may be applied to all, or any part, of the purchase price of securities to be issued upon the consummation of an offering of securities by the Company to the investor. So long as any amounts remain outstanding under the Demand Note or the Senior Secured Note, all cash proceeds received by the Company on or after issuance of the Demand Note from the Next Subsequent Placement or any other sales of any securities of the Company shall be used to (x) first, repay the Demand Note and (y) second, repay the Senior Secured Note.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 28, 2022, we entered into a forbearance agreements with the institutional investor relating to that certain Senior Secured Note. Pursuant to the forbearance agreement, the investor, through December 12, 2022, agreed to forbear from exercising any rights and remedies against the Company related to the outstanding payments and to waive certain other defaults under the Senior Secured Note and related rights pursuant to the registration rights agreement entered into in May 16, 2022 between the Company and the investor.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 15, 2022, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220615__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zkN1XDryNNtk" title="Principal amount">154,250</span>.00. ($<span id="xdx_905_eus-gaap--InterestExpenseOtherLongTermDebt_pp0p0_c20220614__20220615__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zgheLxOCvI43" title="Net of issuance expenses">154,000</span> net of issuance expenses). The Convertible Promissory Note carry interest of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220614__20220615__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zbvqBdt1hZh9" title="Interest rate">9</span>% and due on June 15<sup>th</sup> 2023<span style="color: red">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the period of January through March , 2023, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zqN0c5VPYHWd" title="Principal amount">35,000</span>.00. ($<span id="xdx_902_eus-gaap--InterestExpenseOtherLongTermDebt_pp0p0_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zK6YLaXASyfi" title="Net of issuance expenses">35,000</span> net of issuance expenses). The Convertible Promissory Note carry interest of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zPj9HYsjnbvd" title="Interest rate">5</span>% and due on June 15<sup>th</sup> 2023</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 12, 2023, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230612__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z7JAkqQtRzXf" title="Principal amount">65,000</span>.00. ($<span id="xdx_901_eus-gaap--InterestExpenseOtherLongTermDebt_pp0p0_c20230611__20230612__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zgZY5ZFjPn3f" title="Net of issuance expenses">65,000</span> net of issuance expenses). The Convertible Promissory Note carry interest of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20230611__20230612__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zI32sSvd2mka" title="Interest rate">5</span>% and due on August 85<sup>th</sup> 2023</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EquityAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>38 <FILENAME>R14.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164541646752"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr><th class="th"><div>Aug. 31, 2023</div></th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_DisclosureWarrantsAbstract', window );"><strong>Warrants</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_WarrantDisclosureTextBlock', window );">Warrants</a></td> <td class="text"><p id="xdx_80C_ecustom--WarrantDisclosureTextBlock_zIBYLKFNNOAd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 7 – <span id="xdx_820_zZbl1RNUJYfi">Warrants</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%"> </td> <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 24, 2018, as part of a securities purchase agreement the company issued <span id="xdx_90A_ecustom--WarrantsIssuedShares_iI_c20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zN5No6biie1j" title="Warrants issued, shares">41,667 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants, to purchase common shares of the Company at $1.00 per share; said Warrants are valid for five years, expiring on <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zUC8E42d8e1l" title="Expiry date">August 24<sup>th</sup>, 2023</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of each warrant is approximately $66 and the total value of the 41,667 warrants is $<span id="xdx_906_ecustom--FairValueOfWarrantsIssued_iI_pp0p0_c20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zXDplwKeIdZb" title="Fair value of warrants issued">2,784,387</span></span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the warrants are estimated using the Black Scholes option-pricing model with the following assumptions:</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfAssumptionsUsedWarrantsTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zVElxf5u2a8b" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details - Fair value)"> <tr style="vertical-align: bottom"> <td> </td> <td><span id="xdx_8BA_zJm3qkZpcmnd" style="display: none">Schedule of assumptions</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 4%"> </td> <td style="width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PV of exercise Share price</span></td> <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_909_eus-gaap--SharePrice_iI_c20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_z1BT0cHaYSe" title="PV of exercise Share price">1</span></span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Volatility</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20180923__20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zeTBcoOuuMM3" title="Expected Volatility">102.0</span>%</span></td></tr> <tr style="vertical-align: bottom"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Free Interest Rate</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20180923__20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zdNvz4JpueA9" title="Risk Free Interest Rate">1.58</span>%</span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Term (years)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180923__20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zFtOmMqNY6ni" title="Expected Term (years)">5</span></span></td></tr> <tr style="vertical-align: bottom"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Dividend Yield</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20180923__20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zrFEQSaMlp2f" title="Expected Dividend Yield">0</span>%</span></td></tr> </table> <p id="xdx_8A5_zjfuPdWMVrp2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.55pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: justify">The said warrants expired on August 24, 2023</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.55pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%"> </td> <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 16, 2020, as part of a convertible loan agreement the company issued <span id="xdx_90F_ecustom--WarrantsIssuedShares_iI_c20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zbWV2H4HvBId" title="Warrants issued, shares">45,667 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants, to purchase common shares of the Company at $0.50 per share; said Warrants are valid for three years, expiring on <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zfC8VHQycqT7" title="Expiry date">August 24<sup>th</sup>, 2023</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The first trench was received on December 22, 2020, the second trench was received on February 2,2021 and the third trench was received on April 23, 2021, in the total sum of $2,456,750 net of issuance expenses.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: justify">The fair value of the first, second and third trenches are approximately $10.8, $10.8 and $12 respectively and the total value of the 45,667 warrants is $<span id="xdx_90A_ecustom--FairValueOfWarrantsIssued_iI_pp0p0_c20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zWpAFglpSLy2" title="Fair value of warrants issued">515,818</span></p></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the warrants are estimated using the Black Scholes option-pricing model with the following assumptions:</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_891_ecustom--ScheduleOfAssumptionsUsedWarrantsTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zVngV2lP0uHc" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details - Fair Value)"> <tr style="vertical-align: bottom"> <td> </td> <td><span id="xdx_8B4_zxXZSpwzzkcb" style="display: none">Schedule of assumptions</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 4%"> </td> <td style="width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PV of exercise Share price</span></td> <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_902_eus-gaap--SharePrice_iI_c20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zNnoDkT6AMg6" title="PV of exercise Share price">0.50</span></span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Volatility</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20201215__20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_z9rpupLhw5Pi" title="Expected Volatility">117.0</span>%</span></td></tr> <tr style="vertical-align: bottom"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Free Interest Rate</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20201215__20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zFW1J9F73Pai" title="Risk Free Interest Rate">0.3</span>%</span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Term (years)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201215__20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zWx6JIt6RCIk" title="Expected Term (years)">3</span></span></td></tr> <tr style="vertical-align: bottom"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Dividend Yield</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20201215__20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_z1t4FU9U4YTg" title="Expected Dividend Yield">0</span>%</span></td></tr> </table> <p id="xdx_8A5_z1W67LP466G5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.55pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The said warrants expired on <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zd7iWix5XxC1" title="Expiry date">August 24, 2023</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.55pt"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zERxgiZX0yd8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrants (Details - Warrant activity)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8BB_ztOw1gBNt206" style="display: none">Schedule of warrant activity</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Weighted Average Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Weighted Average Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Weighted Average Exercise</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 28%; text-indent: -8.1pt; padding-left: 8.1pt">Warrants outstanding as of September 1</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zgWrZ1o57Ct3" style="width: 9%; text-align: right" title="Warrants outstanding, beginning balance">87,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zgvVr5xXzDUj" style="width: 9%; text-align: right" title="Weighted average exercise price, warrants outstanding, beginning balance">88.6</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z5foQcP6gjNb" style="width: 9%; text-align: right" title="Warrants outstanding, beginning balance">87,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zIRlhE1ltJD" style="width: 9%; text-align: right" title="Weighted average exercise price, warrants outstanding, beginning balance">88.6</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zNG7yT6CJkq6" style="width: 9%; text-align: right" title="Warrants outstanding, beginning balance">41,667</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z4EfRS3SYc7j" style="width: 9%; text-align: right" title="Weighted average exercise price, warrants outstanding, beginning balance">120</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--WarrantsIssued_d0_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zK64zLnL95yb" style="text-align: right" title="Warrants issued">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_ecustom--WeightedAverageExercisePriceWarrantsIssued_d0_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z7vqhXQ16R2e" style="text-align: right" title="Weighted average exercise price, warrants issued">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--WarrantsIssued_d0_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zi2frAR9Toce" style="text-align: right" title="Warrants issued">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_ecustom--WeightedAverageExercisePriceWarrantsIssued_d0_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_ztYq09v4YV18" style="text-align: right" title="Weighted average exercise price, warrants issued">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--WarrantsIssued_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zYvUnGuitYh2" style="text-align: right" title="Warrants issued">45,667</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_ecustom--WeightedAverageExercisePriceWarrantsIssued_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zh5bN0Ls9Q0h" style="text-align: right" title="Weighted average exercise price, warrants issued">60</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_d0_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zFORyrQsEHh3" style="text-align: right" title="Warrants exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_ecustom--WeightedAverageExercisePriceWarrantsExercised_d0_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zrTkVciJK45h" style="text-align: right" title="Weighted average exercise price, warrants exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_d0_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zLaPhjRgS6lc" style="text-align: right" title="Warrants exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_ecustom--WeightedAverageExercisePriceWarrantsExercised_d0_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zL50dXEitBJa" style="text-align: right" title="Weighted average exercise price, warrants exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_d0_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_ztSvWZlzcKR3" style="text-align: right" title="Warrants exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_ecustom--WeightedAverageExercisePriceWarrantsExercised_d0_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zOz7RF1oXiYb" style="text-align: right" title="Weighted average exercise price, warrants exercised">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zoq1gLO5YWM4" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired">(87,500</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_ecustom--WeightedAverageExercisePriceWarrantsExpired_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zmTxZ6yTyGQh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants expired">88.6</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di0_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z7MHQglGENQ3" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_ecustom--WeightedAverageExercisePriceWarrantsExpired_d0_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zCw0QQ3P4pNb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di0_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z4uHcKnaBAD3" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_ecustom--WeightedAverageExercisePriceWarrantsExpired_d0_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zxwCmQKkAzF3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt; text-indent: -8.1pt; padding-left: 8.1pt">Warrants outstanding as of August 31</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_d0_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zCfIPlGsIcLl" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants outstanding, ending balance">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_d0_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zfaJlc2tU8jg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants outstanding, ending balance">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z5eiwsHAgBoh" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants outstanding, ending balance">87,500</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z2KaL2aRhJ9e" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants outstanding, ending balance">88.6</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_ziC9jWbqiksg" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants outstanding, ending balance">87,500</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zbI297c0Ydyf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants outstanding, ending balance">88.6</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt; text-indent: -8.1pt; padding-left: 8.1pt">Warrants exercisable as of August 31</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_d0_c20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zJpk2wG0d7u8" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--WeightedAverageExercisePriceWarrantsExercisable_iI_d0_c20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zXSu0jo1Ulu9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, warrants exercisable">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zodeKPStZEDf" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable">87,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--WeightedAverageExercisePriceWarrantsExercisable_iI_c20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zSlPEJMqXZZ4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, warrants exercisable">88.6</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zRv5ZXdapHNi" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable">87,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--WeightedAverageExercisePriceWarrantsExercisable_iI_c20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z3qpfUHjwVp5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, warrants exercisable">88.6</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zbng7zRCLFw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.55pt"> </p> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CNBX_DisclosureWarrantsAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">CNBX_DisclosureWarrantsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>CNBX_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CNBX_WarrantDisclosureTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">CNBX_WarrantDisclosureTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>CNBX_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>39 <FILENAME>R15.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164538382992"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr><th class="th"><div>Aug. 31, 2023</div></th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td> <td class="text"><p id="xdx_80D_eus-gaap--IncomeTaxDisclosureTextBlock_zSFWPq0H72U6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 8 – <span id="xdx_82D_z9gFqvDOD0mf">Income Taxes</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Taxes on income included in the consolidated statements of operations represent current taxes due to taxable income of the Company and its Subsidiary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.2pt; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.2pt; text-align: justify"><b>Corporate taxation in the U.S.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.2pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The applicable corporate tax rate for the Company is <span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20220901__20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zOSHUdodBFA6" title="Effective tax rate">21</span>%.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No provision for income tax was made for the period from September 15, 2004 (Inception) to August 31, 2023, as the Company had cumulative operating losses. For the years ended August 31, 2023, and 2022, the Company incurred net losses for tax purposes of $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20230831__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStates1Member_zvU7aXAxsxrk" title="Net operating loss carryforwards">1,848,572</span> and $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20220831__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStates1Member_zqT751q6i348" title="Net operating loss carryforwards">903,813</span>, respectively. Under U.S. tax laws, subject to certain limitations, carry forward tax losses expire 20 years after the year in which incurred. In the case of the Company, subject to potential limitations in accordance with the relevant law, the net loss carry forward will expire in the years 2032 through 2036.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">   </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.2pt; text-align: justify"><b>Corporate taxation in Israel:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.2pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Subsidiary is taxed in accordance with Israeli tax laws. The corporate tax rate applicable is <span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_dp_c20220901__20230831__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--IsraelTaxAuthorityMember_z5WOPRTWF70d" title="Effective tax rate, Israel">23</span>%.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of August 31, 2023, the Subsidiary has an accumulated tax loss carry forward of approximately $<span id="xdx_907_eus-gaap--OperatingLossCarryforwards_pp0p0_c20230831__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--IsraelTaxAuthorityMember_zZk9ZH4tyiuj" title="Net operating loss carryforwards">12,593,815</span> (as of August 31, 2022, approximately $<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_pp0p0_c20220831__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--IsraelTaxAuthorityMember_zRjbSXjIRc81" title="Net operating loss carryforwards">12,373,689</span>). Under the Israeli tax laws, carry forward tax losses have no expiration date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The income tax expense (benefit) differs from the amount computed by applying the United States Statutory corporate income tax rate as follows: </p> <table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zgJhIPUIx80h" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - rate)"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span id="xdx_8B3_zIUTlIVUkQld" style="display: none">Schedule of effective income tax rate</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the Year Ended August 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">United States statutory corporate income tax rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20220901__20230831_zgUCWK1I3kf3" title="United States statutory corporate income tax rate">21.0</span>%</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20210901__20220831_zcgx2Vc0gNNg" title="United States statutory corporate income tax rate">21.0</span>%</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance on deferred tax assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_dpi_c20220901__20230831_zkaxt4a8l7n8" title="Change in valuation allowance on deferred tax assets">-21.0</span>%</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_dpi_c20210901__20220831_z5CA2HrvbqT2" title="Change in valuation allowance on deferred tax assets">-21.0</span>%</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Provision for income tax</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_c20220901__20230831_zxxUW2CdrBk9" title="Provision for income tax">–</span>%</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_c20210901__20220831_zHpoAhLh1rGe" title="Provision for income tax">–</span>%</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zQwQjAucNFD5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred income taxes reflect the tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for tax purposes. The components of the net deferred income tax assets are approximately as follows: </p> <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z1ZUhSk2ZSCa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - Deferred tax assets)"> <tr style="vertical-align: bottom"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt"><span id="xdx_8B4_zPcrQ0cK8JN" style="display: none">Schedule of deferred income tax assets</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">August 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">US Deferred income tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left; text-indent: -10pt; padding-left: 20pt">Net operating loss carry forwards benefit</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zL2THumqnoB8" style="width: 13%; text-align: right" title="Net operating loss carry forwards benefit">3,035,360</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20220831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zsvNG3u0AbS8" style="width: 13%; text-align: right" title="Net operating loss carry forwards benefit">2,576,499</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_z2l0hHKoX0m7" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance">(3,035,360</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20220831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_ze0UGwNCVW1l" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance">(2,576,499</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred income tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zbfmrgAccXf7" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred income tax assets">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20220831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zmd25C1Dq17h" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred income tax assets">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Outside US Deferred income tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Net operating loss carry forwards benefit</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zfbtDPbtDuhc" style="text-align: right" title="Net operating loss carry forwards benefit">2,949,564</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20220831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zeRbYqhNeJ5a" style="text-align: right" title="Net operating loss carry forwards benefit">2,804,533</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_z5Yaff7ccvAa" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance">(2,949,564</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20220831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zotbNCzvpek5" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance">(2,804,533</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_ze0pP0JQLpR2" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred income tax assets">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20220831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_z9yT8Dxhjv27" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred income tax assets">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">August 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Consolidated Deferred income tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left; text-indent: -10pt; padding-left: 20pt">Net operating loss carry forwards benefit</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20230831_zNA5yXQdBTR5" style="width: 13%; text-align: right" title="Net operating loss carry forwards benefit">5,984,924</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20220831_z9pIXewBhq1b" style="width: 13%; text-align: right" title="Net operating loss carry forwards benefit">5,381,031</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20230831_zFnddgNEVW1" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance">(5,984,924</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20220831_z0c7kaHproCf" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance">(5,381,031</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred income tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20230831_zLiITVuvgLsj" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred income tax assets">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20220831_zD5iUELuuZO4" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred income tax assets">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zuXgA7rzIm2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amount taken into income as deferred income tax assets must reflect that portion of the income tax loss carry forwards that is more likely than not to be realized from future operations. The Company has established a full valuation allowance on its net deferred tax assets because of a lack of sufficient positive evidence to support its realization. The valuation allowance increased by $<span id="xdx_90D_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pp0p0_c20220901__20230831_zp19Dr9w6C7f" title="Increase (decrease) in valuation allowance">603,893</span> and decreased $<span id="xdx_901_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pp0p0_c20210901__20220831_zyjRC6S5L0C" title="Increase (decrease) in valuation allowance">1,055,107</span> for the years ended August 31, 2023, and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No provision for income taxes has been provided in these financial statements due to the net loss for the years ended August 31, 2023 and 2021. At August 31, 2023, the Company has net operating loss carry forwards of approximately $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_pp0p0_c20230831_zafcw4QF61Gk" title="Net operating loss carryforwards">24,259,202</span> which expire commencing 2032. The potential tax benefit of these losses may be limited due to certain change in ownership provisions under Section 382 of the Internal Revenue Code (“IRS”) and similar state provisions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IRS Section 382 places limitations (the “Section 382 Limitation”) on the amount of taxable income which can be offset by net operating loss carry forwards after a change in control (generally greater than 50% change in ownership) of a loss corporation. Generally, after a change in control, a loss corporation cannot deduct operating loss carry forwards in excess of the Section 382 Limitation. Due to these “change in ownership” provisions, utilization of the net operating loss and tax credit carry forwards may be subject to an annual limitation regarding their utilization against taxable income in future periods. The Company has not concluded its analysis of Section 382 through August 31, 2023, but believes the provisions will not limit the availability of losses to offset future income.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is subject to income taxes in the U.S. federal jurisdiction and is subject to examination for a period of three years for current filings and indefinitely for any delinquent filings. The tax regulations within each jurisdiction are subject to interpretation of related tax laws and regulations and require significant judgment to apply. The Company estimates that the amount of penalties, if any, will not have a material effect on the results of operations, cash flows or financial position. No provisions have been made in the financial statements for such penalties, if any.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>40 <FILENAME>R16.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164538357056"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital loss<br></strong></div></th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr><th class="th"><div>Aug. 31, 2023</div></th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_DisclosureCapitalLossAbstract', window );"><strong>Capital Loss</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_CapitalLossDisclosureTextBlock', window );">Capital loss</a></td> <td class="text"><p id="xdx_808_ecustom--CapitalLossDisclosureTextBlock_zRxjLd7DC78l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 9 – <span id="xdx_82C_z7tXlZQK8gAa">Capital loss</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 9th, 2022, the Company sold her holdings in Sativusin in consideration of $<span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20221208__20221209_zLw9Iok06LMa" title="Sale consideration">24,200</span>, as a result the company recorded a capital loss of $<span id="xdx_909_ecustom--CapitalLoss_c20221208__20221209_zsnZLjuW35cg" title="Capital loss">2,726,231</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CNBX_CapitalLossDisclosureTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">CNBX_CapitalLossDisclosureTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>CNBX_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CNBX_DisclosureCapitalLossAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">CNBX_DisclosureCapitalLossAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>CNBX_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>41 <FILENAME>R17.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164541620816"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General & administrate expenses<br></strong></div></th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr><th class="th"><div>Aug. 31, 2023</div></th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock', window );">General & administrate expenses</a></td> <td class="text"><p id="xdx_80B_eus-gaap--OtherNonoperatingIncomeAndExpenseTextBlock_zUGX1LeFBZa1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 10</b> – <span id="xdx_820_z3GNDRXzrkg"><b>General & administrate expenses </b></span></p> <table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_z7aDLip9uSh7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - General and administrative expenses (Details)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B7_zkRRd1cSq0M4" style="display: none">Schedule of general and administrative expenses</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20220901__20230831_zxT46YnSOUdl" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20210901__20220831_zf7V85Xymjh3" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">For the year Ended<br/> August 31,<br/> 2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">For the year Ended<br/> August 31,<br/> 2022</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40C_eus-gaap--LaborAndRelatedExpense_maGAAEzYXX_z4LoQHdGhQd7" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Salaries and related expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">461,375</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">379,618</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_maGAAEzYXX_zCiYWpWnW9Ha" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Share based payment to related parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">180,480</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">728,870</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LegalFees_maGAAEzYXX_zjhvfrsiVoFl" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Legal and professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">149,108</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">443,851</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--GeneralInsuranceExpense_maGAAEzYXX_zowgSWKhZyul" style="vertical-align: bottom; background-color: White"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">68,278</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">93,192</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--MarketingExpense_maGAAEzYXX_zDUSeKr4zPYc" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Marketing expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,223</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,977</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OtherGeneralExpense_maGAAEzYXX_zKsXhX5atAyh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Other expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">49,516</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">139,139</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--GeneralAndAdministrativeExpense_iT_pp0p0_mtGAAEzYXX_zOpDmNcV0xQb" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"><b style="display: none">Total general and administrative expenses</b></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">909,980</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,800,647</td><td style="padding-bottom: 2.5pt; text-align: left">*</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* In the year ended August 31, 2022 revenues of $29,958 was presented under General and administrative expenses, was allocated to Revenues under previous year results.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>42 <FILENAME>R18.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164540443984"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial (Income) expenses<br></strong></div></th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr><th class="th"><div>Aug. 31, 2023</div></th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">Financial (Income) expenses</a></td> <td class="text"><p id="xdx_806_eus-gaap--OtherIncomeAndOtherExpenseDisclosureTextBlock_z1x55BcGsgec" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 11</b> – <span id="xdx_825_zMwkgPw0ZgRa"><b>Financial (Income) expenses </b></span></p> <table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--ScheduleOfFinancialIncomeExpensesTableTextBlock_zGwZfD6rIcA4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Financial (Income) expenses (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span id="xdx_8B9_znjXAsjDcYD4" style="display: none">Schedule of financial income expenses</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_492_20220901__20230831_zUcrKjMH1kEc" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_498_20210901__20220831_zGuGRyJHAW3g" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">For the year<br/> Ended<br/> August 31, 2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">For the year<br/> Ended<br/> August 31, 2022</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_eus-gaap--InterestExpenseBorrowings_i_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Interest and bank charges</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,174</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,273</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--LossGainFromConvertibleLoanValuation_zuBlVcyCiO82" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Loss (Gain) from convertible loan valuation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54,810</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">722,236</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt; text-align: left">Currency exchange differences loss (profit)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,361</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">58,571</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OtherNonoperatingIncomeExpense_pp0p0_zSZgT9dfWBe5" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><b style="display: none">Total other income expenses</b></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">52,623</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">782,080</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 610<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//610/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 720<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//720/tableOfContent<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>43 <FILENAME>R19.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164538382992"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr><th class="th"><div>Aug. 31, 2023</div></th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td> <td class="text"><p id="xdx_801_eus-gaap--SubsequentEventsTextBlock_zRa01Zm0aKKe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 11 – <span id="xdx_826_zWabb91Dk7Vk">Subsequent Events</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 13, 2023, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $25,000.00. ($25,000 net of issuance expenses). The Convertible Promissory Note carry interest of 5% and due on January 1st 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the period September through October, 2023, the company issued 5,700,000 shares as a result of a convertible of a loan at the total of $65,908.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>44 <FILENAME>R20.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164539365152"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr><th class="th"><div>Aug. 31, 2023</div></th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional currency</a></td> <td class="text"><p id="xdx_84F_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zasdwoFqnSzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_862_zHpXURhREUQb">Functional currency</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The currency of the primary economic environment in which the operations of the Company and its Subsidiary are conducted is the U.S. dollar (“$” or “dollar”). Therefore, the functional currency of the Company and its Subsidiary is the dollar.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Transactions and balances denominated in dollars are presented at their original amounts. Non-dollar transactions and balances have been re-measured to dollars in accordance with the provisions of ASC 830-10 (formerly Statement of Financial Accounting Standard 52), "Foreign Currency Translation". All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td> <td class="text"><p id="xdx_848_eus-gaap--UseOfEstimates_zdGpwSbTPWNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86C_zBdGvHpwOwnc">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates in the accompanying financial statements include the amortization period for intangible assets, impairment valuation of intangible assets, valuation of share-based payments and the valuation allowance on deferred tax assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td> <td class="text"><p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zoWydCZHRYT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_863_ze39WOn0Kvtd">Principles of Consolidation</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements include the accounts of Cannabics Pharmaceutical Inc. and its wholly-owned subsidiary, G.R.I.N. Ultra Ltd. All significant inter-company balances and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td> <td class="text"><p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zSjJfU0091U1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_866_zV0TnliunyC3">Cash and Cash Equivalents</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. At August 31, 2023 and 2022, cash equivalents consisted of bank accounts held at financial institutions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td> <td class="text"><p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zAVF42egYI56" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_z7MsdL5Qgk93">Concentration of Credit Risk</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company places its cash and cash equivalents with high credit quality financial institutions. There is Federal Deposit Insurance on the Company’s U.S. bank accounts for up to $<span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_c20230831_zsXZ4YmmMrXh" title="Federal deposit insurance">250,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Equipment, net</a></td> <td class="text"><p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zKdVb9dYFvu8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_861_zM3nN5mFmew2">Equipment, net</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equipment at August 31, 2023 consists of computer equipment, office equipment and cars recorded at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation of property and equipment is computed by the straight-line method (after taking into account their respective estimated residual values) over the assets estimated useful lives of 3 years for computer equipment, 14 years for office equipment and 7 years for cars. Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in the consolidated statements of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expense was $<span id="xdx_909_eus-gaap--Depreciation_pp0p0_c20220901__20230831_zxPka4lcudAd" title="Depreciation expense">162,061</span> and $<span id="xdx_906_eus-gaap--Depreciation_pp0p0_c20210901__20220831_zjNy6luMvZag" title="Depreciation expense">198,527</span> for the years ended August 31, 2023, and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td> <td class="text"><p id="xdx_84A_eus-gaap--RevenueRecognitionPolicyTextBlock_zH9eTZ69Sl2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_864_zVkMFXRjFV5a">Revenue recognition</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue is recognized when delivery has occurred, evidence of an arrangement exists, title and risks and rewards for the products are transferred to the customer, collection is reasonably assured and product returns can be reliably estimated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue from license agreements is recognized over the periods from which the Company is entitled to the respective payments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment or Disposal of Long-Lived Assets</a></td> <td class="text"><p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z7cPcYYiIODh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86F_zzQygxnq2Cn4">Impairment or Disposal of Long-Lived Assets</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for the impairment or disposal of long-lived assets according to the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) 360 “Property, Plant and Equipment”. ASC 360 clarifies the accounting for the impairment of long-lived assets and for long-lived assets to be disposed of, including the disposal of business segments and major lines of business. Long-lived assets are reviewed when facts and circumstances indicate that the carrying value of the asset may not be recoverable. When necessary, impaired assets are written down to estimated fair value based on the best information available. Estimated fair value is generally based on either appraised value or measured by discounting estimated future cash flows. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i> </b></p> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td> <td class="text"><p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zLUS1qmp63W4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_zMPjBNjTXWak">Fair Value of Financial Instruments</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following provides an analysis of financial instruments that are measured subsequent to initial recognition at fair value, grouped into Levels 1 to 3 based on the degree to which fair value is observable:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1 - fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical assets or liabilities;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2 - fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 - fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of August 31, 2023 and 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company applied ASC 820 for all non-financial assets and liabilities measured at fair value on a non-recurring basis. The adoption of ASC 820 for non-financial assets and liabilities did not have a significant impact on the Company’s financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of August 31, 2023, the company had <span id="xdx_90C_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_pp0p0_do_c20230831__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zwmD6vnxaVY4" title="Fair value of financial instruments">no</span> level 1 fair values financial instruments assets, and had financial instruments liabilities of $<span id="xdx_904_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_pp0p0_c20230831__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zk7UI53qLko4" title="Fair value of financial instruments">1,343,584</span> at level 3.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of August 31, 2023, the fair values of the Company’s financial instruments approximate their historical carrying amount.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development, net</a></td> <td class="text"><p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zd4GJkrTJvI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_867_zfa6qvHm7Nnb">Research and development, net</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, employee benefits, the cost of supplies, the cost of services provided by outside contractors, including services related to the Company’s clinical trials, clinical trial expenses and the full cost of manufacturing product for use in research and preclinical development. All costs associated with research and developments are expensed as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources a substantial portion of its clinical trial activities, utilizing external entities such as Contract Research Organizations, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical studies. For each clinical trial that the Company conducts, clinical trial costs are expensed immediately.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock Based Compensation</a></td> <td class="text"><p id="xdx_845_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zw0IQJyuYpSi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_867_zj8xAVbxwC1g">Stock Based Compensation</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for Stock-Based Compensation under ASC 718 “Compensation – Stock Compensation”, which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 requires measurement of the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees. Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Any stock options or warrants issued to non-employees are recorded in expense and additional paid-in capital in shareholders' deficit over the applicable service periods using variable accounting through the vesting dates based on the fair value of the options or warrants at the end of each period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issues stock to consultants for various services. The costs for these transactions are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The value of the common stock is measured at the earlier of (i) the date at which a firm commitment for performance by the counterparty to earn the equity instruments is reached or (ii) the date at which the counterparty's performance is complete. The Company recognized consulting expense and a corresponding increase to additional paid-in-capital related to stock issued for services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td> <td class="text"><p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zUkROnVPmps" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_868_zUXl2xHYlfsf">Income Taxes</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Income taxes are accounted for under the liability method of accounting for income taxes. Under the liability method, future tax liabilities and assets are recognized for the estimated future tax consequences attributable to differences between the amounts reported in the financial statement carrying amounts of assets and liabilities and their respective tax bases. Future tax assets and liabilities are measured using enacted or substantially enacted income tax rates expected to apply when the asset is realized or the liability settled. The effect of a change in income tax rates on future income tax liabilities and assets is recognized in income in the period that the change occurs. Future income tax assets are recognized to the extent that they are considered more likely than not to be realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FASB has issued ASC 740 “Income Taxes”. ASC 740 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. This standard requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the implementation of this standard, the Company performed a review of its material tax positions in accordance with recognition and measurement standards established by ASC 740 and concluded that the tax position of the Company has not met the more-likely-than-not threshold as of August 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income</a></td> <td class="text"><p id="xdx_84F_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zSnHwkCGDCU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_863_zAGkIY4cCnHg">Comprehensive Income</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company adopted ASC 220, <i>Comprehensive Income</i> which establishes standards for reporting and display of comprehensive income, its components and accumulated balances. The Company is disclosing this information on its Statement of Stockholders' Equity. Comprehensive income comprises equity except those resulting from investments by owners and distributions to owners. The Company has no elements of “other comprehensive income” for the years ended August 31, 2023, and 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Loss per Share</a></td> <td class="text"><p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_zAoLYEHBGOJf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_860_zwYQG4hFDs02">Basic and Diluted Loss per Share</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company computes income (loss) per share in accordance with ASC 260, “Earnings per Share”, which requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the statement of operations. Basic EPS is computed by dividing income (loss) available to common shareholders by the weighted average number of shares outstanding during the period. Diluted EPS gives effect to all dilutive potential shares of common stock outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. As of August 31, 2023, and 2022, the potentially dilutive shares were anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td> <td class="text"><p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_znBnyLGreJAe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_861_zB3T8mebmmhd">Segment Information</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the provisions of ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, the Company is required to report financial and descriptive information about its reportable operating segments. The Company does not consider itself to have any operating segments as of August 31, 2023, and 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td> <td class="text"><p id="xdx_848_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zVNcwYGTkZXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_864_z3ConaoVnQr4">Reclassification</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483504/205-10-50-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_UseOfEstimates</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>45 <FILENAME>R21.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164535194496"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr><th class="th"><div>Aug. 31, 2023</div></th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrant activity</a></td> <td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zERxgiZX0yd8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrants (Details - Warrant activity)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8BB_ztOw1gBNt206" style="display: none">Schedule of warrant activity</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Weighted Average Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Weighted Average Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Weighted Average Exercise</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 28%; text-indent: -8.1pt; padding-left: 8.1pt">Warrants outstanding as of September 1</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zgWrZ1o57Ct3" style="width: 9%; text-align: right" title="Warrants outstanding, beginning balance">87,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zgvVr5xXzDUj" style="width: 9%; text-align: right" title="Weighted average exercise price, warrants outstanding, beginning balance">88.6</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z5foQcP6gjNb" style="width: 9%; text-align: right" title="Warrants outstanding, beginning balance">87,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zIRlhE1ltJD" style="width: 9%; text-align: right" title="Weighted average exercise price, warrants outstanding, beginning balance">88.6</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zNG7yT6CJkq6" style="width: 9%; text-align: right" title="Warrants outstanding, beginning balance">41,667</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z4EfRS3SYc7j" style="width: 9%; text-align: right" title="Weighted average exercise price, warrants outstanding, beginning balance">120</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--WarrantsIssued_d0_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zK64zLnL95yb" style="text-align: right" title="Warrants issued">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_ecustom--WeightedAverageExercisePriceWarrantsIssued_d0_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z7vqhXQ16R2e" style="text-align: right" title="Weighted average exercise price, warrants issued">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--WarrantsIssued_d0_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zi2frAR9Toce" style="text-align: right" title="Warrants issued">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_ecustom--WeightedAverageExercisePriceWarrantsIssued_d0_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_ztYq09v4YV18" style="text-align: right" title="Weighted average exercise price, warrants issued">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--WarrantsIssued_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zYvUnGuitYh2" style="text-align: right" title="Warrants issued">45,667</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_ecustom--WeightedAverageExercisePriceWarrantsIssued_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zh5bN0Ls9Q0h" style="text-align: right" title="Weighted average exercise price, warrants issued">60</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_d0_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zFORyrQsEHh3" style="text-align: right" title="Warrants exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_ecustom--WeightedAverageExercisePriceWarrantsExercised_d0_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zrTkVciJK45h" style="text-align: right" title="Weighted average exercise price, warrants exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_d0_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zLaPhjRgS6lc" style="text-align: right" title="Warrants exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_ecustom--WeightedAverageExercisePriceWarrantsExercised_d0_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zL50dXEitBJa" style="text-align: right" title="Weighted average exercise price, warrants exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_d0_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_ztSvWZlzcKR3" style="text-align: right" title="Warrants exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_ecustom--WeightedAverageExercisePriceWarrantsExercised_d0_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zOz7RF1oXiYb" style="text-align: right" title="Weighted average exercise price, warrants exercised">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zoq1gLO5YWM4" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired">(87,500</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_ecustom--WeightedAverageExercisePriceWarrantsExpired_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zmTxZ6yTyGQh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants expired">88.6</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di0_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z7MHQglGENQ3" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_ecustom--WeightedAverageExercisePriceWarrantsExpired_d0_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zCw0QQ3P4pNb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di0_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z4uHcKnaBAD3" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_ecustom--WeightedAverageExercisePriceWarrantsExpired_d0_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zxwCmQKkAzF3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt; text-indent: -8.1pt; padding-left: 8.1pt">Warrants outstanding as of August 31</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_d0_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zCfIPlGsIcLl" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants outstanding, ending balance">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_d0_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zfaJlc2tU8jg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants outstanding, ending balance">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z5eiwsHAgBoh" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants outstanding, ending balance">87,500</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z2KaL2aRhJ9e" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants outstanding, ending balance">88.6</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_ziC9jWbqiksg" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants outstanding, ending balance">87,500</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zbI297c0Ydyf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants outstanding, ending balance">88.6</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt; text-indent: -8.1pt; padding-left: 8.1pt">Warrants exercisable as of August 31</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_d0_c20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zJpk2wG0d7u8" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--WeightedAverageExercisePriceWarrantsExercisable_iI_d0_c20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zXSu0jo1Ulu9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, warrants exercisable">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zodeKPStZEDf" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable">87,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--WeightedAverageExercisePriceWarrantsExercisable_iI_c20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zSlPEJMqXZZ4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, warrants exercisable">88.6</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zRv5ZXdapHNi" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable">87,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--WeightedAverageExercisePriceWarrantsExercisable_iI_c20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z3qpfUHjwVp5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, warrants exercisable">88.6</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CNBX_Warrant1Member', window );">Warrant 1 [Member]</a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_ScheduleOfAssumptionsUsedWarrantsTableTextBlock', window );">Schedule of assumptions</a></td> <td class="text"><table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfAssumptionsUsedWarrantsTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zVElxf5u2a8b" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details - Fair value)"> <tr style="vertical-align: bottom"> <td> </td> <td><span id="xdx_8BA_zJm3qkZpcmnd" style="display: none">Schedule of assumptions</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 4%"> </td> <td style="width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PV of exercise Share price</span></td> <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_909_eus-gaap--SharePrice_iI_c20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_z1BT0cHaYSe" title="PV of exercise Share price">1</span></span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Volatility</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20180923__20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zeTBcoOuuMM3" title="Expected Volatility">102.0</span>%</span></td></tr> <tr style="vertical-align: bottom"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Free Interest Rate</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20180923__20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zdNvz4JpueA9" title="Risk Free Interest Rate">1.58</span>%</span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Term (years)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180923__20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zFtOmMqNY6ni" title="Expected Term (years)">5</span></span></td></tr> <tr style="vertical-align: bottom"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Dividend Yield</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20180923__20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zrFEQSaMlp2f" title="Expected Dividend Yield">0</span>%</span></td></tr> </table> <span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CNBX_Warrant2Member', window );">Warrant 2 [Member]</a></td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_ScheduleOfAssumptionsUsedWarrantsTableTextBlock', window );">Schedule of assumptions</a></td> <td class="text"><table cellpadding="0" cellspacing="0" id="xdx_891_ecustom--ScheduleOfAssumptionsUsedWarrantsTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zVngV2lP0uHc" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details - Fair Value)"> <tr style="vertical-align: bottom"> <td> </td> <td><span id="xdx_8B4_zxXZSpwzzkcb" style="display: none">Schedule of assumptions</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 4%"> </td> <td style="width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PV of exercise Share price</span></td> <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_902_eus-gaap--SharePrice_iI_c20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zNnoDkT6AMg6" title="PV of exercise Share price">0.50</span></span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Volatility</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20201215__20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_z9rpupLhw5Pi" title="Expected Volatility">117.0</span>%</span></td></tr> <tr style="vertical-align: bottom"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Free Interest Rate</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20201215__20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zFW1J9F73Pai" title="Risk Free Interest Rate">0.3</span>%</span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Term (years)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201215__20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zWx6JIt6RCIk" title="Expected Term (years)">3</span></span></td></tr> <tr style="vertical-align: bottom"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Dividend Yield</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20201215__20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_z1t4FU9U4YTg" title="Expected Dividend Yield">0</span>%</span></td></tr> </table> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CNBX_ScheduleOfAssumptionsUsedWarrantsTableTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">CNBX_ScheduleOfAssumptionsUsedWarrantsTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>CNBX_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CNBX_Warrant1Member"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CNBX_Warrant1Member</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CNBX_Warrant2Member"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CNBX_Warrant2Member</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>46 <FILENAME>R22.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164538190736"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr><th class="th"><div>Aug. 31, 2023</div></th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective income tax rate</a></td> <td class="text"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zgJhIPUIx80h" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - rate)"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span id="xdx_8B3_zIUTlIVUkQld" style="display: none">Schedule of effective income tax rate</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the Year Ended August 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">United States statutory corporate income tax rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20220901__20230831_zgUCWK1I3kf3" title="United States statutory corporate income tax rate">21.0</span>%</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20210901__20220831_zcgx2Vc0gNNg" title="United States statutory corporate income tax rate">21.0</span>%</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance on deferred tax assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_dpi_c20220901__20230831_zkaxt4a8l7n8" title="Change in valuation allowance on deferred tax assets">-21.0</span>%</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_dpi_c20210901__20220831_z5CA2HrvbqT2" title="Change in valuation allowance on deferred tax assets">-21.0</span>%</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Provision for income tax</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_c20220901__20230831_zxxUW2CdrBk9" title="Provision for income tax">–</span>%</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_c20210901__20220831_zHpoAhLh1rGe" title="Provision for income tax">–</span>%</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred income tax assets</a></td> <td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z1ZUhSk2ZSCa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - Deferred tax assets)"> <tr style="vertical-align: bottom"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt"><span id="xdx_8B4_zPcrQ0cK8JN" style="display: none">Schedule of deferred income tax assets</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">August 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">US Deferred income tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left; text-indent: -10pt; padding-left: 20pt">Net operating loss carry forwards benefit</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zL2THumqnoB8" style="width: 13%; text-align: right" title="Net operating loss carry forwards benefit">3,035,360</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20220831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zsvNG3u0AbS8" style="width: 13%; text-align: right" title="Net operating loss carry forwards benefit">2,576,499</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_z2l0hHKoX0m7" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance">(3,035,360</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20220831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_ze0UGwNCVW1l" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance">(2,576,499</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred income tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zbfmrgAccXf7" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred income tax assets">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20220831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zmd25C1Dq17h" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred income tax assets">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Outside US Deferred income tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Net operating loss carry forwards benefit</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zfbtDPbtDuhc" style="text-align: right" title="Net operating loss carry forwards benefit">2,949,564</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20220831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zeRbYqhNeJ5a" style="text-align: right" title="Net operating loss carry forwards benefit">2,804,533</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_z5Yaff7ccvAa" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance">(2,949,564</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20220831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zotbNCzvpek5" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance">(2,804,533</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_ze0pP0JQLpR2" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred income tax assets">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20220831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_z9yT8Dxhjv27" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred income tax assets">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">August 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Consolidated Deferred income tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left; text-indent: -10pt; padding-left: 20pt">Net operating loss carry forwards benefit</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20230831_zNA5yXQdBTR5" style="width: 13%; text-align: right" title="Net operating loss carry forwards benefit">5,984,924</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20220831_z9pIXewBhq1b" style="width: 13%; text-align: right" title="Net operating loss carry forwards benefit">5,381,031</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20230831_zFnddgNEVW1" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance">(5,984,924</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20220831_z0c7kaHproCf" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance">(5,381,031</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred income tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20230831_zLiITVuvgLsj" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred income tax assets">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20220831_zD5iUELuuZO4" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred income tax assets">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>47 <FILENAME>R23.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164535189936"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General & administrate expenses (Tables)<br></strong></div></th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr><th class="th"><div>Aug. 31, 2023</div></th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of general and administrative expenses</a></td> <td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_z7aDLip9uSh7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - General and administrative expenses (Details)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B7_zkRRd1cSq0M4" style="display: none">Schedule of general and administrative expenses</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20220901__20230831_zxT46YnSOUdl" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20210901__20220831_zf7V85Xymjh3" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">For the year Ended<br/> August 31,<br/> 2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">For the year Ended<br/> August 31,<br/> 2022</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40C_eus-gaap--LaborAndRelatedExpense_maGAAEzYXX_z4LoQHdGhQd7" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Salaries and related expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">461,375</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">379,618</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_maGAAEzYXX_zCiYWpWnW9Ha" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Share based payment to related parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">180,480</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">728,870</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LegalFees_maGAAEzYXX_zjhvfrsiVoFl" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Legal and professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">149,108</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">443,851</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--GeneralInsuranceExpense_maGAAEzYXX_zowgSWKhZyul" style="vertical-align: bottom; background-color: White"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">68,278</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">93,192</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--MarketingExpense_maGAAEzYXX_zDUSeKr4zPYc" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Marketing expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,223</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,977</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OtherGeneralExpense_maGAAEzYXX_zKsXhX5atAyh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Other expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">49,516</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">139,139</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--GeneralAndAdministrativeExpense_iT_pp0p0_mtGAAEzYXX_zOpDmNcV0xQb" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"><b style="display: none">Total general and administrative expenses</b></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">909,980</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,800,647</td><td style="padding-bottom: 2.5pt; text-align: left">*</td></tr> </table><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>48 <FILENAME>R24.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164535276416"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial (Income) expenses (Tables)<br></strong></div></th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr><th class="th"><div>Aug. 31, 2023</div></th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_ScheduleOfFinancialIncomeExpensesTableTextBlock', window );">Schedule of financial income expenses</a></td> <td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--ScheduleOfFinancialIncomeExpensesTableTextBlock_zGwZfD6rIcA4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Financial (Income) expenses (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span id="xdx_8B9_znjXAsjDcYD4" style="display: none">Schedule of financial income expenses</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_492_20220901__20230831_zUcrKjMH1kEc" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_498_20210901__20220831_zGuGRyJHAW3g" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">For the year<br/> Ended<br/> August 31, 2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">For the year<br/> Ended<br/> August 31, 2022</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_eus-gaap--InterestExpenseBorrowings_i_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Interest and bank charges</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,174</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,273</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--LossGainFromConvertibleLoanValuation_zuBlVcyCiO82" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Loss (Gain) from convertible loan valuation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54,810</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">722,236</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt; text-align: left">Currency exchange differences loss (profit)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,361</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">58,571</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OtherNonoperatingIncomeExpense_pp0p0_zSZgT9dfWBe5" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><b style="display: none">Total other income expenses</b></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">52,623</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">782,080</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CNBX_ScheduleOfFinancialIncomeExpensesTableTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">CNBX_ScheduleOfFinancialIncomeExpensesTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>CNBX_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>49 <FILENAME>R25.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164540684576"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business, Presentation and Going Concern (Details Narrative) - USD ($)<br></strong></div></th> <th class="th" colspan="2">12 Months Ended</th> </tr> <tr> <th class="th"><div>Aug. 31, 2023</div></th> <th class="th"><div>Aug. 31, 2022</div></th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td> <td class="nump">$ 3,710,234<span></span> </td> <td class="nump">$ 3,723,250<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Cumulative losses</a></td> <td class="nump">$ 24,259,202<span></span> </td> <td class="nump">$ 20,548,968<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>50 <FILENAME>R26.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164536518192"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th> <th class="th" colspan="2">12 Months Ended</th> </tr> <tr> <th class="th"><div>Aug. 31, 2023</div></th> <th class="th"><div>Aug. 31, 2022</div></th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Federal deposit insurance</a></td> <td class="nump">$ 250,000<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td> <td class="nump">162,061<span></span> </td> <td class="nump">$ 198,527<span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedAtFairValue', window );">Fair value of financial instruments</a></td> <td class="nump">0<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedAtFairValue', window );">Fair value of financial instruments</a></td> <td class="nump">$ 1,343,584<span></span> </td> <td class="text"> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PlatformOperatorCryptoAssetLineItems"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">srt_PlatformOperatorCryptoAssetLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>srt_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_Depreciation</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsOwnedAtFairValue"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value as of the balance sheet date of financial instruments and other positions owned by the entity including: (1) mortgages, mortgage-backed and asset backed securities; (2) US government and agency obligations; (3) state and municipal government obligations; (4) other sovereign government debt; (5) corporate obligations; (6) corporate equities; (7) principal investments; (8) derivative contracts; and (9) physical commodities. Includes both pledged and unpledged holdings.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481961/940-320-45-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FinancialInstrumentsOwnedAtFairValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>51 <FILENAME>R27.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164533699744"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative) - USD ($)<br></strong></div></th> <th class="th" colspan="2">12 Months Ended</th> </tr> <tr> <th class="th"><div>Aug. 31, 2023</div></th> <th class="th"><div>Aug. 31, 2022</div></th> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember', window );">Chief Financial Officer [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation paid</a></td> <td class="nump">$ 40,321<span></span> </td> <td class="nump">$ 75,318<span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CNBX_CEOAndChairmanMember', window );">C E O And Chairman [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation paid</a></td> <td class="nump">79,100<span></span> </td> <td class="nump">334,395<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrentAndNoncurrent', window );">Accrued salaries</a></td> <td class="nump">416,497<span></span> </td> <td class="nump">196,687<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Outstanding payable</a></td> <td class="nump">613,184<span></span> </td> <td class="nump">196,687<span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CNBX_ThreeDirectorsMember', window );">Three Directors [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrentAndNoncurrent', window );">Accrued salaries</a></td> <td class="nump">43,000<span></span> </td> <td class="nump">36,000<span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CNBX_CannabicsIncMember', window );">Cannabics Inc [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_DueToRelatedPartiesCurrent1', window );">Due to related parties</a></td> <td class="nump">223,645<span></span> </td> <td class="nump">223,645<span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CNBX_ChairmanAndBoardMembersMember', window );">Chairman And Board Members [Member] | Share Based Payment [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non cash expense</a></td> <td class="nump">$ 168,551<span></span> </td> <td class="nump">$ 670,850<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CNBX_DueToRelatedPartiesCurrent1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">CNBX_DueToRelatedPartiesCurrent1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>CNBX_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrentAndNoncurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrentAndNoncurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OfficersCompensation</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CNBX_CEOAndChairmanMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CNBX_CEOAndChairmanMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CNBX_ThreeDirectorsMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CNBX_ThreeDirectorsMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CNBX_CannabicsIncMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CNBX_CannabicsIncMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CNBX_ChairmanAndBoardMembersMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CNBX_ChairmanAndBoardMembersMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionTypeAxis=CNBX_ShareBasedPaymentMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NonmonetaryTransactionTypeAxis=CNBX_ShareBasedPaymentMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>52 <FILENAME>R28.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164536481248"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative)<br></strong></div></th> <th class="th"> <div>Aug. 31, 2023 </div> <div>USD ($)</div> </th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BankAcceptancesExecuted', window );">Bank guarantee</a></td> <td class="nump">$ 5,000<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BankAcceptancesExecuted"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the financial institution's obligation to pay the holder of the customer's draft which the financial institution has guaranteed (i.e., Banker's Acceptance).</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.14)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_BankAcceptancesExecuted</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>53 <FILENAME>R29.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164533354944"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders’ Equity (Deficit) (Details Narrative) - USD ($)<br></strong></div></th> <th class="th" colspan="1"></th> <th class="th" colspan="1"></th> <th class="th" colspan="1"></th> <th class="th" colspan="1"></th> <th class="th" colspan="1"></th> <th class="th" colspan="1"></th> <th class="th" colspan="1"></th> <th class="th" colspan="1"></th> <th class="th" colspan="1">3 Months Ended</th> <th class="th" colspan="2">12 Months Ended</th> </tr> <tr> <th class="th"><div>Jun. 12, 2023</div></th> <th class="th"><div>Jun. 15, 2022</div></th> <th class="th"><div>May 12, 2022</div></th> <th class="th"><div>Mar. 16, 2022</div></th> <th class="th"><div>Apr. 23, 2021</div></th> <th class="th"><div>Feb. 22, 2021</div></th> <th class="th"><div>Dec. 21, 2020</div></th> <th class="th"><div>Dec. 16, 2020</div></th> <th class="th"><div>Mar. 31, 2023</div></th> <th class="th"><div>Aug. 31, 2023</div></th> <th class="th"><div>Aug. 31, 2022</div></th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">900,000,000<span></span> </td> <td class="nump">900,000,000<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 0.0001<span></span> </td> <td class="nump">$ 0.0001<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">5,000,000<span></span> </td> <td class="nump">5,000,000<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 0.0001<span></span> </td> <td class="nump">$ 0.0001<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stock split</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text">1:120<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Stock issued for exercise of convertible debt, value</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 569,930<span></span> </td> <td class="nump">$ 225,286<span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=CNBX_SeniorSecuredNoteMember', window );">Senior Secured Note [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotesCurrent', window );">Senior secured note</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 1,375,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 2,750,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Original issue discount percentage</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">10.00%<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_WarrantsIssued', window );">Warrants issued</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">45,833<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 60<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=CNBX_DemandNoteMember', window );">Demand Note [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 280,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_OriginalIssueDiscount', window );">Original issue discount</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 40,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CNBX_InitialNoteMember', window );">Initial Note [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Notes payable</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 825,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized Discount</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 75,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CNBX_SecondNoteMember', window );">Second Note [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Notes payable</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 550,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized Discount</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 50,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CNBX_NoteMember', window );">Note [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Notes payable</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 1,375,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized Discount</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 125,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CNBX_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt', window );">Senior convertible notes issued</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 2,750,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceIncrease', window );">Conversion price</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 42<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceDecrease', window );">Lower conversion price</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 42<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td> <td class="nump">5.00%<span></span> </td> <td class="nump">9.00%<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">18.00%<span></span> </td> <td class="nump">5.00%<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td> <td class="nump">$ 65,000<span></span> </td> <td class="nump">$ 154,250<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 35,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOtherLongTermDebt', window );">Net of issuance expenses</a></td> <td class="nump">$ 65,000<span></span> </td> <td class="nump">$ 154,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 35,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Convertible shares</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">21,372,693<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Stock issued for exercise of convertible debt, value</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 569,930<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor [Member] | Common Stock [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Convertible shares</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">32,614<span></span> </td> <td class="text"> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CNBX_OriginalIssueDiscount"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">CNBX_OriginalIssueDiscount</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>CNBX_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CNBX_WarrantsIssued"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">CNBX_WarrantsIssued</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>CNBX_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConvertibleConversionPriceDecrease"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in conversion price of convertible common stock. Excludes change due to standard antidilution provision.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockConvertibleConversionPriceDecrease</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConvertibleConversionPriceIncrease"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in conversion price of convertible common stock. Excludes change due to standard antidilution provision.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockConvertibleConversionPriceIncrease</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOtherLongTermDebt"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense incurred on long-term debt classified as other, including, but not limited to, interest on long-term notes and amortization of issuance costs.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_InterestExpenseOtherLongTermDebt</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotesCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term notes having the highest claim on the assets of the issuer in case of bankruptcy or liquidation, due within one year or the normal operating cycle, if longer. Senior note holders are paid off in full before any payments are made to debt holders having a lesser priority of repayment.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SeniorNotesCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=CNBX_SeniorSecuredNoteMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=CNBX_SeniorSecuredNoteMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=CNBX_DemandNoteMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=CNBX_DemandNoteMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CNBX_InitialNoteMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CNBX_InitialNoteMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CNBX_SecondNoteMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CNBX_SecondNoteMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CNBX_NoteMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CNBX_NoteMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CNBX_SecuritiesPurchaseAgreementMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CNBX_SecuritiesPurchaseAgreementMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>54 <FILENAME>R30.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164536660784"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants (Details - Fair value) - Warrant 1 [Member]<br></strong></div></th> <th class="th"> <div>Sep. 24, 2018 </div> <div>$ / shares</div> </th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">PV of exercise Share price</a></td> <td class="nump">$ 1<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td> <td class="nump">102.00%<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Interest Rate</a></td> <td class="nump">1.58%<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term (years)</a></td> <td class="text">5 years<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected Dividend Yield</a></td> <td class="nump">0.00%<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SharePrice</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CNBX_Warrant1Member"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CNBX_Warrant1Member</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>55 <FILENAME>R31.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164533287104"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants (Details - Fair Value) - Warrant 2 [Member]<br></strong></div></th> <th class="th"> <div>Dec. 16, 2020 </div> <div>$ / shares</div> </th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">PV of exercise Share price</a></td> <td class="nump">$ 0.50<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td> <td class="nump">117.00%<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Interest Rate</a></td> <td class="nump">0.30%<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term (years)</a></td> <td class="text">3 years<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected Dividend Yield</a></td> <td class="nump">0.00%<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SharePrice</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CNBX_Warrant2Member"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CNBX_Warrant2Member</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>56 <FILENAME>R32.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164534907024"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details - Warrant activity) - Warrants [Member] - $ / shares<br></strong></div></th> <th class="th" colspan="3">12 Months Ended</th> </tr> <tr> <th class="th"><div>Aug. 31, 2023</div></th> <th class="th"><div>Aug. 31, 2022</div></th> <th class="th"><div>Aug. 31, 2021</div></th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance</a></td> <td class="nump">87,500<span></span> </td> <td class="nump">87,500<span></span> </td> <td class="nump">41,667<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price, warrants outstanding, beginning balance</a></td> <td class="nump">$ 88.6<span></span> </td> <td class="nump">$ 88.6<span></span> </td> <td class="nump">$ 120<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_WarrantsIssued', window );">Warrants issued</a></td> <td class="nump">0<span></span> </td> <td class="nump">0<span></span> </td> <td class="nump">45,667<span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_WeightedAverageExercisePriceWarrantsIssued', window );">Weighted average exercise price, warrants issued</a></td> <td class="nump">$ 0<span></span> </td> <td class="nump">$ 0<span></span> </td> <td class="nump">$ 60<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td> <td class="nump">0<span></span> </td> <td class="nump">0<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_WeightedAverageExercisePriceWarrantsExercised', window );">Weighted average exercise price, warrants exercised</a></td> <td class="nump">$ 0<span></span> </td> <td class="nump">$ 0<span></span> </td> <td class="nump">$ 0<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Warrants expired</a></td> <td class="num">(87,500)<span></span> </td> <td class="nump">0<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_WeightedAverageExercisePriceWarrantsExpired', window );">Weighted average exercise price, warrants expired</a></td> <td class="nump">$ 88.6<span></span> </td> <td class="nump">$ 0<span></span> </td> <td class="nump">$ 0<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance</a></td> <td class="nump">0<span></span> </td> <td class="nump">87,500<span></span> </td> <td class="nump">87,500<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price, warrants outstanding, ending balance</a></td> <td class="nump">$ 0<span></span> </td> <td class="nump">$ 88.6<span></span> </td> <td class="nump">$ 88.6<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber', window );">Warrants exercisable</a></td> <td class="nump">0<span></span> </td> <td class="nump">87,500<span></span> </td> <td class="nump">87,500<span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_WeightedAverageExercisePriceWarrantsExercisable', window );">Weighted average exercise price, warrants exercisable</a></td> <td class="nump">$ 0<span></span> </td> <td class="nump">$ 88.6<span></span> </td> <td class="nump">$ 88.6<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CNBX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">CNBX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>CNBX_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CNBX_WarrantsIssued"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">CNBX_WarrantsIssued</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>CNBX_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CNBX_WeightedAverageExercisePriceWarrantsExercisable"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">CNBX_WeightedAverageExercisePriceWarrantsExercisable</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>CNBX_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CNBX_WeightedAverageExercisePriceWarrantsExercised"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">CNBX_WeightedAverageExercisePriceWarrantsExercised</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>CNBX_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CNBX_WeightedAverageExercisePriceWarrantsExpired"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">CNBX_WeightedAverageExercisePriceWarrantsExpired</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>CNBX_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CNBX_WeightedAverageExercisePriceWarrantsIssued"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">CNBX_WeightedAverageExercisePriceWarrantsIssued</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>CNBX_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CNBX_WarrantsMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CNBX_WarrantsMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>57 <FILENAME>R33.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164536604880"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants (Details Narrative) - USD ($)<br></strong></div></th> <th class="th"><div>Dec. 16, 2020</div></th> <th class="th"><div>Sep. 24, 2018</div></th> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CNBX_Warrant1Member', window );">Warrant 1 [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_WarrantsIssuedShares', window );">Warrants issued, shares</a></td> <td class="text"> <span></span> </td> <td class="nump">41,667<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry date</a></td> <td class="text"> <span></span> </td> <td class="text">Aug. 24, 2023<span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_FairValueOfWarrantsIssued', window );">Fair value of warrants issued</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 2,784,387<span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CNBX_Warrant2Member', window );">Warrant 2 [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_WarrantsIssuedShares', window );">Warrants issued, shares</a></td> <td class="nump">45,667<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry date</a></td> <td class="text">Aug. 24, 2023<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_FairValueOfWarrantsIssued', window );">Fair value of warrants issued</a></td> <td class="nump">$ 515,818<span></span> </td> <td class="text"> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CNBX_FairValueOfWarrantsIssued"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">CNBX_FairValueOfWarrantsIssued</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>CNBX_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CNBX_WarrantsIssuedShares"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">CNBX_WarrantsIssuedShares</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>CNBX_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:dateItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CNBX_Warrant1Member"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CNBX_Warrant1Member</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CNBX_Warrant2Member"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CNBX_Warrant2Member</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>58 <FILENAME>R34.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164539356736"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details - rate)<br></strong></div></th> <th class="th" colspan="2">12 Months Ended</th> </tr> <tr> <th class="th"><div>Aug. 31, 2023</div></th> <th class="th"><div>Aug. 31, 2022</div></th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">United States statutory corporate income tax rate</a></td> <td class="nump">21.00%<span></span> </td> <td class="nump">21.00%<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance on deferred tax assets</a></td> <td class="num">(21.00%)<span></span> </td> <td class="num">(21.00%)<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision for income tax</a></td> <td class="nump">0.00%<span></span> </td> <td class="nump">0.00%<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>59 <FILENAME>R35.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164533745216"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details - Deferred tax assets) - USD ($)<br></strong></div></th> <th class="th"><div>Aug. 31, 2023</div></th> <th class="th"><div>Aug. 31, 2022</div></th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forwards benefit</a></td> <td class="nump">$ 5,984,924<span></span> </td> <td class="nump">$ 5,381,031<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td> <td class="num">(5,984,924)<span></span> </td> <td class="num">(5,381,031)<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred income tax assets</a></td> <td class="nump">0<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forwards benefit</a></td> <td class="nump">3,035,360<span></span> </td> <td class="nump">2,576,499<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td> <td class="num">(3,035,360)<span></span> </td> <td class="num">(2,576,499)<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred income tax assets</a></td> <td class="nump">0<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forwards benefit</a></td> <td class="nump">2,949,564<span></span> </td> <td class="nump">2,804,533<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td> <td class="num">(2,949,564)<span></span> </td> <td class="num">(2,804,533)<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred income tax assets</a></td> <td class="nump">$ 0<span></span> </td> <td class="nump">$ 0<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>60 <FILENAME>R36.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164534956016"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br></strong></div></th> <th class="th" colspan="2">12 Months Ended</th> </tr> <tr> <th class="th"><div>Aug. 31, 2023</div></th> <th class="th"><div>Aug. 31, 2022</div></th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective tax rate</a></td> <td class="nump">21.00%<span></span> </td> <td class="nump">21.00%<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td> <td class="nump">$ 24,259,202<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in valuation allowance</a></td> <td class="nump">603,893<span></span> </td> <td class="nump">$ 1,055,107<span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember', window );">Israel Tax Authority [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td> <td class="nump">$ 12,593,815<span></span> </td> <td class="nump">12,373,689<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Effective tax rate, Israel</a></td> <td class="nump">23.00%<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective tax rate</a></td> <td class="nump">21.00%<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=CNBX_UnitedStates1Member', window );">United States [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td> <td class="nump">$ 1,848,572<span></span> </td> <td class="nump">$ 903,813<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=CNBX_UnitedStates1Member"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=CNBX_UnitedStates1Member</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>61 <FILENAME>R37.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164534951968"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital loss (Details Narrative)<br></strong></div></th> <th class="th"> <div>Dec. 09, 2022 </div> <div>USD ($)</div> </th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_DisclosureCapitalLossAbstract', window );"><strong>Capital Loss</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale consideration</a></td> <td class="nump">$ 24,200<span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_CapitalLoss', window );">Capital loss</a></td> <td class="nump">$ 2,726,231<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CNBX_CapitalLoss"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">CNBX_CapitalLoss</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>CNBX_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CNBX_DisclosureCapitalLossAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">CNBX_DisclosureCapitalLossAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>CNBX_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>62 <FILENAME>R38.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164536523424"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and administrative expenses (Details) - USD ($)<br></strong></div></th> <th class="th" colspan="2">12 Months Ended</th> </tr> <tr> <th class="th"><div>Aug. 31, 2023</div></th> <th class="th"><div>Aug. 31, 2022</div></th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and related expenses</a></td> <td class="nump">$ 461,375<span></span> </td> <td class="nump">$ 379,618<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based payment to related parties</a></td> <td class="nump">180,480<span></span> </td> <td class="nump">728,870<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal and professional fees</a></td> <td class="nump">149,108<span></span> </td> <td class="nump">443,851<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralInsuranceExpense', window );">Insurance</a></td> <td class="nump">68,278<span></span> </td> <td class="nump">93,192<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketingExpense', window );">Marketing expenses</a></td> <td class="nump">1,223<span></span> </td> <td class="nump">15,977<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralExpense', window );">Other expenses</a></td> <td class="nump">49,516<span></span> </td> <td class="nump">139,139<span></span> </td> </tr> <tr class="rou"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td> <td class="nump">$ 909,980<span></span> </td> <td class="nump">$ 1,800,647<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralInsuranceExpense"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales).</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_GeneralInsuranceExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LegalFees</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingExpense"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_MarketingExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralExpense"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general expenses not normally included in Other Operating Costs and Expenses.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherGeneralExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>63 <FILENAME>R39.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140164535821024"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial (Income) expenses (Details) - USD ($)<br></strong></div></th> <th class="th" colspan="2">12 Months Ended</th> </tr> <tr> <th class="th"><div>Aug. 31, 2023</div></th> <th class="th"><div>Aug. 31, 2022</div></th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseBorrowings', window );">Interest and bank charges</a></td> <td class="nump">$ 1,174<span></span> </td> <td class="nump">$ 1,273<span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CNBX_LossGainFromConvertibleLoanValuation', window );">Loss (Gain) from convertible loan valuation</a></td> <td class="nump">54,810<span></span> </td> <td class="nump">722,236<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Currency exchange differences loss (profit)</a></td> <td class="num">(3,361)<span></span> </td> <td class="nump">58,571<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income expenses</a></td> <td class="nump">$ 52,623<span></span> </td> <td class="nump">$ 782,080<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CNBX_LossGainFromConvertibleLoanValuation"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">CNBX_LossGainFromConvertibleLoanValuation</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>CNBX_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseBorrowings"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of interest expense on all borrowings.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.7,8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_InterestExpenseBorrowings</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>64 <FILENAME>cnbx_i10k-083123_htm.xml <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <XML> <?xml version="1.0" encoding="utf-8"?> <xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:CNBX="http://cnbxpharma.com/20230831" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"> <link:schemaRef xlink:href="cnbx-20230831.xsd" xlink:type="simple"/> <context id="From2022-09-01to2023-08-31"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> </entity> <period> <startDate>2022-09-01</startDate> <endDate>2023-08-31</endDate> </period> </context> <context id="AsOf2023-08-31"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> </entity> <period> <instant>2023-08-31</instant> </period> </context> <context id="AsOf2023-11-29"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> </entity> <period> <instant>2023-11-29</instant> </period> </context> <context id="AsOf2022-08-31"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> </entity> <period> <instant>2022-08-31</instant> </period> </context> <context id="From2021-09-012022-08-31"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> </entity> <period> <startDate>2021-09-01</startDate> <endDate>2022-08-31</endDate> </period> </context> <context id="AsOf2021-08-31"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> </entity> <period> <instant>2021-08-31</instant> </period> </context> <context id="AsOf2021-08-31_us-gaap_CommonStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-08-31</instant> </period> </context> <context id="AsOf2021-08-31_us-gaap_AdditionalPaidInCapitalMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-08-31</instant> </period> </context> <context id="AsOf2021-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-08-31</instant> </period> </context> <context id="AsOf2021-08-31_custom_WarrantsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CNBX:WarrantsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-08-31</instant> </period> </context> <context id="AsOf2021-08-31_us-gaap_RetainedEarningsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-08-31</instant> </period> </context> <context id="AsOf2022-08-31_us-gaap_CommonStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-08-31</instant> </period> </context> <context id="AsOf2022-08-31_us-gaap_AdditionalPaidInCapitalMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-08-31</instant> </period> </context> <context id="AsOf2022-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-08-31</instant> </period> </context> <context id="AsOf2022-08-31_custom_WarrantsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CNBX:WarrantsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-08-31</instant> </period> </context> <context id="AsOf2022-08-31_us-gaap_RetainedEarningsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-08-31</instant> </period> </context> <context id="From2021-09-012022-08-31_us-gaap_CommonStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-09-01</startDate> <endDate>2022-08-31</endDate> </period> </context> <context id="From2021-09-012022-08-31_us-gaap_AdditionalPaidInCapitalMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-09-01</startDate> <endDate>2022-08-31</endDate> </period> </context> <context id="From2021-09-012022-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-09-01</startDate> <endDate>2022-08-31</endDate> </period> </context> <context id="From2021-09-012022-08-31_custom_WarrantsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CNBX:WarrantsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-09-01</startDate> <endDate>2022-08-31</endDate> </period> </context> <context id="From2021-09-012022-08-31_us-gaap_RetainedEarningsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-09-01</startDate> <endDate>2022-08-31</endDate> </period> </context> <context id="From2022-09-012023-08-31_us-gaap_CommonStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-09-01</startDate> <endDate>2023-08-31</endDate> </period> </context> <context id="From2022-09-012023-08-31_us-gaap_AdditionalPaidInCapitalMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-09-01</startDate> <endDate>2023-08-31</endDate> </period> </context> <context id="From2022-09-012023-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-09-01</startDate> <endDate>2023-08-31</endDate> </period> </context> <context id="From2022-09-012023-08-31_custom_WarrantsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CNBX:WarrantsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-09-01</startDate> <endDate>2023-08-31</endDate> </period> </context> <context id="From2022-09-012023-08-31_us-gaap_RetainedEarningsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-09-01</startDate> <endDate>2023-08-31</endDate> </period> </context> <context id="AsOf2023-08-31_us-gaap_CommonStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2023-08-31</instant> </period> </context> <context id="AsOf2023-08-31_us-gaap_AdditionalPaidInCapitalMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2023-08-31</instant> </period> </context> <context id="AsOf2023-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2023-08-31</instant> </period> </context> <context id="AsOf2023-08-31_custom_WarrantsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CNBX:WarrantsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2023-08-31</instant> </period> </context> <context id="AsOf2023-08-31_us-gaap_RetainedEarningsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2023-08-31</instant> </period> </context> <context id="AsOf2023-08-31_us-gaap_FairValueInputsLevel1Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </segment> </entity> <period> <instant>2023-08-31</instant> </period> </context> <context id="AsOf2023-08-31_us-gaap_FairValueInputsLevel3Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </segment> </entity> <period> <instant>2023-08-31</instant> </period> </context> <context id="From2022-09-012023-08-31_custom_CEOAndChairmanMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CNBX:CEOAndChairmanMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-09-01</startDate> <endDate>2023-08-31</endDate> </period> </context> <context id="From2021-09-012022-08-31_custom_CEOAndChairmanMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CNBX:CEOAndChairmanMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-09-01</startDate> <endDate>2022-08-31</endDate> </period> </context> <context id="AsOf2023-08-31_custom_CEOAndChairmanMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CNBX:CEOAndChairmanMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2023-08-31</instant> </period> </context> <context id="AsOf2022-08-31_custom_CEOAndChairmanMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CNBX:CEOAndChairmanMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-08-31</instant> </period> </context> <context id="From2022-09-012023-08-31_srt_ChiefFinancialOfficerMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-09-01</startDate> <endDate>2023-08-31</endDate> </period> </context> <context id="From2021-09-012022-08-31_srt_ChiefFinancialOfficerMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-09-01</startDate> <endDate>2022-08-31</endDate> </period> </context> <context id="AsOf2023-08-31_custom_ThreeDirectorsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CNBX:ThreeDirectorsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2023-08-31</instant> </period> </context> <context id="AsOf2022-08-31_custom_ThreeDirectorsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CNBX:ThreeDirectorsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-08-31</instant> </period> </context> <context id="AsOf2023-08-31_custom_CannabicsIncMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CNBX:CannabicsIncMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2023-08-31</instant> </period> </context> <context id="AsOf2022-08-31_custom_CannabicsIncMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CNBX:CannabicsIncMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-08-31</instant> </period> </context> <context id="From2022-09-012023-08-31_custom_ShareBasedPaymentMember_custom_ChairmanAndBoardMembersMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">CNBX:ShareBasedPaymentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CNBX:ChairmanAndBoardMembersMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-09-01</startDate> <endDate>2023-08-31</endDate> </period> </context> <context id="From2021-09-012022-08-31_custom_ShareBasedPaymentMember_custom_ChairmanAndBoardMembersMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">CNBX:ShareBasedPaymentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CNBX:ChairmanAndBoardMembersMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-09-01</startDate> <endDate>2022-08-31</endDate> </period> </context> <context id="From2022-05-112022-05-12"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> </entity> <period> <startDate>2022-05-11</startDate> <endDate>2022-05-12</endDate> </period> </context> <context id="From2022-09-012023-08-31_us-gaap_InvestorMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-09-01</startDate> <endDate>2023-08-31</endDate> </period> </context> <context id="From2020-12-152020-12-16_custom_SecuritiesPurchaseAgreementMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CNBX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-12-15</startDate> <endDate>2020-12-16</endDate> </period> </context> <context id="From2020-12-202020-12-21_custom_InitialNoteMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CNBX:InitialNoteMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-12-20</startDate> <endDate>2020-12-21</endDate> </period> </context> <context id="From2021-02-212021-02-22_custom_SecondNoteMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CNBX:SecondNoteMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-02-21</startDate> <endDate>2021-02-22</endDate> </period> </context> <context id="From2021-04-222021-04-23_custom_NoteMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CNBX:NoteMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-04-22</startDate> <endDate>2021-04-23</endDate> </period> </context> <context id="AsOf2020-12-21_custom_InitialNoteMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CNBX:InitialNoteMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-12-21</instant> </period> </context> <context id="AsOf2021-02-22_custom_SecondNoteMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CNBX:SecondNoteMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-02-22</instant> </period> </context> <context id="AsOf2021-04-23_custom_NoteMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CNBX:NoteMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-04-23</instant> </period> </context> <context id="From2022-09-012023-08-31_us-gaap_InvestorMember_us-gaap_CommonStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-09-01</startDate> <endDate>2023-08-31</endDate> </period> </context> <context id="AsOf2021-04-23_custom_SeniorSecuredNoteMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">CNBX:SeniorSecuredNoteMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-04-23</instant> </period> </context> <context id="From2021-04-222021-04-23_custom_SeniorSecuredNoteMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">CNBX:SeniorSecuredNoteMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-04-22</startDate> <endDate>2021-04-23</endDate> </period> </context> <context id="AsOf2022-03-16_custom_DemandNoteMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">CNBX:DemandNoteMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-03-16</instant> </period> </context> <context id="From2022-03-152022-03-16_custom_DemandNoteMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">CNBX:DemandNoteMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-03-15</startDate> <endDate>2022-03-16</endDate> </period> </context> <context id="AsOf2022-06-15_custom_SecuritiesPurchaseAgreementMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CNBX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-06-15</instant> </period> </context> <context id="From2022-06-142022-06-15_custom_SecuritiesPurchaseAgreementMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CNBX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-06-14</startDate> <endDate>2022-06-15</endDate> </period> </context> <context id="AsOf2023-03-31_custom_SecuritiesPurchaseAgreementMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CNBX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2023-03-31</instant> </period> </context> <context id="From2023-01-012023-03-31_custom_SecuritiesPurchaseAgreementMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CNBX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2023-01-01</startDate> <endDate>2023-03-31</endDate> </period> </context> <context id="AsOf2023-06-12_custom_SecuritiesPurchaseAgreementMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CNBX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2023-06-12</instant> </period> </context> <context id="From2023-06-112023-06-12_custom_SecuritiesPurchaseAgreementMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CNBX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2023-06-11</startDate> <endDate>2023-06-12</endDate> </period> </context> <context id="AsOf2018-09-24_custom_Warrant1Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CNBX:Warrant1Member</xbrldi:explicitMember> </segment> </entity> <period> <instant>2018-09-24</instant> </period> </context> <context id="AsOf2020-12-16_custom_Warrant2Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CNBX:Warrant2Member</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-12-16</instant> </period> </context> <context id="From2022-09-012023-08-31_custom_Warrant1Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CNBX:Warrant1Member</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-09-01</startDate> <endDate>2023-08-31</endDate> </period> </context> <context id="From2022-09-012023-08-31_custom_Warrant2Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CNBX:Warrant2Member</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-09-01</startDate> <endDate>2023-08-31</endDate> </period> </context> <context id="From2018-09-232018-09-24_custom_Warrant1Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CNBX:Warrant1Member</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2018-09-23</startDate> <endDate>2018-09-24</endDate> </period> </context> <context id="From2020-12-152020-12-16_custom_Warrant2Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CNBX:Warrant2Member</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-12-15</startDate> <endDate>2020-12-16</endDate> </period> </context> <context id="AsOf2022-08-31_custom_WarrantsMember882227078"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CNBX:WarrantsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-08-31</instant> </period> </context> <context id="AsOf2021-08-31_custom_WarrantsMember882227078"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CNBX:WarrantsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-08-31</instant> </period> </context> <context id="AsOf2020-08-31_custom_WarrantsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CNBX:WarrantsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-08-31</instant> </period> </context> <context id="From2022-09-012023-08-31_custom_WarrantsMember882227093"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CNBX:WarrantsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-09-01</startDate> <endDate>2023-08-31</endDate> </period> </context> <context id="From2021-09-012022-08-31_custom_WarrantsMember882227093"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CNBX:WarrantsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-09-01</startDate> <endDate>2022-08-31</endDate> </period> </context> <context id="From2020-09-012021-08-31_custom_WarrantsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CNBX:WarrantsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-09-01</startDate> <endDate>2021-08-31</endDate> </period> </context> <context id="AsOf2023-08-31_custom_WarrantsMember882227109"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CNBX:WarrantsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2023-08-31</instant> </period> </context> <context id="From2022-09-012023-08-31_us-gaap_DomesticCountryMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-09-01</startDate> <endDate>2023-08-31</endDate> </period> </context> <context id="AsOf2023-08-31_custom_UnitedStates1Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">CNBX:UnitedStates1Member</xbrldi:explicitMember> </segment> </entity> <period> <instant>2023-08-31</instant> </period> </context> <context id="AsOf2022-08-31_custom_UnitedStates1Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">CNBX:UnitedStates1Member</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-08-31</instant> </period> </context> <context id="From2022-09-012023-08-31_us-gaap_IsraelTaxAuthorityMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-09-01</startDate> <endDate>2023-08-31</endDate> </period> </context> <context id="AsOf2023-08-31_us-gaap_IsraelTaxAuthorityMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2023-08-31</instant> </period> </context> <context id="AsOf2022-08-31_us-gaap_IsraelTaxAuthorityMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-08-31</instant> </period> </context> <context id="AsOf2023-08-31_us-gaap_DomesticCountryMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2023-08-31</instant> </period> </context> <context id="AsOf2022-08-31_us-gaap_DomesticCountryMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-08-31</instant> </period> </context> <context id="AsOf2023-08-31_us-gaap_ForeignCountryMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2023-08-31</instant> </period> </context> <context id="AsOf2022-08-31_us-gaap_ForeignCountryMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-08-31</instant> </period> </context> <context id="From2022-12-082022-12-09"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001343009</identifier> </entity> <period> <startDate>2022-12-08</startDate> <endDate>2022-12-09</endDate> </period> </context> <unit id="USD"> <measure>iso4217:USD</measure> </unit> <unit id="Shares"> <measure>shares</measure> </unit> <unit id="USDPShares"> <divide> <unitNumerator> <measure>iso4217:USD</measure> </unitNumerator> <unitDenominator> <measure>shares</measure> </unitDenominator> </divide> </unit> <unit id="Pure"> <measure>pure</measure> </unit> <dei:AmendmentFlag contextRef="From2022-09-01to2023-08-31">false</dei:AmendmentFlag> <dei:DocumentFiscalYearFocus contextRef="From2022-09-01to2023-08-31">2023</dei:DocumentFiscalYearFocus> <dei:DocumentFiscalPeriodFocus contextRef="From2022-09-01to2023-08-31">FY</dei:DocumentFiscalPeriodFocus> <dei:EntityCentralIndexKey contextRef="From2022-09-01to2023-08-31">0001343009</dei:EntityCentralIndexKey> <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2021-09-012022-08-31_us-gaap_CommonStockMember" id="xdx2ixbrl0285" unitRef="USD" xsi:nil="true"/> <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2021-09-012022-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0287" unitRef="USD" xsi:nil="true"/> <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2021-09-012022-08-31_custom_WarrantsMember" id="xdx2ixbrl0288" unitRef="USD" xsi:nil="true"/> <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2021-09-012022-08-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0289" unitRef="USD" xsi:nil="true"/> <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2021-09-012022-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0294" unitRef="USD" xsi:nil="true"/> <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2021-09-012022-08-31_custom_WarrantsMember" id="xdx2ixbrl0295" unitRef="USD" xsi:nil="true"/> <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2021-09-012022-08-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0296" unitRef="USD" xsi:nil="true"/> <CNBX:PostsplitAdjustment contextRef="From2021-09-012022-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0303" unitRef="USD" xsi:nil="true"/> <CNBX:PostsplitAdjustment contextRef="From2021-09-012022-08-31_custom_WarrantsMember" id="xdx2ixbrl0304" unitRef="USD" xsi:nil="true"/> <CNBX:PostsplitAdjustment contextRef="From2021-09-012022-08-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0305" unitRef="USD" xsi:nil="true"/> <CNBX:PostsplitAdjustment contextRef="From2021-09-012022-08-31" id="xdx2ixbrl0306" unitRef="USD" xsi:nil="true"/> <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="From2021-09-012022-08-31_us-gaap_CommonStockMember" id="xdx2ixbrl0310" unitRef="USD" xsi:nil="true"/> <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="From2021-09-012022-08-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0311" unitRef="USD" xsi:nil="true"/> <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="From2021-09-012022-08-31_custom_WarrantsMember" id="xdx2ixbrl0313" unitRef="USD" xsi:nil="true"/> <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="From2021-09-012022-08-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0314" unitRef="USD" xsi:nil="true"/> <us-gaap:NetIncomeLoss contextRef="From2021-09-012022-08-31_us-gaap_CommonStockMember" id="xdx2ixbrl0317" unitRef="USD" xsi:nil="true"/> <us-gaap:NetIncomeLoss contextRef="From2021-09-012022-08-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0318" unitRef="USD" xsi:nil="true"/> <us-gaap:NetIncomeLoss contextRef="From2021-09-012022-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0319" unitRef="USD" xsi:nil="true"/> <us-gaap:NetIncomeLoss contextRef="From2021-09-012022-08-31_custom_WarrantsMember" id="xdx2ixbrl0320" unitRef="USD" xsi:nil="true"/> <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2022-09-012023-08-31_us-gaap_CommonStockMember" id="xdx2ixbrl0333" unitRef="USD" xsi:nil="true"/> <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2022-09-012023-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0335" unitRef="USD" xsi:nil="true"/> <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2022-09-012023-08-31_custom_WarrantsMember" id="xdx2ixbrl0336" unitRef="USD" xsi:nil="true"/> <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2022-09-012023-08-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0337" unitRef="USD" xsi:nil="true"/> <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2022-09-012023-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0342" unitRef="USD" xsi:nil="true"/> <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2022-09-012023-08-31_custom_WarrantsMember" id="xdx2ixbrl0343" unitRef="USD" xsi:nil="true"/> <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2022-09-012023-08-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0344" unitRef="USD" xsi:nil="true"/> <CNBX:ExpirationOfWarrants contextRef="From2022-09-012023-08-31_us-gaap_CommonStockMember" id="xdx2ixbrl0349" unitRef="USD" xsi:nil="true"/> <CNBX:ExpirationOfWarrants contextRef="From2022-09-012023-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0351" unitRef="USD" xsi:nil="true"/> <CNBX:ExpirationOfWarrants contextRef="From2022-09-012023-08-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0353" unitRef="USD" xsi:nil="true"/> <CNBX:ExpirationOfWarrants contextRef="From2022-09-01to2023-08-31" id="xdx2ixbrl0354" unitRef="USD" xsi:nil="true"/> <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="From2022-09-012023-08-31_us-gaap_CommonStockMember" id="xdx2ixbrl0356" unitRef="USD" xsi:nil="true"/> <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="From2022-09-012023-08-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0357" unitRef="USD" xsi:nil="true"/> <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="From2022-09-012023-08-31_custom_WarrantsMember" id="xdx2ixbrl0359" unitRef="USD" xsi:nil="true"/> <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="From2022-09-012023-08-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0360" unitRef="USD" xsi:nil="true"/> <us-gaap:NetIncomeLoss contextRef="From2022-09-012023-08-31_us-gaap_CommonStockMember" id="xdx2ixbrl0363" unitRef="USD" xsi:nil="true"/> <us-gaap:NetIncomeLoss contextRef="From2022-09-012023-08-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0364" unitRef="USD" xsi:nil="true"/> <us-gaap:NetIncomeLoss contextRef="From2022-09-012023-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0365" unitRef="USD" xsi:nil="true"/> <us-gaap:NetIncomeLoss contextRef="From2022-09-012023-08-31_custom_WarrantsMember" id="xdx2ixbrl0366" unitRef="USD" xsi:nil="true"/> <us-gaap:StockholdersEquity contextRef="AsOf2023-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0372" unitRef="USD" xsi:nil="true"/> <us-gaap:StockholdersEquity contextRef="AsOf2023-08-31_custom_WarrantsMember" id="xdx2ixbrl0373" unitRef="USD" xsi:nil="true"/> <dei:DocumentType contextRef="From2022-09-01to2023-08-31">10-K</dei:DocumentType> <dei:DocumentAnnualReport contextRef="From2022-09-01to2023-08-31">true</dei:DocumentAnnualReport> <dei:DocumentPeriodEndDate contextRef="From2022-09-01to2023-08-31">2023-08-31</dei:DocumentPeriodEndDate> <dei:CurrentFiscalYearEndDate contextRef="From2022-09-01to2023-08-31">--08-31</dei:CurrentFiscalYearEndDate> <dei:DocumentTransitionReport contextRef="From2022-09-01to2023-08-31">false</dei:DocumentTransitionReport> <dei:EntityFileNumber contextRef="From2022-09-01to2023-08-31">000-52403</dei:EntityFileNumber> <dei:EntityRegistrantName contextRef="From2022-09-01to2023-08-31">CNBX PHARMACEUTICALS INC.</dei:EntityRegistrantName> <dei:EntityIncorporationStateCountryCode contextRef="From2022-09-01to2023-08-31">NV</dei:EntityIncorporationStateCountryCode> <dei:EntityTaxIdentificationNumber contextRef="From2022-09-01to2023-08-31">20-3373669</dei:EntityTaxIdentificationNumber> <dei:EntityAddressAddressLine1 contextRef="From2022-09-01to2023-08-31">#3 Bethesda Metro Center</dei:EntityAddressAddressLine1> <dei:EntityAddressAddressLine2 contextRef="From2022-09-01to2023-08-31">Suite 700</dei:EntityAddressAddressLine2> <dei:EntityAddressCityOrTown contextRef="From2022-09-01to2023-08-31">Bethesda</dei:EntityAddressCityOrTown> <dei:EntityAddressStateOrProvince contextRef="From2022-09-01to2023-08-31">MD</dei:EntityAddressStateOrProvince> <dei:EntityAddressPostalZipCode contextRef="From2022-09-01to2023-08-31">20814</dei:EntityAddressPostalZipCode> <dei:CityAreaCode contextRef="From2022-09-01to2023-08-31">877</dei:CityAreaCode> <dei:LocalPhoneNumber contextRef="From2022-09-01to2023-08-31">424-2429</dei:LocalPhoneNumber> <dei:Security12bTitle contextRef="From2022-09-01to2023-08-31">Common Stock, $.0001 Par Value</dei:Security12bTitle> <dei:EntityWellKnownSeasonedIssuer contextRef="From2022-09-01to2023-08-31">No</dei:EntityWellKnownSeasonedIssuer> <dei:EntityVoluntaryFilers contextRef="From2022-09-01to2023-08-31">No</dei:EntityVoluntaryFilers> <dei:EntityCurrentReportingStatus contextRef="From2022-09-01to2023-08-31">Yes</dei:EntityCurrentReportingStatus> <dei:EntityInteractiveDataCurrent contextRef="From2022-09-01to2023-08-31">Yes</dei:EntityInteractiveDataCurrent> <dei:EntityFilerCategory contextRef="From2022-09-01to2023-08-31">Non-accelerated Filer</dei:EntityFilerCategory> <dei:EntitySmallBusiness contextRef="From2022-09-01to2023-08-31">true</dei:EntitySmallBusiness> <dei:EntityEmergingGrowthCompany contextRef="From2022-09-01to2023-08-31">false</dei:EntityEmergingGrowthCompany> <dei:IcfrAuditorAttestationFlag contextRef="From2022-09-01to2023-08-31">false</dei:IcfrAuditorAttestationFlag> <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2022-09-01to2023-08-31">false</dei:DocumentFinStmtErrorCorrectionFlag> <dei:EntityShellCompany contextRef="From2022-09-01to2023-08-31">false</dei:EntityShellCompany> <dei:EntityPublicFloat contextRef="AsOf2023-08-31" decimals="0" unitRef="USD">437714</dei:EntityPublicFloat> <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-11-29" decimals="INF" unitRef="Shares">28311352</dei:EntityCommonStockSharesOutstanding> <dei:AuditorFirmId contextRef="From2022-09-01to2023-08-31">6629</dei:AuditorFirmId> <dei:AuditorName contextRef="From2022-09-01to2023-08-31">Weinstein International. C.P.A.</dei:AuditorName> <dei:AuditorLocation contextRef="From2022-09-01to2023-08-31">Tel - Aviv, Israel</dei:AuditorLocation> <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2023-08-31" decimals="0" unitRef="USD">129696</us-gaap:CashAndCashEquivalentsAtCarryingValue> <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-08-31" decimals="0" unitRef="USD">117515</us-gaap:CashAndCashEquivalentsAtCarryingValue> <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2023-08-31" decimals="0" unitRef="USD">94612</us-gaap:PrepaidExpenseAndOtherAssetsCurrent> <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-08-31" decimals="0" unitRef="USD">80772</us-gaap:PrepaidExpenseAndOtherAssetsCurrent> <us-gaap:AssetsCurrent contextRef="AsOf2023-08-31" decimals="0" unitRef="USD">224308</us-gaap:AssetsCurrent> <us-gaap:AssetsCurrent contextRef="AsOf2022-08-31" decimals="0" unitRef="USD">198287</us-gaap:AssetsCurrent> <us-gaap:Investments contextRef="AsOf2023-08-31" decimals="0" unitRef="USD">0</us-gaap:Investments> <us-gaap:Investments contextRef="AsOf2022-08-31" decimals="0" unitRef="USD">176087</us-gaap:Investments> <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2023-08-31" decimals="0" unitRef="USD">274731</us-gaap:PropertyPlantAndEquipmentNet> <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-08-31" decimals="0" unitRef="USD">436792</us-gaap:PropertyPlantAndEquipmentNet> <us-gaap:Assets contextRef="AsOf2023-08-31" decimals="0" unitRef="USD">499039</us-gaap:Assets> <us-gaap:Assets contextRef="AsOf2022-08-31" decimals="0" unitRef="USD">811166</us-gaap:Assets> <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2023-08-31" decimals="0" unitRef="USD">335915</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent> <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2022-08-31" decimals="0" unitRef="USD">461128</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent> <us-gaap:ConvertibleDebtCurrent contextRef="AsOf2023-08-31" decimals="0" unitRef="USD">1343584</us-gaap:ConvertibleDebtCurrent> <us-gaap:ConvertibleDebtCurrent contextRef="AsOf2022-08-31" decimals="0" unitRef="USD">1758702</us-gaap:ConvertibleDebtCurrent> <CNBX:DueToRelatedParty contextRef="AsOf2023-08-31" decimals="0" unitRef="USD">836829</CNBX:DueToRelatedParty> <CNBX:DueToRelatedParty contextRef="AsOf2022-08-31" decimals="0" unitRef="USD">223645</CNBX:DueToRelatedParty> <us-gaap:LiabilitiesCurrent contextRef="AsOf2023-08-31" decimals="0" unitRef="USD">2516328</us-gaap:LiabilitiesCurrent> <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-08-31" decimals="0" unitRef="USD">2443475</us-gaap:LiabilitiesCurrent> <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2023-08-31" decimals="INF" unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare> <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2022-08-31" decimals="INF" unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare> <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2023-08-31" decimals="INF" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized> <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-08-31" decimals="INF" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized> <us-gaap:PreferredStockSharesIssued contextRef="AsOf2023-08-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued> <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2023-08-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding> <us-gaap:PreferredStockSharesIssued contextRef="AsOf2022-08-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued> <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2022-08-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding> <us-gaap:PreferredStockValue contextRef="AsOf2023-08-31" decimals="0" unitRef="USD">0</us-gaap:PreferredStockValue> <us-gaap:PreferredStockValue contextRef="AsOf2022-08-31" decimals="0" unitRef="USD">0</us-gaap:PreferredStockValue> <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2023-08-31" decimals="INF" unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare> <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2022-08-31" decimals="INF" unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare> <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-08-31" decimals="INF" unitRef="Shares">900000000</us-gaap:CommonStockSharesAuthorized> <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-08-31" decimals="INF" unitRef="Shares">900000000</us-gaap:CommonStockSharesAuthorized> <us-gaap:CommonStockSharesIssued contextRef="AsOf2023-08-31" decimals="INF" unitRef="Shares">22611352</us-gaap:CommonStockSharesIssued> <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-08-31" decimals="INF" unitRef="Shares">22611352</us-gaap:CommonStockSharesOutstanding> <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-08-31" decimals="INF" unitRef="Shares">1238659</us-gaap:CommonStockSharesIssued> <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-08-31" decimals="INF" unitRef="Shares">1238659</us-gaap:CommonStockSharesOutstanding> <us-gaap:CommonStockValue contextRef="AsOf2023-08-31" decimals="0" unitRef="USD">2261</us-gaap:CommonStockValue> <us-gaap:CommonStockValue contextRef="AsOf2022-08-31" decimals="0" unitRef="USD">124</us-gaap:CommonStockValue> <us-gaap:AdditionalPaidInCapital contextRef="AsOf2023-08-31" decimals="0" unitRef="USD">22239652</us-gaap:AdditionalPaidInCapital> <us-gaap:AdditionalPaidInCapital contextRef="AsOf2022-08-31" decimals="0" unitRef="USD">18031869</us-gaap:AdditionalPaidInCapital> <us-gaap:OtherAdditionalCapital contextRef="AsOf2023-08-31" decimals="0" unitRef="USD">0</us-gaap:OtherAdditionalCapital> <us-gaap:OtherAdditionalCapital contextRef="AsOf2022-08-31" decimals="0" unitRef="USD">3459510</us-gaap:OtherAdditionalCapital> <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2023-08-31" decimals="0" unitRef="USD">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax> <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2022-08-31" decimals="0" unitRef="USD">-2574846</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax> <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2023-08-31" decimals="0" unitRef="USD">-24259202</us-gaap:RetainedEarningsAccumulatedDeficit> <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-08-31" decimals="0" unitRef="USD">-20548968</us-gaap:RetainedEarningsAccumulatedDeficit> <us-gaap:StockholdersEquity contextRef="AsOf2023-08-31" decimals="0" unitRef="USD">-2017289</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2022-08-31" decimals="0" unitRef="USD">-1632311</us-gaap:StockholdersEquity> <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2023-08-31" decimals="0" unitRef="USD">499039</us-gaap:LiabilitiesAndStockholdersEquity> <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-08-31" decimals="0" unitRef="USD">811166</us-gaap:LiabilitiesAndStockholdersEquity> <us-gaap:Revenues contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">410165</us-gaap:Revenues> <us-gaap:Revenues contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">29958</us-gaap:Revenues> <us-gaap:ResearchAndDevelopmentExpense contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">431565</us-gaap:ResearchAndDevelopmentExpense> <us-gaap:ResearchAndDevelopmentExpense contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">1183281</us-gaap:ResearchAndDevelopmentExpense> <us-gaap:GeneralAndAdministrativeExpense contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">909980</us-gaap:GeneralAndAdministrativeExpense> <us-gaap:GeneralAndAdministrativeExpense contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">1800647</us-gaap:GeneralAndAdministrativeExpense> <us-gaap:OperatingExpenses contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">1341545</us-gaap:OperatingExpenses> <us-gaap:OperatingExpenses contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">2983928</us-gaap:OperatingExpenses> <us-gaap:OperatingIncomeLoss contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">-931380</us-gaap:OperatingIncomeLoss> <us-gaap:OperatingIncomeLoss contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">-2953970</us-gaap:OperatingIncomeLoss> <CNBX:CapitalGainLoss contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">-2726231</CNBX:CapitalGainLoss> <CNBX:CapitalGainLoss contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">12800</CNBX:CapitalGainLoss> <CNBX:FinancialLossNet contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">-52623</CNBX:FinancialLossNet> <CNBX:FinancialLossNet contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">-782080</CNBX:FinancialLossNet> <us-gaap:NetIncomeLoss contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">-3710234</us-gaap:NetIncomeLoss> <us-gaap:NetIncomeLoss contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">-3723250</us-gaap:NetIncomeLoss> <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax> <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">-669131</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax> <us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">-3710234</us-gaap:ComprehensiveIncomeNetOfTax> <us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">-4392381</us-gaap:ComprehensiveIncomeNetOfTax> <us-gaap:EarningsPerShareBasic contextRef="From2022-09-01to2023-08-31" decimals="INF" unitRef="USDPShares">-0.42</us-gaap:EarningsPerShareBasic> <us-gaap:EarningsPerShareDiluted contextRef="From2022-09-01to2023-08-31" decimals="INF" unitRef="USDPShares">-0.42</us-gaap:EarningsPerShareDiluted> <us-gaap:EarningsPerShareBasic contextRef="From2021-09-012022-08-31" decimals="INF" unitRef="USDPShares">-3.59</us-gaap:EarningsPerShareBasic> <us-gaap:EarningsPerShareDiluted contextRef="From2021-09-012022-08-31" decimals="INF" unitRef="USDPShares">-3.59</us-gaap:EarningsPerShareDiluted> <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2022-09-01to2023-08-31" decimals="INF" unitRef="Shares">8824636</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic> <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2022-09-01to2023-08-31" decimals="INF" unitRef="Shares">8824636</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding> <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2021-09-012022-08-31" decimals="INF" unitRef="Shares">1222641</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic> <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2021-09-012022-08-31" decimals="INF" unitRef="Shares">1222641</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding> <us-gaap:NetIncomeLoss contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">-3710234</us-gaap:NetIncomeLoss> <us-gaap:NetIncomeLoss contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">-3723250</us-gaap:NetIncomeLoss> <us-gaap:Depreciation contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">162061</us-gaap:Depreciation> <us-gaap:Depreciation contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">198527</us-gaap:Depreciation> <us-gaap:ShareBasedCompensation contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">180480</us-gaap:ShareBasedCompensation> <us-gaap:ShareBasedCompensation contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">728869</us-gaap:ShareBasedCompensation> <CNBX:InterestOnConvertibleLoan contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">54811</CNBX:InterestOnConvertibleLoan> <CNBX:InterestOnConvertibleLoan contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">722236</CNBX:InterestOnConvertibleLoan> <CNBX:CapitalLossGain contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">-2726232</CNBX:CapitalLossGain> <CNBX:CapitalLossGain contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">12800</CNBX:CapitalLossGain> <us-gaap:IncreaseDecreaseInPrepaidExpensesOther contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">13840</us-gaap:IncreaseDecreaseInPrepaidExpensesOther> <us-gaap:IncreaseDecreaseInPrepaidExpensesOther contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">-123603</us-gaap:IncreaseDecreaseInPrepaidExpensesOther> <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">487969</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities> <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">283623</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities> <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">-112521</us-gaap:NetCashProvidedByUsedInOperatingActivities> <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">-1679192</us-gaap:NetCashProvidedByUsedInOperatingActivities> <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment> <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">26885</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment> <us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">24702</us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi> <us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">0</us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi> <us-gaap:PaymentsToAcquireMachineryAndEquipment contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">-0</us-gaap:PaymentsToAcquireMachineryAndEquipment> <us-gaap:PaymentsToAcquireMachineryAndEquipment contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">1656</us-gaap:PaymentsToAcquireMachineryAndEquipment> <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">24702</us-gaap:NetCashProvidedByUsedInInvestingActivities> <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">25229</us-gaap:NetCashProvidedByUsedInInvestingActivities> <us-gaap:ProceedsFromConvertibleDebt contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">100000</us-gaap:ProceedsFromConvertibleDebt> <us-gaap:ProceedsFromConvertibleDebt contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">389858</us-gaap:ProceedsFromConvertibleDebt> <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">100000</us-gaap:NetCashProvidedByUsedInFinancingActivities> <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">389858</us-gaap:NetCashProvidedByUsedInFinancingActivities> <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">12181</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect> <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">-1264105</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect> <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents> <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">-4853</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents> <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-08-31" decimals="0" unitRef="USD">117515</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents> <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-08-31" decimals="0" unitRef="USD">1386473</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents> <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2023-08-31" decimals="0" unitRef="USD">129696</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents> <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-08-31" decimals="0" unitRef="USD">117515</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents> <CNBX:ExerciseOfConvertibleLoanToSharesOfCommonStock. contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">569930</CNBX:ExerciseOfConvertibleLoanToSharesOfCommonStock.> <CNBX:ExerciseOfConvertibleLoanToSharesOfCommonStock. contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">225286</CNBX:ExerciseOfConvertibleLoanToSharesOfCommonStock.> <us-gaap:SharesOutstanding contextRef="AsOf2021-08-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares">1206230</us-gaap:SharesOutstanding> <us-gaap:StockholdersEquity contextRef="AsOf2021-08-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD">14475</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2021-08-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD">17063363</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2021-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" unitRef="USD">-1905715</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2021-08-31_custom_WarrantsMember" decimals="0" unitRef="USD">3459510</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2021-08-31_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD">-16825718</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2021-08-31" decimals="0" unitRef="USD">1805915</us-gaap:StockholdersEquity> <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2021-09-012022-08-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD">728869</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue> <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">728869</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue> <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2021-09-012022-08-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares">20027</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities> <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2021-09-012022-08-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD">2</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities> <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2021-09-012022-08-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD">225284</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities> <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">225286</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities> <CNBX:PostsplitAdjustmentShares contextRef="From2021-09-012022-08-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares">12402</CNBX:PostsplitAdjustmentShares> <CNBX:PostsplitAdjustment contextRef="From2021-09-012022-08-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD">-14353</CNBX:PostsplitAdjustment> <CNBX:PostsplitAdjustment contextRef="From2021-09-012022-08-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD">14353</CNBX:PostsplitAdjustment> <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="From2021-09-012022-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" unitRef="USD">-669131</us-gaap:OtherComprehensiveIncomeLossNetOfTax> <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">-669131</us-gaap:OtherComprehensiveIncomeLossNetOfTax> <us-gaap:NetIncomeLoss contextRef="From2021-09-012022-08-31_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD">-3723250</us-gaap:NetIncomeLoss> <us-gaap:NetIncomeLoss contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">-3723250</us-gaap:NetIncomeLoss> <us-gaap:SharesOutstanding contextRef="AsOf2022-08-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares">1238659</us-gaap:SharesOutstanding> <us-gaap:StockholdersEquity contextRef="AsOf2022-08-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD">124</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2022-08-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD">18031869</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2022-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" unitRef="USD">-2574846</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2022-08-31_custom_WarrantsMember" decimals="0" unitRef="USD">3459510</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2022-08-31_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD">-20548968</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2022-08-31" decimals="0" unitRef="USD">-1632311</us-gaap:StockholdersEquity> <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2022-09-012023-08-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD">180480</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue> <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">180480</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue> <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2022-09-012023-08-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares">21372693</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities> <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2022-09-012023-08-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD">2137</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities> <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2022-09-012023-08-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD">567793</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities> <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">569930</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities> <CNBX:ExpirationOfWarrants contextRef="From2022-09-012023-08-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD">3459510</CNBX:ExpirationOfWarrants> <CNBX:ExpirationOfWarrants contextRef="From2022-09-012023-08-31_custom_WarrantsMember" decimals="0" unitRef="USD">-3459510</CNBX:ExpirationOfWarrants> <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="From2022-09-012023-08-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" unitRef="USD">2574846</us-gaap:OtherComprehensiveIncomeLossNetOfTax> <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">2574846</us-gaap:OtherComprehensiveIncomeLossNetOfTax> <us-gaap:NetIncomeLoss contextRef="From2022-09-012023-08-31_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD">-3710234</us-gaap:NetIncomeLoss> <us-gaap:NetIncomeLoss contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">-3710234</us-gaap:NetIncomeLoss> <us-gaap:SharesOutstanding contextRef="AsOf2023-08-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares">22611352</us-gaap:SharesOutstanding> <us-gaap:StockholdersEquity contextRef="AsOf2023-08-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD">2261</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2023-08-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD">22239652</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2023-08-31_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD">-24259202</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2023-08-31" decimals="0" unitRef="USD">-2017289</us-gaap:StockholdersEquity> <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2022-09-01to2023-08-31"><p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zUgHR0qPoya3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 – <span id="xdx_825_zmPn1m0VPhs2">Nature of Business, Presentation and Going Concern</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Organization</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CNBX Pharmaceuticals Inc. (the "Company"), was incorporated in the State of Nevada, on September 15, 2004, under the name of Thrust Energy Corp. The Company was originally engaged in the exploration, exploitation, development and production of oil and gas projects within North America, but was unable to operate profitably.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2011, the Company changed its name to American Mining Corporation, suspending its oil and gas operations and changing its business to toll milling and refining, mineral exploration and mine development.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 25, 2014, the Company experienced a change in control. Cannabics, Inc. (“Cannabics”) acquired a majority of the issued and outstanding common stock of the Company in accordance with stock purchase agreements by and between Cannabics and Thomas Mills (“Mills”). On the closing date, April 25, 2014, pursuant to the terms of the Stock Purchase Agreement, Cannabics purchased from Mills 41,000,000 shares of the Company’s outstanding restricted common stock for $198,000, representing 51%.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 21, 2014, the Company changed its name, via merger in the state of Nevada, to CNBX Pharmaceuticals Inc. The Company’s principal offices are in Bethesda, Maryland. As of May 21, 2014, the Company has changed its course of business to laboratory research and development.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 25, 2014, the Company organized G.R.I.N. Ultra Ltd. (“GRIN”), an Israeli corporation, as a wholly-owned subsidiary. GRIN will provide research and development activities for the Company’s products in Israel.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock Split</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 3, 2014, the Company’s Board of Directors declared a two-to-one forward stock split of all outstanding shares of common stock. The stock split was approved by FINRA on June 25, 2014. The effect of the stock split increased the number of shares of common stock outstanding from 40,880,203 to 81,760,406. All common share and per common share data in these financial statements and related notes hereto have been retroactively adjusted to account for the effect of the stock split for all periods presented prior to June 3, 2014. The total number of authorized common shares and the par value thereof was not changed by the split. Additionally, on May 12, 2022, the Company effected a reverse-split of its common stock on a 1:120 basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basis of Presentation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the Securities and Exchange Commission (“SEC”). </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Going Concern</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred a net loss of $<span id="xdx_90D_eus-gaap--NetIncomeLoss_iN_di_c20220901__20230831_zoL9JYAMpCB2" title="Net loss">3,710,234</span> for the year ended August 31, 2023 and has incurred cumulative losses since inception of $<span id="xdx_904_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20230831_z4qFAplZC3I3" title="Cumulative losses">24,259,202</span>. These conditions raise substantial doubt about the ability of the Company to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s continuation as a going concern is dependent upon its ability to generate revenues, its ability to continue to raise investment capital, and implementing its business plan. No assurance can be given that the Company will be successful in these efforts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern. No assurance can be given that the Company will be successful in these efforts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock> <us-gaap:NetIncomeLoss contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">-3710234</us-gaap:NetIncomeLoss> <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2023-08-31" decimals="0" unitRef="USD">-24259202</us-gaap:RetainedEarningsAccumulatedDeficit> <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2022-09-01to2023-08-31"><p id="xdx_801_eus-gaap--SignificantAccountingPoliciesTextBlock_zxzFvLnukb3i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2 – <span id="xdx_821_zqZd5fOxFT61">Summary of Significant Accounting Policies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84F_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zasdwoFqnSzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_862_zHpXURhREUQb">Functional currency</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The currency of the primary economic environment in which the operations of the Company and its Subsidiary are conducted is the U.S. dollar (“$” or “dollar”). Therefore, the functional currency of the Company and its Subsidiary is the dollar.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Transactions and balances denominated in dollars are presented at their original amounts. Non-dollar transactions and balances have been re-measured to dollars in accordance with the provisions of ASC 830-10 (formerly Statement of Financial Accounting Standard 52), "Foreign Currency Translation". All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_848_eus-gaap--UseOfEstimates_zdGpwSbTPWNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86C_zBdGvHpwOwnc">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates in the accompanying financial statements include the amortization period for intangible assets, impairment valuation of intangible assets, valuation of share-based payments and the valuation allowance on deferred tax assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zoWydCZHRYT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_863_ze39WOn0Kvtd">Principles of Consolidation</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements include the accounts of Cannabics Pharmaceutical Inc. and its wholly-owned subsidiary, G.R.I.N. Ultra Ltd. All significant inter-company balances and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zSjJfU0091U1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_866_zV0TnliunyC3">Cash and Cash Equivalents</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. At August 31, 2023 and 2022, cash equivalents consisted of bank accounts held at financial institutions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zAVF42egYI56" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_z7MsdL5Qgk93">Concentration of Credit Risk</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company places its cash and cash equivalents with high credit quality financial institutions. There is Federal Deposit Insurance on the Company’s U.S. bank accounts for up to $<span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_c20230831_zsXZ4YmmMrXh" title="Federal deposit insurance">250,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zKdVb9dYFvu8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_861_zM3nN5mFmew2">Equipment, net</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equipment at August 31, 2023 consists of computer equipment, office equipment and cars recorded at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation of property and equipment is computed by the straight-line method (after taking into account their respective estimated residual values) over the assets estimated useful lives of 3 years for computer equipment, 14 years for office equipment and 7 years for cars. Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in the consolidated statements of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expense was $<span id="xdx_909_eus-gaap--Depreciation_pp0p0_c20220901__20230831_zxPka4lcudAd" title="Depreciation expense">162,061</span> and $<span id="xdx_906_eus-gaap--Depreciation_pp0p0_c20210901__20220831_zjNy6luMvZag" title="Depreciation expense">198,527</span> for the years ended August 31, 2023, and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p id="xdx_84A_eus-gaap--RevenueRecognitionPolicyTextBlock_zH9eTZ69Sl2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_864_zVkMFXRjFV5a">Revenue recognition</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue is recognized when delivery has occurred, evidence of an arrangement exists, title and risks and rewards for the products are transferred to the customer, collection is reasonably assured and product returns can be reliably estimated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue from license agreements is recognized over the periods from which the Company is entitled to the respective payments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z7cPcYYiIODh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86F_zzQygxnq2Cn4">Impairment or Disposal of Long-Lived Assets</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for the impairment or disposal of long-lived assets according to the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) 360 “Property, Plant and Equipment”. ASC 360 clarifies the accounting for the impairment of long-lived assets and for long-lived assets to be disposed of, including the disposal of business segments and major lines of business. Long-lived assets are reviewed when facts and circumstances indicate that the carrying value of the asset may not be recoverable. When necessary, impaired assets are written down to estimated fair value based on the best information available. Estimated fair value is generally based on either appraised value or measured by discounting estimated future cash flows. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i> </b></p> <p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zLUS1qmp63W4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_zMPjBNjTXWak">Fair Value of Financial Instruments</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following provides an analysis of financial instruments that are measured subsequent to initial recognition at fair value, grouped into Levels 1 to 3 based on the degree to which fair value is observable:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1 - fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical assets or liabilities;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2 - fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 - fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of August 31, 2023 and 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company applied ASC 820 for all non-financial assets and liabilities measured at fair value on a non-recurring basis. The adoption of ASC 820 for non-financial assets and liabilities did not have a significant impact on the Company’s financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of August 31, 2023, the company had <span id="xdx_90C_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_pp0p0_do_c20230831__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zwmD6vnxaVY4" title="Fair value of financial instruments">no</span> level 1 fair values financial instruments assets, and had financial instruments liabilities of $<span id="xdx_904_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_pp0p0_c20230831__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zk7UI53qLko4" title="Fair value of financial instruments">1,343,584</span> at level 3.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of August 31, 2023, the fair values of the Company’s financial instruments approximate their historical carrying amount.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zd4GJkrTJvI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_867_zfa6qvHm7Nnb">Research and development, net</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, employee benefits, the cost of supplies, the cost of services provided by outside contractors, including services related to the Company’s clinical trials, clinical trial expenses and the full cost of manufacturing product for use in research and preclinical development. All costs associated with research and developments are expensed as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources a substantial portion of its clinical trial activities, utilizing external entities such as Contract Research Organizations, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical studies. For each clinical trial that the Company conducts, clinical trial costs are expensed immediately.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_845_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zw0IQJyuYpSi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_867_zj8xAVbxwC1g">Stock Based Compensation</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for Stock-Based Compensation under ASC 718 “Compensation – Stock Compensation”, which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 requires measurement of the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees. Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Any stock options or warrants issued to non-employees are recorded in expense and additional paid-in capital in shareholders' deficit over the applicable service periods using variable accounting through the vesting dates based on the fair value of the options or warrants at the end of each period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issues stock to consultants for various services. The costs for these transactions are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The value of the common stock is measured at the earlier of (i) the date at which a firm commitment for performance by the counterparty to earn the equity instruments is reached or (ii) the date at which the counterparty's performance is complete. The Company recognized consulting expense and a corresponding increase to additional paid-in-capital related to stock issued for services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zUkROnVPmps" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_868_zUXl2xHYlfsf">Income Taxes</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Income taxes are accounted for under the liability method of accounting for income taxes. Under the liability method, future tax liabilities and assets are recognized for the estimated future tax consequences attributable to differences between the amounts reported in the financial statement carrying amounts of assets and liabilities and their respective tax bases. Future tax assets and liabilities are measured using enacted or substantially enacted income tax rates expected to apply when the asset is realized or the liability settled. The effect of a change in income tax rates on future income tax liabilities and assets is recognized in income in the period that the change occurs. Future income tax assets are recognized to the extent that they are considered more likely than not to be realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FASB has issued ASC 740 “Income Taxes”. ASC 740 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. This standard requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the implementation of this standard, the Company performed a review of its material tax positions in accordance with recognition and measurement standards established by ASC 740 and concluded that the tax position of the Company has not met the more-likely-than-not threshold as of August 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84F_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zSnHwkCGDCU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_863_zAGkIY4cCnHg">Comprehensive Income</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company adopted ASC 220, <i>Comprehensive Income</i> which establishes standards for reporting and display of comprehensive income, its components and accumulated balances. The Company is disclosing this information on its Statement of Stockholders' Equity. Comprehensive income comprises equity except those resulting from investments by owners and distributions to owners. The Company has no elements of “other comprehensive income” for the years ended August 31, 2023, and 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_zAoLYEHBGOJf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_860_zwYQG4hFDs02">Basic and Diluted Loss per Share</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company computes income (loss) per share in accordance with ASC 260, “Earnings per Share”, which requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the statement of operations. Basic EPS is computed by dividing income (loss) available to common shareholders by the weighted average number of shares outstanding during the period. Diluted EPS gives effect to all dilutive potential shares of common stock outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. As of August 31, 2023, and 2022, the potentially dilutive shares were anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_znBnyLGreJAe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_861_zB3T8mebmmhd">Segment Information</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the provisions of ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, the Company is required to report financial and descriptive information about its reportable operating segments. The Company does not consider itself to have any operating segments as of August 31, 2023, and 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_848_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zVNcwYGTkZXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_864_z3ConaoVnQr4">Reclassification</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> </us-gaap:SignificantAccountingPoliciesTextBlock> <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2022-09-01to2023-08-31"><p id="xdx_84F_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zasdwoFqnSzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_862_zHpXURhREUQb">Functional currency</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The currency of the primary economic environment in which the operations of the Company and its Subsidiary are conducted is the U.S. dollar (“$” or “dollar”). Therefore, the functional currency of the Company and its Subsidiary is the dollar.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Transactions and balances denominated in dollars are presented at their original amounts. Non-dollar transactions and balances have been re-measured to dollars in accordance with the provisions of ASC 830-10 (formerly Statement of Financial Accounting Standard 52), "Foreign Currency Translation". All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> </us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock> <us-gaap:UseOfEstimates contextRef="From2022-09-01to2023-08-31"><p id="xdx_848_eus-gaap--UseOfEstimates_zdGpwSbTPWNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86C_zBdGvHpwOwnc">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates in the accompanying financial statements include the amortization period for intangible assets, impairment valuation of intangible assets, valuation of share-based payments and the valuation allowance on deferred tax assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> </us-gaap:UseOfEstimates> <us-gaap:ConsolidationPolicyTextBlock contextRef="From2022-09-01to2023-08-31"><p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zoWydCZHRYT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_863_ze39WOn0Kvtd">Principles of Consolidation</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements include the accounts of Cannabics Pharmaceutical Inc. and its wholly-owned subsidiary, G.R.I.N. Ultra Ltd. All significant inter-company balances and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> </us-gaap:ConsolidationPolicyTextBlock> <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2022-09-01to2023-08-31"><p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zSjJfU0091U1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_866_zV0TnliunyC3">Cash and Cash Equivalents</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. At August 31, 2023 and 2022, cash equivalents consisted of bank accounts held at financial institutions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> </us-gaap:CashAndCashEquivalentsPolicyTextBlock> <us-gaap:ConcentrationRiskCreditRisk contextRef="From2022-09-01to2023-08-31"><p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zAVF42egYI56" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_z7MsdL5Qgk93">Concentration of Credit Risk</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company places its cash and cash equivalents with high credit quality financial institutions. There is Federal Deposit Insurance on the Company’s U.S. bank accounts for up to $<span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_c20230831_zsXZ4YmmMrXh" title="Federal deposit insurance">250,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> </us-gaap:ConcentrationRiskCreditRisk> <us-gaap:CashFDICInsuredAmount contextRef="AsOf2023-08-31" decimals="0" unitRef="USD">250000</us-gaap:CashFDICInsuredAmount> <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2022-09-01to2023-08-31"><p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zKdVb9dYFvu8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_861_zM3nN5mFmew2">Equipment, net</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equipment at August 31, 2023 consists of computer equipment, office equipment and cars recorded at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation of property and equipment is computed by the straight-line method (after taking into account their respective estimated residual values) over the assets estimated useful lives of 3 years for computer equipment, 14 years for office equipment and 7 years for cars. Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in the consolidated statements of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expense was $<span id="xdx_909_eus-gaap--Depreciation_pp0p0_c20220901__20230831_zxPka4lcudAd" title="Depreciation expense">162,061</span> and $<span id="xdx_906_eus-gaap--Depreciation_pp0p0_c20210901__20220831_zjNy6luMvZag" title="Depreciation expense">198,527</span> for the years ended August 31, 2023, and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> </us-gaap:PropertyPlantAndEquipmentPolicyTextBlock> <us-gaap:Depreciation contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">162061</us-gaap:Depreciation> <us-gaap:Depreciation contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">198527</us-gaap:Depreciation> <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2022-09-01to2023-08-31"><p id="xdx_84A_eus-gaap--RevenueRecognitionPolicyTextBlock_zH9eTZ69Sl2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_864_zVkMFXRjFV5a">Revenue recognition</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue is recognized when delivery has occurred, evidence of an arrangement exists, title and risks and rewards for the products are transferred to the customer, collection is reasonably assured and product returns can be reliably estimated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue from license agreements is recognized over the periods from which the Company is entitled to the respective payments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> </us-gaap:RevenueRecognitionPolicyTextBlock> <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2022-09-01to2023-08-31"><p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z7cPcYYiIODh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86F_zzQygxnq2Cn4">Impairment or Disposal of Long-Lived Assets</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for the impairment or disposal of long-lived assets according to the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) 360 “Property, Plant and Equipment”. ASC 360 clarifies the accounting for the impairment of long-lived assets and for long-lived assets to be disposed of, including the disposal of business segments and major lines of business. Long-lived assets are reviewed when facts and circumstances indicate that the carrying value of the asset may not be recoverable. When necessary, impaired assets are written down to estimated fair value based on the best information available. Estimated fair value is generally based on either appraised value or measured by discounting estimated future cash flows. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i> </b></p> </us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock> <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2022-09-01to2023-08-31"><p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zLUS1qmp63W4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_zMPjBNjTXWak">Fair Value of Financial Instruments</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following provides an analysis of financial instruments that are measured subsequent to initial recognition at fair value, grouped into Levels 1 to 3 based on the degree to which fair value is observable:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1 - fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical assets or liabilities;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2 - fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 - fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of August 31, 2023 and 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company applied ASC 820 for all non-financial assets and liabilities measured at fair value on a non-recurring basis. The adoption of ASC 820 for non-financial assets and liabilities did not have a significant impact on the Company’s financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of August 31, 2023, the company had <span id="xdx_90C_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_pp0p0_do_c20230831__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zwmD6vnxaVY4" title="Fair value of financial instruments">no</span> level 1 fair values financial instruments assets, and had financial instruments liabilities of $<span id="xdx_904_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_pp0p0_c20230831__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zk7UI53qLko4" title="Fair value of financial instruments">1,343,584</span> at level 3.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of August 31, 2023, the fair values of the Company’s financial instruments approximate their historical carrying amount.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> </us-gaap:FairValueOfFinancialInstrumentsPolicy> <us-gaap:FinancialInstrumentsOwnedAtFairValue contextRef="AsOf2023-08-31_us-gaap_FairValueInputsLevel1Member" decimals="0" unitRef="USD">0</us-gaap:FinancialInstrumentsOwnedAtFairValue> <us-gaap:FinancialInstrumentsOwnedAtFairValue contextRef="AsOf2023-08-31_us-gaap_FairValueInputsLevel3Member" decimals="0" unitRef="USD">1343584</us-gaap:FinancialInstrumentsOwnedAtFairValue> <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2022-09-01to2023-08-31"><p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zd4GJkrTJvI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_867_zfa6qvHm7Nnb">Research and development, net</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, employee benefits, the cost of supplies, the cost of services provided by outside contractors, including services related to the Company’s clinical trials, clinical trial expenses and the full cost of manufacturing product for use in research and preclinical development. All costs associated with research and developments are expensed as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources a substantial portion of its clinical trial activities, utilizing external entities such as Contract Research Organizations, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical studies. For each clinical trial that the Company conducts, clinical trial costs are expensed immediately.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> </us-gaap:ResearchAndDevelopmentExpensePolicy> <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2022-09-01to2023-08-31"><p id="xdx_845_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zw0IQJyuYpSi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_867_zj8xAVbxwC1g">Stock Based Compensation</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for Stock-Based Compensation under ASC 718 “Compensation – Stock Compensation”, which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 requires measurement of the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees. Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Any stock options or warrants issued to non-employees are recorded in expense and additional paid-in capital in shareholders' deficit over the applicable service periods using variable accounting through the vesting dates based on the fair value of the options or warrants at the end of each period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issues stock to consultants for various services. The costs for these transactions are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The value of the common stock is measured at the earlier of (i) the date at which a firm commitment for performance by the counterparty to earn the equity instruments is reached or (ii) the date at which the counterparty's performance is complete. The Company recognized consulting expense and a corresponding increase to additional paid-in-capital related to stock issued for services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> </us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy> <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2022-09-01to2023-08-31"><p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zUkROnVPmps" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_868_zUXl2xHYlfsf">Income Taxes</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Income taxes are accounted for under the liability method of accounting for income taxes. Under the liability method, future tax liabilities and assets are recognized for the estimated future tax consequences attributable to differences between the amounts reported in the financial statement carrying amounts of assets and liabilities and their respective tax bases. Future tax assets and liabilities are measured using enacted or substantially enacted income tax rates expected to apply when the asset is realized or the liability settled. The effect of a change in income tax rates on future income tax liabilities and assets is recognized in income in the period that the change occurs. Future income tax assets are recognized to the extent that they are considered more likely than not to be realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FASB has issued ASC 740 “Income Taxes”. ASC 740 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. This standard requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the implementation of this standard, the Company performed a review of its material tax positions in accordance with recognition and measurement standards established by ASC 740 and concluded that the tax position of the Company has not met the more-likely-than-not threshold as of August 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> </us-gaap:IncomeTaxPolicyTextBlock> <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2022-09-01to2023-08-31"><p id="xdx_84F_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zSnHwkCGDCU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_863_zAGkIY4cCnHg">Comprehensive Income</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company adopted ASC 220, <i>Comprehensive Income</i> which establishes standards for reporting and display of comprehensive income, its components and accumulated balances. The Company is disclosing this information on its Statement of Stockholders' Equity. Comprehensive income comprises equity except those resulting from investments by owners and distributions to owners. The Company has no elements of “other comprehensive income” for the years ended August 31, 2023, and 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> </us-gaap:ComprehensiveIncomePolicyPolicyTextBlock> <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2022-09-01to2023-08-31"><p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_zAoLYEHBGOJf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_860_zwYQG4hFDs02">Basic and Diluted Loss per Share</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company computes income (loss) per share in accordance with ASC 260, “Earnings per Share”, which requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the statement of operations. Basic EPS is computed by dividing income (loss) available to common shareholders by the weighted average number of shares outstanding during the period. Diluted EPS gives effect to all dilutive potential shares of common stock outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. As of August 31, 2023, and 2022, the potentially dilutive shares were anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> </us-gaap:EarningsPerSharePolicyTextBlock> <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2022-09-01to2023-08-31"><p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_znBnyLGreJAe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_861_zB3T8mebmmhd">Segment Information</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the provisions of ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, the Company is required to report financial and descriptive information about its reportable operating segments. The Company does not consider itself to have any operating segments as of August 31, 2023, and 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> </us-gaap:SegmentReportingPolicyPolicyTextBlock> <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2022-09-01to2023-08-31"><p id="xdx_848_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zVNcwYGTkZXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_864_z3ConaoVnQr4">Reclassification</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> </us-gaap:PriorPeriodReclassificationAdjustmentDescription> <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="From2022-09-01to2023-08-31"><p id="xdx_804_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zA1Tut4YNa4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 3 – <span id="xdx_82F_zlOfAqKbIydf">Recent Accounting Pronouncements</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2015, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis”, which provides guidance in evaluating entities for inclusion in consolidations. ASU 2015-02 is effective for fiscal years beginning after December 15, 2015. The Company does not believe the adoption of ASU 2015-02 will have a material effect on its consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-10 (“ASU 2014-10”), <i>Development Stage Entities (Topic 915), Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation.</i> The objective of the amendments in this Update is to improve financial reporting by reducing the cost and complexity associated with incremental reporting requirements for development stage entities. The amendments in this Update also eliminate an exception provided to development stage entities in Topic 810, Consolidation, for determining whether an entity is a variable interest entity on the basis of the amount of investment equity at risk. The amendments related to the elimination of inception-to-date information and the other remaining disclosure requirements of Topic 915 should be applied retrospectively except for the clarification to Topic 275, which shall be applied prospectively. These amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amendment eliminating the exception to the sufficiency-of-equity-at-risk criterion for development stage entities in paragraph 810-10-15-16 should be applied retrospectively for annual reporting periods beginning after December 15, 2015 and interim periods therein. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued. The Company has adopted ASU 2014-10 in the fourth quarter of 2014 and does not expect this adoption to have a material impact on its consolidated financial condition, results of operations or cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2014, the FASB issued ASU No. 2014-15, <i>Presentation of Financial Statements-Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.</i> The objective of the amendments in this Update is to provide guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if “conditions or events raise substantial doubt about the entity’s ability to continue as a going concern.” The ASU applies to all entities and is effective for annual periods ending after December 15, 2017, and interim periods thereafter, with early adoption permitted. The Company is evaluating the impact of ASU 2014-15 on its consolidated financial condition, results of operations and cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2015-16 (ASU 2015-16) "Simplifying the Accounting for Measurement Period Adjustments". ASU 2015-16 require that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The amendments in ASU 2015-16 require that the acquirer record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. The amendments in ASU 2015-16 require an entity to present separately on the face of the income statement or disclose in the notes the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. For public business entities, the amendments in ASU 2015-16 are effective for fiscal years beginning after December 15, 2015, including interim periods within those fiscal years. The amendments in ASU 2015-16 should be applied prospectively to adjustments to provisional amounts that occur after the effective date of this update with earlier application permitted for financial statements that have not been issued. For all other entities, the amendments in ASU 2015-16 are effective for fiscal years beginning after December 15, 2017, and interim periods within fiscal years beginning after December 15, 2017. The amendments in ASU 2015-16 should be applied prospectively to adjustments to provisional amounts that occur after the effective date of this update with earlier application permitted for financial statements that have not yet been made available for issuance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p> </us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock> <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2022-09-01to2023-08-31"><p id="xdx_801_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zOtjZrQ2oLXb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 4 – <span id="xdx_824_zoQatmsGZYv2">Related Party Transactions</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended August 31, 2023, and August 31, 2022, the Company paid approximately of $<span id="xdx_904_eus-gaap--OfficersCompensation_pp0p0_c20220901__20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndChairmanMember_zzDYIor6CfOk" title="Compensation paid">79,100</span> and $<span id="xdx_90C_eus-gaap--OfficersCompensation_pp0p0_c20210901__20220831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndChairmanMember_zQ6ssdpTfoV1" title="Compensation paid">334,395</span> as compensation to our CEO and chairman.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended August 31, 2023 the Company accrued additional $<span id="xdx_907_eus-gaap--AccruedSalariesCurrentAndNoncurrent_iI_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndChairmanMember_zaFIKrNa7BO1" title="Accrued salaries">416,497</span> in salaries, including socials benefits, to our CEO and chairman. compared to $<span id="xdx_90F_eus-gaap--AccruedSalariesCurrentAndNoncurrent_iI_c20220831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndChairmanMember_zCmQNQs4Jvm2" title="Accrued salaries">196,687</span> for the year ended August 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of August 31, 2023, the Company had a balance outstanding payable to our CEO and chairman: Gabriel Yariv and Eyal Barad in the total of $<span id="xdx_90B_eus-gaap--NotesPayableCurrent_iI_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndChairmanMember_zqx8rKkos1J4" title="Outstanding payable">613,184</span> under related parties compared to $<span id="xdx_90B_eus-gaap--NotesPayableCurrent_iI_c20220831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndChairmanMember_zehIJaPykONe" title="Outstanding payable">196,687</span> for the year ended August 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended August 31, 2023, and August 31, 2022, the Company paid approximately of $<span id="xdx_903_eus-gaap--OfficersCompensation_pp0p0_c20220901__20230831__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_z4WgbAZa4ce6" title="Compensation paid">40,321</span> and $<span id="xdx_90B_eus-gaap--OfficersCompensation_pp0p0_c20210901__20220831__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_z0kMEv2vSnK" title="Compensation paid">75,318</span> as compensation to our CFO</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended August 31, 2023 the Company accrued $<span id="xdx_904_eus-gaap--AccruedSalariesCurrentAndNoncurrent_iI_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThreeDirectorsMember_zexPZ54imLj4" title="Accrued salaries">43,000</span> in salaries to three directors compared to $<span id="xdx_90F_eus-gaap--AccruedSalariesCurrentAndNoncurrent_iI_c20220831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThreeDirectorsMember_zPxSjVLo2pl4" title="Accrued salaries">36,000</span> for the year ended August 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cannabics Inc. (the parent company) balance as of August 31, 2023, and on August 31, 2022 was $<span id="xdx_90C_ecustom--DueToRelatedPartiesCurrent1_iI_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CannabicsIncMember_zM2GcEfYdVQf" title="Due to related parties"><span id="xdx_905_ecustom--DueToRelatedPartiesCurrent1_iI_c20220831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CannabicsIncMember_zU99ZllDso17" title="Due to related parties">223,645</span></span>. The advance is due on demand and bears no interest.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended August 31, 2023, the Company recorded a non cash expense of $<span id="xdx_90E_eus-gaap--OtherNoncashExpense_c20220901__20230831__us-gaap--NonmonetaryTransactionTypeAxis__custom--ShareBasedPaymentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChairmanAndBoardMembersMember_zjr6PraKzgHf" title="Non cash expense">168,551</span> as share based payment, to the company chairman and board members, compared to $<span id="xdx_905_eus-gaap--OtherNoncashExpense_c20210901__20220831__us-gaap--NonmonetaryTransactionTypeAxis__custom--ShareBasedPaymentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChairmanAndBoardMembersMember_z0LMpBvonJhh" title="Non cash expense">670,850</span> for the year ended August 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> </us-gaap:RelatedPartyTransactionsDisclosureTextBlock> <us-gaap:OfficersCompensation contextRef="From2022-09-012023-08-31_custom_CEOAndChairmanMember" decimals="0" unitRef="USD">79100</us-gaap:OfficersCompensation> <us-gaap:OfficersCompensation contextRef="From2021-09-012022-08-31_custom_CEOAndChairmanMember" decimals="0" unitRef="USD">334395</us-gaap:OfficersCompensation> <us-gaap:AccruedSalariesCurrentAndNoncurrent contextRef="AsOf2023-08-31_custom_CEOAndChairmanMember" decimals="0" unitRef="USD">416497</us-gaap:AccruedSalariesCurrentAndNoncurrent> <us-gaap:AccruedSalariesCurrentAndNoncurrent contextRef="AsOf2022-08-31_custom_CEOAndChairmanMember" decimals="0" unitRef="USD">196687</us-gaap:AccruedSalariesCurrentAndNoncurrent> <us-gaap:NotesPayableCurrent contextRef="AsOf2023-08-31_custom_CEOAndChairmanMember" decimals="0" unitRef="USD">613184</us-gaap:NotesPayableCurrent> <us-gaap:NotesPayableCurrent contextRef="AsOf2022-08-31_custom_CEOAndChairmanMember" decimals="0" unitRef="USD">196687</us-gaap:NotesPayableCurrent> <us-gaap:OfficersCompensation contextRef="From2022-09-012023-08-31_srt_ChiefFinancialOfficerMember" decimals="0" unitRef="USD">40321</us-gaap:OfficersCompensation> <us-gaap:OfficersCompensation contextRef="From2021-09-012022-08-31_srt_ChiefFinancialOfficerMember" decimals="0" unitRef="USD">75318</us-gaap:OfficersCompensation> <us-gaap:AccruedSalariesCurrentAndNoncurrent contextRef="AsOf2023-08-31_custom_ThreeDirectorsMember" decimals="0" unitRef="USD">43000</us-gaap:AccruedSalariesCurrentAndNoncurrent> <us-gaap:AccruedSalariesCurrentAndNoncurrent contextRef="AsOf2022-08-31_custom_ThreeDirectorsMember" decimals="0" unitRef="USD">36000</us-gaap:AccruedSalariesCurrentAndNoncurrent> <CNBX:DueToRelatedPartiesCurrent1 contextRef="AsOf2023-08-31_custom_CannabicsIncMember" decimals="0" unitRef="USD">223645</CNBX:DueToRelatedPartiesCurrent1> <CNBX:DueToRelatedPartiesCurrent1 contextRef="AsOf2022-08-31_custom_CannabicsIncMember" decimals="0" unitRef="USD">223645</CNBX:DueToRelatedPartiesCurrent1> <us-gaap:OtherNoncashExpense contextRef="From2022-09-012023-08-31_custom_ShareBasedPaymentMember_custom_ChairmanAndBoardMembersMember" decimals="0" unitRef="USD">168551</us-gaap:OtherNoncashExpense> <us-gaap:OtherNoncashExpense contextRef="From2021-09-012022-08-31_custom_ShareBasedPaymentMember_custom_ChairmanAndBoardMembersMember" decimals="0" unitRef="USD">670850</us-gaap:OtherNoncashExpense> <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2022-09-01to2023-08-31"><p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z3kHD7j9uta1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 5 – <span id="xdx_82E_ziZ88Wu6bLQa">Commitments and Contingencies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As security for its obligation under a property lease agreement, cars lease and credit cards of the Company’s subsidiary provided a bank guarantee in the amount of $<span id="xdx_900_eus-gaap--BankAcceptancesExecuted_iI_pp0p0_c20230831_zAvFvkfyLf7c" title="Bank guarantee">5,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock> <us-gaap:BankAcceptancesExecuted contextRef="AsOf2023-08-31" decimals="0" unitRef="USD">5000</us-gaap:BankAcceptancesExecuted> <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2022-09-01to2023-08-31"><p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z3g3uDVdRAMk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 6 – <span id="xdx_820_zr2rYOmYpUgk">Stockholders’ Equity (Deficit)</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Authorized Shares</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is authorized to issue up to <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20230831_zcSC7Ij68Wig" title="Common stock, shares authorized">900,000,000</span> shares of common stock par value $0<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230831_zl4VRxR25Yf2" title="Common stock, par value">.0001</span> per share. Each outstanding share of common stock entitles the holder to one vote per share on all matters submitted to a stockholder vote. All shares of common stock are non-assessable and non-cumulative, with no pre-emptive rights. The Company’s initial Articles authorized <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20230831_zQkar9JR7Mnj" title="Preferred stock, shares authorized">5,000,000</span> preferred shares at <span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230831_zXhvGdakyud6" title="Preferred stock, par value">.0001</span> par value, no other attributes have been assigned and no such shares have ever been issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Common Stock</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 12, 2022, the Company effected a reverse-split of its common stock on a <span id="xdx_90B_eus-gaap--StockholdersEquityReverseStockSplit_c20220511__20220512_z14s04EETD9a" title="Stock split">1:120</span> basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended August 31, 2023, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220901__20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z8JPRd14xF85" title="Stock issued for exercise of convertible debt, shares issued">21,372,693</span> shares of its common stock to an investors as a result of a convertible loan exercise in the sum of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pp0p0_c20220901__20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zJHxP2ewukx3" title="Stock issued for exercise of convertible debt, value">569,930</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock Based Compensation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 6, 2021, the Compensation Committee adopted, and the Board ratified the Company’s Equity Incentive Plan. The Plan is intended to secure for the Company the benefits arising from ownership of the Company’s common stock by the employees, officers, directors and consultants of the Company, all of whom are, and will be, responsible for the Company’s future growth. The Plan is designed to help attract and retain for the Company, qualified personnel for positions of exceptional responsibility, to reward employees, officers, directors and consultants for their services to the Company and to motivate such individuals through added incentives to further contribute to the success of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Plan provides an opportunity for an employee, officer, director or consultant of the Company, subject to certain national securities and taxation laws, to receive (i) incentive stock options, (ii) nonqualified stock options; (iii) restricted stock; (iv) stock awards; (v) shares in performance of services; or (vi) any combination of the foregoing. Incentive stock options granted under the Plan are intended to qualify as “<span style="text-decoration: underline">incentive stock options</span>” within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the “<span style="text-decoration: underline">Code</span>”). Nonqualified (non-statutory stock options) granted under the Plan are not intended to qualify as incentive stock options under the Code. The Plan is administered by the Altshuler Shaham Benefits Firm, a licensed fiduciary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 2, 2022, the Compensation Committee approved amending the Plan to increase the number of shares reserved for issuance under the Plan to 15% of the common stock outstanding immediately following consummation of this offering.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Private Placement of Notes and Warrant</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 16, 2020, we entered into a Securities Purchase Agreement (“SPA”) with an institutional investor for a private placement of senior secured convertible notes totaling up to an aggregate of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfSeniorLongTermDebt_pp0p0_c20201215__20201216__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zk1bwJMLs0nc" title="Senior convertible notes issued">2,750,000</span> to be issued in three tranches subject to the achievement of certain milestones. The convertible notes include a conversion right, at the Investor’s option, to convert the convertible notes into shares of our Common Stock at a conversion price equal to the lower of (i) $<span id="xdx_90E_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20201215__20201216__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zOnfx4Qw2mV6" title="Conversion price">42</span> per share or (ii) eighty percent (80%) of the average of the two lowest daily volume-weighted average price for the Company’s Common Stock during the ten (10) consecutive trading days preceding the conversion date (the “notes”). The investor has the right to have the conversion price reduced if we issue Common Stock or convertible notes at a lower conversion price than $<span id="xdx_90A_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20201215__20201216__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z2jUUxfFyUuk" title="Lower conversion price">42</span> during the period that the notes are outstanding. The notes are due one year from issuance. The notes will be interest free, but in the event of a default, they will bear annual interest at a rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20201215__20201216__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zKgTRMPKmjBa" title="Interest rate">18.00</span>%. The SPA and the notes contain events of default, including, among other things, failure to repay the notes by the maturity date, and bankruptcy and insolvency events, that would result in the imposition of the default interest rate.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 21, 2020, we closed the first tranche and issued a note in the amount of $<span id="xdx_90F_eus-gaap--ProceedsFromNotesPayable_pp0p0_c20201220__20201221__us-gaap--DebtInstrumentAxis__custom--InitialNoteMember_zdqkQGqtXS27" title="Notes payable">825,000</span> (the “Initial Note”). On February 22, 2021, we closed the second tranche and issued a second note in the amount of $<span id="xdx_906_eus-gaap--ProceedsFromNotesPayable_pp0p0_c20210221__20210222__us-gaap--DebtInstrumentAxis__custom--SecondNoteMember_zXO2H5cmHXXd" title="Notes payable">550,000</span> (the “Second Note”). On April 23, 2021, we closed the third tranche and issued a third note in the amount of $<span id="xdx_906_eus-gaap--ProceedsFromNotesPayable_pp0p0_c20210422__20210423__us-gaap--DebtInstrumentAxis__custom--NoteMember_zoOezx6QHnwi" title="Notes payable">1,375,000</span> (the “Note”). The Initial Note was issued at a discount of $<span id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20201221__us-gaap--DebtInstrumentAxis__custom--InitialNoteMember_ztOhqMrdg4x1" title="Unamortized Discount">75,000</span>; the Second Note was issued at a discount of $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20210222__us-gaap--DebtInstrumentAxis__custom--SecondNoteMember_ztfJSHYMovW" title="Unamortized Discount">50,000</span>; and the Note was issued at a discount of $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20210423__us-gaap--DebtInstrumentAxis__custom--NoteMember_zjVD2KhK89Bl" title="Unamortized Discount">125,000</span>. In addition, we issued to the Investor <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220901__20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z9MaZauuZ4G2" title="Convertible shares">32,614</span> shares of Common Stock as pre-delivery shares in accordance with the terms of the SPA, which shares will be deducted from the total number of shares to be issued to the Investor upon conversion of the Initial Note.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 23, 2021, we entered into a senior secured promissory note (the “Senior Secured Note”) for $<span id="xdx_903_eus-gaap--SeniorNotesCurrent_iI_pp0p0_c20210423__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNoteMember_zQyCa2JUTnWc" title="Senior secured note">1,375,000</span> with the institutional investor. This follows the SPA, a restated securities purchase agreement dated as of February 22, 2021, as well as accompanying documents for an aggregate principal amount of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210423__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNoteMember_zIcUp6BkM1f4" title="Principal amount">2,750,000</span> having an aggregate original issue discount of <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20210423__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNoteMember_zOQ8UQOZidle" title="Original issue discount percentage">10</span>%, and ranking senior to all outstanding and future indebtedness of the Company. In addition, the SPA granted the investor a right to receive 100% warrant coverage, and we issued a warrant to the investor for up to <span id="xdx_904_ecustom--WarrantsIssued_c20210422__20210423__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNoteMember_zYxRMBTU8Rok" title="Warrants issued">45,833</span> shares of our Common Stock, which expires three years from the issuance date of the warrant, with an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210423__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNoteMember_zoc83BqupLwk" title="Warrants exercise price">60</span> per share. The warrant may be exercised and converted to Common Stock at the investor’s option at any time until the expiration date. These securities were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act, and Regulation D promulgated thereunder, as these securities were sold to “accredited investors” within the meaning of Regulation D.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 15, 2022, we entered into a forbearance agreements with the institutional investor relating to that certain Senior Secured Note. Pursuant to the forbearance agreement, the investor, through March 7, 2022, agreed to forbear from exercising any rights and remedies against the Company related to the outstanding payments and to waive certain other defaults under the Senior Secured Note and related rights pursuant to the registration rights agreement entered into in December 2020 between the Company and the investor.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 28, 2022, we entered into a forbearance agreements with the institutional investor relating to that certain Senior Secured Note. Pursuant to the forbearance agreement, the investor, through December 12, 2022, agreed to forbear from exercising any rights and remedies against the Company related to the outstanding payments and to waive certain other defaults under the Senior Secured Note and related rights pursuant to the registration rights agreement entered into in December 2020 between the Company and the investor.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 16, 2022, we issued to the investor a demand promissory note (the “Demand Note”) in the principal amount of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220316__us-gaap--LongtermDebtTypeAxis__custom--DemandNoteMember_z1r7BHLwqZX" title="Principal amount">280,000</span> (the “Principal”) with an original issue discount of $<span id="xdx_902_ecustom--OriginalIssueDiscount_pp0p0_c20220315__20220316__us-gaap--LongtermDebtTypeAxis__custom--DemandNoteMember_zYH3mYZktDZa" title="Original issue discount">40,000</span>. The Demand Note is payable on demand at any time after the earlier to occur of (i) May 16, 2022, and (ii) the public or private offering of any securities by the Company (the “Next Subsequent Placement”). Any amount of Principal due under the Demand Note which is not paid when due shall result in a late charge being incurred and payable by the Company in an amount equal to interest on such amount at the rate of fifteen percent (15%) per annum from the date such amount was due until the same is paid in full (the “Late Charges”). With the agreement, the Principal and accrued and unpaid Late Charges under the Demand Note and amounts owed under the Senior Secured Note may be applied to all, or any part, of the purchase price of securities to be issued upon the consummation of an offering of securities by the Company to the investor. So long as any amounts remain outstanding under the Demand Note or the Senior Secured Note, all cash proceeds received by the Company on or after issuance of the Demand Note from the Next Subsequent Placement or any other sales of any securities of the Company shall be used to (x) first, repay the Demand Note and (y) second, repay the Senior Secured Note.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 28, 2022, we entered into a forbearance agreements with the institutional investor relating to that certain Senior Secured Note. Pursuant to the forbearance agreement, the investor, through December 12, 2022, agreed to forbear from exercising any rights and remedies against the Company related to the outstanding payments and to waive certain other defaults under the Senior Secured Note and related rights pursuant to the registration rights agreement entered into in May 16, 2022 between the Company and the investor.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 15, 2022, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220615__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zkN1XDryNNtk" title="Principal amount">154,250</span>.00. ($<span id="xdx_905_eus-gaap--InterestExpenseOtherLongTermDebt_pp0p0_c20220614__20220615__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zgheLxOCvI43" title="Net of issuance expenses">154,000</span> net of issuance expenses). The Convertible Promissory Note carry interest of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220614__20220615__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zbvqBdt1hZh9" title="Interest rate">9</span>% and due on June 15<sup>th</sup> 2023<span style="color: red">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the period of January through March , 2023, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zqN0c5VPYHWd" title="Principal amount">35,000</span>.00. ($<span id="xdx_902_eus-gaap--InterestExpenseOtherLongTermDebt_pp0p0_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zK6YLaXASyfi" title="Net of issuance expenses">35,000</span> net of issuance expenses). The Convertible Promissory Note carry interest of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zPj9HYsjnbvd" title="Interest rate">5</span>% and due on June 15<sup>th</sup> 2023</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 12, 2023, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230612__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z7JAkqQtRzXf" title="Principal amount">65,000</span>.00. ($<span id="xdx_901_eus-gaap--InterestExpenseOtherLongTermDebt_pp0p0_c20230611__20230612__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zgZY5ZFjPn3f" title="Net of issuance expenses">65,000</span> net of issuance expenses). The Convertible Promissory Note carry interest of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20230611__20230612__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zI32sSvd2mka" title="Interest rate">5</span>% and due on August 85<sup>th</sup> 2023</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> </us-gaap:StockholdersEquityNoteDisclosureTextBlock> <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-08-31" decimals="INF" unitRef="Shares">900000000</us-gaap:CommonStockSharesAuthorized> <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2023-08-31" decimals="INF" unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare> <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2023-08-31" decimals="INF" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized> <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2023-08-31" decimals="INF" unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare> <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2022-05-112022-05-12">1:120</us-gaap:StockholdersEquityReverseStockSplit> <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2022-09-012023-08-31_us-gaap_InvestorMember" decimals="INF" unitRef="Shares">21372693</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities> <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2022-09-012023-08-31_us-gaap_InvestorMember" decimals="0" unitRef="USD">569930</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities> <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt contextRef="From2020-12-152020-12-16_custom_SecuritiesPurchaseAgreementMember" decimals="0" unitRef="USD">2750000</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt> <us-gaap:CommonStockConvertibleConversionPriceIncrease contextRef="From2020-12-152020-12-16_custom_SecuritiesPurchaseAgreementMember" decimals="INF" unitRef="USDPShares">42</us-gaap:CommonStockConvertibleConversionPriceIncrease> <us-gaap:CommonStockConvertibleConversionPriceDecrease contextRef="From2020-12-152020-12-16_custom_SecuritiesPurchaseAgreementMember" decimals="INF" unitRef="USDPShares">42</us-gaap:CommonStockConvertibleConversionPriceDecrease> <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="From2020-12-152020-12-16_custom_SecuritiesPurchaseAgreementMember" decimals="INF" unitRef="Pure">0.1800</us-gaap:DebtInstrumentInterestRateDuringPeriod> <us-gaap:ProceedsFromNotesPayable contextRef="From2020-12-202020-12-21_custom_InitialNoteMember" decimals="0" unitRef="USD">825000</us-gaap:ProceedsFromNotesPayable> <us-gaap:ProceedsFromNotesPayable contextRef="From2021-02-212021-02-22_custom_SecondNoteMember" decimals="0" unitRef="USD">550000</us-gaap:ProceedsFromNotesPayable> <us-gaap:ProceedsFromNotesPayable contextRef="From2021-04-222021-04-23_custom_NoteMember" decimals="0" unitRef="USD">1375000</us-gaap:ProceedsFromNotesPayable> <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-21_custom_InitialNoteMember" decimals="0" unitRef="USD">75000</us-gaap:DebtInstrumentUnamortizedDiscount> <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2021-02-22_custom_SecondNoteMember" decimals="0" unitRef="USD">50000</us-gaap:DebtInstrumentUnamortizedDiscount> <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2021-04-23_custom_NoteMember" decimals="0" unitRef="USD">125000</us-gaap:DebtInstrumentUnamortizedDiscount> <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2022-09-012023-08-31_us-gaap_InvestorMember_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares">32614</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities> <us-gaap:SeniorNotesCurrent contextRef="AsOf2021-04-23_custom_SeniorSecuredNoteMember" decimals="0" unitRef="USD">1375000</us-gaap:SeniorNotesCurrent> <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2021-04-23_custom_SeniorSecuredNoteMember" decimals="0" unitRef="USD">2750000</us-gaap:DebtInstrumentFaceAmount> <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2021-04-23_custom_SeniorSecuredNoteMember" decimals="INF" unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage> <CNBX:WarrantsIssued contextRef="From2021-04-222021-04-23_custom_SeniorSecuredNoteMember" decimals="INF" unitRef="Shares">45833</CNBX:WarrantsIssued> <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2021-04-23_custom_SeniorSecuredNoteMember" decimals="INF" unitRef="USDPShares">60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1> <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2022-03-16_custom_DemandNoteMember" decimals="0" unitRef="USD">280000</us-gaap:DebtInstrumentFaceAmount> <CNBX:OriginalIssueDiscount contextRef="From2022-03-152022-03-16_custom_DemandNoteMember" decimals="0" unitRef="USD">40000</CNBX:OriginalIssueDiscount> <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2022-06-15_custom_SecuritiesPurchaseAgreementMember" decimals="0" unitRef="USD">154250</us-gaap:DebtInstrumentFaceAmount> <us-gaap:InterestExpenseOtherLongTermDebt contextRef="From2022-06-142022-06-15_custom_SecuritiesPurchaseAgreementMember" decimals="0" unitRef="USD">154000</us-gaap:InterestExpenseOtherLongTermDebt> <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="From2022-06-142022-06-15_custom_SecuritiesPurchaseAgreementMember" decimals="INF" unitRef="Pure">0.09</us-gaap:DebtInstrumentInterestRateDuringPeriod> <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2023-03-31_custom_SecuritiesPurchaseAgreementMember" decimals="0" unitRef="USD">35000</us-gaap:DebtInstrumentFaceAmount> <us-gaap:InterestExpenseOtherLongTermDebt contextRef="From2023-01-012023-03-31_custom_SecuritiesPurchaseAgreementMember" decimals="0" unitRef="USD">35000</us-gaap:InterestExpenseOtherLongTermDebt> <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="From2023-01-012023-03-31_custom_SecuritiesPurchaseAgreementMember" decimals="INF" unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateDuringPeriod> <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2023-06-12_custom_SecuritiesPurchaseAgreementMember" decimals="0" unitRef="USD">65000</us-gaap:DebtInstrumentFaceAmount> <us-gaap:InterestExpenseOtherLongTermDebt contextRef="From2023-06-112023-06-12_custom_SecuritiesPurchaseAgreementMember" decimals="0" unitRef="USD">65000</us-gaap:InterestExpenseOtherLongTermDebt> <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="From2023-06-112023-06-12_custom_SecuritiesPurchaseAgreementMember" decimals="INF" unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateDuringPeriod> <CNBX:WarrantDisclosureTextBlock contextRef="From2022-09-01to2023-08-31"><p id="xdx_80C_ecustom--WarrantDisclosureTextBlock_zIBYLKFNNOAd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 7 – <span id="xdx_820_zZbl1RNUJYfi">Warrants</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%"> </td> <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 24, 2018, as part of a securities purchase agreement the company issued <span id="xdx_90A_ecustom--WarrantsIssuedShares_iI_c20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zN5No6biie1j" title="Warrants issued, shares">41,667 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants, to purchase common shares of the Company at $1.00 per share; said Warrants are valid for five years, expiring on <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zUC8E42d8e1l" title="Expiry date">August 24<sup>th</sup>, 2023</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of each warrant is approximately $66 and the total value of the 41,667 warrants is $<span id="xdx_906_ecustom--FairValueOfWarrantsIssued_iI_pp0p0_c20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zXDplwKeIdZb" title="Fair value of warrants issued">2,784,387</span></span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the warrants are estimated using the Black Scholes option-pricing model with the following assumptions:</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfAssumptionsUsedWarrantsTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zVElxf5u2a8b" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details - Fair value)"> <tr style="vertical-align: bottom"> <td> </td> <td><span id="xdx_8BA_zJm3qkZpcmnd" style="display: none">Schedule of assumptions</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 4%"> </td> <td style="width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PV of exercise Share price</span></td> <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_909_eus-gaap--SharePrice_iI_c20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_z1BT0cHaYSe" title="PV of exercise Share price">1</span></span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Volatility</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20180923__20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zeTBcoOuuMM3" title="Expected Volatility">102.0</span>%</span></td></tr> <tr style="vertical-align: bottom"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Free Interest Rate</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20180923__20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zdNvz4JpueA9" title="Risk Free Interest Rate">1.58</span>%</span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Term (years)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180923__20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zFtOmMqNY6ni" title="Expected Term (years)">5</span></span></td></tr> <tr style="vertical-align: bottom"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Dividend Yield</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20180923__20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zrFEQSaMlp2f" title="Expected Dividend Yield">0</span>%</span></td></tr> </table> <p id="xdx_8A5_zjfuPdWMVrp2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.55pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: justify">The said warrants expired on August 24, 2023</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.55pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%"> </td> <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 16, 2020, as part of a convertible loan agreement the company issued <span id="xdx_90F_ecustom--WarrantsIssuedShares_iI_c20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zbWV2H4HvBId" title="Warrants issued, shares">45,667 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants, to purchase common shares of the Company at $0.50 per share; said Warrants are valid for three years, expiring on <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zfC8VHQycqT7" title="Expiry date">August 24<sup>th</sup>, 2023</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The first trench was received on December 22, 2020, the second trench was received on February 2,2021 and the third trench was received on April 23, 2021, in the total sum of $2,456,750 net of issuance expenses.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: justify">The fair value of the first, second and third trenches are approximately $10.8, $10.8 and $12 respectively and the total value of the 45,667 warrants is $<span id="xdx_90A_ecustom--FairValueOfWarrantsIssued_iI_pp0p0_c20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zWpAFglpSLy2" title="Fair value of warrants issued">515,818</span></p></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the warrants are estimated using the Black Scholes option-pricing model with the following assumptions:</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_891_ecustom--ScheduleOfAssumptionsUsedWarrantsTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zVngV2lP0uHc" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details - Fair Value)"> <tr style="vertical-align: bottom"> <td> </td> <td><span id="xdx_8B4_zxXZSpwzzkcb" style="display: none">Schedule of assumptions</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 4%"> </td> <td style="width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PV of exercise Share price</span></td> <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_902_eus-gaap--SharePrice_iI_c20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zNnoDkT6AMg6" title="PV of exercise Share price">0.50</span></span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Volatility</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20201215__20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_z9rpupLhw5Pi" title="Expected Volatility">117.0</span>%</span></td></tr> <tr style="vertical-align: bottom"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Free Interest Rate</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20201215__20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zFW1J9F73Pai" title="Risk Free Interest Rate">0.3</span>%</span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Term (years)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201215__20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zWx6JIt6RCIk" title="Expected Term (years)">3</span></span></td></tr> <tr style="vertical-align: bottom"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Dividend Yield</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20201215__20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_z1t4FU9U4YTg" title="Expected Dividend Yield">0</span>%</span></td></tr> </table> <p id="xdx_8A5_z1W67LP466G5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.55pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The said warrants expired on <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zd7iWix5XxC1" title="Expiry date">August 24, 2023</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.55pt"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zERxgiZX0yd8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrants (Details - Warrant activity)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8BB_ztOw1gBNt206" style="display: none">Schedule of warrant activity</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Weighted Average Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Weighted Average Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Weighted Average Exercise</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 28%; text-indent: -8.1pt; padding-left: 8.1pt">Warrants outstanding as of September 1</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zgWrZ1o57Ct3" style="width: 9%; text-align: right" title="Warrants outstanding, beginning balance">87,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zgvVr5xXzDUj" style="width: 9%; text-align: right" title="Weighted average exercise price, warrants outstanding, beginning balance">88.6</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z5foQcP6gjNb" style="width: 9%; text-align: right" title="Warrants outstanding, beginning balance">87,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zIRlhE1ltJD" style="width: 9%; text-align: right" title="Weighted average exercise price, warrants outstanding, beginning balance">88.6</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zNG7yT6CJkq6" style="width: 9%; text-align: right" title="Warrants outstanding, beginning balance">41,667</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z4EfRS3SYc7j" style="width: 9%; text-align: right" title="Weighted average exercise price, warrants outstanding, beginning balance">120</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--WarrantsIssued_d0_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zK64zLnL95yb" style="text-align: right" title="Warrants issued">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_ecustom--WeightedAverageExercisePriceWarrantsIssued_d0_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z7vqhXQ16R2e" style="text-align: right" title="Weighted average exercise price, warrants issued">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--WarrantsIssued_d0_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zi2frAR9Toce" style="text-align: right" title="Warrants issued">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_ecustom--WeightedAverageExercisePriceWarrantsIssued_d0_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_ztYq09v4YV18" style="text-align: right" title="Weighted average exercise price, warrants issued">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--WarrantsIssued_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zYvUnGuitYh2" style="text-align: right" title="Warrants issued">45,667</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_ecustom--WeightedAverageExercisePriceWarrantsIssued_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zh5bN0Ls9Q0h" style="text-align: right" title="Weighted average exercise price, warrants issued">60</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_d0_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zFORyrQsEHh3" style="text-align: right" title="Warrants exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_ecustom--WeightedAverageExercisePriceWarrantsExercised_d0_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zrTkVciJK45h" style="text-align: right" title="Weighted average exercise price, warrants exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_d0_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zLaPhjRgS6lc" style="text-align: right" title="Warrants exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_ecustom--WeightedAverageExercisePriceWarrantsExercised_d0_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zL50dXEitBJa" style="text-align: right" title="Weighted average exercise price, warrants exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_d0_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_ztSvWZlzcKR3" style="text-align: right" title="Warrants exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_ecustom--WeightedAverageExercisePriceWarrantsExercised_d0_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zOz7RF1oXiYb" style="text-align: right" title="Weighted average exercise price, warrants exercised">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zoq1gLO5YWM4" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired">(87,500</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_ecustom--WeightedAverageExercisePriceWarrantsExpired_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zmTxZ6yTyGQh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants expired">88.6</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di0_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z7MHQglGENQ3" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_ecustom--WeightedAverageExercisePriceWarrantsExpired_d0_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zCw0QQ3P4pNb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di0_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z4uHcKnaBAD3" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_ecustom--WeightedAverageExercisePriceWarrantsExpired_d0_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zxwCmQKkAzF3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt; text-indent: -8.1pt; padding-left: 8.1pt">Warrants outstanding as of August 31</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_d0_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zCfIPlGsIcLl" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants outstanding, ending balance">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_d0_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zfaJlc2tU8jg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants outstanding, ending balance">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z5eiwsHAgBoh" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants outstanding, ending balance">87,500</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z2KaL2aRhJ9e" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants outstanding, ending balance">88.6</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_ziC9jWbqiksg" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants outstanding, ending balance">87,500</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zbI297c0Ydyf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants outstanding, ending balance">88.6</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt; text-indent: -8.1pt; padding-left: 8.1pt">Warrants exercisable as of August 31</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_d0_c20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zJpk2wG0d7u8" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--WeightedAverageExercisePriceWarrantsExercisable_iI_d0_c20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zXSu0jo1Ulu9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, warrants exercisable">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zodeKPStZEDf" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable">87,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--WeightedAverageExercisePriceWarrantsExercisable_iI_c20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zSlPEJMqXZZ4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, warrants exercisable">88.6</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zRv5ZXdapHNi" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable">87,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--WeightedAverageExercisePriceWarrantsExercisable_iI_c20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z3qpfUHjwVp5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, warrants exercisable">88.6</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zbng7zRCLFw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.55pt"> </p> </CNBX:WarrantDisclosureTextBlock> <CNBX:WarrantsIssuedShares contextRef="AsOf2018-09-24_custom_Warrant1Member" decimals="INF" unitRef="Shares">41667</CNBX:WarrantsIssuedShares> <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2018-09-24_custom_Warrant1Member">2023-08-24</us-gaap:WarrantsAndRightsOutstandingMaturityDate> <CNBX:FairValueOfWarrantsIssued contextRef="AsOf2018-09-24_custom_Warrant1Member" decimals="0" unitRef="USD">2784387</CNBX:FairValueOfWarrantsIssued> <CNBX:ScheduleOfAssumptionsUsedWarrantsTableTextBlock contextRef="From2022-09-012023-08-31_custom_Warrant1Member"><table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfAssumptionsUsedWarrantsTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zVElxf5u2a8b" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details - Fair value)"> <tr style="vertical-align: bottom"> <td> </td> <td><span id="xdx_8BA_zJm3qkZpcmnd" style="display: none">Schedule of assumptions</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 4%"> </td> <td style="width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PV of exercise Share price</span></td> <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_909_eus-gaap--SharePrice_iI_c20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_z1BT0cHaYSe" title="PV of exercise Share price">1</span></span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Volatility</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20180923__20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zeTBcoOuuMM3" title="Expected Volatility">102.0</span>%</span></td></tr> <tr style="vertical-align: bottom"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Free Interest Rate</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20180923__20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zdNvz4JpueA9" title="Risk Free Interest Rate">1.58</span>%</span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Term (years)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180923__20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zFtOmMqNY6ni" title="Expected Term (years)">5</span></span></td></tr> <tr style="vertical-align: bottom"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Dividend Yield</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20180923__20180924__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant1Member_zrFEQSaMlp2f" title="Expected Dividend Yield">0</span>%</span></td></tr> </table> </CNBX:ScheduleOfAssumptionsUsedWarrantsTableTextBlock> <us-gaap:SharePrice contextRef="AsOf2018-09-24_custom_Warrant1Member" decimals="INF" unitRef="USDPShares">1</us-gaap:SharePrice> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2018-09-232018-09-24_custom_Warrant1Member" decimals="INF" unitRef="Pure">1.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2018-09-232018-09-24_custom_Warrant1Member" decimals="INF" unitRef="Pure">0.0158</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate> <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2018-09-232018-09-24_custom_Warrant1Member">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2018-09-232018-09-24_custom_Warrant1Member" decimals="INF" unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate> <CNBX:WarrantsIssuedShares contextRef="AsOf2020-12-16_custom_Warrant2Member" decimals="INF" unitRef="Shares">45667</CNBX:WarrantsIssuedShares> <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2020-12-16_custom_Warrant2Member">2023-08-24</us-gaap:WarrantsAndRightsOutstandingMaturityDate> <CNBX:FairValueOfWarrantsIssued contextRef="AsOf2020-12-16_custom_Warrant2Member" decimals="0" unitRef="USD">515818</CNBX:FairValueOfWarrantsIssued> <CNBX:ScheduleOfAssumptionsUsedWarrantsTableTextBlock contextRef="From2022-09-012023-08-31_custom_Warrant2Member"><table cellpadding="0" cellspacing="0" id="xdx_891_ecustom--ScheduleOfAssumptionsUsedWarrantsTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zVngV2lP0uHc" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details - Fair Value)"> <tr style="vertical-align: bottom"> <td> </td> <td><span id="xdx_8B4_zxXZSpwzzkcb" style="display: none">Schedule of assumptions</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 4%"> </td> <td style="width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PV of exercise Share price</span></td> <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_902_eus-gaap--SharePrice_iI_c20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zNnoDkT6AMg6" title="PV of exercise Share price">0.50</span></span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Volatility</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20201215__20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_z9rpupLhw5Pi" title="Expected Volatility">117.0</span>%</span></td></tr> <tr style="vertical-align: bottom"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Free Interest Rate</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20201215__20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zFW1J9F73Pai" title="Risk Free Interest Rate">0.3</span>%</span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Term (years)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201215__20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_zWx6JIt6RCIk" title="Expected Term (years)">3</span></span></td></tr> <tr style="vertical-align: bottom"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Dividend Yield</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20201215__20201216__us-gaap--ClassOfWarrantOrRightAxis__custom--Warrant2Member_z1t4FU9U4YTg" title="Expected Dividend Yield">0</span>%</span></td></tr> </table> </CNBX:ScheduleOfAssumptionsUsedWarrantsTableTextBlock> <us-gaap:SharePrice contextRef="AsOf2020-12-16_custom_Warrant2Member" decimals="INF" unitRef="USDPShares">0.50</us-gaap:SharePrice> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2020-12-152020-12-16_custom_Warrant2Member" decimals="INF" unitRef="Pure">1.170</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2020-12-152020-12-16_custom_Warrant2Member" decimals="INF" unitRef="Pure">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate> <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-12-152020-12-16_custom_Warrant2Member">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2020-12-152020-12-16_custom_Warrant2Member" decimals="INF" unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate> <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2020-12-16_custom_Warrant2Member">2023-08-24</us-gaap:WarrantsAndRightsOutstandingMaturityDate> <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2022-09-01to2023-08-31"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zERxgiZX0yd8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrants (Details - Warrant activity)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8BB_ztOw1gBNt206" style="display: none">Schedule of warrant activity</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Weighted Average Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Weighted Average Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Weighted Average Exercise</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 28%; text-indent: -8.1pt; padding-left: 8.1pt">Warrants outstanding as of September 1</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zgWrZ1o57Ct3" style="width: 9%; text-align: right" title="Warrants outstanding, beginning balance">87,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zgvVr5xXzDUj" style="width: 9%; text-align: right" title="Weighted average exercise price, warrants outstanding, beginning balance">88.6</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z5foQcP6gjNb" style="width: 9%; text-align: right" title="Warrants outstanding, beginning balance">87,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zIRlhE1ltJD" style="width: 9%; text-align: right" title="Weighted average exercise price, warrants outstanding, beginning balance">88.6</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zNG7yT6CJkq6" style="width: 9%; text-align: right" title="Warrants outstanding, beginning balance">41,667</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z4EfRS3SYc7j" style="width: 9%; text-align: right" title="Weighted average exercise price, warrants outstanding, beginning balance">120</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--WarrantsIssued_d0_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zK64zLnL95yb" style="text-align: right" title="Warrants issued">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_ecustom--WeightedAverageExercisePriceWarrantsIssued_d0_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z7vqhXQ16R2e" style="text-align: right" title="Weighted average exercise price, warrants issued">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--WarrantsIssued_d0_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zi2frAR9Toce" style="text-align: right" title="Warrants issued">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_ecustom--WeightedAverageExercisePriceWarrantsIssued_d0_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_ztYq09v4YV18" style="text-align: right" title="Weighted average exercise price, warrants issued">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--WarrantsIssued_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zYvUnGuitYh2" style="text-align: right" title="Warrants issued">45,667</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_ecustom--WeightedAverageExercisePriceWarrantsIssued_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zh5bN0Ls9Q0h" style="text-align: right" title="Weighted average exercise price, warrants issued">60</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_d0_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zFORyrQsEHh3" style="text-align: right" title="Warrants exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_ecustom--WeightedAverageExercisePriceWarrantsExercised_d0_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zrTkVciJK45h" style="text-align: right" title="Weighted average exercise price, warrants exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_d0_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zLaPhjRgS6lc" style="text-align: right" title="Warrants exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_ecustom--WeightedAverageExercisePriceWarrantsExercised_d0_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zL50dXEitBJa" style="text-align: right" title="Weighted average exercise price, warrants exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_d0_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_ztSvWZlzcKR3" style="text-align: right" title="Warrants exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_ecustom--WeightedAverageExercisePriceWarrantsExercised_d0_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zOz7RF1oXiYb" style="text-align: right" title="Weighted average exercise price, warrants exercised">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zoq1gLO5YWM4" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired">(87,500</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_ecustom--WeightedAverageExercisePriceWarrantsExpired_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zmTxZ6yTyGQh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants expired">88.6</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di0_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z7MHQglGENQ3" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_ecustom--WeightedAverageExercisePriceWarrantsExpired_d0_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zCw0QQ3P4pNb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di0_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z4uHcKnaBAD3" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_ecustom--WeightedAverageExercisePriceWarrantsExpired_d0_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zxwCmQKkAzF3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt; text-indent: -8.1pt; padding-left: 8.1pt">Warrants outstanding as of August 31</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_d0_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zCfIPlGsIcLl" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants outstanding, ending balance">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_d0_c20220901__20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zfaJlc2tU8jg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants outstanding, ending balance">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z5eiwsHAgBoh" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants outstanding, ending balance">87,500</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20210901__20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z2KaL2aRhJ9e" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants outstanding, ending balance">88.6</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_ziC9jWbqiksg" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants outstanding, ending balance">87,500</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20200901__20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zbI297c0Ydyf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants outstanding, ending balance">88.6</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt; text-indent: -8.1pt; padding-left: 8.1pt">Warrants exercisable as of August 31</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_d0_c20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zJpk2wG0d7u8" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--WeightedAverageExercisePriceWarrantsExercisable_iI_d0_c20230831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zXSu0jo1Ulu9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, warrants exercisable">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zodeKPStZEDf" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable">87,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--WeightedAverageExercisePriceWarrantsExercisable_iI_c20220831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zSlPEJMqXZZ4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, warrants exercisable">88.6</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zRv5ZXdapHNi" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable">87,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--WeightedAverageExercisePriceWarrantsExercisable_iI_c20210831__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z3qpfUHjwVp5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, warrants exercisable">88.6</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> </us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock> <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2022-08-31_custom_WarrantsMember882227078" decimals="INF" unitRef="Shares">87500</us-gaap:ClassOfWarrantOrRightOutstanding> <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2022-08-31_custom_WarrantsMember882227078" decimals="INF" unitRef="USDPShares">88.6</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1> <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2021-08-31_custom_WarrantsMember882227078" decimals="INF" unitRef="Shares">87500</us-gaap:ClassOfWarrantOrRightOutstanding> <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2021-08-31_custom_WarrantsMember882227078" decimals="INF" unitRef="USDPShares">88.6</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1> <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2020-08-31_custom_WarrantsMember" decimals="INF" unitRef="Shares">41667</us-gaap:ClassOfWarrantOrRightOutstanding> <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2020-08-31_custom_WarrantsMember" decimals="INF" unitRef="USDPShares">120</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1> <CNBX:WarrantsIssued contextRef="From2022-09-012023-08-31_custom_WarrantsMember882227093" decimals="INF" unitRef="Shares">0</CNBX:WarrantsIssued> <CNBX:WeightedAverageExercisePriceWarrantsIssued contextRef="From2022-09-012023-08-31_custom_WarrantsMember882227093" decimals="INF" unitRef="USDPShares">0</CNBX:WeightedAverageExercisePriceWarrantsIssued> <CNBX:WarrantsIssued contextRef="From2021-09-012022-08-31_custom_WarrantsMember882227093" decimals="INF" unitRef="Shares">0</CNBX:WarrantsIssued> <CNBX:WeightedAverageExercisePriceWarrantsIssued contextRef="From2021-09-012022-08-31_custom_WarrantsMember882227093" decimals="INF" unitRef="USDPShares">0</CNBX:WeightedAverageExercisePriceWarrantsIssued> <CNBX:WarrantsIssued contextRef="From2020-09-012021-08-31_custom_WarrantsMember" decimals="INF" unitRef="Shares">45667</CNBX:WarrantsIssued> <CNBX:WeightedAverageExercisePriceWarrantsIssued contextRef="From2020-09-012021-08-31_custom_WarrantsMember" decimals="INF" unitRef="USDPShares">60</CNBX:WeightedAverageExercisePriceWarrantsIssued> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2022-09-012023-08-31_custom_WarrantsMember882227093" decimals="INF" unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised> <CNBX:WeightedAverageExercisePriceWarrantsExercised contextRef="From2022-09-012023-08-31_custom_WarrantsMember882227093" decimals="INF" unitRef="USDPShares">0</CNBX:WeightedAverageExercisePriceWarrantsExercised> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2021-09-012022-08-31_custom_WarrantsMember882227093" decimals="INF" unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised> <CNBX:WeightedAverageExercisePriceWarrantsExercised contextRef="From2021-09-012022-08-31_custom_WarrantsMember882227093" decimals="INF" unitRef="USDPShares">0</CNBX:WeightedAverageExercisePriceWarrantsExercised> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2020-09-012021-08-31_custom_WarrantsMember" decimals="INF" unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised> <CNBX:WeightedAverageExercisePriceWarrantsExercised contextRef="From2020-09-012021-08-31_custom_WarrantsMember" decimals="INF" unitRef="USDPShares">0</CNBX:WeightedAverageExercisePriceWarrantsExercised> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations contextRef="From2022-09-012023-08-31_custom_WarrantsMember882227093" decimals="INF" unitRef="Shares">87500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations> <CNBX:WeightedAverageExercisePriceWarrantsExpired contextRef="From2022-09-012023-08-31_custom_WarrantsMember882227093" decimals="INF" unitRef="USDPShares">88.6</CNBX:WeightedAverageExercisePriceWarrantsExpired> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations contextRef="From2021-09-012022-08-31_custom_WarrantsMember882227093" decimals="INF" unitRef="Shares">-0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations> <CNBX:WeightedAverageExercisePriceWarrantsExpired contextRef="From2021-09-012022-08-31_custom_WarrantsMember882227093" decimals="INF" unitRef="USDPShares">0</CNBX:WeightedAverageExercisePriceWarrantsExpired> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations contextRef="From2020-09-012021-08-31_custom_WarrantsMember" decimals="INF" unitRef="Shares">-0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations> <CNBX:WeightedAverageExercisePriceWarrantsExpired contextRef="From2020-09-012021-08-31_custom_WarrantsMember" decimals="INF" unitRef="USDPShares">0</CNBX:WeightedAverageExercisePriceWarrantsExpired> <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2023-08-31_custom_WarrantsMember882227109" decimals="INF" unitRef="Shares">0</us-gaap:ClassOfWarrantOrRightOutstanding> <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2023-08-31_custom_WarrantsMember882227109" decimals="INF" unitRef="USDPShares">0</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1> <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2022-08-31_custom_WarrantsMember882227078" decimals="INF" unitRef="Shares">87500</us-gaap:ClassOfWarrantOrRightOutstanding> <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2022-08-31_custom_WarrantsMember882227078" decimals="INF" unitRef="USDPShares">88.6</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1> <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2021-08-31_custom_WarrantsMember882227078" decimals="INF" unitRef="Shares">87500</us-gaap:ClassOfWarrantOrRightOutstanding> <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2021-08-31_custom_WarrantsMember882227078" decimals="INF" unitRef="USDPShares">88.6</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1> <CNBX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber contextRef="AsOf2023-08-31_custom_WarrantsMember882227109" decimals="INF" unitRef="Shares">0</CNBX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber> <CNBX:WeightedAverageExercisePriceWarrantsExercisable contextRef="AsOf2023-08-31_custom_WarrantsMember882227109" decimals="INF" unitRef="USDPShares">0</CNBX:WeightedAverageExercisePriceWarrantsExercisable> <CNBX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber contextRef="AsOf2022-08-31_custom_WarrantsMember882227078" decimals="INF" unitRef="Shares">87500</CNBX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber> <CNBX:WeightedAverageExercisePriceWarrantsExercisable contextRef="AsOf2022-08-31_custom_WarrantsMember882227078" decimals="INF" unitRef="USDPShares">88.6</CNBX:WeightedAverageExercisePriceWarrantsExercisable> <CNBX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber contextRef="AsOf2021-08-31_custom_WarrantsMember882227078" decimals="INF" unitRef="Shares">87500</CNBX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber> <CNBX:WeightedAverageExercisePriceWarrantsExercisable contextRef="AsOf2021-08-31_custom_WarrantsMember882227078" decimals="INF" unitRef="USDPShares">88.6</CNBX:WeightedAverageExercisePriceWarrantsExercisable> <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2022-09-01to2023-08-31"><p id="xdx_80D_eus-gaap--IncomeTaxDisclosureTextBlock_zSFWPq0H72U6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 8 – <span id="xdx_82D_z9gFqvDOD0mf">Income Taxes</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Taxes on income included in the consolidated statements of operations represent current taxes due to taxable income of the Company and its Subsidiary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.2pt; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.2pt; text-align: justify"><b>Corporate taxation in the U.S.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.2pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The applicable corporate tax rate for the Company is <span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20220901__20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zOSHUdodBFA6" title="Effective tax rate">21</span>%.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No provision for income tax was made for the period from September 15, 2004 (Inception) to August 31, 2023, as the Company had cumulative operating losses. For the years ended August 31, 2023, and 2022, the Company incurred net losses for tax purposes of $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20230831__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStates1Member_zvU7aXAxsxrk" title="Net operating loss carryforwards">1,848,572</span> and $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20220831__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStates1Member_zqT751q6i348" title="Net operating loss carryforwards">903,813</span>, respectively. Under U.S. tax laws, subject to certain limitations, carry forward tax losses expire 20 years after the year in which incurred. In the case of the Company, subject to potential limitations in accordance with the relevant law, the net loss carry forward will expire in the years 2032 through 2036.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">   </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.2pt; text-align: justify"><b>Corporate taxation in Israel:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.2pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Subsidiary is taxed in accordance with Israeli tax laws. The corporate tax rate applicable is <span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_dp_c20220901__20230831__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--IsraelTaxAuthorityMember_z5WOPRTWF70d" title="Effective tax rate, Israel">23</span>%.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of August 31, 2023, the Subsidiary has an accumulated tax loss carry forward of approximately $<span id="xdx_907_eus-gaap--OperatingLossCarryforwards_pp0p0_c20230831__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--IsraelTaxAuthorityMember_zZk9ZH4tyiuj" title="Net operating loss carryforwards">12,593,815</span> (as of August 31, 2022, approximately $<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_pp0p0_c20220831__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--IsraelTaxAuthorityMember_zRjbSXjIRc81" title="Net operating loss carryforwards">12,373,689</span>). Under the Israeli tax laws, carry forward tax losses have no expiration date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The income tax expense (benefit) differs from the amount computed by applying the United States Statutory corporate income tax rate as follows: </p> <table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zgJhIPUIx80h" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - rate)"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span id="xdx_8B3_zIUTlIVUkQld" style="display: none">Schedule of effective income tax rate</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the Year Ended August 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">United States statutory corporate income tax rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20220901__20230831_zgUCWK1I3kf3" title="United States statutory corporate income tax rate">21.0</span>%</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20210901__20220831_zcgx2Vc0gNNg" title="United States statutory corporate income tax rate">21.0</span>%</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance on deferred tax assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_dpi_c20220901__20230831_zkaxt4a8l7n8" title="Change in valuation allowance on deferred tax assets">-21.0</span>%</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_dpi_c20210901__20220831_z5CA2HrvbqT2" title="Change in valuation allowance on deferred tax assets">-21.0</span>%</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Provision for income tax</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_c20220901__20230831_zxxUW2CdrBk9" title="Provision for income tax">–</span>%</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_c20210901__20220831_zHpoAhLh1rGe" title="Provision for income tax">–</span>%</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zQwQjAucNFD5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred income taxes reflect the tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for tax purposes. The components of the net deferred income tax assets are approximately as follows: </p> <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z1ZUhSk2ZSCa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - Deferred tax assets)"> <tr style="vertical-align: bottom"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt"><span id="xdx_8B4_zPcrQ0cK8JN" style="display: none">Schedule of deferred income tax assets</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">August 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">US Deferred income tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left; text-indent: -10pt; padding-left: 20pt">Net operating loss carry forwards benefit</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zL2THumqnoB8" style="width: 13%; text-align: right" title="Net operating loss carry forwards benefit">3,035,360</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20220831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zsvNG3u0AbS8" style="width: 13%; text-align: right" title="Net operating loss carry forwards benefit">2,576,499</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_z2l0hHKoX0m7" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance">(3,035,360</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20220831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_ze0UGwNCVW1l" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance">(2,576,499</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred income tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zbfmrgAccXf7" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred income tax assets">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20220831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zmd25C1Dq17h" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred income tax assets">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Outside US Deferred income tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Net operating loss carry forwards benefit</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zfbtDPbtDuhc" style="text-align: right" title="Net operating loss carry forwards benefit">2,949,564</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20220831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zeRbYqhNeJ5a" style="text-align: right" title="Net operating loss carry forwards benefit">2,804,533</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_z5Yaff7ccvAa" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance">(2,949,564</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20220831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zotbNCzvpek5" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance">(2,804,533</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_ze0pP0JQLpR2" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred income tax assets">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20220831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_z9yT8Dxhjv27" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred income tax assets">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">August 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Consolidated Deferred income tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left; text-indent: -10pt; padding-left: 20pt">Net operating loss carry forwards benefit</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20230831_zNA5yXQdBTR5" style="width: 13%; text-align: right" title="Net operating loss carry forwards benefit">5,984,924</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20220831_z9pIXewBhq1b" style="width: 13%; text-align: right" title="Net operating loss carry forwards benefit">5,381,031</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20230831_zFnddgNEVW1" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance">(5,984,924</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20220831_z0c7kaHproCf" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance">(5,381,031</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred income tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20230831_zLiITVuvgLsj" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred income tax assets">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20220831_zD5iUELuuZO4" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred income tax assets">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zuXgA7rzIm2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amount taken into income as deferred income tax assets must reflect that portion of the income tax loss carry forwards that is more likely than not to be realized from future operations. The Company has established a full valuation allowance on its net deferred tax assets because of a lack of sufficient positive evidence to support its realization. The valuation allowance increased by $<span id="xdx_90D_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pp0p0_c20220901__20230831_zp19Dr9w6C7f" title="Increase (decrease) in valuation allowance">603,893</span> and decreased $<span id="xdx_901_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pp0p0_c20210901__20220831_zyjRC6S5L0C" title="Increase (decrease) in valuation allowance">1,055,107</span> for the years ended August 31, 2023, and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No provision for income taxes has been provided in these financial statements due to the net loss for the years ended August 31, 2023 and 2021. At August 31, 2023, the Company has net operating loss carry forwards of approximately $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_pp0p0_c20230831_zafcw4QF61Gk" title="Net operating loss carryforwards">24,259,202</span> which expire commencing 2032. The potential tax benefit of these losses may be limited due to certain change in ownership provisions under Section 382 of the Internal Revenue Code (“IRS”) and similar state provisions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IRS Section 382 places limitations (the “Section 382 Limitation”) on the amount of taxable income which can be offset by net operating loss carry forwards after a change in control (generally greater than 50% change in ownership) of a loss corporation. Generally, after a change in control, a loss corporation cannot deduct operating loss carry forwards in excess of the Section 382 Limitation. Due to these “change in ownership” provisions, utilization of the net operating loss and tax credit carry forwards may be subject to an annual limitation regarding their utilization against taxable income in future periods. The Company has not concluded its analysis of Section 382 through August 31, 2023, but believes the provisions will not limit the availability of losses to offset future income.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is subject to income taxes in the U.S. federal jurisdiction and is subject to examination for a period of three years for current filings and indefinitely for any delinquent filings. The tax regulations within each jurisdiction are subject to interpretation of related tax laws and regulations and require significant judgment to apply. The Company estimates that the amount of penalties, if any, will not have a material effect on the results of operations, cash flows or financial position. No provisions have been made in the financial statements for such penalties, if any.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> </us-gaap:IncomeTaxDisclosureTextBlock> <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2022-09-012023-08-31_us-gaap_DomesticCountryMember" decimals="INF" unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate> <us-gaap:OperatingLossCarryforwards contextRef="AsOf2023-08-31_custom_UnitedStates1Member" decimals="0" unitRef="USD">1848572</us-gaap:OperatingLossCarryforwards> <us-gaap:OperatingLossCarryforwards contextRef="AsOf2022-08-31_custom_UnitedStates1Member" decimals="0" unitRef="USD">903813</us-gaap:OperatingLossCarryforwards> <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="From2022-09-012023-08-31_us-gaap_IsraelTaxAuthorityMember" decimals="INF" unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential> <us-gaap:OperatingLossCarryforwards contextRef="AsOf2023-08-31_us-gaap_IsraelTaxAuthorityMember" decimals="0" unitRef="USD">12593815</us-gaap:OperatingLossCarryforwards> <us-gaap:OperatingLossCarryforwards contextRef="AsOf2022-08-31_us-gaap_IsraelTaxAuthorityMember" decimals="0" unitRef="USD">12373689</us-gaap:OperatingLossCarryforwards> <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2022-09-01to2023-08-31"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zgJhIPUIx80h" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - rate)"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span id="xdx_8B3_zIUTlIVUkQld" style="display: none">Schedule of effective income tax rate</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the Year Ended August 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">United States statutory corporate income tax rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20220901__20230831_zgUCWK1I3kf3" title="United States statutory corporate income tax rate">21.0</span>%</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20210901__20220831_zcgx2Vc0gNNg" title="United States statutory corporate income tax rate">21.0</span>%</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance on deferred tax assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_dpi_c20220901__20230831_zkaxt4a8l7n8" title="Change in valuation allowance on deferred tax assets">-21.0</span>%</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_dpi_c20210901__20220831_z5CA2HrvbqT2" title="Change in valuation allowance on deferred tax assets">-21.0</span>%</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Provision for income tax</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_c20220901__20230831_zxxUW2CdrBk9" title="Provision for income tax">–</span>%</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_c20210901__20220831_zHpoAhLh1rGe" title="Provision for income tax">–</span>%</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock> <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2022-09-01to2023-08-31" decimals="INF" unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate> <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2021-09-012022-08-31" decimals="INF" unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate> <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2022-09-01to2023-08-31" decimals="INF" unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance> <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2021-09-012022-08-31" decimals="INF" unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance> <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2022-09-01to2023-08-31" decimals="INF" unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations> <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2021-09-012022-08-31" decimals="INF" unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations> <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2022-09-01to2023-08-31"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z1ZUhSk2ZSCa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - Deferred tax assets)"> <tr style="vertical-align: bottom"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt"><span id="xdx_8B4_zPcrQ0cK8JN" style="display: none">Schedule of deferred income tax assets</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">August 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">US Deferred income tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left; text-indent: -10pt; padding-left: 20pt">Net operating loss carry forwards benefit</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zL2THumqnoB8" style="width: 13%; text-align: right" title="Net operating loss carry forwards benefit">3,035,360</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20220831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zsvNG3u0AbS8" style="width: 13%; text-align: right" title="Net operating loss carry forwards benefit">2,576,499</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_z2l0hHKoX0m7" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance">(3,035,360</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20220831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_ze0UGwNCVW1l" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance">(2,576,499</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred income tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zbfmrgAccXf7" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred income tax assets">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20220831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zmd25C1Dq17h" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred income tax assets">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Outside US Deferred income tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Net operating loss carry forwards benefit</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zfbtDPbtDuhc" style="text-align: right" title="Net operating loss carry forwards benefit">2,949,564</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20220831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zeRbYqhNeJ5a" style="text-align: right" title="Net operating loss carry forwards benefit">2,804,533</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_z5Yaff7ccvAa" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance">(2,949,564</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20220831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zotbNCzvpek5" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance">(2,804,533</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20230831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_ze0pP0JQLpR2" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred income tax assets">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20220831__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_z9yT8Dxhjv27" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred income tax assets">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">August 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Consolidated Deferred income tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left; text-indent: -10pt; padding-left: 20pt">Net operating loss carry forwards benefit</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20230831_zNA5yXQdBTR5" style="width: 13%; text-align: right" title="Net operating loss carry forwards benefit">5,984,924</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20220831_z9pIXewBhq1b" style="width: 13%; text-align: right" title="Net operating loss carry forwards benefit">5,381,031</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20230831_zFnddgNEVW1" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance">(5,984,924</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20220831_z0c7kaHproCf" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance">(5,381,031</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred income tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20230831_zLiITVuvgLsj" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred income tax assets">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20220831_zD5iUELuuZO4" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred income tax assets">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock> <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2023-08-31_us-gaap_DomesticCountryMember" decimals="0" unitRef="USD">3035360</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards> <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2022-08-31_us-gaap_DomesticCountryMember" decimals="0" unitRef="USD">2576499</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards> <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2023-08-31_us-gaap_DomesticCountryMember" decimals="0" unitRef="USD">3035360</us-gaap:DeferredTaxAssetsValuationAllowance> <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2022-08-31_us-gaap_DomesticCountryMember" decimals="0" unitRef="USD">2576499</us-gaap:DeferredTaxAssetsValuationAllowance> <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2023-08-31_us-gaap_DomesticCountryMember" decimals="0" unitRef="USD">0</us-gaap:DeferredTaxAssetsNet> <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2022-08-31_us-gaap_DomesticCountryMember" decimals="0" unitRef="USD">0</us-gaap:DeferredTaxAssetsNet> <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2023-08-31_us-gaap_ForeignCountryMember" decimals="0" unitRef="USD">2949564</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards> <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2022-08-31_us-gaap_ForeignCountryMember" decimals="0" unitRef="USD">2804533</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards> <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2023-08-31_us-gaap_ForeignCountryMember" decimals="0" unitRef="USD">2949564</us-gaap:DeferredTaxAssetsValuationAllowance> <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2022-08-31_us-gaap_ForeignCountryMember" decimals="0" unitRef="USD">2804533</us-gaap:DeferredTaxAssetsValuationAllowance> <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2023-08-31_us-gaap_ForeignCountryMember" decimals="0" unitRef="USD">0</us-gaap:DeferredTaxAssetsNet> <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2022-08-31_us-gaap_ForeignCountryMember" decimals="0" unitRef="USD">0</us-gaap:DeferredTaxAssetsNet> <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2023-08-31" decimals="0" unitRef="USD">5984924</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards> <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2022-08-31" decimals="0" unitRef="USD">5381031</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards> <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2023-08-31" decimals="0" unitRef="USD">5984924</us-gaap:DeferredTaxAssetsValuationAllowance> <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2022-08-31" decimals="0" unitRef="USD">5381031</us-gaap:DeferredTaxAssetsValuationAllowance> <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2023-08-31" decimals="0" unitRef="USD">0</us-gaap:DeferredTaxAssetsNet> <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2022-08-31" decimals="0" unitRef="USD">0</us-gaap:DeferredTaxAssetsNet> <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">603893</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount> <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">1055107</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount> <us-gaap:OperatingLossCarryforwards contextRef="AsOf2023-08-31" decimals="0" unitRef="USD">24259202</us-gaap:OperatingLossCarryforwards> <CNBX:CapitalLossDisclosureTextBlock contextRef="From2022-09-01to2023-08-31"><p id="xdx_808_ecustom--CapitalLossDisclosureTextBlock_zRxjLd7DC78l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 9 – <span id="xdx_82C_z7tXlZQK8gAa">Capital loss</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 9th, 2022, the Company sold her holdings in Sativusin in consideration of $<span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20221208__20221209_zLw9Iok06LMa" title="Sale consideration">24,200</span>, as a result the company recorded a capital loss of $<span id="xdx_909_ecustom--CapitalLoss_c20221208__20221209_zsnZLjuW35cg" title="Capital loss">2,726,231</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> </CNBX:CapitalLossDisclosureTextBlock> <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="From2022-12-082022-12-09" decimals="0" unitRef="USD">24200</us-gaap:SaleOfStockConsiderationReceivedOnTransaction> <CNBX:CapitalLoss contextRef="From2022-12-082022-12-09" decimals="0" unitRef="USD">2726231</CNBX:CapitalLoss> <us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock contextRef="From2022-09-01to2023-08-31"><p id="xdx_80B_eus-gaap--OtherNonoperatingIncomeAndExpenseTextBlock_zUGX1LeFBZa1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 10</b> – <span id="xdx_820_z3GNDRXzrkg"><b>General &amp; administrate expenses </b></span></p> <table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_z7aDLip9uSh7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - General and administrative expenses (Details)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B7_zkRRd1cSq0M4" style="display: none">Schedule of general and administrative expenses</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20220901__20230831_zxT46YnSOUdl" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20210901__20220831_zf7V85Xymjh3" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">For the year Ended<br/> August 31,<br/> 2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">For the year Ended<br/> August 31,<br/> 2022</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40C_eus-gaap--LaborAndRelatedExpense_maGAAEzYXX_z4LoQHdGhQd7" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Salaries and related expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">461,375</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">379,618</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_maGAAEzYXX_zCiYWpWnW9Ha" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Share based payment to related parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">180,480</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">728,870</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LegalFees_maGAAEzYXX_zjhvfrsiVoFl" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Legal and professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">149,108</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">443,851</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--GeneralInsuranceExpense_maGAAEzYXX_zowgSWKhZyul" style="vertical-align: bottom; background-color: White"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">68,278</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">93,192</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--MarketingExpense_maGAAEzYXX_zDUSeKr4zPYc" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Marketing expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,223</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,977</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OtherGeneralExpense_maGAAEzYXX_zKsXhX5atAyh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Other expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">49,516</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">139,139</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--GeneralAndAdministrativeExpense_iT_pp0p0_mtGAAEzYXX_zOpDmNcV0xQb" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"><b style="display: none">Total general and administrative expenses</b></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">909,980</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,800,647</td><td style="padding-bottom: 2.5pt; text-align: left">*</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* In the year ended August 31, 2022 revenues of $29,958 was presented under General and administrative expenses, was allocated to Revenues under previous year results.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> </us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock> <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="From2022-09-01to2023-08-31"><table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_z7aDLip9uSh7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - General and administrative expenses (Details)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B7_zkRRd1cSq0M4" style="display: none">Schedule of general and administrative expenses</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20220901__20230831_zxT46YnSOUdl" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20210901__20220831_zf7V85Xymjh3" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">For the year Ended<br/> August 31,<br/> 2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">For the year Ended<br/> August 31,<br/> 2022</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40C_eus-gaap--LaborAndRelatedExpense_maGAAEzYXX_z4LoQHdGhQd7" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Salaries and related expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">461,375</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">379,618</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_maGAAEzYXX_zCiYWpWnW9Ha" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Share based payment to related parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">180,480</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">728,870</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LegalFees_maGAAEzYXX_zjhvfrsiVoFl" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Legal and professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">149,108</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">443,851</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--GeneralInsuranceExpense_maGAAEzYXX_zowgSWKhZyul" style="vertical-align: bottom; background-color: White"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">68,278</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">93,192</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--MarketingExpense_maGAAEzYXX_zDUSeKr4zPYc" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Marketing expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,223</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,977</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OtherGeneralExpense_maGAAEzYXX_zKsXhX5atAyh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Other expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">49,516</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">139,139</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--GeneralAndAdministrativeExpense_iT_pp0p0_mtGAAEzYXX_zOpDmNcV0xQb" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"><b style="display: none">Total general and administrative expenses</b></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">909,980</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,800,647</td><td style="padding-bottom: 2.5pt; text-align: left">*</td></tr> </table></us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock> <us-gaap:LaborAndRelatedExpense contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">461375</us-gaap:LaborAndRelatedExpense> <us-gaap:LaborAndRelatedExpense contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">379618</us-gaap:LaborAndRelatedExpense> <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">180480</us-gaap:AllocatedShareBasedCompensationExpense> <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">728870</us-gaap:AllocatedShareBasedCompensationExpense> <us-gaap:LegalFees contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">149108</us-gaap:LegalFees> <us-gaap:LegalFees contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">443851</us-gaap:LegalFees> <us-gaap:GeneralInsuranceExpense contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">68278</us-gaap:GeneralInsuranceExpense> <us-gaap:GeneralInsuranceExpense contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">93192</us-gaap:GeneralInsuranceExpense> <us-gaap:MarketingExpense contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">1223</us-gaap:MarketingExpense> <us-gaap:MarketingExpense contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">15977</us-gaap:MarketingExpense> <us-gaap:OtherGeneralExpense contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">49516</us-gaap:OtherGeneralExpense> <us-gaap:OtherGeneralExpense contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">139139</us-gaap:OtherGeneralExpense> <us-gaap:GeneralAndAdministrativeExpense contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">909980</us-gaap:GeneralAndAdministrativeExpense> <us-gaap:GeneralAndAdministrativeExpense contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">1800647</us-gaap:GeneralAndAdministrativeExpense> <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock contextRef="From2022-09-01to2023-08-31"><p id="xdx_806_eus-gaap--OtherIncomeAndOtherExpenseDisclosureTextBlock_z1x55BcGsgec" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 11</b> – <span id="xdx_825_zMwkgPw0ZgRa"><b>Financial (Income) expenses </b></span></p> <table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--ScheduleOfFinancialIncomeExpensesTableTextBlock_zGwZfD6rIcA4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Financial (Income) expenses (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span id="xdx_8B9_znjXAsjDcYD4" style="display: none">Schedule of financial income expenses</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_492_20220901__20230831_zUcrKjMH1kEc" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_498_20210901__20220831_zGuGRyJHAW3g" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">For the year<br/> Ended<br/> August 31, 2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">For the year<br/> Ended<br/> August 31, 2022</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_eus-gaap--InterestExpenseBorrowings_i_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Interest and bank charges</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,174</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,273</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--LossGainFromConvertibleLoanValuation_zuBlVcyCiO82" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Loss (Gain) from convertible loan valuation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54,810</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">722,236</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt; text-align: left">Currency exchange differences loss (profit)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,361</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">58,571</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OtherNonoperatingIncomeExpense_pp0p0_zSZgT9dfWBe5" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><b style="display: none">Total other income expenses</b></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">52,623</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">782,080</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> </us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock> <CNBX:ScheduleOfFinancialIncomeExpensesTableTextBlock contextRef="From2022-09-01to2023-08-31"><table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--ScheduleOfFinancialIncomeExpensesTableTextBlock_zGwZfD6rIcA4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Financial (Income) expenses (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span id="xdx_8B9_znjXAsjDcYD4" style="display: none">Schedule of financial income expenses</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_492_20220901__20230831_zUcrKjMH1kEc" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_498_20210901__20220831_zGuGRyJHAW3g" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">For the year<br/> Ended<br/> August 31, 2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">For the year<br/> Ended<br/> August 31, 2022</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_eus-gaap--InterestExpenseBorrowings_i_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Interest and bank charges</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,174</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,273</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--LossGainFromConvertibleLoanValuation_zuBlVcyCiO82" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Loss (Gain) from convertible loan valuation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54,810</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">722,236</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt; text-align: left">Currency exchange differences loss (profit)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,361</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">58,571</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OtherNonoperatingIncomeExpense_pp0p0_zSZgT9dfWBe5" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><b style="display: none">Total other income expenses</b></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">52,623</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">782,080</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table></CNBX:ScheduleOfFinancialIncomeExpensesTableTextBlock> <us-gaap:InterestExpenseBorrowings contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">1174</us-gaap:InterestExpenseBorrowings> <us-gaap:InterestExpenseBorrowings contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">1273</us-gaap:InterestExpenseBorrowings> <CNBX:LossGainFromConvertibleLoanValuation contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">54810</CNBX:LossGainFromConvertibleLoanValuation> <CNBX:LossGainFromConvertibleLoanValuation contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">722236</CNBX:LossGainFromConvertibleLoanValuation> <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">-3361</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax> <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">58571</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax> <us-gaap:OtherNonoperatingIncomeExpense contextRef="From2022-09-01to2023-08-31" decimals="0" unitRef="USD">52623</us-gaap:OtherNonoperatingIncomeExpense> <us-gaap:OtherNonoperatingIncomeExpense contextRef="From2021-09-012022-08-31" decimals="0" unitRef="USD">782080</us-gaap:OtherNonoperatingIncomeExpense> <us-gaap:SubsequentEventsTextBlock contextRef="From2022-09-01to2023-08-31"><p id="xdx_801_eus-gaap--SubsequentEventsTextBlock_zRa01Zm0aKKe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 11 – <span id="xdx_826_zWabb91Dk7Vk">Subsequent Events</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 13, 2023, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $25,000.00. ($25,000 net of issuance expenses). The Convertible Promissory Note carry interest of 5% and due on January 1st 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the period September through October, 2023, the company issued 5,700,000 shares as a result of a convertible of a loan at the total of $65,908.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> </us-gaap:SubsequentEventsTextBlock> </xbrl> </XML> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EXCEL <SEQUENCE>65 <FILENAME>Financial_Report.xlsx <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> begin 644 Financial_Report.xlsx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end </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>66 <FILENAME>Show.js <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>67 <FILENAME>report.css <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>68 <FILENAME>FilingSummary.xml <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <XML> <?xml version='1.0' encoding='utf-8'?> <FilingSummary> <Version>3.23.3</Version> <ProcessingTime/> <ReportFormat>html</ReportFormat> <ContextCount>89</ContextCount> <ElementCount>194</ElementCount> <EntityCount>1</EntityCount> <FootnotesReported>false</FootnotesReported> <SegmentCount>28</SegmentCount> <ScenarioCount>0</ScenarioCount> <TuplesReported>false</TuplesReported> <UnitCount>4</UnitCount> <MyReports> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R1.htm</HtmlFileName> <LongName>00000001 - Document - Cover</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/Cover</Role> <ShortName>Cover</ShortName> <MenuCategory>Cover</MenuCategory> <Position>1</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R2.htm</HtmlFileName> <LongName>00000002 - Statement - Audited Consolidated Balance Sheets</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets</Role> <ShortName>Audited Consolidated Balance Sheets</ShortName> <MenuCategory>Statements</MenuCategory> <Position>2</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R3.htm</HtmlFileName> <LongName>00000003 - Statement - Audited Consolidated Balance Sheets (Parenthetical)</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheetsParenthetical</Role> <ShortName>Audited Consolidated Balance Sheets (Parenthetical)</ShortName> <MenuCategory>Statements</MenuCategory> <Position>3</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R4.htm</HtmlFileName> <LongName>00000004 - Statement - Audited Consolidated Statements of Operations</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations</Role> <ShortName>Audited Consolidated Statements of Operations</ShortName> <MenuCategory>Statements</MenuCategory> <Position>4</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R5.htm</HtmlFileName> <LongName>00000005 - Statement - Audited Consolidated Statements of Operations (Parenthetical)</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperationsParenthetical</Role> <ShortName>Audited Consolidated Statements of Operations (Parenthetical)</ShortName> <MenuCategory>Statements</MenuCategory> <Position>5</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R6.htm</HtmlFileName> <LongName>00000006 - Statement - Audited Consolidated Statements of Cash Flows</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows</Role> <ShortName>Audited Consolidated Statements of Cash Flows</ShortName> <MenuCategory>Statements</MenuCategory> <Position>6</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R7.htm</HtmlFileName> <LongName>00000007 - Statement - Audited Consolidated Statements of Stockholders' Equity (Deficit)</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfStockholdersEquityDeficit</Role> <ShortName>Audited Consolidated Statements of Stockholders' Equity (Deficit)</ShortName> <MenuCategory>Statements</MenuCategory> <Position>7</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R8.htm</HtmlFileName> <LongName>00000008 - Disclosure - Nature of Business, Presentation and Going Concern</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcern</Role> <ShortName>Nature of Business, Presentation and Going Concern</ShortName> <MenuCategory>Notes</MenuCategory> <Position>8</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R9.htm</HtmlFileName> <LongName>00000009 - Disclosure - Summary of Significant Accounting Policies</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/SummaryOfSignificantAccountingPolicies</Role> <ShortName>Summary of Significant Accounting Policies</ShortName> <MenuCategory>Notes</MenuCategory> <Position>9</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R10.htm</HtmlFileName> <LongName>00000010 - Disclosure - Recent Accounting Pronouncements</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/RecentAccountingPronouncements</Role> <ShortName>Recent Accounting Pronouncements</ShortName> <MenuCategory>Notes</MenuCategory> <Position>10</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R11.htm</HtmlFileName> <LongName>00000011 - Disclosure - Related Party Transactions</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/RelatedPartyTransactions</Role> <ShortName>Related Party Transactions</ShortName> <MenuCategory>Notes</MenuCategory> <Position>11</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R12.htm</HtmlFileName> <LongName>00000012 - Disclosure - Commitments and Contingencies</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/CommitmentsAndContingencies</Role> <ShortName>Commitments and Contingencies</ShortName> <MenuCategory>Notes</MenuCategory> <Position>12</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R13.htm</HtmlFileName> <LongName>00000013 - Disclosure - Stockholders??? Equity (Deficit)</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/StockholdersEquityDeficit</Role> <ShortName>Stockholders??? Equity (Deficit)</ShortName> <MenuCategory>Notes</MenuCategory> <Position>13</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R14.htm</HtmlFileName> <LongName>00000014 - Disclosure - Warrants</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/Warrants</Role> <ShortName>Warrants</ShortName> <MenuCategory>Notes</MenuCategory> <Position>14</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R15.htm</HtmlFileName> <LongName>00000015 - Disclosure - Income Taxes</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/IncomeTaxes</Role> <ShortName>Income Taxes</ShortName> <MenuCategory>Notes</MenuCategory> <Position>15</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R16.htm</HtmlFileName> <LongName>00000016 - Disclosure - Capital loss</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/CapitalLoss</Role> <ShortName>Capital loss</ShortName> <MenuCategory>Notes</MenuCategory> <Position>16</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R17.htm</HtmlFileName> <LongName>00000017 - Disclosure - General & administrate expenses</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/GeneralAdministrateExpenses</Role> <ShortName>General & administrate expenses</ShortName> <MenuCategory>Notes</MenuCategory> <Position>17</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R18.htm</HtmlFileName> <LongName>00000018 - Disclosure - Financial (Income) expenses</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/FinancialIncomeExpenses</Role> <ShortName>Financial (Income) expenses</ShortName> <MenuCategory>Notes</MenuCategory> <Position>18</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R19.htm</HtmlFileName> <LongName>00000019 - Disclosure - Subsequent Events</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/SubsequentEvents</Role> <ShortName>Subsequent Events</ShortName> <MenuCategory>Notes</MenuCategory> <Position>19</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R20.htm</HtmlFileName> <LongName>00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role> <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName> <MenuCategory>Policies</MenuCategory> <ParentRole>http://cnbxpharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole> <Position>20</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R21.htm</HtmlFileName> <LongName>00000021 - Disclosure - Warrants (Tables)</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/WarrantsTables</Role> <ShortName>Warrants (Tables)</ShortName> <MenuCategory>Tables</MenuCategory> <ParentRole>http://cnbxpharma.com/role/Warrants</ParentRole> <Position>21</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R22.htm</HtmlFileName> <LongName>00000022 - Disclosure - Income Taxes (Tables)</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/IncomeTaxesTables</Role> <ShortName>Income Taxes (Tables)</ShortName> <MenuCategory>Tables</MenuCategory> <ParentRole>http://cnbxpharma.com/role/IncomeTaxes</ParentRole> <Position>22</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R23.htm</HtmlFileName> <LongName>00000023 - Disclosure - General & administrate expenses (Tables)</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/GeneralAdministrateExpensesTables</Role> <ShortName>General & administrate expenses (Tables)</ShortName> <MenuCategory>Tables</MenuCategory> <ParentRole>http://cnbxpharma.com/role/GeneralAdministrateExpenses</ParentRole> <Position>23</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R24.htm</HtmlFileName> <LongName>00000024 - Disclosure - Financial (Income) expenses (Tables)</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/FinancialIncomeExpensesTables</Role> <ShortName>Financial (Income) expenses (Tables)</ShortName> <MenuCategory>Tables</MenuCategory> <ParentRole>http://cnbxpharma.com/role/FinancialIncomeExpenses</ParentRole> <Position>24</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R25.htm</HtmlFileName> <LongName>00000025 - Disclosure - Nature of Business, Presentation and Going Concern (Details Narrative)</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcernDetailsNarrative</Role> <ShortName>Nature of Business, Presentation and Going Concern (Details Narrative)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcern</ParentRole> <Position>25</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R26.htm</HtmlFileName> <LongName>00000026 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role> <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole> <Position>26</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R27.htm</HtmlFileName> <LongName>00000027 - Disclosure - Related Party Transactions (Details Narrative)</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative</Role> <ShortName>Related Party Transactions (Details Narrative)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://cnbxpharma.com/role/RelatedPartyTransactions</ParentRole> <Position>27</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R28.htm</HtmlFileName> <LongName>00000028 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/CommitmentsAndContingenciesDetailsNarrative</Role> <ShortName>Commitments and Contingencies (Details Narrative)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://cnbxpharma.com/role/CommitmentsAndContingencies</ParentRole> <Position>28</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R29.htm</HtmlFileName> <LongName>00000029 - Disclosure - Stockholders??? Equity (Deficit) (Details Narrative)</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative</Role> <ShortName>Stockholders??? Equity (Deficit) (Details Narrative)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://cnbxpharma.com/role/StockholdersEquityDeficit</ParentRole> <Position>29</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R30.htm</HtmlFileName> <LongName>00000030 - Disclosure - Warrants (Details - Fair value)</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/WarrantsDetails-FairValue</Role> <ShortName>Warrants (Details - Fair value)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://cnbxpharma.com/role/WarrantsTables</ParentRole> <Position>30</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R31.htm</HtmlFileName> <LongName>00000031 - Disclosure - Warrants (Details - Fair Value)</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/WarrantsDetails-FairValueDisclosure</Role> <ShortName>Warrants (Details - Fair Value)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://cnbxpharma.com/role/WarrantsTables</ParentRole> <Position>31</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R32.htm</HtmlFileName> <LongName>00000032 - Disclosure - Warrants (Details - Warrant activity)</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/WarrantsDetails-WarrantActivity</Role> <ShortName>Warrants (Details - Warrant activity)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://cnbxpharma.com/role/WarrantsTables</ParentRole> <Position>32</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R33.htm</HtmlFileName> <LongName>00000033 - Disclosure - Warrants (Details Narrative)</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/WarrantsDetailsNarrative</Role> <ShortName>Warrants (Details Narrative)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://cnbxpharma.com/role/WarrantsTables</ParentRole> <Position>33</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R34.htm</HtmlFileName> <LongName>00000034 - Disclosure - Income Taxes (Details - rate)</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/IncomeTaxesDetails-Rate</Role> <ShortName>Income Taxes (Details - rate)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://cnbxpharma.com/role/IncomeTaxesTables</ParentRole> <Position>34</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R35.htm</HtmlFileName> <LongName>00000035 - Disclosure - Income Taxes (Details - Deferred tax assets)</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/IncomeTaxesDetails-DeferredTaxAssets</Role> <ShortName>Income Taxes (Details - Deferred tax assets)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://cnbxpharma.com/role/IncomeTaxesTables</ParentRole> <Position>35</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R36.htm</HtmlFileName> <LongName>00000036 - Disclosure - Income Taxes (Details Narrative)</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/IncomeTaxesDetailsNarrative</Role> <ShortName>Income Taxes (Details Narrative)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://cnbxpharma.com/role/IncomeTaxesTables</ParentRole> <Position>36</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R37.htm</HtmlFileName> <LongName>00000037 - Disclosure - Capital loss (Details Narrative)</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/CapitalLossDetailsNarrative</Role> <ShortName>Capital loss (Details Narrative)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://cnbxpharma.com/role/CapitalLoss</ParentRole> <Position>37</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R38.htm</HtmlFileName> <LongName>00000038 - Disclosure - General and administrative expenses (Details)</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/GeneralAndAdministrativeExpensesDetails</Role> <ShortName>General and administrative expenses (Details)</ShortName> <MenuCategory>Details</MenuCategory> <Position>38</Position> </Report> <Report instance="cnbx_i10k-083123.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R39.htm</HtmlFileName> <LongName>00000039 - Disclosure - Financial (Income) expenses (Details)</LongName> <ReportType>Sheet</ReportType> <Role>http://cnbxpharma.com/role/FinancialIncomeExpensesDetails</Role> <ShortName>Financial (Income) expenses (Details)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://cnbxpharma.com/role/FinancialIncomeExpensesTables</ParentRole> <Position>39</Position> </Report> <Report> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <LongName>All Reports</LongName> <ReportType>Book</ReportType> <ShortName>All Reports</ShortName> </Report> </MyReports> <InputFiles> <File>cnbx-20230831.xsd</File> <File>cnbx-20230831_cal.xml</File> <File>cnbx-20230831_def.xml</File> <File>cnbx-20230831_lab.xml</File> <File>cnbx-20230831_pre.xml</File> <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="cnbx_i10k-083123.htm">cnbx_i10k-083123.htm</File> </InputFiles> <SupplementalFiles> <File>image_001.jpg</File> <File>image_002.jpg</File> <File>image_009.jpg</File> <File>image_010.jpg</File> <File>image_011.jpg</File> <File>image_012.jpg</File> <File>image_013.jpg</File> <File>image_014.jpg</File> <File>image_015.jpg</File> <File>image_016.jpg</File> <File>image_017.jpg</File> <File>image_018.jpg</File> <File>image_019.gif</File> <File>image_019.jpg</File> </SupplementalFiles> <BaseTaxonomies> <BaseTaxonomy items="344">http://fasb.org/us-gaap/2023</BaseTaxonomy> <BaseTaxonomy items="36">http://xbrl.sec.gov/dei/2023</BaseTaxonomy> </BaseTaxonomies> <HasPresentationLinkbase>true</HasPresentationLinkbase> <HasCalculationLinkbase>true</HasCalculationLinkbase> </FilingSummary> </XML> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>JSON <SEQUENCE>70 <FILENAME>MetaLinks.json <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> { "version": "2.2", "instance": { "cnbx_i10k-083123.htm": { "nsprefix": "CNBX", "nsuri": "http://cnbxpharma.com/20230831", "dts": { "schema": { "local": [ "cnbx-20230831.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "cnbx-20230831_cal.xml" ] }, "definitionLink": { "local": [ "cnbx-20230831_def.xml" ] }, "labelLink": { "local": [ "cnbx-20230831_lab.xml" ] }, "presentationLink": { "local": [ "cnbx-20230831_pre.xml" ] }, "inline": { "local": [ "cnbx_i10k-083123.htm" ] } }, "keyStandard": 169, "keyCustom": 25, "axisStandard": 12, "axisCustom": 0, "memberStandard": 11, "memberCustom": 15, "hidden": { "total": 44, "http://xbrl.sec.gov/dei/2023": 4, "http://fasb.org/us-gaap/2023": 32, "http://cnbxpharma.com/20230831": 8 }, "contextCount": 89, "entityCount": 1, "segmentCount": 28, "elementCount": 312, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 344, "http://xbrl.sec.gov/dei/2023": 36 }, "report": { "R1": { "role": "http://cnbxpharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R2": { "role": "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets", "longName": "00000002 - Statement - Audited Consolidated Balance Sheets", "shortName": "Audited Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2023-08-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-08-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R3": { "role": "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheetsParenthetical", "longName": "00000003 - Statement - Audited Consolidated Balance Sheets (Parenthetical)", "shortName": "Audited Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2023-08-31", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-08-31", "name": "us-gaap:PreferredStockSharesIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "unique": true } }, "R4": { "role": "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations", "longName": "00000004 - Statement - Audited Consolidated Statements of Operations", "shortName": "Audited Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R5": { "role": "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperationsParenthetical", "longName": "00000005 - Statement - Audited Consolidated Statements of Operations (Parenthetical)", "shortName": "Audited Consolidated Statements of Operations (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:EarningsPerShareBasic", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:EarningsPerShareBasic", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R6": { "role": "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows", "longName": "00000006 - Statement - Audited Consolidated Statements of Cash Flows", "shortName": "Audited Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "unique": true } }, "R7": { "role": "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfStockholdersEquityDeficit", "longName": "00000007 - Statement - Audited Consolidated Statements of Stockholders' Equity (Deficit)", "shortName": "Audited Consolidated Statements of Stockholders' Equity (Deficit)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "AsOf2021-08-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2021-08-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R8": { "role": "http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcern", "longName": "00000008 - Disclosure - Nature of Business, Presentation and Going Concern", "shortName": "Nature of Business, Presentation and Going Concern", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R9": { "role": "http://cnbxpharma.com/role/SummaryOfSignificantAccountingPolicies", "longName": "00000009 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R10": { "role": "http://cnbxpharma.com/role/RecentAccountingPronouncements", "longName": "00000010 - Disclosure - Recent Accounting Pronouncements", "shortName": "Recent Accounting Pronouncements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R11": { "role": "http://cnbxpharma.com/role/RelatedPartyTransactions", "longName": "00000011 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R12": { "role": "http://cnbxpharma.com/role/CommitmentsAndContingencies", "longName": "00000012 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R13": { "role": "http://cnbxpharma.com/role/StockholdersEquityDeficit", "longName": "00000013 - Disclosure - Stockholders\u2019 Equity (Deficit)", "shortName": "Stockholders\u2019 Equity (Deficit)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R14": { "role": "http://cnbxpharma.com/role/Warrants", "longName": "00000014 - Disclosure - Warrants", "shortName": "Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "CNBX:WarrantDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "CNBX:WarrantDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R15": { "role": "http://cnbxpharma.com/role/IncomeTaxes", "longName": "00000015 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R16": { "role": "http://cnbxpharma.com/role/CapitalLoss", "longName": "00000016 - Disclosure - Capital loss", "shortName": "Capital loss", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "CNBX:CapitalLossDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "CNBX:CapitalLossDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R17": { "role": "http://cnbxpharma.com/role/GeneralAdministrateExpenses", "longName": "00000017 - Disclosure - General & administrate expenses", "shortName": "General & administrate expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R18": { "role": "http://cnbxpharma.com/role/FinancialIncomeExpenses", "longName": "00000018 - Disclosure - Financial (Income) expenses", "shortName": "Financial (Income) expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R19": { "role": "http://cnbxpharma.com/role/SubsequentEvents", "longName": "00000019 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R20": { "role": "http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "20", "firstAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R21": { "role": "http://cnbxpharma.com/role/WarrantsTables", "longName": "00000021 - Disclosure - Warrants (Tables)", "shortName": "Warrants (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "CNBX:WarrantDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "CNBX:WarrantDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R22": { "role": "http://cnbxpharma.com/role/IncomeTaxesTables", "longName": "00000022 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R23": { "role": "http://cnbxpharma.com/role/GeneralAdministrateExpensesTables", "longName": "00000023 - Disclosure - General & administrate expenses (Tables)", "shortName": "General & administrate expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R24": { "role": "http://cnbxpharma.com/role/FinancialIncomeExpensesTables", "longName": "00000024 - Disclosure - Financial (Income) expenses (Tables)", "shortName": "Financial (Income) expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "CNBX:ScheduleOfFinancialIncomeExpensesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "CNBX:ScheduleOfFinancialIncomeExpensesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R25": { "role": "http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcernDetailsNarrative", "longName": "00000025 - Disclosure - Nature of Business, Presentation and Going Concern (Details Narrative)", "shortName": "Nature of Business, Presentation and Going Concern (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true }, "uniqueAnchor": null }, "R26": { "role": "http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "00000026 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "AsOf2023-08-31", "name": "us-gaap:CashFDICInsuredAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-08-31", "name": "us-gaap:CashFDICInsuredAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R27": { "role": "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative", "longName": "00000027 - Disclosure - Related Party Transactions (Details Narrative)", "shortName": "Related Party Transactions (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "From2022-09-012023-08-31_srt_ChiefFinancialOfficerMember", "name": "us-gaap:OfficersCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-09-012023-08-31_srt_ChiefFinancialOfficerMember", "name": "us-gaap:OfficersCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R28": { "role": "http://cnbxpharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "longName": "00000028 - Disclosure - Commitments and Contingencies (Details Narrative)", "shortName": "Commitments and Contingencies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "AsOf2023-08-31", "name": "us-gaap:BankAcceptancesExecuted", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-08-31", "name": "us-gaap:BankAcceptancesExecuted", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R29": { "role": "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative", "longName": "00000029 - Disclosure - Stockholders\u2019 Equity (Deficit) (Details Narrative)", "shortName": "Stockholders\u2019 Equity (Deficit) (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "AsOf2023-08-31", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-05-112022-05-12", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "unique": true } }, "R30": { "role": "http://cnbxpharma.com/role/WarrantsDetails-FairValue", "longName": "00000030 - Disclosure - Warrants (Details - Fair value)", "shortName": "Warrants (Details - Fair value)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "AsOf2018-09-24_custom_Warrant1Member", "name": "us-gaap:SharePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "CNBX:ScheduleOfAssumptionsUsedWarrantsTableTextBlock", "CNBX:WarrantDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2018-09-24_custom_Warrant1Member", "name": "us-gaap:SharePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "CNBX:ScheduleOfAssumptionsUsedWarrantsTableTextBlock", "CNBX:WarrantDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R31": { "role": "http://cnbxpharma.com/role/WarrantsDetails-FairValueDisclosure", "longName": "00000031 - Disclosure - Warrants (Details - Fair Value)", "shortName": "Warrants (Details - Fair Value)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "AsOf2020-12-16_custom_Warrant2Member", "name": "us-gaap:SharePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "CNBX:ScheduleOfAssumptionsUsedWarrantsTableTextBlock", "CNBX:WarrantDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2020-12-16_custom_Warrant2Member", "name": "us-gaap:SharePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "CNBX:ScheduleOfAssumptionsUsedWarrantsTableTextBlock", "CNBX:WarrantDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R32": { "role": "http://cnbxpharma.com/role/WarrantsDetails-WarrantActivity", "longName": "00000032 - Disclosure - Warrants (Details - Warrant activity)", "shortName": "Warrants (Details - Warrant activity)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "AsOf2022-08-31_custom_WarrantsMember882227078", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "CNBX:WarrantDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2020-08-31_custom_WarrantsMember", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "CNBX:WarrantDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "unique": true } }, "R33": { "role": "http://cnbxpharma.com/role/WarrantsDetailsNarrative", "longName": "00000033 - Disclosure - Warrants (Details Narrative)", "shortName": "Warrants (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "AsOf2018-09-24_custom_Warrant1Member", "name": "CNBX:WarrantsIssuedShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "CNBX:WarrantDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2018-09-24_custom_Warrant1Member", "name": "CNBX:WarrantsIssuedShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "CNBX:WarrantDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R34": { "role": "http://cnbxpharma.com/role/IncomeTaxesDetails-Rate", "longName": "00000034 - Disclosure - Income Taxes (Details - rate)", "shortName": "Income Taxes (Details - rate)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "unique": true } }, "R35": { "role": "http://cnbxpharma.com/role/IncomeTaxesDetails-DeferredTaxAssets", "longName": "00000035 - Disclosure - Income Taxes (Details - Deferred tax assets)", "shortName": "Income Taxes (Details - Deferred tax assets)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "AsOf2023-08-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-08-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R36": { "role": "http://cnbxpharma.com/role/IncomeTaxesDetailsNarrative", "longName": "00000036 - Disclosure - Income Taxes (Details Narrative)", "shortName": "Income Taxes (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-08-31", "name": "us-gaap:OperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "unique": true } }, "R37": { "role": "http://cnbxpharma.com/role/CapitalLossDetailsNarrative", "longName": "00000037 - Disclosure - Capital loss (Details Narrative)", "shortName": "Capital loss (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "From2022-12-082022-12-09", "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "CNBX:CapitalLossDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-12-082022-12-09", "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "CNBX:CapitalLossDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R38": { "role": "http://cnbxpharma.com/role/GeneralAndAdministrativeExpensesDetails", "longName": "00000038 - Disclosure - General and administrative expenses (Details)", "shortName": "General and administrative expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:LaborAndRelatedExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:LaborAndRelatedExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } }, "R39": { "role": "http://cnbxpharma.com/role/FinancialIncomeExpensesDetails", "longName": "00000039 - Disclosure - Financial (Income) expenses (Details)", "shortName": "Financial (Income) expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:InterestExpenseBorrowings", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "CNBX:ScheduleOfFinancialIncomeExpensesTableTextBlock", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-09-01to2023-08-31", "name": "us-gaap:InterestExpenseBorrowings", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "CNBX:ScheduleOfFinancialIncomeExpensesTableTextBlock", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cnbx_i10k-083123.htm", "first": true, "unique": true } } }, "tag": { "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r564", "r579" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r63", "r237" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://cnbxpharma.com/role/WarrantsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of warrant activity", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r43" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r138", "r149", "r184", "r185", "r192", "r195", "r196", "r200", "r201", "r202", "r203", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r325", "r379", "r567" ] }, "us-gaap_NonmonetaryTransactionTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonmonetaryTransactionTypeDomain", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Identifies the nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange." } } }, "auth_ref": [ "r345", "r346", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative", "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r260", "r352", "r353", "r429", "r430", "r431", "r432", "r433", "r451", "r453", "r485" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r539", "r541", "r542", "r544" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r183", "r193", "r197", "r199", "r498" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://cnbxpharma.com/role/WarrantsDetails-FairValue", "http://cnbxpharma.com/role/WarrantsDetails-FairValueDisclosure", "http://cnbxpharma.com/role/WarrantsDetails-WarrantActivity", "http://cnbxpharma.com/role/WarrantsDetailsNarrative", "http://cnbxpharma.com/role/WarrantsTables" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r43" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r538" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r545" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 }, "http://cnbxpharma.com/role/GeneralAndAdministrativeExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations", "http://cnbxpharma.com/role/GeneralAndAdministrativeExpensesDetails" ], "lang": { "en-us": { "role": { "label": "General and administrative expenses", "totalLabel": "Total general and administrative expenses", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r73", "r457" ] }, "us-gaap_LegalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LegalFees", "crdr": "debit", "calculation": { "http://cnbxpharma.com/role/GeneralAndAdministrativeExpensesDetails": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cnbxpharma.com/role/GeneralAndAdministrativeExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Legal and professional fees", "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings." } } }, "auth_ref": [ "r72" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r541" ] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://cnbxpharma.com/role/WarrantsDetails-FairValue", "http://cnbxpharma.com/role/WarrantsDetails-FairValueDisclosure", "http://cnbxpharma.com/role/WarrantsDetails-WarrantActivity", "http://cnbxpharma.com/role/WarrantsDetailsNarrative", "http://cnbxpharma.com/role/WarrantsTables" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r43" ] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments required to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share based payment", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r3" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r304" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r528" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r536" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://cnbxpharma.com/role/WarrantsDetails-FairValue", "http://cnbxpharma.com/role/WarrantsDetails-FairValueDisclosure", "http://cnbxpharma.com/role/WarrantsDetails-WarrantActivity", "http://cnbxpharma.com/role/WarrantsDetailsNarrative", "http://cnbxpharma.com/role/WarrantsTables" ], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheetsParenthetical", "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r63", "r434" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r63", "r434", "r452", "r586", "r587" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r535" ] }, "us-gaap_IsraelTaxAuthorityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IsraelTaxAuthorityMember", "presentation": [ "http://cnbxpharma.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Israel Tax Authority [Member]", "documentation": "Designated tax department of the government of Israel." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfStockholdersEquityDeficit", "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercise of a Convertible loan to shares of common stock, shares", "verboseLabel": "Convertible shares", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r9", "r20", "r39", "r88", "r229" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r534" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r539", "r541", "r542" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r546" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r530" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "us-gaap_OtherIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncomeAbstract", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other income" } } }, "auth_ref": [] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Principles of Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r49", "r495" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheetsParenthetical", "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r63", "r237" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://cnbxpharma.com/role/IncomeTaxesDetails-DeferredTaxAssets", "http://cnbxpharma.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued liabilities", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r15" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r227", "r254", "r255", "r256", "r257", "r258", "r259", "r357", "r358", "r359", "r501", "r502", "r506", "r507", "r508" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Stock Based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r261", "r263", "r264", "r265", "r266", "r267", "r270", "r275", "r276", "r277", "r278" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r78" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r530" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcern" ], "lang": { "en-us": { "role": { "label": "Nature of Business, Presentation and Going Concern", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r60", "r94", "r403", "r404" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r19" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r78", "r79", "r80" ] }, "us-gaap_Investments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Investments", "crdr": "debit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Available for sale Investment", "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments." } } }, "auth_ref": [ "r381" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r227", "r254", "r255", "r256", "r257", "r258", "r259", "r324", "r357", "r358", "r359", "r501", "r502", "r506", "r507", "r508" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://cnbxpharma.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of deferred income tax assets", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r93" ] }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingChangesAndErrorCorrectionsAbstract", "lang": { "en-us": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r117", "r125", "r149", "r203", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r305", "r307", "r325", "r517", "r567", "r568", "r581" ] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r530" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r542" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of exchange rate fluctuations on cash", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r334" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r530" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r227", "r254", "r259", "r324", "r357", "r506", "r507", "r508" ] }, "us-gaap_OtherNoncashExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashExpense", "crdr": "debit", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Non cash expense", "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other." } } }, "auth_ref": [ "r80" ] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "presentation": [ "http://cnbxpharma.com/role/FinancialIncomeExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Currency exchange differences loss (profit)", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r330", "r331", "r332", "r333", "r475" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://cnbxpharma.com/role/WarrantsDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Warrants outstanding, beginning balance", "periodEndLabel": "Warrants outstanding, ending balance", "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative", "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r260", "r352", "r353", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r429", "r430", "r431", "r432", "r433", "r451", "r453", "r485", "r580" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r542" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents at beginning of year", "periodEndLabel": "Cash and cash equivalents at end of the year", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r27", "r78", "r146" ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r541" ] }, "us-gaap_BankAcceptancesExecuted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BankAcceptancesExecuted", "crdr": "credit", "presentation": [ "http://cnbxpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Bank guarantee", "documentation": "The amount of the financial institution's obligation to pay the holder of the customer's draft which the financial institution has guaranteed (i.e., Banker's Acceptance)." } } }, "auth_ref": [ "r56" ] }, "us-gaap_NonmonetaryTransactionTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonmonetaryTransactionTypeAxis", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Nonmonetary Transaction Type [Axis]", "documentation": "Information by nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange." } } }, "auth_ref": [ "r345", "r346", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r541" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r542" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r145" ] }, "us-gaap_AccruedSalariesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedSalariesCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued salaries", "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided." } } }, "auth_ref": [ "r57" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' equity (deficit):" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r145" ] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://cnbxpharma.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r150", "r282", "r286", "r287", "r292", "r299", "r301", "r302", "r303", "r412" ] }, "us-gaap_IncomeTaxAuthorityNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityNameAxis", "presentation": [ "http://cnbxpharma.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Axis]", "documentation": "Information by name of taxing authority." } } }, "auth_ref": [ "r7" ] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsTable", "presentation": [ "http://cnbxpharma.com/role/IncomeTaxesDetails-DeferredTaxAssets", "http://cnbxpharma.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Table]", "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization." } } }, "auth_ref": [ "r46" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity (Deficit)", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r85", "r148", "r236", "r238", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r250", "r253", "r316", "r481", "r483", "r491" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r349", "r350", "r351", "r353", "r354", "r413", "r414", "r415", "r460", "r461", "r462", "r482", "r484" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Functional currency", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r329" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r53", "r54", "r458", "r459", "r462" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r530" ] }, "us-gaap_IncomeTaxAuthorityNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityNameDomain", "presentation": [ "http://cnbxpharma.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://cnbxpharma.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of effective income tax rate", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r92" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r458", "r459", "r462" ] }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsLineItems", "presentation": [ "http://cnbxpharma.com/role/IncomeTaxesDetails-DeferredTaxAssets", "http://cnbxpharma.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://cnbxpharma.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r84", "r208", "r209", "r492", "r566" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r272", "r273", "r274", "r416", "r560", "r561", "r562", "r574", "r586" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://cnbxpharma.com/role/CapitalLossDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale consideration", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r152", "r153", "r154", "r180", "r360", "r405", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r447", "r448", "r449", "r450", "r451", "r453", "r456", "r457", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r478", "r521" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r114", "r152", "r153", "r154", "r158", "r166", "r168", "r204", "r207", "r272", "r273", "r274", "r294", "r295", "r309", "r311", "r312", "r315", "r318", "r395", "r397", "r416", "r586" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r227", "r254", "r255", "r256", "r257", "r258", "r259", "r324", "r359", "r501", "r502", "r506", "r507", "r508" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r9", "r21", "r114", "r135", "r136", "r137", "r152", "r153", "r154", "r158", "r166", "r168", "r180", "r204", "r207", "r253", "r272", "r273", "r274", "r294", "r295", "r309", "r310", "r311", "r312", "r313", "r315", "r318", "r335", "r337", "r338", "r339", "r340", "r341", "r347", "r395", "r396", "r397", "r416", "r478" ] }, "us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfEquitySecuritiesFvNi", "crdr": "debit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Realization of Held for trading investments", "documentation": "Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity." } } }, "auth_ref": [ "r102", "r144" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment Information", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r186", "r187", "r188", "r189", "r190", "r191", "r201", "r499" ] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r113", "r121", "r122", "r123", "r149", "r173", "r174", "r176", "r178", "r181", "r182", "r203", "r210", "r212", "r213", "r214", "r217", "r218", "r237", "r238", "r241", "r244", "r251", "r325", "r407", "r408", "r409", "r410", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r434", "r455", "r478", "r486", "r487", "r488", "r489", "r490", "r549", "r557", "r563" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Principal amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r51", "r52", "r219", "r342", "r501", "r502" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingMaturityDate", "presentation": [ "http://cnbxpharma.com/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Expiry date", "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format." } } }, "auth_ref": [ "r575" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r31", "r32", "r33", "r103", "r104", "r107", "r108" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "us-gaap_CommonStockConvertibleConversionPriceDecrease": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockConvertibleConversionPriceDecrease", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lower conversion price", "documentation": "Per share decrease in conversion price of convertible common stock. Excludes change due to standard antidilution provision." } } }, "auth_ref": [ "r252" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r529" ] }, "us-gaap_LaborAndRelatedExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LaborAndRelatedExpense", "crdr": "debit", "calculation": { "http://cnbxpharma.com/role/GeneralAndAdministrativeExpensesDetails": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cnbxpharma.com/role/GeneralAndAdministrativeExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Salaries and related expenses", "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit." } } }, "auth_ref": [ "r556" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r9", "r114", "r135", "r136", "r137", "r152", "r153", "r154", "r158", "r166", "r168", "r180", "r204", "r207", "r253", "r272", "r273", "r274", "r294", "r295", "r309", "r310", "r311", "r312", "r313", "r315", "r318", "r335", "r337", "r338", "r339", "r340", "r341", "r347", "r395", "r396", "r397", "r416", "r478" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Share based Payment", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r44", "r45", "r262" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssetsAbstract", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r8", "r24", "r310", "r313", "r347", "r395", "r396", "r552", "r553", "r554", "r560", "r561", "r562" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://cnbxpharma.com/role/IncomeTaxesDetails-DeferredTaxAssets" ], "lang": { "en-us": { "role": { "label": "Net operating loss carry forwards benefit", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r48", "r572" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://cnbxpharma.com/role/IncomeTaxesDetails-Rate" ], "lang": { "en-us": { "role": { "label": "Provision for income tax", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r285" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "presentation": [ "http://cnbxpharma.com/role/IncomeTaxesDetails-DeferredTaxAssets" ], "lang": { "en-us": { "role": { "label": "Net deferred income tax assets", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r571" ] }, "us-gaap_CommonStockConvertibleConversionPriceIncrease": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockConvertibleConversionPriceIncrease", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion price", "documentation": "Per share increase in conversion price of convertible common stock. Excludes change due to standard antidilution provision." } } }, "auth_ref": [ "r252" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "presentation": [ "http://cnbxpharma.com/role/IncomeTaxesDetails-Rate" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in valuation allowance on deferred tax assets", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r570", "r573" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r532" ] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of a Convertible loan", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r26" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r533" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperationsParenthetical" ], "lang": { "en-us": { "role": { "label": "Weighted average number of shares outstanding - Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r172", "r178" ] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Sale of equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r76" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r539", "r541", "r542" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperationsParenthetical" ], "lang": { "en-us": { "role": { "label": "Weighted average number of shares outstanding - Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r171", "r178" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r537" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r540" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r17", "r118", "r149", "r203", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r306", "r307", "r308", "r325", "r517", "r567", "r581", "r582" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [ "http://cnbxpharma.com/role/IncomeTaxesDetails-Rate", "http://cnbxpharma.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "United States statutory corporate income tax rate", "verboseLabel": "Effective tax rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r150", "r285", "r300" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "presentation": [ "http://cnbxpharma.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Effective tax rate, Israel", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile." } } }, "auth_ref": [ "r570", "r573" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateDuringPeriod", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest rate", "documentation": "The average effective interest rate during the reporting period." } } }, "auth_ref": [ "r18", "r51", "r231" ] }, "us-gaap_ProceedsFromNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromNotesPayable", "crdr": "debit", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Notes payable", "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r26" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r543" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Original issue discount percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r18", "r51", "r235", "r342" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperationsParenthetical" ], "lang": { "en-us": { "role": { "label": "Net (loss) per share - diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r141", "r161", "r162", "r163", "r164", "r165", "r173", "r176", "r177", "r178", "r179", "r319", "r320", "r378", "r394", "r497" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Reclassification", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r550" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r64" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://cnbxpharma.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net operating loss carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r47" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r95", "r120", "r149", "r183", "r194", "r198", "r203", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r305", "r307", "r325", "r382", "r446", "r517", "r527", "r567", "r568", "r581" ] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncomeAndExpensesAbstract", "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheetsParenthetical", "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r64", "r434" ] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://cnbxpharma.com/role/WarrantsDetails-FairValue", "http://cnbxpharma.com/role/WarrantsDetails-FairValueDisclosure", "http://cnbxpharma.com/role/WarrantsDetails-WarrantActivity", "http://cnbxpharma.com/role/WarrantsDetailsNarrative", "http://cnbxpharma.com/role/WarrantsTables" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r541" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other receivables", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r551" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r304" ] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://cnbxpharma.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r355", "r356" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r9", "r64", "r434", "r452", "r586", "r587" ] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://cnbxpharma.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in valuation allowance", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r289" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r134", "r283", "r284", "r287", "r288", "r291", "r293", "r406" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, $.0001 par value, 900,000,000 shares authorized, 22,611,352and 1,238,659 shares issued and outstanding at August 31, 2023 and August 31, 2022 respectively.", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r64", "r384", "r517" ] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DomesticCountryMember", "presentation": [ "http://cnbxpharma.com/role/IncomeTaxesDetails-DeferredTaxAssets", "http://cnbxpharma.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Domestic Tax Authority [Member]", "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile." } } }, "auth_ref": [] }, "CNBX_OriginalIssueDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "OriginalIssueDiscount", "crdr": "credit", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Original issue discount" } } }, "auth_ref": [] }, "CNBX_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "WarrantsMember", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfStockholdersEquityDeficit", "http://cnbxpharma.com/role/WarrantsDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "label": "Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r65", "r517", "r585" ] }, "srt_ChiefFinancialOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ChiefFinancialOfficerMember", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Chief Financial Officer [Member]" } } }, "auth_ref": [ "r564" ] }, "CNBX_WarrantsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "WarrantsIssued", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative", "http://cnbxpharma.com/role/WarrantsDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "label": "Warrants issued" } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "CNBX_Warrant2Member": { "xbrltype": "domainItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "Warrant2Member", "presentation": [ "http://cnbxpharma.com/role/WarrantsDetails-FairValueDisclosure", "http://cnbxpharma.com/role/WarrantsDetailsNarrative", "http://cnbxpharma.com/role/WarrantsTables" ], "lang": { "en-us": { "role": { "label": "Warrant 2 [Member]" } } }, "auth_ref": [] }, "srt_PlatformOperatorCryptoAssetLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "PlatformOperatorCryptoAssetLineItems", "presentation": [ "http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Platform Operator, Crypto-Asset [Line Items]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r19", "r151", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r342", "r500", "r501", "r502", "r503", "r504", "r558" ] }, "CNBX_UnitedStates1Member": { "xbrltype": "domainItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "UnitedStates1Member", "presentation": [ "http://cnbxpharma.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "United States [Member]", "documentation": "United States [Member]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "CNBX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber", "presentation": [ "http://cnbxpharma.com/role/WarrantsDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "label": "Warrants exercisable" } } }, "auth_ref": [] }, "srt_PlatformOperatorCryptoAssetTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "PlatformOperatorCryptoAssetTable", "presentation": [ "http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Platform Operator, Crypto-Asset [Table]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets", "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity (deficit)", "periodStartLabel": "Beginning balance, value", "periodEndLabel": "Ending balance, value", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r64", "r67", "r68", "r82", "r436", "r452", "r479", "r480", "r517", "r527", "r559", "r565", "r576", "r586" ] }, "CNBX_WeightedAverageExercisePriceWarrantsIssued": { "xbrltype": "perShareItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "WeightedAverageExercisePriceWarrantsIssued", "presentation": [ "http://cnbxpharma.com/role/WarrantsDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, warrants issued" } } }, "auth_ref": [] }, "CNBX_WeightedAverageExercisePriceWarrantsExercised": { "xbrltype": "perShareItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "WeightedAverageExercisePriceWarrantsExercised", "presentation": [ "http://cnbxpharma.com/role/WarrantsDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, warrants exercised" } } }, "auth_ref": [] }, "CNBX_CEOAndChairmanMember": { "xbrltype": "domainItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "CEOAndChairmanMember", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "C E O And Chairman [Member]" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://cnbxpharma.com/role/WarrantsDetails-FairValue", "http://cnbxpharma.com/role/WarrantsDetails-FairValueDisclosure" ], "lang": { "en-us": { "role": { "label": "Expected Term (years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r266" ] }, "CNBX_WeightedAverageExercisePriceWarrantsExpired": { "xbrltype": "perShareItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "WeightedAverageExercisePriceWarrantsExpired", "presentation": [ "http://cnbxpharma.com/role/WarrantsDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, warrants expired" } } }, "auth_ref": [] }, "CNBX_WeightedAverageExercisePriceWarrantsExercisable": { "xbrltype": "perShareItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "WeightedAverageExercisePriceWarrantsExercisable", "presentation": [ "http://cnbxpharma.com/role/WarrantsDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, warrants exercisable" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "(Loss) Profit from available for sale assets", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r126", "r127", "r128" ] }, "CNBX_WarrantsIssuedShares": { "xbrltype": "sharesItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "WarrantsIssuedShares", "presentation": [ "http://cnbxpharma.com/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants issued, shares" } } }, "auth_ref": [] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableCurrent", "crdr": "credit", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Outstanding payable", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r15" ] }, "CNBX_ThreeDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "ThreeDirectorsMember", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Three Directors [Member]" } } }, "auth_ref": [] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://cnbxpharma.com/role/WarrantsDetails-FairValue", "http://cnbxpharma.com/role/WarrantsDetails-FairValueDisclosure" ], "lang": { "en-us": { "role": { "label": "PV of exercise Share price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative", "http://cnbxpharma.com/role/WarrantsDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "label": "Warrants exercise price", "periodStartLabel": "Weighted average exercise price, warrants outstanding, beginning balance", "periodEndLabel": "Weighted average exercise price, warrants outstanding, ending balance", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r252" ] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r6", "r13" ] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unamortized Discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r50", "r52", "r569" ] }, "CNBX_FairValueOfWarrantsIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "FairValueOfWarrantsIssued", "crdr": "debit", "presentation": [ "http://cnbxpharma.com/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair value of warrants issued" } } }, "auth_ref": [] }, "CNBX_CannabicsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "CannabicsIncMember", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cannabics Inc [Member]" } } }, "auth_ref": [] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r539", "r541", "r542" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r36", "r37", "r38", "r39", "r40", "r41", "r42", "r86", "r87", "r88", "r121", "r122", "r123", "r181", "r237", "r238", "r239", "r241", "r244", "r249", "r251", "r407", "r408", "r409", "r410", "r505", "r549", "r557" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r539", "r541", "r542" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "verboseLabel": "Other comprehensive loss", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r9", "r12", "r130", "r133", "r139", "r335", "r336", "r341", "r376", "r392", "r552", "r553" ] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [ "http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r121", "r122", "r123", "r181", "r237", "r238", "r239", "r241", "r244", "r249", "r251", "r407", "r408", "r409", "r410", "r505", "r549", "r557" ] }, "CNBX_LossGainFromConvertibleLoanValuation": { "xbrltype": "monetaryItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "LossGainFromConvertibleLoanValuation", "crdr": "credit", "presentation": [ "http://cnbxpharma.com/role/FinancialIncomeExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Loss (Gain) from convertible loan valuation" } } }, "auth_ref": [] }, "CNBX_CapitalLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "CapitalLoss", "crdr": "debit", "presentation": [ "http://cnbxpharma.com/role/CapitalLossDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Capital loss", "label": "CapitalLoss" } } }, "auth_ref": [] }, "us-gaap_OfficersCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OfficersCompensation", "crdr": "debit", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Compensation paid", "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold." } } }, "auth_ref": [ "r555" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://cnbxpharma.com/role/IncomeTaxesDetails-DeferredTaxAssets", "http://cnbxpharma.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Axis]", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r7" ] }, "CNBX_ShareBasedPaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "ShareBasedPaymentMember", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share Based Payment [Member]" } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows", "http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Depreciation", "verboseLabel": "Depreciation expense", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r4", "r34" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "presentation": [ "http://cnbxpharma.com/role/IncomeTaxesDetails-DeferredTaxAssets" ], "lang": { "en-us": { "role": { "negatedLabel": "Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r290" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets", "http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "negatedLabel": "Cumulative losses", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r66", "r88", "r387", "r398", "r402", "r411", "r435", "r517" ] }, "us-gaap_SeniorNotesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorNotesCurrent", "crdr": "credit", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Senior secured note", "documentation": "Carrying value as of the balance sheet date of the portion of long-term notes having the highest claim on the assets of the issuer in case of bankruptcy or liquidation, due within one year or the normal operating cycle, if longer. Senior note holders are paid off in full before any payments are made to debt holders having a lesser priority of repayment." } } }, "auth_ref": [ "r16", "r517" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r539", "r541", "r542" ] }, "CNBX_ChairmanAndBoardMembersMember": { "xbrltype": "domainItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "ChairmanAndBoardMembersMember", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Chairman And Board Members [Member]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r14", "r61", "r62", "r96", "r97", "r151", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r342", "r500", "r501", "r502", "r503", "r504", "r558" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "CNBX_SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "SecuritiesPurchaseAgreementMember", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Securities Purchase Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_InterestExpenseOtherLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseOtherLongTermDebt", "crdr": "debit", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net of issuance expenses", "documentation": "Amount of interest expense incurred on long-term debt classified as other, including, but not limited to, interest on long-term notes and amortization of issuance costs." } } }, "auth_ref": [ "r101" ] }, "CNBX_InitialNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "InitialNoteMember", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Initial Note [Member]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "presentation": [ "http://cnbxpharma.com/role/RecentAccountingPronouncements" ], "lang": { "en-us": { "role": { "label": "Recent Accounting Pronouncements", "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle." } } }, "auth_ref": [ "r110", "r111", "r112", "r115", "r155", "r156", "r159", "r160", "r169", "r170", "r205", "r206", "r296", "r297", "r298", "r314", "r317", "r321", "r322", "r323", "r326", "r327", "r328", "r343", "r344", "r348", "r361", "r362", "r363", "r398", "r399", "r400", "r401", "r402" ] }, "CNBX_SecondNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "SecondNoteMember", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Second Note [Member]" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other comprehensive loss", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r23", "r24", "r70", "r124", "r386", "r399", "r402" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r152", "r153", "r154", "r180", "r360", "r405", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r447", "r448", "r449", "r450", "r451", "r453", "r456", "r457", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r478", "r521" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance, shares", "periodEndLabel": "Ending balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://cnbxpharma.com/role/WarrantsDetails-FairValue", "http://cnbxpharma.com/role/WarrantsDetails-FairValueDisclosure" ], "lang": { "en-us": { "role": { "label": "Expected Dividend Yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r268" ] }, "CNBX_NoteMember": { "xbrltype": "domainItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "NoteMember", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Note [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://cnbxpharma.com/role/WarrantsDetails-FairValue", "http://cnbxpharma.com/role/WarrantsDetails-FairValueDisclosure" ], "lang": { "en-us": { "role": { "label": "Expected Volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r267" ] }, "CNBX_SeniorSecuredNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "SeniorSecuredNoteMember", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Senior Secured Note [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://cnbxpharma.com/role/WarrantsDetails-FairValue", "http://cnbxpharma.com/role/WarrantsDetails-FairValueDisclosure" ], "lang": { "en-us": { "role": { "label": "Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r269" ] }, "us-gaap_OtherAdditionalCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAdditionalCapital", "crdr": "credit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Issuance of warrants", "documentation": "Amount of additional paid-in capital (APIC) classified as other." } } }, "auth_ref": [ "r22", "r385" ] }, "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpensesOther", "crdr": "credit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts Receivable and prepaid expenses", "label": "Increase (Decrease) in Prepaid Expenses, Other", "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and development, net", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r280" ] }, "CNBX_DemandNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "DemandNoteMember", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Demand Note [Member]" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentsOwnedAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentsOwnedAtFairValue", "crdr": "debit", "presentation": [ "http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair value of financial instruments", "documentation": "The aggregate fair value as of the balance sheet date of financial instruments and other positions owned by the entity including: (1) mortgages, mortgage-backed and asset backed securities; (2) US government and agency obligations; (3) state and municipal government obligations; (4) other sovereign government debt; (5) corporate obligations; (6) corporate equities; (7) principal investments; (8) derivative contracts; and (9) physical commodities. Includes both pledged and unpledged holdings." } } }, "auth_ref": [ "r55" ] }, "CNBX_Warrant1Member": { "xbrltype": "domainItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "Warrant1Member", "presentation": [ "http://cnbxpharma.com/role/WarrantsDetails-FairValue", "http://cnbxpharma.com/role/WarrantsDetailsNarrative", "http://cnbxpharma.com/role/WarrantsTables" ], "lang": { "en-us": { "role": { "label": "Warrant 1 [Member]" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r547" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentration of Credit Risk", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r58", "r105" ] }, "CNBX_DueToRelatedPartiesCurrent1": { "xbrltype": "monetaryItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "DueToRelatedPartiesCurrent1", "crdr": "credit", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Due to related parties" } } }, "auth_ref": [] }, "us-gaap_GeneralInsuranceExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralInsuranceExpense", "crdr": "debit", "calculation": { "http://cnbxpharma.com/role/GeneralAndAdministrativeExpensesDetails": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://cnbxpharma.com/role/GeneralAndAdministrativeExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Insurance", "documentation": "The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales)." } } }, "auth_ref": [ "r73" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "presentation": [ "http://cnbxpharma.com/role/WarrantsDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "label": "Warrants exercised", "documentation": "Number of non-option equity instruments exercised by participants." } } }, "auth_ref": [ "r10" ] }, "us-gaap_InvestorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestorMember", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Investor [Member]", "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value." } } }, "auth_ref": [ "r577", "r578" ] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityReverseStockSplit", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock split", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": [ "r89" ] }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "presentation": [ "http://cnbxpharma.com/role/FinancialIncomeExpenses" ], "lang": { "en-us": { "role": { "label": "Financial (Income) expenses", "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions." } } }, "auth_ref": [ "r90", "r91" ] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCountryMember", "presentation": [ "http://cnbxpharma.com/role/IncomeTaxesDetails-DeferredTaxAssets" ], "lang": { "en-us": { "role": { "label": "Foreign Tax Authority [Member]", "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile." } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheetsParenthetical", "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r64" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "presentation": [ "http://cnbxpharma.com/role/WarrantsDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "negatedLabel": "Warrants expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations", "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed." } } }, "auth_ref": [ "r11" ] }, "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt", "crdr": "debit", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Senior convertible notes issued", "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer)." } } }, "auth_ref": [ "r26" ] }, "us-gaap_OtherGeneralExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherGeneralExpense", "crdr": "debit", "calculation": { "http://cnbxpharma.com/role/GeneralAndAdministrativeExpensesDetails": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://cnbxpharma.com/role/GeneralAndAdministrativeExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other expenses", "documentation": "Amount of general expenses not normally included in Other Operating Costs and Expenses." } } }, "auth_ref": [ "r74" ] }, "us-gaap_InterestExpenseBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseBorrowings", "crdr": "debit", "presentation": [ "http://cnbxpharma.com/role/FinancialIncomeExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Interest and bank charges", "documentation": "Aggregate amount of interest expense on all borrowings." } } }, "auth_ref": [ "r100" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive (loss) income", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r25", "r131", "r133", "r140", "r377", "r393" ] }, "CNBX_DueToRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "DueToRelatedParty", "crdr": "credit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Due to a related party" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable and accrued liabilities", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r3" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r113", "r121", "r122", "r123", "r149", "r173", "r174", "r176", "r178", "r181", "r182", "r203", "r210", "r212", "r213", "r214", "r217", "r218", "r237", "r238", "r241", "r244", "r251", "r325", "r407", "r408", "r409", "r410", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r434", "r455", "r478", "r486", "r487", "r488", "r489", "r490", "r549", "r557", "r563" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfStockholdersEquityDeficit", "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r518", "r519", "r520", "r522", "r523", "r524", "r525", "r560", "r561", "r574", "r584", "r586" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "auth_ref": [] }, "us-gaap_CashFDICInsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFDICInsuredAmount", "crdr": "debit", "presentation": [ "http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Federal deposit insurance", "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": [ "http://cnbxpharma.com/role/FinancialIncomeExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Total other income expenses", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r75" ] }, "CNBX_FinancialLossNet": { "xbrltype": "monetaryItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "FinancialLossNet", "crdr": "credit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Financial loss, net" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and development expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r59", "r281", "r583" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r69", "r98", "r388", "r517", "r559", "r565", "r576" ] }, "CNBX_CapitalGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "CapitalGainLoss", "crdr": "credit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Capital Gain (loss)" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r5", "r380", "r390", "r517" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Impairment or Disposal of Long-Lived Assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r83" ] }, "us-gaap_MarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketingExpense", "crdr": "debit", "calculation": { "http://cnbxpharma.com/role/GeneralAndAdministrativeExpensesDetails": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://cnbxpharma.com/role/GeneralAndAdministrativeExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Marketing expenses", "documentation": "Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs." } } }, "auth_ref": [ "r73" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Significant non-cash transactions:" } } }, "auth_ref": [] }, "CNBX_InterestOnConvertibleLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "InterestOnConvertibleLoan", "crdr": "debit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest on Convertible loan" } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r531" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r27", "r119", "r494" ] }, "CNBX_ExerciseOfConvertibleLoanToSharesOfCommonStock.": { "xbrltype": "monetaryItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "ExerciseOfConvertibleLoanToSharesOfCommonStock.", "crdr": "credit", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Exercise of a Convertible loan to shares of common stock." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r28" ] }, "CNBX_CapitalLossGain": { "xbrltype": "monetaryItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "CapitalLossGain", "crdr": "credit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Capital loss (Gain)", "label": "CapitalLossGain" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Equipment, net", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r5", "r106", "r109", "r389" ] }, "CNBX_ScheduleOfFinancialIncomeExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "ScheduleOfFinancialIncomeExpensesTableTextBlock", "presentation": [ "http://cnbxpharma.com/role/FinancialIncomeExpensesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of financial income expenses" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://cnbxpharma.com/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r81", "r147" ] }, "CNBX_ExpirationOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "ExpirationOfWarrants", "crdr": "credit", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Expiration of warrants" } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r548" ] }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "presentation": [ "http://cnbxpharma.com/role/GeneralAdministrateExpensesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of general and administrative expenses", "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": [] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basic and Diluted Loss per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r29", "r30" ] }, "CNBX_PostsplitAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "PostsplitAdjustment", "crdr": "credit", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Post-split adjustment" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperationsParenthetical" ], "lang": { "en-us": { "role": { "label": "Net (loss) per share - basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r141", "r161", "r162", "r163", "r164", "r165", "r171", "r173", "r176", "r177", "r178", "r179", "r319", "r320", "r378", "r394", "r497" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r530" ] }, "CNBX_PostsplitAdjustmentShares": { "xbrltype": "sharesItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "PostsplitAdjustmentShares", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Post-split adjustment, shares" } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtCurrent", "crdr": "credit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Convertible loan", "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r61" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r530" ] }, "CNBX_DisclosureWarrantsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "DisclosureWarrantsAbstract", "lang": { "en-us": { "role": { "label": "Warrants" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfStockholdersEquityDeficit", "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Exercise of a Convertible loan to shares of common stock.", "label": "Stock issued for exercise of convertible debt, value", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r9", "r21", "r88" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows", "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfOperations", "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfStockholdersEquityDeficit", "http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Net (loss) income", "label": "Net (Loss) Profit", "verboseLabel": "Net loss", "negatedLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r71", "r80", "r99", "r116", "r129", "r132", "r137", "r149", "r157", "r161", "r162", "r163", "r164", "r167", "r168", "r175", "r183", "r193", "r197", "r199", "r203", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r320", "r325", "r391", "r454", "r476", "r477", "r498", "r526", "r567" ] }, "us-gaap_PaymentsToAcquireMachineryAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireMachineryAndEquipment", "crdr": "credit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisition of equipment", "label": "Payments to Acquire Machinery and Equipment", "documentation": "The cash outflow for acquisition of machinery and equipment." } } }, "auth_ref": [ "r77" ] }, "CNBX_WarrantDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "WarrantDisclosureTextBlock", "presentation": [ "http://cnbxpharma.com/role/Warrants" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrants", "label": "WarrantDisclosureTextBlock" } } }, "auth_ref": [] }, "CNBX_ScheduleOfAssumptionsUsedWarrantsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "ScheduleOfAssumptionsUsedWarrantsTableTextBlock", "presentation": [ "http://cnbxpharma.com/role/WarrantsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of assumptions" } } }, "auth_ref": [] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://cnbxpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue recognition", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r456", "r493", "r496" ] }, "CNBX_DisclosureCapitalLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "DisclosureCapitalLossAbstract", "lang": { "en-us": { "role": { "label": "Capital Loss" } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r19", "r35" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cnbxpharma.com/role/AuditedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred stock, $.0001 par value, 5,000,000 shares authorized no shares issued and outstanding.", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r63", "r383", "r517" ] }, "us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeAndExpenseTextBlock", "presentation": [ "http://cnbxpharma.com/role/GeneralAdministrateExpenses" ], "lang": { "en-us": { "role": { "label": "General & administrate expenses", "documentation": "The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": [ "r142", "r143" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "calculation": { "http://cnbxpharma.com/role/GeneralAndAdministrativeExpensesDetails": { "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cnbxpharma.com/role/GeneralAndAdministrativeExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Share based payment to related parties", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r271", "r279" ] }, "CNBX_CapitalLossDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cnbxpharma.com/20230831", "localname": "CapitalLossDisclosureTextBlock", "presentation": [ "http://cnbxpharma.com/role/CapitalLoss" ], "lang": { "en-us": { "role": { "label": "Capital loss" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(2)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(4)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "60", "Paragraph": "1", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.30(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "940", "SubTopic": "320", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481961/940-320-45-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.14)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "610", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//610/tableOfContent" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "720", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//720/tableOfContent" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.7,8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "10", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479567/321-10-45-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "SubTopic": "20", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "SubTopic": "20", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//250/tableOfContent" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-19" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-6" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482864/845-10-50-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482864/845-10-50-3" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(h))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r494": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r496": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r497": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r498": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r499": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r500": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r501": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r502": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r503": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r504": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r505": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r506": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r509": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-4" }, "r510": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-4" }, "r511": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-4" }, "r512": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-4" }, "r513": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-5" }, "r514": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-6" }, "r515": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-6" }, "r516": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-6" }, "r517": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r518": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r520": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r525": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r526": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r527": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r528": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r529": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r530": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r532": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r534": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r535": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r536": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r537": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r538": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r539": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r540": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r541": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r542": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r543": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r545": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r546": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r547": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r548": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r549": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r550": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r551": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r552": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r553": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r554": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r555": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r556": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r557": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r558": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r559": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r560": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r561": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r562": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r563": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r564": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r565": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r566": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r567": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r568": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r569": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r570": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r571": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r572": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r573": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r574": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r575": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r576": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r577": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r578": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r579": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r580": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r586": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r587": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>ZIP <SEQUENCE>71 <FILENAME>0001683168-23-008557-xbrl.zip <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> begin 644 0001683168-23-008557-xbrl.zip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�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�_9U+?K+3/(J1U\_!H?\HEHMBM+HI5%]#E8GK_9?"S[C M?W^%]USS+9Z+!%S,0U>>1CTA ?O)'K\E.XE_?UUG (A_B 7<3CK?"7MSKPU: M!ZU?YGXQ7MP 8@^;5)7.*PG[9<]QXAE9CDGJ"K0Q7^9X+7-\RS:A?8^H@&SJ MMF?_M2/]H1'3F_E%IYGPS0__-N]-/5@FOQ)Z6C;%AWN):1=3P8Q-4%42H-KV M/E)E<MLRWOR%4=QZC8/4,!$'MW3DZ.JEY#WNX^Q:3]\!)RSS"]$4?9OK(YS] ML;=28"ZW N6D(4<P5;]<(3S,(TBJ8)53\HI'0VJ1=CQ;TO9$B,?[*:L>QO.6 M'?S&V9]V=ZF<^#[G8G5JBU</+:X:%IR64?-]U'OQ^*@Z?J+@"EA&:\ LJ*F: ME9D%STG<YC,,93!*;G]8]N3AZ3#:ER5R,?>Y8!H(1P*>5WIJCC@B3Z^M4X'3 MT2>J"E0"/FFXDB=$8;=Q\TY7J)PZRPVN[%?\U[]_U[=%"]9.N+8YCT/!G@'R M-:\>&XO7I0C1*[UOWQA_XZJ$T]V2&D5M0:TPXSN'5:MUE]E?%ES)?*+E16?4 M;$?WDHR6SD*:AAEFO)G<#,]D]W(:GM%_H):7$;OFH%OU1/Q+_;0RO6<O4++I MZ5@+08?/23K/:5J."AV/G=K)Q*JR;BA@JL=(P*-3?0+?B11D[]XP*NJL7]9O M>]08YU41BT2-C?:M; M?I ,5P1P+BO0+=2-**[3A(M\H)9P?<A+6P$9):'I% M!*[9!YTH5\Q/T:$R<_7S;,#9'/MMG?B7;?0$H9=I=#HU//PL)V\J7W3#>/5! M+C>)WZ6R*? .V%N4,.33.HT:O4'B(+E>IT>@HON2XF\',L:[)I,-$7VPZ%"S M\BI,:@TF(.6I+NF#ZL'8X /6+Y^+*-;9H#FY?/X;3^(CZ/&"#-QC99 )?XCK MBC;!"%0TTKWRSV&Z[61KR'=F:X>%\^GL=XB+A.J+A$:!H#*FI(:/>!NLJ<<3 M/#S04WG@E:#<SM[XQ.8&JM^[UX'Q?<M$)9OQF!"\Y6O*VD.65X22S*LGNK\' M9E&MET4=JO<:.&V1T>KQ>_;@$_'S;?3.9'3W=JZ8!!2:W*.KD:%,?VWR7Y_( MW-%8&XU6'PZAP!9O%;K0?L:F(D\3]EGL)S53PP8]GGW0>Q<U*ZM#\TR-_S'< MM[$%DU-1*)",B<HN>^0*77N",O-L7"FNWW#0#YN,(,HD=:'"UE>G7X'Q6U 2 M4(9'&XWXKVV*#H>-8NJO?0SI?G*?+9?9=F)B:10M<7;R".JWPEMN_ZVW>HP@ MZ>MGW,+W<::4-L#4C4'O/N,BT"JA3[B#V04I9-W\8G6AZUK=N_/W9'/#K/,, ML4OP$K]RYNA'T3\#$DTPA([KU"R(F[Y'9B%)_)8;UK?K09@$?7XWWZ6!>O-% M^>>43Z]JW$SJ;96^#^];\6U;YH9?Q5"N#=OG4/;(%SY4'RKJO8%69VJ5^#D] MT87W+"LB=E;!ZOBOQQ5K->XE!ON,%V2A=-X5UY87$T38M/CSG3GG_8PKSFHT M+5)8%& +WTS?&?\XS2)KTR#;[<2C#FM&**\9I<'$C]I:3.\8=8RH+T]T3CMW MWWLZ5!M_H3JG[?=!B3JS/Q+&V[VGB]10'$-[OG]4%0,ZI7WGC;WT8],;1@+. M]'?KV<JR(!+0%9H[1PIM"[#S6JB0(-$(74_AJ[&3?AUK\W,U"0J$]Q)PE^:P M;@S""3T8&Z#H<S'GS<->O:V'=E4B\D(IYZ$%FNV/ZXFL!/EF? E2+8]M W8> MZN@=&E@ZW[,XN7Z9_4S5;WU>"9GTIXJ?T JO3KA7B)RZ/0]O +K%)8.54SW! M]9M?\K"N[QG)I<ZKWI)5V!+.JQ;3T(;N#\ISB"*R.R0S$^0BWYN#,5\(P3,Z M 23 73H879QFT%8=6A!N@0(E8D>>CJ6"\C+LW4[N$?N)PO@EK(A!9N_<CNZO M*_)'EUI']W_?U9/QKJ!5SX*,*M_+7\Q^D7U0^2X#9W=:*MR"Z>8<L0<QKV54 M>,D;ED-",T.<)+[1?0\L>?*L.?',PIZMAU-)GD_EYKQGZSVH#A95S5_A?Y\' M 3LP<\+9C"E(&2*)!9PEI;\WY-:F?V^]M,CXR?LX5HE"ZSRMD6;:NJI)'R[D M<>8%1KCU=H(#)'X!VHA3 44&R6Q^6(=RH*""N>*CT43-FNZ0T/^'QX/L!QQD MD-,@$K%43PSWV#U$[D3*J[4QU(RL!OOW_[#__>YBRH!2$'/V;(K%\<3ZI?<D M0) ,&"<4B3IMLBU\+E(DH.MHZT/RA^2="LRW2?#&=&M+D;2_P-#2XW/&X6Z3 MT]Y4>!\R#!<YODMX%.%$1@]LM\FEFDS7E9_%-X9V6V&_WBL3TAOQ1,'US[CG M_J&=CV^S_GQ*ZYNKL:X&H\$G(HPL/6O/?$AW@P4'7;@O#NSM5U:DJ8&?'U6X M&5K(%3K0X .NG<'@WB3-G-)?!!\SR;:P(0=E,X@L6[+-X74LE'PG1S/S19+9 MY(%UJ+6YO>[S@VP&HKMUR>T"<CO6G',\V"N^UV%((4V39KU?3= &D9B]+2ME M$O!4I3%LZ#/9BLDV\@02HJ^FQ\C9*Y)$",B>H\,L+$!\#7QG/%_:DL-G;=]O M"*B7Z>GP)#Y*[8)H1TX V^[Q:,8<$[;L1XSZW:IK7R1FF.^BBX-53(?O=^4. M;&N3=8"WT*JJ&]I^LF^G.KVL$7B;I9^C5$3:R_3I-XZ#&DV&%OQG;!Q*H?4P M7OU.H=7JLTF;:2LWI3Y&B4IW@41%MA2$AL<2C$5+7I7S%4?W!X^8@]8K^D)H MW]#W09751#9/,*^F7+UWW5I$<6'*Q,_'V'CW0@ZGU6=]OJ9/7L >;SS+9XZQ MUSAF,@/G91C,5SLWH8G2H"1]$2$R!?_[&0FH2^I*B@&QMD@B&;RCJV;A!<4; M3^=G@ZPSIAQ=G50>O3EGR]+.LS$.=\8>MH.G0[IY9>)1F+T-7H[M6I3"^.84 MX09?F3G1OLO[PE8X ] "G5UN$9G2; =51]9/*S+'A*E?R<Y>?Y68=S#0L!-# M IAEB.>3SFP$*R42;/Q%YRY4?\T<,6G3ST]74=HVYZ- ""0$5[9K4%ECZCO! M9]WL+WZ)-AC?NF+"\-DF)+TAX1%/WQYW2O>!YN*$VLF]:^3J4V'A"[E@Z+$I M7ME+>:Z1ES,E4&J=).)S2(;P*?\[$)G'_4"JP[""$D'X?([!V#>""?X%71>( M8GU.K*$ZRSC)Z#[X4?T#07.7^V;4V.PO&P;3LTJ:H:>?PKCQ)*";!'"T**&8 MZ2$>1%8I30%!5.\ZN+:'(M8\7<ET+SF7?>(=K/,3OHL$W.IIPWAZD^6:&+E* M<, >_)0U G6$/A5]?M5B_,J-#@&?Y9##$AC2$WJ=7#U(E9.E1"%(0*)%*+^G M.\M2T;[RNN/ET< 4S0=D*&R&C2:^>IF'5ZHG@_@U!-*HEX4$R'>\37RYP;FR M=_1Y;1!O SH/7HW;@.%5JLA&_F;G'X1XCW\2TJI_5C$'W&P?LF-.]FP!8Z7W M>KF(O-'(EO)*2QO=('6G^_44%Y)C^&P"F(6P-IZ82C3S*>LA57YOY5\B?'%K MFN]N!:.58J".8AVG5ONG6H9U5;&__6U 5_7YTD6)>\4*\S(]WC'T^;#.=^.O M=A(>(GAV2("4N%7ZA2<="Z[PZ)\@3"G\*@D8NII*+OK):)!@I\_<N1-OK,</ MO?KL!C>=93W5)_ <KK(8C'SREU)D_RAE^8]23$!QH/-R?YYC6Z^1@!MQ;"2@ M5CS=^55*]</C2$$$WPF8(((%1Y, %Q@GWK0[W7A5=;Q5\4,?5^XE2^W.)R96 MOK]RQ^J1.7+HO"AUE2+7+Y-X3I24YK2D?%JE])MOGUYH7=UM4/<[+-?@0S\N M#$6?BG3:"V-H2Y!N!Q"7]('U==RT:U_,9<F8V2_J*T62$X[/OK]H?$#KLV'O MX5E_6:!/O) []PZN,HGOB_P\X-F^LC7QG%QVE6I.8-'%.(?GEK")TP42,*VP MR7[_#63&CN _$U%$ #N\23HZ8^^/ .WVUL$I". Q.!]4O7Y8H6_+9<Q^>_D8 MO:F6"8P8#'OJ/#A+%4C]W&.85\'K0YK.+V#M.N7^6JRU^']Z*D]NJ8V%'_.9 MTTF ATR4IC+6I=N;9H/(CIG&IW_O_+X]O,U<=[%9>]GI' -+;HYDGPC>%/M2 MD@W3LIV:(5DZ(QV$QC>AX,<I0EMYG7GUKA73RM\G(;OMRY^CBJWF=-N+D0Z] M3*LPI,47JD2%$"\-XJ&U+_0*OC,@%=/Q-FI0M?P+-PF ;^S$2GIOW39R8OYD MO!GFK_4>>B>U9T*0S2%J#^:E^UB!C65,ZN?#:\C@Y;J/Y/6?+^1%,>5M,UG/ M>Z/W+(9Y880<'#F(/\R&'=^3G*Z+A4V_3>P\3A-$M), 3"GQZI$C<Q=M^XHW MKJ<.O"^A0T:L<:\U.5.XG1*L)YU( *@2_JGPM,"A(?3NJSV9S1S,C]Y<)JQ8 MDD(EEZMDOH!CN<GT[&_1I13E\&K6EPO'%G>0X'#P>2A3T9U"O"\JM+4H92)# MR4?+'[FZ[+=7Z&:P<RU^H9$_]M"67BMQ;&7@[K-GH7?Q/3H2XKM&^.N:TKEM MG'[8?4R- R$X"6]! KC4"-9?R/',7(:H85^O(W?/>-&E'<P914>0R@&3JU;4 M&W+PW'+_C9?!C#M$:K*EZN69JRZ-'J8Z&$''4<"N07NVD)B AL<OQ:&ZYP+_ M]G;RHJ+N=&,^G9=@C9=@[6*N-'ZHQ!5V?C#"#TR];B\YZO3%3B?HRH[4@A[: MA9Z"5?F 7.PCO?X67>[1E<Z5N#HS]#T2$M_6$[)8F8O R*!!44\>C\"0]J&M M(BV-Z6II8P\H;P494H5W\?,>MQ$YY[L%YVEJ*PG\DR0 ^]T(;^-POFTUSL/A MGY%E2*=FM;E]I=Q (>TCM(=<L'PFQPXV6O =^WD2$/>1'+Y,L2^:"#+/- Y" M8$1I>!Z94HNE:2)PC4>?]CZ!X9?H4(ANYF,1WGGBN3_=P)81CM ![\UCR?>[ M_62\4AEGK9'0?S#1Q6FH9ID9],[?YME-H2N3?,<+O.7(>3J""38PNNP@1PF9 M7;TV@3TK)%4Z4P)YNVVB0SQ3640PQ?*A+E4C<QR,XA9Z:[[:6_5[E?G'L5+X M29P]72DI@T7")?')"P[11$',P6''J?7VGF%UXEFQ./.J,YMRA[ @PQ-3MEG- M][I5R+P_)OA? I@,0:(M'KQ_&_0O0BB8!# XH>A.61(\2 "=(ICP+.E?D?B? M^GK35BNKT;7.KEJPY#'_@@1PJVLI)KN)=0UNXIW&RK8+&U+-7[PT[E%M_D+1 MJ"P@N:8"Y<*J=<ZSMCA40(R(+"&_);M9K;[KE/NH^]YT?'Y+9_3F.9\)!;+7 M,/BBZ(SP)M-D+5XA:U&,()47<Z$!+U4..HG_:^=0Y3$Y@4$Y?B4ZL4LQR;-0 M?S,P5@(#B"XN'V-@XB7S[G\RY?7*Z!7B_ X8WP_"U,&%Y 3F:0[R90<4XEAA M^X\E84BZ'AF\=:;4Z<;J1##->!Y,,<>W>*Y)_96H9WC@!0D8E>TR0GW"00#[ MHA *-EV7V;FF00)&)]10@U0$6_P[I>@G+3= +_U^2QJ->QZH/!KQEK8/8A6: ME_BL0_OL][?*?.R=W8F 3=_KC"I[FMO(7@EW\7SF0?#?CDS#_G;>+)^Y2//? M4CUF\ 5XUPK^Y[6FUY_7FN:M'ZRF^:L=[PM^W!<L_G6/)NID-"_'A>E9N__H M%M_L0,3Q, GP<B-C!Q8R8&Z/)*,/APLA13$$CV]M'LQ'0G!1$E"1#CNV8 KV MQN%RR&F(#WQ";$/;@TY<\:C!+E@U+$Y!=/= ;RNR943;\UG6N'RNTF,@+XLB M^%S0AXE5P;7M:6]"A*<&E.P2O[2M"!LQ>%\L[6#/W)E?_D6R;FZA+OP;'OZ^ M/,EF;SBD(GIUW==Z&XN32< %/C#AC .VP.O%=B8HAW\<AEO.^VOU/]12$C"3 M[G[CCDE_'(S!MHAB4..HD"Q&@L*OB5V$M;]+WR=M;]X^C9]/=>,?6YQA$)S2 M6"NI<"O-9[K;_WS;BXO@ZH!DJ"A*4R"N]=PCSHVTK8JXD( 7#$1YF)?;(LMI M ;D'FR"XS7RS]E,O0%D0L@,[O8]QHV0MG?D\U:J\XR /M<?G.'XDCLW3[K]W M#H1*"\&-ZFVNR9_W-EN:46?..*A\;V'[A4;+/>#17MY\I<- 3DOXW..\%=T5 M*S+KF;!3:C)<PUR ]29M]8.)X8HP_/DVM 'QQG;F&W-/^'N.R>3WS5'WXY&9 M*EI.B7AUWF8^SH2[^N@2[J)KUI?I#*S_0G3_:I?;>NY^_-@>J_/@-*!(%3N> M);CY8#?L _SF:?6VC%>8-(39,,EZK&:#IV9F:JEN>"=W<F#5PFNK./O1Q,_ M87+U8IS'BTCP%HJT;2W=X!)?H.OD>+*7;)\(HK-@X>M&EL<G\(CKG=KV[9]J M7_.<@1R%[CF\&5==;O.AM[M# LZ6G5]Z*XZEZ?#BH] ;1-_?\A]D+<GU> 7U M]&4<.<T5?SCA1:73,(#N]X,YCV\[G[XWK,*!7L(OZY>%_9X3Q\S@72RJ4[JZ MJKHNY:\63=_^QG-Q5H5>Y_H@=&+4\5U&/J$G3 ]18E?1<IC@A-H(M8=0>_M- MC[6GZ[W!LCP-#NRQ;YCP_[;\-9,OB4_?J^^=YXA=@R@_VV'UEB[.S@MY<&R7 M-'[EA/FG<9[C42PA"SZAL'&_QB^O]UG+5O0K_Y/L;KGX7!CO2!5\K);)RM-D MKS=Y.FKFX@](.)IG56^E$#3EWYQ\6FA8=?RQC$]D2;- _N!4<C%I\L,Z$<P' M-1@NFE#P-.G]-55;HUJX,?M6J9NGKMJW3Z6R/&/)UK\GR%]H3;]G7T-9_ZZ$ MX:?URQ2%9:F-CMKLIO]Q6N&CNW742MBO>WM3OL^-W($@NC7]V 'B>'W]LWJE M= P_M*I?2.=0/5>W5>9?SO?'_(LKKS<6](@\)'MLO=_.\9DI<J*[20(2Z&Q' M)IU.# ;!![]AO45S-P^-Q(=\2 "3/TKFA(.,J(=0K;EP:SP,ZSY!1O1U;8GR M5<5W'LF'4O+99$U5".\*Q+\H<!;:+5,+$(:G$6='3M85@PYS8+TY+1&_Y=V4 MR\AY_+?:OZSU=JIME<CBZ!;[ <I/!;<X7/\ZI*B0I]1<]:72R4^Y+NF1*!8# MD-M6MJ#RYWW$JE(E7:%8>D%^\=!UIOY+T^8GM5G2Y1[4/9?:ZB/W?CXSB+58 ME\LT&D:-E!086GVNL*2AJ.53)]=">@[80N+O$3*NO/@?3BF_VL^,LL8F316_ M#1.&3<[ 2,#[B=*Z1L=&&[+P#&M/6T[\*[-(P".'6%SF2ER8#"383A5MD&& M5>A.F;6WU5[Z-LP?>5M0SY8U=+7^M=OL<=Q,IL2+"7ED'OXM69?S!^0H:/2? M'-/0/D9>_JJ;A]I)X%T2D)^61Z26P8]^F;\XG!X.V>92_LT7!1P_\LDL#"M8 MUJ3\V\OS76-]<N5&9B=%BERY,=?_.8XBI/D.S[5+<,&OTIW2E@T2#<K]2$#- M0PH,"/&1DWI-;O\A^.6$#$:.:*B+,/K'X6&)";,3/6@;Q9__E'WP:I"HZH9 MO6*=RLL-T*3#).8@->A1WHP=_E=P7RHLJ*XX45>SX<?.F"+K)X5R-V[5U@:) MWI<0D69/N<XS&+SCI\87:M1Q3-.Z:'B%MI>2(XH6S7O(\7T.DMJI.)&RQOPA MJ-^I\1TU6%SR>S8Z7W1BKC=!4WN[ +UD7:QV^"XOU 6#FS>I_1IQXVM#NCZ] M89KDT@.VC2US"T.\G5C?I:SBMX4F=#FT^T\B>L%41Z.JWG$$69^G>WT?CIZU M=(H71:F_,^*1.D+5BHX25*?CC_EY]62\4C0O1<='BCXXO2M^?P'^77+:Z.A= MAH<S9F![9]-A$L=9!D#N=5]WC!C)IM<7PMLV4XR4O6D.<G^OKR+@9M,K>&9D M1[0F0U?6?NLH/F"%:FE1,F##?'/F^IC\'3G3:LS^M1YPUA?]U^OWV%*WW5O3 ME%KNY1B\@MXN9JKLTC>SJHG3XWC]#?X0]):96"\_R(N7Z;P&51WW]Q0Q>,$C MI=7E]\["_-S5&UMVFE'3@HVRM7:7V%/$.YR]D7P^+_*<C GZU;$_D-XQG@L) MCJ^N#$Q.%,_1I@7+CRF.&LM_OH^KLOUYS(>;&_$\2**#7JII3>JOR[!Z:7@. MQ4$"_'\EHN!A9&AH@Z3XX<KYP.4Y5WDHUXFSM+H<YF4@[R@5"1":2*SC2)Y) MT^FSWKN6^33[XL^*8*M(_4X?XX!?2X_P#DCN&]=<%8V%UKN#]]]K<N%OVE[% M;&671HN^G.6;.3(KU^H\Y$WX/5MM+VD]T)$NDK-.01<?@*K>:>$H4>CV=BP_ M#=?8NAQ/J_;5-V+0 "<@X;%9T(<; []+!R/-\ 8<SM[GK%ZSG3FY:J'RC:[> MVH4@":;>W<A?RU_QVG3*/N<VKLDQNE4N)9)A8[6D;^^R-X3[XHW<F*DU&X,+ MM"YE/YWY??IN2-$KU9=S1103/'JB"OL653I*?-B'=UDX'4*<1A:G.^:TKX#+ MP40.[Y=:#_#!(\0CA8SW4+G&87_NBZ%.6Y(,=!+K4\HJ[<O-4YH!HEX;UEW, M!C8]]&:E,#G5RBDQPUI,VQ:39MK''AR3]$J7D8]"]I5;1L*SGN<LBGQZ/;85 M^"P$T[!*FV10+:::AY,@NV/A3?B4P 9*%ALO>T[67'=L87'IAHI:U<:AMI3P MZ9"A_3.UF['B1?_KP;V7[-VB-G?5>/P&KM=4#,$,B(/W:$?U2 #"H[O%&8:2 M4IUZA"'FX!H_,D;>HYSYVK"REHG;F6%Z"1/0!,D^R'>=3A)U.4G;VR2>'_\X M(;U-]TIQRE#XNQ!U@6XXA#_Q',S@A+_^="@X3^8MC(=!825!^LK#M+*'AI\6 MSPW9)"/L^<"1JB/WL87+F3^G/6M;,70#=1:S["N13PZ%JQYCO)I+[.R[U8WY MO?D\]7:[GL6SAAW:$M/*@Q9^/[3Y9#YBI_VV5[0A"_\NBC)U4&@/3[]OI+GY M87JB^VRF[&D<HV]/-(NND,J]<S=P0N8)XY_1<O[N=<%F7R?3P.YI^C_%W+Y1 MM2F7!L#.U=J$E&P;Q7)L3[V)-A?C7C]#MYW)UZXI-#+V,TQT;E?/F>'2XL - M_H3YP&PBASK<>0_>.;4^IS)<YBF<=<>F^&ED3K:D'B+=Z&2Y*8EIUCW0.K3+ M'5?N+9O6TC#!;;8)V; M1+Q4@&PY*1%%]+93=#-"9!\T\,PV: 0LE[O"N48] M24#UB@-K>>>ML#%%BI^?YKOZS32<17^NNYW)TPWKI?+N88[U0$@6L^I".R4W MX&.[8IN/YUQZC&+C*<R<1V+H1OHX#LAP'TI.*>NAB2"\\3Z+V^A8L<7E7^S& MVI3TXA^>_VF\HWV:J\<CTYF_P;RWF0=ATVBC7RNG']6U_2O62,#T/>M555@& M#TT=9XKM:[DM^SM+4"5/==NN#U/-54^TKEW;WQ@(E;/'GFC/:/F?W(5D7D99 M??!F7CNRX %M7*Q@Q(-O.DOX?7YX;ILR>&)R:?\#AM /DHO_K#Q1X_R^6Z&^ M<[$Z=G%R\NTCSZS8\UH^[2#,!<.+>5VB37KYPV5+ 2XQA.(E9YY^#TARB^2' M.2VF[10>$;OO(G$29Q'@_++/WCP0PY.[RK0)N]_>)KKF/\D0HZX-W-4Z,N[9 M*H5=W6 "(Q^7.MO8J1FD0QH;'<_.P6,1GRDF!=^DNK6=<XJ:7I/WL+IRR25A MF26[]\?6K.E[+"+B?1/\A5] ;?:"+0DHV*(3>JV/R%_^^ 4['RW]*'UXWL!- M2@KIQO?DUGM03_U<HAY,@MG3]"BV#C?/Y"6=?G'X24N;R(#;N[MC^R#3VTT1 MR/(L!-\J+LQKWT)7*[P"\D!#\CU&ER!B?V%DVUL^1^U'N.TC6^WX%S.T]:*8 M\20YGKP[]<F3E%89J8GA-0F\_Q=CWQG55->M&P3I13I("0J"2!.1)I#8D"9@ MHY>(B'00D1Z(=*D1$1!0HB)-FI30(?2("$CO)0F])M1@0G+C^YWOC'._'_?< M'WN,/7:RUYI[S3F?^<R]]ES+DWPQ[HET1N> PTG4OCL'$QK"MUG]0V"LZT*E M<H>XOR^S)CTR- ERGM(EH=2)B#=D/)5]!I1C'.H'X8JG7"T)]6,*=HWF>V!Q M[K=0>3\P09SM-_DAZ0;T48;%,&[D:?+AU%65M]-\G0:L6A:KV^OD8\(@$(\* MDX=-W)RF FYG'5P9R7MMD!-VS>2JC9ZP4@>8^4[)UB>K:#.I=/%W2AU IH8J MQ=@GK1K"8HS!IWSM&#^[-<0@?.C%PC-$DEY8'W5,?[0>,PK1>3R!5D[\65AB M]-@G,HND>3^_?#MWZ01IK+-L#60CB^\LJ<=6'S:T7> /\ #L,X&3-%N$B5?4 M'D U'03?=P ;IY>5<;Y K->U''<5 V) 2%['93L?\B1WNB9KR]:)YDK^I5!@ MZ[4<A$Y<TSAE7NQ[K_RWF90/.$1PW\,"\FNW4B/RW7I@!_CT<\;H_'3YZZR: MWC>,83$MG#$:O:O^PAYEH2+#I7JA"^H-M;H11!M3%K *H\*'U!RNSR43(,'9 M6R\RV,JNMK7L>Y4 -/LQ ]9Q#PM@X8);EY2J^U+PJ/; 62J >2MSFM+OON8] M(6.('(**X4@B^N1L?>C#%Y)QEABF#.[6??%1+'.+S25@9LU"RG#\$6+"F:)+ M!;S.I>07PT_X^8,T2S7N)&%+!O24BC1'JC\.T*A4! W!_^%5L=/_KBF>_U>" M'/KWJT6Y)=,\T'LB[QZ-5VU-GQU]3_NW;MDP+A\>BC6-$E<>JNZU:$8U#2W' MS,V=5_^Q*'J1"=A?AWJ%\^Z&)=,HUJ?1S+]WE'N3-'#CF@-Y;'<R!<#7JB&L MT-L5OZL;#5KXB(U]M<AX&39VC9E".BH@/6?4F<(-$U.A\?#V+X1[*2U[;)8@ M[_(=N7UU!^&5W5SO^O+[SY#8>H^@':4OLYMA_G!F(L:W:H$*B,/M3[H"V@;N MDWX68)FA#S'&BJ$0"Z(%-MO=QO_!D:D["UB+@3Y.Q])B=4/VX.1O,GX:W0KA MX>V7JM+0 >.VS^9E6]BQ!(4JHGM<,3 1@Z5?H#/$SYGO^!U<Z7YH1[R@ DPN MF>%1R6FO(%$Y\I:QYTY7 TX%IY#Z#_XPY1>I"134QW'9(RX6VY@6?5X>)7$X M[9=6'"^V"!(6@V3Q&5T^5<_[:WXS2@Z?.#D2AVD=:^MB%!P-D#0)P_T"F&.$ M+\1?N/L61)AOY?]C\)T*"/TF4//$]-?S0"'M9-^LS.6T%8&<5]_Y'"](P;-1 M[M[,Q(S..3[B"XH8_F#E];,A/_UM)862B$Q)W02&A92<P U[X9-( EVF#84? MG%"1'#,%I&A"/FTPSWYX:9<KZO/@TL=<>5]+!\+!<T(UQS>,ZWC:,GQ %;_3 MR5$'9(7:,T%O</K2L@-9BP[4&4$XT<S^LA:JF4'OV #R.<2T*+]'_$ B]1C; M $,2Q!+!586'8(UR1->4%[+ 51#,H6TCGEOX%>[JO7C[;K@RBF+MD]2.-(T- MD\B_298C/)<(W^T0X!*#C5F,P'@>4JZH8#0?L[&%WH5[IVN/5Z+%1^DUT=!1 MF,<3+1:GD49@SCP>#KU.,U"IW"Y2,_0]BKC$AIE_S48%7,WM0E,F;M%(@]R^ MDNO!54]0-:I&62R>TO_E#U""\BN,GN!7T"U7+K"1(SBBK9H_M>ILLGMPN5C^ M;76+\X]O: G.X_+R\>W(Q+-QI9%G++<E$29N9B*/N SWW!ZEN?H.^-9\5#6Y M=&8B>#_OJ_T[9$KA?>, [L2*UMQ?(C5'&]<YOZ3ZB40#%/B&)>AE\FX=1A]7 MM3$<,-4& RJ,W=Q^*???V,GRSJZO,]\'C7S\0T<XVHJ+(2[AR0+=+T-O"2VN M+&W9BV%-Z=JP?5YCAUC*.I<DN"ZZ?>?G/G@%&:I,>@25)HPG-X5BN,X0M?2J MQB2&2[Q*O1P:6@0ZK[Z?CJRH^KW<5!K&1G:R>)!#-\0YQJ#B_LE3(J2K+]0< M$I^KQXE3:>W&K)M]^V!ZSOO4&O=D+\/<>5D5SJ<_B\L8QX#IX$LY&QU_Y+/\ M2@S*3][KLK8=?MIHBO[!0&%W_Y9]J$M$!!49P?P6Q*ZX"F=& ,\X:C7 #QY] M#_L!YO:<>H+BO#K.BU^=.T>*G#XR&S_)C0WE!!>-:AC!8Z<8T@DF.>>RZ(1N M2>I)G& 9A7HVN8*SN\2YA_P\G[ =:]]2>&O VOHXXOIL()/J[PZ\.CI#7'%$ MFUW[]#.EY/>*>:9;@TO'I]L3U=..*MT?<$U0 5AY^?=$WP(ZH9L(PGWG-!II MD"\&E_V66T]+UC(APG)[_);0Y<;/U^CO.*IX2:1)!BS9J45B%G]WQFAE>MVZ MPV]^8WA^S;H!LEE%L#$81R$]F]@*=.5."8,Q$J>#:1PHQSZF08TH2_@<]6WN MU%#,7@='("W)?U,<B/O>^Z@_Z#%!H7#Z5LU)0@9%$=8E65?;6W!P&&4Q[O:B MOEMN>7[2" -."@,2$]#7T G[C6*2)(=2W1*!6H2+A-X9<_EIO0=R:_P>1P/" MY2E=!B8E>6)EH79"=</Q(1-F!0^UN\P!>)M/!8P<0_5F6T7?J^_K7OXW;SJ3 M."QUSB=U9.%!CT32"U][)X((MJP(,\#O2A' S\? XYIN^;F-+PN7=97(>I56 M(U3<G?8&?8B#JTS]\]5ZD617I2V68O<LTW!D.8_+>)9J7G5 EO6=]0M)BXH% MONS<=1;<M+A"!<!)4!E"(.@+,XRX%&I*!; )8J<TV?!O!\1H",#"DW@"\QW+ MH B N^;_2*7#B/=EJ #A<L-D!_,H3<F*MH<L)B7UBTC0(V\VXO9U!@0SV>+2 M M><S4U3X.'0^Q8^PDP@"SZARU#PM(\[XXU^V$I>J!VM#TGLS@F/$9A\<9@* M2!S\CPM)YO-3R%\T;KIV"-)VAYQQR]JGB*5B+.*61W-K2!Z'?>Y<F4L5TV\# M]C6[W/0P2B+H[P5M.WS7^1XS>SK8<]V#!=GO> .[Y2 )4_ DO0X%54S#X+"Q M +_!K!NUA'9^'/1QPY-EH<GH/8-Y*D _!=3BJK>8>ESRD#!Q/%];17<A,53 M, O4BM7_44T4;,O0-Q"&WISX.W^*'9D=03;I =^E'9C^CP9R32DJ-XA)A(!R M\B4;92K EX<*('P#(WU$XI:J[5?WJ(")\?8PV4&H!8'+G" 8[:?$?J.P^5.U ML8&9_;T40.=IQ]\$R".+-.@%8FDQ$==)D<+3(K>VO+9RZ6H$K_S]>;:Z62>[ MG[>B(4OV1?9VALE?/\P_'(SBURC\[/(E_E=%TF[B07DDY2(1B Z&=0^\OI:4 MT3$;8C^L:O->IKII^(%:\O6*-,EEGV3W'5$OV[/A#G)OF,WZ+<2*@U7S8C.T MU96+#<SA\C5@D$A'"W@&AATAMB8ZBM_6H (&WR70L!:H&,87B%K2A,RT@P_S MPJ*_\-^[XNJ/>&@//VR1P%+Z<R?(>Y[T6 $,%2"0V]45MW*D[ @\VHO_^7N1 M (D7V",I81 )9=%IO=:V:1$2CFDFXJ"G6QN0KR(FF &@-0$VF:5M0[[5RFJ: MX'=JXF#O(F6BTY]K\X\./,.F@PHX\]01$0VZK+FXS.R+(!W?"@Q ;R6290@^ M]+6I@E2 :/GO3P5C&33\1R$)7"^!DR,AP!P(/HEX4M&( 2?$ZIC_8]D<I+.! MSIT@07QYX@6"='@0IO&C4:?*W UG6+6A@W(WO8.!Z);J/OCJ@$QJS@OE_3*/ M.VJE@;M]JYYZ+*R*!# (M5 %^]?7 PZ'_ZY.5_^ODBC@/R5^B^85,Z$J_U&@ MWF 13?Z/.@^_4]Q5.>_"^.K_SL!5 ]Z3Y7Z W96.)<(N_'MF((11-Y *V'+: M@](3%#6/-ZF _;*S@ .[R[#.AF%*7<$NOSO^VY0-UR;)!+84#SMG7LME#? & MO3M]=:MC+#%\!/M*I!K[[N6:R==/URQIUX$-KI-?O=[18:D 'M0BKH47-MY2 M0.-GNO8#R2AK CQ.#UP-:_?PI205(<@O+AV^ZAAO!LB WOFNF?0)Y][C94S- M\E\(%OTM)/IX1><B'5W>C*R&SFKK0>Z-Q)0 1Z$!C[T_%G'K")$F*S"\R8AF M!:QDG8Q.Y=4KNJ>[]M99O$HE\\FG)?:%RKT\%#5W[.7P3C10WR4_@_R)FT*0 M,ZROLC&1%4P3P/OZX-U:FDIY#4&7H)9>7.VB7*%N2A3IYKPP-[MJ%Z9W4[.T M<>E,3\\J:;B([]K3E;IBJ3/5+ZD5,[9 ]Z//P6T,(?2XKJ5^&%>1OM'C\GA6 M8N(._AYNA'VY^4=WZ9VNO%6FU!EK\@.G>"--#T>A[,LS+^Y8' 6!NHOL5V%\ M2*&7(G'E"N=&MJS]ZVQ\7]LLG=).)H]7;EIK(W-']%ZO#T%=:O#Y1=IJ?^SF M*C^?I@$!ZTQ2)T_P@?;P,H&6*[.N3B5_AF$*H7<>QST3P,_(,P"$4#*2$G3P MTA"C.YR70\;T$N]QL6R\%Y9N_QM@IN"9P=;H.*(%#MV)$ Y\T6L_U'*F1R&: M;*3-_N>70[(!TW,YM.'F,@&=S/G9T5,PXG [L?<Y:(BU$V/ @II9>+ES]^1] M!*H5R+"'V!=UIC".KMO< L1JP3Z>947_.@.!VD$2U4'J?V=.@9,K0X)WU?I* M[T@QZ ,#V))'9V@4>X!82DO"$J@ .9HX!-7-.4,ECX<U!=J#>P*QR>LY$H39 MD:E'Q?FV:Q:^S$[I;:Q&#+9.H_-EOFOW7<%GPBZL"UY!SD<X#G_1FT0B@E+\ M5YY+[,]VA5PJ-&/@85HQG5[51XNY3K+9S*W$]. 0<4G%<_;3Q/N+W^,!"IN6 M@*<9 7W];I S4'-B]&>7*:?I0+&<D.Q!AM^=T^3W/S#9A/URUUVSH!D]6)/+ M)7H>SL 5*<3/5]IR]L0#+(S9>LUB:B BQUVKU%Q',0B#Z'5_*"'TI&"'_:W& M?KE?N-@5T5B)DTW'> )LJLZ3&/IYD0;"+.(?C((I^/$:1G&'Y5= 76F7&1T7 M.I>ON<\//IW^DOK\X.\)@Q^[9CG?&&IQNTE;>;C]2 B$:"EW?R9B>K[IH94D MY>Q11X<V;>B4:".66T@_!:U8ZUEWU2Z#G;S$=XP\V!:O9H?_%']WU3.Y8*]( MG<M:G6/BQX#M@_$Z[M"/+YB%P-8![W1D]Y\&#Y8_;Y3<C<U3TT<+VX8//'SX M+.M$=F-&+P&J3D\Y:X.MIRA5K<VBUM)"G (1'?!C3>]X*N!@JP"V^NVP"6X- ML):E-7Z1SO4]Z-TFG'8"9C4)E1UY]H:#<JXK$+4Y0"G RIPDU5(!?\1"#!SJ M[P25"YYDHD;)NF)4 $8!107\7@O?)/]Y0/DW#,VVC/QU=Y'8TE/!B!S$_U[ M-I!'H8?U.!-W:(C8^'>N]#"[>+5D:S''W[(4\V#7^%Q[H9AQ(.H_*IKMP%NB MK% 60N^I1U2 D^D/C<]N7#<3YY'.[0E!7^/(KH_MU2Y-!W"GC+^11>#'P"RH M5=\**J %0KYD>GIBLCQ"6S5![CX-QAH?P 8=-:4O]/3+.6[ZEQ@F:-D>]"#A M],)4P+,&G03DML.6'S)1B>BN%#6_KSE!,:7PX^:1Z"W-A2W'0QA!6YQ[_.H) MS/J4<.ZPX4_[!;TKH,ZIK]L7KN]OV$50?HLSUS;EC-^OL;OB'J3]%OXX2C_ M\9+_GY$_"#2<T=+&KM?ES8"O)Q=B*32.GH\A<5&I\,3UDO$!L%J&&$JR#N39 M:&L0&W]--OZZEM4YYM/<5UJ4DAL7GYAO>((9%N]N,"6Z _\1BPJ85Z+P]QD3 M.EI])J9-Y0];9SHK]6K:]#D[-$C-Q1;M5 "WMBI.P5#+^-*<9F9IRWB+T<41 M#QE Z+QM%K_TG]CJH>58LBJ\W?N/Z"9L)X.&O!FF)X4M@NL98X?^+4H5(0D9 MW+<3Q0(T5S7Y2P]M8,=[2"J@59\*(&;MS4^=GYL%G2(>C(V-J8BG2<KI><6O MO]!D8(\T'G2U7_8I_[7E. &]C_LHV=J@Y39W;J2T^J-FH(KAC/I0'6U@3:.^ MTM-\JO3U E]S+H$TO[26PQE>\"/\WRF_37RQ??=:V<"P4E.1 3V3C8&S-V6 M#UG]K<??P7T8[BY\2TA8ZJ+]<_</Z]8YX50 ARL^@Q)KH]1#<ZP4%&UL2NJI M@*BI3M]785 JX-)>3XM2H&ZYPA=D2-"<U:!:MN5X[VD#=L8YY<BN*UP)(,'T M3CM[FUONHK%'AC4IWV7K7OG61NB#/]*-H04)#P^_X _&MU3Q;X]NMPPAE5BM MNJ"JQN8&8M:_KY5+.*;N)LO-61Q6$8V0,&Q-A<X?4%BS7+\B2"70?FRL?WM; MR/-E;UUBCXI5KO>YGYZMD'NP2T/96.^HK0651INOUZ7ZU">NST2),_5N7=?A MG*><'<8HG7#6@%-IH O$CR%88*M^E60$6:[O(4XF\JDS9.;U\"]XG\T9_V]G MK%IV/.!CI:M@?FTE[,>@JWT@#:>05Z4>\T_HG-IZ4W?_L (.O>FA]OB,SH'J MOY!39K5AZ@$+$E6(-2TLA/H1:MO [(JE6TT/L>X< D'C+Y^;$ /$Z\KE\-_0 MM#&U^N*AC^7 L$68"W6ZF4Y?>P/H.2H_?_*)@?XPC_!0/Z7.CK'7)_,6@TBC M<YYW;-[6>HC61#?2U)'3':B+F#I:V'T+QH"'3(<,:=:Z$SF_#W:%'.VVW"6I MUF:@-FNZF"3>Y[:=R.(GV]2EYT:OJ.QV" -_MB20!$DK"2>%5$ J 52:<=A$ MU.ZE B0/,\:)MF]#8_EI*-P.G*KM^*.T=8'P;-YBC QVQKCW2#35CKVU,JA+ M[64]?[=LN/J4#5,1?\^%$IU2A9_E<X[LCF 3V2T^#A$Z!CF@D\M#87(AI8N" MA[D9'8-YU]M(C\EBSX $B*L5%0#%'3^D(5QY"Q?L]\E7FG\-4)#0C)K!+/TA M-G,GA[H@60H?CJ/)LVKSL-_GXQ<AFCP9A]KF>UQ;!C 9;"B-F'"$XF&4V"TY M"@5V4(S$FW8B.*#Z0T]'H,JE4^YJ^A2;&6N#NES.S[%N1,@F/L9,X+!KFJC] MGM90<\BA_"/Q:\2ZPF\I*\:=;I\?P7)%\1IEHN;VWW^O+->/QW0W["[Y5&RH M(Y#P=CNUW>TA'+K!T,[:\'<?5^8O+TY6Q.="V'_)G@>;_TFL:DMP%4\J#")8 M%ZM5A<9)Q7&1:[6?)KOGN=LX37$@BV9_ER@O4-*&C2Z927PM0*4DV?9.]K7= M<ES?^1\ZJQM(1-3H=?0J15-DLCM EP;]FKVT6)):/LK_0KEHZ5_,NZ&5'%A. M+W!OKV%L/CEA$8U8,CJT>>G4U=Q0$]BIO 0SG*9IM1LR!:>-]A@-7\%3&9B5 M6,IIXC5T9XOBX,ND)R*792KB]4YZ9/R[YS[% !9(XT540 >$_'<U<)(A%8!* MV_4<\?]9)?RDQOF9D.LY$].EL0]CWQ=23S=\[%!81%?[[.>21$CME)&,7: E MC':GV-\[#<"'0PAODA7T?$-#S!10W-54>[?DOE+FT2S1K#SU=&GE[MA8:X C M>R#%K!]ZHS9.^TI=_(SRR,N]AHOWSJ!<36Z<JE])*VSK,SQ4*WA/,BA\L1V6 M1$SM"K:(W!=I=K9J2>XP0-Z0/WHH>EYVS1Z*0L:V)Z/P61/?UUFW)?'8PK#1 MGZ4D36*X/GN^R/,;PDQ'<7:/*ZHBA#Y865VHBS/:J7U]FD[/1*XM,0C^Y,'2 MY>G#,N*](!IP]??NPO"?46X[T=IPXMU-M/!L+ V8Q]^VSY%,_6MKD'(^(D)/ M]24'3"*7RH6&PP2)1^T->8N]V&;9:JLIC2V%;8747TG]+TIW=]UFM?Q4#EOT M>$F/PT:".<L+ H%W\3%Y>>YC1^(2R/1=U\2.32/A&6FM1TMZF@/(T--<6S;X MTNM[4%>'94^Z=J;I1N$?N.:@L@K\,#9TYK*>6O'7V9N*F-2G/E(>KYQEMG<U M%\V1\Z_"I'HYOST9VW\]%7#CB4"76COCK6VMX)POQ9-!\*D@,319%=8>39I3 M^8MD-"80\YUH$BBN4C'@!23+@5M!W*-0+>G<DT8?Q^*3ST,V <FS(-T)>J59 M"EZ&4/;EIY;1CPY==\?S:$GYS-J$)4G\4<$FY(Y1J5=4& _Q> $H[IZRVB). MT$FC%,L_\WE6/[=Z+<4Z[!JQ"&,:X_YX3G9LJSH%NB56:3(1]/$.KCJ$SAY2 M9M7&M26#+_I24QN=;3R2(/3DT<#L/O]G@C_STLGG%E[)#O:?YT;Z)]]H#$P. M.%KN;CB:R15GLY$LH3*L=(2\.% CA"P+PY2$\<)^KSC24 -%-)^?]*0"5G[^ M!KKK$VBYT9AZHO:M J+2C52+AJ'/]3'"]]G]#PD[6HTX[QLVUQ3\KAS.W?;\ MV^!T(X57Z[S@VU,HHD6D.Z)Z+@KFD73J#]M'10B#'F:RU'F\:6Q>-/_FM#(\ M+_A9!F$/<UC PACXUN=,6JX-W[R0S,E<J.P\OIDL\"<O*8OMEJ>_E>Z/JNO% MYU\9.GH7:!X5'9K6-=>FC.J1+,@7;7<('W->!%[")>>\HP7Q_YM&U'93 31+ M\R))O*5_,;!4[6AZ-[6':?O/DX9R-O<LB\2KJ"TY$2W8N0_YUD/*OW&DZI.$ M;;#GXO5Y9$9[: %%SH@;_8"FT:]XI6Y3)JAA2TL-?JS9O7AF,EJE@PWZ0^0- M>CH^O%1!:W**"EB0@I&-G\\QUL8 IXJ[BMGO=1=T"+";7QRENS"=<_KN6IU< M!NN'?K0/#IPLSDST+2[+P'IS6ZUE5'8=OM[ZVD\%*)'0_'$TM'7 (RBQ1KS[ M7!3^?KL;I]%;$"Q03>B9'$;#\'A0+ISRIN5+8^,H<GC32W'Q>W6:IZ.K86E) MD,/)X.Y0$LCI>9J)A:,(Y2P: S[A](?]#;N28:/SK-G+XE>J+C:E(.L/19_5 M[7#2*!T#X?32:&T&1]I6+M<5X<TS_#]7RN:P2::X^?#]#=6<<^P]O.4?NGO\ MVY-:':,7.=/"NHYDIH+$K1804ZEZ0U2 .UQ<IX^2G,,QXJ'PU#@P\UW5IZGS M]ZO<+^_TA=)YDRR@TDDW:,[?W1/@)P(L7 _VL0R8%VFB*ZCV,?;QBO\A]LA2 MEOTKYQT+?)%'BT+@ YQ)QCVU0;0['Q7@K%EA8GG1 ]^2>/'0WF%+.VG^KV)I M2;_F)(RF6+[(P^_$>[\ A+P<4_J_2-(_"+H0J&<_DA23\\;XN>$=K@D+AC<V M11##S; >]SKU284@X-X:D)9&&]_W+@R!2!JUP7BUM0CGN]T'V-P.&SK/H-*7 MI4FEEI2KQ*T%4X";XUT",&[S9>-N/>GJU_03N21B .LT93A,*^8B+AFXR2'; M5/?N_&)FY7.-GC*C-OS7>?Z6J_(5NM);SR;-\LTNP)X'G@Y'8RP-K"8FM8IS M(E#(@G;]$26R])BDZ$L8/H\&&+5$/2K@5C.< J;1\!5,^>NK6K,6%LB1?9*< M_^.?TDF0(\ETBO@!?T$XU+E4ST]JJC\IL-(FX5F6AIF1V/$3$&2;\$!E8O&D M!,1G_%T7YRY&>@5I[MGD$N6RQ@,G P[S?^\C^*$/AIL>?G-I,'F;(Y&U8CIR M?[F/"G@_G?GNRJM[[ "]X/6#'09B"T[-^EEM7OM7#GP/C],3CK;^>5K;Q@NP MLUU8V;+J62/#ZB%Q;_5-3X_*[Y#M,HM$T=],?V.9%?F")CK) R:#WJ6QBI@J MHJ$F2*WB+[/K1<(XB#_=>\X-JWZ\$&78_]O@E.!Q&UHDQ!D<;0;'K'2R:=E. M$1-,8O3)*7LVTL/1'3D6]7QT&Q#\.) 93>X_!!-IGFP!PX"%7.TU!A=&KW+< MG#<?SI<*PM<:XI5BP_C'FC35"@1J=9)S7=JT8VPL^[&=5>(YR-&P7]\J-A " MK6;7M6TNF]V(OK^HVTK_"O2.;D^/+. -CY@[!3SXUZLIR/^Z6+"=Z=8Y*D!* M$ TY9,L^ME#X^QI+_9_76+"U2^,/2?JPGM.$\9.(9<HCA5.ZWHRP'RF8)JX/ M:VKA>B>5]N[9!-.N+?4.T$5Q\0R3IL:F-.VNR^4]R#LVT@U@1@3Q2],5/4_I MW[RKVGEEM[""G9[N;1F"< >,39)/UFU]R=JH14YU-<* R>B:PI-DCLPNI6XX M^YQEWOQK;;9ZQ3+1CK/3N4!9KM.[UY:KG8G1"[)/AC]GM U66^<*?;[/X,AZ MH_]0M+ [J'@*W:T0W.W^P[,%:&>GR^#^HBMW2O,2NZ-.&*$4QA.X>V2 S\DN M*X^8,RKJ/]N'V3M[QO(E?4IW4)'AP(/JX ^>J$X8<Z!WA_]6(5$D](.Z N=T MB&Z*!?L9?J9T4@>BU-_^/#$<@P#4A,N'B6<NC;*V>7EZCK\T#+QW?97176 ' M2P7$;6V5>H,Q= UJ0S]:+W7;7X^_#EA)^;""+U:G OB:[A5_TK9GK/M8+M49 M8V]<69D:N1;!!-K'QKE7C 0RT5@[/L?.C5$NR%.A=/24_!HRX<T+,.NODR\& M-%QC(]#GP"JE:)E[M#TQ!!=#^)#US>A+S9NQDO!(O5I_7#)7\&?2;2J@AX%( M2ZD>9X+WSYD8S3H(31FDA>E I\I;AX*I ]:'U\N <]"7$#\27Y)ID81AP'2 M4G[7GP(2SX1^,X7;4 '(,"8/NQ62G3[DX6&87!P"&QM_M7<168>/[J_P]._\ M.E@X2:=KF_YGD6*V//]Y57'9AF:_'2W ^IKZD:8+[+TO,1YC/P?OIGS8FD'7 M,G#EN:()(AW6:2/7[ IB]%+XDD30?J>^B7H?WP_F;<L/S,#YYV*F>[Z 6)K2 M'.S6SJ-39"1%0IE4J["PN*STV.?GD?B\KIG\"=OBKR%1)CUUSB.+V'"_^GY3 M@D5K>NW]-=[ F_=]W+EWG[S]Y9'T@@5B4D#SNE&06J#ALZ%(HA_$V":O*LWK M,7M;XQD=333.YAJBRSC M=:4Q6Y;.7^-_.7VTVZ17Z Z[_22OX_QH&7P*BF! M"J#K$VMKCI^R?%9[')D#Q< 7T)J?[OZB*:%H(8%MU>,)/NK'D%B*T-8CR9T? M)W=\[>#A3X>T;Y_],WTC]FY.MY5DC.IKN8N2#/#"$HY;6*;7#N,TI"7+2HW) M#]U0^J-\X5K:8QA[F"HWL;:\+<_.B I@MONE#G)-<H@1V%,>]OGD[(!!'%\K M9:-TDN G\N5G3O*OIHW#7$T%)YI*>7J_K"VFB3T"GV^.Q9QT]:&W)#%Q9=W3 MM7C;K?..0M*;9SN(!#P0JQ?7HNH6)H=_=U;L,",T;WHR;<3+6B9&?WY9@C.7 M?SPBJ\#,Q$9THK#^H8]>7RI4O2GS+3/YAKQ /.2IE@%.E/XND&V';RK(7KHQ MR1'N\:,>4,,$MD=N%AR&$N>1:5>56*-TN X3::Y*5J$"T(HPK![&W@2V*'DA M]"':P0:E O)>MTQ&)ZT#N52M\N_4$D3GG9+V]DX%7F+:^UI+]"SMEM[3ME-I M[1>[6?[K/0[N,5Y!LR(0^;DY$XFM?3HD>N2K^,% 8 @&T57.1XSLS+I0$XXI MKW%Y@#X]=J)[6'7M.%)H;0PQ?AG5CSZ0UW-\90I8KZD)^)FU6#EO-\.BW6W< M\LA!OQ7XX%(E66%DR"H3>O^EM$KQ<?AS?I\??YXU%U"$5W#^+UYRL=3/-OJZ M\? .-'.0=*">'E1 9VQ[/?B ^RV\# -^#WG0Z:\-H_"/;@9'?_Q!8/_Y^UM0 MO&]FF)<^66X-,H&FZ TD1-:2C<#[[\=YJ0#V/4)'D._GP$<50CTC3W%K:_8H MDCSY'*&@(]0&;8U(/#>L4#!^H5H O^9[];/Y14.Q3E+67@7QIUG1BQL?B=HZ MUBK+6:";@]I:WEB%4^LL2RZ/8ZU&[#+UY.]N L@<>H[X_N5NOGA3'GO3I=UO M!O)R8S0,I^6LB0TL(QXEF]HJH:[2G_W\V*OL&]0SI/+&GXL=%\-)(*AWP/Q) M-.8>6D;R?BK*>BTWL>/BG2N>5WW-V\S3]#1*!T02,/V?1:MF8.T/?<\]XSA; M(>,"[-A7M0H3V<BYZT1^>.579:1,>OU,O0QB !@=\H0R !$9#_]$? @\Y'[[ M;1U,%Z;JFA4Z^FN**_KNO1M248I?2,F#C:COJH,'OY3V,D.-N"=VK5K.K@=P ML*+BG,\I"CS)!PF=XAS>2APLA&J.JAKU? 5)N.O/;5Z.46Y\P<@DWL&_!F(A MFA%BT3F"0V3=?!=QX9A^"E!-*N-^:%N0K0]Q;/(DAZ*NQG3(%-7:K3$BM=\% MM&V?QPF.^'!]QGTGJS9SS[ TZ85<^F%[WG'IGBDP3P_+Q=67ZU++:UR$W'PP MOT:0$GG^B&58H_P9+9R'$!<05UQ O.RY;#3:Q'*IK()TF>Q$8% [M @.B/$H MU=UJVIW5@V[WBKXH_@XXT&"L*GKO<)(=9;]<_=WO\WWC4JXO,+>!8W7(F>0Y M8Q0ET3 ;;0\4OU1377VV.MA7/D3*_(GVB'(R4]W&02',;<'B,(C $W&E8KJ< M<MMP4=L)7]5QK;NYT-8]3#)]MN#5D[ZGTXLJ%\\=<=[1<X3(&;N%<AB_WFYA MZ6^(S6K1:HIOYW/),*E]\PZ^Q(8J_ZEG.S)5WA8PLEURH8E04KDVMA<;+YP- MN+*R/#^S9Y4^QT7TP7P4P\9VJD!LYB[6J!Q/3[2O\P;IX/6L;0:XB"*=<T!X M^V&.;%U%56V3KP1[OFD=2LU4MY4)=%"=-AEA+: 0QNVFP%GJ*=A9G.FE:!GT M0C^ N29R%_=[9;]XCIL85&0YIZ\(=?&>+<GZ&?@EI<7@<N-3L7!Z\$>'>:@\ M_M3$Q!37&<@<$ME]WZ%>_$4&G9%*@"T[1;7>&4\%M$[I_!A1:#*0F?38$3#@ M^]5BD?6-]VGI1C4]<=2/M_)*>0O/G%5@KGXH&"LUUK'%/:,35<6]_"T4;_JX M@YY0V@/BG>O ^A;#A0<*K%1[[4(CQ(IY91_?K-<)=B24>5/XCSIL-I*>#&H; MZ7P=-&K>7OD@\%HK1L27+-PM][![CA$O$Z<@OW4 YK5MS_++MCF^;ZMX!%CY MY1&@B2W5N7VRE80Z \XD&4+E77Z^1U4AKY^](@R+;;8G(JD &6Y\-J7.#?'G MKGO&<).F$\8T&<A\=?9:D%>IY+"?C(&S9DKD:4GI!G@"9-<'R(+:B*'1R*_= M=4N$C\I#3.X^&E4U;Y?B6'A4^+JQK<&LNR)P^-BUZIML0$Z[63DC*9#3U/.G MMV< 3!5]P;-[!MX%,\8\.VF2SVYWOW#O'<<NUXI73P60)<:!3A'36U<@4I;P M7_3G+,0LXS=2Z]&A[/J4BT3.4"MY&(;Q4;/>[I.44KY"S>/W-1JVBT^*URD: M>-V15"/7A1 86+]>5]KR.D!SZM>GT.V)_3+X#6)%^<;9[E1W7SQV=VKZ'D/3 M@! 'IQ!\SOF5*>1S 3$!ZY6'*>>W6_,79\E9E674S*WU4$F%9S8\?I0AUKT: MIH&/*<:]^_T%'VFS7G2VP;;YC<O$TT^A$[CM'-D,A.@^%]=Z<$V2\V?;+VM> M?'VB[J)<DMO]@)5O\/[<6B(2"R;JHZH*\'8S(2N7,F2%.UURWT!:] ?(K.]! M2H$))G6CQO.OEF)^C@Y"?STU:A*8"?6!CQ6._=BGI9+KB&EKSH_0=<FW@="A M^%:<3K)[&MZ4_-$B ;9I,8S:5R^KZOA3<#@6ZUCXF@ROUEW.]E_(#^$R7&SB MHNG3##M XM_?.>'8N#9][GX8X32:_#'@-16P^2"2"C T1X+.06\,MP"MIFSM MIP<",WB$WFKYS07@4)]*&E^9;ME@SRO#B;?/>X66"2Z1W=4MB6W%:_(;?@N] M;0P^00-:3I_M9MAAR/NF&#'3U^VF<>*B=035S5L8,LSI:?2SMQK\!>G.'HJ^ M9 G?1U!=@AX&69I3X!JPD%:'K$E[TK#KV<[#]CCMX'&(^3A9T907G3\U;X3? MQF+EXC1<XLQU.<(E@SD/*GQP25Z'W3]Z%_S3;1*2\L]\*G'K39$V?>YN]GT[ M46M +/#9F)(R6=!;-5*#^P9_Y8]UPQU/-'YMR]P&BXZ1QK=DETX1G6)20I]3 MG$K[ZLS;S([KQ/0E0OG,:_((MQX-;FU;*S$;:22>4EBXU:AU0][TY@N?E#7+ MAH(N;\&)]0@6**_2I.YW'P;E;<:;=#_V<4@&+=M?%2>?M-ER\_8/[7D;:VVL MHB"KAPEU%4+LO_2\TC;"6 GT@<4=_L$EKRM."I[;JOF_"I3BC&G:N4>LPH;X MQ\QQQ1YQS^C?ZY5)2>8<LJ0P-BBQD_5'#\H%U.+G!#),*Y/XI9J.(YQJU>E; MU.#]WZ2.!: )O)5*B"Y'[P,&8(=(E^(L]U#";0H;VL9C"L8;E$!9=(-_[PF MV?6=NT8%5,!HW'IJM(?(#R<K#"06E)--2E]1 2C&.IGZ:;$8XOAM4]Z-L>?J M<3'OI> >Z1?I>.C&06EQX';W(E59YQK":-^'!S<?&S$[/;*<C9T3W0TAF>G MC/"JV\V^!1#WC)1UBQBHGM=E_%ZFOE<=8]5+U"DBDSW24L'/6%];*Y_D-PS@ MN=%FYM7XZ@#[*3?@-C$XPR(KZ3NAV"W@=2]?6:Y'<8]GR?RM1Y)$]5(]L?;R MSL;B4G));#H<*"N\,_0E%8/H0%5]!UUZDY[F9=PQ<TF[1-!E!55W@/U6T*YT MJL>/?2Q'KB&"?KG=,3,M0?S*F>#DY7"DH^'X0DN]0[E> %.RVB2R-D.>G-N; MHT+!BW%H@KAGIGI\U3[C-@IJE:^]EKYP5ZA[3(88PTQ>#Z&ESW=(1H,OIP>X M!02Z]<QJW_%>M%"(U?GN>VRF$-(..D40C(L^F7_MQ;-A';F)9T@S9TX+_'G8 M@UZ[#G^$/X@*]H\MF*Z>=]7_?4>&7JM.)@#W@/(+=W:\ZQ,C&%N6307<OO6( MK"[^T?F91W7O?(W"6WG.;LAEPCJ383V)IM(?OMCQDZ1AV.IK%_IE[_^/6D[: M6<^S?]5R*IU(6:^#74\)+H"3(T6Y-NN#]K'UWN%ZL&[OY%D4UN\9>/>^^R#E M0N -RKE IDZ06/R21]ZH@OB$[16OW1Y1'JWPM>LJ[_'>Y#B0*%T&<-+\$Z8* M,:ND6K5<6>]]V:N-/B>3"CBPR%D#<H:IN?PQ3D9PQ9-Y\).MZ:M]N;:GS/@N MRO#ZM19#\%%D[QTLG)X*6,A9H0+@%K9N4F\U[40:/PJ^WCI(Z%,]/^@]-+3Z MDR4(X)!4HOGC8-K>52V#$&%0>B[;'&GQSBM]6^&K(J?P=72^7+$X&XV*9U!X M$ R>7KDD\14$.<FVO'.M116JC!<OP,J,:_.&R?^ZM;F19_O9^XI9XNXS#=(" MA>\8-X-XTGN/",-V7DM#9V-M> OTS2*9Q_ODZ4X'/]<4DQN1?UHG<(\M,VW[ M)^5DM&XV>;2S;6$^*8,;K4%0"G^50A]-Z:Y?>,-%/BS2BZ!H!!#TPH\WDL17 M4JD 6.%ARHW-*2V[U@R-1 ')E/#$E^5:)[E"Y:U@X&)A?]IE]AG&#O8GY;!V M7D(')0;QWP-AKIX$.D.C7 .1!]X<<\2JMO1#Z[3ZVBS+J]F(RZ?N&*:JB\E> M>YW'Y#,O)HQ"MC!6?HQR5Z[9;I80M3 4SA"Q<17[$_8DC]B!C[4A;!5$?,4? M5CCDK;<(-=G4?1TIG</*,L.?#?&_(ZVH]I6W4P%)#G=V!(A* 5!700EG"A5@ M(5<Q_GMNIG.I1K.5*8R+OG;HHPAWM8J#!:D4;H_*>PQK+R>.4@&W(!'P<?UZ M*@ WPO6WLO?6WQE0BP@8WM27E@05,6/*FU0)FAZ=:E-+C9GB3BG.$E@UC_!C M7ONTO(X+R9G.'INE4OX;;#4!HN&1/27S1#/469-=J-G"VTU?Q&9"3FX!N>9S MF #9%7*<1>8#9>D,0$@GUT6Z$,MT-3&DU@ <7\O3G.)AKQ#<AB4$7P)2A?V> M7A@@\_W=ZG@=C+&$NE$!GVO;$,2+_XA(=ZO#(7;+^/.V)!@?>Y<3@WQ-@MB& M6 PF *1 ELHTOU@O%R%ZXF&=4Z:=C(2 1+]FN?NC"OLKPPH.@Z7BS+>59-XO M7]_LR@ZX*YZV^7W)X<8'PLAP<]?3:.YO>!5XJ>+H4=[B8.3&PZ<Z=ZXD@Y!8 M*H#Q$:Q]D=@W39%.KP<?;B.W[G*)'I4+$&DIXH54G/I)U!9L_Z-+I7CS@ NK M#A5P3:T<M6*HDE-=!ZJV\A=H[IQJ.>!&WDIYRT32?C0!JGZ6("'T?2&U[@,. M''VI^QM@!1X, U6_!U7;U'%,@7M*O(7OE&)T7(X$:.VOYI?F#Y0Z$CO ^-<; M4"J@-Y$*^*-06+EY]DC#>S*6 \_5)G]'V3$1UCK5?,OEJ%SI)*.*"F"E;].F M_1=.Z1]=#_PKA'AS=Y#[,*(_ZW?QF1<S['Y%ST-=U1#6FD\Z[%<2*&.TL'$= M>O?4&ZZWC%J4 S=O'JC6;ZC5\_&S:4VIVF.$;HI9AX3&=3I<$9I_B.Q!#/ C M&&'*JC )<HO#7N4IT,;Z>PUWUMO"G1AX-%8Y?.X3@3BW[@2:#9E&7#<S$QK< M#@& 5VJ1+Q^^35Y6/;]4D8&%QX#H?FN#QO^D?Y17$[C/_#KYF=E%II\?Q)&= MJP+SI\/Z:YEE8HX>A/.$6'U-^2 G<4Y_(%^3?_5:00<D\=IH8OJUF,8%+9)L M4*#SH)?^CU6]G6(U8#@5P..Y+?"RGOA<!DXG36FOF^-COT@%V$WX&/?9]MTT MUUPM()HZ/\&9Q& /#7)WH:\7GT_<8]Y!,Y8H'+5M?!3?Z?#T(7T*F_5SZ1IW MOPAH_*Y]0+];ZA+&0-:OR3' -A+]J[Z#FRD==;.I\#^>6W^7E%3!@C-]);(Q M=>D8[7H(B751T/X*RU[S]6\/DY .FY/]JV$L1#".B]O M6#&H'!V9JKX)'7 MLY@'D1:W,0*[M).]@([,:VJL"[VJ/7[_=;[T,ZU7$LDG-?$K5X&OP#Q0I6]J MN7GK]G1531<'XQP'MRNY7U^ C;_L>XG"1T$]O5HNXN^ -[G^.NDWW /9;:5G M).&LKA(U<+5ZN^5Y\V3FEWT&DO;U&#WI:I"".OFI>ON+L'OG1G8G?M"@R1_[ M$8.*"@-E8S-BH58X+I[ ,.R\+K*^-J97=SBO=H^][CCSXW2^G UVA88L?(&] M73F\!/6H@V8EPY%][I?9JD86=3%.65<0?E;ZDIIE_N.J?2.A8YF#WI?N7'_ MJ%:Q^"#.-*/Z_03^\G5MKO8Z&/%FF#JG8)<X,]L$S''FKVO?6BA/!D!;+N$U MO"&;(3F(HS^UARG;OM^\OU,!HJYAUT;*)LE:Q98=C#=8_/D6Z::3D;V6JQ ! M/W"-L6(M8[K_9LW#BDB-?@.A-3LE\CF8B.,"$=&ZR=)>['(D0P6X6YP+*H(Z M51&+"H@J)-\V^?'@IUGOFZZ9H7]R'VY.+U,T^UA]ML'/^G/;KH$[;6R*K;2- MRJQFHCU,3S<PW%0>#Q]K7$[=XJX1NFH">[VB@<O"9K3!1&C.):D7WC,@0PM, MY2>47,H96!(10OP&Y6$6TAC<?@[;5;6HAON0I/WKVS&W'SO26=##;]C*1/3/ M3Q5WO5]$L*T=/U!.U/(#)QE3 <RFW?-8@EX$ZQ%PXD@'O'-@3W3 EW=-<74F M!72#%,>K0TVVJ8"[M<-?:H?D%\,E+2<^?-R>['>[U'_%FM]$M&RSXWUQV.B< MU#,[#%22K?*0IM7H5?>6)BOK[L#S3BKZB=Q?E\PJVB3&+^#*H\/4ZXA(F40H ML'S57'K/P%@M1,RKVRCJ<273SW=^:,,D*#>A=HD*B"]HNW GD(*N%X-M(6]+ MO:WBP\Z4)3\FJF#]OP[F%V#E-!V=_!A93CF$^&S$#XV]!,9=T>-=.]OU59TN MYB!MI(A^^N]VN\S@[ADN8A&9G5E(:+ ,3#P XJ/)GN9R-$S0"T_@7Z "GLR\ M!>^J0K1#4C87GUJMTBQLZZQ1YH$.**3$,U[MO;S53H[&EK&=(#;[5EZ[ZK2( MT^YLV=(S<_\WJ4@+R93D@[1/\V0W@B"\Z3[F-HT1>"O&\C=FYPV5,;_[F5T' M44]\N:(ZCF @>\_]:I'%7TO7!!-DZKUF@[(C]W-S=#HFJS)_DY4()O.=8P%3 M^56N.B5Z/4_> I94CCX$+SC&'TPZ\6AY0$M@+YE()3X?@L?/:',34 &@BWA- M<=3$N B<<B>/"H@"XKQFU./(9TQAQ-295S35V[K=\!.L2NMHE2K? N/:9@)# M#-M3$A=ZYPEE1JV;-MB!;@]'RBW_;R+:](OB7YKI,1"::PD&>F,%7S?98&>] M]4>5_&Q$;(0P0YY2$1KF/"M_U;TS5)\$67#N5 !CF1)546R!V1WI4[#7V^<; MW@Z;#RUEZ<^>*>>L5(1=PJ4V7AOK5$=P0L&%;G%%!F[+!'/=O?0G>9$?:L6* MU>_C+:*@Z@5S(MFN7ZI&!#=3]5:T6.*TZC075NI*R_\&;?"J.]Z"PK(-(QZ8 MCX XR':CI4-L ]Q$\>4+;_0%C,\N8&)O@D,?J/Q0J"Z/JF4=GA/&&KF2HY!U M*?&Z$IX33)HK<PU!GXF^Q>X6:K+>5[<<Z5!I-(:>:P%6%M*1R_.>1&,E;PZ& MHC"K28@^)QJ0:B%(:!6_ AO* )A7?BG'TL\;H*?3&7:WLBS6IQ[7[X^8?_FI M7FO3)SI,T-6?$EK[_FQ B,N9F18G^><;/665X @0Q_272E??6R>(.$]'06_2 MER"&#R>P:UFFD^-8^6@V"%0;9"-H2DR9X4@T,8#,/W?WI?##NJ,?Q&'+3U\B M)+H*:K9N41HB6%[^78I-M&5$<9_D'Q]ZT_3*8G7>T0>?L=*POKL/K8GUC>7D M"\,O[C#]>>WSB*E])XGU[YQH>9N>6#+\+_H6EQ&%\1VV1'=WK)6VWC?7J;*\ MTO7*]0<&^=--9_*7=-F0F7"1:RO- &C*?Z_.)D\%_/ZG'DT6]M\KN/W7-]B? MN/(H#!PH88J6,R72W)G&,@2:FS]S)";K!L);6\)4H'[H$T8/-,50(<1XN\@S MOT/^R!?M[LV3\=;U_?GSR7GO\4QCKV18^1R%\G#D>!P*XPL%RU#T$!RIXTG6 M-&Y7];<T(1M#!8 )=H'>D9%4 *\[C*+X\;U8\N\0BY2P,2'35SG2X*VIE\#] M(WX_%+Z^!?CM+=07@R*+V-"0VP\+K@E <[%,4/K#Y.N'_+:8.M75L"Q3W?-6 M4?J]HH0?_@MO37]JT#<+/*G?STG/):D-)$/?_=@_UK6AR;,+BZ$"JIFBFHP6 M8%P;9PM>-X$_#80Z\NTXJE71!29<U+)9%DV6*P +MP#+5' (CL1=,-:3B>8G MNN_[T?!=V7R)6=T70'P]!7BJE;C1\;AH"D;['4+:SD,2FQ="-GYX*C0Y84@) M11-2][J^71^0% ^_[I&Z>;&*O[_DUG1BJ&Q;V#NYF'NA=UQ'8M2]AW=S:4?! M_>L<T_OD0MI1-'*/WO\$?$F-=OCQT0'3K[VB?S!<*?=AO.5<H&/[4<2X%4$Z M]:MMY<Z9^7D]^K2#CLO85]=4UXQLGY"=B6'%M$=5"YKN+J5;H9 ^D5V(,#39 M B2R0F,GO"X@U'S!,[G<BF> 0AU?>UF\0RQ9$9(X?\B+I.G=KVR4<I5X.G<6 MF*RMMO()./6;ZR2GQ8<H1[JU>B]L!"%\E6WCHZ#IL+51R.+8TMCGW;R3J2_? M(E_Y1@3*"'WYI0C_WL%^T*?EYV-$*,#L.7HG-UT)I@)^67/.XZ\%$GL6&-=H M@XD@)?S5X$NKZ,%)KZ_3MH^)@_CC*KA8H'<%%?"F&04CBGF[Y%P:)!L_\7Z9 M9#Y@5LG^<$O-@DT^)/9^O0&?572?F_5B/K%^P=TF3F&%@(C%Y$C+2KUP>R,G MR?GMAA?S?N$_UK9"D4-P?&!'$+/_Z2W&G\-R[LKC%NYQ%BH (3Q N>5&HR#1 M-)DDQ37P\Q2.4BJ V( )TPC[W<*%1[0C^-V"O5"?B!&'T\:9PR:UHPM<%R_> M:)L)#;G'.+#92 5(,;7=HGR '?JKKOOMQ6YF$#+:8P\#\"INE/-X2MS+ETO> M%;VE-W?.IC]1?QK!I<,13"#V+="-H\5%J( V)(IF3-?%DJ37_^4::#(<]-_7 MC;BZN>AF[K[IPD&XC%3JDASAC\(SWW\ +Q<Z,L>BQ3VL9TM,Y'ECPP=S@H% M2,_GB80ATJ[% [SF"Y;NT Z3+Z]$:M>.[]>NT<XD78X4->C7;G95^T82'[W[ M:U<7_V5A# ]N6_(4<"1R>0?O[KQ&<6@;P7"E*MTY9T:J-^Q>#'4;JWX>Q00] M=LFL?<K@I!5>;IYO))$4\'</MH1\:)#M]AB9U?3;6L9U<=A&;;[L_"05( Y> M55V D 5F883U+2^08N#9(:R^HK8SABB=],M;-.OKI9^M"Q%LSV_\7?CL12 ] M)1;."5L8X_KK]F7)JM4T[B!B2C9I8J,"(J;+*3KW;*VA_M6U6;XE@=PULA*P M9S/)D91&B^=_MQ/@.A;7UJ0"(EW Q&^]!*9N^&G%V,*3A&[0V<9F@:&K]SZZ M,5B$%K UPH2__-+,\.UO.4O,Q<$[X:=<<J0C2&UJ*>N7JU'.H:#%]_BNX./F MP+)<$AB'.F'49I];,?F;XXTN RNXMH0Q SQA PW"8T@.F0X>UP'55Q%[9K'0 M.=NDAGML]-6IW>ZK=(345KH@PGC,P$G7/S:D"7G<H+&S204D4P'[@G@E"EL9 MBGAPQ5@=UR%+!<2AP^F$IC]>VZ!1M[)ABJ!Z!RV;$H>J_^M9&CP0-,S9PJ%! MH@,>;M]]]X__##X3U%/%PS&U\4VJ.(A 8';75%D:K'#CR9QJ@GY-X).D\[:G M;BEK@H>:G6DH\LU?77DNJB[F=M:<+OO;[K:T\&WF#0O=<W$TBWAP91MM&$K# MDS1D91TPFC6)?%L=\^ ?V/E_ A!@%F7HG0%OX OCO_#_NV7R0"O\6'Y>#+RI M_O<CB&([F:VS=41!7*7!BF$VZ".CAFK??VS2,D(9 N[>:/*C A[7H]( 0:'H M&+(*!AQU5KK(:4%,T&)$Q+A*UET@DSO]CK*LOXRSV'&9]$9WCFB@=0@L>LI0 MYGV2*'BB8ENWC;V4U&*R.?YD[A(AK0Z?D_G%I18\Z9H[V:>8Q\Q@\/K=,2P9 M9C@W'"81V+ ^;=%0CP]>ZQZBOU#)/WNA-V:Z&J"C27:O41X4K43(573K8;F8 MV!:'<<2'^0/01D=GRH_$BR+JZ0,9PQ^<IY ,.3R-8]T?G? K=ROU84.*7T// M2]:=GKG'\X&WRW*XY2)Q>\<XW4J;[7PE/%V:P4C1X.?^ D?N7DD?&!O;6<0N MJ!+(>$NJHN'D0\2WDA+6"H\7/BGQ90_5\D+9WY-=,3J&QM9SPQC[#+'1"G_2 MK376WX3("'98B+#H V/< %W0Y3L@0=?V=:PF>]BS%*'3XT)3:A9.WZ &A+(T ML6E45%JI9(KP4V;TBTJ>K5>:'0!4TKW1,*G [>ZMI>$FGJE-7^6W4P:2NUTU MF\]9('<'W3G4:C5U@-WV B-?LQB)!OG(KL;VY+[<;I7Z%WV4\EJ8X5J+2J!1 M>Q%>L/OL,@+C*6?08BPZTW$!&75_QD89\/DF']_CX#?N-TG=.: 1QQ8DA+7E M@T<_4='!([LT]T)P@+:Y8!>$/Q!N2U0B</9:##ZM#(=J+2?D&W_.;_T%B>;" M/%D^2CD0B*Q;#?;"U;?TB=N,;(F.)3FO2GUD,M:&H:MA 04S_-"79?35UA>_ MA$?_>S>V\@\B[7]D7E,!;MZO92R'KIX\[/F]OU!PK]HH.LGJN_\V$V,+O)Q^ M:((*Z+@'-0!VG,06P%;-[DOK?9@/K.KXPY7T=!#)%67M6NLR9>2^$2JM=O/; M(K13[Y7/U&<"4R<7P\3D.H<[OLHT.5#2.<;U:N!AXF5AF5Y<::C$USLE@ ?A M(SE1X3F!Y?)C33:X4A"6"NC!#VU,!8&LK?3#;_^P75P1R_#TO[CJT^'_XJA% M":^0C&! 8^S2!KF[O<3%SFO?^54_\*?ET4B#=QQ9LNA6J)]2>Q)(1$[K=%.$ MYM7W4U8OEM0N*A.2Z[3'HA""VKZNH=Z>2J^<:N+OL/'J90@! [1?-,,Q%N-8 MYV1%A>IC#S*_R(7>GN7T%W<5"XI]6G6B00]2T!MSE_%YR7".7S 6#X6FD[(( M8W$9"6\SS7:?#F=\<2]6B<FNQ\6SA=?U[87>ALO7'NGW?G?6D&W5:78O'-:V MP&6') 4;)3'/3.G5;^("P_SI].A'>"RY\KR)3%WVYPD"$!O\"EGRYV"JT&.V M?&82%6"=QVUHK@ED[5M \08F&]-3^&,0^4V.0779^K$.K?WJ'EU>4/'O-8,4 M5;+5\%62BT?UQ*>A'#FCIRRL C5:\9\ LC*IX?81S&*LJ2=+UAB* *RG%6I/ M!93K2-+@)LG17$UW.,#Y_[3WGF%-1=O:Z$($1.E(+Q%!46DBO8-*$VDBO:D@ M+13I 0(!"TJ7+D4"TJ1W0J_2P2@@O850I"<T X3DQGWV_L[Y]OUN_W-_G!_S MR9/US#GF7&..]JZUYAAQ4#[,WEM)DN%<MYI0E"IT&:4U-70N=%.ZF0;?H5%^ M80HO\^%4^M/U^5&OT.0/O)++].4?^OG?*@9FISTG4I<<X&XE4+[([_LJ]V[[ MNCUTG5/U6$18/5T0^XDG1WURNS[NXZ2XIIM2V=-,FSC&HV?9ZNFK<*.1I721 MUCVFNC"\1>5LX\;]=;VH5;.!B^=(EP1]G'')M<C9[E.>7_TQ>TR7#ONC0O8X MC/8Q<K_!:9C%2 +WK*[W2^EDGIBC**WJ3I<$K>*WU""Y32_G(73<.[^F<39G MAZJ^8 ]A-Z_(LX%7>44\U4"QP$8I#&6\R8A4:DM$-=K<Y37K36/PF5.=>2K& M+AA[JRD.]3*IS? G5$&B-,O@X=B7^4PF[1/97OI5,VF2^7',M58[YF%5T&C\ MJ!GP\<&=^&0Y]Y:O^9RI70/EV[M&&@?YZ1JSLE3K+VG,[$'>JIPR%H5=0D$F MGR4K:.8&/JI7;U113L&BN.1 CP9Q(R@8U0 F<,_LYR'/M:N-E7=M9J;4F<O= M#9AB*3W?1$YCK&"T^. ?][$/(T_G(ZG EU:@Y\,O 5S!W'WICKBR0W1[XG MN24[(104%'51:\B'"#QZH HR<]YD[9U:)YB+[;.X%$_!^F(0YUZV*W=& )'_ M16YU:L/AYK1+LG>\^V N04:P&"?R5?TP91J,[V3W9.,X7N6+U8+U5GK1047I M<D >#*'[48?.LX-EHQU3"F42V(][TZ)\DPAD.>J\]U^-"]Q?? >G*X7Z8T8X M=X.B3.),)Z['#<K>Z3VUDEVO%RI^OW3ZN\F)=KGDJSM"6NI*"DW [.;B]J07 M3N].QF=]O! ]!5H%\QX"H4'[']O+(E<?PU'K83OXNM2N-BY;N7K1'6G&AOB/ M5 -(@&"\;HB7&=TMEVR]@0_PEN@:#2ZX%;GL1U8Y[(_/"W@3]_S)/)Y_S!<\ MQ-7?XGLW\@9-_;[L7-X%F>"]BBUC-D:70&:H!,9.ZQM.I1L5OB1>\,WJF?UK M:72Z/8P6RC 36LO+B,&FNA.!VSY3#Y[]F47D>\JO=Y6)?1.>Q.!&=P?P:^;K MD3;W+G7P^_.(XWY95KQA6-"XEMA7;;G8ETSO\:K-*;KAED2S; ^?-^^'11HH MQR2!88]^9QM6\_QOW3NNN/<A%(C$_HPN&YY8\Q?QR9:Z;ZO(M =C<@]8^F6Z MIQ3-/TDBN>9;I&7KXY_SQ1J]]J(WLK"YA)-<H,4JIG?COA !\UC9_%F6Y96" MWX-+7I"BE!Z-P(SV:N-OD[;DAPX9?NH],Z)Z&K\:XY_2NV6;UM EHU6J0?B/ M9:#V4^/?)(.:)C2]%;/K)_(Z\E;>W?_W511#B<"^>9L"[#_2C;(VP6;D$% J M+ D&?+5J'VR$AX'^YW2DFKT+S+78]K>^,/K%@>OFFWY[8*&.5X-E<T$_J+B6 MJJ[C!+N?L9*?B4YFJQP,@*U.HKG"[6;?6(G"S^YMIKO#W1S!6'#OCUG+AY5] M["U6%(:A<KR_5/ 2L8A.$O!H1;O+@3:B""R_..M-Y%X^VEW&WV_ ;F[./()H M+,QO6]P776MXQLE7&Q]]-'"A<2A(/V)X)%@BCS-R:"V [U?N1SN2958G C2+ M9?9PG.6"-/(\1 SW1&Q[L>SF([PUMG)@@ @\ML7DSKPN^.[>"XM&F(IZN!T. M.3TMZ>8E$Y:AG3^7L$:\=6\QEMB\O:R5&^4S6QKRG5) ;3P+4HHZDP4_8,>U MHD/D805B.$/2-.BR?1C* [(H2("SX6\73X"J%:SWB8!O.[^-_YF&!*)#'_1: MP,?ZYH,#\G.4*2F^SY2J.!5:((6U'7\S#G^?;']9$L?L]"?=I 1KU&LZX[9\ MXB^];_-5,SISAY^'_A$/^'WU^!\0_4<?'LFPL&,GC,K2]8IQ:>DM1T>*I@M, MMR:D:+Q>45+H6[W7,E2_"ORK)2_)6\!Q+O015)FPYQN+_N>;?TZQBUPAR(^X MDF7:O2B?10[(^Z[3SZO%YG/ER5ZLMPV5=Y\2 8;BJ%7_ZX9K)M=Q\6*19;6T M"PRO%]#&SE7UF%!ISQ\AOM^MK*!F#0T-X>S";JRRGLSWWL]+!W%C&GI<Q;97 MR^JY"*Q[,9V]<LV/B< =+\)WSIEH6-<"MIU *88S(8SW37-'F\*Y.#=XK97[ M;QM4< XV/%$X0DL5@55ZS'<\)K;TQYYY")US=PV:Y\_=O81\[%#?CLKT;6%0 M%H,L9K63I.*JV#:ZK$(_:D$&='S<CM*?>5\M)P)^C&OUICVP/)&P&O%E_6UW MI]F.7=!9<,M(S1/KM=!UK%]E,3<_=%/D;1Q'C.RZXDH6A<\B9N1T E!A:W'7 M_"L?1J1ICMI@R[N0*4="UAC^UG'.=FRNKN6TL$C*B>$1XR5PXN6/7\\[RG50 M[GLX)_JH>1@:J=6+BCOQDQ+[*[E$0#VHEP1RV-M1UO3=H#<&4(EQ1>UBF0]2 M,,9-BQ_O=TP#ORW8A5U]R?+TF'O""WY/\FV ?B:!$_=]J\OVB@_*^07BQI'2 M(V?VV\(,UO>J*]HYRFB-T)/OUS C?1&^]-2V4G7E ]?9/"_TF^T#6QW7$2J. M"\I7+<46IHLWU?P!3\+'7[^-'K!\>Z(N+#[$G2E_[P+7IA"\J&A=WO:;[@7" MF/&X9GCZ](Y!0'7?Y9.$TK=?GRG1W06S+BXCPF\D>(AU=MJ%W_KQM=9(7J'F MEO$QES<1N%#QC+&/2S*"D[]A:OBJEQ)]G7?(/2+P-O7L@0[I)X3+OWY6;);U MH5Z(X>K1GQ$#;MYDK/[#2=\ML!"<*LUD2=A0O-;@9S]W^.).**VS)I;\(5@G M31@J6G_P0/+X1VU*!TB*RG![H:X.<][BZ/W5&KD\).O&// 481;)L//=+&PN M]FB.H5EMJKE7AC8WVB>;'O2C37Q:$UR@:,,"UVL<YWE3>_?K!;7]%%<_J7@L M6]^;/CA-B^-5Z2>6%AN(4Y<[<WQ650VZ/=[C]I?_A%Q.NM7,[B94:<?Q7>@[ M$7!Z:8M[*E]D;$SRM55GV?0G@;&ARGEC)'3;-4MH)'G<%\53CMO2BT<#L(\E MDD#MWXJ8_]:DBJ*G7JYSC\WD)N*"O#-_4"'A-2&:7<>PC!A'8SDE(C!6L-RT MQPGA>HR=B.--+>X1K]<X,,Q)*B$_*N52F0ZQOFG9?Z@?82/VT]5=M*#YC+9L MBO'A:/_H755-<F_.&I)E62V'_;3%(@@4%3C3IV"O$N[1@I5=TS$"-<1;)S[O MG9A$>R"SYW>-.4?"2;%\ZO8Y*D;3(&C@YB_^AD2NEJA,LE!29.$@5?8/&W5, MLEDP_!62V2-P]%D2@2^M:(^_?PMW#(*NO\??&J'R3119*.+V\Q)8D]U5UGP^ MW>H\T7X!*F?GZ0NQ( 2EF=T54\; ;ZNRC;TQA9%L6#O)ADEOP7%G_R#9;3F@ M@D&TN"5.GHO NN)<]:O84$2@\QR$BK*ICQ=9'9RG>H(8\S#H03#1^@VE'&@O MD$54LB6?A3?$X1QI/0B1?V+:,:21GXA 36SU=#3>!ML[VL"_ X[VZ7OTI,SW M60ROJ=?B=NPB]L6A[>EI*Q$8+1*:QGX'?\298M;Z4*:OMQ4E"N>L;"RF]ZXO M8_\\WMXU3XMKE)HR%9\@;=:U?^6W^:_M_T%YCGV\ VXK[I1F&HY/LC@>$-@? M.%V"U8*__:-*A\-_IN[>:9,&I\>]"V&"-)N."MYU,0F$CLX.A#Z2!4&";Y$W MS\&:TVU@S;:9?^"@%J/L+4]G?UO&EI>^3-.6C\5RJ^JTUOP^:-_)O7IMIQ]D MD:AVGB<58]D=6%_AB6[_D%*U41RCDEI@\>C>RK8>\]XS[PVC8:K?A2KSN?#= MR?6;A6?Z\S/G;RWQZK@((1<UDY[\41'#E][CH,2P<<?QIZ,AHY,3]?Y,2.R5 M98Z4.2UK_M$=^CER?WS-G[[6NRKJ 80=F36._A&H80%D[)L-/T8O;MGMRC(B M6NI*L-[->-=9_5KM'4S>LJI1N;HW%O\0>S@JNAB1)1!^DRPZE;6^O7DP9495 MSY(?,"+?BPVQ3=W2W>^[5G3M-!V'_L:9&@V5.4]50O9XL" =/:DR%.N/3=Q6 MO=C.L@H++=8%<64EEO=K5'KH>0/H^3421=,<C#^H[ 8^(=_]"=>?B":UMILM MV+6:@HV427^5JW@?BHG'CYI>POMS'KA[UX2JE4951,[LM PAEBNBL]C7]@M4 MIE.:J\Y73VZ'_0E';VB9MPHMT\HL4[86ZVTJWX"<LO,GYP2]'Q,^WKW,%5:C M=.GK-A2VS(HI!D_"6/!V+*4("34FT<].Y0LVLIWZ+=/HWT[DNXJ(G#R'9_*< M."_]B,"?L7STWQ9YAX3[S6'+EDXL9C0[*H)6Y$86N,)>!(C^)?8J_&J+N8<B M+4/Z?*F;EB$_0QYMFB)Y.G &DVPN027ADLMUP"\A<)86>U?!M+(9N^<.'&8T MZ^[#2^FC3=CP5F?4&8^#1V2;?.3@KL0=\='MZ5#ZFHL7D8+Y0'!^XI9VK#=" M"E.-MQC/, !+8$W[KAO'RE'ZS-[EL,U&IG92O:8/;$7!N,"$V[^$#Z?:A"&] M0EN%2?3W>G_:19CFRDUW2)(=_T;^@5G0!<M5Q&SO0CUDPO>D)+#@;]ZMK3\0 M9L_J:N?%AI]^O.S97^IQ"9+1UR9<,RD BPBY,[8VMNS\1,Y-1.+F]&66L\PL MJD? V?M-<;6*]S[M'RP(V66<4%WL=.,[>CCG1CV,/WQ&<VZ%>31E<5FTV=/S M^"4N!XVLH[(7_RR*Q&F8K3L^=@A57OK2!DI<MBGCC7(NBHL,42:!H)1:]E$1 M,G,J?A5!\H6,KWC=7[5%PJ-;RWTQN3*ET#A<JOF26 G/Y\ ?5'/&S'S/N@7= MQ9$-%5$DP,L%B=Q':]>JL"@ZB1YQL# :Z=4(,5S[C-SW01]5/"1Y+?Y>+PDJ MW,!RN%XA*RLL#F- J?*&P$E2[Z"<H1SG4ZJW1Y:W*MQW^1H;V]/E.%XF-863 MA[X*Z"%!"#NHQ\ L2H6RD@A4)AUQXMAZ->$XJY!;+ZE4L*N.1.#;$U@7/5I: M%L2.-XJ?/+],BI0_9%/316$[B,!P_M(BG@.I<QZ%[7[E@7O8P@4_HT9&AK4P MH]55]LU:GL!VOB-53BG$\-<(DK/QV+@>E=WSV+]7 -V_8]A)*]?L;#TAC,+Y M)6%V4,\9*OQU&UHTX8O1N&9'FQ202!JB:L=/FK7P'/OW<(=,-,$#UY)UF_LK MZ+=T<)]*IRH3#Q<ZEDZ1?VD4MBWH:68CB?/ YO:U@6#TUK]Y&<>$=\O=5E+V M%4X6M";D4NZSZ%.]DRJ'TJ,E,J$.6-4C(G"_!DD(>P!AZX6BT8*1#-*72)=J MD80W"Z'*\8CH;H^K]O9?* 1_WW&=' %AWN#&"%&"D1)$P$8:AE>_C=&,T0!P M0\O11& R!DX$&%5!.NZYOM#1!2IL];H*AZ+1'R]Q.T=29-XF;P E<64+F]'# M;>=Y1@O?V#>@&IW].F\K">MB1KOE$8&N5:R&?-@QER(<[_4!SXP.^!?/*9%Q M>*]0Y=1YC<V33)Q8[Z R+#KK%E7<B6?-'A$ _KX5%NSM)B>PB45R-.]4UJ") M '<V??X?PZ8V1]N+N/FD>&QB#]7G[.#P8=AVTM_I_% A]R#952?WS\.1"JW* MJT"P>%/,KP-9C&V,C!V!3292?"[X-6F?J,K$\'S*TN14:+%(\ECVX'#D:Q)< MH@""17KXR,(O]5>DMZ.N8.$@;$"+@?\KTIV>XI/@F'>0*7=:;&H/61*3Z;9T M !'X00)C;B69Z'0;H34X[C[4M92Q31Q7."P0*^R*C2?=PI]_O-GN[0E7OH?+ MY9&KJB&Y'BB)/RV&/="I-@IL"6M?K\=5H-!9Q,YQDH KD'D-=6E4P30J/ND, M7.Y%'IZ0)G"_M=SF\@\RW02P8"0UR3>%_Q76O'^P9[8+'MUVZXA_6QH*0R>1 M'2*N3AB_H)/WJ4B?[;21LFGG4'Q*PI/P*\II1, KF;15;CGM*$]<?E+T^C:K M'1&P)S&4;94(;(TA3$F"\ XR'4&.!D7",)3_F(/W"K8<ME(-*>&A.J7-"B8" MKTD.]N]^%1(88%P[(D3@2ER/K%$M$<@Q)PE=VZV_"^TCC_NK:?/_E"825YL2 M/0\KTO5?0\&S:,V(3X@[7[J0LCRPUV%+, X9?M(F7+U]$F4V??B7 OE&\+A[ M17IJ!T'Z&3U>U/;JG74G(J!6LT($%J_"NAC1ZK(D,;GSW3/,SA%^?B%4.?GO M>G)(NFG6I\(!-;!4*A7^>SK;\.^7$S&GL*X5K)I['DD@ -CB5;+#MDW=7P=: M&/V8)M!?82O$0Z:) /9J.TD'YAML29<$%WI)MQY!X@NU4IP4_0PWMM_5J^%< M';I$XI[)$M0.J\9#?TK[5RNL;;>G2R!O#&QYG;.N85DF(VP?8+GK31"IGIK< M60:1TL!;P-=.%21&"JW^^>EI]\X_,N-HXEF]"5KMH>W;RO_C-<._';;4W.&6 M@5[!3NP;JE2O4:26B\\TPL($_7MAL5-_TZ;^1Z+5W./(> $<%SK;VLZPX-&5 MJ@YNNEJR_=;VW@I.B,>9H$X&:G^3P&VMS&\71-$X4\KWV%WP&I,WW"(7]?=( M-F?F$R( QO.T5D8<L=1^ZJ&[&)]RK?FVC2J[U.]3_1BHVW.4&[6P9)G\[NS9 M/4KS=]L![*J41B'4O7*%8M\J(DPMPEY;<_[4W.UH3-B]G@UOH4?.QGW/49?Y MR@Q!+]\L0I6YWY9LIXKQ>. T?(N_]H(6;G"=/^[3\4ZD[24<VN27F$I-!91' M0"* SEVL,.)^YNV7@%T6!']')XX+@BT]$K26'W#/3I&*X6_ZD)$T<. 7<QY^ MQX,1LM5KX,SY,%TC$1P4X$4UPV#=\P$(>?H9_;F]S!GL%.J"OS^>5],0/M:M M\?U4<DAG)=F<*U3ZZ\9$\6\27*[[_*+;K#*UFVDCM<G]\ES Y0$O-?:7_4NA MNMJ>Z#@0XOVNJ-W/VH8ZK;D3DW6#Z+2K]F@%W([!")9K67#:#8N:!<E]U*[9 MJ=I^%\'MOMB_I47UFZ#TJ\*W[&$?:EKD4$%$*7__1GUGEN>0'7_BXFB5A[+L M)IO?#[4"B/)2Q)>TMT/43L;CZ%CYJB^+R_K?P,&61F$^.F[J*KZ20B)S+E$- MRZI<L OUZ]C4.-:#)W5U8SY?19[Q#Z2Y\\_IGZDH4TU.A$J8+K<U%KLP]D*I M/94_>Y+1>D@^B&#QTI;=VS MP+TK67"21M0K,UHK8\T3%(0:V@+\PI+9V7D@ MRN-;[6R0TYZU]CI$W7A+Y^H5A8R&I[>0(I_G/9\ZX.*Q=%PE6N62/(H"Y?T( M1BL-@J7;8&9 9B"S*MLV0=1%AB^5P"@4)NR'%$[59670_MQ\/WZ /EZZ,%K MM94N[J;?&7>I.NUBPHC;OM8]6 !G+'H5O^F!>XQ_[@MV+CJ/G)HK[D^8T@SB M[5(]FUH<7WIV[N*FWY<E@;"6OE5;PM5Z/^A&0VN,N]V4P(TVM=0E@"T?T*:/ MJ8MH852:/!8(M/W GS8U,^"BOZNF;!FJ$&_>CD'417U6WM6!D<_-:=)0"U35 MVYG3C5X"8G-/QQD@6\M/IC(*?M1.5XB*/I$^J'A!*7O^(<03R=*8CVON+0NP M8\VA>",<Y[D^."E>K-'B"MJ2VXCK#;V7L4Q94PH)01O48WQ.'9/Z.1<':84[ M1/W(8B7&_%ME-''YY6"-F[QL<!V=C/DJ=6^/>&XG57+V#AY=TP:LZ;<RZR0D MN'"#8+U9Y>3Q,>T%\%JB?9*E0BQ:$>91XO+<5;@\T3X5L++N+1Y!4'.").(W MG<@SJG'QRZTZUCK!1IV5,\[Q2+*F^)T/S@+.R@[]2L!:DRTS7JT=$UL5<&S- M6'?KS4[DQ/=Q E:<4#EP+B1J"X)J91B\'CNCTJ^K36<5\1+]<EV:^]G+1O8] MBP5A;'O,X8<]H_MCV[LV2A$>7%;?2L+)UT7:R[U[ $=$3\PC'A_G*LB=M9F@ M(4-)?\BP0B@-N>>X(_MQV8Y^[Q-S,($'4OLRXW%S!&$1XH;<M3HT4+IRP7// MK D>U\9G,35TH_Q=P=Q"G_?9UY4F==4&D/2>Q%:OT%C9D4Z \,[,\O%(H;UF M^LVF*"=7^VCWI4B+L/4FCV]16[^/P ,M_)X.*2X60OZAU"]=X\?IU)8(4C8@ M+LCK@XZ:K90%4$R=G#V?Y&S4"P$S53FCV+RE@UVA,4NCUQJ/-U/R#>QN[@K_ MV?0GF2^G&<DP(E KPMB,F'TA6.B1,?&)5V4)'LN)B*C5;&['4*S%!%RDU$ D M $^392]3RO7OF1\3 0[1(WT6M3SDDMSHA ZS(NNHI2A_IE:# K;7VV9)2DM> MN=#%E)L(%#S4)CG/P,2S)\B]NO/$1VKW%UVB%)3DQYL/R0<KVL1<?BQ.Y]E< M;):PFM'V.M"Z>VTF;UN KI';>,>QS^8ZHF'T75DN1SDK1];B]L[[QP[J(C_U MJRHT"3\0'S,W_:+98V8KKL]\HR&/F;,;:Y4Y>S(9?Y[OH*:T^T4ID BP6;"< MAJVQMK/[[CR:<'S?\>?G)<RCP4[M(3O@1<D\] 66MB?O]%WA.]&WK)'4-9#^ M%+M:IJM_5N)QIF6BA>Z%7IO2]D>7)^.98-A-_1VA9_TABX[)OVE7!'D;%(I# M]X,MT>&%>;\GFC+;J,<9YJW+&M[2#D?"8AK0&Y8IMDQB1Y\I"9!#9V$IA8 ) MV9QD?PY3H(;&A_VY]4IZ3 'WE3.)_I>+_LS0[EQ0QM<"Z1S'M9-VM['AD?W= ML\>JH1"5GAUX;Z@BT@)75F'QUA@S/PH8I[^\WQ&*NP,<D4M:0NU_'5DK[Z\M M=B$LT0'W>]?!TJ/9C/%SS">FA:*%X$9S7R%/Q"J%QPL>V?6U0I*/LDQH/N*2 MB&GUN*XDD243:$!%D8=_^*NN3,=PS+;;/]#U>&+T<:JWJ)W?4QJ@[XGVN1 K M>KDP$JJP8CD/>;)NGK6L_C!K_#FS $U]H"\29?-U)C^]B,JP;B97@79;4U"1 MP7M#A\3ZR$$I+N.+'@IBUSF4:@Z\57D-?;%CAHA?Y=NS78AE'9_%A :ZUO[E MVHHV85NIXS2*N'#WO2]MB%CTCHMT'R\JH53?<[3UD@MK0A'M5[,T:;<#FS4F M?<3"A@YKKC.W@U1[=:1XI@;"T)4[T/THFU[Q)]1WF>?%Z/Z1SX#K8XFN"#=) M@>H2>G@6G@C(]\+1$X4N^ZD8:]QKRBN\1R?E[/"F7&Z[B5:?3>F>*)BSA>Q6 MK<W#>["]\O$$6W,%/K?[/5W0H:;=ZT8;!R2@E>0"XC@:4=&5X>^<>9LPO";[ MS?. GCR%YW2"T+P,8IK>"!2>2%EV=JB7T&?_L)+Y!C$U"9FI:[YK]W6F-/J> MY4X5XU'OYHM-5GCWU^E>30UP?RP,NWMK-7&*'N01U_3-#QP@%GIT2<5/I^19 MV %:KJ\>QOG[$!YAD1HA(O5AZ>?-L4)$F"B3,YU_B4]'G\7>K$%] K=TCD/1 M'PUWU(SFF'^9>!V7E"$![F F2C?;H($Z7VBE8 6_4B0"^KBTLLU3]V(^S$Y/ M2U-PM<QGGQ8=/ED^381%YRA!#A(.=H[9>RWV%ILITG63U6B34K;B689Q78*> ME,(U-;J<\B]]#2HRDB6E%A7X;VYF]$WMX"C0*0L0D)**U;'"TL'+*G_L2L*J MD!Y,M1C6Z](<#NQG4\=?#I;7RAS+Y\W5499E]]ESM'4)\Q&B!Z]5E90\;5)F M\@N>QCSZT9^WX] <1?XC/LNYV[@^QO.\T'YHT7?8S*/;_RK9>I/FMWE]$RQ+ MV\<%ML;J.JZWB .^2ZH<[*<3(+P(/7OK(=@WE^O2R-##XHDR_A-R6>\W/Y9; M_70U1M5?^.J8R,W6>5P'B3W//.R1.=,;O\!L6$/%97HN*GR'(*+*"\['K7]+ MY=0H$J]W3)<R-0\9'(BNNABJ+P<8"8>(N?C/6 _UH%K5\NH0#DPM%(I]*[0E MB^F'>SM<-NTSK*6>=34!#!2:5WHW8<=E-?>J-_V*37?CZM7C.S:0$Z&*L"XB MP*JH7Z;IX>V-TOE]'6Q5>^_FQ#VJ&>_?0<M-2"K\HXQO"VSPI^.U.B-TEE[= MVUZ:;4;A,W24$EDJ\MLKOT0LU&F++;;UC,[O"1],*AYH'N?7R/J-ER*( ,1: M/9D\J[EQY?)GU?U6$%JCK,AR.@+/%7P<P6'<9MTBP9C8AXG5-<M8#F\7_%"K MQ ZQV075655\]F/S\>SM5A'?ULP/M'3Q0WLKYSBLKZWOO(IMQ]SA/9WK-?95 MT*"YQ.7Q G#,49&Y^95>686AKO71\OGV84;4%?"UV13[N5'/ 0/YY9K:Q0@; M?M;3M%3UQE^L<E8S@WQW4U7#JFK7N;$V!3/O:EB??S5W+$#Y,\@BU0X"#6;* MBM;/]'ZQ X.ZVU#/UW2<H8H9VKC."L@;D\K1L6XV/U[O/OXY>9X/\LEVD<TR M/2(PO8F*I535AK;7UZS</A2FIMP!5'HZ:..W;#+.*]P:JXJF[\7'P,%Q%P/W MQW^-ER51<"87_/R^UAHE@.;Q]UD.52S1P0V4;%)+H2$V^PI!"HYB5S3\]:\Y M +&R*)C%3XQ^3TD%QZ*FZXS C-,^?BU]"904';+'VW)4\4"^E"ZGO4YX?/VC M&'\'>LQ?"C1;>_1BR+>0TC5EUIM!3OFLV+>!U[D4JC4Q^72<Z?N,EJM=THV\ MF!>K^?HG3@M3AWM/7!84)]&58^HQB;4[[A:K-C\;K.>4O4]-\T7S+Y0O[NAH M<"!EJHYX5.(06P_3WS6:BGTUK[K& W>+XNB;_[Z;ME;K5Q\:D 1G5M056%*W MY[MRR<%<>&X5.QX8:.)7AF7K\PMY7&]QWUK5\=)H6;/';'1C7V%^$/5XMO!P M4TQFM%_,HFM<%5)%B;;((JOI72Z=!NLQW\GG7]<"VB,58653"Y8PNZ[1[AO5 MNC>W'*Y?#RQ2;AN?!7%"TD]_%4+&+<0R\[1=^U>*7\LB@?4+K3P>KN@88['2 MKK@D(I#?'>TGX+[R8_*XFGG-A5643F:W*2K3!Q08*AN',^?\W+HBG<H+:DC7 M7CD1B+S'HO9X"=Y]5%IFNWS<: >&_,2!GJ1K27_\VI%ZD?RC^%Y<%\E!/YJV MDQL7GO2<)RG//MSPP* IN6";"+A89,8TRL3;HPNQ!E29OU58I8*-3,9$5C'* MN78L4^<K8W8,9^F[[0[E4GM1W:1X(K+)XYR1UH8PAD@DJQ,23@S+:!@XI4^O M;G<(^K RT2;:G] G[-@S]AS]:A/F?6F3>D\5)/6?"/*?AQ?S_C/;ZC\K<_Q] M\DW_M[[9'OR4]C^>?-,ZJM5B*9-]"UQ,L#;.?PQK31GT9(0C XMXDU= %XC M2@W>EPA4CL )"2)!L3O?_#CDLNFI)E4<;=^T<>PGH#L9[]U;?>RM&Q8KWGU^ MNQ)/B6.!("ZU<5=[NF>L/E \4=_51\XTPQB@]W_0_IJOFZ.7ZLGXU/_RY-Y3 MQC=9X(P:7 1F81/\QU)#>V46[&-,YZ6QG.=8J.1$#A\+N8(G;W$PPRO8<<3@ M:X</8N;L&0_^ 1C)B@_CO95KYFBA)NGJ]ZT**ME:!'.HVP>_*V=7I*KA'IE ME,/&T<SX*C=TFJSIE/QD4K-P<X&&T?J29#Q%K3BU_5PS1 11X!S66]@!#WMB M,6?5A\I@12">)30FO&)37MULR\&8+BFGKBH2.*MTG!D>.<@PO[NL=B>$"$ Y MMZ7$N" /"(P$89BGSYEBZH/W?4:3610F+5C][J"UL;)=872:HQI/BP?CB>I& MEC/9L$QG^S1!P2_^4%=:]N+U==B,*+ ?-^^Z^UOW&DX,\^",5T0/=&FF->IQ M/:8?P1Q_<_<ME A\;T+B'BF#-AEJ:?-/*D\N<UB XHUD9R?C\K5S<!F=<2BG MO->=ST;'!SQI^+3([((;!Y2\3PVH[BI3X"G.+#JR>,=&NN6_ 2G>![QO]L;X M<3<PS&<:00(_)(E _?V>&Q_T/1O9??OG>WQ.Q6(5&8\]_<$%'[ZMVD>]N+"K M_^!/TY@(U'R)QXAD#WBN&Q9I+&XHY-Q:V:%-F%Z_]H-*LIU2&4#Z2GWZ(1S] MDWGM5@+Z]55QCOG?:GB7JSBU,V6ER6E89:EZO]JUF/R&^5K,I9-&EH6(%J'" M!Y=GG;4IUKY^,1M+$;9<71<L!TH'H+I+6SQ>J#IK=LOYF<%Z3RN!EX@LV8L@ M"V!5!?483R[_L5J?UBPCU:JW#7KB_5$\AI!G'(916)+02ME!-9/QLW+1C&&& M_H2=X#K+$X*-4.?AK4HCWZ-3$ -BR<<%,1G"JL]_$(',IS.V'_!7//T#)])M MUEX8KSP5'!; SSF$RC6TD>.O-#H-AW!5?AR>O>Y1JV?\G;KCY)RL-,/C':QF M.WT\_7$69VU=>]0ZZQ]F/?9H]*N34X=F"-YMJ55ZX%GE:/>]>]73Q:_//L7' M'WCJMF&INL]BW,$9(R*.$TR38.0Q#/Z,@SKSJ ?P8H-3AY#-#M?'H,YN._0> MT,\X#M[T2SD[ES 5P/%C6!<L&VS5QHQWOK Q%\*5#;U#]9%;%JF3(-J\!&IW MG_PS]6'VV)<4>?O(:Q>XRH-,U8HM(<\V/(H>H'![BX:4<FA@[^/ML\)T +73 M1H6G'Q<F3-NA;GFX1>9]Q8PH@V!Z%0O9=3@9#.=#RH-N5OG@(87;K\W7YO<S MF;L/K+/BT!X4/-)@:Q5]\;=OJ87[^E75V1^G;,H;^V)-0V>M?AY6Y3$'!5Q1 M:M]%L/>2,_3)?=<N?"6G]&#I[[>_CF#%=DR,N57M-=:(&W _^@>O%WZY()=@ M'0KKL9*8[UFBYFIW.1P7&JWG\(3,2<.OD"C4F:[(W"G4P_<2%Z;0/T0\J\4$ M@IT,V['8W!2Y(]40$YIL<MTZ]^4F'8SF"3GOY!*\XTKS%EA64:6@]5?W)U2, M URTPS[LX"C7 ?"B&E+1.U13\^<Z+UP.]#S0N-"CEQG%Z!R];]:^B77ZEMK M9X6?";U@ZN;J4TQLN#PYWJ*_M#4?&$RW_].=(^? ^I6V8'16XX8J-Q1$3K@P M\HX(O+7I$9BR'3P0%'3:A 1&$*X0D-A-UF.1;.<M?\]KD;<>'ZQ^*E^B&IGD MGG0$!R_YC@LOUXV&-G\J?:3\\IJ,U<J9L9M=#X@>_>N+^6%/^BY7SUNM8C;[ MMVXTU.X:"C^HQ,KQM#@N5,9[:_W.^OKXZ^$)R]H.,VDKCO3I'Z'T.+)C'SB! M<5ZAW\O8_AXRG+]<.7"GKH(#)_,4W"]U!5;?$.?S\U.G@*.334O\TZ.H."HB M\*Q'8,;J=N$#OY3&)%@)T@20V5+EGH=WJ(2>AG_VAGF@FJFJZ[VYQX3'WFGP MJ)UL7@&%P2](N5GPJ.AC6C\?C8E],I%;/V$3H%P]&: JS/=-\5^@^5FKX!NG MFZXD8YRBS7HAKZ3R['NWHCW='1[!;P2:-T:Q0;IW+?6OOG2[^5 !6BG#$+"T M/^]$GDH$WO%A[DPL*P157)Z>'A$>H3$<D%SI[Y;K0Q(&\,6WE>D(R B?X^[N M4_]/52?5C"2#=-UG3H^$H#=7L._#?$5./_<DV5L**=ZK/'G-(BB+M-HMKC^% M=W^6>3!:=V7DAIVNS=P =QE7R)&:RNWU*0-*8=@%9>JY'K_C!9JZYLCQ:R+< M!SRS'\AQYSVF]3@5S&5MD1>IW7ZL"%/;S;*5K.!MB=B,DH8ZK.,;UYLZ09;B M+".GO1N\7>3VV*R@9T8^2 8(_[>LV[&#M((CXRBKTC6&BV8*GIGK1=ET:B&7 M",CMX=SN&6=CF)@74IRK*C/X%*I"1J Z+Q)9PWQ.8F,:6NUA@\LY4Y^U4.Y9 M%'X#T;GNU9GECJ[0>\AK^F#5/TP\9LZRC!7*CONV0/>IOC)%EV9BF$64YQ*' MRBW^+'7@U16,XQ*G]<(#7U20PFVW &_%FEB)Z'58F6452<SI#?8I"M_7SH8W MD'U4E_Q6J:02V_39U )S822(8OZUSCK]8OC]!_ 6:KD-<P(;]GWWP"<BX.!L M8_T+OAN7R,AK;O@Q.W%#E=W4]@*!<N-81F8F[HV;S]DET)",#-/@U7K/4)GU MBCI-?XSC<6 5PGG7A_;> @6?A?;-3)JL-WM'%:ICS%T@!LGF]3C=\-T;;F.= MHLLZ9 V\K3%VVL4X^8URMSIK:I9'P85K<;<&<P)6,!HD%SZI? '/\,.U3+0< MS^%^O<DM_H5Y-:3_FL=A\5T\)TY(/B4.A1./4*R0&/E(._5=92+0](M+ECPF M$V$XM6FR=7/\P65ICOL-2_N0WH5Y"7/YK-:E>1FU-X89CY[6IB]9SJXD*U92 MQ(ULDF8BR1TMYC[7IV<9))4JDCEM=$@WIIGZ3H7,"IVP(@*7"8#%/E3,WM33 M6!F*'V2_K=\^*1!D"E4T7!)C6[1H.8:[?+X!MO1/E[9B$ ^5Z-\:T?2&84A^ M^)(/9&9;*\O*]2UTM;*PHH+DEE X00PE.-Y%DE;*X<""C,M*CP[[*^2/H?X$ M@0S/BB$TOBRPAMR<UQUWNS>RCJR[?Z02TI2QQP2A&[)*U$_IDAEW7?S>U4M- M9W6[$VEU<%AT%/>!E\$WQ;+9L2E]XEXDN_V.()<&O2197T4'/'347 J+6<L4 MP2-OY[$QHV&%BULF'NV.MF$ST*RG!)8J<SR\]M+P6,I^G\G9N5!ANCZE\XR% MA79^;[WWU:98%JJU^%"YK7''PX(M&QF,>E;VV&)7G$_9.7P], ?M=-+(;4!U M=?%B"+FDC@ O6U66[N 7V;5/3%K](-CHAQ!:_$6P2;HM[<;Q=DY4[IQ^,F / M;[=6:O] X#6?M^ACS>)/,UR0>BJR>FLI$6DT4S!>1_^^OHEBK3D@OW="H24! MI>TL UR:A0<"*\*$RWB*<5;6,;R$73!-?%K+5"&<+#C W>57>T=%Z!^0TS2J MF4FD\QY<'BHJGN5_%KGEDU%!-K6!8+)P+@$[VUW>);M\HBW(OK4H9:F'=0RK MH%U+=BY\%7\E*NFRW[;K0;,B/,E3;\DK$<J(HZ7+\(31ORM=KT?TKD6:5WJ] M$D]=3X_2)_E8_2<!3Q8[7)Y('EBW#&BP3?*^] OTB%)D*YKI<2Z<UG#[%/IC MN*3NJOTZ5X.B?Y&/+2/DYOYW)9/!@13I!$N8%"E6Y ^W<FR])MO?=A%_-<%I M'$?'/AV^MBB9?6>=+&Y/Y?1P:/$U$0#*<N/[PFLW<A_4.UA&A*IMAH2 JQI( MCE3$[;@N:S5RZ5U<Q1Y7YODN/%_3,1BS>3R(LAM;EJZO#JBAU)CB.3M:"Y7- M@+T#U7R;\6$;_<WIREJC>PRQ#UB_LY, ?-^5H]HOT]5?$NNPYMW\/O&GVR*X M]L\'FTL+S@?7PQ(T0 5"7]*W.N7]WE\TS0)]V/C>=7P+]:$ZFLD_/HO.Y<HB M",+U%"SRPDW1FAT]S3->]?PGUVO@NVHG1S9=R.R29D?SFRN(MZ5+EA&*&7[. M!1>,^O3A<T]&,&)+2C6/RE 9#"]D7SEFVF7"8%GJOJ^V;.@R3-]KO-$WD390 MSJ[,NN^5+?]YWD7$KA=&G]-6%?6D]MODQ9,[/S)YM5?6>31)7FF%")"%7)Q9 MJ,O+NEJM\^ORXYO:^S(T<>@^J2<J;]IK\#^_N[7(%<[5M63I7$R!M4<G?]_V MH=HO']4'0931^AG&36..QL_;-/>]%F]W\ 3?3E=??.VK2WF\KO\#K2/U9F<X M.E^GD2K:L5SE,^!91#*G(GW3;2,H'85<A4M8FC%HX]'))A' WP*%\>H=H%KE M^)T5/_8ZA\Y'H_=.358G(Y1Y(1YGMPO'[.K! ] ,<:84BCZE.)9"'ZB8%-JY M?B:X!>[HG^7[ZE$X.;?W1*@L/VF&B_Y[8,'P0]S*G(GX^LC9L*B><F!\&R6> M$A&.6L/D)UU@DHFX\<D7B$,?\A^4)RS\Z;"=F8CPS1&I6QECJ?6+^21!]EI3 MT3BB;@\ ITY:0"<B1(:-WF7)7$2]YZOFRNX!O 67!#LFZ\_4V]^6EG\QG>87 M." #E8>$C _%A8'([<86#>HQ,64[3>W)3;<+SY9"GT()RXC2%F\4M2A<\[UN M#"<J+\O)D.XN\.($&3B!J8A69%Z^PK45+/TKNWYT2.?>$/.=G&M,:D@E3U7N M]O<PQXJP!>&ZH#+!;L[@38U>.<62B+B4I:4W!T?]4ALA%#@[U&)XH'V31[CD M!\D@ZI?@B.NAB6N//%->Z'EWE)MV*BM@4J>WT9BV3%=4>]IGN_V'(<_GC#]E M'GW7#6P%0@+^3UYT/OM'EEG@U&[)%I\"BVT_YJ@A 5GU"D^[21 D</+]OYVB MVO4ANZ][\_NKSAT^.;<521>OA3H;$,U&RA_F$9YWQ4/BP['7K&H")UK9C[-I MIFNME3>2"ZKJDVY*GWPLZCS.;_BY(XI.D'-;2K;GLN<UX^!-SE4''*3?V[-* MLOKM7'W@:GC"O\*#?> DS>NE<\QE$B][_[G5U^.R1X^ '-ZHEY<27WYN.GDO M?%'HP-@.5:;44EGOU\FOH1XU2":-,*RO=\JF<<*+YVM*WBN @T')PT%\Y,XE M(OD6[O$3$[3(;L*JUZ*1Q54#"M#VT/V?,M/+!WQ$X.EP:-+I$^54E[ZU.H27 MWMKYU-GB0LFX 07EJ)N VX@'.70VP\?E@>=$"L_-[[0+NODMYG(G+PS36\,V M=%39L3A3S4C,O&;![(W.K6MO'95K2[(W"';#PCO#WW9$?]*<FK3> !Q@+V9N MQ;&:%/\D B6\C_"Y,P6L55]03^YJG_CUWJ4OL\[/ILG_48M#<@;GO/!G9135 MWG5>G*H7\N7IKT)8)K%K0Y,7<J?^5N2<L%/P[I?M9UD-[-OA0[F!C-HK&QKJ MS5U7&1IE?KR!%^P*/7JZ;CZ3:?DL4%&99XPO79M_K,SP<Y0$>U**8&.1W8]M MNWG">U<R.2+PI&X52QA3OA)?1R9:^))^FN\ F1;,MD?U!3_O4M:^8[1D.32P M,VDZEKJ-R5O-:_MP@:ORI"GR]VF*4)FT3H)F.<_-X2H[L,<:X^O'.F-UXCY1 M%$UG^E,Y,I#.C$'KE4!''J$1KN-XC-&<Y0.ZNH(YCO$JCQWV5Y\XUM>.2^=U MCK,Q^?#I"KY?AVFNUO@TS>-H&V=H: -7ZT8IW8T]2E'[P-,-DY@[PQ,I:ZHA MIOOA*$-=U/F])6;1S^!K@GZ<%/W*K4)#>>=%+<R\)KI/>J^KM >Q$0&6)V8A M8S8T#:.NNRN_#J=HARF-HQ?5DZ\=JDC)A'VKJ.Q.X\UKDHJVOUN-F*/;67BT M+JF;-VVE@1T"DW?-M7AP?M1WP9+65H'QC8T1S4,<W^O-B>QM>FL)IR*/F=_2 MA3G'491GB=E/^(Q'Y(N_._-1_T N=[90VY8?0=!0M@],-.MLN_OCX6#VV_M1 M^V>7(Y5N#LX#.EK7]4J_W%A)Q^[H'.=C?!18%TW'5&<$#FR.K]/[&\CX%@^= MF4'TD-JZ&D%;<KE)-:7@(+9/16MN!AI[>BY$H 9K,DIS-5'I(P2F^Y3Z^,H3 M5:'P,$]\ZU8\5KJE23F?(OTWXX+9;'5O<?W)Y>BG3)E^WR&');RTN*HOD$TE M=1]PO]A*U1GAZ0;?;WUU 72=_0#68G=A?U#.1R<J*?ZUKDB+L&+KR+M-!?]R MSOADP2%#\R3]KY#]7O:=BMZWVP6[.@^:IO:X*(U35W_KZN3A1GM1=3J_)37J MPB?(A 9X&IFU3LYR5PNF\>9LZ<FK;]MXQZ]EC:_4:"9-A_-U$H%00FT,UN4* MQ%5KU)UC=^"A,7>P9>P=U3?=;4J56(JD/2)P*?.XR_)!@("$Y:WY4(C=W#'> MJ0:["R\U&QS]S=29]]8 ,^!ZCR/NP49D8P7TL0?]G,;!5%%="M-FQ'#46T'N MH%^7E.\^"#A^&O6@F?)TVGW4-.J/BW:'!A%P"94HP$44.A\C4NF7!C(KDNS" M^&CVP\EID<\S0U@6<>Y_]"=2MKL+^IQ^/'Y^ Z5^P$Z7"TJVU\8R+4C.TJ7Y MC 7TSOOW=?1QG#Z5;X\1/;0,6I?>D*Q_SE.6$_<G\0W^$>R1IY[E-06PM?1$ M#X>;&]\;SQNO;UFM5SQR3??-I4\?I6; YT!S?IR#HZ*6JP=>50[EVEJDOMGA M^BSO@]XR[,.*@ILA>]E5"4*W!>ZPVO.EA0.&&_ -(Y_:0+(9W5PSW6O^U77Q MXVY,DG>^T>^.K?[<+G>;X!!V6Q!X-L1=60)HWJ=R61Y;'KZ@@RL8%>/+FM M MO<S$'?]Q,"BRP@Z;/HV.UB]8$.EV))A_I,_. 6-*HO=2M:M/+L]8KM(93MPX MT97<D'[Y*^O[A:W!_I_E2R%UW8M0S8:8YXVU=2.E57EM5A^@':6/BDYWRW39 M>MAFDL>I16I!CLGS]O'^JZK<OBRJ[H7O?7XU!257U<E$^TN.7)KSGDP/;GM3 M<+_92 \QW= PK).9.%"NTKN@- Y5*5$KG-[8GQ/(L=R)S'M[H])TOZA%$RNM M0F\M8+11T^CW4EOZ\WL>>K26IMW--+#HR,2/QNC=./&*P>#BLO5PGY)5\;F- M^H3>/K_)=_HC1SM6Y>^QJIL7+KG71GUUSTO[PJZ?A/)WY_WU!(V^4992*!+E ME%Z8_N)>&JM84B5YF"I/747X83.'!!W<C8OQ(.0W4["<E&2Z,ERJ\;6.@M\; MN?UH%U651ZC99;P;30(1>.YB:?PPXM.)TCWEEHG%UW@G1?-@OZK9 3<:IU(F M7Z%K+[3D\$ V;1%4Q4[FTXU:Q,M/MSZYLK\J%(K?=M$ZM+R%J#7QP]1$*_<G MN;/DZ*ARO,+!]!#Q"T)7S-)P+RIOB>CPQCR_&F)A;IGW+-6LI0X59]+C;!@V M>97L4Q-E>O&%C>-LLK"S9!),W[84$^X5N68V,*11=8M^&ZP1"12X7INM[61+ MC7;;GV0__,KUH/*.^$N7G*?O:"^CJ2I0%CZ?>)/(TGCCG&D*M$K+?J;YU90^ MXGA?X#GZ63K&48)_ .PAVOF6]G*F2?(-P( P5.OTV-;^S9!'2YO%#KYHH&"F M[V/]SXO\[&:3;M9?0B7L?PH+..F86;0G>67D6/$=V<A*77>>V-S=\J#QT@IQ MV$_U/G<YNDJF73MKDB -=M*.7I5@'X0;&I?A%?+-YW4\Z3+ 5ZL3;-28PNTV MP1;100:47D[U=RL]JBU9U]<8OBJ>C:4^KH^6SR^](W!B;7(#B+NO\ M/_^C6 MA;>!2M&4%.'?+Z6 &JMO<"EG)>=HZZB"LF#_U]7-0(__/69)1L'^_:EZ_O_N M(,+_JIFF*PWK>5H%_^F,N["9:LHFD\4\ZN[NS@4='7#-_]RJO0M&W*%E+XY> MIW\WNR;Q%A:V0.8*Z^')E7%W8\T@(6"9#BXM(O!6[&'G%B$<CK+>_:GQ<\-" M6!VV#@NZV;^4NN08RO*'GM(II\G>O.+O,:B_(\)((R0>]F\0PC-#DA=V>)/< M>),(598GBPO=R=P@_*W%]],#&/=H_=8OI'CBLD('-ZR'XPN^5>4G<]QH\\B7 M1*?<+9;VS^?;<B\"E!LQ<5V<OLOG<1WR-[XQWA]K/V6X\8F;PHJN;F0!0G_? MEIX(.%OBA4<M5D6A[95U!1QH;H^-7A6+/^$?' L?Q.]HK^Q:\7K=U0O(61:R M7(8%T9EE,7LLJ= /?'6+0VDD\ .@6J['E/T#,^)]BL975&A^UV@'"Y.,NN20 MEEL>KWD"4OC<2Y-WL2R8AG]&>T E1BS%,GHEZ.?.YLP<<N_*C2JT7RIK%ED: M5_<">91^^ E9EHZ.R9/M8O.K.[P%M<AO8HS(PKSZ-I;/Y?.FJ_$"EZG/IOMW MPDXFOPHKJ))GKSC6"<9'V[V6-V%RU]L?=[RX(#EIXLP7U9T0?]6M[7ZI#@,5 M>6S@A-+B-S&6J9&7#)B'DT.*3O8)DD*KXJYW%?VX)TN$75OUG*%52/:+*V<_ MJ*B7D>PN%H_3O9U/K[AXZGE*?$@;Y/TTDQV/FW#KBVTQ=#R^JWASM';0K).3 M6_!7E4T*WY5HSUB(;+[9,88:?_J#*A'7O0S&J73)G.X6 :-EJ(3K+#]34V3= M50?6(Y=SSJM:^+VEFF[,9PC'4P5PR@'ZQJM!G*<WP>H-UM77^^'SOC0J%A$^ M0>*9T[-$8#&9M+L[N:;TND&'Y>=:-<K>MK,Z734NJ?%II>]:FV)J9!/7D0;* MMBYEQ2$S6<PU9OF1I]1C"M%@5QQ2KZ$B'U8MW&QN248$K$SQMPC]U>ASNCG8 M[ T2T8W3!6H/-2*P9(NY,'S2102.QS%N,17IB;,I3'DOQ&YJ"HAS*(K83K2# MD61]CNX_%LTWF;2^:,8->:]&9V+8%)^%^!Y2':M_.JOW6R("DRPDDB]^UY>, MCL[Q9K0D(_=+%P0OS?\BQ6-AL [.QF&\!+;W,U:ERR3P.(M)1V[HXJUWJC.> MT7>_"U6?R;O-UMT_?9%&F_GJJT%DJ,^E',V5.[U"PW[>[N+51XT/0\QVR?"W M:V9Z?-G-[;0!.;(D7I? VV$V"J]RDVWD7\GF2V_5 L4 >C<R*R&4;U])]?E& MF)Z6L5FE^I/ C]D.>3TB_[?T_&_[KRCIGR_S<O_]T"<0Y-B]%TE@Q/ECV]'V MO#>Q%"D12A-EC@+B"W+W-T6>,LFNPQ\='IT7MK$D4Q&81T@\N*!R^DLLEF1] M^+V)@'4N$?CIVZOYAVHT5)X(X)R1[V"'RD[M.$92;)]+X/1&V9[3IXL1+L*. M2N*_A,KO_7>/_^[Q_ZG'V)DN]([*P;]ZY-O.>/S7'GDNP!810!4JDY3XQ\D7 MDDW0) (6<?\SV7(U9V<SNN:_Q$W_-;2H'3-F>[G]-_0G#,-/!,JL/E\-W6K_ M2PCV?TQ'(]+I/\C\CQ5\)0+AF3A3(O!@+8ID+T#G+BM.!5361(!6#E-!>/]/ M!1J'=>M!A8A SH$Z$>B((]1Y21K\=Z?_?W0B>?N</1+<:B<"I,TK&B?;U\>S M@)?]WRK?A@IB7L:]PZL[ELU;@G45J\Q2/N:%/"A'A_4)&-J^-/M#!#R=LNF) MT_\;4$L#!!0 ( '"L?5=+%MHKGAT *XH - :6UA9V5?,#$Q+FIP M9^UW>SB4:_OV8SLVV>^WLXK2AI1L*INI+"1)M%$J4U%(DB23QDQ226&2I.QF M%9*$A!#-D&W93/:,PAA"#,\8FX?9_1ZM];YOUOI][_>^[S_?=WS?[S;''(=C MGN>Z[_.\SNN\KIO?S1\ 9/?8VML" @(" ;^ _B]@#4@)"BX](&7,/P1$1,1 M$186D4 @1,562*Q8(2DA*2DE+2\K)2TG+2DIJRPKIZ"HI*2T0D9%55E155Y1 M27$IB( 0_(ZPB+B(B+BBE*24XK^]^!6 G!BP7A E)+ *$)03$)(3X%<#2 0 M$!'XL8 _EH @?$91A)BXA"3\0)$L("@@)"0H++1T:OC74/AW0%A.1'[EYIVB M"LZG$*L"%(W"8I^*Z>S*KU1R:0%UMYR^=$-<0EE%54U]]1J]M>O6&YN8FFW= MMMWZ5QM;N]WV>PX</'38]<A1-P_/,V>]O'W.!5X.NA*,N1H2?O/6[8@[D7<? MQ#V,?Y3P^$GBL[3TC.>9+[)>OBDH+'I;7%+Z[D-5=4UM7?W'3ZUM[1V=7=T] M5-H@?6CXV\CHV'?F-&MF=FX>6EA<PB4 " G\;?VWN.1@7(+"PD+"B"5< H+! M2P_("8NLW"PJO],9<2I 8951F)CBKMBG^97B.EM<0*73EUHDE'6-::N92]!^ M(/O7@-WXCY#]'=@_<%&!%4("</*$Y 4L.A/)]891E+-ZAQ0 $:BS;'DZGF; MOMZ*8%S0 9Z\$S7G8J8U.&!9O+G)/C<<R5%$V/2VL45(Z+J,4.0@1=:1=D*4 MY4)P)'74%)X]_*:-SMJX>@A,&]U0G^E$9:/[WE,^,Q\W6J&M)6T?R2<_S,HR M6YU#2207\X%S)9"Z7@3 !W)O$Z#=Y'.414',13[0:^W8Q@<&,E'B)@Y&G<[C M;>BZ%QL?+A[)K_G4S+&;3JT)0[\PF56)"'IB\EZ[F9ESP9@=^4R^Z-:8N+': M]S?2I<C.=]I:_= ;BZ!JN4=Y"(=)JU-H.5P'?D8('.%RC,WND,^1J,@(!+?0 M9/;Q.[0^F;K*LZ[/597RV[8\(XC+ML9<F[L$7L*DU<B>4U%W?G+2:"S_:JV1 M[<XS%&M*4UN&839Y@?T+KX_ %71ADP=2-Y%6<;.W-$?2JOB GY0Y3QY%S>9= M=]?D ^1H=PHX/G?C,VXUILSE<R'#W"W?UWSW%*[_A9MJSD:=^^NT#Z;38C0O M6LIDA+CT[ZQ7D:-G:5^*(^XK##W!!R@]B+D9_*A\PE<^(+RP/+ =1Q=?Y,H% MRK?Q ;PZJ8!]>6^-3>.O<QM6/4"M:-6H8=T0I_?M:TT]S9W:&Y3V?8J'JT<5 MI_&!'0])4Y#>1S(8R^M SP@N,7+N(E.%<:S7&IQ$C3_-2[/085I7X6611YVD M?3=])Z3U?<Q$Z^_=LH))3)&^=G>,2I^_-B^"9&@"*'6K7#XP,A'F!1ZCK<,/ MH$"G.!1M)3>;/(J@];,A'XUJ=-')\:=0,(^G/F,8A7YK&&8ESMD#]H=Q;$R? MKBD8E-&G:NP6^O!T:'.6%X+P^)+EAB\V%81?FI_;#HF>%+#J:__!0B=J]@9R M1MR!#PA8P5\W"7,O^<!O*A&H*;J+V1U81N7X>IDJXCS8U6G+V]IB7W(/\SWU M=!3O["/?Z!SYA3!LH\>(.^[)..0\&\P'4)Z&C%$^\'FU81E/?'H_#-T59@4E MC>^O<EH>W-6+&3[W#3H&VO@W%V=_<?^8^9W8W75_;+_:4&')YB>"]997PBG[ M.A@\+:9E9J3%EDS?*V_DO$(%C]M\DY7N5 -875HO%LOX /&-S$\[3BU+'*Q[ M&$#>H@ FD,<S"?68@TH/OXM&A]T84*+LC6HC?54;8<BEA >>JJP8&[?KZ.=P M[^/][7AAZT+[?["MPWU)'A6A4=A0._Z#'?L0_K,DS 0S>QQ5;-U\P4.']\X0 ME6.ED?X8^R#[_I5AU4V(S_3W2%<\:VXG]SUR43AC'E]I9;\<MS,?$$<R#L&L M&,*LU.9=@3*897N@0R\QEZJ<VTQ2;/U"AJ@?+F<?V%Y9KS&L,VG8U-6]Z(HI MMO\@^7AH*T]%K2[GSSLX_O,=7CTK92G;'KV9$?+RM0>AJK,T&WW72K.<V?ET MH+XH.W#0S[3/O"S'_*+K[G3VS;B%EK_DD97PSUCU+KX_7TK@\0RA5LO65ZG[ MGZCO[+"HC)\4U_+^/3_(G\ILRS\K,P+H5",CA;4M(KT#)XO]7UB?"3:(_G@8 ML#/V*^I"I$I=CG77KWGKJ, 8?EN",LS3^EN)A+-#4+"")_G #>R3Y>#3_?_A M32:S27UZ#S488J5;$8UH/N"<ZU^-5"S?0L,K8 *KJ&^+_;U>8<+23QA1;=5* MIRLV*L9LK>>,_D5CK!#HWEPV3#82)IN6N5P8*R^]>M4XN.GFI!]=J$TO8X.[ M;9G#\553R'4L%:*+9<"_H#%XF]_+K1"JFKL)$L,]F99Q_4TOQU.U"F,6^8!= M:QRE3&YWQ895>!6M'6,GT->Q_@B"A4XZ=*-3,ELU:+=(^^'BT5,I!V.$="ZM M_>OI_3FZJ*)@+L QASF70H+W>1W],#]32_Q@S2HC#R5N.S)=$K1MKN*5DS:& MVEMA)=5IX1 DU3'\/.'\O'QO=ZUGJHW[E6=XA6N_5_Q1]+@4:E$8=K_K1),E M^R]G/84"4;.?6Y=1,R8309;3YZV"4'N94J]4W/QRGZ5Z7J$FBFW44=/Y9EUO MX6H3</'0OC-'>C.G-+PYW-^YBD7U,F&J]Z A&8["4/]2'RMH^Q4<X -OE[H: M:JFK0?ZP WXG>SOUMM&*)]KHOOZ24/EWQHL31S-FG#Q\OM6>/GM&]53[L+1O M)K2%?12C0$^H,O"OHVI][4B(,+[J>7<Z=)>"6M0JT;-USZ50/[4?/E"!'TB% M35)<AG$$]4W\]Q:$_-G<%_T_D(Q;L3Z_=?LF;LP4F8S#2U#\@Q3ONASIOM@0 M%PMU?NBK;;UU[,X][?!&1%C[;,;OQ87L;?F!*A@&1?E13N1% 0@N)_7@9>D) M/5D<D(RB'FBPM J(8FNR'#3'3=56R^?]\L;4#KGGCP81(*P,P02)3WMQ=)$_ MIS86UQ&>&T%KY -=UF@;[%[H23IV':A-IDN=\PK5LWGKVU#T5F/XH+O5(41R MXC><(*X%I\I]5JYG> >[,4BLL'MH^O'WP]\$Z_)W8581EGA92?HEG \\7MJ, MCO^9AI]EW#'[,,&Z(=@^OGV%<E\)Y4*(3.U#]]JG#E]^+;M]<"$\<W;$\@]9 MJORKQE#\($"ZTR?^8,S1&$17:]JQ^B':1MEM$UI'1KK/$I;/"\0U2#G>WZ<1 MRI)@_D;M8H([4XEXN]#/X6![D-CY5Y=[@TO+2X*%;>37G;UD?E)Z%OTAU;2% M$T#[:NC^N<@\U&Y/^[-C]QSN#*DFFHZZ]OUY(R,^\).^LR+@=NS%%<!N^Y&W M SG0C3KKUMQ9C:^V&L?,CR3ZI,?6ZMBHZ0Z,9+B A&ACO!8FV*FKT'*?E)U] M^^FC#+WHNN;T(*%M'RW_VM582([NC^ 66_&,IYF&=W[2RVR>*JZ5)PVF1@QN M@#::R,@Z_'9NLT](_*.(\Q<NY&0&)*NRP_K;5KW7V]5UX&CKY?$AEL&C:;%) ME[Z!F_'6+\[8'J@_KVWWPICW%R,MZ5O%?<GV3M5$SGUN-83+NI'U[/?Y$?TK MQQU*R>1H0:'9F*HCQ>_+6F=*../QKPF-\3KU(OD,9^Q*J.PWCB=T[1FF;5?B M[IGHTZ:)7]P'MUV)\-QVG/DI$?VG!A;ZOVE@34/GC39Z6*<FM7\CO%T;^U3A M%^Q%BXI] :EV[G]UN*4R^$D\2PWAIRD$;0]-#;I&X#0P+O/5)-W.G)FOZFW^ M24$Z-[)*;^19QWU4(OOBI;BOS)19^BU[PCIM_!]FJ37]N>/NUX;US@?@20P6 MO/>?!IM.AU - 5ZLM#GC?L!B:U+WP^M>A-0K3Q0#NEO^5]7_MV:ZW%NZ&!+I MV4WJ'WO,9#ZD/9C5<4H<-#G#KBZ1R/R<S/Q+*R'_W$JB!YVH60='=H)TF5U# M79V=\X)G5YYQG3LL3,C9-_0R%;_=2;HOM27:"]PWA=C33UM*^"V].ZAS9'U\ M=425]_O7=<CXR\0"F5J4.G8WTS6:8TY/NJ9J:+PF<K.WU8FF3E+<D3MG+<65 MIC,G2 B.L5>=V..+_B?I/$''7\<^I:Y*20^N4G$P;LC?=\3MXN56W_ACC%5O M7^_%@_NE-B F1PVBN+YC3FKC:) >1PJ=]#@.CZ+_-3C\UKM@N;]@W[NG,2% M[&,HYFN#3<&\2E0SJ<0[_HV8QB7[XP%NM*$I5XY="I'=(-;/68R$V#1R]X:: M^V,\88B0"3E5;\=',<K=/N:,!K^^[MZ3::@T=')&XM73]YNNM?>#S?V%[[NJ MT9%=^^OH#89*Q^U#%G'9REGJ/F97,OA AS(V_ZR+Z:VZ/=SKT_-^YO5"%M=: M0U/<#*)ZV9PO+/=[<:73$;3CJ (GAAM9>N1-4F6?4>K72:7!Z_V?"CY436V] M%]Q4II.7J=0(Y<T=X[[D.&=6^@_*(* JY]?%Q7*K^CZY;?5PV:TOZ1&5ZHCC M36@^N!0:NCXFRT,Z)_-+M[L>T2=0P=K8KZ4E[/"!6>&[KB=Q"E ;#5U-N8-7 M+0^DD6]=^DXMRKL]4/C 4<>AO>>N[>EH53O6J3N7,%I&OL4M*(]^JLQ^;BKG MZ-6@=$PNI3;D2JF724IRL3SW^6++,\^@.Z*5U#WY>JWDHR1%'H4L0Y*PQ_'$ MP*;,B.%V,3.7WJ'RQ\T"^O8U(=N*#YM'GE\<B;7I1D:C"_4F,IE5.PD5A]T! ML#^JR+PL5%YM-MJ=.NG8YE[:H+-Q8ATA4\NWP8-+Q)]'0KOC3L#]EUET*(FB M(F5^D5?R]2YW6)GFJ:\:$UB+Z&)EE<QRO<O40"^. F* '$E2@^QJS+2MP-MY M3S&#(RY7:WBO,LWDW@&X\P/)X7%3[BE\0$041%<C[R %D Z0GQ:C]K6)V-EW M!6W/IW/UWJKUO0@-C(F?5; K@YHMM_.,26XCU'NO42NLMN(:D(H6/H-:B(.@ M827R3J+FX2N^2@V^P;<7:9,[]1IM#1ZZ)X>PCN$TN$GD<R=<W<$D3+\3=&L- M4=/]4)SW?'U!]Z;S64E75[KJQB4_0!3A>@I/E>CIY%FT# N*Z7<WVTIOKMNS ML8*CP%29(+-='7//7>A380YWL](%_0O-54XTU:]\W3->XW\<UTQ^:YLE<U.9 MY<2\)[EEV.=3<729T_J!B 3B0\_PN#%T:;;L?M%O6^<SIEU+46$U*J=1XN7V M;&U.8$<Y(L?M'%$*:Y>#H;*J?:]N?.'!4KX6()EMRN%4U[OFN+7@S_(!:JZ_ M>/=82&XX?92CX9&5%:K]";\1]-];&"MX\: 84< NI2TXTQ5\9/8\!)I'VS\ MR#?+S9WW\HGQG7R@P"FJW)Y)J9C#Z8 CU<7@'F_!WL.D8PD*)F!T%.Y\["9A MH2)[YQIL&E.!1F;H@$0[YAKRBU&2$8B_F7&IP*1FB*#IO"7E3N,QO52S(!/V MXMM/Y1MDC:2WW+>,R A$R5II0=<&(VY?X&P;S#$U\/VU=/V9 J*Y:E;]V!2L MKCLAP97H.X?Q!<616/_!:/0)L/FY=BV]BDQ53[YKXGLU2?K^"__'G$^!4^@\ MY!M4Y0)/G",)\FZ]Z#O^?7O[9X/.C*"@S7&A5=>/[IQ0Q)+8@6[O(B;JP#J7 M5JQ>ICNTIW.Q[D/C,;L;PXDV11\I:A8Q",3S#1U^@W(?7DHK820 0&:O\Q4= MUC&>A"-(H,L02&88%U;%=L.[1?Y2-AEUTK_U:3W.XQ3Y501<,4CL]/' )U M!J?"+:XR]0XP[<*QQTE(V/S/37<YH.6^ZR?H3Z_L$5R?DCLA*KE68]^7H+QV MRLI=C,/KRT&I5;W/1CXG\ZP*3T1Q"F"[#<2NAE@@'YB[74)B=D64'W@*[:([ MI;A9NM@] H;#HB\U7M4F=<C4H*Z390UA+;>&?.F7P1YZY9AG>Q)\GO<\>Y.] MT#H756T5H=$-LP=M%<&+5L2<577%_HV[W1^>"(-Z!OE ]\C@0Y0,3]'7;<TM MIH1##V,HO-;MO'IX]"[S^#BNIW.9DGBQN9-U32!>#N753\4A[VQVASRJD+*" M/3M5P_>7MJ^8_J*T7VCWP8EZS9,2W"+V=C\=@WJA\)C4U(?<ZR<O;%ULN:(# MDF 0:(A[!J3L>-."TX:H#37Y_5^_G"N^J.)D>>)-Q,4+3L<[_$5YS>BW&XEK MLOR>^[AO:1$9CLMI3%!QU S\C2?H$,JBDH.HOS0]^!(D.35N]\!,]$NP4->B M\Q4$;?X>'SB+IIJ42]*8\+5B$(?M/,9 [2<?O>*4;VVO;FLM1E'5O^9JPS;C M-:.TUD!<\#MKD!R&/96%,;>.'Q2$C"//O\IAA4XF)>F1E=@VA2&L\=VNJ%J[ M;<\FO#[Q 7 _08!CS2R>Z+*Z![YV)^4H34@9I":M<[B79"QL[&VG]VUM *\) MYX@ATR@,M:?CJ7*@;2GJ+K[89.OJ!#MPOC?YJXAF<N[D=EP\5R3C7:UTG_BV MP7(^4(<4X$@RA6K547>+&*+P0"X[.J0AM:/^HP%) [4.T0E;E*:%(7L3!]>* M5:";E4'!]+/,]WR@1SKE92VR\: K][MQ4D'T^VB;-%XS?-NQS1Z4LCHRDZ=Q MY"NUPH!63GKG38_9M$E1JR^>_2*[+*NN""6D2AF':RJ*^,:L@D+UK^ #A0EA M0?YR4'"M<JHVP47(.7':UAO[2'?;Q49;F9Q0[@]G)425^[*WC*L[73<(,G"H MIH2> ZW32Q4F7!MD=VIZY(2:#<?83B6\UGHAM_[%H06[8D58P&)\X/9I;L[I MU&U='U*W*XBNR-6+&ZK32>DK6E1C>T&(P808LB<RXIU=Q(Q4H!MS,".IW^3F M1(+RM-B.>**/VD<Z(B.TIS P/'S<?CAW\,L%WGS(QFH\BCH_$<'>AWGK9W7" MES9R=]9>_YGI7)L[MDGSJ.XZW1'@ 5Y],7M@J@)U]QU\&Z0,UE4U$ 1]%_VC M_8N4WA46;9ZX5O+DV0K%\'HJ(;;?9#'_]05=^!7/V/D5=N=@H_:&PMC&O@<P M90.&MSAFV=])DIU8IU-S6H%5<6B++3T.0+]QF9GLRWIQY\^Q4^[KP 1: D. MJ7&\TZG*ERQ_[NVB8U-'U+L;_4;5&=980MQ\RDX@6-=U4HE<*2-\E+.O# I7 MB3!PBIJD3>MV)"O'G=VT@R*D$V/N#.8-&(:1I)JR'0:^2AGKO+3_]C7=J-1> M0W>2:@^PJ/?RCR(?N!(+$'6K(0=_12MMJ!0>6643!#_FT4RS PHG$[RY U$Q M"$O?&?,Y%(2G4T1Y=>"H.B-J$1GC65SVP.1=N<^(O'V<YH,M"OF1E;V?7=OX M@-?^X M^"Q_/SRZVFI3XEP^QZBM&VM4WUN+D^G"?\$5%O/C!,O,<R9HXZHGM M.8S">?UQ?*3,5Y'7X\2D+^ILE>.0&5,*/_ DT>E&N0D-)>=C95E06GRUL*3R M[L2;3S4]%W%CVK.+IAY2G%\%VA"*_:NM/36#4"DJ\,SB@RSP9]P@*73-0)=1 M:M0Q(^,#)[HM>U\EV"5?/?GV2 R]+WL<[CLR#,S*5GGZ+F;&3$!/V(77[F5) MWO,*PZ8:MYLQ5D7L6H7D1VOB&C0*2DE/GDW8C8B6#B"I7F[<L &P:3)EQ2(? MN)^?M(:]HPN3L-Y(X^P5PB?2IE;8*ORI_7L[#0R-^< *S/?.R3Z;1^O22\[K M>)[D3KA.X1^ARD,\<C1$ Y.940HU\&G7?,$UH@IST^ )&+GS%7R'D#/$.E\V M_6(OG:;6%B36DZ#CBVU%SE_<^M+=%)YOO,TUID105?T1VMO _CFK:!^IQON. MO[B^W^'P+G?B%T:=$AN;OWY>UT,SN75B8;=!\BQL,K3<#/9:WN?$;QF#:]K* M9>CCT:;'1/U(NNWE68W="W/G5YXQ+R@RCRE"Q9"]4(0K;WGB3A']4O# MW Y M5+M3<N%TXHZ"_K4-]5EE$HA]6TW8U]^.OA>O.[DOH-EG(NS=[(1WF1SD3BXP M9$BJ5#%VID'7Z-[EUZX.ZI67=.CHDT*S(C&G->*^"0:ZC[.U..NAK&><$ZVS MZ'MH*9+.N7<-WR\V^>1]S"H\?%CNF=+7 +FM 8PQ=/8UV\VIVT_'-8B$Z6WE M [!5ZE\U9-C3WA^H1150JK44?BU(<.XTG,E:55A8+) >'[-)\5K74$(5N<=\ M[OIGG#)4CH9T:L ^[@.-$Q*?U)(MC J34JI/E3@^+9T]A2[YMK)T]U:=6>V' MJJSF.42Q,=RN6$RA.4LHZ?DX4;K(:<4H63X=9/!B9>9J<HDOB,4]YS;<'W[D MLFL-(S.U)]>\NK^@G[$-47,O>QPIR;&]MUMFSC[78%;!LAHT\HN/;_#[\FG? M5JH4KE=__4O10+L'91=Q_L?GGTW(?'!T@F]Q3TW>RZ CL0)TAZ^K_=/8%B%- M8V9^@LD#E2D/+G_?KL[= V6"(^AWW)@B@A1'OVV28YEWW&=]9^+EQE,ET=U" M^GXEX)"GP#C:_BK>E#%R9;/=PQ) ,S 1KJVUF(8!PYI>RBV>5IO%!M!_\%$L M'1-KFY?C[FOD(-+@,;*Y6D-"T@O,0[63O?!4UF&,;AE83$A_H-JY-G_#@ CM MDAFNB$U[[2>$BJW9V#).R8$E:H91&?!G"/D-.B21[[J+0I%T*=MQIQ@MY2F; MSJ;"$,^*^U*5S:;AA8PYJR*SJJD>"CTTXB9O3=[=<A1S%:NZR[2@4E+RUC7) MLKA?IL]&[^SKKDH.+Q158LL-$3:1Z \V74V;&"LT/-66FDIOO9>/7,VK0 &4 M*F+$8O =SDZOP9PM@R(=:6Z^RGTKW\>VO\;>WMT=7VLZ0 A9['BXJ?*IQZ'S MX;V<Q(":O:EAIRW3OIE,XR<^X.FZI*W%^+?6G.QQPRG7C["Y<9+Q=?I\@#*! M^E0R;K/]\_G%5WG<*BT>W$K&=M-Q1MB=;Z #[+,^O-4=.89ZKT_(UGH6A:4+ M1(Y5Y.U$0VOMJCKW.\84;N$#^XSP3).9PT\SJ5_WY9D4;K&J,+-7]5ALX49G M+J"8=+\V'B8/.BR?N=VGA!+</=.G)QY5U8*YJ]EZUYF\Q2WDR,(7?.4NG+;, MPJ5.,BCJQ%M#@#"N592%:?A?02<P[]EO+9=9JDVWLN"FNX&GI#>W!KZ!6"F3 MYX?Q'PC], )*!:5G&#^S IX=S'AVS2@0)$;@6<,Y^($51)H]'Y 1@^!;OM7V M+A[PD:<T@U\68,+1G(<UP$_!D\<M))D/$(G7+YTA_CT8$@3Q_PBV!S7P%"V# MX)3ZHB$A/<BUI;\[,9@#N?&!_G@^(('*-YY: (OX 'D#3Q''!W@XG,#'1_C/ M,$D5_0M(N'"K/I"T\91'\"/7Y?&WX.!Y$<0?P86)-+0=_K1//XOFRP=PKIRU MO.HV\LB'+AXG#W)F\X&%!0BQYB@?V$'A T+X(2P=QB4!786!N,&X['F*^.6Q M0[6XD9EXRJT\[@(:3&,K[(.A2:+9TV2:W10?&!D9T'SBQ15"<:3X0"R+P+'8 M0!OA+,"P!/0@YS^%5IH)_G<H0RU#9;<L]/]5C!%!D #GEOY[;M%V?.#?B ;W M)QG$[[KZR >*U5 ?'L(RMM(B_)#QDF[3R#^#6W92>-#C<#A"<7#]_>;%!\+( MTU8!?"#B%M8"9M, ?@C072*'1D/+H$8:8+(JQ%$?2#$_'^GG[,[S 18+E-Y; MP LC\D3Y0/U"'4];"63QL$5Y'"".L_:OL1?-ETGBOZFI;4:415$\I,$'=$:0 MRRHR;5GP#:-3RP2Q/+]X/H!" 4,-J%$U/C#@SR$DXY>C^E.Q_Y\DK>$?N 3B M..N6(DE3."7CJ/^TUJVT8"9_2-?H_YMBU_LC]'] F<Q25_DM<$X+SB[@";\ MGTU$'+J"&JZ#N:A0^Y\2^!_?^!_2_M\D#07N)_[A(RN(',=EAO:<%)GIQP<( M?W.T?DXY?+(-/YT,?IL0<1TY8^GUQ\&^D3V<Y&KH3E%HY7*[,WY!HDE9QZOG MI@(E;8\+-&]!'].2V3?MQ'%@_$ZC<F)HSEU\VC%K_U32P5/X>!/U!^=<XJG3 M$MVOUB!%W%.U(S8DVI-\1U/82'[/?P%02P,$% @ <*Q]5Y!3GI[ >@ M]84 T !I;6%G95\P,3(N:G!G[+IW5%/1%RX8I'>1WH)(4Q!1NE11Z6( MI3>1&F) F@0("8* = $!Z1VDB_2N]"*$7D)-0'I)*"%2A]][T];,FS7SYH^W MYH\Y]WY9*[GWGKN_<_8^^]M9YVKF:AEP4T=#6P- 0D("@%T?@*LYP#, Z8T; M_SFO&]GU24Y%3DY&1DY#24E!14=#1T=+0TM+SW#K)CT#$P,M[4VVFTS,+*RL MK'2,[!QL+!RW6%A9_M,)">GU,V3DU.3DU"STM/0L_]WMZA> B8HDX\8L*<D= MP TF$E(FDJLN !\ 0$).\E\:X']N)#>N;:2@I**FH;V^H?8FX 8)*>D-,M+_ M6'U]->#Z.H",B?P6_R,U"F8#6\H[[BR2'^-RJ 2>5OUF-1S%"4J]]0BBIF%C MY^#D$A(6N7M/5%I&5D[^L<*SY^H:FEK:.J]>&QF;F)J9V]D[.#HY@UT\O;P_ M^,!\_8(_A82&?0Z/B$_XFIB4_"TE-3<OOZ"PZ'MQR<_JFMJZ^H;&IH[.KNZ> MWK[^@;'QB<FIZ9E9- :[LOIW;7UC<PM_<'AT3#@A_CO]#R\2 "G)_]+^F[R8 MKGG=(",C):/\#R^2&S[_N8&)C)S_$<4M-0-*6W?F.Y(?J5B>QN54_:86D#+$ ML;[U&*5A$Y3&".'_0^V_,/M_1BSH_Q6S_Y78_\8+#: C);F>/%(F@"K@XE5N MQ%W -4CB@1DH?;$5U;ED0@4Q[$R%N(+9#VTA+]PT3UP*'^S(0J=@];:RG01( MURI_KE'^W8PZGSVJ_%-)%.T)O@)0._6@ M%25E9FM'-)'XOJ*.'<A5%NE%6\ M2!H 04]U16[WT7+6C7,UO&97.QW11KMZY.A>I?3:SZ^#:_/%W$:!RO2^JM&J MR[DVS#59L_48FQCI5I'G:5W !Q/KXVMF>6Y"-#S"HYF2[D-^C+&J#BP7Z>U. M?%'H(-A)UZ(TU.1)TGPOEOI\E-G>]@O#6AL;,=I.N.",Y7+X0Z3 [)]+_J8H MR^>?6AZ_(;6;5KID(2&L?[P"0$&1"%+B/XQ$:#LWG#-_4P+[,ZCG1/-;W91= MH&G >U6NWU-7 %>)Z"7F-B'8B3I1!J-,L_("]QK%VUU7RB\W/<=3?# N,')4 M*41T6][.NAX#G $?(]B&LW;A6<\)/9@GDW7ZF-HR]\\ G4#6JP-_'A-E?'6W M#37<!D_;>[KT^5WM_NP58(4M3/JG.:IP8!=8+KE."7C#)O^8US,5<$:"= :A M&;%ROY<88<F_5.G?U63=S*_NQM)+=*DOWY2V$\4%J3G8)OPS240,7P'JV'?5 MSYZ[)'LX V_B:M :L<7BH:4"CTVB]OYU> Z3^\?N4..E>I&L[0Y&4W#DNFYQ M$1JZZ[IWLRQ97_0F;W7_8Y3R]GH[49@OK-:&#<Y/7,_?\.M:Y)K8ERF*F3-Z MHHMNM PCG68A.:7$0[I-+LF(!E@D$_H976I,<J&N-X^'T^"#SR\9Z]012&+L M)<UC/+?61>RY"/ZEN)1Z@/_K::>Q/7[GV'B!*%?#TFWK:9'?$I^1-"K4YU;- M>%1WY!7@,VZ1^,$44]_X.7>N*<_ABU.;YE2[BLP&Z%RQ%W/?X_GP3]C4BM]7 M$;$0,L330)4)8NL5@)QVLB9V=@GCT^5&:KYYJ(>%JK^34;2H_&:N1;G/JFF7 MB4@\^1#B=7(J'CU?PJ;[32!5W?J)H[X6<'X:<P783<0A+2XRSZ'91'\M9KY0 M:\'FZNFC&5EFWMK^UV;ZP%Y!_#R333[RUA7 R2W"YI;W KL5+JNG5?=7$S?X M@WLTUR+]8.M-5]>\)-3F$XZE6I]=)'8) +?$70$Z)$*L@35XRBYE:Z&,5-SE MVBS#>] Y&;/E>L?^'#<V,;-J)>L&_!7.NRUZ)8-1*\NP:N+^:'1BO]9)B"./ M_R7KWZP:F4/$GW:</HH4;H3_RNZCPM \NE*59A8J<"<?*\ 2,[-!PE^U;QV/ MA&JI.@]> <(7>7$VGXH:<=89F+E^(3P\PNX^5BJ$QVEM0_D[Z?05X,T5 ,W= MA:QI_\U'?*$$@H+!W^F?0JSJQ&IE^7_)EU7.K1!^3J@ZN(6>0B\_0B'?844F MK6?*B;7#IJ+?_T2]]H!M'E<F7@&6TZ\]3;.C\CIZ ,D=;8^F*J07H+7:!6>B MZ.;HF"61VSYE;F@G+&7$%<"Y<BY!,Q+3'IJ+WTW^N#,%\]J<[R7[,YCL*+(0 M!IP@(23_!J'1**SF3JQ(#[W&)/U4LJU2:F&6TPB(W8CWEQ)?3YL=;GIW\DR+ M./<;@I?K;&>4%O?YI0>'6FB-.X"/J>) ]_N*WG.LQ$5@5-^VAP/O$@6PE=%7 M )H6O>6O#9/K=6GF-3AXC%*Q/:E74I_6[359CE.3&%AUKPTCG ]#; G /;.^ M[E8B_*=-F0\"("Y8U683W^+1^K M-%!EZR*[W56"RUE%B>B/.\'TANS>QKM% MWN>?@*.8M5?5P6OWNNSM/:@>H[(KS@CFQ#,\J"=3$D\9>/D QE1#[Z,;U<(U M^15ZD>4G%240,/Z;C&G?1AHQ"53!:<;4@L(45'OW 5O6O,D&(\LMD5C@ES.' MZL1D"4Z '<D/+66IL;KVY90K $N+Q7>X-;X]< =N4 *[ F"L4TB@4I83>>^Z M0SON.AZ3G>?%2#T!+IU97TY:BQ)I\9X8D1!I;D7N2 F6Q8+6N85[3J\/C1C^ M^'2:I$+:<0;T)K_:ZX[W.Y L9IM3;52ZF*+"/*X?F<+>%+*.P[)[ BJ3U]-* M+F9\!0A-N$AGX"@BI#[8N4DBQQ2S(#:@9(431A$B+EH1*D0=/"/A:RH\F4MO MBB;-_]LDG9.J]1')\;7C5Z+SNA'R%_5*/KAXPB HME-!J%G/34GW;.WV X[, M?T,!JMC(?T<V=%LGA+YRY?*R:29J!2E1-L[ST@/%2^J=16F\TZX%_E9O5[+G M)D(J^4D6*$#[2[CXZHO;"9E%@9XV[^%2USQ5,2\0XI/G8'S\&98M03;2\^:X M:_9=5H(L#P^^EX4DY8SC<@HA=)&C0D4<[UX4"-:KFCBR2/N\^[8.6K(5Q\;] M426WI1ZS?\Z29VXS:]>UQ'SND&<ZOYV4NDX03BB<>:3>Z!$8M(![C!IK\[KX MK&IW!6 \]R(RKV2Q;ET*X(7#_0LMYS_]'*N(>OC0-#*J0N5=IABJA?LZ\"WP M;COTWB4;:._)0YA-+\7>P9BT.']@5QABD=A[F,U8!;U.*&XQ2Y3>*$J7):YS MZH+-2U+\ZZJ"UK54[:1Q&+G/F^-.TN!]ZU+&72@VK7)N8&EYPKC)GZ@1(..V MTJSN5G-S=)_R@Y_3466B*L0-K=G97F?R$<$"ER:"(0&EL!B+;7#E&]FRW+X2 M,M%>'F_!,YH%8D')LS.)*\!O]1:A%3>>;O<BHEJ+LIO312F/^'V+*<;[09IY MX@#_NH2S=["D)4(Z\?=R@-N+JH2.3-K1/>^[T>GO'@@=3)J*\;TW;\GJN +4 M@W8%5F*IKR<;A5OO7&"TP)'Y()YM*L#;7'/C0G\+J<TS"J1_J+ CP/$.2['M M+FYHTA7&3W I?VPE-2\05KZ[JA>W9;\+M#;U$BU[+]8!-UA!A0'9<?,V-R_I M(0A!H@4>=/9$TV>9 ZU]^\-"J%CO@D#5\9U E0'BW-D[N,78I31,Y%<6 UPJ M_Z*HF^L%UR<V:X$_GFH"06:";Y]89VQO,,[F=2T!E=1*(:7XL.>XRQ0'&@VO MS1JQQ#1X2F?IF\Q'-NGMM4G%1;#2:[;:97"SIG9<B0N0HS;-HF&LD[K<+.Z' MA@+/RIVVE8L@N!HN0'J)&>:/ 47)[+.6>0CM8J;EJCL8^V3928.O\^$Q>GPS M')WUA)S%X'\XF/I,WJ.*0 :F"ONA7O1^I\/KIF,[$@_*N0/*ZN/RE)PJ3)0? M=[N]:$X>.3W9MDFSP;V^3GOTH!6YW^(4<]:3TKK*YIA=5PN]1N<TB%:$1?#$ M#6?2(_/3GFFS\;\U;4'<V]K3=AT;7/=(=H/3IU6O5]9K+P(5S<S0DVI +.[! MMR%V9 [\2"/>:#@I;M\8;[,#.0-O+%'&1LG8L!-INY.:=]E-OO;+E,64UX0* M7@%NKG,L3P\L4M?ABL)C>Z"@WBR.XWT*8ICZA),";WE;@<CIJU#/>D=?[D > M.\YLQCDK_PX@SY1$6<5Q -^+YN;:-U/3)E_RE%XP:'3X<A"4C$"WX(HXITC7 MG*PN(._H,:1AQM=C"=VS'S<2U"G<?OM2& XBAF/Y9F(QP"*LE9-Q_00JTK&V MO@UL+1:9]@)>UG73U"GB5.J2AKIB"^W6?068+5E$&;;5A&*W6%/X,^+L_XW M?P%A*'/ !8V%!?V#'GE6\9VR1'A!^(?N6[%/Y'LQ1BV*&"AC1Y6.M+)PKTX0 MYL_/M+O&,M=YLN7#L:KY^3"^^WA_-_SL+5P3-QT)=R\FZF*0@;OY\:9'FV@> M7^2]N,]7 (AXU@N3:N1OY3TAW&+MBBKM[+G5N,I=HH[PF<8W@<9X2*ES_4VY M)&!6.2"@]KNZ@[>;4"TQ5,O!L)*NZYVW\F=E=<\#N#0N*E5:P>U<P$]M_'8R M*FBR_&9'O(^W_D/&ADH4B'B7+=9_Y0HPYX]A#TKK:IH*R=N>ND>W-.NC1RNQ M+_CO%R7GB4JB_[)$Y+GMF<+EU*(XD:0,5JV/=PNIJ %7'&VWZAB>L*T/W&\Y M.\S*SF8<R7#K4.'%0\M;N.KBBK9OHIN^V36$"&E]L^-6&UY,+*<;Q>0$:<TY M_XJ1 U362?60([3/2?":W=RHF<Z5VJ4@&=Y7!GA!(/^O+SKC>KR50VN^9H.D M@7[&$CN3N1N+]_&J'UU;R/CB?;EVSY#.?I_CT>(Y]^V%K^6<\MTP$LJXG MQ!,O%^8EP00N'+<9WY'AIE!21]Y20H;N'5-$+B\Q;"B\3K6.R]DD<#ET)/I; MF#+=2?'S_!C<ZW*^VC1ZO#3721@F1B\ON/4HH$);6)?[=-3L\E[:/=AZ2JW\ MLZM>IKGX-[Z=P'"1CA#5JR#&\-W<@ A^6&29$&Z26K"0CJ[2O9''PW.\_83/ M\QG.$S/A0Q..X6-,2Q2%5SDQ["GPV"D9#T<N[],1_0T:&L:\ N1 [>EOP5!; MK;_N>YHR_]2P?(% >:+=V;V-I1KOHJY*)M#*G\[B^4Y/6,]L3EPHX-5T%(_/ MD-=I>W>TF^Y%@:J3:O0M&YMG.;#3#NX PS\OL0NNFGL%_-1HR?<3)*>>(I]: M%!;O6$&/RI4@S0B+M7"E@T=1KELP;#4?!A4X9WF)1C(ZB[RV1BRL/N<%>3#( MJQS_.\/P>IH0SZ[3/8!8BI6OA8QB&$G /DR]$/+!?$;)+KMG-3P\#1Z(H+;7 M1.82^ .\<6*Y-MX.6]_%R$B,/'NI95L_ZI"D%248)05\HAC.0<AFG ?=@OD\ MP3M\KII^)WUAC.(TE;"+4?]]>9O#_=>N]K7@9MA081PW1#T;K[E@?RG"_R[N M3M1*SK_W4C;QJL": (HEP@!NZ2-<%R_79<U&]&8/*P<1.ET\>G8*A>T==QO# M.;%U[8Y9M,2\%;WI'M0G!!!?V(B-#4NJ<WOP$6M686\<LTOU")HP&J,&#!RA MW,JLQ5B16K=4MT])E]*>1<H>BCLUAPLZ,W@VTGJMDG:KH#H4R&-J95O=\F<T M2U_2]'_OOE7V\][E409HW2:6"]F+Y#N'$7UP*P1P3>-D&1SL5%%;6 __V30 M??N61#)@)RK><T/LF!FK&JH9V.[(Q[R1"EWHI)?H')_K=A>,<G32BK%!>#9D M'I$L@MO8<9,QK;*5=H7@+UO3-MMN.:^9M3.S?W#*U,K%CWZKX)+55GG%\\F6 MN(DR/^?'2:/)^*I5\O ,;M%-E[%X$U";NT/V%0#<U^/ < /^:3TN@6C2!C<D MEJ\@.>MWD)60T^C=BMI2A8!&_D0,N^YZ8,4&%:78M$ K /'=&<$P<BX#5LY, MSIL%U]63U=01?H@*^*V2!*<ZAF&4*3OK3K@0*05@ ML)G37$PMF M9\GV6!: M56=DLA8"9=9MGG#]:[K[#@->^_H%\-RPZT*^LJ<R3+5&+E9<%3PDL=)3C(2I M<,,BNPTW/MHW(/GO+#,NK)/2F&3I.Y,>KS_#,0;#Q8KUD 7.7 \2BW40OKOE M*Q$:YT^&S/!RH7"Y%3'UFFFO!2FSGU%[CQ;S/<H05X"',O^:K]U2]"(=2[1; M#G#"[H6L[+->TW=)+;/!2UBI=^?>#UQ_8_A0GF.]5?U:B'I? 4*$SNB("=@' M:2N5;"[F/:TY,S5Q6US!31;5_=QRR<%?? 4J=0 7$B,UXJ0=A$<S&W7FB&1G M!O+6>$$MT,C;JKTV#B+?F;MW<Q:=,Z3X1^^<<.UGK?<!6MO[-DGM/UVC<:H] MYEF=R1-M<C"TS>=70[Q=3=Q6 ]#+D4_U21Y4<R''%:68RJ!SS6NSV8E_\=?Z MN6M1;NK\$6:??KXU)K%PXX2>J^LLHE2649XV84L/@/BZO<0 %\'J?O0O(R)U M)D5HZW?EID;[NOT!75[%2C++E31$<^TTM=&:5E$S5F.-'R%,^48;W,YD'VWB MZ]IY6OP#SFZ?NQ*1%9"FD+7RY>B75/>]0U+B5_H/=3AFBBGK/#,3UWT4NK,Z MVP'G#_ F'?M1BP)XQFYQ0]-7KW!]+?'>G^L7+?U<?ZTK.Y.>* X;W ;)/,,? M[/'XZT_34C'>+_F,;'MR#L$[$>J(.2N5I)=SM%@QZ"M#M3P+L%]%3E&WY^T0 MDN>2P1SRO_J'O+)PKVUBT:C8%BAF0?4WNC 'DN=\*M16A!2/'M?(J7C?QV?+ M*2]-<L;,[?I$C8[Q*8/GRPK29=Z)^BPR.*726,W!8"Y:49M_\-&C>_TR2R,D MZBSZ_R-!*KBCK ?GO9XZ!B(3_AG6IVL_)/,NT1?3!W\"E][UE/;48?4)9TW4 M4E;K#L .6'"<<CT#/EGG]D-& ^#<N##".V(I7I$0#[HN/+EV=Z056T4GYC80 MP"KD(P%%*L/>.7>5XU4^1N1RNM]^9!OPW/TGOCWDS;B20?$6GRNNK>R XKV: MSPR5DAAO]OI4^VMX6WK4B7RA>*/A2XT ]R=\:4")BZ^7C\YA%U$M]S"@FYLW M-Y WX=0(ZQ[.?*NF*)J'^9*X(H[M3?7*7]<%/B,AD]B-0YD0LS#1BK_0C!_M M8YY)#C;NI7"^9+$_T(FXN*OUP4M^70E(KSB T237_#X$0'PX?W.1VB8.!U[D MPTVN*RNGT*-](-&MAVW(K93HH^\AMT\*L\W4\ 4FUE\!R"XN$N%(7!8V+ ;! M3QQ_/@[G9_\L\,C"V?@E5? #"PX>@ *)#=S7=SD]=OHPW[3OEZ)IP%W298DY MBV5D-^HF8I*/X5J5*>#2580C.S^(<BF&3]X<:AU^J+6C#D:@VG].=PW9K9A$ MM#T^MXSHF>YA;_*J\S,.?WLV-B_)RHT:!S!ZVGR *C:-PS\VQ/N07B?@M'; M%<!!-4:%\B(#(;21JI$C$MCB'8!E*MY,9NHK<%W1GPV/89A\=US!W6U3C=RE M/[M>?7#LY]=JE*$&1.:BPMT4$_"LF[ 3+IQM\'5?R-?N +\'.7;/N^_!P&CW MM+L^??7D))L1)<$#IR8NG,DBQJ\+[5(<\EDUOBX.&VG >YGF+=S/9O,UDX23 M)/GQ23F2^K+_"L!Q*0?G(*8474?18SV[;G6',>DLJ3_!VG$V?S161I;M1DP6 M%\V&862X #V1KR9[F:K-V\?9C /;^T'(VN18!#VXO7JJ'-,J!<)U1XWVNF,3 MWC-FN,0F&J#D3SVC3%H1DUE5/3E8Y"Q[)Y ,IZ07@ 51<H.E^UD^^5H"!-^ M%E#";5,'H,$^$C\2='I5%G;U8Z=3*H"81V"^2(:#<*!EQNB$[CH5F]B65T)_ MDIE:/LY7)AG+B.]IN_6TP2^R$"R78U> ZMC0XR%F$%$ T\XJ=)DC=&"]U?-8 MZ,4R='L<<%/9TZ9417MNPJE(.40T3R(']>K\.^EAEOE%/-P.GW6=RJ\ T9?\ M,(:%%F[?'$&NVF8=X%VG@Y0/=RF5;CV$-%R$(*C.M2Z^(?AAA[_\VB)$B-Z^ M'Z;]5*J9@]3H=')XW[^^?#,]#[19D.<.8Z&:<Z5&\6Z08K*"D=6@ZT"XCE8: M8@A>1'^$OQ87DQ\?J7C\1K>9G#OH"D M+W/LTQ/+N 0KPO!%>4%%A;/T6\=% M:NNC9&D5^6FD]O1\:(%+1;;HY$%*)8_.ZT%1)'!<?#IBI#P7J'>+Y*/W:E2" M,A2(%70O']H?1-X("XZYEX73EPBT83KWQ3-B0.$(#N);>BA<I.W5.T'3O.C$ MW\])8^0K6\;$VU>TJA)%QL>5N !$9BPHO!TB$7$%H#QWQ^CI8HRS<N==/HA! MH)Y%B_17@,==&: "V'ZXZO+72_':BW1QU>H6B](E6-N8=%MLA^N6N$"#H!OM ML!RC^86ULV>?D/LXRU38&@> I._QJE,Y ,Y^I@'G)C;B.PE4N+!/0KC5L%[" MSSFAW80_C6)4#DO-1;=)B=.YB!$;\G/;%=#,/01PDTNK\7I)-XJNGJW) $IQ MPOF@A6V5#]O&P_ZE%0M$^/7 'F\^X5-!#" !7NUAU\^1LW]6XBZ8A:%>5M-Z MOJ^KJAD=3"+[]ZU?7CE@>TV=R(S?)SPCHE8"/)>G@HN(2QV(1QF%-Q?TPM_] M=11DWSS15C6_ #Y*6@\$*_UD_]M1"T"\G;G\?06XI:1X)@C7JVNNBS4G%JQ$ M;E3LO=O]"U#CZF_Y[CF1,*2&K9RQZ;D",+:(X*1ZE^B5Q"",75ETZC2P8-WH M1/5^FV_-3D$PL2.9TX^K29@FIZGD09''CT6(U][7V=7^TRVJ[2YBQOH^WK@9 M4PU=SF*&&4(X%[6?<>QESM@BER5]*GG'D,M966S2J%G-7@6KQ7#"%>"SWV(E MF,Z@_WU9QP##I\?*C$4N%^]O9II$9V4B^[,[?$@S?N%>'YVN3 4^E@@VIS\) MN;Q%E-.<R&%#AV;EFZ/GGS(\U8H3_8&J8IT=NXM^_+@@^T;$W?\?_S^N<>\N M"3BEH/][Z@O[X/&IF#KF4<L$:<>6,/V+[RTDA<2J(\[:0G:QA_60C]2RQ?SR M:/O-=+QU;OV@2!)\0C'T+]6O),J<W@++G+M[49.FNHY60YPE[2XD/^R?7LB& M\OJ/=_7ZWW-8F/6@T"S7*$RVZC_4<*FV!,S)8<)$OH#^/IT/$_2-R'</[,Q" MELN65=#HO.RK3K6:-*B@^G+[C22,/A TCDZMUTVD4/_7R!W#<4%.+V-[3P1Y M9PW<'%ON2U%YID>TT+2"_4E.&:V5]RH-,?TGV8>P]/>TLNGBBVB2Z[12U6V9 M1+M)&#;'#)/0N$+W8-@:KR)N*U?'TE<NFQD_1%@<&_8IX%H_\#6G-1_<%RRN M (X+W-J(2<;DQE[5!WX16XC15H^H O?.&U17@#NY!E^M4GE<>G0VDZ0T7+XW M")EUE=;0W3"%JOPK*HN9N1W*ZT'U^]3?8 #L93K$7?JG!HDF_7VZ'YO6(9M: MJE+"&>?S]+F'Y.K/TB-!$_45U&<N4&< 26W&A^T= D2TLY&E_D\OS2.]#FUT MCWLQIS7*KF2(LT+J-;$X&ZPB-%)#&]DO,''<E^K/,GO0]#$!Y=;35-!D.)C" M["C_+O;;*8WE3XO<KUB"0_IXF$ZAZ]>]&_;*1(&B]9>0;(%Y>S1W'H\MHJ:L M]T]SDGGT)&A7Y/'A33Z]3CZ;@M=3WAO2RL!#P_1JB]FNP\$:#R.-ETOF]WN] MYZ<7M%.QY\QXB9?X*T 0/UXC95W\TZCT]ZC@H8Z$K&1<*9",&.* I^PL+IM5 M5\YHUL+5^.A637Y=7I?^9Y9:S,GK"/8QDH*Q9/S)X]F=IV7:/BJ !#;8B=[W MQ40RIBFWTR1[CXQM$1HATHZ-W*C/30&Q,4?[U$H^ABXF=;M>\??-/M\Y'C1Y MD7SC18CW@\>B5/+G]V8)0B\EBIV]"DH@WLW\]G2 ?MO@FE,>HV^#P)K(\>S3 M>^3B !8#]?^Q^%KS%8!&3>3$0U4.Y/^EY#K8G$2D&X=(%VH_[@$7.:9(QDI6 MX=H[5;E@JK^SZ"OAS"OB%%"WKBO 7!2?AH4Q>-TQX8Z1Z@*PL0*)+8IZ(-XF M9&T)'G=I>IE3Z))D/*KFKKC/!,\N<Z:@63Y,/<."&#</K&D[[5RF\_;FI47M M>=;W[53+-;TQK;);RT,/LB#2ZY?FNC>J_7E65,O]ON+C@INC46P5-[S9F\7X M*(@YE0LM4*Q:B4O'%4 '+U-FW,\S?%/@!]V'4[^IBY@J\J5N<1T;-F*R]?BY M+44C#?B#L>*L2.#WN:\]"V$B,H0F(E+O(/-1T9ROA^RZS;WWZQ/X_H++WS_D M.H[+H*EXC<F&AY7?* MW'"M,B373_ \'M]2W]8GW9"IO6</MV]E3N]!N$;?Q M@ CIAE1UC?J^?\:/#A(%6OWV=UHQ=5-*[BL@EB47A:\GQJEE!#!$NNP-&AD+ M/G>/.+4&,6PF+)3/HP/*DB$G3LXL#2I_-%RZV]*@3FL!F539A]R>_YS9W?=> M*DS)5$6\_ZLO6_ Q7>3/VG7=H/NJ-FW%*2*AQ^^R$?.O?+4.R'<YZ'3'J&]X MDN<6B%*FC]ALB1=?[XZV\A;W@+);AUY.;%*<@NWL*"B>NY=\F6L.MD%:.OL% M_.VPM#2ST'/GFT_2,DI!?(JYET!$=&QM*:;L[!8V1/UUA+UNJG];IJ%NI>1E M.PCC?#VX!4H=GR>">NE&._'B"X*^T]VGCA]R!+.2/\BOFM0A)H-=@W$G-%;M MF-LU,PTB#>L1IV0;LO0MM8FE-3&\LSF&5F%/8:MG$\D*>N5;)?.=O .EE :2 M%#.=.3;/#%YQ[O)8U4D7)9_)SWTCREFV3=0R[NH]KE76X-B#(\2S=@X4&C_' MO.;3"3.;A*MCD #8H<;H,:\66!9X-V+A+]@>;%LG<+_@-!!DJ.#8=NC&N'E6 M'REF=?GFVZ,0#\'+*\#+MJ.L&5D7$:/:^M<-_=^HPO89SZQ;3Z=U_]@6-=A> MI*D8?SU1N57=W.X68IZ1K_) ]I1V6S_-3;P@4UI(&Y9IS<&_DCFYS_<S[#-B M ;=BFLD=\*(7XBVJ2;_3XP7-7N_SD-0G#/G'PVQT+.2JN:"YL^WBKC_N1F59 M-72;UXSMUA"-N;7LZD(TR-QO&_$]D6=%V;#3++WM.?IA!-;6S5Q?NP*$7MZQ M),KUBF.EJT(#GF(OERV<ZVFVI(N!3\K%TCTXM7L;*XM4W^D6/U"YP9G8LUE1 MSOTGFC:H*T9#F=Y_$&:BY1\N$O"@OR"!9%6VS^P*L"B_GEHM' N1:?HMU"+Y M)/NM7)1D$",9Z:]N!>*DN4%\=%F9$0]=\3T1L85Y8KLE;C_\7!4?^4NWG!@* M8K+4S5M0SBNOZX1^NS0">*N:KYZ+K?0?T_*%*CS=.CEP4?"SH3=\K/1GO]/. M]_BHLMU^#%J0(@SC]\U#)?-'L3WQ)YW#E>"(KW2"/J0JRPX\-DUZ4+?%4;7E M&3$FOS%[3V.->;!(!#;<^PO!C#M'?R>^<YSV[E:Y$W,L,6_9)T=U6*MYXO(G M\T%#%D;UDW2 X_;K^(5:R(Q 8_R:EMWSZ&]W=#K7/#>' O;:^,;S'D&KZD B M*B]G7OOZ;M?'2!GH83(D(>ZT8(+;S;?8Q^*37^1.?FB: Q48=V[^1+<?XHB@ M#CFNV"ZJ-K:-U+K*$FY?9,WMK+[$E0_/^Z.D8MK-"1*!39DY)8@_;;<MSM(B M>ZOE"-^GN5,(A4^C,D$NIPJJC)L_I*&L(35Z;"^@/#H%U-LQ\D/:% D0*+,Z M?<O#7UU)$?(=.2C+C],RB9:6(C7TQ7^/[^RMP4EQ&J=BO':_'A%]7DUDO6ZH M:E%8RQ+0_OL,.(5^>F3M3L0F@Z:X#G_;,$+A-N4NJ3Y!PM G"]86?5MK^KM_ MPVFB5GE,EM@6><??K8&A.U#H7P<TBDXT/_;IDTUMD="CV?O=I9N$:%>&?9&^ M9T#_C/RW-:='XH-]3P=+[LZE$R6M/$[T<;T=W\^=2K=2/\1*GXRT+B?FINH: M9 G-5 HR1>0\J"U9A"OC3A<AT^Z;^@M+V@[@[TIQM,WN7QK3/9O'90C(* 0U M&"B)1X8<;X?3B:A)^LHZ1]@F6K[)N[?".M-_/>S8!?'"\5W'6E"CFR#5:#'! M\*'H2DP1;_;;G^CYZ765QSADN SD"L *(R]CJ.9+P>CV\]>T#VHYK$/8>FW* MWU\!:+P7$"MF$3NP5.RX>=(80=E<+E5;9*%_\<Y<B-A<Z@6%%7!8\7.1KBF; M:?)@=)>=A\3):P)PD@[!,UZ^#]RCY39]8']VJ'DCS#:*ITY*D_!)=7TV;U#4 MZSL\^$P$\AS^0@&)/J;7,),^%*P?L=0BC#]42K%S/U!=L7%^CC!'5>$NLPJK M:PORV5 BDDJ/1*7#)C_S3$7<F^M'8:Q=[U36)DMJ%H?EB1K49/0:CMFQU/ZI M4[P6GX7_0_]+T]95!\A!N<$3^C>@^6(O<P.YV)*="W(#F:'":&\6P$(-M,C@ M"?V<QG_]T@QVSJ9(/"I)<'G8Z>_FLAKN1/=J/*86>CBS/"U76E(?)2U)@?21 M5<6C 1N)]5ZLYMN&0<,0YP)HY?NSF_XK,I!]H'R%6S<GU**3.'<%X#-;KUR0 M)AE[M?GU%."*EAW_GDUV_2KSNR3-SG/7MC [Y_W'%NZZZ)JMZ]_ ZN(L /U M_V_!T(D75O!]B5,YC8?Y">.0IWG.%2"B\^D5H,+S6D7(,'):@$]K4MUK6QJ; MHY5^_>AM?D\H,5A E</R=#*DSTI-WVC+*?]Q8)3'!BJ2;R%IUEKTK@#\;HP, M5P"PZBEU1;3?7X2#2NT?XN_"F$/-3#'P7I<)6=-<A19'-D/>5(9E^7[L[;%= M]-JVWH0XQIK:F=YULSY8OS;&^]9]CP=/!QI< *WJ=RY&>^XY_V>KX/_G45BK M$!_XJ$4]M[MT[MZA^=B61"IW Q&6-CWO;R3! !E;T!,/+;B,+GT"\$;UW]W9 MW/&?UL*7?9O/"7S,R;O-W>5'LS7(4R4WNY^CF-- FG/D1@ 5 "!B3JH=FHLE MZ,)BM_S9UJ$_0=+ZH#.]'>7MK"I\NKYYGPSH2$^#+W&W5_R! @OPJ,DZP;O" MYD%Y64^#);<%W5];WHQ6BW_Z-\"I =.?*RD*2OAC9A_75BF'.:D<3XFX**ZW M*@2R_3^O+..=L@6=T(%\>JXLA+(,SRYC%=ZQO4J)O><W+337%$D;Z]8YN]^K MW"<6?P>C&3*08)>ZAXN6_RA6#.4?:0SHZ!CXW7A/$: .\/.7\K7?(U6BFQ#W MJCM@=3+ZYX.9IR]1J(59P B'/5FXV#F7Z7(',"%EUPW1R1^2Z6UH2][^T111 M2QY:< 6@9MV+_3NW)8FFDI"&_!RV-@L*,DIL>G22S6CK!G2FAKA[7E0Z$Z:N M /</\W]_@FZH*VKC>\+*-+EGMPC)X6+_G$<;%9=^L*XAZ7<J!-J;Q^^,=R^F M2V.##5/[;;T1R ^=?')3R2]Q/3F,P>?4[YHL.I5;MY6[7.2C"1E1BWD% +]5 MKMTH],<JBS-?"18X3NS&[*G117<S?#&EDH7H:9M7OA8+]<ZSD0C?=4S5+>WD M?/'(+LGG4D8YK%7 A3WS+K&R0A4M(3!64\W;U-JZ$3GP1D[+7.IDFLP3':C< MZCFLQK*%MZ&!FT[LEWLKNVR=#NNQ31;8N0GJ\?33Q#,E-LFZ3R\V*S-CU2N* M"R('9QYX\7RZ(ZY%1M^\AVE>"U3T$TUG9D?+N1Z+^F>!#(S/]&^,_O>N"WQC MJ3LF\J?32>=>%WE*?#C*YQ;[3(OLS2G:M>/BH=OAIUZ\88V%B4?,'R:.[_3B MCO/2U^4)E4-\[,C?+UM\OF])QC(0(;JC.YJB]15.:6YO9VZ3[AH2I2YIO%?T M5+:8L4BZF:U3Q+4V4\FD,PPYY@ZG9+4>FHEUCAW+UE-HZ5RNW"7%J,8J,!*R M0O:3'#_M-E4GA&>[/6V?:KUG?S\;%P!1,3:/3^JJ,5!_%/)_M5F%OZ!0:TX= MP!?-;Y=.FF"TYX:IB=*6CKPE16YL-Y$Y&5>Q_>4*8#__V<$KV=$H44]OR7;+ M;<]S[CC/$^ES7.$Q)?XHAV\SF>QCDIT4R?G6JI]X602O:Y&];=SEE_G+&D^J MZ?FEA0OG_WQ [CO?Q*<\>$)HL-,DD+>?'S<IMT_+$4<H<IR."C.&)CW-HG,L M2NV&FD[_#5W*&![T#/?U-OF'+9Y1603'[4\72.A;'_Z4WO-*TRUMJ!2JB=Y[ M>Q8?=\C84U:RNWK;VG/ZN,RVH$N+=#=*M458$*D0?30ST,X>IZ6YU_G25[EY MW&;AK4GKCA<-R ^A9UO1T 27?3^?'^M^6U44T!MA0]2Y<YVM@,EFEWM_4F6V MI#QB(,"EKJH744M.#7JM/L_!8[#<GKLGS0H/).7XR2Y97"F*ATAE,NRPM/2& M#PDG[G)V"5'^;RO"20/&&(M:E64;F WT#*6BQO;6.?)&R',C[@7^-SV(2V\B MIM?UR;"B/JE@8IQIU)>6(]1?:_]2^(LPD[;J,6FQF<QK_:,RL7!#:=!L%'8Q MNWI(=#=2N6_J<L(5$HU.#+BQ(*?'-T=?(80:L K#Q6!_>O$Q=.)Y.LMD,MIB M*S=.@N2/Q>77%+_]^A?HAB7C89X*E(_==6-S&2S<XJK[UO1WH64_WV7;[K?I M-TS+3&S1P'+L,ZO8$!76K?(\O6R7T6? =*?[,A1?^]T]6(.?OT=L<&R.1QR7 M!@ 'AK?V]CB,J?<(%[D.')*[')PJ'7D-4^+E5G:QDO*;J*)6P"L@V2@0N^9; MQM\8OR$Z[]N?F.R\O+N9!7>LW?4JY96=$H-8P*!O/C/QN'_73]F.\BKC](;4 M&S;.?/LE-EUN&*^1ME\MAW7Q#=Q>Q,X<?_5&+19>E$QG+0% EC(>E)D3:>QC M>=\8^A%#LE3>=I<GEGY3*CG+RJ2O,]8;QOG!"V9<]I92]_INQ_4/0_@M>T]> MBL*.Q=(0QG;U9X65WZC.S7!;@UVIP+2<(&@-!)P'?I>'<0RA9$J8H%N^9%W/ ME!QUO*Z95</RN@O#;<_.W';%#]7\I>Q]GZ\+T*9_8-U.0O!KRR>^5U8':R1- M&Q2.Q(OR#G"01I3_.N!E[^:ZB,X86OR8WRL2XG46]^X6F$LW,O8;-2\#3%UP MF4_G:(BO&XUH]I8I+Q\(J)B/59G\?*N'JF_@E&L=B:&RH1ST*0%++5I2Y<5E MCQH_$3^I%_P8=;Q>[D $87:XQ+N =_ L02#6+>9_U0N:<5SI\"HZ) #8ND$Z MX0&>^'.(>MGSW[/IS=!OA((R1LD(O)Q%O77)WP9-2K4J2Y9("/Q0?!LAW,ZB M(G*N,X5X1-PWQ!LWBX&\/\R5+XL?J%&=1;2E>Q]73EP!YG*W]J8)=OBB6:-O M_32:PDM[4H&SA$V;+R,_2SXM4OR1&"'Y2#2>B)__6RY<(U);VSCQ(+>N-KS" MJ0%:S'7[P?[L$UYPM9JT'(58J2</KBHZ_LDS,08J@LSB^;TQ^QAZNR[LZ;AV M8_4S:.&\=>/K,]THL0<D_:0R[-T![-#A!.SSYOH)=O.Z[H7NO+UPMX1P2K5^ MGDOOR<;!#VHX)+:G'*>)!:9AAQZ8L??'V;75FW186JROT2F[+[:[G$M5SL'R M.D]=J^RWQ0N.J)5<%4OI(LYYO)'W0C'-9++[S3955X"J^1,YFVJWP-7F^V/1 MRJ]=MVN 8DFY=;T.S'-W<R.Z-FCNY@;^GY&?3;6:\M:RFAR8/R5;C"6OA=T) M&_ 50DGJ_GA X8<MPK/XEZVL\[4:G$YIQI8]W?QAG9M;F_X1-9A>O(PG3FIZ MO6AC@Z&Z49&G5X"PFCG_:!4T=W.XXZ-/7VV9>:<G)FU"57E:U,I=DNK,<RU: M##5TLR3VSORG)? =;B+/JALB)?D;WXF>G=(,$%^1^0#O_/Q@M+ :_[K>_)0& MYN+1V5A;C)=YE)CW^3WHV>(QU.?EA/197RH^CZI(^%'4%"C8K?Q<'>()AOI( MEM?8?L)K^3"^9?0+.E"6742?RM8,]H61:_\ZG70+29+%"Y=5Y88\(CVH$^LN M?_HH>ZU>><NT)+Z22CE587\GZ^=L45:IBZ&VR TW^2!5$K.XQ=F-.)DAU&<9 MOOOU2?9)H&:B\6[WMX:(/O[7I!7V*)>U"J6[G"^20VGGP$+8^5;WY>F:@B&Y MXG'S<JU*KUK&6&Z]VK;&\5JP]]W<4 VUA_,<'[,ZVIQ:+LJ53-RY2S?]7A?D M/WXG>]C/L6V-+S:;F=E$YQL3!MWJJ&EZRG^10[!ZZIBYLQ":6<48993?@53) MY,/YDH3Y"]5 G+24J='IA"L6E7.4A6;O&7GH];,^2#DMT>-/^W#;QY'S=ZE3 ML05;7&F]P#QI.^^FX(^9*ZE$DXZFBCQ_7^66^OMWM-KT]0**E_5DQ\Y^*<AT MC6H*+AIF/:QCD+)VM CW+I$W<C)A^SOQ0WK^QP]="W;OZV5T/3+ZZ19U#EFI M17S^.KYD2LY<.,%+2 ^QTU__WHSWL\IDE6>NZ8L3AA&!AR^Y_\BSOISN5+#F M#FAZ>4L*E2YE8Z(39<<N//M/1F<R=\*J31TJU<VT!*&73HWNT%CYJV+'2KF9 M"?&&FQ0ON7!W-Z&<V/O7. ZXE\H]+EFK?J19."^./KW]EMV'@Q6U98-^2,2_ MK6UQKJD2C?U9FKDBTYORUC8TZ'WCAH.7BQW/U[]5FX=@-"*_EZV$.QG,1*7Z MDO[^PXOHMY!GGC<3T@\ZE/R=TJ<"QF)K')?@FN"^A6YQG/ @R#XN^'"@3W/; MAJ=:=))9+[-R4H"]=4B&&(SD734>!#O<271;'(17-0I<!$E9(3Z6Z)6"?RR MZ#[LWQ89C $]1, J^9GV)J%]SOE?>E9$7H"7+B\9Q"9:V.\,8LZ$H^L+.Z@/ MHBS7SPK;INF%-X51LI D8[F-W(AMP>O(!/P?8<?CJASBM(7.'L=PL_2[BPSR MV!6?G!J5EO;M0NTS7Y2Y!X$P9N;*+<D>T88;B$N#LZ]7@$SP)G&$M/Q(NJ$V MQ5M(M[:1KS7T"5!2^2$RPRQF$?6T2BL[0M'"BT/+5K^$LI <Y.W-^TEHWD/A M;H7QUH'N;-0P(A)=,*@'R#Q[G;GVE/H>YUEIYJ2VD5$##[!F+Y@T;CI5!Y42 MZ+GE?IP;(?KDVDIC0+X#_72Y.,LO_?<-W;IN/C*E%.%56XP%SS252QJ_\2K' M%- ?E#3.B9LU5T5L+6"^L7^NH+D"V)1[B/&_8%V.\5"8ULS;6G*S$;_4-FDO M![-[D7.+%4MSYU<U(V47';O+>K.O!=VIR=.?M[J8@N<R:ZT/]4)/)Y?C$!H7 MC-_+AH"G6K-'_X9=H41#9'2 2^!"02$U^>.7?RDYA@#B_W?91%A=7#*0_7WV MP_["=!^9C'+(E )]GN6292\9Q^4=$E6=6U\SON1/&,W&XE5__X!KX(#MF,@H M7_.,O-]93]70R(=B>+YN(-L$G!0+V:???BBMD)G&'Z'^Q3:&FB;@-\^JW_2. M;-&9&IAM#SO5LX8W"7Q-CEI'MTBLG'2BPI UJ06[^VBX"/:SP$'N]*V'?=H; M\1\G_"\@)2SKY!]BJ*?R5)JRTL;M.UE+^_;)G&"?Z_L;K@ <P-QO"5IUEYK? MMMW:AQZNGR"<]+84;XDMM&B?T9];C!22@L:@2B"[ZS+)37KN8U5OA4)0@.A2 M\!7@37L4\,&$L5CTK:5.0GG@-/MXT$T??K\$D^&D-1VII*H9?.P-(I\!,0.[ M*]&!UFNIEVOZNE5@RY.O'N@D\H,T]:()Q_YI]YQV>8&]DS!S<W,J;D[BS.)) M__GVBBKM5CN9JBV?RB+4VHV=>(EY:J7KDJN-_?574C[:<^;P5=$YJU0G\IW] M%>"3Q.LSR4S!PP3W<S'.10O>]RY\3">R&!T.H%I?)1/QND>X(A%S9W8#73\K MD^YT)F((?'T%,$+1$TUJ^?\]47ZR:LQUK.#:=&M4J_6>,\=_D:;:J5)/:/7F M)357=,W\+K-/7\9Y^O @_#M2F)R<70 3\_<@C)W6@K%=QKGZT5"/;-^ZGP&K MKMBZC]P!WTDF#-0!#L2P2R4LW]&L:H8Q7KB\:';N(@:W+Z=C9$<J> 4(,<.S M(3J!*OC4AU*7N H3PXFV6:QLJ"Y'!5/V>S9-VH$?JUQO?"6Z]QDV:?-F(AN% MXDG>S[%)DG"RAN-0G0KT]>'2<VEFA6_[-&8M5 >:)**FV46>C)V7\WO?<GPK M,#R2[W]2LDA;5U-57]52/:Y4;J6?0+%3 4$;*6<RZ&7QBNJ87II4;?AP&47% M+18WD\G_@K:2F^#:(ATPXU[BKE-VTF:JS4,68VX2#W9<LPQKXH<=E#2YHMY6 MF%IT0Y0*F)+A@NF%D-6BS^N=M??XS+_??2MPM[Q&./1Y0A^%%RGG]=CNZHNW M6-B*2U:+Q:OZ&&.\HYZR2-%GO'"2X5J@ZS[(:D,&M91);]V5>6G.*U5$@7:2 MP>I1=-=<O"6 T<\(8%J+GF9M;A B$9>@AX$1R,>.GY;IVJ'T%5(O&";MZQK& MW;#II&YW6!)N5P[&^)*.M4D2?^<1^7Y#"R7"O Y+:',O[?2\!O2#QXL:*^[W M%-7I0[-R<% 7KP+#K\S3_CSJ;;68R4.E5N[7GE$WZ\52SR@Q^^$Z1(G..OW- MGYK.N =3*=H"Z<>LAV$AYXPRQYVLN"2!>.5?M9U,00I'E7GG8BN*>FR\S)TA M;^M3Y?,,2%<;Y(\J964R% <4@.LL_CP.'!U,T&W_C)ID U^3.,R'GQYS()8A M/NTP'4E?'W'AHW6O %$]BRZFS1,4\Y><\::WE9UE:HV?WT5G?##Q5AKV&HM5 MKIPY_UE(KM[C'KJ!&CMJUE6<$=;]LH,)IO_D?2XV7(L$%J;@%<1O@C.=XWZ? M6<OST!P%Z%RN#2].!4@N5+B:'I2EOVWLPI5Q%?Z0&1RDYF_7_!=T,4HT;D@] M?E2L/GQ99$QBV/GRI8^)1N+^YV2=Q&==T8TZYTO#*=]=##8)LIZ?S.KI/N.T M. G[YCY^RH65LJZWXQ*9Q:I -G[Q!SUH77]66($1[<E7K].(PQ*,4UCTEND8 MZ_<!4+(GUYAL2^J4=_6T4IVFR$Z]+HOJ"<K\"$GQ=&3C0UK;Q,LQ*?_;OGY' M?2NL:]%%FZB2.<:=4MVHTKM)>OI=5P"0A,SFXDW3E5'HU%UC,DX20YN'".\3 M#@M_CAE\J=E0]8>(>V(_NLS!;Q[GQQ$J(%^GX([OCN_>WX&B_RUZ1V"-W@ER M[NXM3I!,[5'F#+%TG[5C0.8 \_\J1E&N1P#FF%K.+PQ^AS'W#@+0!^T1*@HM MN+T",##*=7UBERH)*LOM&/?@CFOCFX?<O-])ZR98:Z/-Q53T\DG_I/%R-M\K M#[[3R?AMZ2[I :&,CY)8V-O=!&NKTLX;?!=/C7VDS<FK1EDA:H4X3K[@M<@D M?D_ZY;C%COIN*<7\B8?1KRS_2.#C6%)$WXV(NSU[RK#-U!<0=U/HV9($,BV& M6)A$\\3M:]:^N[4#_A!K7(Z;[CP56OM*^+!V>078^;FPE)/$,1*U]T:1SN0; M+&RE/E9)"M-0VT[45A(H-IO7_JOF!B:M20Z3%Y64[_89[1BH\<U%R1;*LE@8 M6O"![/9.Y9ZAH\O'*>7[.%:G@^#&Q(5*(JB7RSC2[KMS$_W74W,;79_2YW]^ M#A#_45!2RK"'(21@ W/8^I!S\?*M1=XI9J/WU6KY75@M 0'1LZJ1R0N-HFK/ M=MVPZ9Q=%O'FJOV5Q(41?[S:/_=X$F42^2$XQAV/ZO$KBJV]H'TY#9?*;0W- MGOI0ATYG&!O(:_BU'@.KJ%[N[;;R[\F4Q\M^++?:]/MJ;GGO=ML8EI\VZ?9W M%.+>ZU\314#';M## D/+8JF9Q/J[ @7B='/Y[K%-[IE')IE^<FW?-3:[E06= MUV[Q_[9VW];+DU_G+,R?"E984#G;'2F]-ZQR4E725)!:4V45GE<7S]@JE4[? M%OK3*^VWDQ>[H,8%1+,+S9O4GCMD5ZQY/^F%G$+/W$OV3%#KNXQ?ZSL(47!3 M<JQ-9]*XYGLZ<FQC[%IT/I\OJ5<?\'A1C$)?\TX+?6VT)F@$BV<-3<G>!'*/ M%X#%H4Y8[ J=)EG M$IF[9X"%-,VOENA4^/H/*47_=LR:@572#YPCRWIOU$J M_>_@,EY<^(6EEO>ILNS8VI9G'15+G\4, ^2O#2>LZ;#G-'_:L"7<A>??0Z>_ M:'G6O2SN2OL?..4Y#=5IA;P L;5+EFSKC-*Q3LU=((-"3>Z_6[>T@\[S;2\H M7=3%&G@;=^;:]E<L3GE$SF@.G"__) /?1PLV_:5 7AA11HBOA*Z-QKT5U@I6 M&D&6>H['%HJ-M>L"3016/;;<SA_@5R\9IV[7-J1JC+ER#SK8983$D#*^FU+= M73_36H +X JR0L\??ZB[%)[^LK;R& *Q_?U&V6+O4B9PR2OI[Y/^R@35=Y4L M5K"$E59,$Q]^T]8-RN'Z77:MY?3(:%S94OB.CE(9GI];.M1,$!(9KJL4*QBR M>A\9/C-.-MHS(WG/I3Y_$XE&%X0$Z_T57^AX:G]$YYZZ?:Z^ K&B-9Z0UN5C M -MI_DS80:AW\;7-YY&E*$1EN@CD3"S)KK-#W#V+%I]Y.TBAMVX.B(1:^(CB MXRZF]I1+CRT(=R[R"HF89>IWWBFJV*(1=]999<>H*,&P+;&#A/15.C]_D_$E MW,OHMRNZ%WGD^0*/;#;CU27.R2.1Y@/YKTPTOEJL59W^S/+R*5#^;DD.\.(Q MG.;?X$0GM3KD]Y7Z>B2=7:Y=$K>OU09&=I322H=ON':]-G0=^$Y;>#$MU-T MZ3![!4"5J9[\RJ9#$?6.5$^IG_T;O0)0MX5= =3N(A7&+P>KKP!9ILC]CYH$ MJZSST\XK )P&\.=:]"P]NP)D?U7-L"?F=:>JKX=58D,)C^UAW^[;%<M,7 '^ MUY[SSAZ,U.U7/\LZ(0=XGL:$W(^DR"G,$GFM]945-2A/NM=.G H+.SZ:VDV' MGBG/4[XCE$\R$HV;>E@ %)3O3!Y?)V;C!BO-%[8,95D^[AW#>670W2>\DJ<Q M1[71V9!1"%N4R:/YSH,AUR5?#F_6BO)&M>-LNJ6;;\Q_6>R5;8#6+7L*(*)E MYI\>_HN?TQ-\\6AXZG%%O6F5'*$D4B1I^TY3W<)\<&9BSSPD 6Q JW&8LMKB MD&2O_RA3_;6/L';-F)(%EC$BNC6CXJ@AA<V7_6WPP:1;J,+6 BSS]PL?FJCH MDQ!_BFJ167-6MA'0X2T=S<.L<@^YJ>1%P9KF\>P&*U'_O#K%[^-?*V:P>:\H MA08#N.=Q; P>W=V-IKMK<<]]8&;L?_G\;'7?Q>E)Q5NHJ%TJK"'X8,9GOTX? MY-A]WUJQ2?E[>#GJ472;:T.&]O-NP2LQ"V%;^156'&N5*6R$Z'.HTC[C,4UP M3QPD_.B-A$LQNLGQ%L>A.[#T?[07%VQD$NV^6PP05H9K[8)[,<85CL_'RCND M[W)>XC8>5S[(O)-NTIPSMJ&;.B4&2QU2Q7!.P:/^M3W/X;2X7UX?1?./%C,= M:H]7\@N&A<YOW7/[0P'##6CXLAX+]4855$\X_HC5.V3W'3J(H>0EAU'N\F(7 M7O:>49ZI^$I'A<W7+9.**.NI^XT4<QQLVNTV^*#'2C;&C1O7IC*E\0Z9Q?XL M[,E5W0S&0K*K4'T_4NM##)+6A6LM!]-^$W17CD(^ ZT6*E^95</' Y%:M/0] MK>VS2O_WB6;'I)MK_-P2MYM%F/SU(U%\#N@V -NW//^1*+L:4&@76BI24A>; M<R01TR)1">&:?S7K8C#WM/206NQIK\:DX*VW&]"#;O=+^8F]G>- \6/+'%#: MN]#<<>_MYK OM"M5FN=',H/]>@(88V#9]YYA@E6L7>W8JGKUQ3HJYN5>X<]4 MGU!(Y%M+N91!IX@#%">QXI\T1,T-AN^+\NB;%8D8P55&U[*F:?Z('X:LIE"X MS=O3G4[GZ!C$1[E!0:)U-H;2"^:I%;WYO=)3U5ID.]M_,V,C1JIC% GCB3,) M-5> 06LDS1?)9TI!-M4_9CM9MR"47>,<-=OWYW_;TT4G;RCX*)=.=;T%/U49 MT$W9+#Y\_?YGJ9G\AO[D>EWM5)YZZJ03=Q!U35AB..K\B)2CTFI$/'Y:KUIK ME G>VMMO5:*]W>WKF.9=W"\4T>U;JNNV&D]?DO<TX 0(&3\7'48K5R7^!3]> M\Y!#)!Z_ANZ\'7OL(L(5(RE;'+V8\3^5]UU!4<7/FH,(*(J($B2K!$&2Y)Q$ MLN3,$"3' <DY*B!9,I)S'I PQ &4*#G/D,.,@.09PC"$@?5?N[?JWELW[-:M MW?NP#_UPJOI7YSQT?]U=I[_O9V);'N2!X')7(UY9'%^D6'/C_SA-*E^;3+3F M:&#& LU0GV8^YD**NWC1?23RU- YTL+&RD6IH' UE)0>RG0&6DI3/:6EH/)* MR8E.+QKO?,(,QW38U+WGZ@#Z7?@*(E2T#JO&M41T):X]1(V8BV=$90/KKGN] M>*[O.NX,JA@#-O_BEW#+7[AQ*;T%A,8K7K-B;@&G)+/=*++JBJ)045LTI/&A M4':EU>I4M8=&E^J>7I9(2;0&:CB"]+?C 1,=.VLH[8LEVJ>3#^&)OCZ:Z.;T MQ<A2U]+Y/2&J%M!+>?(K[@]QN*F$7,F].4'0VS75F>TVZ/"20ILSR0*CK-F+ MJI >J)'S8:!P@&07V,WKL:HJ;7E$9OV-@&1EV,%E8(^382U)6R,?]WE$JHUA M@BQ39:WM[KJIR=#S9W?ARI72"_M;KAB96N.&E#]X\N3Z'\@3!D1^>]UMLA\G MI[,.R[%-+VZ;F#]T^WELSG@^5!6CKJQJ:?.*?'$9;4X5:-B"=OU!8M='B38R MVG435W2UX^!LM6!=6=)H=FSICP5)TJZ/-BXLRB0[ND'[TZSB/SVW%;F$?S.\ MYD6!M_>GP-@&$&^V623" @,>!$3[BNR89:#+E9O0A$DH<[59T,V,E5_0PZ>* M.73/JG=>$.O^KNR=.):R52]5:AL908LQQJX^_QN6GT\VYM*R=Q8_4RTF-;?K MQK-*J?,57!*7.[>[Y%[I.>FHIWO+!TH_4V:VT3,@.=X_%:D-&%PCOF9';2/L M>JDE),M"[-2\JIN>U']+T%.D=SR*D2 JO);#E0L"&1\;A=@;]Q<R)PVPO/;H M6&PTR6GN0H>$!<YL;36/_CF5U%XRP!5#LLECU: S7*>MAQO)(A0QPWV1XE<Y M!KPH5[,9*-7Z+2!Z,19<D3>AWYX+DOOLE_119L)$/ZHWA.#/S5U<6:!\"39X MU- P]Q'U0YL1 O'&N'S_=0'IB!MJM%U8%Y=OE,[TV #8JF(UT_:1PAN19^7< M*C'309^+7[M##4)^7 )[S)Y+<:+*DL!^TG:F;U=<WHFW.*\L24<XPIE0OE8; MKSZUK>_4T_F[F7KY4HCJ+B8,3DYO?50'1I!K&65%>+4'KCG6QX<1N'WJZ'37 MZ]YH:Z1#WP(\YRKQ$&N/]P^@3Y&*68,_O1=7SFX!1YP?(*VL&N(=T%?QH<=* M==I8#[")8Q[-IP,?80.Q5$:6J;:68XUO>3)FP^(!EFUK,1JL&4$. >5F0U:5 M9K935O40Y=K#@-!GN#D*GEYZ8_NS![GB.F+3CM,%.64-P^^^B+ _G!H2HJJ M^^M4)AVW#=P_T/CW?Z$GI\< ;.T%:<5Y"-25!T?&?%T'NI=H?TCC6SN1:)_N M+F+X!'+%GZAT'[7(ET6#%#VF;YC_\""D[^U2NI',[)^\).K@<;RPP*/C(_>Z M, )66,P&>_TR"_FI2[3$2]3;!H-+NO H, >]KV(4TM?[N*N,4IH)_Y3YJS MH<%YB/;#IUV^Q[_I[@1AZQ0?"%(-3S#2/G(-?N5E5\V5&Y>>;%BZS]>% _< M.\JRP11XW7_Y@-P;AN:>!T]^S.O.%3I7GN6T]6J;<2EX11WK@I)>E_N4U\8 MD<K>Z 3JIW+EY;MQ()_S.6M**DMR3&*2.I306=4V99NJ]%*FYIJ0QC ?#8'" MQU9,4F?KYB@MC0@/7W&$=Q(B(AJN#.-,7MG2^II!EK"];#"[Z-K' [BF2BJ' MG_WB@0QH2\3*0F7W@W"[40E=8H'T6-Q&0/=];"1""73XA==$F9KP/M'*QP"K MLUHQ5)]NX-0G^Z/>X7C!JP7FB9&Q46J5-B/-0X/$\-8_BIW>PN9/+&=MG<;D M>FE,5UN'*<Y$PTA^#XU;/%J]U<,G7(!3,P55@Q!6K!N5B-5O2G99)BF$( M\2TN([(P4VEGK;6A1"K/EB1I/ :7=$3M& :54I5.**9C&MN4ZG\S;(M7'TAC M6<U[@6"=@3PF]'*2,"8HXOO,_LJ \/C@MM0Z,=H\\A;0,!$#M?$ >2%$F%%1 M48U;JH+'-Y?6A_7]YXV'OG5=-PS7"I/!E+X:&JCM"*CH:WO,%PH&94"RAD$( M)E%'1<M%2.G+7-RKRM.8E):Z3?5; ,WQ$6F@WQ1$_,O!$2)%U7O#.H60'PLO M[?6B[W/@5&>.CY1C_R5U-L2F(IX7Y]@3P)OAGPN)Q9- ]P#+,S<\-!,?[ZR= MX%QO 2'R4GO*C;.9M!V&M2JXF9>1@].%?W'*7(GQA 1R"^A^6S ;<LU,XWI] M"P#> M9^*O[S![6_GG;*?ZL)J YW21[2PU]R"Y@4@M_@B $^?_U\_LE/J1V3 M-_K8?"ER7.@B=/J?^_6A#:).1X+N8']:N-+M4"=1,^&%T9_(T.NC?YIG_W'* MA4-VC/>N>-['NT"HB<;RV^[< OP2ZPJJ,FCZYWZ[[8BQ$>I%ZP<T;W)%B@5T M%^P _1D^@8H6,@M7F(9.5 7R@Q7.! !C1+W?[=&_KD;/&^GA5%SG)<Y6^:Z. M, /8'J@4/;'Y?2Z)GZ0:)THK.DDB*'@5_9F^ ZCO8BTKT&1]"I#KE/,'$O0 MG1,M7^N3S;;>UX_Y1+<3KK7*-;NY"\9>+\MHOQJQ.SPF<'_BB('YJ ];QQ=^ MS7C$FX6X]D* ',<'2+\[\CS,\[".LP[0<XWRW[P!(X <( 6;]@0]5CTO1MZR M!KCB?8'2AI#HC5N O4YE;'CCW/R9Z5-#L?[XWU--R8 E[P@ <KHQT-2"NY"9 MP"K#O4>9+AC2 (,U=SLJ622PK&\P#PI:*EGQ"8]0CW7[U$VX/0-JQ3A?J8CD M&1]J*9(6^7IOVNJXW?TBM*GR0;_\RX?63[V[WYF>U +T 7 Y@A)QL'K?[P\W M)XL%E&C5WP-#M!Q*[@_@N6>^/XUR0X#N/O:;GEYSYNK>69+U1)O?^;IES?"N MC&4):E9IYHWY5NTN5^_OF&ON#6?Y1 E&@X1Z!=XH[>HUAI-_=?J='\D@T8'V MP7Q! Q5KLEVQ&&%>=M[#5R+(>1V,RNO!>6N^ZM<33TF*)I[73]O!F+]12@MB MDH[=\@<Z*O8QUP:HL8R1;<XWW/UG+QNX)$RK:NN"7]A;OATG'/%\1OWCP Q9 MY*0/%]L*>P@3.G9TE[LOK$"AD^./C)E6D<AB#,JTXI@)/C8N8Q!S.GA@E+ \ M,+3%PSDOR)!28;9X<6%X8[%C%H;H4 2]5^-9L&7K]JQPK%J<*XD3,F*CE14O MOM/&19D8?SF;)M)E%I6YIB;.ZR >*5D-065$0ZXD/7HQE"-DTZPV!K\N?FR+ MU@%GKGF+'2DQSHM>Q0)?'MC\[>L'UAPRFKO)N+*F@< @*6K=H%P*CS@#/5([ MRK9V!M![][X>SU1_AFBP2[+29_M]2BFHOT%>H$&K4S[) N?4=[6;A3].TZ## MPDX'0+02V9GW@$BMV8A<6U?'@M?O92"[99((05"C,8*]G$7/>2+KYYA6VN;D M &J?QCG=7X1)*5G6M6?,B^UK,."@S@'U[BTCZ6+5A<S#_.5ZBXNL$P?!Z":_ MXH;PX_%%D4D$Q?2BIN1Y @=,0%1B3&@JS(#K&>=P!Z'27@LDZ)#1F$S*AXS; M?RR+:S@I#FUHO!4NB$<_UM1M-\MU$8G\.YFZ:@&;(@6=P_E(M4PC7TENX#QW MU01+AVE-5=:B-URV;_Q?53',%58Z8A;I,UL[4D82/ZKON_OK20;T[E7Z"5-. M!V5H?<KDIJJ5;EVM/C"Y =>H5CM@F@UX@_*U(X]YFF34[YO@3O=E"TCJL!I- M:>O*HH/4Q[37;']AYTKY!C>(P[JB:L/(072DPSED&GJ,:0"/;E2^@_3)=,@5 M:FU#\?K5HL;U:?[-M3#60'&S[EQQ4S&]>^4?;L6#[<HWHA.X[ZXH\-\J3*\] M9]?"M9F2N,JN8R !N?E38O]SB$G"BKX"/PN]54R9O1'TUJB6&^Q^AS,]AD9[ M[ >Q> X\!2NL394G,CTV=UCNYC*=F1ZDHQ+-[UZ<*8?\:$._-Q/,:ORG&_7% M;*AV><2F; GTK;; DB4^]3=%OQ]/+U!-W!2]68=Y,U?GO#_4Y92KOL\G&GSW M5ZY/"JP2[]#L!:A9"4^$Z].1(6$+5"[_>V]>1UL-<8\,N9:\# $?\D;B,&0O M=CON%G"_?.:5.1]L/63FU5'BAF"I=#SU+)8:#>F*11I)VQXX8I;ZA-Q\50^> M$LYDS5,#SY?CYW:E:9#=T*D;DL&2E4&'*C4_J@7NVJ>\Q5_:O]=T$^_X&,/W M?>I^.CS0<)]9;HWD-CG(>(7?]J/<,4]BJNN54\B]4W-2B:R(FPP/NO/)&F?* M,0J ZYN\R*[$/3),AO<>MG@+*7_LOG)*-9"EF-#4'7T+( $.2#'5PXI3]*PC MQ54MR.)#=]7LL<.]_6+E!Z)5KR*\8KDH+P28'6S;XGX1IZ_'K.$*N6D5X5+T M?RN^*/-44ZY#66<6\^ID]4.26\#^U9P&P*G93 I7("&/4+N_ICE9,#4]<S!5 M:;B9FM_!X(_X'F_N)<[UU-QO2CNREOUP./^!YRV S/!FVNS%I[Y+<&UC57,\ MV<F!Q?%4AD_Y-/06H#@5Z.2SGA^3X4_UQ?GTX+[@@[6FQ0D7&D4FT9\'_?Z* M7R0,2J]Y<,5>DDY]/B3E.S3IB73Z&4O47W_5^'"036+ZK0,EPP,2PZ2?>GE' M*M5 G&*7.C1$O;^]9(K"GUR')566[K?3'9<M@^MTYJ1(O[M^#GZT:%B.<0[Q M_;!-E[7G]!4K9M3U!"N2DH]-EU^3K*ZK(X;@2NJ6+U^+Z<0<$[,5?1<BGD.= MA)2+T%/[,4#2C(,9G\TF7C7A?4/S**1HUC>TU\_4UD$X:".R")HRW_Y#?FFP M_LBHB^K*PQ<#DM.?3,CP\7'49DU'V[QX_+ J[%RQEJ,2K?\)5.M0!@,I(%4) MCEDAF>]N >=S'Z48)@7 P@A0^$[>RW88]\%!N?)&>UK9O7LF@<A0W]J([PS= M5"M[^3L:9>^6OM($_;MDJA<%^:F3*^SB-("+;<PT%O?J1W[$EAI7U#5SUFBW M5?W1=R3G]CPIK)OYB-M%D&.D>N3B-[2U/>C\J4H?-'Y7+2C@%D @-,>]A>W? MB)<LL6MJF?Z6+!5*Z9J)<T)"<^.O991$,+59#GN%V[/0O"*_JC:3AN\B2_&C M08,M2'4; UUM_%IW8.T1ZIH#!C5"5IZ2DN^(/9G_&]S\1D9],%+'B!(',E6+ M'\N&VZ(')HSQIVP2O$@2\_?-6XOWY]]! ZMG'TER %>*B8JD#FX!X?[!4P:K M'$8W--@BUY8UHQ\N AT=<?P2'*&6S&=,%;49F$[LF4?1,BFAKS]ROW&$X:KZ MB^]K_IYP,3K;+C9<JB P_A4F#L4UUH$P;[[@FM#U>A$I#B\*M(9F:&-+$0N; MO[.WU3H'9B(8YG8W1;R CR_F)OB%^L1\/0N+188,)?*<D_G'7FPN;7DL;T5: M>#+^7F&4$?MT)F%@CFH@3QGX,H[Y<PNPR&U9KN"MOLO,^TN0*!:B"E;I@1_0 MW&34N -,I5@49/B'>F*N?&^.EC7D-FRH=<]+#L<G,$'8G<I %K0DN.:<S]37 MY5@^P<F;N89373@ SSP86]RWZ!VVCH$C6UHRH;)%?5:<&NI.Q^G.%WQ\.3QR M"=NP+H2IXYX^EFF=44S!-IF/[G1\-;S+2JA';DD>3%HV5)]&03U@#*F/JG0T M,.[?AV=DD$KVC27O^VGAYB2COE>!G^LSA2U',.(<@SPO/5,&-SJH(*V-+5P? M$0JMFJH ?^*3W.)V86B5ANFC]P<VKW5^NZ@(O^P$KM<ELC3./7W;GIKMT&"Q MZM&$/$QT/.$XF#93&7OY2WDSI52U>!36WI7[L@L&3'TMLUWWLK&:0IM*N&A; MO4$YWVKP7.:0_8RB;858^#R5<;JT[N[EV7<M>?*'KQ/ );TU#BV4_.F4)P-6 M'\N)B%;KM&2H%UTB'$H6Y5WM(Y\AG]%JO-K;,^A9MV+^!P&@8'K&.)1FM:W_ M(X-8PL:9X5;+>Q,Y2I1X4@Y=,&$G/FWG7@9:8MIXE\8_4E?1P(@^Q8V)&O^$ M_/Y^X GBB]04L_/8S[0PG7$2650/@3F#<=%H::A;.*DC#+Y/4K/JO%XE,*JP MMBNNRTAZ:F2%!G?.>[T;2>P<O[=G-OY2=7>.W+\84:C@UM^C9O]MWX=R?,PS M^/T!X_%XK@ _Y^#A+:#B%I G2!ZN!RPRO=!J\LM5W%1O3U!F,?V<//G!UL1@ MTS?/3UO_3W"\@G#%?+$G[V*;+YR.?LH*8F>\ZM?RL>X;U1,AHK0Q#2]7IH6% M0W=MJ0+E61A]PJ=*X]T1[W,.C+P[<<9O@PAM'5<Y6.D]MB[+$ J_6\"\V-+C M.[0.BL.9-T_-B;#FIEW3$8/SG%*3S!<F]5<%3\>"MA$/_ X%).TORIV6?E'X MG/V2%*F+N.EU6[=7ZNS%%7[3*Q0=4-XSKI0RU9@4,4@; (L[>=KLT"0USM8R M)Y&GDZ0L>(P%J B.SMBG++TSTP%1K5P:Y/Y-@0<027V$T<LL^).*C\(GGW8Y M.MHA<S6!1L5_8.=:O1YTO KW) @'C7W.::1:&,6\;&S:W_\Y<A'T"*SCRAZ8 M'PQV/(/'UC''$QO_&/D:WY+\FLM#'DV0!Z;SR8H99>)H2T/_/ +>/$>-4I$ M)J=I%;2NCB?@4]6)V452:K-QA0^X.+TO)3(>N%I(,$OL?SJWIGLD6B<Y)S&! M-:&LG1$(*'MK1?U39#L.KH,Z?P??/_MP?HY2<YPBHV$ZSCPR5>L.]XRM;IX[ M=$XV5:;C6_8KE_"IS2+3 VK4'_O&O7^39L.].ZA!7[0T]OJB2GCPA_VEV_OD M%21E$0]/\+3&T,_+66%WUOP7R>Y]$B'<S&?/QGE-QF,?==M5^+5D6#HID#2\ M07ZDKZ[2W@R/E3#V7 &.I0O*?LQ* K78)5Y857)J70;U<, %\IQ!ZCVDJ82J M+@=[JU#W77&_,R5$FL!9;NK7%J$G2BL>N>N(3I_>%C<S!^^&M[P,*SGL6DG[ M 09_GNGB/ANMCTM : 0KBF+VGELI4"M)DIK[#\,DV,OWDA=4/<CX%E4:!G8_ M+M#C2?8[:\G<;UF-,?Z?/(J2TI*"AR$4IERU84'BQOV!E0Q'C:-X^I?;$#_% MSP)&/% #FSKC/XN/,NN3DZ7R*],M29_-ORG>B<&8OB43S/EE 8Q@4TQ>H5V$ M)FI@I03!CFM&\ ,N 1$P"[]LV8[T<Y$;]K7BX+=9^#-G?_K2B66?Z>2)&8B: MOAMM3T]G($IX]]'(2&-8L:+6Y(U+6FHH6U',* &^#_Z1=PT/G6^O*HHQPO4, M;*:8J!'W+,2[(Z<QL #O3+#MQ(66<$>L8N?&MS9@<!6O 5NX 8PGQ#@4MZ3+ M?YUP>=M@$7;7;EE_UCA>J0WD\;JR59!^@A1+B\Y6Q@:@CI>4Y@1<']<6TB^? M\ V6M6DG]*=NM_9["X4T485YPI-5>4B<O'54[J7;"U@F<H= 92J1N+PCJG,[ M!&/TUW=OAFTTF7[\V!6S.BF5;AP[WB="O(KN%1YK&57/Z^183GO/7.KMFY3P MFE;&.;\IX[--@E+)5* \\Q.R+G:!=!NFR4^SNM[238KAGAU>+0TH3*>=H]A/ MUQ*^%]=5^G_?DO$)3=57V&;Q38=645M]T2-X@FJI_F]NT?8AF3:7=X4998_/ M:HXB(6VQS:_/?S^'XHJ@3RO?)IG[!IAT*5W(MT[%1D@5,X%ML$O([4C($?Z> ML5ID(H*@K;TQ^9Z5&+#(A2."[J-4> O1_EZ%-2G6,(^--E+7+WJB15VD^H81 MR^%7L!P+0[=\.5JWMB$;_R-C]976A>_>WH5.;*^<0XQ6W\@^V<V$%/=WM'"O MFK!&T]/!@,*E08<@BCX%OF2K,A)_"_I[.R8^O8D10K< 8M"9KNH>[FV0^KJ: MFT^@K ,MG15]=8-K!G$PZFI8C'0 FO.N^#6XUVJN=\"M+!56;%\4LR7V%@*5 M9-@;")'?:G J0)V"Z*$-WP>V?I2E_:A$Q/.\0U-D&3I%$C:G)2SYL<P;)JS_ MINE'\?2BU[,K#TY'2E-Z&_$X]4=#1QZD)$O\''D4$BLX%&B9*-.*9N+Y8N/[ MDM),+?7X[1BY1T?0 ;)PT'$9J[KQ18 =HGQZA?0I%HGAL&PAX4LG%O[.? L( M8*+HEI$4>YIZK2:5%!3Y[].B\-B)K\M2ISUD$C^%K)<S/G2!D/#(H,]2N9B- MS:[$X5^LB^J'&TEES?-!3>SXQ7@)(<:X-311Y+Z$7M'*CABDP<QP]9UE'I&F M7MC16=WH4:(Y2B.?"DNE"9V5>$!TS6Q&FQ07;<N+R;;8F= ZK?VBLD@'^7"N MA&K!]E8I8#(H+_63*,N=[BPM[?:0P(G#[GR:H/Y12ZE,XU#B9^U@XVZF;))L M&CW$C&$^,27O)@FT<77_D-$CMJN1XQ=B^77]TOJA06W@"UQT\*M 0VCB@1#I M!A=%@LVL%SG>L*?UNUV-MGY04>,;C+O#'] MX*?4#=6R+QS9Q/#<6GI!BD:A MU:$^-=FR5$_WG(DYOZ?#=;%CXVPP[(;#S%'\F4/6D/!]H;6ORC\LKKN-KS+6 MUW[FXJ]'A7$%\F[LN=$WF0NT/,-M]GUV/S@[K5Y[<D-E?PN@D!"62JF1;Z,+ M;&#;?.;)--W\$TE)V<T_'V=&NB<2K-=VX;&!\]_N:>_SF>Q]V,(63PLTO:,M M;Q%>3E^O#A/\ W$R1)I2:4S?=>>_SXE\/5Z>6[[8.3-H7B\=UT0[!.P]EJTQ MK/]E!'QBUR*M\F/R%F#-^&6Q?WJ0);[K&Z5?LI&PU6H70C3AD9;VEH'4$S\7 M/CZW36^)_-X;AG:T;:==J5'?M(F94E55<5%*^&I1MQS4'+6J]FK])M'.\?-$ M<4\-&1$S,BMJ77I_I/B:Z>NN#N.!9+#>DN!^KF)#0D]GK=*[H9=*V6D#TZ3O M#89LOR7".!13K(/T#3*"S#YYK.13'YEV)-(AZ7>!T5F[XQQ&>L8BJ@*!5@^= MYJZ]4"K'JX@ W+W[EL%J^=0,ZUDGXG4D>Y3)%QX./HX7@V2\C)D4O)749Z+; M$974SIIZ>IJ$_ GA[:Y1P?0A3[#M P2)GMZ'KY(Z .)!#H'2J.Z^X!>M9*4I M1C*#6ZW?W/J#\-<U\ RQ3&K'7*F"?3DCPMIJ5@:/BW*TYJ)ZAG6V[+2(5IB^ MBU!P\?'GS9?#DP+R%=+2PF/8"BS^B1ZJI.#@P(8G-,>EJA:K':%M,9P32:_8 M:3:FR*H.."OIV<Y<WOT:"QQ:G1:ZF>B^PM,.@Q[W_1TIP?H-J,[.Q!C!@(K2 M;?78@]>%A--&'C&PE)]BI7/I':[;G(1(/:J/O-OG'SX9CVQTE,$A5W'[+5U- M2DR,!P0##FW*@VG?Q 26MGC!9P1=T&D+8GXP4 G=3B5@M4E\7L$)OS&;AM= MYV+VT[ON7!EPDU9=ZFN@/3T1@9#2K;8@CW9[LY?<"@C0X9)X6AF4H9K@5)%T MX/6J(\41966II'<JV(/R]>/63_C2IFAUOR1F8& 7VSB"X?CY@<J5B/G.X$DE M#^A%2Y!;EIWK?IH1*1VO19ZD4S#RQSE5.DUGS3FQ]NZ9"V*>M^F.B'2:LM?Z MW@*$]/$RUVBP?K'SU]Y'(@I:0X(3N&\1^PX'Y<O]:BR"0J#'H\,N^U+3K/B9 MO6BS!WY7'#LT*PG9XGOG4^"Y/>-]XD?(E FS'(.9YF#J]A:X $[F?=77^0?* M+P<YESU.$8VG(7=,%G:R0$WG 5GCN",YO-DG\^:P)B-O"@>KR9ZMUN6G+A&J M)BA3'HS;-%1*$ A!$YR <WN,!(+-[R83$4F*@KET,&XS!@A/8VC6"F+9R B\ M$ZTX?$6XS @.,)T(70V@-R9M$0AQ[5 %#XN^K:%E+'MMJMK;'K$=R]H>5[4H ME0[+L[H%!'X_T+@2?]#"WM0(#7#1KAQ=V&PO[WV@0>YH3"M5[.;$77DWCD+3 M4RO/[[1FB?0S3-JJ*5U2_Q37=3I_S!>L$W>VT^\_GKTAJ:B6WU-/K6]_>III M,NZ6TJ9$S)Y^0]1MRKTX._Y=LJO,5>ORNJ,Q)G$?^O**E4.@7Q:8B>0,% 5M M*$&X9+GS=.P\TZ7%?@?.$UW [1YED]1"/1\/Z!V33*6XJG^D+)J3H*H.BNI[ MNZBTE:W9&>-+%C5"$V>-<RH",>Q #1B*C (_-[[YVFDTM*<NZDWY:(=.IQ]6 MS>T@GJ,.?FA\UI7QT;18F$IA-(+^C8:T.HF\GQU!US<_J2TW"V^N^]83F<KT MC9/6^KCN4"_R&<]6AC-C57KEPUZV@=^<2CH7L^TMX2[;];#"YES9SHZ$#?); MP*-[*]?=*BSI&RVJ6C6FUM!HT W#UJ5X_@%805!O:U&4_)V[)&\^K!W$]/YF M"*(:(J4:VB9E7<YU6JWY(E[F%3,;0:>;]HGI5'Q143L=>&4E5IY5GLOQ^3^O M5B4"3:D ^"]M12**?M]B0S0=/+'4?I4A88,U/NVHKFS!I2!1YK[C@7F:X."U M0ONL\RFCU(A!K'R<6,TYF"PM37EP6$R3@"="0RB[9*3 7(5EUG-':+0JVTK/ M(NWX9"Z N*-"!G:N'L>;TN^W&@9VZ'J CH<*P3/\:^O]O#DAE&T>G,?5#P?Y M7H??M:K[+KCGOUG1'FTM^XU)LF-6]<,;27ERWD-?R9LF?1FF;8>EW'FDJ_'% M!*9HEG,+&XNZ4D(S=(=LA$11I</APBT8?H'GRPKY'0I?@Z9ROHHGQ5R*NVFU MVGU\'M_ICZFZ3,^PJ#86;"XL7W2D''LY_*$UPEHN8=[BYZN9Z2S\]<181AJO M QY]K!55.&3BB6^L#,HT1ZRKLG+(=O-PPT_F7;M9Q[N A*!JGH%\<JA/F1/C MXS,N8<WN;I14)^**2PIF^)M5C14T\C)IYVE<@DC=Y)]]D%XIKK_AXLN3M^G# M=V/CG)][:8KA]UOZ5NVIHWS"O5;,KQZ-!P2)C:O)[C^YN\2AT!&>%&>-EP/+ MP%\'2R,,$@)Y:QPPE\WEE:98 R-LC-F$YHEAKO20Z^K2T" O7P*12MX$,C'V MZ%H>'7QYO&W6/ 6U*C$?VJBTC>Y[T]GX-7*E\:?USVV*LYM*M-6[J5N 70C6 MR&>5L05(.$-E%*7 RSZ:S#-< -I2D+"%YO?E-]LF.:U/1"W&=X<++%4'6:E# MNY,'+CV;50E#;0UUOX;X)6:X4O=3X?^48$)./-ZY(9OS[)!^;*X,XNQB[(" MQ"X."Y5-T7S4F=9*^U+VEZ3&I]UXV/2>D[ZLR$;PM1R:-0EM:6J@U]PV#=(K M3Q#WU+_?OO;L7BPD;+V>XLPGU*6)APK[0 Y^>G!G1G7&:\FP3K_/6)%A[ =? MAB9OF_)&=4&46E/S+*TFC5>RXZ,.EO8$<OZA69*)%BYX&[D):5J(I2G0)QHJ M7Z)<L^(;N27))_Y-4*3.##%PQ+D&G5\7>))S/7429P +\6&*+P98==-MGU1Y MTTCEEPCD+UP&Y<:.RDVPE#;(;3%<$(M*B@JZ)KC]&'<[JUE=)]=2\B<-)GA. MWY0G?FF@9ULTOO*2R+M_Z!9 \VNR9FQVY./(<3G=J6 T6NI2:!HQM6;4,K5Z MJ=DPQO(C03<*&^=WM-CTA:X[_MK"SPZ!7^Z;(@M2U&BTG:7<5ONX^MZ4HBP> MG90O9Q:&.NE%^8;T8-#�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a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�V^#(J/?1,;$?XCZFI*:E M9V1F9>=\*2XI+8.75U0V-#8UM[2VM7_K'Q@<&AX9'1N?G9M?6%Q:7EE=V]W; M/SA$'"&/3\YQX0"X.+]<?XOK,A;7!3P\7#S"<UPX%]S.!2[CX5_C)[@BITGX MU.$JJ\ K(LH[$<E%7XG9!+5VJ)XY]I%0LPO-7M\]A_8CLG\/V.O_$;)?@?V& M:QP@P\7!3A[N90 ,G/HA8I#K;CMNZI_+^FW9*H>%@8TPT9-R34@(2/\XO<Z: M+U@R"#U9B@%>CB:#7K&ENX'@;JBP)$II=",G!FA=7])YYIJPUTF9":D9+GM[ M13H03=\Q%WA&L(D!=BZ =U+_^%A@==KP46K<O_FU:IGN_:S$'WA,HY,O!_BL M^6KVW.&6Z*DO,F(C.B2^\NA)^-*3G<1:@^P71;!Y&W(%[=#PB;]8;OV]9=73 M^K)]M=0R&$]$LWM.^G/Y<C.Z(]$C]ZSDG?"$V-AWZBYN/#%EW1-:%U*[M,F2 M-79?4^CKX'[! %?D,D80*X*@@*@*,X_/7/[P1HOW8@E;6??F>3B<>1QV+XQ M^[Z,%D(R3Y6?XWZC8>JF7=)LOHTM^I0KQNTX0@)2/?B(//Z?<R"IM<-E6;;; MX>3<(&S/_H&5=_%#6!HT787PU5Q)@%IN8(Q+P$WO42.!^$=W#$'?0G"&,4"C MGO=]#/#I>QT:4$)30AH?H7Y[I/JZBJ9 ]P[8I(4O-F].JCLQ^JKLO4[=>%HU M7)I?3?B4++[@>74DG0X'?(*:?#@ZU?M,9"D$9P#R1YN!B!)D4G49W#K4[4LH M1'4?=M7BLZ4C^_! 29F3"NN-Q?'ZW.C6U4?-][;C"UXH2+)(YU",%\\9?E2? MQ 3(@V/ENX2;BB[LRR7:O^9P8YDCE-"K*>"7@QP(UN*.[,Y!QG0,NQL><UG M,>*>Z%/B%@A)+HNTZ#\G301T<73M1$KBC<DI6S</DZ%DSF:T+B>%U&L-F?<3 MT[A*SW!K)M>B;JLY7N-(N%JIL56("X-8A>",0_Y,W>\?J5I$7_KV\?3J&TL: M-HI&ESU2?6M 9P(Z>L_KD;V)9II01[C8/KM^E2\IU>32;G;+Y4 =A- C\N(_ MAI;K"BXU;FK/+R6(TB_[3BDY<$9,V 5+]_#!$I%:MH/2KS3R2>DV,RXN$RGF M%W-YNE;Z0+VM>&A_\$Z:[RU9YH2ZTLRFHZ_T0Y_%\.;:*0XR_Q3BPOU-ZRS- M+_)=])<([A$#(^:Y[L;*IT;)EI1]X^JF^Q74H0.!82(S9??D.ESG7DH4(K%+ M%G3 ,< ]408H 'ZI^?RTQZ<B=%MUR'O'E8^@<6G(9W>E])=<::7<B\CZ?OG MO@WF-QKD*G)$ZE%NC5.U,_B\2 G!&?P+B7_(OU;1U[88H)BMR@#NA1]F1Z\\ M=XL_R"]<VDG+(@D'>C^:<5*=ZRUN3CMQ**THUSYZI$OAY3ID-J^6$])K-XT! M #8,0 +^T_.>VN@P0T=0[],KBMK,]8-"_;)>%"CAV&:*DXL3&& &#S*K],=' M(VD%[7?,=1R;YKMR)B9G<-OZMJY0DQ/M?"5$ 3*6;+B#N=0&UR 7=B $%ETT MXIIVJ8U.SUON+L8 A:92?::$67_!J/_CXQ <#;2BJ>H-5H?Y5R5,VC,TLC6R M/#J7.,PL2%Z4M])NN;D*%^>X4VB$FT87?.P?"W5(?LCC5J[9\_E&2KWS],ZP M,25X1=0>6S\O8P!_T)^>'3QAKTWZ9\(-0K+%%8+!7^Z:W1+M5IP=]4[=SXZO M[QM==8/'D@\<WX]V9LEH=Y?R#+?XS.3VSWD0"U7='TF>IURK8OD7Q;B0.27D M_Y?YK\E SPAF4$+(=E21L9QO)ZQ$ 0,T6\=ODC9IRC%76(,2(NNK[NYZ1F\: MD^O6HINY:.;.1G$!RU#@@"XKIOE63U562G#]*!*.V(F@:9ZZK,B5-^SD8H]8 M7]+@9XA<AUF=JB&^6#N/'."(P*S=U4O*K=^T&\>7NNO&/?= M_2WPB,,ZJ/: MQT\4(U4N=GA$\@[[3/,;FM#U:%A]KMS<:[:G7[N2YXK<>R_>8)(A7GC_NSD& MD/7A0Z.TCF,@!X3]&&"[63-BZ=;<+84D)8GW$VF/0]T.&:'&3BH8@)@\N9( MW?_A@ZZ-5T)B*FVKL>H!!A#H0;\\,3Y#IG9BU] GF5@,X'N3:*_M,+[-M-Q] M.TVI_&NTGV,3&>Y(OG"I=1D>PW&0.#N-F#A+$OJ3;LYO3IG-8&<X!W6GN[+, MQJ @8:*Q.!<ZN, FAX>4KX_/2GP3?5@3-V5EPA[KZ]O]5Q-"&?=[&)V,DI?T M,$ O2 T#U%%Z_&H*\$B8NC%H.F"[H74X6PH'6%/G:<4/#[,FFO3?]!_G9W=O MPY^K)<5U2YR,9&Y]Z884E>1A@)$:OKAS+FPY(1,U@ =[K/KM4+47II<C.\J7 M\1*2T"5#$:)VO!3BX-CA&J??0=7>V //::2[8( D2IPEZHVZ'>C455;4@$+K MV>'VPYE*D0$E(4$/QQ;'T!HYU/K8T\B^DOA(YS">IW.TER UVJ)COP+ 6>RW MCATP+&U<$Q3*#^LTE9I9,'V>A&8=--T_LG*"B=E&"8 ^>+JL&L'^ 6HO=[_[ M'BSOUA[$^LD\\ B\F52^E )]5 4O?O2TUEU+A">X,-2\0'RN1O=WX8OJV?4@ M>",USKPPP.$*;D=!J7GEP$;>B\]CX[$O*M8Z94Q&(BU/#+.&/0N,T8\'?8'= MJ1KAVJ:Q;FAZDA,ZI?!1NS7"1SF,04W\#<4A([D%;G/,DZI'RCBSQ=O'@R$^ MK),J$I.7I>*F;_B:)*6*KQH5UPZ]Q !O>6/]<=&/7)M9.\R_HEL&%+>KT&&; M/>NRS$\JSTY4;%D&K^_?&DR[9\"#L][MD2%2ZCEQ9'559*O":46IL*)0:S]O M1+SOH%8" Z3V?C%@!&T\OE4C"U_PL<#M2![A^V3Q4?J.*?].E>%\!O](A!;% M52L#9?JTKZ3';^@HIMID:@0D=#.$$*]4T,T#.(S8YK76X3!7/\WUTA3MB$*_ MJS\A6OHL"[?%>^B9RKLK]U0XQ,\L]J^>KJ,A](<-B$3%D/1-ICL3YB=]2WI; M='T'G],@/;46N&VH)O0)!H"U0/G!M77+NX4&>K<8<$\9U+YC *.#S>%$;)I] M!J_[ QZDRJ\TNB4@28>01Q'>'1I3-\'F<FB/0@T^\]*B5$MSZ/&LSN&-XK#\ M]KZ#>IGNA#.8V">*:V7#O!N;2Z^G3I2??EBZ&_:9]G1?^:1F,B1@\,;3O00Z MBF=$VVO<0^PQ_2*-%I7/*A;8#$)?;7=Q1@Y D5&6MDG^MDB0/K!W.+(]+T Y MF"'/:N-3H*@D<^8A==JO7C!M>)<M5O.C,F)CO%NY=?ED)(LX[^B2LZT0Q0DB MM;OD&#*GGI[8]'+:?%[\$P6K0('X^ZOHON7CWB^?UNK/P&<NZZ_5I',,%/K= M3&"3;EUZ<38ZP\,*?<XU>[&/4Z9[=RQP6ZH'I6DI]@]3.S6V"X]1UB-2Z[?J M1:)2_<*5(@43^HOU^5!?A?HUQ*B/YX=?2H7\)/4KZ74B VZH5R7?,U-]X@OA M^I X4X<PAA\8:K=6^&69Y9<XCD90:"&/MV>'& <YKFN8EK>$I)!P\$@%:Y4 M@4C;YT%B$TXDQLN!<,K>"M@#\Y,[L+Z6AIPY>X1\?P^!Y7L)'WAZ&HQ')*_J M6=P-G5)Z$*7M/2%[!P,\6_4 N]G0H;!+"_0!-FV\C^S[R9GP>LYPGN!92(8) MNF;EHF4/2J5D(+QN91!GP>@9Q ?2,Z_TD_A( 74)(6CTY/FV1K'FDE[A8P9U M;,&$VAW@+/C^27"[9$8D+(.;N64Z<SAL^+<U3?,GQU784K5"D8X!IH-%?ZL" M?W6\]>L2Y_RUQ-\GC/B%)>:?Q(VJ*G^IWBZ_EE^%)3YS+0C7T?1HAJE]*(VL M0#&3\'YIS3ILGZ>53;&_!QYA5'-Z^_CB+O6"0J;>.*CH]C2>NUU)4J,!3$]3 M@>I5Q3[%IHW#' 6% ^S $G+ M1,VK7ID/SX-FD SBQLR>!!J?L_]"N=V)%?* MM[^@9'>B6;6J$IW*_;#]"XU;/U;VAWPZ?3E3WNUTAMKW<?H")?COJFK?VYUH MF5E\ZZ6^L_6+O*P>:=6J:G7$0+XHMVI>KE_2 7Z$XR1HPZL MLZZB3Y\*.7I MJVU'0)KZW8W9V00L:Q7GPOKRR\5I55&?FP(E9A:DU]Q\.+\?I'WKB_[$X__] M(+<,+%R /:X8!N[GB.M797X^O9':@RH"=;_\PFW0PKP&-#H6Y\"262L?RS?J MR$[17G^GMJC"=<T^^DXM/](/UE#A4\]GR/A";L6RXX7:ZZUN@&V;^0RB?Z%M MHFAGLZ8YN?STD?O,.YX,\(>9=Y3S:Q#5OMJ=K<2%O+!EQ342=18IR6T2F0_= M$)*%F&<A+QW>56A+RDVT]12R]^=M9&FG1\JUDW2_4!$7_\03!KYDT6?YV>,= MW;/.0KN^KD9E2MPEOBQA@K(J%\)6,87-#:[W(U<ZV?9YF76TV9P#';X2+C+[ MI1L-\Y^ELK#S;0V2G>'CF-HT?EH]HJ;WWJ\>[I)R:/&.:GDT[Y#W'=RXZN-L M2[TD*-/B/G1/U'8!6B">!^,?4M9[3-0B\TQ1"6[%]JZ5]] V+.JT^;3^<A>. MJ0N-$4-)>5C:ZVV;VXK%G9VWO5/KG_9P2#W+6A]GE-"/#>G6XJ6??*LT!9C> M/AGFBSLMN]/9UE$4Y? 5]],)2:1!9MRK2+WK+"9.91!5O'ZVJ"U0NN%@G(Z: M(ZIP;&0JNXI 9[G4<#!\S+;[Q5TN,!>1B/.H\[H/Z(>8PVMFY7Q+V5K]DA<N M["=)H*.?VY.,?5^[2BLU>^&'OG;:^9<XW1!0?P73/&#N?UH[F8 !5#VG?@A[ MGZ3 $=.8I$X0HZ132^"_I"PS<-N!=\3Q]@7$PHZ[=)@6NK4HT$C-]+F7*SPB MT13_![O+4,@GU/H%M;?7@YKZ*Z"2B%@;@N5W@@?I,7N6>G'ISY;#FB*56\C5 M<4P5::RRYC-':@RJ)H5"GDD\_\%AVN7A9"KP@K_^1+MBFM[GU>$^;?;!+=0* M*5M&47'?7)1*:>5K:H.@V,4P@=FW"S%=NGX-9?!][GI>:F*Y)KD*I2EM"+D@ M<H0WTL.6X<+=(+$7D\'>;EIW?%46[DV*'RP??N()SP$33 A%9%<D H[%JM_N M)$!(H/J!*GUY[".%MK2EG6J7(J2Z19+$EM<->\L_\,A.*L\2<Z5/$$U/,>Y9 M&?BHS@W+L[L)\(2^>'1[P72W3680/Z(H<]5A<JPS""9IU$YZ=:1#,\%\.D)K M;=Q0XG'B&N_DA)3@W3-70D+N[5"7HSPB^\R &W<3WPO2<-1J8("\_G8?[J], M5<JF80;7XW-Q>NDOM"4=7]THN]YRJ9X8T4$_%2\?OH<<R_\<T/7 <2JYL8CT M'<T@[-Z0G_N=ULQ ,-\[G!Z7]C.KG,==BRU0AQM## $,R4S\J\W85+N-?' O M?N-+UZU!L!47GGNC_-X5-\^$8#.XO_-IB)?2Q[DYL:TD(4/F^W!VF*&N(*(] M-(1-XYH9^]F>1PL^NQL%_2<]0RHNI6YEVA]I(Q[M,D=D5$6P1<B.)7R)=(!Y M&H#)+,->S(O2.*3XUS\AC8PO-LQSHR#D[^)*3%<$,5F<RN?YQ^@2L@2P;[71 MKLOJT8^7A5$EQ=JZ$$>_V:(:OT?\+:!%TD0,Q<T 5O5Z+!4OW]:9V%LFNT&4 MM?=/"YGB=OH-G=!\'-.;4KJ?T1V0/2W>NO7VND3W66ZCQM-;;>!9T\?D@H@; M8I,"'JLJ&[R9PP>:"D^LO&-/S;SM0F8U@J7X;3G\2NJN2B_F11*[$)K=?CE: MW^R]CP$N^N":H&\I!8C3M<9?$Y[$ %]5ZA;<=S3._!8Q0%_TGDQ4^F/K\8RX M=+U/UKG'P]S>"5>OV:9R]+H4?'2HK A-F^=F1H%M&&SFT52Z_B?S<:;-A(AZ MN'8[\L'L"XE]]MKR0N%=FL;O!.VEUDPTS5>LF=GZ[:YT^\BLC730?"G>L-A4 M7@QZXGEF-?QJ1U(WJJ7R1L@<)X/:P*'*8IEUAY[64\8BQ>YGCFFO.+X)9'[D M\?MP0(&T(?49Q1Z*-6=#3^QC5Y50(A?+:#% 0\Y.+4WV_O5"YOC9S&":1CC] M3G_':E'+B)S1T^6:<I]:AR#O"5$(-;\N+YK<O;)5"UX$NQ=\TQ1^JKEO-W!$ MC=2Y4M'-]J#Z21GGHEQGCPZH#+_B"7CVH;L)N^ES%45+PDT_F_K+.[D-RQRT M^Z8]BT8:ECN!+1+A^=FKJZD8(-URF_&!3\;J,T4WNK=4[8TT(&<^_8I<;X9= MZMA9"(4U1WL%S+ JLEUH*%IG[F:*&%=C%G/M!^82QT]+TH)HA@O34&2I# WN M8#OO35TL@3:;2,W9 '$VG$6.\&K=A%4(H3#1U2;01+ MI/C HU3R)L^2WN:6 M:KD.3BO>ZQ<^W* &--' (06QD7MAT\?WX[[^^).>SBK6P,>Y)9W'BY17;N?4 M\3__*I8:31J75 FQ87@*0Y8:47>[1BRU)V![B49C.3AX)T>*'S[2&4NUV+43 MJ#,H7-5A?-%HW#V\@2-<3%CLN9I9A:6N>Q WLQGN:[^$(1_NF>60TBZ16W=& M%,-2H[KW4B+-5*[?CKQ.2B?N>H=<EBGKG$9]#!!0Z^<ZC7R(IN/HE2J![8Q2 M=W1X<^ZT2$(%#$?"P(U\5T7]=9O\5#R$,MX81O/4.LD:6+QO(I^I*O\>JA.( MN@FA*QT**^^K7BTTH]YM)>NHO"E"<_E;1:<MG.-BZ("F_))Y+J31Y YEBPP5 MTI"-J04LH-$=C\WK5_88X&YF P8XVM/?N66L4M7KPITHL=^A%N\Z)M#(U>G_ MF8),&J=UD#X3ZEGP4$-0YBTVU'HX!DAY, LY/;X%PD:* 0Y4O?DP .1Z86+1 MMJ+TR@(64@ID]O,M;)OU'FF,1JMATP^_[NP*C!3;<[5;+]MX]4$]Q2\Y":[ ML'D*.;DN0X/MP"('8A%-_M3W92B13^SNB\48>10F\O]J;P+Q.[>BY[F ?JOA MCVWP%DKWRZ176FL8@\3C#C1^[\CBC[%Z;T(]^;>56,F?^US]$W1G6!F[EF0) MC,2;GRT)UR-2M_O#42KS@2/+DGD?^ \04_\KGJ=G-0(HSDHB$Z;+V 5,( V% M9!6,%%,JS=ZK/PIR4?U;_!W_VUXO_^BU' ,T9^[4%>VS9\(F2*BU'^SD-N)Q MUI\M5/_OQOL;T^#?PS*6-)D*]>IK\XN#*8INOB6UF<9&1)XCDK5_?>;!;P0P MU7G<\E[_CTW>Q:[8)P;8^GQSI^X,%0/]?:J-=(_^7P;\[T;'@:B#2T$:LG=: MS\[>ZY;YMH-+R"!7:V].KLS7C_,%NNI)UU<-)(YUDXLD-M22?#TLS*B;2:K; M,^+% !M7^=!ON,PH8_PY7'VCL<>*;S:^$,A7%0SP^[U+-_ P!$KN[J<QM#&G MPLN3J=+T@TA::.8UO2I3M\+^GG$3A&X\PG^7P"^K>8ZJ+^H'N#L=&;-Y7 7\ M>;4UFBG3(Q32X!F(GE1P5E3E:KEBV+W<T[%[]:LG1W#&KFM@RO04\O7<L0MG MRA"[MI^ZUD9_WEW'Q:-+@KTX^A_!+7RDR'LGW=*L/?H5 TO#6\(=1X-T9+/I M;_M8WYB_BS^^-1*,F$:Z)DZ?46#KSDM6Z._N84)>_G$SZ[M^=_9H#*Q)D:B' MM2"?"Y*VWVSN\'/=D-XC<$P-&\VE!C':\* LY^(/R^J*!ZKETO17[86N,6^- MS3PD.:7 $[S6)AWF%8B2O+>-#FS" /67E<[O"U$<;V$GNY1.2N5Z2119*+T^ M*3USGS1DSKK1H U!.GFV979]7[.KD1#G,V="9F.IRP-4Y"&[!HTB"/05B:0H M'Y<SOVRC22%F*XD.^Q<"H7KA:HK?R"D(DPM],4"@Y7?LD1,)0U[@_,/#$O1% ML917DS'3 ?9LM)W6;)_U6&!EI%*YW)TM'"RB]R:H17B&!??CC!3W7 VM._5I M@PS[XSND-_D&M(H'2SY7S<29C*[)8P#<&]9K%%B:EO^&LG"+(W(=]Y'7O@)( MAJ]N%0/5@FZ?%,C3+W[SB;N6-+?U_:I]S/:U)AN#)1Z8:BJHI8L#?04#$*X% MM&PTITQ9Z8J2,#XWK8@8M>W9!1K!JD?@?S S6#<TW#*N([5L[F[&\*)AYI&' M(<TQ,=0GCG?8E0_F%P4VXXZ[25)>UP@X/2[% )O<UA[S:K9NF_3S^I-&#!/? M&3J".2^C8D.9YI>\!4W-R[@',<#LN!OD0(8##02#L;<U2M#[(.S\W+SK:MZL M=RNJ')88OS2S$!6Q?9CZ\?0!FBG;E8&PM>T1MG-C9HW%)JD;!I"?@\P0Y2(B ML*%Q+85;;QK_@^BAEI<6_X<2I>.@8]!]<RARE])+.?!W?K8F0<S)=!@ ]E-Z M_9)J)4&.Q7,%%DNU0_\X+1 1Y _^1L88>:-TWK%61M'XY,_._AN@9E;G!W]> M#3J[E>['1-OHU^>AZ'AK=S&.C-?M;$K6G8"PI0Y0 /WNGKG_VK?_1&)J2EH. M ]BQOH-\%>:MP&W-4E[_Q8_N+S(]/VOR89G;1P>V88 =/,U-5EX]$.6^DC " M_ONW,0#Y0#4&2-X#HW#.6>&I^JN0%J2Q9!N\XJWQHP@T^O GU-@X\(:KE^VA M XLST,_A-UO1Q)FN'AC@S2[X1W^,><C,C^*%I9 _9N+/M])I\N^1N?_/CY]8 MHXG7,<#UJ6WT5P'LIG2GJNZW%+A3(X]P.0O/0%Z=7T6IHCG08RJVS*,3QPPR MN]W6XH/J>C2T,(T^!:INJQN$Z=<.6A?O%8C.Q51D6\@0#Q8<9(RY?B#E_=Y, M^9FL_LD!W:8L4X!T-@-P-72^O]9U&,UN/4Z>$2M!7><P![DX-O;8T$APG((_ MH,^/ 8_AHZ!?^,Q\J;D%^$JUFM><FJ!7OCK5^R[&>UDTGKEZ:;7FT<5BY'K% M28+!0KBK"9XNV*UQ<J0'S;BKU$3!X"TSM!1\N"EU#WXYS;7N.1%;&0:(<;K8 M&,6%:NU-< C>\O;)0D(5D(K77UO2-#'D)UNRC>>IJ09/OKNSHR&6TD:A-!&L M>.RHH2$K7IADX^U2H)3MX]<DPUJSLR%R2Z)EV^Y+G+FN[.<J_Z8WW XE9 &' M5#4STPQ6L9Z=>Y-K(Z*5B.?[WKR]1!$/39Y2P!<WVSFVZ7E>(A)37RG1?:4] M*KRZJP$59@ '??0IT1]J?J,U466E<X'J_6AFI+(I@XQ]/*&K,FV+>$'(3&%0 MJ;27_)#ZX<0:_\2T"E-^I[]&'+6O<0*7W[&F*6&&[6&J1?J$8I]J_8T^.4VU M$LU@'GP1#/#.OZX2O$]E;Y&3CP&ND4*.0,?!1?QC=&SYDJ1R$PH,"NY\X6 ; M$!&2HYGF(X.<1[:&A:OZ]9P+(1S.A!54(=A>96B6XN3".NAH!1+F6;*78&N1 M?2?*,DGXAV6^= [B(9745?64L)1:*VR_L[83>X93:G^Z!VZ!(NT*B2&]##K8 M;H4-A1TL*L( ^ZMQ$+O%NOU#D.HFE<X&)$T_O#D<PG4\@&;(;3 ^(!BJV\:N M0/H ^XFH!@$A];.0W,BP)%;0O!)"1!+M<QO]O0.RO"833\(YSKV4>NKLKG(/ M7/1W[BS0+:T8H"<#-%%ACSI3ZJ_"PO0>^A$*WPFNU?31 B0,M//="+MY?1+! MTN*KA.P["X-BR^\/8+CC]/$)--TU.#N=;"Q[.PJUOFS\1RP,D EH@\CG'(B) MU1ED^1TV8/!/X (16]AV#:QY,-6GV&<L#)K(;&!#/QF'GQUC(:!$==_4K5S, MA4Q'H(4@)B888'F 8G,2CO9-77V<\OJ3;I?Q'R,:\I%'+.TTE0FV6J>M%7V7 M$&CJNE3_C)QBQBHU<GYA(YM?3:;C6<%:ZFJWI"-7:6#GE^73!=T.&![$1FB( M_N+55CZFF.27- _OXPE<@4 9;YYQKU1!+X];5-X:SG>2"*&TG4V]=H0[8+G] M<:YY)O>)>;N^B+DKQ>W&^>0>15TU"%O*.);E#LCLIQ*-#Z3<#7+SB^O;2B@A M FQ&R.C6'=47,# E#3/U:/TB)F1\O%># 6KQ03N]]'RH8R-L$WPAA+ TT&GP MD0E8-1?;\(*.3. =6( C\?!-_!3>Z0.& 1B"2ZQ6VJ*H2RC@VY' 913;YV9) M%D3):5)^_=*7:KE<]=31D _YM<.Y1_7OKDU,TZWYY/IA$^UE'V3YVQ$:227_ M$-D^FVCYU*!&Y$3A;5,0P4,")@J"$!9$[Y8K/W)-[SWMAE1#O4!RHIQ%!Q69 MV&F3W]ZI3E+(W-TA^BUJ:/O'<1.*V&I^&T[Q,^M.=F3RS"H[N7/(3 =? DGD M[=$6)6$W#>3 ;#Z/"L)6Y)@,NL3_M#RFGJX=0:E'6 9URH.U/AB?5&/\Z'&+ MCGTC47DL^KX28\+GGDSAZW5A=(><-EL\G1?,S2Q1G:VMN-9N/1I9!1<HWB9= MA&L_[.=[J>-&QW//<+'JZ$:)E.0NZ=<C_1C8DQ@WZ@QQC;&F8U.RZ0?WVJ3S M]-9$2/<G?;9NB+<CJ%QTV3ZVN<9(@Q^ZM^_K=G(?3K1P^U?O3F7:SGZGV7BN MLCV9TQ/_S$UD@U(F+MW4MG\Y:Y,R-#6\=,F\Q9=]</M6WB;+J=1K0J_LI,F- M\/MI;^@.Q:A4YYN8V7;Q=*RBA*,GOG]R9X/;R#-O7-'P:1P.P5D[]71IA0MM MB9W,?]SG7I62G[,4HO9_7NR1-]D5R!]D1AC(5H$0CK6?@UY%0C3V"CI'")YM MQ#++/=>Z;G8?,G4?+($M=;=2XDM<NSR$>YHHJ$H$/5S5*/OER:"5;&5M$@FQ M*-_2*I\<Z\^3ED_A]E5?1ENN?6AJ*F0Y7%%9"F&1_/[):\ 5S38B5BC>;U_: M!B[S;S3<#/_V_,VW5(;!SV0RGTA:XIOUW\?GI>XKY.EDLPL>VZ)+:#% 2.W< M!IB$QT]^5-M].9^W3W.\6,7^JG*5*1=I8:K)QUB+]"=7+;#E$IN\G)\)^A1H M*4OJ.5." 6[2)L\F>O)8Z86(X\F@_NMB^W3A%TY-AS?-UR6NUU9D=ID[P6X8 M5;F;L243%G4!3A3S1$*&^FN5-I6FNS>]]:$BG'/;-]EH#1.8)4Z&?3*ASGQ% MI!T3FC@3K"HN9'(1LAQ$7:.?[\NBM>&BC;8BJPR;-*+%'2QC#H+WW#28G8J* M6J8SN#B0NLEM>,_%\0OFMBT*@TSM7G36IDK=QS/>*19B$-=F[*(,SZ+ZR(KS M'$C#GA"] VB9Q-?O3E_.2_+*,A^PUR)B4?/CZ2.[\BCL \?VZSH-3ZRK,('G MY8W=(0[T:3FTE_1D25G:Q%Y0^92OJE<B[3.GS0IX[1;C(K07]@'>AY&TH4^2 M?/@W9>G6YW-)UYD4CVU,JDM+(W%M6U0B%4?3%KS3^->DUSQ03VU3:6&/^XU_ MJ"B/_];Y*-K@77((F2GCB6ON1_M&'Y!:W_+ -17?'H%/K@),"]D\^4E-5Y.X MTI<;$OGNNZ=55=941#\2;&<?X\4E(/&Y+;OJ)XL'N5RBER[ 3J/A\.U."EF[ MQ#)>BV3AHCH&\(?-3E"[LWE0:3?PQ1)0+7 PW\=-/%[CUTU#NJ0+C'[H:J*A MYA<2&;FL$ACV:&&^"&5),]L=QQCY8<HB.5+N16\N&?&K[TL!;*YSGONR3$(4 M2W?"2C)FR(?7I'-4%>[G4#HS:O7B*'MI]3,/XFC6+5RS1\]C 'Z=&QA QZH* MTG9G^JP5_2S_\R2_K"?LMO>=LY -[P=S^4JZ \*KSEF%B_L+\-O;VN\.N1PE M3D>DP$^2IUO802<'V--U[OHTSTD_K9*)WT&A8Y+'!ZTWE@^R36LHXK,;QVRM M(O.UHB=D[F#+&;']"<,$!L"!G'*!9U\;H .6L*VU,?I;;=W>V<K>V;K&YD8' MVC<. ^3J&:-.9&1_5HG_2<7:M^'B558,T& (<7?% *V9>\>Y&R"^J9SOO+RV MXFA!5#8&L%\RWC\P7AO6Q59O:!0#@O1Y*TJ[JQ6TBVWVQAY _NAT(D(I=EL) M@3;#;F9*Z'PSR/[*,2Z:]GK=BIT]"A^+*^N/ 9Q@@(ZC5.SK%(+M&6')?Z>2 MS7+V9GQ.V&77X8E[SQCXE.L4M^,HI_(^]MCU@R=L^6=O"EA5&%:5^]_WEHJ= MI2\]QP?>KS V97I U%1] 4,@- F2#XE[C#/G.Q.XHIQ"Q=Q('.MKL"]YGOD M><K0<9313A3Q0H-RY-)SE>GQ*%[:;POY&]!P&6)TZW:V$#T<RCIFTZ1"'IP_ M4K==M(T2/B1/G65@<FK87PFM,RL!%&C]7[#A9A"6<6<\*CM:URXYO&ZZC-:G MWW?X<()<2SA,=QJL7_S@C<^KRCW2N:=S!B,G%QYF1-55;A[W0QJE(8,.==M] MV+8!X5.;0"\"T]_OD1\=V'!O10F.G"DQH,] NZEHNG5T:ABV#X B1XHW94IL M94H(OV2.[D*0YDE.9^6MT.,%2,N'NN)CRP6-S9;Q#ZU;X1X@?42,49UJ_OE. M.Z*V"C^^S]P",VGKV< ><C5;L+V+$NK\0RDO#) U#YE.10MOG%J,^UA0F&@4 MS8-V>HP/&>U/#R#85LJ\[B1<].P$/&_44W+25W+2>VZG!3R;5+<F-GVT@@'" MC'I]<;]FK,4<1:WU/U;"?4LM#&4\7:HQMSQ,VVN]-TB9_=4F--NNKGCC4"WZ MSA)3OVVK(>\+,->R4-W;CRY=):Q+DF$RB\DJ^M_GOAY/D+ZD8-]3ZJ_\D-^_ M:O_4X;0L(KH>?9T[5(<&Q<W$*EZR](J><V,+OXTA1+ <CY-'0R[I/3U9U6ZN M?+;&E4<JMQ*K^^KWCLN=N*'O\0^6D]PS1I%[XGG;22>C7Z5H5"S8X$YLRMM' MVHXT'/!TXZ%:T"H]MA,<WV)UN.D2\<91(/?S2A-N^Z8&,VY_ ,S%<E'R^F ( M>WA_L4J%[RK9/45)S_L$=K'S\6%.VD//B@82/Q6_TONA\U+[S74ZJ<U6ST]U ME-<5.4_4 EZ]GD3OOZ3[=O/>[?J(\4HU"-ZJ:YEHS+NOBPJN20\GZ%Z9M4@L MB[=ZO@8'5MY],:ZTV-8PA/=B^]UG;=Q7?B-,Q;*T\.E+A0>GELNPNWLSI1\4 M'%N>W D@??D!Q,\^@Z"5&G&.2.6*7E%4HNKB:'S,9/NL;$*\+-Q8^*E@V91# MM-1>6NA^DG6V-@G !-1_(OC@1W8U8A*DH?JV!$EFS5S/ID4D-Q">H/V1$R>G M2I?)1UTBF!-(^>T?IZJR?XLJL-"*AEIKXMB.\O9Q+O>IXQ'VI)P.N$KZ,_@[ M8( )M[K]2?1#B.T4MK5V.KY/^+1<LUP7= ;')I1TSZ(2XOLVZ@@<#;@R_-?D MM>P8?:S?H2>P?672\EX:>KQ6K.FLU0I8A87]7)2WJ)K4\HW.*BFF,0 NXH@* M_"^L:BW)%TM>; AK*,< FU73QUL0+G#9-F2Y I4=M"%*DNW>N"D"VX8M&H[\ M;$C>(=^(+I\"A@%N4=A; 9N.-]U(L+L#G ^R7+?Z)PS3$[$_.;,S@O1\74U* MS&**&]VBTE !KUA)]^P7.)U:';&3ALZ8O^1*BB\P.@L'3R=EPFN890<,$J=F M%6<-'==CRT%UX&B^?X'B0?'%>XTO<CR]O+]@@!'Y\8KFX6TWBNG=)/>L6\*Y M?8QUJWBPV^&P1.JGV1-VE'94V,.0K=&/F@_EF_H3YM!L 6-'L0PU,K6#>@&9 MUN?S<J66TX,6?_#I<[L+N=D<HP]@35$MW84^C/;T@2Z..-K2Q,SO]?SCQD3% M3[0-?/D*H";P8UTN*75!C_*ZH* 17OG";\0S,'M/&_W%M2E#"O"+;WL R^[H M41H;?!++V *#X?D<CJ)N_LQV%N[G2<Y);N@O<YMZ:G>$]H)]>_F7R2D\%_<' MG&/DCT8@AR,G)!7ENA3F!48\L7HPM+ZG-G2S8PH".?D_D8[_F;QQN8^E&SD6 MXN0Y1.Q*,NX]Y,[M:/A2_C0438G3IZE B=/EGGMF5M?_><?]2 QDK#JYJWO2 M 4E_ ;KL<DM>:<<HTR6#.GCU K<Z[61?2R=N&\4S_/M,M%J=P,)"J->K2#"7 M2,+-C2:<+0TY(X9"9,_C?A=%6./)T%%P":DD0P6OEH%WE\3+VR8.Z*)4L:=0 M+4GMBX2M2==J=B\6K^EO3)M%#T^YA(4?O-V\W)G"^ 08$U]/DAS 7<'99\2- M4BN)&2<WH&MV#X_(]Y;=C7U=&%9S-@0+FJ\(]8GKS8RV(&"-EJ/M#!85D;@: M/C3J?:=R9/. @F1B7+IOL*"4:+/ Y$N"XM[-L ZSGLD%<@O<FG4XH62 4OEA MNAGGJ!V%(?V>NF#S^+ _1<@![-*Z SSH5LG*8E&XX%$:_S>5!ZC'5V7*A>$[ M^^BK:K=$)/,5IVQUIG9OH:H,0H8$%571"$6[E7NW$Q4 -_38,AU*XGDLD_@V M?/>@\')L\TA^MGL2^Z[T;G\_5>34TOT^H@R!)ZD+SW$G<+.6:M1FT<D>V4C0 MW>JZ&$MAXOS+BS%WFT*/UY0&:@"[\Z]>^N%38JLJ/?D [5$FQR'EE(]E.VSP M/KX'9!X!.O_L))YP.#D6#7Z* ;"3_B'WDO_^@\[3"KIERM*5#0;G<B+#@A<. M:@O@Y,(@7R%P^,2<SA?[[KRVXBBKLI4IY9 R_JERF&!SW?<1R'8<]R;GBX.U M!V_.2GSF9[@==#_GBZF1GPT</&B'J$K%'A1VUPDVP[YC>Y XSGTIO;/O7NCC MR#)LNS-]AL<&.[,W/KC(]J-LL(5Q5^F\F*,&G.IX=LF]^+3RZ&S_.ALXN.>, M$.=(C_,G%18,8#!RAJM\1K67,'\!>OV,>S_;H+ECY-09:A89V[EK?N2R?;JD M"AZ"8P Y(O#P(0:0[0<K2,72=<NVBN5!*9$Q'5\_XK>49F]#[Y62A/:%-2W, M<XS77K@UUX)G.U*SPTYEM%NM/%P@3+%I8B-KZ=O?M;"Y0>Y.]6(VR8-]ERC. MP6>NO[%#_D!2:9C'95-B1'.@8+;F\P?[<'?EGM-JM\S5XU.N*_P!XCUVUM@* M.Y;4VAHV1U0@)<CS;N7"#T:E4[[?E%*6MT$.QLK>LCYJZ,OK(@.A4_<=.2Z' M7G$:KS41JF_%#7H1IL GO[:7\,TCAF'B6SPT>](&K(IML7;XD!^Q'?D]#/"* M@&,W#0.\+3R3\54WDM[PO%=UK[7.]KS%*IT1'X*L[N]9">9@@('EA4&G0+AY M74Y"^"%53MD8MBC%Y%E_#43\J*G,\,!F@R8))<PXNSFV/4%1 =*?7]IQ.1QJ M'MS$#R5082"FD]0F-I)%([\NGZ4:F23JHF'@&ZGH&W4'Q]A36^FYVAIU+56= MP 2=C<V\/;@K]IL-4VK&P.C)R6!E:P"?B_I37C(=^.W&TGD/8MUR&U0'QRG+ M"WP/790Z-D;TL15XSAH#:,"..K26*.QZE*/JW6+'?9I#MR^67+2YII+_A5Z^ MRM5@0FR^5U?/FO)=733+\?Q=W=8[7WV?$3ZQ;M0NM3?8CLWH5Q)>GR(5798/ MM9*:#$^OG"^SZGKZX,.TG?H-Z97EX7#+^( ?O][LZSI?#P/BF;WX:I Z9R^/ M<K2VV?MP#2"!)+-,,1QYQ]40=%MQN8C[5<"*>+.#R.[:1Y^\"]]Z'A;'I38? MG'KO\WQ+"PM9,0!@GL#!I?2WN)'B0O@\.(1^_=4GU+O%\E1-1X)YWR)5$997 M/@Q%M\802^.2+4]]L3VDH+&.<84/.TP:5E^;['"YI!!\I_P:<-K(6%@#>%9H ME7.PW \VI3/^X*4;^TW*DBQJ4D%HA.)%Q,OG<+&[% DOP5 FGURG1SN(_$*K MX1L&"?C]0Z:U;B]T7BQ$T8<+'FY8X):,NR\7JLJUUTOM07A+EQQ$0X4>TS-( M.@_RTJ7LPVF/:,VF?!41W,&1^UJ[U4DV#GE3!NUT'S6*9]EP?#>L!V?F94IP M5B55'C=NG;?*P]*)M=@3"3&]AO/2H[IB-I4;FF4B,+=.5X18?KBC0_TYC:G, M!TY*0L"/W_-V,?8"A#76[N;H.Q<Q@&$N^_/2:D$,<(T Q1H\Y 7!'.F$0K/ M%1[&8 #5A6J%?!#YBIM$I&+QL=1M^W+!<&*4=?Y/>X83?5D\0=$SVT*V:1R; MI./6'X9P>L91BB7^!=>J2T_9$5G*,6-N]30L%](.%^;7/_:%M'RD'3 Z^Z!/ MVW@3'GE=Q<]NHH3,-.R[3*GUPYW-\))^GYPK4RZ%8YX']R?@/G)I/@3=Z^K6 MQ*%1\JPO>=DET]O 7FZ&"P]P14Y;Q^T2$4Y>%X="Q!I+>A.XR1(83S;%3K3D M=@GOE9OMY?,EK9;5C?F7FS\$[_5Z<K9E/$:)]I7>E.HH]A+R]U/A@5__>*<" M@)VNH%T<4 R9AH]]LA6&$C:HO$?-N18I<3Y'C&XRWL<GJF5=>6#([I#>V=G] M+%B#'?<F$#DS_ZG15]MUNI7>9:A!-M?!GOOU,PH:WN!T./093J:>N^@/17OC M1&;\;,7-=GM+8H/9^, &^7QKC3P&(#E2V>M4/;+92#9)?'YM3I:(*//+NZYF M0"/5O>/>2,&-U]_$:6T$MCX"Q)HCC$YZ$KI-KSP8KW19Z!4,=)=27Z%[5.8: M]!+<0MAI;:RV8Q>7/GU]J#"ID/$YODH&+Y77_+J6VJP70?]FR>&5B4:KB=F/ M-!-<"28!3&)S+_GS?:];"JI EK;#NZEUX&:+DY0=O%.=#%*>#S' 3E&)/WS_ M>L N<:,2180?US*=W"3N1V.D[O@S]2?7PI++2BL-LEG?;47J>=<$-8Z2&PP. MV/@RC4Y8@DV2]K;6U*M\!Y8NB>"^RUVI'<09D+]=_OIFM&M>4$%5 (,E'4.@ M27"$X$GPZV'\DI+71 ,VFI_NTO5\$Z.2@&C*4BUB .@H9!*RQ&6G42K/A_)M M_/%3D ?FXR^9OTB$NWX^?'*1(Q&]?;9WLP*1*C-X#'/T,!EU^_$=SOVZ[QB@ M5D%49M!\/-Q\TC!B0[(;@]V<CZG(]GU/!J(QP"/(&\^'<8BL# SPV+(550+^ MAI439QO]TK\C<VZSUNVT[J@M(])]6]$G:\FG,5(ZT"/^"\Y]Y=;O5+%S&N2C M[L6*E?W"%MZGI.^2YUD<'RX3C@Y#C5*%*CI,PYT^9G6UZ%8(I!,K=EU>15!7 MFN671H=>UALWR&BSG:'55,'NULQ]RX,80*+HJ%PJ.#L3 [260!Z@ULQX+<5I M:%LN:[ZU=R(GX#](=3KUO1,'LQ+<5#8YJH,O<$YB@ WT3^_(/O)=GM\Z9/+7 M+3&?X,,"-OR>H[TFEI7ONS$)Z3!'O\<Q.=<.Z]D\)GGND]53BO/T%'8&:].L M.*N[]D-/*1WB$X^D&\<U)WBOMIGMR &J(=$WY-( K\9<L:2/X8!9L#?7L48 MB*<M15?V8WDGMU@*/=6$60'BF0."FQJ?R([3K;T>:\T2& F[W<< +[XDB[%6 MA(G..;-.=5I11QD8M5,Z'EN=]JLOD^0H.8TP#PU_I6]'-'&RZ[P+H-M0),H; MVK&+8(QY3OIH,[+%OD3I2M;7J"*4I.?SEX(NX*!A":-2EPR?< 3"G5GL<>_% MO.VC!TD)S)G!8;XL#+E= J1JA&7AUFV;!4:SL4=T8O6XV*VXV7F$7CIL<7ZR MPYK!D)^LU8(A2!SO).)^8<#!AZV4<G494$G+W-V9%_4+MX\H<;JMT.!W>0Z6 MPS91AM]OE>@*ULIIWF@W+'S&7Y_K>WU7 1V24UKBBMAKZ5LTL01[$+7=W_*Z M*4Z+Z++A"RQIKHQ<M+EV>C?2H_ &@=O6]X0SCXQ)=WO5RLK*\H_-^EZ?<E\X M-?J?5AQBSX>-@2VQ'0[$,9+"<+7 @(56MNT)NFOIP'Z1K!'%XTGGW"G"77/4 M]1/3V'03:$=EY/77'+<^M+@6FR<O%33/UMQ@:"N8+WJT'(@<*?3V34.[.$[U MDPI'VV[.OWINNT<TR.EZ*)/Q\KJA/^YQ_[[B^40#V/V1[GQ1 -C";CX>>GH? M$-2?HL, [_P@(USMA.-_+>K\<P'?A2O](@FE='@WG GWA"<3!*^T$;62=0R$ M'QR^EDXE2H-4/23$KQ?_VM/;7VS7K6143E US0H^7H(=M:6V0=$>F=B%MX3[ M>EY\HN>TY -C8HV'%/UV=1 &6/X(F6:%_B(:WT9.&!H%C]JPL!&9DSNNG/D' M0A204Q:'<.KX5D9GA/"TQV7L,4;H?%$SWX7L=X&W(Y1$WS$R;Q$R"?J%>ZQW M71.G99D77[&NV6/#GFXLL2U-L-0O5L/M6<18Q]CG#X12I4S"E4P>+T> 4/L: MIPM:0OR[>WS&6WU="X1),KX3Y!['('AY]I&7;T"5:#!_EFP5)7JS+G!2N_!W M<9&ZP5<LOF^>T&][_UW8_\:P%;??Z;K&R8H72/6 [^>Q'+?/'..V_/1G^RBV M_O. MY3J9GZR<XZC'%N,TG^#)E[]<@:.C3)L:CJYX.@7\O\XW@C3Z!WRD7;3 M;X4^&#T92?F-0:W^&7ES.J**2:?6BO.8P)FT9Q<9:NKD'V]'@8ZNHH\I?Y-E MG))]88 =4MRV[QWQ6E#" %(#?Q&P\E@]H7_=(VF^?;J\X9/;&U8-F30^7=!6 MER'ZUO'&^/#- :63!TZK'>(7-S_SK_FK/>SPUW\Q[-3.Z)U9E+-KOAE+M[R% MD(E>L26Q:VEN 5?=-VBDJZX\&]_116)K]1YNJ$F/1F__N3FWVE^2Y1>3V)G& MKYHX$/KGHU70S!7KZK]/):FM,3?A=ER88'^>G9F=!WAKQ,2<1"C6I,/PN.X[ M@LJ^'7H:@M4YSRF\_%+75ZV]?1@ !UO@U?_>7^L19'?\'@667I]_0*]9._M\ MU,ABVO^GI/N?#Y,Q>_H&E'IC*P9HLUO&T+D@+CGTYO6KH*W^IP_PM76E".K3 MO5X)4VHJ4X1C -OM\"E1I/P<E%0/J:'S6(!T7<6L7,??=')BAX(M^!B.9G@P M3]T/F>4,^RRIUSHBUJIZ:(R\"49!F8DQP&?ONA.!6DE[_H?'\D>%>RG0.9,& M=.D 449!I]F-=%.O0)0(K.7Z\^]S[@W9+;Y-L%GENK+8%D4MC;<I.(H:)^RF M9Q+:&LS>I%"5TIVP C]$G$M\]GS?84Q"!*-;O^*7K/M*WTE&V=T>/%#9D6G5 MW"F F:18C?L6SHE7*\C$.V3GM#.Z6E)>^W!;K(WV>8]WGREC9QS$%AP:6L%\ M/=0!I>.0C7X(:;1$F4S*[0I9@<=+0DW6->$-&("B\*5SC9)2Q4"UG,.-^)SO MCZU"S1Y]9^$'ZB\G%,R'2PY*+']-%%5*6NN0JPIL>@!IX+?-H=UZGY;+TQV4 MSI^04,<\EHEUACWH7LS<#3K8O:N45&<*!7V+0C-HS#/8$<\%&6:W=EB"EOLK MCFLO3-?,?!Y R66LP1$CB/%[V8Q<]6,]HI,\RHT9+]+" W*LC/&7= <6O^Q2 M)V;K35H56S@9*I %W[*;P_L2 7=Z07Z;W.(+^7,7R,XXA+:;!/E1E*%L1J\U MZH!I!5R6V2+=1$%Y1WD=_1;$.-^?W;IC!*90FE,I]?F8F)=$&ZO37U"=S>+, MS?F@@O$"N4_NAYWND$\KV+A3=GUK,B>M>YRR(<_'+%<=%E@T01_VJ$E46$Q) M>/SB$F$HD<R6&T#AVWEQ,6"LA6*$=N;^--:=L VD09.8:=<2A-05G>WQEX T M02]9778W>!1YD?-;T:.SRF$5.ZD1NLMM?;F<<@,.K.G%2%*(< &,\00=;YVW M1GT4-;8:QD =M=&I<Y^(MIW+H4=(CU!0= 0QB&SJ)$2Q[\XD4!R([1\_\S\K ME>'? <]RO)'QG2V!9BX:FF( HH)-YRI[4?V!9[NWAM)$^]Q][^C,*:>Q\ [T MUK%L$HJ)%V2<(A[OXA?D9EK./RR2=\B"F$U61TBT6M\.;7-<]#5K>*?G*,"O M\,Y) (*TU0B5? ^C5.2/*!]K]8,UP'Z<3ZB%/5+U&DO"Q;((V*IA;>*.C=5' MIN%\Z[D:L=6^R2Y+O(:;=&I-5?$>)*X7)*A;K+N&JIO)"01?CM(22HNEM"6Y M>D'.N>,[H9O#=FAB/_ZH ]:3\8%@,P9XZ8 !_-W#^Q3[=#N8OW;VV&& @$$D M=D!>RAA)"$)J8D/(W@U!![C7[9"#=PHOGW_#O A]LF0.AS1:>3_# ,E)?"A< M*.HFQ6;Z[ML/5^>"RC% IC+62[6:1:I%:HRT7US2]Y^LX**Y@LIIL:VA\C\* M0HG'BU!0NNI\D=.<D>U"9AC/?Z'@C]%7*_W9[B_1)4.P)CES"-_.U1^60%'< M3:[!(L'B)J/B<9O3.^,PVKH5"VQEQ?GI!R.PDPGI[:%!X[2BJ>8D%1@4&(LV M&#L1VW\*"_23HCE6$<">'TAVF5+"4L(?(<B?>[G]%!@]Z\^!14!L^4+58,@< M-K#!WQ/P2Z"I?P!HQ%:B6:+Y/Z)_&<MHI0E:^AR2!A+K_EI<X-LYAB(,P!MQ MXL/=5/9G G[%\5\DX)_GU4]36GK.#7>">PI/5!2V-""U,,#/Z9/R8_K\S5S] MWPKU?YI]_[5)W9X+VMVT9(9$>V5N6)_>=<< <[#F^$2:9OK^-7VKU2Z!9H2S M_!*WB:ML8> +[M5")$<A*C:D[A2O TLGR=MF_45%=5CZ0TT%QW@0;'I'"W+, MA+H"66W ^HW@7JBC6-.T.)F*APCGN>V.3;)OVHL?/R=Q*JHI#C[30?:="B#5 MYLLRTZV86:T/R@=2+#Z=,B[Q18??<Q=>SL4 >+O(IR6^&, (2\<^!F@:WHWE M*@I-6=CR?@#:I)JG@>F4UU2KJQ<6L@VRA&\SV' H\831XD8W4K$D18NB^+(/ M5F_=\Y_-YU,,EM9YK&-Q-Y]U4H7+)MH8W*#H *WZ>"J/9EK<:41[K=<A01A@ M%-OYD.\CC3& ].$TB@)[=+7<;^+I>;N '+<]>--W "4;M93X04>WC'\\OU&, MU/&JQZ2B\N.74*-#0A1OOHJM1I29+4&6LYK/Q4,J&Z$0LA!VK7FD:C0N;M:- MVFD,$.B!XL-V:"?;:$(,@!""-%:C:;!]DX\;!L#% *?TXG.,><A*#:BNI;N] MC;=TIN51K+Y_;29VFW\3<OSI-!6TUT5\'$2WE.MN/!^0.JM'VYBAU_W%FD:B M.D0P4E#(GD$Q$,2+&\F0Q2:,&$%)]LQ"4$<CD!TP!BA*13,M[]3]AK/GTJ)Y MLT1FJW675OU81IB]I9V098G%T61U]UOV5QU;=L=,'B>ZTK-09J54I!'DHE6E M<&%0B;B=_X8K_(&0XOBLHE23"]XFV^N:]6T(T@V&[2F.MPNP!W (!C!1^I/K MI&O?>L*$(./<#P?L,A(/;DFW#T8]A(>/*Y8JZ[&-%MW6.(SP9\0-]UC*H@C7 M?[<K\K8 \ER?N*3<_M.CNV_>4J^.32:)<1F^@JJ>6O\)Q9]GRV(YR+%X-JZ6 M1\4EW;+!EE0]MDE$I'?,8+W_RKX"Y5W:H'OQ(X!]MT,+M^KZ_/L1&9XONV $ MU1?KFU*QHH["DU#*O4H!?N6W$_2H9D3HGKI/]E_2 3P[!2'%]IRU51C@%08X MLQ*?X]7Q%I\!AT2Y$VKPCZ^4Z<9^+FDA/4YC@?*K?H[AJ[K]=8;QR0A>DY#_ MGNAMR2\^'BR^TM*$5"="TSL:D !2%\IG/FYDH1!L_1A@'@+_B;KQN^(:75VI M@[[.MLRI^X7]X'_!=0XBZS]32!W_M @6%8%J'O>5>$*[Z[#[R)\0ALEAZQ7> M$?(IX[LLV./C>- N!L PZGCR8ZP!'>LDU2+0U"B;P2VP&+3&0%[C%VI& #= M OV+YU+Y?^4*M+,-]L< ^]._&K'R>X^:')=66I:[3TY,=Q)\QO;G921\,1-U M=7KV32^AX'I%.P:(Q>J5,@^1OD?-G>LI]JV!)7[1ZI8Z<Y.!V9]GRE]6H]=# M&1U?.]O? $$::V1H(#TM%3\'Q_>?,F?U>@1-O+W3('?#?,17EP62B0$.L\XG MJ%OZOSI!_X2UG]"SVB,Y8 T[%-L_9?'Z0TW(5VDTK7#3ZO)ZW4UL@Z1Q"%*5 MSB%_L!]R#IU!*0NU?@#]5VOM?T.J_0,D9J2A$3WW+,X!&:>^.X^=YMO 36PR MLF.%-,X!88!S310: _PC#OZ2-W\MOS\RX/3_) /_!W!T4A@/U\9C@-=>K^N8 M^40OU.URQ6Z302X5IE"@KG;,^H)'UF%AN^#^*HTWX"_VKVM)D.DHN=GYK%+4 M.^$JGX*%MJI'"[O!W=I\*;S\TF7!G'GJ%X*Y.9KHAPH#2[RZ5!&*X=U#WNU, MNAXM#B\Y<76#Q0I%-,+T%0K2,RS'HP,RTXRL8J_(V3--XA&8A<HX]=YD.K,J MA;6J$^P;P@=NW=J^[O4R*/U=@>D+O4NXD_Y29YRX@^6IP?M!:&%WWWG%H4-E M_\X=2U6901V^"A'EVS!$B_A),-QKUUQ^P)<!RFB8W[!*&Q:GP],6G_@@LTCJ ME 38%OM?S;T'5%-=TR@<1$2:B%*D1D6D@R!%I 1$0$2D%T&("DH3D-X)B((B M$ $%!20@O4:DU]"K="3TWA%)J"&D_ =\GN=]W^_[[EW__=>Z:_V+;%9.SNP] MLV=FSY[99^\S0/5QY#L2=Q%6L>?5E00MW,"8S=;<P86'7+PVZ"B-6DT8UJ\) M#WTK_85U3BL8EA'P09NC^8YSB<Q(IV_2;MN]/NJ %BX3_GE&L"E.;$"^J\LO M[]V3D1B'.UUOXG_"=[*EP. 'WB$M; GGQB;'+,9OBU$^;"O18IVICN\[Y[>7 M<J8W_$:ZZL>37(/9%#?2Y[[<\=/]Z[S!(9S0\G N5Y;P2I0,.GJB\"/]3<\9 MQF_IE$"7<_<%.68GU'4N/*&Z=J^@(>$J>'.P/%JA_Z?%P^H6+B.H!&PY'[8_ MR0/XNKVF9-!FE9+*CW</C;1^!'P=)&X3<OP!QS 9<-BG/2SGU+8WX)_9FQ!S M>VD+8M:V$?I8HX0E"3)(U J,$<K(<V#%6R:Z>;D(E<A@2Y!%W\<-S[D<&.@Y MIK_/T)?0+G-PT6#IQ)UO2V!KUCXW;=SG<7HS?Y%]YZG2:]\0"XT;<V_56DKZ M9OFDDDQ_"R7'DD$\@KN0GGR;GV&K1N[UK-URW#I9!:)TW!XPQV?M8OQ1C!)E MJ9ZM2SO9)@\'1X,. RKYRK 7UVZ&=V.58I5*ROIN.38'/EMMKNS2B& YZ=Y! M%#Z';I"-&U .+EE]9*P6<Y6AL_4:(NJ%-@?%B%B.]1[27<SJ4#*V2G>><NRK MTL5!I>?3XT$I$I=5WM/4$[H?/\#YZ9;W+U'DHTH6GCW)\HHQ33;GJ<A?Q"CN MYM]]K_V$797EV83IY@7_0U^]%-\OM86I#A[R+53-;G>2JO(6D!D<L,EX4A5' M(P88C\\&/;RJO5[=[A,1II<[4-[M=K);?@M;3TTQL:!+TFL19::_+S 7%PZR MLD)D&)4=B7B: (Q4E3R=Z54C1]C")6#D G-JGVT?G15SC>Y-_;X3+AK,);I_ M_E-QBN^B$4<[=ZI;] '!F?L 5@Z64NC<-O9A^/K([7U7NS'__%:_=O2'1D*N M8D<+R%-!K\7'?>KF\.,J+=,GYCE*?66S-F_3XJ2O4+@(<#WG+57UP(J;%25T MCI&$.56]1*(+6M$CU9RV)WFJJX"!]1.7%HY]!^/&)=W!%GQX4=I9LBJ3>HDI M)";C_*CR9!11&-98=QTM;:%/I_7FD@.L2 3NVOW=Q.J"XUIRXEMH8Y B+S"X MKPYX(-E&FYZ^Z"OMKNU_:KMY?YD^X\W3T?:3(+G=@@#J5HZEHI2IJ>XL#<;? MDVDQ4T;.%W_U#&1M7I.B6'FHU^*=E'P=JU:0Z!/3,^V V#<0 :\9FK]<T;&J MCO[M4(XYD^$2L/?JT&V-U:6)(FKND18[NZ9'QWJ/ &7I7)0 M%I+F::%2[\? M^"_*K$NA!A33.H&^C1J]E&D[+Z?^<8OF?LTK-E3JOB_]ELKR/N->IVDBO>5- M!U--KC^LUS.Z$!*C?IHW\V8?M: ?)I3;PQ/WSK)Z^*FMF&@TGZ%R=&?XYTCE MV0\"\K5NIGAH/;?2,*E==8[NK7:X2DQ?JXWXN0T-R7E7_/N;24->)':LQW 6 M:XJQ=_+PQ&K70F67<MAG:H@/T7=H+!0^]TZZ.JZ1;CSN\\#M+XE=T=_8*(+6 MHS04792YP:_KF%:3.>&&05VBQ++\*0_"^2!C\Z^:#L%1$4VV]2O,QN@W"M19 M#CPL-VE;145DU5NL]%ZRA)S5\)]97G_H9ULG&MHS9<=7]^&A2)ANJ*#+U;ZF M)\TW!1L4Y6F=$F=1K);W(K,GH:J.>Q]TBWI?EE5#0];J7W6L*S- 1[<:>Z8] MHDK]&&:BGQT^#/\N]_3]G90%5Q"G\B^AX3S,+72S"=01]?,WPD VKKP[X$2Z M]8%H-&O?#>/-G?2^6:P7X2J'S=A\A;E'IT6UG$"_8T 6-Z4UGV_\A^IB>&*F M7Q\UY1S\=9GEY<' AJ=NQ.C,'NB&S%[92L<-IWQ7)1/JM#/V4 :"')015[9I MF6A2B:J,$?_>6-R:]UVQ/K?XC'6;LGE*X7*'9071=BL^64YQA:*K,TI"Z\Z- MF?]Q&_JSWK@1=ND'__IA5#7GI+4N]?+^!C=C\R6LU</SW':_Z$(>#<O_N'SN MU"DV7,5S].<#'BG 3EH"TVW[3WSLGBWQ>H_=E!D9Y!YHM(L+O!3'\\'.[T() M_&7+B^\M)A^=G?D"VQ:S1@EV9)""OP80^&8?0B)AR_ W9-"6=&#&@<.JQH?2 M05(QZ@![/I&HAR!2:?V&$:(/[/9@'("A%F<B@Q;LK>/JKM^X"F8ZW^^VA''8 ME>\TRW-/M2FC3+5"=,)WOP!P;\+P:1 \7?P$X&7P;NW_(DD;-X0UJU*2$@84 ME"2-GF"]PRXH2,2?] +'^:+7;&(BAY[EK7%HEV59*::O5K'/VTZJM!J%GN[M MZ^>Y:G_W_BO-^-.:+<A\32# SEK:KP^0;3-)EHZ"A6UILG0RLUTO)_B\6HB^ MM-)\YIK\7-T6MA\]CZ&?MI+?U1&\W7M&XW 19C:%0;QTUZ%<*1N['Y;5E#5B M'G%%@G$H.?TP87R,&N1B><;NDT@CLD173RE6L)/'7&W @PL>H]9:/69A#L;< MU'-!"C&*[FJ_VF.$FFU 58S<40D=KM<[2!YS?%8C^+KR)25#AT@?H[1MZ>?G M8Y3\SZ_?=?97'OE15=2F@X*:.?*$;*79'PG%L&T7=GT!5>8 ^$YH8S*H;15E MB_Y\ZR"AK.\:=>_@0%W9&&H2_)''#$]+!4 N]8;%XA))YQD4'P6H]*$VXQ;* MFL#^2W5A@Y@Z)YU3JN&5)?0N1E*+C9V0U=24J;.+$]6 $;%GUE,#21P2A0J0 MA%=B@(\'QC.8!9)!=_,<CHX&HG#4I!!E-NJ[9BH#<4&T E^/B\ (&5100P85 MHOJ,==X2+*A#=SGI_-[9\86OW&F]@U8R51/1!*N8#4/6G2'KR!T6K69+ED'" MW3TRR.D<ZZLB5:Z(I&MC]3-;IZ\&74>W)3"5)B^*U;\<9JWX](OWB6";TH'" MF2/5H#O?B ^.TKP7?^H$<JG#R87I<9#/BL[=@4%_ZJSQAORV%R_U<N]P/%V1 MR1Y+\3TKY(GAB>2K^:;E-)#_FNZWI]R8:Q;22IE95.FBF0[#SJ#9I!I5;;,Q M]E300?'U;%Z:S21:;?%6.!*ZUC]JMU7#RI0YRJ&8:?/X2TA?U"LCG#]U>M-3 MT6^:G[0NW[6V^]3.?HHYM$>=2MMY9E)R4+NZ*)@O5#AC7/A*/A<VLJ'X_<CF M<)#<FSI^ALXK WQOO]*64_$9&T[\"L]VV5Y Z@VDU^'>78UW$)V<BKZB9]YS MZ5-ZUZLKV1=N'+P5;>>^YO"$,:SJGJ!]!K\+_1.^']V1:3>HDU]H0LRL86?< MLW]]+;NZ=2?-4[AJL>ML\[D+RU=<IH)N!G/<#"G5D:_R:C-S;<T&&=$JA@I$ MLDH9*K,8/A)8H;H9=!9TDUZ_7PUT)."_BTDRGM.X>4#$9[4JE314['S@K<]8 M:X7+@078Z_P 70R9^H9_<8UZX!/W>U21$>U571#(CV(@65I+F@R*6T<4N,#B M%S46#_0>R0M*"\O=G*!8#[E3]3IFX6 F^93F+^$H DH((M[YCF(49O? &JSP MPFT_APP:&T9L3\)NSJ'$.^%=6U_K/5%__0(I+8 L5Y$\6@*A'\'QBVI!&[ _ MO[C#',Q@O1Z$]?"_&QPC@_[\M$(:+IG?7Q^N0'9M91A-:-Q/*V6ES''4']S M!!*]-4A/"OZ&7'\52X)<G&&,/O0+3]PB9!=3E@)U ?NW?M!/+ !LFB)ZNU 8 MN+$\OI5Z=4_Y5T'.?V YAD2S' 0: N1Q(8N,+=!3_Y">YY,[!OB>^^O[O5N% M!EN$7$$R"&WV(FL_K+R4"_FM8*ENNXJC-(NP;_9/)WW= 53?3NY=^-K[K>2W M)V*LS*]X&;FL]8>6X8I"QOMIR*ZV/IX= !]?]D9&#_K0;)#D5V P4.J@\BRD M%UH#^^)V80_\T7 05ZKR^K"MO%9>@GMSKP5!(/"!QUEAVYB/R[X].43X\]B MR$(32,W8"^5=/8+&6/$,UF:,0S'A7OYW9N'2T+DHR4@X5&\,(4SY$U(F H1J MLP*DD6(R"/$**5V.IOKYNCG/FO4WOY#HE_KID)>JOD:<,':^@<IW6N^M7IQ0 MI]74BR> 5OP&BBF'_ZHNE(G(,W-,O([$#[,TV"7T#2&31T85BT_'>-A<7#0? M\LPK<_CX*2CMO*S]+?G>#0>=@]^H+^#_U(NLQU^0>T<<@_; _X)P@?ZM;>H_ M'<_ FN%TF^6)DP_1)2(W9]>?/AMS3=@<"RO4&D<THEJ&A][1S'%8#:8E5SR MMY#FX);3_T>*=23RAR:+!P9E1(B0"+6V39Z9"!J!@NZB^HP LN\AIG,*:=&+ M,>M -&N^:EQ6-G K5&[6T$TMZ%=4CBUL<59-_+@+9G.D3Y#7 B?Q@8:F9WH! M*9:L"0#-M](?*50U/R4R4'#\_MR-^LUP$6H;8I[-L2ZFV,=9I7<=H-GK#W_D MD 8IR[=3&)IX+^PSFYX9/%8$Y++&7PRJR"=>#_+E<G71*OG-NW"%9W+E&W?6 M_Y)YT/^9X?\,1#N,_=F''=\%67K]38#0V9]D5##[GN&@UR*Q(IW:!)@B_MEL MV#2>++'M,=XW7XDW7@Y'#9L3A5_C@K/6;B)#/!RT18I0<>/[MEGT(X\K5<@@ M6VL/%F7GW$W]KFTQNE/<[!K&/$.-[32<?=$103,87YY:X992QM-K\55QG[.] M-=2&:N18$2R_,.:6#Q%B=A&TR0]NM=&V\<8.49IR@%\1-&P*[,J]$M33]VE% MOZ1<I&^^*"S)7C[#E61%G:R22=TOTI\E?ODV:BJZ+,J7"V'&^>0UW[P1K*+[ M(@7ILP+Z[0J,;O>+7R.^-1JIY6;C(86=')WH=K50RPW=*GC["SNSC/8R,%$2 M\N;71>A@/GZ,,/'"/!B=;-UNH/D<IQ_^I'ZBHJ-]0H>9XI>YR0^)4.-XSE=W M1Y_(<_D-TD<+A5Z_G3W)GJ[+B3Z9[+)AR>8X V'A5MF5[S(OV&=S%<&::9=A M\LQ^M2>5G?A=3U<>TF/_$Q&T_%-!\IOV["BDOS01RK<HRCFAG$YCFKG]C>)+ M,QA12 7R>R"4F_Z^NJC<I54C6VI).8Q>V?GW?N]CN+X<3^D2A+E&-M<2]WR$ M3C5GXLJ 1E9'NKJ1* T99%Q(MPS9&4R">2)FP8S3XP3]A.U#R77M8D<E+;^V MN'MIVA5,%^7AG\R+&C>XG@0I"A\]B0D[^&:BF)B=Y@CB5).3#U"3=90[!9%0 M9EGX9_N?51"-(O75?]_CSA1TX9PI1<?XT&&@HB"#<^D/1_.6L5/!+RX.[28* MT[0S+'8+,(3TS9?JDT&O/\YLXCFD4(33+-NP5L;1S=:$_69MJ.G@K\O#!>+I MYS7XDY@;TV&Y33PC+"VP)BF",AF4^A2VN0.;A]IH"':M&;Q*%NK^'1CPIM?M MIL?:K1LR ^/J >\ _T"\87I'R@Z*.RL 8(D_QH($LA.LZS8QX5@TB"7Y\ MOLT6%TP&W6HG@U#]9%"D.^S)XO0.:]TVXVZ8#!F4(HL#G-L]<8((BAK6-Y@! MFU'.ML%]F2&#;D[S\ ^>:15Q>:$HO,"(>P9_ ]X1@1\2P;A!Z)XCEO \W%^R MTBWX< 5/^KM-('8V=7/&4\+@!V K6.,/C \(P6QG19IBS5N#L?CS/<V<?*@Z MQRVSYITFSD5SXZHZ-VO=T7%/>UP(0.$ &32]0@:U?JTB?O'WRC+K]H&$Q7'Z MN=M9P^1NZ$KZ#3X0LX#ME^Y_[GWC%J4>QT3\@=^<1;1,,Q(,OTUG3ISV.+V] M;!=[]KNZ!I9B(D"X^,"0]0F+2<R/%Q#+CYCI!E3(E !V#^F0NVJ@-7O(^4Q_ MK)66I[*1<4X!;'_(UI+ O9<Z*R<BRN_PKD;L(/.&W=[N9-3N]D$A:^BYNU)" M;BL!2MJ?GF _5!89'IC)J!<!N@ 9)H/V=XRTN,T:'$UD]^KSP >VB@[ML%DJ M]'7XKWA"&V[(!<?_ +%D(:G\I<H-CP[QLAK]:.<F]=6/ZM".(VM4NV5'>\]. M866OA_J'NMQ>0Z[$2AU7J&E&^-*-##C?E4/C.XJ* 3?VD.)DT"M>\\T,R"I) M"H5YY0#=H84-$NS<)/P>>"KJRS.<XN;>J?B=<LC)-=_+>2#'Z^E*I78U;/;S MQZ%N=OU4]?7\]VFE/C#")0XT\01BAPSBT)L)<"8%Z^!AD6Q/]@9)!NB=<0LA MX7G1]"(M[]6BST\G?J0E62E2=!#L)^,G$GFINZW@!3[0US6<!>/K>ZZE>::M M\/AXWM_[W X_"PYD^9&;M,MH%G5,]D+I[:-72W#:CAL^Y_SS19GV)F)?VQB* M(R)(E(3<SGW N__Y])_MG4$BY6;:7S^&:E\= \F$ W_]94$,7Q'WQG52: &S MNRZ&6B\P')9^^]RI(-_1D6$OU3U&BUZ^C.&-Y++7ZJZTTS3Q*9KHD5O5FIAE MOVTV-EDM.O/,3S^&.1 A^5*>"1^LS+[MO:]9;'QXR\+LXV7)/*:GU\^'G.7- MLQZ\C'OWM;T=M9II_,PPI/W2")(A>)JZP Q>C[^1(-<L*3%1<*Y+4" R:;/- MLWU=UQ[*N'-X4-*FHE@3%U.3?<F5XU&;&SW>)A:> =(#!B RK;7\U.+HJ,[O MF),3+7X2._2!>LF[J5]QVW>'D06_GMBEUL6!;S2O;ZM[.F^-1 0=WKFQGSF* M@RB_7$TO*6?2 DG<*Y*=--AV?*+!FW1HL$-D4^GSD/^T8<VZ+_->?(PIH_WV M> G@\MR=1TE1(-()]TIKKFE(YXUG#&R^3H%=DQ6AK5-N8DA_+V\T#N:QK<IX M56XL^]($[L+4+G,0)/8K9\4[1_0)9JTI795^V/Y]?-RH5[;=A076Y;KK#4MI M@_.8R:B8O;CRLL:>Q0BMNMOCB"J]^TK0IB'=4\]A+,^72A-4LB8TA.X6I3O- MWFY(F^(.,)&C[B-Y]*U4-5>E/31_.%J0\8NI1:S%L<DAYV+(RC4W([$:RJ\6 M9N/F6EF;6B9>8?[I%_;YXYJ4,AQ4[_3E[QA&B[Z*X#/2B)LMOV?$9E\8(-$" M@CIYQGA96U];"6BYVJ_QT/7%*=#.WK%=_J-(H!/_MFLTAO5_?2Y@UM_'1PDQ ML_'$S^X!?RB?Q*?ISN=QX!8+])]IFV9>([*_44J45'3!Z62 4- VP_6VL=8O M9U*==.U;AS1=QS-EY><I;@EUGN(4T;RQPEHPY6_P4PI=$OK8SD.X_631>$>T M9-&CPH)!4)3G0A0QK_])E+#W/1=5[A+O,842(RI8-=S7?GP\-S>C1N]-*_.% MH4]U'^IG=R"<]@EM;]WS[ H=T\(VSK6Y\RH;W\K- #E7*7<L<&&[9< L#T<R MN@ECXVK^W^\B,]I?Y3M4TXY8:G M8+N]7,9;.%[=>>5"64F;^Y)S*,#6P7M* M$^)Q(4;E[8.?7A#T6)#"O XN(V_*K-=;I&#Q99MMG$1<S+*;E8 &.XM=W47[ M5H<K4=HR:PZES\ZEATJ_-5Q0Y>6AQ$>53C9'M^8MMG%0W5"+-!3DS;1#68=U M"0P76?W8-E-\1_JV*T7Q<89H=FC:/["'?5SVOOID63F5IX#";\7>#*> 12.Y M:,XO^2[%V,P-RNQZTF^9_F[025B)SO"?LQP4<%]7F)[V4M)G(A" _6L*S2G: MU.TB@\#?R* *,NB'X40?16^!V!+@D&ZG+T794GC)'D*_<"82D3VQ"7(I5!/3 M&X$>#$VR7^RZ8/F*Q%Q+>\'B93,86I60?4*WFX1>UI1R4-#ARKT2W#K*=$"? ME=WF"[TKEUE8=L9(M-5\K,7FI.<>-ET&&W1.(,CTIT;*[E)F]_4$N2Q^?BR- MN@1.\V0D:E/6+">K??H9?,D9B#7,<WUA!#^-74A/^M.4MNI23OC^6"+0'\IR M\&8I%7P_X>CB1.B5B#B%_6S'P%_3NX YR[A7V?ZO"Y#6\0L.I=R43_U]8DCH MOQB_?*0!:37WB _%QWO?00^<2C[M9SQ?BDT ';_&$V %J*U6Z7.W4I"0.1F4 M7P5H>VGP/)1NTOOE_/V$GX]%[:]:#%1:)/85SD9IGES&%!S"=N.AN\,%43L4 M#7:!;#^?#1(TG*1I9GQ,?MUTCWS_K?6%1;U";'10 (/)N]FRKT6=5BC6??HG M9]F?>6X%R;E$CX9M(V_[)[EI+P7=")!OD!WV%5VX*FQ]?:K)]?G\9T+.RZL7 MK@?,5A5XPQKV.1CB\BY&H751-:]O';RN*1,ZQ;3]4X6 M? ".LT#8PQR3C?9 M3BV-<OC,F[#U[#UJDVETGY_[S$;%?'C<>@.^-2-S0D,T$T&U.-0Y^ GL'"=9 M?9?+-5'W1!)7!-KKB-FM($I>S(7,:\L%?\Y;_1\>%*)B4-4,TQ]Y:D/E<T': M$/=L),:KXV"XM<]/K\17]Q2$P"LS/1V[G49B2G3>/+K1OZK>OZI\@0S"1(S# M G5Z8O^^T_/7G>GC&W>A.'5'%(I_V9Q3(P/X@*S(H,;KCL0#R$W(+'LYB8#X M\MR1YP/PH8"30:>[4?L+!,"O>?5L^G KT*.HQ/<?](##$[N=61[J=?+^N MM+3$5__LC?E:T".MV6KG\GJZ.X$:F[^%8 Z/W8*_,_A?SU,:BO]@]7Y_RO6 MW')+SC(VUJ"2L&5%8M[7,46A#,#GTRR9Q_5NI=!",1%CV-#W@5*POU",I#]= MA5LV!DG^C0O\%X]*E0\JP2HZ]3LI] B<^@:LEG_92&J:8:PTP8W?8'JJ2B@K MG0QJ"P_0V4ZAY6T"& XTB@+JDD% Y>(::-[$ZJIU7+GZ\-S<3'/((X_8B-FW M8 &B Z(4:YDFTJ=Q]>OE!!/=X-0#62M)P1LDGJ:<E#-M@%Q@@%SZ_^[G>G(Q M]LJ@M_W2SMJ91Q-3VILQLH]D9#ZT07T[ 0Y4&T>=Y^M>YZ=>N,.VV(LOK@8W MNP'\\SR2II<=X[S1<P59^W592?J[DVM9H1Z.M]:;V5C1LF"[8,?^[[RTK/<C M)(9LD$JE_7;SBXFD*@Y0QO\+_J;]1>,_6E4PFVA1'WMI9C_[,F8R#_H0&,UK MM<2\@&JB4$'Y/ZN/( ,ECK)? XRM<$#H@,<.*!FW;___ON5C?3WFYQ> L$GD M?CIAW=QV)R/EC&=O4URF0^IGR+#OH1$@'L?*ICL0CG(K4M4V"3 E*L;I#S&2 M-+_E=4^9_+?6OP?W%M!3<WD=R_4/*1I_ Q6H42?-L\\SS^^[@J0H8O\[.S(G MFU[X+J=D85=CI\>")&'_IC3'A)::OU1.^QV]A= Q W7^7<O];V5#@_PX+-(& M@B3(H/]:L4P&?A?X@-IX_MPP+>I/';26O/TP%IW0-Z8H .@AU=$K'/*=S^.B M&.E6O!(*1ET<;.NLD_6=GUR/H%C39"DV5;K6+U*C-CNI<7_HRJ%B1K.?Y:-Z MEN6+"W@N76I1_M8"V?M#)5_D3;X-N?MMW-=,?<E9[0_"MEZ1<_HDY*U48^0G M#N=0RL@W6_UF!I5"7Y72&$E;]OX17K$K= ,_^!2GD85K;""#ROQ5LAU:[Q2* M)AA[Z-99VW_6#:%5UE7A[MC-98443W[\LIB>4V!Q8/SV3)OMU^WREK-J+F*3 M34,1\U(47KK$E!)ABU/KQF7EM;5EY3$WKC U==X;G60[[ BN\&POT#E'L/B. M^9D<ZSHL:^*0;5X[D/_8L(T#9)J47!,E6'<!I_75&ZH#U.Q)S9AJ%WM67O6H M8R_*OZ/)2CXQ(BK)Q8RCMXD(;JYJC<R9&LMH7(WNX*[-C\Z[K;JQD,/SK@7T M:(00V"=6F*YS&6>&_/1UO:/=ZPYAV")MZ:28GZL=&L(QS,##K>TOE]OA*((= M#VBA]H\XZ><C'SPAZ><NE8=!- TZQ)L8F[2BC?TZD ES[2E?%-I?F6M2RK.] MI/@MY,@[LY$<GS$QKIEK\<-)W''S\Y"0@/>G:V-!CA;-#".44A1I<\BW,E/G M^])^BCF*+8=X;9)Z<EO'P7XP!5^K K%8[-5Q4ZQU%>TH],&D")UGI,>9H3BN MX,K[WLM%ZV-YWN6S%O"W^7Q%)16.YP9F)W_/EKZ4%*/;?7*!2S:-'NP;^ XS M( INZ47*Y'EYR 6-JW(U*$?2] P+4?A;13;/!<E_=.P\<[K72DO[WFM0S/V; MR25K($%&>S/5L2"A?SW!;VEZ_O:-O$Z!B?/!:?,_3HS1YWAW:[TU_L"P;N@Y M,NAY%Y02UPB,LJ(^OI^6C2K,VXFO(]A:[V;SEJFYKA_ZW[N)DX83Z\1Q)IG> MAWO:&&>X@IY7X4,MV&,?G])"UI]HZZA3LK,?9I*OP^\"^A3*CM$A4I7"#P_ M9-!YZ-/7>=&Y>E&7DRJK-DDV]4]R7,XC!1_G:L0ON((QT^=A?0G3N NH60V" M;//TSM5RTBD #Y0,HI>>0>#I[(&X=0R&E8(U,7CSDUZ.H8A["(*V^Z$E-TDS M$++DYG=&@ Q"1!/.J)(XIYSQYX$.4IH0A.0@SH+6T1=P4H2:B,D0HC#@M(1R M'%,%.]R X!)"G4?"&O2Z:!F@IDUEC)OGR:"W:6.8_2TM+!ET#8]BAO6VDZC% M8,X//C#BTD;(H/$1\$#.VG2Y6D]6IL58RZRFXT+"5;4$^?H'-!?H;_QR )@: MRHG1;2-H[\;N1C.2NHRD 0R-GGC'H3+?J +%N=N]],^Q00.@NR%;.SV"ZN6, MVWEJI"N=\/,"D"EU,HCW X[_T$HG*P"AAMU)G-?GU7XFW2/I?2YXD(L^'!]O M@:V-"YE%;62ZN#EU<D"$268VF<++Q_MVOG/'O1RN:HN\YYOY#5$#UX'B]L,4 M%L.PW]H"A5=JW1KW./8BKW[VX!$U?21BQ2G1![]G$IS01274NZ8U2=3)[)C_ MG O>Z);C>0:QS2:#5FC$B23P[+UR8LJYX4F#PW/W%LB@+I?UG0*]0\@*:N<< M"H+A(X-H7[;-B$6[@*)WZ29B-.@5 S_.IOM!4)5Z*-L[48LWS[_W77(A,;\[ M5+F5%YQZP_+3=BODHQT9U 2QG=YAJB.#ZL)P^K FI95_K@P8IS^C,'WO-X2) MKQ9\V=MPNM,E4A8[<A":>(*P%HE]'^!12N0^<0?2&$]B/_S755"I3<4T \&U M>%BZRYS=?57D==>;88.+CSB_M0H/N ]N=<J_/<T_7(%@)+#UES"8T>U65%5Y MWU^(\J3R\E24-W',8OCJC%^QE7T]O#@F\#5$]^B%.O#_W!IA/[B/-S*''IP^ MVA<%V>$ 5=S4'SCSH02DI\9\5"C4VXB.RT0/TLM*%$^WY(1=^X9[E;F\:$,1 M=3=#R0<Y[F(+/CA^O!>_3J1Z[-W4"L&$KYFY*A;W.K_X7M(+%CUW.4XT"G<" M<&GG(,P!Z>9F(MV'_4S;C@VV&ZXG)FRJ$;\/C>1[+^#RU&/OA>DA.L.W[)@G MZ?0JF/V%7I-!=C[\I1[K6,[;#EIY30ION3,J*[^,B?@H<X&:"N>3J?3@<W%O MO6>72FHB'POP:#K6F[+CC*[L.V> W%CQY9$?IRYLM+RIG+R4["ZBM;"HO%'Z M0J/@N;>)&=;B=Q9#[:CI+^-N3;NY4:E\*^H?\T%>R^'#15B\#D\67^L7+^IH M!5T5)RQ<R=B=_EKEYGB"$WS^W1?[33,98U'I+Z_L%A6:U:T_1%05\["Q$P4H M$?V.-1:9A5]>\#S>BY>84!/^['7VPENEYQO4P<%FOCQ%<[6J*C4)^-/^K0]D M-7AN?Y/I8=%XP>A[)_"J!>LYF<^?'H\-MG\G9%B$"VNT\0KW#B-@V/-Z \^7 MJRH&4NZD5IBF1XO)GCJ937&M!I&8,[\H1=&EXS;/R:EWGECE7IT4LW;*L;W\ MX.N^L4+(D(R:)QG$N%0!*_EX:#?XX]KIEB6M_.K[)!W^\CGA[Z9-%Y=?"IC> M>N^JR2U T>ZJ>#B8<U._[W@OQ]_EX7Z45,<NG';-T[@=J=#_F/+1=O2Z.>G1 M<CFZ5B+8CF)&8($)+46QE- 6Y"$LW_56*F>!?B__UZ7W+> O6[FSU)2+!KB$ M+/Y0?Y6]=KX[8DJM@RSFSZJ>T9PO/#,?'9N$:*VUZIJ,NNF&KA4;1'/A_?JH MWW7,3)]+][SI^"4];EBBB:\DL?!"V.LX[2:YV;>"X>,8>.AN ,2LS.&M^*.2 M*.8[CQ_(?FTM>BW1?O^%UPDW]%0M7RIMBA!RSM84F_1>EBM)ESH>&>;A9\%7 ML"$E@-8+WBO+X)HROQ^J/2W(54X-ELW0'R#PSNO\RDK6B@\Q4N6X99WTJ;XI M](K70H$O!AKHZY%QN@GWG?I>'W4<@MX![F*U6)CZ]$EZ+'C,O^-<P*AD+**R M829&;M6B/$0JL5N\:>\%M+K+Z^5@293%N^5"!^>.&>N0D.0=3(H+#@@A78G] M6IK50Q']%;HG!GB&G)@3PY@IC/ZU;V+$Z4(NX-E=X@0B\GL3I*^%NB<<E4J2 M+95*\-J-7WOV*63ZR^)?I$GMGDVTSY@C@]+- +,"^_AP0M'^RSQCB5DR"I*] M\_7'TX)*;MLMW/K=?#G\P$!9.>-EJ3!;KH7PP&DSL^LZNN<=#09,B SW=0P( M:QOZ P\Y^=IN6!'6/M97ED]%UNTX,5>FZ9ZWVTW[O9^1_EQ_B%+:1&=5G.@N M[0#WS<DBCGI#UAFN]56K,2>^OI]R=4U6#Y"U[NDVY$ NX!&VW]HD41QE28W; M/# R=W(N['T.V-LVNXC*JLBA +L;^^F7O/2J8N&^-_93J";5U^Z%RXI>$WH M*_SS_-[(PJWI)NS-&"6,.JE/PK9G3B;FF@:W"A>3\?-//NBD[:5EY+>\E' 9 M]IX'.%Z=,HN'FAP3#/K:^T+SH:!'XC-":ABEB+)-RM&W:;'.GYYZ/@O($H[1 ML3(_8':YHP$!!Y=X_\HL8?WQZ/.P^BD3$79UYM">67B!%OB5>_LOL><QC&)C M2Q)<V1'JLQ$>O5F!I>5MM5R 2LJ#@W:\XWZJ5;.4<CXQCGY#%T&EL$6=VJT* M;HH\(^R],3Q*ZF6?B/Z\<&.93W.R<SF)9W<HD+E&SV5%^D4N" 2Z!LJ8U&KA MTGO1ISWDE.8:SL8P\"XT&.!'!?.3=Z$OG;+TN<2E$MM2VPI.<!\]X HGN!*S M:N0QC*8#)42W^T/.?$-?[:+S&[\IGY&/GJKY 6O0J*$L?8/9?W,M#3'11@:U MH#^300UW(0N^_Y;-)_&Q4D'V@Q'EW,')SF_C!UF+4]WEI<X<]G>7]&/OMZUP M C4T_$_GN\VBSE(0ET*O012'IG$^U,&>B_ZRR(][41"2^%B=&%:C81+:)%,U M63\D5?!82E"A0)];<MY].%VFKR<KN[T-'=Z!F6XB0IOKKI;T1]8D/%ULJ2EN MX-L1/1O-0A<C*3?KTG*4>&)?EJ 0UD"?@@SU5U9A/XR&$Q/2G'&"XB\]XZ#T MZ^EGLI@ _;^%?+-+!H5YF9V"GTGU"G RUE9BN"7O'MDEY7I=3#;XU44DUC>\ M9Z"&L]#AYEYBNDK:M&:V_14Z@:4WS5#(Y)5'\+TJVJ.$++][<3[\(>$+WN86 MO$7$*<B.D [.1SP$F/:-@8#]!AG46G=AJ 8<D#[2P?=#AYO )CD^:?K.1V%$ M(>WE;Y=R:L5:Z@(;LQ5\:"I?C7$96[SD1-M2?;3RCZ<ZFP*4T9L:E]GDE78A M&'WGT^)06@?8_A",8,1/4$AL1.P(KD. RWDHB-GQ1W[& TWZTPTG/:A7->&^ M]@EG/ .(@#GFQR")M#<[ *]&@R0%T//R@S=4P1MBRDL\>M121]E6>V$_=\\% MP($'<, 9/#&>2%S'!5+),2S./6#ZU%H;::R-)(U1.EK&XNGA7;:9"B/1ZLPN M/9K&O+:O#J.4;!O<3CE2"7<NEYE: \CN**2UCNZHY;319KG1?3A!(>\V&90J M;@"$D1TD*4#PZI& -33 +)HH*>/UG,&CVG8 3RT0ZR<\4>C#O[ 8'9ZKY. M>N6W2:"!8I"OL$<K8GLN0,>&8#,9"5[.E% F,@BJ16)N!6C]:)>OHG2RAL^' MO0H #I7X PR65UH&).^!P.#._?)=VM#820=0Q .&K.^=!X#]'1G4C&ZZ<;2R MY'<CK,1F(HM$:^$0I4#GJD,,% <<;>TC<!6 6"XR",>!(@!1S]&RGM9QQ]@( M"HWB^+.%$(PT#)<0"9G)T&V6:9NA,?(%C!# WSF'.:ZCO#.!/9>7;<:G,5NS M0$/,8:3IL*.6 7[/C]>+PO%D$!AH5^-XN;#XC5OQ!J!1#IX8)O#>T<F,$7U9 M G/5_:D3O434T?$([-7CY<1H@ _?IS'ZJT5M0:ZP]2/(HNPV G.F]W9Q_6F: M91*D%WJX5"=T+(:8RTLV8RC,%N OG9W_Z^35 *RI"WGT1GN &,K>HYB"9?YH M8>W7G))G0!:@.F)#D!75HYMPX.8]@-I) WX>RK*VVD,85AH;^(<*MNM*O0"# MGQ5$*5 #SFAP-]#R(!N)5B^/OIQP,>YQ(A+O=@2>_!?1SP(^ 41W.^/\Z:R5 MRH^A=0C,>98;,WYG S811^^ABG0YSF#TQNWZ+V 440EA3]W J -W@I%'T)#9 MQ:--?*F\.D _T$<\GL\_SNUSF>O'(2.)1V_.&7_.O9? "-=301ZP8>5)=(D M.).H4$==!!^O'7:<7;)! ^(0/R_(I\"2\7(B=@_H\)P=P"$(ZQ[&\R. 3.=( M,]J]CS3CX G7#_PJ:B;=4GQCEN$*;+P+L:H)-'T)&^9\>I67- 4F""\<)QCR M+P(Z^ +H(".[)R;Y/6-M$QGT6I;$HSBO@V=Q=]E<1N%,.HZUK1(@%S]X=,<9 MSRH%/\3O].*\-Z-@*V;]9-#F/+KC.)W-P=%YQEU@_'BU079$;8&P#;L*C!PJ M+NQO;\Q2)!R_LKL5=<S9H_.,^ +43!J/DA4"IU&B1P:=<+L#F_DZ?182IM)O M0CJ4WBK\%V06B4<42T<*\A4'0I'Y.],8/><WIO.J_==W8%CDQ^.1=GR@<*B- M1"N(9>.R3;B(%UX^0'\+[(*59KU3DO77KL3LE6:NEL7IC=8.:-ER^CQZ0=&! M[$T"F_V=,F'N[Y0)Q4E&A>\B/N.-U)A-)'(. +-$Q4\&1<\W0/88X\D@=9-. MI?-54;TM52Q#O\_1.:Q8&CNQ,%\3N;/Y>JENEU@,LX%Q$IYC-4+%_07M[-RH M(O._]:!-M-A^]$:''VR2+HC/TZQGV:F2YH0MF&+"BU[%QE;V.$RSYI?JO+U9 MFI%_TREXEMO\X72V_9ABYGABGNVB3>0HG/?*\DFWA!UMU;GXD-FZOF0+^TY- M1VGMNW;\Y9+W&Z>TGA3]]J*,L]K7 "U5;N(>(0!#L3V?P>B\P9(*>^3\#K4] MFQYX\^7@40H:P8?>VXWEEI3:8IL&T$2-_@UK<V_9NP4,0T@QQF=JCV!,%H&E M6*NFFP'[84]+L5QLUQ]XUPFO_'9<BK/K#KY5V/,KC2'B*5MPM"G=X0F"A5QW M7!1DXT!;B%0/8Z/6TN:&;&!MC] (-&!YU?O3!DH.=MMW[X@I:.3![!_>RM2Y MKEW5F-_RYK#]C NI!=I?)X1SD8:SKQK+LAIC18Q]O<*0XI9WGL0U3BQWB05] M>W8%I9/H)&BR1XFK'/R%O\:#=M B@^@IL=8S/ARR)"IQYH.TB8?Y6/$W9O/> M:6UFO[]M6/=ZN2R5))A)FL></ME2<<*H+KFT=QNJ 82>('_3U6(@4@L81,U. MDT&LBE)0 JW4T->0CPA9-PWI'3A!?G\.M7^DC<Z&P&S[,M#?I W?S0P;[\@Z M2A!R@$R00V; 9J=A+*CEPC>0C9G!>!+-+E:7N+HC008Y=A\E/^E-D$M+P%N1 MN#>Q:JC%=57PWL@ DG >/1<ZF]A]UN^@^S@KS)*3[5+=%\!:^_H#0S<E%#!< ML&0XS@O>/'T 6'O8YG;_,<9W ,9LR.P4Y!R@FOS M#6M S#@S"8N=MJH+XQ MLW*<2Z6VFPL]Y$ &G=S O8<M2:3 <WRA."]H,PQ/O\)+.CPZQ_=@:UK*#6H@ M3CB?-2<;X'P+O#\I!YOY F&ZWE.;RMCPIQTDT,Y/*Q)-/Y:F0NEBG_+N.)\\ MB;L#L,%X=BGPX9+]T1'1 RV IGS([$2@(F#88H'9INY9&HD;-8_"L^] "#% M=-6/"/YM#>G=3P /G;WG*96$^QIVMC*D+P/3KJR_0Y2_>6K(YLFAX[0V=Y:B M'-;A.,_IB%XHFZT5:43[/A1W=3H"M?*BGYKX+>$X;XW:$1#J"$@>UZ8&S,OG M]0&>VK0 O(KN.KX^SN!RP B0!MC=V7$E$8"V7D#H]3Y'9^V>XY"D,&TP&42Q M^(<9U S'@$J4:8 S/*J9;%D4%", 0JH!PSUU'& Q?6:?]+4^ L&8%A-F#G MO;!E\<=@@R0:Y)R2E_>T-OCW:.VQS*-\TA(.>4G<R#E*=!L'C$112DFBR4/R MU,D5@7^/21_#1!X ,(*PF03?)=B";S%D;V5H$^>97 K@;T&03@! EQ=M6OW[ MNP, -&>&AB$K/B4 '<8 ;[/R87W[0.P3I'[$C0"=2$#%#@'Q)505RF$GP+B3 M=EV \(>&BK:]MX"9'_V19X!WT::% +25B<)HRV^CVZ*!IIZ_%B?(J^^CX$?Y M=EX?$Q5^1)01T)*LSW);./6AC*H40%1D+XRG"+R[](<%>@ +QL&8#1K4BI\S M@9(9<"T\DQ [2A#2"=IC69\#!L_>)D%>AY0U"L,P"#:1:#(_+;<5VY!J!HX( MMFGF BAI!B@1<-GVWEN&_!K- /0JR^DF;@\PO: _0$U'7>\$@,PM28I5 +FW MLQAQ5S,^K\]W_? SXSLF-U3NOV8_$P;&\I@,-\$K ([?4;6,QS#NR9?@6.;? M^FM2ORWT\+$N]7M,WW?ED9-<+TO24L)W,0FEZ*_APDE#VFD#X6:/^:/\2.Z@ MC:^17[]V3+[W7A[[:+K1.T4$I9],5+O:KSVYL<WTOC)]2BD,I2CP[9QCFJ.$ M^1(H&&$U/HPHT3WAX["J518)5'X'2E03&SO:$0+2_OKRQ/RZ5HD^"Y?>HXN2 M'ZO"Q7[D3T>S6#D:6I$0?\6RB;25*53CZF-OTU<'3X5<6NTC"MI^^51+<]2" MHZ@BR.)KGL6]QQ5E>OTC(0=&X3D^W2U9X%;81PX*%Y,H.\]!0=L^J[+^LD0U M#M!&J7&CE<OS*RXA,1"S(L,=%&Y;65T.TA-YTL+HY+-X1\FX2)#GF,R@;9I* MN$F&<?&G"9KKK>C+^4;:BF\??)<X;-)1%MM('Q,LB1AWU:%D[Q8]";'-&#=, MK='*CK/EUTRU"EH-I5Y1TZG OH0P:>?)GRA;B*C5\#<\^\.Z*D'AD;IAX)-T M$RJ=[MCPER>41ET#T =ZUO(^K-ANL3&G6?79.U2\MNW,$;.4YUZPQ9CNI(O( M<_2B'\4%B*U>"MO0ER1\BQNCP0]^/S$]QE:(+><L=P)[H5=U'IQ3?>UA%3&K M8[]MC"G,?L_&>DH3-%WR,,H5M(6:-(B%-Y83(*E3I@ZAGF\:G,H:940O/MIR MV:88\=.SYLG2<KRN+;*FSBH[QF!&RZ#_[7#?9^$ B)];+_GV6Y_88'9D%MA= MBL99GM(6!FV4.&9R136306:GO!YM222 L=D!ASGD<.?MZWI7]X\3 #%.G+: M7QM_1\\4HE5-31V"#C\""5<["/4=V&#^E]QE^M6I1*\=;[N?#;R*B]MNVKOI M+F/"]* N+;OEV;X^_3OO<?GI;R?]L!8_#8>DJBW,AK4<QFV=-A8.,=T<5;*9 M*B<Y0!C&<_[VZ!I^&&QI<G6L%>Z0=3LR9[QYFF]PXE-_>P?5Z<XD]Z<]+^P2 M8"V;S-K9]IH>/L[T]\H1-MO1=^.#ZPT;OW156'/M\[)L:LW62MZX1Y/U(*-2 MA?WU(]W7*IV%H%:*919+"-6*RX3VC0&IW62KST_-[S1IMD,D6G4N@AN#%&"J MV/AF1NX'WGX6@P\<'0OY/6L'G[R1*-.M]]%G77X!2HKP6#7Q=\2JFF(V(Z0% M[F=9/7U\\G[9MS<UFY(J=!UE#[G;#U2B:.>E?WGBG[,B>5LX;F\5^7!(C]=& M2>KDS+CZY!9[0^\FXZ:5OMBBQ^EA=K;,[8819\W9>;ETJ1'^Y['#I7,YN\(6 MCL\TCUZ6J%9=?K93X>>3$=![ ^&MY(IURP(CQYUQ/XUI>J;;XT8TMRD7]8*4 M0A2,<D%'Z3^.RG]_]M$\LM7S;WD@[M0]8=E-N4]D?%TG2OK)(S] NN3@:Q$Y MQ,%2&MGPDM,GA6I4^?"7J==&^ )ZKP(75ZN@Z@S'[[\C"/\N\)K5>470\4=7 M%88\#7#O/-LEI5Q,,<A?JPOXS>=G&/',):A#C/"O;P>%YO<_/#:A3[1P5Z)C MBGGV4;BS0,0@/(#Q#3 W%=1= 6;X!F<R*/#R\>L^"@+_XX=#!Q(S) BV8C@( MV:Q/^[?O!610F2023P4-[B:^!H*%/I,E?\"Q9W# \I-"Z9P/L6PX?=F-IUC! M-\ZX.Z*A4QIXA8>(^Q_WE@D"L*-%[)Q,V'2P[D-_!@RMY@E8HV"F/Q#0*%"! MQ]FAQ!/(>LBW8AB>EM#[#G)$(@92OE$<@9A0(S'#FLP( )[4E],D@AJ)90]- M$("#DF&SS/^5P+1#*V' F3'"4>^Q KU1@7[&BA.DD<T(_ 5 %IO-T%F-_[R$ M.L(:PS",1-H$&R*.^3^^/W\*VZ%%@4B- (TKPMM*?&10:"D.F*=5J5!$W#N" M +@TOOG3!W'"%=:VZ79 .AM(G.[1ZEJJP3W 'SB19TJ@QS"T /IF<&\-MABT MFT4L @*E/B$"Y2&=+$!EVMPFS@'Z5I&@XHC S[(=OZ;D#R=A1YPT&8=BOBJ< M@"W]-S%D_)>&D#]P\20.])P.D9X5"'GFQ#'I_Z*U_(A6X0W4?] &_\^KC0@D M*=AD!CSR $6D"K1I1F"&I\]I\#:SCI)!A4RPUV#,,/1<;,@<W7,>V) :>C C MH!Q0$W ]9$?(#K$_8\B*HO2GO.:/T[EWP14R1 O['^3Y1\,<_](PE4,S_[M/ M>0\#Q^7:\&\J>&K_*X'O"=081@CV[FH0 N_UWV7!B=,Y5/;.FG7*7W?D=> P M&CI$W/L8-?I@7*1?5OZ^YOP.LJYDFD4KQ_N2].[@;\>G,>A><ZWT<2&N@&&6 M900-["G@W_C+UB8:5ZL-E\9]GA)<UHF9U#J7Q\%SZI3<>HL?)#;I1*"E^E2S M2622U;6*W)H1,__LO>]<*.Z7F:1J@\3OO_R'E:2]O]2YP$X^+CXLNL!YW]=5 M$#+KXIUQQ88C2>ZY]?.']($LFV[>;,H)JE<2M/-0^IY&=_SI9@_$"GEO*A8R M%RKIZ$$5 LYG&55O\UR<9B<8PI;X@#$2)([3AS4N84V()V<!OY:-(#P%F05< M:5+0'FK_-QQG,L4-2%P-23Q,L>Q!;O,PDD%TB2W0G7.O '^%C7"TM[E[#HFG M:81M) #?_7H)PIMG -9?1I.( [#&.LPF\80H;'.2XM<:X ;,-,WSAQO2VQO/ M4X+78I'(^Z49L_"(0-X*+-7KTI8?)D7=%R._,M'/[,_5II%8 #<6ML)H!\AP MS0%\:F7,HCYY\'[Y2UU7;H-H%;W7=W[_MBB2B]DLWX2E%+H98@U6IH1JRI.- M 9U\<JZ)*>++%OW.11.U1]76->R]F[#& DVG[Y)%M'?W>1/.I/V0(H/"QV+' M)]E_64V"N^A$]*D^=@6!"#0Y5KBPPH,X%TMSLY%WGUAABE_?I_M =VT0M<E4 MOB8Q-V:]Y2BY&#.$FVH>S12ZO;RNS&,S"V%=[ULM1SB6L5E:%$_=:GA@RG0) M*EH\-)\LE(S <AH,I@U;?VK)E6'9B)"X<[)08\)(8=8/G><C&KL]K]@&12[> M=40O_C)<X**'9X!\ABPEL;P3YLVBHH35C8C?W70'MK="1]$Y'6 SS]?8$]L/ MASB&/<N+MT72*Y_>=E;JM:L_PT@-O[MC\6J9/ZJ)Y:[BF1[N6WX+KXVW7K!J M5DX8NC-3+-+-%3S3\GY:_K/0;/2@Q.X1Y\+["MT8AMH&T9V6!W58M?T]RQPW MQX))YLA1T8_SM%L]07%@=]*O><J5 (>?8T.>M&ER%[A"(FS6[VE=XN1.IWHD M"Y)H7[&ED/J<7C$HRI=(?![-"[FPD,V_F^?^TZ)R 5%P\Y\#>?_;HCH6]WXO MA3;RGU1_E4;WGCM?>J%D9'R2>*?%+.5$N,"?DFL):^O..EP^,*K*\:1[:&Z% M,XU59GTM>GDGXP] SBH$.X<R(*PM&@R0S*]EO:3I759F7;6C5M%2IF+64Z8Q M F1>??3HXOE/;4BP&*Q.&_3P.)=(P'T[.]N44Q!8AE'IOYT6UU[=,"HP)%9M M%+4:!GZ@>.Z>D<[\/SP 11K)2PM+#ZO+:D;OU.=]^!O@_[CH2XLR@WYF_=N) M..;!J'FIM7\E/LG<6PV^_S7HK/M\QE_'K$_H2HSH]Q]W[ZB<5H?1JK5=H3\_ M_.4_S];)VO8H+PP$AYO]1Q:5_S\6B@B=0BIOZA;QL4-5G-?<.H+1?#7^YL_% M;+"M[15#TPYN28VKM0>8)D?_+JS#'@3*A1O8A@[L_ARD6J=Q$OU]29+_TRE9 MP9-6BMN6F:;?7/.'I4O/-W8O1[UFV67Q8<\[]%L]],%XX,@@WS4%,D@(BG.. ME">].MPDT,()PE^@(Q 370JL1\X\!+ND0>K6(%R+*JSL?><(P9R-@,W_W+7L M"D,AMI7$Q["0+=+I%=1L[<XF_OPF"B,$P61 QP<:U6GK&%$=O82:5&YY[,/Y MP$;?[]>FY\9U0S:9;$<A*H@,WL &?)$NX[O\T=.7 $.9"->9R_CE'4@&<1)N MKV'U-;<L_ L#Q#'PN=9X;$B38/[JDSM&UM=Z':\=S+[W,+"8]"EO$'_E"3M% MD)3Z)):PMS9GX.+VHE[\TP+%>VHGX0&'N:(S\+*85$QF8.0KC\G3-;?VJU[S MB4J9R(T\PL6WCIF\\D=NR",%.E^\>1>''SZ-&YU5)8/$MW;;\+$/H,R![-/> MU8;E0U('\3\B[[FJ76?A:7%XJQ-<=]4#4O?]&4],<D"51\K2Q[OQ)7JK,$RU M@B 9!!F 3:?=59+Q-B#! $\ I5[32V*&OJTG@\RMNU>N\.(!3X-6MGG<-*QX MXI3,9_@4?C[CI-OP&OP>A%-!N)YM@!)QL.!07%3W3K\\=&G**&[*:"JJ]C22 M AJ<S.>8U5VT<RE=1(YK#VF/@89IO%:0M\IX&]CWR*+@DB(^2=>96M"^>^VO M;0S_U[0R4;C)PQEL;WQS_TWAU9]BD)+G3A:B"E)QXW%KS)3T]P?1\M\9[^Z; M9;C0ZTWXS G\J!BOR9Y\&>#;OW2UT-N:#&(G&%QQ$TNTR;)\9SOF6;?U]*RE M*T+D45(.)\8MV7"P4$EV?>]FM5TYD]W7M9]['4[M<UKSRQ?:0PHG!"9['";B M=<I"1VZ_5_^671]Q<8QZD,6H!I)9EL>3.WQ-YJON+3%VBD<IL0T;'5+YUQO< M4>&6DO -,X8O,<^&![8,LNW-:Y8<!S]X6,[>2AF?OEQ@![#=3-\]0&S@]U3G MP.33:D=L972<*)J*4<E44D;C4-%A4JF%4DK_4]I4OB%WR$57G1N;4XG<&27? M2@H<:&"[MS\U=,;<4)K8^3JN5%]2V4)@'!;?G6988_.-Q*^Y?M&?M:J*DKGM MW6!1K>H&S$OA.0[T+_+M.$1<@EZ\235T&Z$M-]P=,G\.V*5+R<Y8SC8V2R8L M2Y*XJZB(F(@8CZQMUZD*:%5EPW*?5^$Y]'QF-55)M(Z=C6@GH^#X&8X!9;GD M!8I&L$JW7TG<M[73K7-7/NMU&$6K@E1FMJ>^NQ,O-^E45&KY7> ]='^VM%CV M-,/59T)';T.9QRX 6VY2G'3%-Z"@?NNG?T5-X^!U(802))YH;,ZUW9#K!;Z@ MH&D#N(SG'8786>4L#'Z)'#@+G+#X?I.[WJJ,P>_)6+W3J8N1YIVT[(:GZ(A] M?HSVT:)SL;'G;$0)O"LP!5WJMVM0SM(-L1Y5OZQ1L\XBNM)J5S+(ABDZFFF> M^'@#ARY>06?I#[@?MAFI5P3S"=52/*6&]Q37J,Q:\+=PV(^NQ4E8C/FDUL1U MYO"FWFC363<KT\MMY56CX8)>OKP#HJ<%E?_[;HS_"X6://K_ %!+ P04 M" !PK'U7]+W[,! Z #_.@ #0 &EM86=E7S Q.2YG:6;%5_575&T7'5%2 M0+J[6V#H[FX8>N@90D(Z!)1NI&'H[NY&D&9 ND.D4QI%<3YX_XGO_'#7.NLY M9Y^]][FSYKF*R@I"PI;C+P1?W , B.> (Q P! **0 1",!S!H<CX# $'(J M Q%PP/,A#(Z P1 P* (&1, S[50. (*0T"A""@0 04\MP+A"" , 80B@$ $ M$/"$A # $0 8 @!% ( ( . 9^!GZ">NI^:D:\#SG.6!P.!0.!\+A@.>Q3QD, M!H=!X3 @' 9X9O%T"(7!H5 X% B' IY)/=4"87 @% X$PH& )XY/K7 # Z MP@% . #P3/E9PQ/I)Y9/M #/"IXG/4$_83TU YX%/>=/ 87!@# 8X%G?T]BG M# J%08$P*.!9[A.+IT,@% 8$PH" )_5/I)YJ80 H# "$ 0#/9CR;]=3]9,>3 M?L"S-\^2GL">2#^Q!#Q;]3SX"?L)^@D+\.S<\_%3_A1 *!3P;.23OJ>Q3QD0 M" 4"GGQ]DOO$XND0"@!" 8!GFY^W GNN?38:\.SZLW>PY]9G.P#/2WA6"'M& M>B8->-[),P_8,_ S-.!Y1<_5L.<YSP%XVMB3D4_ZGL8^94# \\L!^&_]@/\6 M#/AOA8#_E@3X;PV _XP&_&<EX#^S /_9 ?A/,. _28#_2 /^HP7X;S#@/VC M?\V _XX!_[_@>'X\_Q8 : C "S0*I?K\_A T?#;3T?J"KQ$X]"K92@V%0S$D M0(?UT8:BD<\TLM$4RHW%8\DLNI6F8XTE$^G<UN/9RDVEDUE"[L?K8TUEW_*D M0C H59K+9XJ4DMG X\T5<V5"!H9&+RR0%RH-:XQK1$#?]:MIZW12_194EBJM MOA42=K74+#7H3\:G_@&],VA\.><0=I)XNM[CM%*80Y;!#NX(_YW)B"E8N]@6 M^<>//^O^<J?%_RPW586$YP#N,<2$W;T$A #*"D2:\5BFYZ6LP5W[CJW\IX0U MVE]1.H(7YE>;C-I*1;J]W[&'NZPIB"^T.:]6>^W$3XG47BQ-U BUG3W<@N(' M(-0(XBF,>Z>#U8ZE6K+(3J?OX(@R8N=_(N=+U0$?E\ISVITJ8V@-LD#U>XLF MG\YHF5,__*1$M?"=@X%RO>[&F L<3; BUP(K.7?)C&<[%#:LFL313#R[&WZ8 M./6QWI.%,J/0X83?$_K0.BP1W!<8'/ K9;A<R=MNNJ*[9>"^4QI7*'1AXR*A M3SJ*VJ-+].9'_^*(KE-F[B*%9\>@(-]93@[9P#)<C^S$#2U)VL"-W(R20OIM M&<RU2;SD,^JY/!U ,ZR0ZX.1V?;#F1J=S2IF<$'@T-U O\TRI09KE<IUR\EN MW=5$H<R\>"Y@>4OQ&ITMU7&&,,/"!R0\0A]D64M*Z6Y0B5@&1R6.MULJ'J4R M,Z7$90INE**7"D]GLUG=FU04'3.]"\N^ZB!V#SWJ, YI&N>W\E%&,BZOT%I$ M9<GZ@L5*'[9"E65G-HX;N5M>A.>[+L7B-[A:Z=-J</:A[7PTMU.Y52FO[(YM M[+RXS4UNK[\)F_@D8*-7Y&?]Z 8[<>G+?0/.P$="TVF#V?.C0ZMO2/LL)C&7 MPX1.WL/(*Q%3A8<&UH"K6R+C=S6B2^"9WEM&!4_644/[CY!6\WQF5,,T"-W< M$.$D)3(*;Y?U<?72+,5<-JU3+BW8V,ZG8N%RR2*"\VZ9.9'I>BPCL:95VY;8 M:\4B>861S,Q.]*YZX5.#O/>F-QB!X@YV>WG>-O?^]I%XU=,D[6 *'X3&\0E; MI/UN5SJQI+[NW;D/9=,5EGUU@/+#@4T[OT/@\<>?!2@[T0]8*G0>''T19YW- MJ,Q_/K9XU\Y\_$9:5JL_SZ/Q^X(OD07<4#)\:-[Z-_J^^+I5M)+>ZYN+/K@O M:6WB/(A 9#E@D+=QA#)KYK/*<ML>MJF;PEFI\%;WHY_ZW[_\8+A9A=+YAST? M$2*3O%_],>MN#@OE"O+VX LRXF.[$OHJ.PRML]6I'^_+Q'\>C4!'5=ZT"7VE MB#-Z)?1-^_/@KF(?WH"<<$,3<8S;'/M"SAOIR]>)IDH$5.2WQZ D?+2_W+L] MLD8JH6U&<'X$G4"_V$Q]A$@SY5=]DAXC^T%_^1BC #BS&+[Q)0.0(65CV*-Y M[-6!S>*1&I(T"B>E%R?4%#9I8Z<@.Z<$X<YAQ2:K8<[8(HE3-/^+Z; ZQ/9B M[RCZ$\,:.:F.?!A!(U/$H!7=R[%1!9&KQ(18FP*R)J(0FDGV# ^E!9]6)66_ MJV0*VM<'0J-#M)9G[]%GEF1N,A+F/UVEUG.D]'&G]SU:CFCT'].<G2K5T@2? M<MNI8$:;DDY8D;EKHN+NE;ZZJ37<9E9/GJ7%SS'@8EMX#^YBG=L3\84[2PR] MT[S.-#D,3Y!VAL<#&Q-OO/!EB:A<U=4&]X,-]7(<!Q0S-^',*YCW" F0<7G: M'D,!2XE-_B7.?#RX*V$CN$F\*Z!:3>Q!W>A?^;=HE1-_*[S%6 4]FF%8,LTN M_+52,NGT:*1',0-RC'&LG$Q,9S/KKYGHHU[9W&G&W:)7*VK"R,G*JLZS=)*3 M%1?!#[.%5S9I_HV?^3Z0]GZB>U4$+H 3.(6+1G&=E88:E\SFJF@GT$U;,_%7 M&FKC+?0&N;I:2YM*Q3&,"[B.!2U1& ;I\7^=$@J7">0A U_,C]?N,_J8_#&R M-4Q9ZC0^8'5"QY+;3<MH:"TNH=F#FOWUXPV(XW6##R;F.2A-NK >B>25<$@D MLW[SF>*2RB_1Z9*;:"6:C"[SGDCPNWJYDH%06@Q-8#R6?8_QUDM;TZ(GJ8H5 M"TWZ7]"B:$^HCBY6DLEWH6]!GX)U.LI'V$!L0VY>Z!:Q+':*EU*<;-5ANY3V M4)J93V$)'[LQ]=XDDTT;'>H/BZKA!$ ,1)WB6[)6ONEY*L+ =.7J37K6ND+T ME#M1W&*]>RD*+@-K2INI1<2%FAUW<NR((X_45+:*OT(W)9WEJ1T'U^80:)J. M:JE>FV/5^<>)T-7#3(=^ ?MZ^@#"X9?,' ,$3#/\H7IKT?F&= ,3/^*;,,8% M YGL?9LT1B/3\$D%>7&$5^EM?>W5CWW47*COV KLF.6M=':=,DVSA;0750!5 MEU7HR$"=[&HR =0D!*'L^DYB1^ER_:9>,Z0F*\&C72V<\, V(H"4XJO/<GLB MGEDAXT6>=A3WQQSD.C'L.BV?*JALXVUQ)D-45IW2.)6YW'!MR>=?,G_5G 1& M_6')Y[\P,3L<" <G9G?I6ZZ*!UC/[=ZZDZ47LR\MG'!/?M5GAZG%L0 ?55AK M&&K)'.7'&SK\=3A_Q*)9S"Y:3&RX<Z.'9%<&[)J%=V W45+.N0FT-G7&:X8= M46"_E(^:.N'TGOS6K#O.MGOXTGG:1XM@"[H]-L)'I@K<++FL55?2"/3S@)[1 MS>9641Y/$J#J_WA9'QJWUAN[C0[Q[OA5=;G^WB=3>X9DTN'C3 =!HU"912Y" M-\4/[>_:I/3G''U>QA:)&*/TJC_#65R62CR=YDNU1QI\LW2Y0/P5W)/8%4,4 M4Z:@./M2>K^:/F<32'/X[";OT&@##__ORKV#=XVLVU9</VP;O.A [D06[-1" MCY'*AI)UJT-].=K&2A],,H5^CYR2OS=H$VS 4VZ1*Q/C34JNL$EDK?:FME9# M/5BWX>7RLD[C*C,0GA\^:R216)Y/F#Z2P.4^((YQ\+[X8AF7Y/^2_X;M2&^S ML!:8J(H*U9O+&C4R]IED,+HP6-LAXR1=R-]F;%B$U4V>5G[06A!/$*+,ML9$ M_\W\#VNN2S[@.*_8M/8/FP^7BZ]_#[\WOK?$7'>9%>*6Q\7A>N/>2VXSLDPR M2A>WD_EKG09[GH+(J"KBW\6]^ VM^V:2HE&N?]$L(S""LV"("9P$X;)TDDIG M&,,7ET"E1G?W::<+ "IH!^XS)M***\AI+H]XKUW;;B:RA>HPV%C)+<H;BURR MS -Y<-U,<QC!-WP\^<@T!"QX3O*!*R@A7,-6S;06^.6:9\SL#[I$\X-4R[J: MS1!W,8]/^XHF_GBBVJ4@UD@;/2'#7E2[-F8[6HB)G0VQL0>?4;E'"I^RU#*H M;D\:'QH*B: 6% @LV>$5*'-J:PW\VP;U5/3#]/*/AX3T[&NEW,M3VQ*7$)!Y MW*FZ-_@6#:M['N*+AGA*(8!Z_.T1(@8A,:\^3H_X)Z':)-KAA;F:^5WS4=UY MCVMSO Z*2#(,>BP3W"V.\%ZT$6O7^-M(%\H(KM8!@YK#RM"4J6\_D%\RGH?1 M0N5\RM+Q5V38=*&!YW3<1LLXI1DQGYIC^GE4XVW-@\/X ST(Y:Y$2<OBVE+D MWX;R=K5'9;:"T6W5H4M,S"RX2"!6FV+'$T7G*2&"Z4CN[W2!YJC&27@2+X"A MKCO>4BFQ37-J7;;>MT-F%#>D?8/\U1F0OX/6E4ER1P;1/T@^<_!\_N9IVK1L MU.%*J;_(,I>LRY,:JJRD7MAJFRR?P&2$[V@0H^SI)K>L/*F4R+,88;I(MY<H M-XM T[YK@02BZ<PKQAB%,N)!* YLO-_?.0,;W*_V.68B67 NXS4:$JSIK2F8 M'%1MH\1+S$LB':F83.HBN$#VWGAV^+6A>@WTAMA)2EI&;L(>43I-:=JD?JFM M*CD1CB1WNC["B04IP$$E795AO^06?WAY>NI+PTSMN,7(A,<]59THI0_$R5E$ MR:Y%DMV*/D([VDG[Q"3[:8<+&?0%L*2C@!!6@<9AMS$?7QR[>"0CMYY2-G<B M1?)(K8 1LX@9A\$7M"&I;.F^-!D+T88MZJEZ0'LY3V^%#"9<CN@1W>05H:A] MA;[];&=+I5(>4@EWLMQ^OAG%3R<I 0O>[BPI\8J)_FT(+V>^XO"=^V# F.A- M.8V)06R$/JR"@ 5_Q'.*WU4:FCT"HS?[1?JF@AQW+#951O=*&R2$[K6=Y"AW MR.KR@TMBQ"TKBNOE*E/]#_-+1FW8 4SYR&!1V,0?)/+>RH%PCF)+)@2%2/OU MH&S?=A::MIF34!)N.0,&;J;RBK ^MUS,3-[Q0+9W$OWW:[5>J*HROP%JJF2; M%=VF#*COFBTDT8:_DEJ]+%4<Y,%<DFU05L#$XMH+5=EBB<./EB$WI"Z;<<?\ MZLR6J281G'D[D(\@?9<,+4ATBT-7QN5LM18G*Q;%8X+S42X?BBF_(LYVDR*V MT92S)RD'D<MZF<0I9<+&]'40C=Y:XY9ZT3D*$8*Z3?IF[3I"^"Q!LB%9XR"2 M2KSN4"JO$G$X:0;0*GC-5F2#-6+'WK1B1V;8S=H8XF@.*57W99[>5QSR!OO! ME'SNY6:C:);R\YB:LN6UXY*,JS17(I&,<YB&()W,/LFIV8DOXB-<05TMTGW> M1''00,@+#IR1J@\#Y3S'[U6LPTYUE=[*RDN!=*J""=ZO".7YZ;U(BZW1-[4K MB8,8E!SL E>'*^CI,UQ ^;Q*U"=D=F-'6J=A=J?+_DIEP&ADOI1CEB((@3]K M"3%MD8JE\\L,9P&=F+.TLC?TM0X_N&KT\RA$I0.]I>6:91J59'-?%BZ["W>$ MUJ B"DQ#&1EP,62K0#5D'_#14I4Y7I6\N6RZ6'4=OG*]L(PA12K[96]"U XN M]Q.Y;%9?0!6V]K/8@,96W[T]A8$<41+.+^DPC6/I=T":KRMS\"I+@V-C".HN MB$QT(DB_&'CVCV;6E8K^B_(5RO#L('6E6&MJ3>:R&%?]4&1>?4OZU_WM;G)" M-W[@B(CZ]T9A2N',8N&Z0N5&76^S3U'O)Q6:4],\)N[>H1F42K3X-),Z^ /3 MDA4)_M&)LB\JRF>U\OZ&-?^Q?[%*/&R?*HR<Z\A&H!_Y 7-!NLFD2S+1/^.U M54B8<4I'>L^R99B-K?B+-ES+YF&31.TN_[7Q^(@F_KY[0A "19K^I)O7LN<M MKM.L0C;AAQY6DI8*F%,[1D@I.D?S';6DGE=&5R3#ML]<C#[[@K]]$+/VE<=I M%_[V80Y/5[.@(GA[)G&]0-(;EZCMQ+KX$']K6?9VV+MR(6_?Y O$.HA0Q>ND MI7VCH6TRE-%L( K_+T1K&$/2597*P?I&V%E.H8?J;W_"2(RK9=(:&W\*GY!^ MR-=7':4VRO)I$4T$Z7%V[0.4R=V83.F4V06^2M!,OO1A6_-69L%NOI0>9CVI M?I6R+EV)VRKX7M??RO):N_J-U_Z?O&%A/]+@F1TDHCWVRFT<.Q]\(87ALFW^ M8IKJIW5)T89J?^T/%0V'Y;E^G@R*()B_K/MFKNHQOE!V9^B0B^; %QSM"CZ- M+AO0GOZ:FXBI)4_X:70YE\\6J-#.\,-R %-H-/XHUZ^PK^1>3"=K$,$OF\JA M!*%@"""0)(IV*<-T"_!.%$072$N.JX./GV422G*01+LK2Q&%3U-,SHI-SIM. MSL6.V>F:R<BV%6]_]0PA/2$24"#J'UE76C0L/\R>.NZ>.EV?.O\[=8H)&<3H MR#:L&(R%QQL1^(R5R\G7:HM$D4-)]CJ[/RJ7VW H_7,8^M#1;63]56?9)H?% M1*W3QD&/Q)9=HNZ5&^TUY48T6]3A=%WWQ$(F$3O$3'[$8[LJ2$XL]OM"N,.# ML I:TP)!4!V"+ZLU328CB2MU6_R7F'U L5^'NUO+3CM<IX]LU!D*GY4ZH3LP MX&'C [,O-2WQ]28QF.]80X)G*0YTA;IE%VZ2#3A:VS7B9'@%\Y<6J>ITBN>8 M5#/A;4[-DF++A;AH"Q*&"^SM[0U!#B$?R*^)ARBMG,0>/459>1JM!S*+?-O\ MD^)&*D*\Z[\L-0<**<U6Q?R*$: ' R&I751\447;/1V"9+#'Y0CRFBCQ!$%_ M AI*WV_+<\I&JV6/JZ=?5\4N"1F^X+9, NN=NF]'8.;NQ)KU2&S?<1CRD=CJ MJ1G>$X[$=76 NP3MF!UD24" ]4'.#7W<=7V>]?D>)!#WQA#EQCH"O#&RH5S? MO9[[*LJ9>6WH6H!-"WD&C*QYL7;:@_13?&-5??V<<XOMXM40Y];/FHT9RH#= M#=J-'RJ&]Y!WXB,'NP6UX,%?-8276%N7G%NSCVO8YYL/&UL//9N:WS?[*:$O M:LGNF-P$V*"Q-?[]$9,MH*W9AW7K[<UM)T+R7J21FBTCI6V"WJT_-=,LO[:U M>'0O@B6%?,UU&'?="E58XS=%&DA;>@C_!."T80$TN7 8</9>\>S%A.V*F>%Q MX+^%XW+\& BG;>1 5M)6Y-JCE,"U=?8^;O]ND+NW-:C&N"[-S"PZ)*;PCB3. M[%3O'];Z%\YU_RDA38T]>MPZ<.+^F,TA.D)[?3 1]B9\+)GQSG04]I:/_@E MR0,>;ZJ<;T;%QOSDME M81\60)AJ@T=CO>_QZ*/9QI#XX7I*_:+Z>KT$87WM M8;,&X9#Z]N@CX0GGUMKD$6H_DB'549P!KN*FX\S9X0@V27OO1GOO]D7 23'5 M#AX5@$[Z,#1Q*__\<)5J^RSN=&43N,9Y?/ZX)8=\.D"5#C]D;?%M9]$_5;Y; M:\_=X<'^^>%R<^3?*Y#KUK?XF/;9X]B9D\V +>SX$P:I[8?>Q:YSP@VJT9>6 MYP>]#6:SD^:X(L<-=*[#;FFX'VLBS^JQU[?5UY=KD-[^^]$T=; (WG8/.GPT MZRD).@&Y'ON?7^$CN';P:C=?:J]OQVV@;5^\^;QJB:6),5>YH<WFGNMF"=K7 MP<8-UE"B#)P>W#S^9'FH5WLU4(ZC^A,D3IW[X;%P^1#H\L".O.AI'74#"ES3 M-\.Q?;,'1>#H]5U-L.'0]>$:;.T;N31(;C6]\J0K\H?=K>5U8>3Y7JYM<_XR MT;[@?KO]EJIB=_%N%R7Y7SS.5_ >;ZZ:^]N]:))33^JU=(_O6_!)WPW^HQ'^ M3UHS&+/;%&;7W(&$EY.7!,[(B#BB/X^7"Y-'+?''=HFGBL1ZH5/$T5S'L^(; MNI>[5?'7 9M_*#_^AFG"N_CY.#R17R#9]FJOZR,#3IVVS'BVD+:/"@(WRA"7 M/WX^/IX$G)[EG';U'AC/[,;]>R#KJZXPW^K-^]=4M\&W^8\=YV7.^8U UE]S M3*#IRP+EQQ0;C0= @U48!H"MLIK%Y_U0<MA++#J&@OKH:$(0-A+-92B=;/A+ MSLI\0VUZV1!20@PQ(ZWOR<SX+[I#T;]@#&3P.XT39%Q;R031NNL7ER?8# 5) M$F[*/;B%I1:KYTB$D8&.]2I!-69#F0O'T5+5[2B-2$35A(W"7U&05'79IXI5 MW]72%*2P K%]Z@8+G7/9PM??=#!1,_@ @?Y?IR%*^,>J54"R??]C^8.!@J8 MWU!+B(!0YEIRQ#^B4!K?'%: :^KQ8@0XC$:JQP*AB-AYI[GVM\KSM5%K3+M3 MOJ[XCF0F;#M!VL@#KVH)?,YV0;;)X53@!X_C_*^-5O)$3ODEP(Z^L!HOP8/, MR>3CVDU#,;WMH[AD;\V<>[UKS:6O<I\7SN?7+G/R*&-$SZ!NL<UWF\&:C.&[ M;)&,[61TM,7,F*+810]6>)B5OW-%$F1#V1C@!:.86N,5/PIU"OHN_U8Y5T1) ML8VV$O!4U@C@(*MR#;5?19_6_,EN0JO-<*["I8_%CDGHH/QX\[/QC8GUI!33 MD0HW8TBNTF@_&]^X'<-GKX?77%]8QD<Q$BB.5>N[*;(:2[%'BBKX.5)%1C^1 MX+C9JY'$O#PJD'A]G)Q/*MB)2"PEP;/![0S1RU .B\?[ROXV+GC>OJ10KC.E MO%MG=GQVS'"6A3F.::*YX(N 6C/G0+'C:XF0I \#T?(F9%'%R.S1H]&4LAM7 M#6D<9^4&!=@Z+,7EIK)$1OJU8_%U@V8/"Y]V3(_'6%1/C/4*)QP)FSG8='.< MM8'$JTGT;J@/J4M:E'SWQMJ4>WSL7^%.;4OF.<4W/-'C#D"1H$C\-PMO4.]< MVUGSUDXF:-ZZ-7.G,8 C&V+]W7#F5-1K%L X.3^6QK([5=Z5HE'_8>%VV,9S M*#8S2&+A9B<1.5H(C90E6)\F>DS0R3L5+Z?WDJ])F\_1WL!@'(^GV]Y3SW&L M6/X:V(-(Z#SI#OG)<:5_4<E1;_50N9^UJ<<F7?1Y[C6],7UHYVDJE7J#<;LA MV?57DXAC8J;Z#OT8H7 %!8[1'HZB=Q,%8PJ_9PHR7F);9LG3LPS@6*KQ.//1 MBFBHT[TEYJO?Q;%V8Y5:?8VIQ9,:/<%%]XUBU'7^L9)<I#9#Y,PAJ%4?@[_F M93]YC?4;!3V>,BC'96DC#\?/TJUXN$O#HC6282L^^MK:*,B234-P"PVHYE-' M[.UL/9VTQ&UTV=*UG_FSO2S^KM'0Y-@?-BUS]GA.X9YGO3F3CO&W+KTMZ^-: M]\^4NXNRO*9?;S^BT<XYN17VX?B><B-WC^4E67&D+H]^.M*FSD*D!6=BA"&_ M:[_.-Q)J[]*79F0@FG]]((;/'U+!+(=5K/Y*G8$AM9C+QY+\.ZC>*^X58043 MPP"YNEZH5+N4H[KW"9:*EUL!X?J1=B$=>HZ6MSAB$&I=MS-1B3;2TDQR$"@M M1Y5:*26>[2O'&XV>D4%!5P[Z;6.3Q4X'@-E*C=R<FHNR1L;M)K7/UD2$J\)T MO^N@D0[M<?MWOB[47E40M 6CO/]\-(5<-IM,@SO._+;! $RVWU[ONRN=Y(AK MOUHL]&XH3,LN:^'+)Q"'3LOK)+)W43I487(,@5A0K!=?@N.+DX5G,.RB*@AR MF$(3/]O4T9>LY=*VM 7CI5@HN<F@PZV($(E.1\@^8DG?OAA:)99RLM"E.A+P M5RC6<[(!0<7S8V[!A8,$*Y7,:\WT$"J;D0\U9TY8I%!9/TC?,'R0#A09PT4. M9;52T,V-=UBNL[G!;\_A!C;P,G\XCLA#QX70BT\8RM *XPJW'NKL_1B58/50 M31#35FJC,Y0S"IVRG=DSP)!3$V?52XD6/Z8CQ+719$GIF;AP9W-,,@JCFIV- M[FDT ]04R'JP)L5+L</8;M,<23QDOI P:?G'X,;B@4ARF*8](A/AKRO:BH\J M^"3"3%_@6,^J':S(R6>_HF+YJ*(8:5BN^($4T\R@I5BH<D^AG37V!L->GVTA MJ5ZKO[1OU\^0$B&1VC#N7L"+&M/WU^.@(7WHU(,IJV_8-4ZX@K<ZZ_A8FTXC M_EW\+1V6\)H^%Y= 4UW86?1FDG J0+$J&1]?^KM"^BCZL>\,^AF%*%E1%]Y; M7O3YR7VS4GR!HRL3DR D]=I==4KY>-40#(+\>%&M8V3!UBWD.L<17Z:"P^)N MZ6V[;U:MVDM)%V63G!@N7U_!\[*C\ZT(4B@;(B;.IUS\=[YJ>.GH<84@#17* M^EHI*A&6184O];\AHG%C,\"-)[.!F#Z,S=JMUI96$(EL!J#WG:=NHO,[YK=1 MK%D.A.L1\[^M?W0J?DD_1KBV 56E@"1K226]59085Z<)?Y_P=F+6G3\)D9CQ M(FTD^[5IITZX,Q,XOSI?<.MWMM+3U? 4DU6%1\5O+)UUBD!U.,28-AW68,=? M@L3OMLYM-C4IEY0+;EK)T(;\#/6JT+HU<Z0E<L.CTYYP^_> 3YN0T=B6$$(6 M=WA3JI2Y,M. U>P%_"!-4\;\]%>5;_EEZ5#1^Z$A_>Z&8A+]F$*!?[XLC<,V ME&]=:R0\B)VQB;8HU,%XYYO1IZI;"LF%S:F$U82T6[XZ27K'@6$?KH[S/&W3 M1B%S1*:YY)VS2L?(T0;%J6*U\_B)1L"[P@7CD(UP?I^U \+CBG#14%U:\^%@ MG$S+-:E6V?O3#+R?'R_W/<'P'ZFZ)%U.59EAS0B4#*PRRI/(\P3"O4V-)?VB MB^9R!=&*@@TCRBFR"-L1AS684&]34\X+SO5U['N7/FIU>ZN(TI7]4!JPD#-_ M50'3=IWU[T'+GLSE!@JI_5)?8PF&_ CK[@"K,>'^KZ+DWA^9/+YPY.@W(.TN M_S7AR]9K9G7]]5T,E66_PK?]HQ&VX\<SINTR6,["B$S^'9;=P4G3;P.:WOXD MXJ[X],8:I_MJC;95%&$;?S5*HP/CTKGFMXVN(M%BH&\_LO_"T5]?)A/4I7]2 MU1E.-Q(*Q@E.\XM@^?[6'YN6O6Y\E#YI<=WL(+CIEU",&5MQ8(3^-_T(DYJ; MC4*#AUW%1Y$.*?2XX#<=]HCR?2L?&\&[OC$,N=]D:B6MMB8+J43WW2=N#?ZX M&.<LI(<BX/FV=$N=R!PG<3!UQ(\B;2:&MU<9<H-YYGW;>HRZ/WLN0B,@MYJ\ M5Z;TO9<KNYRZWX0>MY/3F,33$LVY)'.%-\I,C:/:OQ1=:+VY<<MB;JQT)RTW M9ZNXW(ER$ZE)5*W($VI#76UKF"[\_#NAGK0749^)G4W5\K4S[T]\+6G/'_8" MY$XL2M98TC'@P&6-)&[L8V17-T9<[URVE#+FXN\\-2-*8@_RQJ0OY[Q-C;+] MGR>$<]GS:XJZ:QO:&ZZ[%Z_C$^S;:X[(ZK_3U&J5U"4($O+U*K[DU?_0<FCQ MHD"T">%>)!:?/%!?U([#T9]G@A5[C6TF*QH;0LT12ET)RPFBC<'UP^).P9JR MBZ?<_OR#-Y=\X,U@%$9Y$_HNL PH)A/!WO\"%R=[IR/51":_2&[\)':M7Z1* MNZ,Q1!#P._T:74Z:XHVU,@7O*P["SJ@L-JE<LEHZ6OQ1/VYEL8$E[M: +MX? MHMB!OP6&N5LT:!.\DM'9DU[?*0^OQ$B"0O%'?!J_"A%VKN"I-<;B-Z"):+^6 MC&(;.^SWGA6__"0'F96W\Q!8DO[Z#9CL9UD>\\",\9+,SK+<>1#O7U=QS&7, MQV!FW^I(U\34719%61%%#SXE0H\8G0K%,&W83W:Z"1SL+Z.""%*^S-!\@GY[ MEOX&[B".7G?CD9!7RI59;2AC-:T5V9(P;G9Z\NW1&-4!'% A55UT]KPP/H:* M&-I.3\*\LM(?):RC42*\L1P"E43R)%Z;ZB!X03;%>(F':!?^E^#$Z+Z7Q,44 M-"4VXU5J+2A)&7EV!'^,:=ZA)\'<R&>:XO,P!:OE)@K^M*YG,:=U,&H%T25W MIFLKI^?R?LE7F^@.Y:1O>BWIR^R,0>9;J.!F5)?'$Y-4I&)RHMQC Z_1Z7TC M70 KKJPJK%M_>)U,D770J8K:-#Y\ R<R@FN\R&7\(]?DF#3]%SY_0RRGC5MB M,DAV2?L0.3F)6:>G-[DF1ZTS\-K701FAMDJ^J9<E(%TN]"[FT>+-W#Q'GXSZ MNLV4F3OF]\/4 E[B+0Y6S2@VAVQ,GYGL WHZC8*ZNM\]%P3?+AF^(5;S<8_A M^WJ:2&ZXCC=H1I4)GPVC)52&755X/\KQ6+X 4N_TC7^0:YSKO"*8?J&>1B** M=6,Z=:NG=?^Z.H*%A<%UN@!/LKX3\W53VMX$ZWF,E.D*M=)+W#73:1S0".UE MU=5UPRB+.$8E08H<OC)K<S]+3]@HU:QJ[B!\\A7A#$4<=S&:V"J@K3*_<&=^ MAI90Y:OLFT<>%7W:649QI2%: I0Q;J+=R,P;=FIP;J&2#CEDEA.D2EU!$;.< M8NY*YO$;[RBX"]&^DMYK*%4YH$6[-RO8(SG43^\;*MXK),)1@01>*;*D36^; MU_3J*-GP>"O$.&],W\ANE!%!D*S'B\8N0_R:'_WM&$-H(XD2V;S,T+R%*HY/ MA5H?';J&>&K/A^*OZ/A;WR4;3*DX)^=!D^/K:&(U;NI'B3AE10O%77KZ0Z!N M_VJJGC'36]"4'*?Z6@S9.N.W[Z*[?Q=L4K&;R4ALC 5B5B>!P9'_N-/2Y&(% M9L6$*@N^2^E#;O5G:!KE75E?L=._T!-H\Q5#72V=;:@0T%YP"5M:J(ZR-,*& MDS"U*W-3O:N,R$B)NB#M+F=%DN/)BUX*IN1OJ'A+ *[,((L^94B?GB- D'I* MP+NINM2BO?F78STULB(7Q&2B:6X+%ILY_UH _[2#XN2-/A-\=59?2>.D];WD M[JS'-2/$BGWD3R-D3 ?!'9*!!0X4Z\?X_@S-F%%&C(2\HRP*QT9],2VM=]<] M'^W?W*U)E<6IX-!FKKAW;\,*J/GU0CFC'6\4V[99XEDJ"]F^O/EJ=&^!G_,N M/TI,#=,?/8>^>/%3][5K4BLG^1) H/<P0RPDZ9>["3O>>L!)1N\M26?/VA#P MM:6>V)_0U9-=8T79##2PQ*M7T2C!Z<QNF=C)F<TM?"Q!QC6OM>Y<XW!DTYA9 MM7IJ!)OQP5 .,+N5S*)ZV@#;1@([QRJAPA7%!N)"#KR!17[-P?&-4NBM>+H_ M:Y'#=F^ASNA4ZOKW.(;-R0T.F:Z=F,T!,+5O%H\-S\82CNEB@%F/TW##:S,6 MZ?6?XL,CD+Q3]:WX=\TS.7D_6[*B3C)L_G[1>)F?S("YUHC;3E?+L#VCU6CN M8K3^HG>3-$9:X#<8$[YVS3^]R)*HH&(Q4=4VC:S0=I8OY4\SS&\QB%70$2" MR?7]AC^&:\ $"\,LI]@H1YQCN^7S(FOG.1L.8> <\6+".D5<(&U63<)V5;,D MBK8Q28O@KYVA!W+FBTA)LYO$Q%?T-!K%;(^6@_FDV^]_B(G6<-U0#5'VDW=N MD50W8JOU4V*WW$-,IT%;".OU3=KXS4N(Q1L5A691ZUE"Z\:LS6GD5F'HSAS6 MX'J8-0/!1JHC]0V_N127UKHGD4VB"?<=WQ78_&;(&HE6XH59GB>]A$KHSJ6X MM(3_UZ.XW01:L.)=W0&D3:FT3W)SPYJ VBO$>$Y>9J5$^%+;^B<$+(?]76/1 M9A-LJL1D/L6N=12W!P@P5Q#XEO!G[]Y)88U1JP=YNUQD0_,.4NL/T?UG1I0& M465G#B O=E"E9](WYNHM9'/GJ1)??S#!ZL'0F)(&NS7NARH/4833OM'CEQEG MKRZQ&DW>MS?3"I(>'^K,'^7,]&NU53N16>3]$;(2=[MF5?GX^055:VOA#T== M<D3Y?.-'?6G+09G1/ZU?.:!^^RJ*C+L]W*8:J@89NR9 )MO:T#6NOZVME%:$ MNO:X5.)<@R9^&B1D:8<_54996'>V7N\I4%%;H&SIET*F]^RUN:I_XF O(/=* M<T'D<P5UF12N3AG82+N*-<2@U?9Z[\S+IFRF.:%+"0,JK1TG)6"=WDV><$@F M^;O67V"4-,'L7IO [5U @ V6/[6&ET,A/;:Z(^3V]TZ5P+R%F*!A8'[YG=DM M:!U=XF"AA[<IMV^RR4IR\SL2BNE7QAU_ZW58:S4!F]7 =XL6:8L^!8$JBI+@ M'<H?RZ?*2$Y"R(R25[9+]F?S_]3>>QT.QWV/##];\U)#B+::81#9\I5:%P]K MKQ,Y/]U=*\S:XU]J?:>RJEH[N:8\/]!7O+R!9&=(FBX>7P<('"XZ3Q]6Q V; M]%Q9PF7;6C?.KW*!U^?\[KW+WP=:Z4YS912&*SXX873K1YY3A8;WD0U+/]WD M<Q\MNUW/ K!='"0.*AAW$Q0LN,R.S-1,IU8@:%3R+?K?1O\X6FW23<[M?6T1 M#-M\/]%E-XA?E2 PC25H@>IG^\Z+!O[2ZN+QW(O*(H"]JM$?^D+@?'[A2#'> MRF;1_M,*1)&SB\1V2N&EN3D3F*,:<NF_,R?^7A;;H<+9X7KA,M=YV$+_G$50 M4ZG6E>^?/7O?5;&ZRX3U.?/6(8)W<V,A[D<BMH/6<-0!EB.6S#'%I-D!Y#AU M>*?!VL;KI3!7]U&8K'O7\!5S.IA#YCR/R$;<N4TWWL8B$._W(S%%A,NIPHU MV\JK^'U<C]/%=JE?FV:CO9 [3H=5?6?V^&T<\"G/3\@.UR[F\%Z<Q#7>M\UJ M"?=QKG634@]F;3<D@2Z\.IOC8;N4<)O!3>LIK_,F7NP;H-5]C#%F[QO]G0/: MLVSOO;R[AQ^(19<_6@K_2N^"4=XOK7B%#-\Y=PD@XON=MV9_HWR%CG"P2.!X M>O-<H+0Q"ULZ23I91NS_-GJ7&7]V@'%OWW8S-=9ZL6G2,/Z#$>6J).[ J<[% MZ<T4FOD^XM.E2U#;3[;"&[-65^"2S40IV8'X ?]^W(F"X]R>H_O2/#S\Q@1Z MNQGF M2$6#0[TR%N8VR'#3[>C"#;\$58BIN!4XO(&'\R7%.>X% =N%_9U0FX M*9EO%5,=)$Y=".4Z)'VV1A2W*@LJE8QL1"^)4"AZU%%!,F7WA')W!%K=>\\* M>^Z.;L%M<C_-BKFZ2A5NNH6=!<M\6ZC;65Q,3=_^V8K_K:OOX;1C M7?,$_S ML_MK\\;<X>QQ]VK=_I6"_QO)J[B/%_GG1TC2U\)U#W[F;B>UD-HF6!3FY7=: MBEKGRVU:D>)4DU64@PZ0!H) NV9#*A%ZE#'\OFO>,97KD<;Y$;%$S>!<VO8) MVTKCK2V>X(%/EOWR&U[_-[*1 O\>%7[:SAM^"[_<%?3YR^0-$G;:H?;VK;OS M[=M^(>GEC+KT5A WV=-N_PU-L/[@I: ^KL<42'#WK7]@!L6_]%JQ*OV+\_UN M8\73Y9%5_3PJZOL,C-[[0-1(0G8 &H=2/<U L#X.URL+B.5 Y,L76M5VEW0* MT2C(>*$LN-O]H62";-DD5[1*\82" KN&5WNC"90U.-6D;O(3:5RH2:<P'$;- M$-0WA129.M]E<ZA!&@11^%;#Y3J<P8Z'W$=SA$$^3&?1\R=SM8:V1(19S3M+ M]=!OE81K1';YV49UF91H'DX&C5B7;D,GB/M:X^C7&W[^(K?UPWTAVC(W)W@G M:W71ZKF,X\M.AOV>U$D!'UQY%R<S1@0"JS)<-D;\U>F<'XTL#]M%4"<4>C)X M#%8RD5%FXY+OG=A;KO_=D1,+:6RDG_&F3?KSG.X&K A(!A(>O=\>[<]<X! [ M<FVI!NNF]H"Z],<^6<L^4JWV/$2,M)BH:S057OP^4/WYR-4#<?DC?$_F9P(! MY1L4)MZ9N*XXH1)[;R>F;87L)"X9&WZF;<&7G6ZYU3&*/4M;5)O9]LKWM@\J ML=*@*D VL4J0+\/S8$SZI6M-!848ZU*;Z<^'D;PHH0I!/S:<CV\;2K>1L]'V M3%=4DD#-,DURLD/H1$A"A':C2]"]=N*-W$@9+>\A+&8)]A@EN%;JX&;H9_8& M&.X[P^'FN2PWC3VHFMYOY=0P@;$*/(70??OD E<5"+-N4"EK>:Y_9]1<GONQ M?4K)#JN*;4Z8PS%+OG;'JW)0K26I7KG+E<=ALM=*Q7&10^;#<6'^L!][;=MJ M)GM=C\3X=FTOABA'0RG1Q'%#J4SKP><0IW:\A(\B#^1-_6;IIUJ\VA/V63[1 ME54M]&&B5#;;E$3.->VU*]"*75_VX\JFJ<[:!H\!8PY;5+.CO2!D!R5&#W0- M [R$U:,P)G_AUO9U-UMGY;,HX<WE][TB4,_-)NR?[)NM0_RMA.$QE-4(7=O' M<W+NE,<TM(P1<F),(TN!18/,7OTK11.MMT#2AA1*_6&:2"J5]4;+0:_L>A?. M*4%]1;\>@Z7Q=XP"E/,_'@]OC!\+ETP_&D4@-RZ$H._G?\ 9VMN8F^_@;VPZ M51'$'Q6>N=T)4LT32 ]X(;J4&IJ2*;#HT@-R=%N$3!PLC).G3=)[!I<QM>N_ M7[@3="J@/&DP6@0;,$ U1M(]YWDUBN=3<=@I@-/V552D:Q@A9]0#/[6YG)<G MN3R\SLZBH]M'L N.@2E5+\4:K&&H:@2)===4%->MG-]F(Q()XU93%%#R&N?3 M96]Q [4V7N%=B7,Q_KM_'_U.K\@4.8RY7IV(%8%[MO-25?3Q+.1MRE_,FJW MT=!__Q@?=HFI[C9</F(US:C.$B?^,95GVELS1PK0R?-Y,1EX4K55/B[(D!?Y M)G#Y@09-EF4 -^E"YC SL_-AD%TVM3Z,S8.VU="05<F(+8Q?;P[=LES6$I(0 MGCN^'?:IL8PF"",RR,^@8&KOJRH6CXD&A:6FDF(O-_B"J=PZ$RGH[@N&VZC\ M.?D6OC>+ D6IG,+O8(M7$P;XG,&XDG^D0;$<:(J<PS8A!B)Y2AHRR4AI#(%H MW5LH9Y$$P1E5UM]%B<RQ[X2[+;"@9J)Q9Q@'))6/6)'6!-8WU1&-G*Q1W-^B M;,SRAT3&?^]9/'W7VNZ'(X#--*S\G[)V(63H*OK8MLICE>LW!'<$714LG&_6 M*/R;ARG3&@[8IU9P%P> ^:J\0!M,<BR^J%WZ/>4D^[<#V+:.!FU?SW %L5VS M4Z-WV!JZG;G^=4Q\&KB3"+'DDO;ZD[2=5"Q*A?TS,Z.(SA4CI)UG+U;E"SOF M@4YR@<NQF\*DV&&N_YTPG6>4$E8*8SQ9R4A8@:Y5C3]C^D!'+V%.A2=^I]G; ME31EH# \,8W!JMX&C1.%*3&*K<:2>GMAT.GW13':$$.-F;S$AX(P$)&??4F& M3J&$/8:LNMI"0<(O7>,*G"C!:MTR+E0N3:R)CP(]K/I-#O-X2* J,S#M@08A M80["\[(X:@ K(5KH:QR!0Z[D[B)FWNBBUIY>C3G6#IYZ^WQJ=W/$6SDV"V+Y M!=^2"3#O;1Y)2%E=@=GKC&J/M+13NQGG7EL&XIR)F/=$BR<7,6K?Y'2/R_?H MW5MK( F>^AR6HSDI-Y.-KUZ?_=EDFIH[<O<H*8%-.ZRI</;?I?*3XSO_3)[1 M*XW/>;5FO25 +C,GS"ODJJ8#9584HG>%BZN?8"Y2D?>L9NNT?\Q:7_4R*JK' M8N'KW2T]XQL!#4WSRBU.:&Q+5(B4PPS,P]]1*6@:Z-S_"RN@EO_)W!<LL-6) MVDM7/,-=!363)_KLK&9\0'.+U":=A-?)1/X^Y/HWK4RM!F*@,G1_U3B2/D7+ M7::' >*CG9V+T%E,;4O$D:\K,R]<KE'+O:$\!*#D7]REZY@N4$=Z13-^&DZ+ M^_/:(EN#45[N-UX@.6$T3=^H8AD.Z4?=-#<J</L7V]_Q$W=K=/=7BM*7ZM-C MOYM^#*0%[W)^<]$S06D2)S3<JQJ.GO+>.]'[Z7]0>^QK.#/ EO=GO=046:1" MS57;#+GFD(0,2_;F(36'F)(5#^]"0WV?CF+F7OQ'L#9M%ZFV("/G<:A&G.RG M2@O507G>LDBB8 5ER)@(RYY!LIR)^U]*LAY;B"X^SE(/TT8ED-S>MM(PXU<) MPZ(C$06[T]0 !R5_\\ZR];AT7<<$P@R+_H2%^]VUH;+VSNXQP3R_4^&RD)[) MG97\<EZ/<GIV5A!%_#<%XO==<T^OEF%H$>49^/S@O7$53Y#YWP9/R;-WAL7* M0?:J5@=N^IN9X$R/9B0S\FMB,<E93<[7:F*3#OC1K=JFC!4$1;"<V$WLG/M6 MFV(7NSGROJJ"4DD3;%-? 7FO[YMUW@TLDZ-\@JW9\<(MQ(9K2=I+F1-@T$@D MV\R';4)]?61'\X@>MVQC/SF$*%]N4R[GX!7ATKUQIV'+/X.&O%!-]Z1Y7'QD M>M+&][HFWG\82[A ,C^;2W1M2ULP KR9AK7.1?@VF@&V]Z62RD==P?2G/ITL MR5"FQ0^VS0@+=/'^6O)6D_=L-T5[F0Y*E["*9&/?<9DLQS3IY83P* H!HX#. M"@C?J*+K9<'1KU]68.-L'O',"9LL_$CW1&AT,IV=P>MC5$F7=[(A8-N/6^F; M;(B 3U3>WG3,8EK8V,KX!K\6>%]_7XUK$E1K=!0,$/M3:;6VT?%;I\&:HPO3 M +.WPL9&U.FEYCJ/2^( OUET)2EM6[SKX+_SBB@+ZEX0A1F:4GQ*IH_\[$WS MW#M0^M9D;D#-E@3ZB'6.[FHV>=M"GN >JB*C\BP)Q>GDI,*VSAY!K/WNEMUI M')?]0LBVYD+J>A88/[GE.R5,\Y_4V&_#X;-;^"]2]1I&\'BB*>D+A-%]/:E4 M(CKUQB FW9N(*-*;&^,J?O3L(%*RU/C-!HJ<&3U0Q;=E)]";P&WMWS0D='H/ M\QB=Q7K8=!,=-IO=IM-[0Q,D_S"H(-/:D0NT&_,OAPON./)*AU9KPTAA8=2% MMYM4K!C'K&%X=/IO61>ICVAQM=,X@U(D+J?V4G-*&U;_6F IEX]YILR0J-2 MA7]@B!OX%,SZAV48OL\8 .'-9<0QN,9"/-"SM!)9DE!#(_4CM4A&Y*D5AN+C M4K.82@IM[,(Q5HEV0@TYQ[>5,U!-;K"&VK/"P?-6 %-F2\R'#8VN_@R=>>+* M%AU>Y]3KQ#0NA>SY4SQW"KH;Z6R!%R1+V0A=I0KL<+#)FG]1;22*0;GQ[6@> M&C;R'^'EP[]S$8RHCPS+5ZZDXKDQL.H\)RP##XOT^+C\&\."PW82)/XU'\;E M6$J;',:5]O?;*_V4>V&%NO)4$@\:9$1:2QL%"EZJ9/] VHD;BS.@TK$4-:]M M75(KPJ$9E?-B],MBS4U"\G_%6MB,VD0EVE2,.DPE.ER,N@(ENA*,>@HE>AJ, M(/T2D!FC/K1$WYG1P*O$()#1,+S$,)[1**W$*)?1N+3$N);1I+7$I)?1='C/ M(#XFS6E7^C'%=+]D5QK/_*[$_!^C!4JI!3:3)5&I)5ZI&1M9J3"MM4"IM023 MC4*IC083Y.F3'0-A:'4'^P79%W1FLO5+_9QC^7>>%MN)5G4VAV"84-MAVQ8* MLHM>\1Q+-N5;@RC ;%;WSR!&&8>8]>BXA'[3\PW0=S\L90(I-D/--&]+$%C[ M;KE1;IEX5SYHJ\MY %-JG^4""SFS42"K(#![!4RPJAUG>9-*ZC:F=-G.>/M ME^"Y!/_/5$>?4297/ <2WCO8 GVAFE3+_CHY6HME <.4WJUZ3'AFEHP+%C44 M9$F[+ *9U2]2/_YC9B(L(Y8FFI8O13&B)=8II29=\?$[2*UXD^:$4^.J519$ M%R52@*V &=6\$-BY5]NQB]X#]<3%?R]^$&%TT*U-H>"6U3,VN^'S/5Y_-X7! M%]O<"I_CQ3ZW5_Y, 4YH)HZ0-#9JYTP3;7%)05F$%4LIK7&VTVHRX1+6 Q;3 M%(KS0^ZT[RK1D)'L@*UAT'H? /8P6@8[>Y7=:)><B</^_GN.<X1"/=)H^T1* M\#;A%3@W2(NH]?"<Y-A89=U72"./+!O]:/4[CTH.XVK^QC1._W;Q. ;8N-+! MRX%D<6*)]75A)627F]X%1R-/9,ZREJVJM;*JEZUZV,%\\:B(#'^8L;B[8P)R MSE9W5UGWCZT>A?U^^EAA8*,<C[V1J:J1B[U)H*I)@KU9H:I9@[U%OZH%*B<% M (C^#U!+ P04 " !PK'U7V;,H2E2K !_M #0 &EM86=E7S Q.2YJ M<&>D>G=44U^4;I F3:0W(184%1%I4@0"(DVD(R M"B(E B(" 4(B(B U @+2 M>U%*I(1.D!H4D=Y"3T"D)Y00(('';]:\-V_-S%MKWLS)_?[)/?=D[W/V^;Z] M[\G)Q,D\X/Q#'7T= !T='0!Z^@&<3 &T /1GSOQSG3:&TXOQ+",C P,C*S,S MTUEV5G9V-E8V-HYSW.<YSG&=8V,[SW^>BX>7CX^/G5- D)]7D)N7C_>?0>CH M3Y]A8&1A9&3AY6#CX/W_;B?? 5QGZ0K.3-+370:<X:*CYZ([Z00 0 Z1KI_ M:8!_;71G3FUD8C[+PLIVV@%]'G"&CI[^# /]/U:?W@T^O0]@X&+DOB2CR<1C M^HSYLC>O;$A\[MDK]RO;^,P&B>)RCJ_?L;#R"P@*"5^])G']QDUYA;N*2LHJ M6@^T=73U]!^:6SRVM+)^8N/TW/F%BZN;N\\;7S]_:$!@Z/NP\(@/D5$)B9^2 MDE,^IZ;EY1<4%A67?/E:55V#KJVK;VAL[^CLZL;V_/@Y-#PR.C8^,8E;P!,6 ME_XL_UU9)6WO[.Z1]RD'A__X10>@I_O?[3_UB^O4KS,,#/0,S/_X17?&_Y\. M7 R,EV28N#5-F9]Y\UR6#3G+>S\^M[*-Y8J<&9'/\?4@*[^X_,)5TC^N_8MG M_S7'WOVW//L_COV;7S@ .SW=Z>+1<P% )IY7M1UP+^"CO-A[SA:TEY NW4$ MM63]TB,WP"4^_'YW_BV]K6Z(:6DTY7<#19MPAPF!-W\# .[]*-DYEZQ:MW 7 M3002RK,*2Z"7AS7'+U<Z2CO<>XH2TU2^&),1_\0!2"D\4IE9R1(G74ND19+! M9Q\Q%0:()@O_OO]*!HLJA+L<=\V"QA$O^LP[3@"\$F"YA>[6(,4(A;!HY7 C MOQ[*[BK+AKUBV^3%)EHF O)#:IG'=MJN>_!G]IM\/3VOGM&;F>QJ"2V3A]S9 M1%/CR:,W[NH7<:GBWH)G!'Y(%+OOMD:":T"G(X?.BM2,-]OC;:6 QBVQSG5/ M+M0D=G?<[ G-VCMH.Q*CU(X?GS>F@P82R,_!_#B[F:O-67()0\I<HP4G !M] MNP6YZ1, AU_6+6)W)BGHF+6..:S9W+T1&:$**KHRL6(E"/&=XOYXYLU48H;) M47KIU=Q]@;9^G.U"';;>TZI-_4;MV'+HGX1I^.8;X"PN0*D4+' ,@K+-*X1G M!A#* ^<>1)A^QKJO%\;\ OSXOM*V.-X&!E)%"F&,)X!W,;!++12$"V=$>',E MK7:H"U9?V"M[9T*I#>!M-[[Q]SFM" &)5!>U=:^U\<M>,.1W^[6?^#[FU_DF MW43J@P5W#9K"N/H-BE4'B/,J:?2X_((ZCZUODR+ATW;Z9GS<Z)(ZD(;!T$/S MK6N'RN 7)T1*D\]&7_YD*9$C'F/5D\UV?%.?)'+,8D78$-LVOGL"Z. O+S00 MX?KX[O%S,=I!&8H#1D^4C@'-)[<2D^:@\#954V=GJ6F59N^;=JE<Q-R"52C^ M+<CB8GT<7AZ:>E7'Y.=@K=:EOYJ;DOVW6UV-Z2:IUL;A5=!W@E07<4/9E<)S M#QFE$A S?$M HA&GP*K8+=I'&(_/U]GTWL_<!@\2+ _(.A. Q!]*J SJX[-@ MBN1,/A>2DM#3N=%/;40#@ON(*,)RR+&"N_!H<>C>Q%[JKCXUFD*XCS%?C'D> M%\#4T+0U1;]P-],7/P5!\K5[-HLW[4''KET;YJ@AQ36@$D'S"5]!"[<I>-T9 ME7XC[+*GMQUB?7_^K_IE^$0V&AQ6\4EVE:QH^?;;;\&&ML/0* !-A#C7Y<5* MZ5V8ABL/[GWVI-X<0(^3$X"?=%*GC8>9*N&BQP-P .7+?*9Y%UR0Q&!U+#94 M@*AU9RWDOAS=4!W?S]1Z!R- ?=5"L3H!,)P *&WS;'6N:)J(C<<Y')-2<'4M M"_WPI5:5/>-(8M?1C1- F_0;+X[O:Q \2 #+:R2P&(][+?H[.(7^KRO])BHT MNT;Q--B1)JN&\^#S6A6Q"DF>,+3D4F+/_.%H$"?.?*&[D&2SMM#5&NFA&^N1 M&E\S;E9FS3X/M!.FXFGOKZ:3G]-0\B< )GOWVGT<.*9&#YGI<?/S^R6&#P6< M^ MQP9!W%-J"-/]J:YU$5_9YBF 22>"]LWV 'W&+5].?+L[GG28YAW,4Q0\? M G*J RF'THP0^.4(8](56P7\1"/WHTL&R?V#UL=\RR< (@DT22-\/ &T=]0P MZIO!BAF<4.Z4%&U*6^[QX!S11/J]V.TJZ^50RP%"W8A4ILZ5SP_6;CU24[XB MMC=X/ ED:Q990$RES/N%%5)L#8;E[;7'-_R2QWKB[7BN,[\.":4,,/]%MK?& M9)VG+"S4C3?SE6F7K\C\?A;T01.H$J>K\$<%NW%$E- :]^6X?(3UJP1/Z T: M,W^:NY+;P4[($"8C62AL'=F<-81BJ,N#RH$W^_$%$-NSEH*3'Y:B2KH-X=#3 MI7@"YZ> VHX9B9:E>5"PX9"OFE:G8',CNM9Z\?-YEMGOSE7!KO1K4M+D!8I4 M.=36GL27$NNQ*1\KV)TRKB_"&/U+23/&)]$AVIODU.Z'8$=V,H]> 9_5=2$/ M?[E^536!^9>N.0XC3VO"B%"LOK=^"_XU>V% ?H8)LCN<M@H1<8ZMN$/7<5Y9 M=3F-M&%.QK8TT6*0'=D4B^/K4?U'="_/-9. 5>\!\!T_E0NL@*,M$UHYAG<% MP?&F%3A#J9B59EDU3[<UU,Z[YZ YZAUS2F^.4"OR)D64D'U^!<<42>BU[;,U M2_Q1&V**<5'^ON@-3@=RY5J? .8_(\YB'K^$)NN*%6S"06))>_[K^7B(-#]T MK5W%<&X=@^&T7A^SIMIZ0X#L\>^N6K)]M-X^%S3 W+B678?]GLVVEH*[^X70 M>T]-YZ<3XZ_;L=L]Q<P2?.M9;*2YB.,K4/BX+7$,Y5&^8@5ZO3G:\85,1G6C MZ*D/B,8=6W'9HL])*1W1J _QL_;36,_:VG>(RKL[1]U*]XPX9\FHDE/S4LQL MJ8JT3/@5Z.RR5;7]I0H7C.%-Y7V%=SIE?ACXBJ?25A3@D(1P0X4/PRP1X:7X M4A=2FOX2PGGC4AU!W*7X81TIFAQ%"2**V2O#?%$=^:*ZB,GFGEZF"=E *WR9 M2E:ERQ?;TP#'66XA)&)EQ[RN'UE'&FU/K-6Y=@6[G0 834B6B7@(\BU&'%>' MN]J;3GXL\OYC9EEOW,$%Q[?J<Q27(WO8%4I76>:5]JR[PWL>&A7:.8XQ'14 MSR(T7 0^* :@-."#O3HP0N/Y&!)3W*^Z6D.A*%<]QX+SNHXRX,^SZB/4JT=Z M\$$$FS,M2Y6^! K?>=049:]ECC2Z^RK,TLR:J&QR5J(EL'4COP@"K$1M*!=2 M@XB^:;V%T"B66PI!=ALQT[S=A#A9Z)5I8<!1HA8M#P.D(/&%6QU]TITRLY3& M3B#:NH/+25!4\^53JP+]:V,B(3WS<<4216IK.UID>QH2?A$Z/&^43^B3[I:# M,N,58]%R7_1+-UP^NRU%<B6<T\'[[';!HRD0@Z:AYAM%*XIU0[.SN$E=B-J? M.\ZOTA\U[XOSG.[0!)@!#8UAIUXAL1\"(YLA;I#2CLXQ\E]G:)S&0=2N:M34 M>*M[?QA<A!+D0DC?$K"N"T-)\%>ZFR1>/B@T8'BJ<I>.6KI30%4F2:_[D"2P MA_V=P/<#,"NB<61%H=?&U!O;AG*"(Y:^HN.=\D;482D9>#KY(,K4PK5R@1"I M/R3I\ HT8T/S /5AM,RW1E;H]@2LF5MNFA6P(7#,*G>D?H&38NWW_A5B5$EL MIG0 ?A4^E,T!YUQ1N9:+;^69<AUK'&+^EF!BG%7?\Y3Y)1>8_K@#Q$H5P,_A M.@@5R HH^.'H;J;ZPM#/W_A),4'F])C+\6&$H0;.J7?]Q\+2Y+(Q*F?!*G^@ M4>P\\-S/>*G.=TKO/Z3/7F5NN'B]"P OAIPF1*H*"UX1B5#<D44X)YO62^DL MFL6G\_&9WRU=0M25H!)X<(AGL]-">2"'54=RGFY]"[+@$M,?QL!E/F)VB/K- M[,@YXD.P(*Y7(OT+%/[3X]J"^$MJ2<<SB0'4-HJ>E@B_ @%6NT180%-)Q'&\ M7Z1?LC_;Q^3]^%P3SJ>VN7L7!IA7]E ;8<0HK_!$RC&0W_:4K:\P3GQ+-#G; MQN\H*^ I]UB5^0A"Y:9$HMIR_XJ!AB5&-CDWRY><1)35/F6PIU$K!WTXJ=Q; M73_:N"AC5[YCEQQ6CJQAW$3+Q'^1.R*P4U1 JV:PV:H8^^RF>_*=,MF>W^J. MZ\I.\=GE '@JI;?;1O&MJAP"+P7?5E/4&\;+34__&&1VVK([-044F\5!6<KI M+:-(V"(=AA<2>Q+T= ;*_VK#>(Y<8*XCOM(3B?/[86E'\ ;"!X_+#:GI]#], M<@M>!W'K@FQ*3PV8:P55GP V% BM[_8;RXMR(<$>?#-)71DA"\G/M1W/QQW9 M+:]H .V@T>0]BL "F OLFE87M_%RCXTE#8<7B/V6(,W S1C(BQ"#,<RQ5V N MV5*R?FZU\P\>5*\F]V'DP?>9M1(DMXW;$>=518E;IZ2RI1@#OS #TT8W-3=& M3=M,1O;E;QUD$/WFN7:L;(G,'=<ZCEEVCC363%;O;CB5Z7^65RJ^C0MD89XS MW]=G@%O0[2^'MWIEOSV^.5I>TP?"\V>3>R.L\3PW8O@]0\4=6XYG\?=*AJSM M'91Y57HB7C=FO1>FH@;5&:&<7:U$ SZ2\U;X.F?DRY<.JU(V2N^F(_3OR!(2 M9+HEUSDI$J H-(C_N ?#T#):@=O>E$\>,5I,<-*]F9,X=^:MVCW\_@8?<6M> MK8R'0N@<"[Q4#VH,?S%S*VN!60'8CL")+&QA#432YQ@H>5,VMCY'?_&)SRNO MKW9Q*J'>4]D6,N4(_E0^+2P1.H23"NSO(.K5WE4TP/"Q IB?$6*.WVS8MA^Z MM($H-U/"W\PQVE2<BGJH\0D@,CS[Q9G[_@^Z(C6[9>4T@!;N8**)UUN;QWNC MA>/(]8U-J2+7:SJQ<8(R["J!H0YH8A-^.0RN 'VLJC\_8Z0&T9%MOHR_HW$N M4Z-_ ?P17(WJ!)V#J5)22'80,/-MS"VV3 <?KNIJVY 7JN,]ET)P^JBQULE= MUW$$2XVHEA8Q@GK14N4]V.VX;?N!H6=G1K@)X$<7P)32>O0(ID!A$\TAM49N MU#RI^-1L^1JVTXH9[ -30*2C[V#1FA\H&!?>UO[U=9]E<1<>W:DDU2@*<&$K M3#X[-IMHT?_A"^&>TMZ4X;G)OLRD[8/X:R,FK3<(]!+(P,/\!:]UG_G6T+D: M_A:29'OC",ZB,>/J;569EX/E!>[?N?WB=&\*!OIHB&YU&N.<%E+:42)N&&Z2 M;N3\$)JF"^EPN;R4H8R3#7H^ANUJC86SG_YLB<*6\!I+WDH=S]DK]<]OLW%] M!(A^0'7/X=3Q.^0X2BFI&.]1@8(PHD+_1$FIW+C*)OZWBI'MO&HE P]V#/.! M5J]^O8.4?QJ91%17SM*F],802?_'$TO9BE8SW34-H"=,E59URN(FX_D#S<J$ MOKM'5A\_X-%^,C4%9)/ M$J2.;F18DHTZ(3D0'N[/KJF-7PP) ?$9]:*15RT M6O+JE.:":A$D8C"LE*!V,68@ZUZT0?2;!A)_H1=9O.FB]*\[3*]U_($V>^"I M()/C#AJF^9+?,>\)("SD*B::Z0V_!L'TDO< 47.-8L+\UZH=B$M?2,%Z..X\ M(AI'71KW91,,ZR3=%WKX16E98:UW" .FQ?H:2/-C\5+V&.8.(L*L+DG*A_PF MSJ"^9V:$[B-'L(:*R9E!;5Z Z?\ L0/CTB0![2:28L<<UPI_671 \#.U9L-+ MN-S4LPQ9'=<:TQX"*$YD?]I[7T-FLCDII1T9*?ET7&5T=]QOV&TGH-1S$;ZI M\>J.)E8L:1G$=)K59(-XFNF)S 30NSTA^0 %+SYM#DPRR1Z^DG3.7QG+S'=H M(I6D0Z?T^U7 LOK>1;LWZG^2/@(S$2SJK,<X(".5+1\JUV&3\@X_(%]9RR7' M!!-BDUU$-53TDC^>EE@(O'34L0AED%C\9/A-?Z0E/ZFMQ,9!?0J2R@=X>>'- M1HP/^-6!D^#&M)F@%7-EM]SL9R S3(P6#Y>$-A$VBKN]XFPPZ4$HMSOQ!:Z' M/L<KSP'K$C'7?ZA:J1&SCUF*%6,PERC[7=EBET--&D91LZOM<_HC@B\M'?5? MV'&%U,5E0G:U/09?,]U/S,R99WT<9I%(K<_A[-MB1[2!CL5A]ZHHA 5.3OW" MOGF$X),/\LB:F6SE"TK.+H($>M5Q4/YQYPD S7&J!X:*\^1B/(+]+^(<H=U. MJB9D4\C?4_R\K%&0"]]AN(#@8II.F$A"OEH<,R\=<:N;<P+1+>SR#B[<1K3M M0N9!Q)AC=&I3S.4MQY<O1==?X-;;PN71,D#/LR/[CK1G8!Z4P2]N_7C.JG1) M#] C\1Q+PU0E,JJA\Z9@QNO --7*W1S.WT?(22"A?WV'I-7M($YA*?M;%\@< M6;#C7#7:P_U@,;%;EY@XUF).OD%#4C6)$IUBDJ1E)#HZV 4[>_53>E$UJ#Z6 MS=-ILS,1[%#FWL*LYH:Y3_JKPOD00)VB3)[JU13)"PER#VA^4C!CW4%<,Q_9 MV%.[/UG!^M!>[_89IXSXP_%B^"2P2CH6X8:, G.6/TTWKJ$XYZ .7]=0,A87 MR$7WOH9DC9*[VV+$W%0K$X*R=ND.9DC^QRP)60(DKW<P<^(E :.1-^7W[Y7^ M14/V7Y%*)6_HO,P*"1';^WL"8$,X9PM3@L@3I+JN\A=J"E09/!O3>UM-[X9] ME1QGYRM)"Z7KB:QUS.-JKMM6Q-_!U^EWZKZ#B$9SW%1)6G49_!+%TU[A6*PC M0&K(5GXB2UK&R.0VJ!DRC' #3;IT(_A/ *>Y7BO7&]WA$\ "D/A[.( <67FC M,R1N%&MG-9%WGD7YZH<V=[\V#?;OGC*_Y3+\48FM\SG@:JOH$X ;BI&BJT=, MF4A>-AA-WE[8<IG\0 X)P:KN@&W"NA1[A<P3DW(X/Y\ (*C3B>P"70 YE\#% M*$'KH*D?9,,^[[L]$9_N=%YXW&<PCXA"@1S!E,=<:JDD?>*A6\BOUL8=)EE_ M)QPF7B8TAOPG5-#YXO:I<X@NT#=$9PN$+$T4:.]U&1SO;+Q6NS\NYMRV_83E MM3*V'O6(HK\ GKK2X2!.+$=&*@"9>N>;^*-$)CP^!VQXEL;<F,J89STR*7HM MJY'?"SQE!"S9F/8)]H081'#IVN*E),FOP$#X+Z)ECOHP[,TA_GO=2O,A#LH+ MB DG@G$(7(@*(89_D =*=N^O72WH"T([O=>S?E=/6%(2VSL$+Z(<?#+V\G]< M<$D^)M'+TQW,>9]&4":Q%-Y?6M1>A8P*-0*N] 5VC\RX9*=L;JC)1?62K-85 M2=%8()LZPU_AW$&@.5%M\=V^[YAI^?NW.<Q &9P,N !CO>GSVY6+;FU<GBZ[ MR%78+T68S98-H@,XXX%GF9JP^@VJFUO?PV?CM.8+'+B)T&K;O9%GF9C)NYU< MN>*$./0>P,[<0>8B775;SY^WZJ\I8?.ML2K2ZZ<,E\F\X)!;L *7'YJOK6U) MV('<)V$%+5GUKI2@7@Y(^8(H6O)KP0%)>SZ.D7 R(51&0S1E2KDB](=(Y"JG MN-F!4ZOJG[>@>TZT%(3;7$B6.,FYN+V?Q_7X.A$9Z>SOJJI_[YZMY\S 7>^W MV,(@J_6K1Q*KK57+H7M_QM&2P<:=@;1Q',JPB.&ZSJL<0I9AL'GUW 6_@NWN M^8#^L;?JLK3/".<3@"B5BT(B(;IQ[6[E3GBS;;=H+Y_$YMJ%>J>XT3^GE1]H M/A6)]^*&]G=FB[U;59FMAN_S1Q:LGKL;?C4U-45(]1P'/%JPP_=/VD#^[:%S M*GNGJX*=]YHX3>,[6EEA4*(.4CU%\3WLF?.2*]QY4NK"UPGP'2YL;W?0.,3E MZ*P[_!(M;'?N_?&-("6J4T%S76#P+QZOJ!N]W/E^ZBN_.?GV=3\U1?OG]]J% MQFE\5SL!J "HPT/_: >"]PHM&CT7EB*55QRY1=7D_QJ3\KQMJ>3@4ZU*6O#R MNOF1#NPY<2Y,E9ZDV)7&E$)<>^ ZOGZHSR'_X2TCT/_/=T(:[?J=BH$&)7I1 MMT=/3P#&[@ *&T%ZG0</C 4#F_EH.;>>4107RN^*WA:QOATUHR\LW1<_D1BG M6ZA9AFB[M\<9!JI1[.@7I?+I>>QZW'Z**ZPHAG7KW)]P#*LRLLA23SIDJP&6 M7XJYTR8!M %0QLE/:9^H+L1L\GM**_X$P*5;U+=P N"KB77C]?%*9#_ZUB%( M?\$JF<)#YJ2DSF_1P0<<>$$36Q#".V2A@>AO7JX;CH).2P?&?R1W?4YWEO%5 MOZ0-#>!GG/2Z\9')*IBEIC\45QQ%5<Z#*4<FW38,]:R']CY_YYVXBVI59X?= M&L(P4^4&5$7R83AX*B "H>R_.6<&P6RG*"^#;%31N_LYG!'':L?8;*[=5AP= M_"[UW)C\$9#7KM-I1'[&!"^T7:]T&%>37=V_'D%BP=RSI[I39LI6#B-B.9HT MGQ6M;#2*/+5RWXEKQ^"=.<;C]9?B@ES* ;#@HW/P7LQ=6A;5@Z1E23*8:$%] MV,+]&7C28__MN=..2S&#U7@!K( GA?D*L?A LM].K'GHP.F5FO<P[JTZ'X5T M!*0:#B)<(RA31&FKX0VJ)BS=5U3RL6.E_G>SX&T5I'LQL9BL3QG-7YOCAE^C M=("'MXZO0D,?90T_&I;:_/S$MCF*B3#U]HZ:'!CFL:SV=VJX!0#WI?*< -Z9 M45X#P_992)IB.]CAE@ZL0M@1+8N[X[K2T81$QKC@'-%X+E8 7-72W_[EVN + M"(([UNG1YUG1TG-#0K9Q+(0HFO9V^-D++EG7M[&"\[[JNW0D@8W@(R"TGX!L M!X>K*(:? *JPD=2;8R> EVFK]E%M3H PV//8#H4^*ISVZ5B1DD^.)-9U&0,, M<G'N@>I(CY?G<GTRC$HCVN/?J:,/&6O3%U%"BW$1AR;,O^>J/;(WA%SPL1;4 M%QCBQI\/8Q]NZ40Q[65[3XN$=$O^K3_>*E=XJNVHT;9B;%KC^)8_ZGK.F?\> MO@#^KP.44WANI;T5D'\1_UE:&6"NNB2JAQU+4:@[\Q#$BOR-//H.EU]ZULVA M_OPPO"5BT'":#AOH"^ U\RS\SX8N>GL]+^HIKZDVX'\$,\]\7X 4;WK)C :; M]C4WUW\S-M%7I(3.M6!&9Q5@<T/1;(!.^[37/U]HG_8WU6#\CS [[6+V+P\7 M3%_O:?OSQ1Y\ZZSWSD^F5\VD-5T-B>0_DK[W%DT"Y[,@UW;LMAV3+9.O>Q"$ MW J>\L&+T=#][E:<G!;%V--C<:J4$F7WZ5O,\L_=6T&LE%*\8C>(GVIR*L\O M5Y&B1>OE8=6""_3?KL+W@J"WBC R/B^1G$+IINT8[3)D'>S)D3&%OGWCLCTT MXNC^@DJ;8^'XSDK:3G3_5&('5X)'\[VO=A70%\XF\(SQ;M/NRN6G)D&WE8 / M_=5ZX1*7,459N@_9YOS5']8&.!ANEP*?/SF>GA7Q2<_F6+5<FRXM!?8JS%*, MR5648+S^%3WT%_F SX2?(^>_+M,V1P_VZND3"FCG9/1E;_7NA'T\ =2VW'2) M7RA$#Q9>V.+BVW*'5ZTXB"/-:@UZ;C]KKOX(J_[>AEVQ]=L?^%7_A#?;:.] M=SX[$GZ5XE$2C.K U8P%7/D5X0VU\[>/* HN76\-.<UD[\:3)'X.[5E$:Y*T M8G/].6\BH%-%6^X'&7Z/;5FVM!TDAN9]H@3K?DBX 0V&DT+XLIU+;E$B,4\B M4+#'2Q=W:9+MK3K!S#FK-MHK6/F:[Z=A!/B_X'H:6U__7=C^?X.N7O[3893^ MF5(99]86?;7K="./P;5METN#\U1EVC,[.';WBK1+<'V2NGS3LCW-LN)OXY&F MCW]V]0'_2$O=7BWV"F;$56OY\/XL9A^LOPC4,B"O.5M^G.ZJ-!KS( .>?2[ MHM/4>@-XGS^&;CVKCU$U%R^!LL><O99GKS.3:F$L],(QBCXF651CG_=UI0^V MP5\>K>FUD>5UPS/7+8"&JY?".MP0'_'(U?5OBN0[-_;BU9ELK2WC)&0:\)># MFMM-%"Z/W:1?\)7BJ7',%3<OE5E[2&R03P#^B,/1(TQ+H 7./J+O7$RKMIE* M88U[W+Y)GAZ=C@O@SIY8S;=5OSK-1XHF?5FZ*1=?AHP,EDYR+R;'INB6WUZP M$+&J>LPPJY&30"?+[CWB6R"<E!M_WD'CN7<2^(YS1)W\@?,HQT/I#8%]3IN' M9>/QNK+WAR__FD^*^<;^W??[EJG47GEGT?7-!3>+^6YQQA"QD2=D8>^6"ON> MWS?6ADIHF F)5/*'YLIN&@&8:8],8JYP@TR8NJUC3\M-WO]DZ^N=;EB],U$Z M*WJ!P$* EN^;Y'@Y,?1._\8ETH8ZW]^\7N,WZ5W"'T O8C&TJOWXB/U@R='F M 'RO-.M?E>3JDKH4E^).EXLG !&Z3H29-_CSL2PI;#^NV?@K-/2QD[<_=.J7 M?3X2=!,UU#)=RD!2X%VJ4D<H86])J>MM_CI:.\HT-\DZ)B_.@J>Y=Z8?3CIE M(5@KO"?.@W Y-,+.0?'1"6!V/Z]5+\;)>#H<^\>SX&O0]O1I=%Y.&/$T^VBJ MS>=O_$;*O/$996-?/KXR;,QBQV.1^?HSI7C._4_DPKQJ2-X$^F>VG$VVVW'O M":"&CM3W%6K>:24"T_),+[^MB<4YB@J 9D775B$BN3["FS>?F^[P_34N0?5L M@,P:!K;*]]@DMK=NS;R(K(X+;WT(9Z<^B,!+A.RVP*^9B_]8<FAO[7BE)$%" MA?R^<_-] Z'R\)Q^G._"^JIG8-GS)"%!^=7G=CKUBX[98-E@C7]7^@^<SKO% M*5&:_/=PA3W*L-DL\**HMB):)>P;A_L?]<L>8'I*6&JJA;5ALM:[.^])6_;W M++@?)$I>"7.=]&O\]ML].?;N T*? ,\\YQDP%/G0*ZSQ[M=]*S\?6K[9L)>- MSLON0?6_!:(33[FR;>J(M-C6=B#WG.LXOS'>J])X,5JYX'A4CSK\1SYJ^A5Z M'T3FSZYE/.)HX$)\8;H(:[4+M+B;Q3>X>Y 69']S#&<YTZB70_<[<"<NO 54 MWCZVJ'I]J3J6=C1-6=,D>8;.J\&/K(B/U\>%A:&VOT:Y1+/D_+Z?G3REM>0R M;%V+MXT1^@LE:$$ZNOE&&<)=TP?FH?!!F*)J)OOCYD&]FE_,\>/]$77NP:=U M:;-2UWXK74/(Z@TQTDV-Q+QVVW< #GL5S/D^@WA?1J4T6FL>@)H,'5<*/8T[ MAU=Y6@[ZDX_Y*3L:%"^"-.^LVWX=&W%>RX5[!K:CR4< "' A>5$NY1PW\5! MJGXNI6)U=4%5^03 XD$\@L7,FL1^6A='^"N0/\&!0QN[^U5(([0!/[-O_?N7 MZ@V"!>F:PQ+#7>_3?*LG_4)RQ*RI,J9[48B?;GLVK;]@3M<*[R*=2F&FZ*"& M-QL27>,"ZB^LH]/UF09^MD[W:UIC[M:-5:B+4?P[+-V^_BB#1OTA=.ZWCU0_ MBE^L>1A,1X@Z0M<$<7XKS)Z8/SHK>/XFI[08/D%4[+=(6'W4T*SR8]5*V4Y% MAN._Y*_6/8A+W+W3F$'2U>58A3D^:$<'7(I('>>979GEDUT5-CO-HO1P3Z[& M1NRW,=!N5J0N9$IW.M!3]$OMIPQ5#[O14H7#-=M7!*/OGB<,%R^ 7^$H/H^J M7>XV^J*;ZB\FO6?_HOR,LF-L3V\8=\\UH9LAG'F.^^SWL[,Y9LFRI"73;PLI M]3732!Y:,96G4)NH:Y(LJ2C[-_[FI.,+ICM/+.9#5QP"[D:44(SQXV$OFP5< MO/[H+[@DNTJ_\.;JL>_+MHL'V\X^F5H]CVX9D9GNGOX\\[HHE9;X8IQ%J2:B M3X]:F/AT6N H'U=5&/5F-*VAQ4ZZQM\(N[R1>#O7BTA2<+O5G&IELD,8NRT> M-_[Z)[WRLQ^"O]5(-B#N6R]. .^KNZP.Y6^HIQ?@5C:E-S;%C;_ISN2 #UPY M@GM]%SBXMR^Q'VIG#%8\C C1$UK#%2([ AUO?6T,KBHKN>R['2ZDJZ%;Z-LK M*G2O_@)B<LCVT6E*PMEI<(2,&1.[-0PV;QR W1E+?CW]();L-YO3\WS_3P7% M^+O814H2B;Y3N"A4>$H*%:DZB#)\M4IJVT_CB\ZG7P,_QRZTW+YGA394F92R M37E__V[E'C:PTJEP<N57'P3"SHC9_Y3K\\1 ,*'FLH<QW=7;;GH']L? 6<4- MCA/ 6955.2#+07Z7A^>3NH &W#,I6GO %/C)5$D<WV.1Q] S7T\ +C;8P/VL M!XXK*2Z9=7^P1>ZK&25JD/!"77,?3"RCSF&T-J^EA,E_?#O)=_%4'BZRH@+N MA,],;P,4E%>>''9X5+X,Q$=\&QXW7YR;\NGF+*)8/2"6-X<5C;@H"C"K)AF] M/]P!BW)^BO$UCU^'S+6ZK[0NB--R7LI;?<)>N-/FDK0LTB,^KE@&8PSF=!A? M]]R[>\21BK[K3UX5DHC2G>@\S92*OX[_/8"M/+LS,E+G\B?UDT1,EV%Y_.(G M]%I:<5L0 ^DKU&_6T-P8RM[O'_3E <8X7K#70 C<K,;<JA#I3=PR&)>"@4J@ M]X^WS(;W;$\ ZS_,#B\FVOZ(20&\LO(T5BL=.AP5W0RH;!OYBU3/:S'%<*XT M>G4:.NFUC+IDWZ\:!EK$'8[=<7#]!'BEYO\<SO>#,MQ>J\*!C$ '2YA :#QV M]\>&[*53;NHIN4Z\V:?>P/(]-!J_9NV&S>T=M-]'PH6TYF?HK4<<FY-7=H]Z M(<92GZXC9*660G:!0S54<Z*%VRM-6B(<%TO$H&L::V\<?[G-*[@DN"J7)G8[ M:O5A^T@PY^V\%G7CT!O>G+'7AGV9&PT9/I?S:]"[<Y?\RGVE<I&I8!C#A/F2 M Y6PJANQ@:B]?AQ%Z7[;$N_)53G#,I^676&&W@1]'6TI"W@BM+82=8@@ TF) M4VN!6^^7@B/].7$;!W\)H<C [7HJS_P<16LO\X6'L97^F]*Y]<E<:]X_7J98 MK4>TC+W0/*H7L2 ^V7HIH]W ]^;D_/A==9FN9\\/\YL8E9^1S@<+'4**'HI7 MQYPQ:JO)MO-.JQNK?N-SU&!!0E?::#QU;+V#K@&9_%,S/?LWX3+7. TID_^D M9/@O@2.^MMLPH*X;&..7S;Q+N[9Z^!-/\V5;JHZQ1;#)?+_6<EGS<P_J&F6' M6&="R<ZCP(?:]?(A:F8BDX]^Z6X.ACP]I0'315^S+*SZI3YS6'K*&\Y8R[3] MKDSP=],)NZ[@HB?8 *E>0J^O]\?\V1:5YH@.(*O7&S!2["JIH)_-K3$LK*6\ M\39L\#*Q$_EP[[!QNGEV0<E?'0R[T7)C)!U"7^(E]B[&<U6I<$K7J :0KGEQ MGEO%M#*(,)82J@GPSV' -?0'VI=V72*(J@Q7&IB(;$4I_7XE9U";XG%'^%7@ M6S<$JSU:9,DV%(MP!R XVGB;= MEK.6X!N)&:*?#Z1;=4$5+B/L83>DP2FD8 MYA=*B6@#8P%T&H+T43;&W>D[KV552(^8!Q_=,O)&=L=BB5L:G'F?6?;ZKLL# M5J_GO67]-Q0P7'OK5C%QZ/CE6CF/>W]QF)>RXXYNKE 7_YFC-V5];N]P7U0K MYO7*+\]=+YOQ.59M4_MLLJOY8B;^8.W(8"Z3F?RI>83]VC,(.>AMY@?!->NQ M5C$OG7B4V_;*FH_S%_?H+[9,B4Q3G,W870FT'Z)V[!W.J[-/SJIM&RVI$!VX M[[LJN=SM:.OGKVC\F1WN@#Y\P1IVRU(XHWB VB%J4R' 8R:S&NBQW\VAUFP/ M_%!#$Z/8_;A51)X]I/Q@_]@C<\NU_@#!:@@D6"8N:%=&=*31/WEB79!B.3CS MR\$8K=<$&\828YY:T>= 4M2!8U);+YL;[+BX"P99^%YK*(OM;>T/:U7 7$G\ MH26X%3)..PLI3MI VW4_>NC_4>7C:UWYQ\5&W%6122I)+B+3\^489=K7>Q(D ML4^X))QU?^'TC*WBQW'^[0SDIW.L'P/VRWJ14<),N8QQJ?X+S@A6:]L#?GZ= MU]?B-#3E(L\N9CPE1>UQAF<)#WA0[RV(1$LV!3]5J"V4<S>S$3WZ)'WOG#^? M**,3!6Q3D]S1K=*UB?*B0]M>+]\+:A$\<_G%4]V/4"&U+A^53_EDHVP72]-6 MF>Y9F$,EB1YB>7QQ,&U';Z3B64,43JCV!UVLWUL60<F:"W'-(S@7;"\-B!5> M_B!@:!5W/'(_#7%3RD]Z$YRQ6"2K7M1BH$4\AW0C.77A,H\SG<^%7; <L^R5 M*WOU<^?VH[6FW&XCQN<K*H;%'4#F-J=R^Y5&LRE* EZD%E.E*!T,$'G7/;E2 M0_3I8JT5LWGMSIJIA_HP#Y,F[9@0_=)SW<AWR7_:V]TJ%,13M6H+Q;]O^3K* MYC-?L,!Q8B$H5H@-!SF[.&_"K=9L0M])//4)P>]6SM$75>%9XF;I@II3QR'J M0^$0]S4B;.C',]?*4-%%\PL/Q$\ OA^4=U$\:2^:4C>?:UNFZ7SN?,M@*?%M MEV_P8=C-V&*>Y$*;FO'&S=\?*0U3[>J7!ODOB!J;"G]HF/;F.EXHS69ZMH.1 M@FIS^=618UX**%^DLPO?U 1P/EX/[ME#/:$EP=1]^V,/Y9)HH^_4IBMT 4Y1 M*UVO%XC5#5G ;"Z'C,#\72=](*;1!,IADQ__1/B\<KW3=.C:>-K84;/54OHJ M_%M24EC>%_?&!#>_%WC-)(;K0JOZ -8ZL:!CBS*975-M_G]*X6^G#&;XC[+^ M^T+[OPP=(3[>P?"8Q1U<88'S@5% H8>GF.['XX$L=9)_AS%K4=-"R6[ZY_PL MD8"<$;Y>Y02-4$:]E;0>#*VH9NO,C'NC<8R9YI>_M:8.JU:''DW!80S%7#J% M<8]BX[%K#HDDB8499.<62V^NNYP!8UFBM@ST[#EV3]%7\+P&H!"\7X4Y#MR% M++&S2\1?+W=,TF?0OEHO9E>*=6#2G!\62ZZ2*:"5J=[$L$1W<=FX^SRA54#N MI?O&PJ9TH[=2&';IAU'N7R0VO/,GU\2N&I0S6QH*/*RKK$>/Y'\ 3?4-B-EY M%[T6D6@1NTY+W.WG=PWT*-S_@+(,NIJEV!!W-I\'>[WM7%2NT-ONL8OQEDZT ME%V6- M#?Y.[V<^_5=6C=<Q$RSDW%SUE@2$9CB'<KB!T\?N]3*=U 7Z5WU&E M5[N:4P)CBU/8S;\W+4;&&0E*J^_I&M"J80)E$S\48HLJ@U^/R]A.64]-,:<M M]S'_? Z@C>&P$D7*? U?X+\#SWWQ]KDZO5\G8_"UO]3.9O/ 0?\9UQUP7@@R M,'=!>A*A0QRMC65;34GQ=DTAS5D?XZ\_-WP;IN,Z(B#X+"& 4 XP6)C#N?=W M':L3BR-V$9RKYD_6DE/,6ZA1YVWTZ=\G* NH/LUX@8)FDQ.()X!PJC,H/&W8 MK"%+:*&J?L1#JKG7UB"U/NZ&R)4_RKS]'/#^1D0X53<7HN)9BN 8BU>8JKG- M6]#[^FA6#COS^^Q65P V%L.Q.JM$Z9.?Y1QAK'V+:VG9_U#]1I#M\RN_ %N? M5I& ?EZZ*:@7^?. U&Y0_I>9:0>'CEKM[8THEL=_N*13$G>>]3"+WBP U5J] M1;76B0F,/ \UT$GY%3?GCXL'.]78[81BE;[L>4V> !9. *'/B/T?T-%'T4&< M3+V^0>PI1JI5UUY^^TBW<S,Q212I8-R!J.8,F^M024I.+9L!A:/#GFSX:0HF M\+DQ%-QJHI>M1K"9,.=0. GGTDGT!F,5Y5)>NP>[ ;"F7LF_?D:IAJM^RXT[ M=L;4NP*AH$J%H ,I!5>7X1=1_-\2IO:W4XVN2(:^/:=2*5@Q-#>_F>*IZLXQ M0_+B%W<+N%S/P3\!RS$AA-98I:R< *H<0N9;SZVY243OG2UHKHU2WO)\_XC] MSF+L7ZMS,B,?C45=Z<?2\;59<)%L(:P+[.7[H.,>DD>V,D[ TSOC"-^01#D! M...E0X^ODHHC;E5L5KR!+D<9WG75_9QR77T%L$UWD>A>COP^Q[DV1_=2E:L0 M&FH1S*^1<MY];#CQ2N8118+"TM\[<$Y2JPU$5]-_!LH#)OY2"9OI#!SM'%?T M%WD,#GHK>)$>\/2<VFM7^BBB[H84+7JA20EFZ85&\=J#;2?+B[*+/WG)0CNC MA6.V>7D2C,_4[&WAIG300\UNZO&Y[KBD\? \OS?0]V[W<ND&C5Z?[??&U;U$ MN-BS=G0F-PXYN#/A<8=S9GJ3Q_8DK:7K5X S:[L5/F!:&E71)1@/.@^!7QZY M5#=2_J(&5^SXX-I3_[N#J8)W99J4<LZU=LX!Y5L9J4H#5/LRM[38QM5>UK9B M<<VB'7&3^XD9=/UFVCZRQZ,VSME1J'*T&H_)$/6>\\+2^/*8I\7-G-L"O9(9 MRP?C!J>S%XV?"[?1#7,>]XI_::9@,!ZE"'D;_59<QZSP%1S]2W$]>\'M)7[X MVJ@OA\Z/-SH#FQL5U[C1G8^F1B?B/Z[.^4]% 0Q 4\SM*DD9'D[%:VG).?O< MFK14%S<,[/*6K)/25%T6NIK0BA,>[@"=@\D1.#G_CL]*5HZCRLLO1O5I),A( M.MTJV!/%HKW3^M>'\6?W4(RQ(EWFDU,K(#?;EA?7':,6F6.ZOY;PN,T3Q%UF MFVB0>8=8;V*U#E$*39N-?U9D["55OMI(R^^+W \7)QHH@NT&Z)R/'D"]+$B[ M<.$X$<K[%*_BCJ\_Z/A]['-ZOZ-H1.ANC_R&/V$SMIAZOY'XX [8H+R#M::Z M3.F=!+171U$LAY @RQQ87'C*KYXIA ^^K1O!#VW9@E84;(,%7O$/SM;W_KJ7 MD:!G_OU:8E=V]0PR1OW*$TK5CNT(X4B9NRB;Z[') NO&3.RLP[F'SV,&F$7F MP;@3@'$]47)53&K(5PID@:Y..+:(FMI7E"G[(SU]8:GG$G0K;194@\DN6E5\ MM]EO69]F51<^I1V'%?#^<5/NZ[>9T(\JY&)W<%5KN'2-FJ)Q_0B:\V;W3X.S MQ2Z ]8#WG;O?+Y8 #JTT%;_;\^]@2="6K2WX=(J)?1ZS")NVD#;UK%,VS(29 M [@!*3P!M+L5EE8CG-P/O5*+5_I8A-^/.SX3:>=1L_HC@<-$U*463#SQXVZX M&1BZXL#I>W298O3GS^]MJ?N''$Y&MW'P@O<!8Q4[0D]&*T<640-I^^E0=N\' M0KV- +:L\FZ6'):__TX?(62E?H7?:^POF_4+9WAJ](1GD)X!P)^-*NVDV$0' MUX3/'4+E$W:Z<86?EGGIZM9UA;X&EAFJO?_._HWQ[:%IP=SMPN*VUZU^%IR4 MK+RRGK*>B;4HVR;&]6'=7]EHKY"I;C!+>+D;5WWKX-3&!\!B[@)I%Q4V&GK] MZ?<O]E--3F.M9I=DL $E;OXR7VKK9VHE%CT\A21W3@"$N78#9.BQ4O*DD\O M5D:?LPQ0\L8)(%EK!>P23["PJDS?59=0;U,$>=#W'28KXV19DY169FO,.VW* M L.Z<^IV"JDD>>Z^IFMZ/?1NU%(UC%;=O2;G@#S,3]/8S4&2J0\Z44$>Q0M1 M87^E6^R>8OGE);#'>H).Z*6G$A9FMHJY.>;;L\EC,K+<9/L6X[E^/;C55X\^ MYT]525G+)[$OPD$V\98-" O2N=+R)UJ0X!+# "\VKSBA])O%@LQS]$KY9N-H MPQ>S2KX<]VW_Y@8/BB^_8A;\?8];Z2NOZ?JX120Y*2BQ(]@'XN'MQ=@9W^:# M5%=051*E$WM7NB&2(LHH=9DZ,?7;B)FOP,*I4O93UOKC7B=7"5 Q:@G\]+@3 MSGS<3YQ%X==ZCH.U,?V>ML=0"<O#%QA7BC-QS8122A !GW/[2\I7/+1OWPU7 M7?J<#?^\!LXEN=W%B SNMK*[7?\VI<5]GP\1?D?Y!( I7:IN=JRKBMQKN,UJ MEHV.GX;ZZ@^-F6,S#)"YJI;%@:'&,;HNW#FXG%>8T*'"C^1-*"I,G;),M;#< M7M/_=K-3_\W55Z#&4-"OJ+_Y5ZOTNGQLW(2+(U&>1!M)"_[!K.EM[(&5/G!M MZ*WX__!8Y/^@H##O+7>IX25KNSR9CTRX'-^+C[\BW3PYC;). #: \YYJRBJ M6SE\( 42+-;DM=!;&M3A[_Q5I^^"K/CG:(:W E<^,D&WGAS:K)T V*AN^')M MJT['GT#A\LT2O8 Q ^8(5D>[UR'UEP*M)C98W&29F ((7_9 81ST'D>Y40D6 M00/,G7**G5L"4$<\#0WD<^N'%-C/N:WPZBA"PIN?G??MMCYX<+[9MUS4A++5 M3IQ9\3]$1:>W?9O#&92X\Q."=TU_T+FQNW@^<GQT!B#^ C. ZWH%M]SX#>G: M\\*%M@F+5:6IY_KX.P61HTN-;^H=Z(305SI-O5*R(QH"7B'H-V#^>,X/.,;^ M**^](WO9?NV$($C M\IIF<]E7NK,TDL^H6MV8=/JDL1];#^O_D(]59/S@Q?L MH?#LK_LZ*=XO!F*W?TYT0Y64F2]:Y4/!Y );U 7W0[_J8K!F@6&)EE>1.Y<M M\#:/^+U1B>5[D;N"*S:'QAN2!;H>>;B#P+I(Z2U^?1<5CV2"!R"EE_M7SBY# M7&9##F?&5 ?BO/IE&(BD71?MF^EY_ 0E9;@9*UK:[93I.2Y[)?YM$_.,$(./ M?5VD@O2'1D0GAX.:\MX"_EY0/F-YP?G$4]9S#KB@IX1-S0H2'5UI/=OJQM)L MA;]&_--:;-=6,N.>DIRL$M46K4_-\I.&O?_M8Z-^F98KCXS8H20>&4%B-296 M359>3>+:^?+]D5"SQ7DD>0I@PAQ&*3:FI!=84Y6^H4EW6XLF[=W [O4C12'+ MG]RUCYWC+5S80>^)DD,(-R\.L ,E>B&K:JW4'NO!L82><LMMSMNV71"VQIK8 MCK5 3"AUA=8K8OPC+N';9ZFZWJ+E"?H"OZI!,Z<YY,B+!E%=<C&Q-B6@</)J M4;Z_3["_-V1IJA/D]RRQU^]6)_T._?<#9"$ >C4KFJ2XT-KANCO'UEOQL XN M4EO?9("^]7*1YT[Z#\+2/9GM/7R+EI:7D,UQK\-5"/C\'"1M]L_QKQ'N47RC MWJ\HYI\=5]]*_5;F6[$\ 8@VW_/V(4-C!S^N,3\ -HD'YS_SZ0X@C!<&['\ MN9<&3=T[\N*8TH=43#C@L/**/R^HU53QSC89.ZB(07/.L3TZ39V1S9+X5(GJ M,=CC$LVBM<#7-E.S,M""=]:?IS<%#S!/5;+D[(Z1>&2D37%DLX%HC)BX@4&! M7$OLX@OCZFDI/.!\U3Q\7>9[#S:0#&8ZS6;>J .;O?BQXL)]9:@J$5?DH;O" ML!8P ?2!*+<2M:DN#@L<5!>!ACX81*UO;:(Y3!DB^:K8N\26S/3%G[_3_2GK MG0;8E@[[1B&/XR7"?8-H6IT\'5]74P96+>M"[Y:>Z7QD) "4_L6LCDXDV78$ M;J1T&XMBXOWQD!M[/]Y8C^';4G,,$'>DNMMB;K0MQHUNCF<#5>5>..\DKPON M^0_VRNLR+5S9$>3T:#FTN@"";+%=BX5\*0I#&; G#\U^?E;+3IJ\LJ%XFZ7G M?J!+HH:8ZS!,;_#X[MJ@8:G[!J0@H+1H19)-3T&2CFZ;,!?;U/O:^J/V*Q48 M7)J$#?.-+RV.FGM0/5H3:P2\U5-]VQGHJBU^YOX^^.'APS5R,_%J1%3AH'AC M8X#'O*R^JC=2^A?7 <;$;G.NCKA?C#TRAYI)26\<AL6A"@L.H:-23LUU4U(C M5\G78S4O-J@)5%RG_R'=+$- \4"K)*OQG'Q/W Z3F[[8]/%*O(0\$^:OF^JV M\G%*ZS$TQ__^@D<P99H_&:E1RAOV./ZUY;XCDJKU[9-^S5,Y -U,G S8HR. M7.KJR?5<4_Q9I]&=CBOUZ]IZ7R<DE,27ET3U3@#" $JC-!MTRX18/C'B"^29 MS3[OFC8QXC%K]D[YRD?:9^V0;6Y.P549L ;U#,DA!3$O)=*1;#;;A\A=\?.> M+=^^DZSHBOWY"[[S_,)XR?S7=SK6/MO$@+RQWVS^R7KS<<KBRO%)@-O!^J*N M9RQBH4_OF?_MON'Z'\[ A?.2_*_W_%P6=U)0D"@$O#X4$16PSM;]B&?1K*]Q M&F:@]JBU+8NE5F2\YBQ\!CE432%&7@I.2<;^"FDY0G9ZF[NJ_%SCO^S5H))] MV_4$4#^JIO%']=F+*XU'#Y2Y;U1X=67Q#F)DH.H>G+8?=(SP97K2O)FIG,YD ME/9XV:_*!7,?JXPY7%_1=&2>$Y>#SA:^XJNGJ?NK&2ZS#/>V[B @(]648HR" M71R;,AZ[?&W(2,I7L/MR:I#/ /<]JTLU%70,0"UP89VN-HD<<Z@8>:M\\[+W M+SEDL_$;SSZP$E6/%N7+!E3?^;X_!PGYO5,\]VH5U%B$P3)FZ!0$R'":SWM/ M2CV@%4J_/PA-S)*+D@1W9C&2!-[_D5ES &*&?XH6U&A_.EJT!&;$5]+%ZSZK M":6,#YDGJ7PEQN_PW3!*;S[D'C0](,D!ALYPYB7:X(!A>]G<=F=K@H7W386^ ML]"U4=T>%KA1M=Y?58N9:U8Z :Q9+K^#L953=4@,@3HA+_:M8H\K#[BFD%LR M&Y3Q6NH]6HPO+2"_D60_/_#F6$@J]]ZF<:4:B/70OZ.1,QS.X[I2"(6WBP3( MA-.GBK9B-N96'/A!2L6"1RI@KEUEN+Y9 :T0_+Z? B;VZE XYT\+2XU>]4*E MOIDI)UA5(*?[JJHB0]UX./XQ[<@GI$>L_5N>;:;C3E]J<[=#9?8"2I/X.YL< MC(J!-: B4<J_[89 &H5&O$Z]]/DQ8=H,,;MEV3SN$0\K98O[7A%Z0Y@MG;#T M&*5R(<'N7^O?[W\U"$0&_ME-\N*"<'SM >'MF7^\X"3%CQGW7R%6.#DY=>"L MA]Z4/)60);PI7UU./!S[+%C4W:2YE9@6_#_[:]#_ ]HWE\+5R7= Y5!_9.OS M.0;J Q)GE$*PJ6?"D<.18"H>%@!R"?YI/E"GL\>W&=.0_W1+0\ST"Y5NP*L" M+=37M<VV831N$7_EU1E5MMH[:O5_*J5. "^"%?4:ASWEC;E7#QG(?\G[/#9W MF,@"*7W79T/]^39M+4A1D(NL?B52N+>JU9H4GEPH_$BKJ3;K %&YQU;^<%89 M^$K6Z"X&H=)/\EH_ 113(F$Z VLVX=D^Y;.Z ?>^EGY-,LQR&%(VXURP#T\A M&;0WCG82GZPEC_/HR@^H)'_7OPQJL51[-XJB&->P*$B@HQ^CT_ZHWOM@![SQ M<).1)B#ZEQXYJDZW(G "X*#>FS\*-C>I,F1R];SE>WUI[E6"[KYU\IH=>GD] MMM ]2V#XC3[5N#R ?Z?76_7KJMA>04K?"T]99#WQ^RZ^I5#5(/_7H#;_%Y=; MB3HNL0_64C1'(]#.TS"-@2N0 =PG,?O"JED[0Z#,K5N=3#-K\5& G5[D)$*W MGN1"_DD)M:JK5&S%2>B%O[H,04GV<F]VSWLG!*\)=+16;D74W,W2'?>U-^[3 M<](ON@*39"^_?%M7*J&3.XAU;^L<[,& JJ&SZ%)1(6NDP>6"]2N(E 2_+(@. M)Y_K$)9^:K76,T4D1O S["C '4#L[9_,%,%;=:Q]7HBA@-OE9E8A/K>PO]/< M4I&?>I&ICU,_OVC*CIYC*,/<L7,; D-4XC*]/ %0J;NAES<Y.GRUOB^*I8JN M-8)Y_JYW)9JB/Y<9>X=]DN$J.>C!%O.!#4F8L-(GY7T8E-LM,;.^E@)6/YX1 MY$/ CJ@M^=F0%\SZ\/,XVE5^"XTI:E3R)ON\'@QX=+#V<X^OB_J4EK:W%BOP M8!A&Y^,+>=-H\%=1)7\FK"]=O_5EE&Y_G'?4OB0R$B,P#!N^W019G&I-4GUG MXA3Y]K?@T2)G-]I+U25O0M^%;PSEQ) 2PS]I\^RH70=*/16G=81S)NNX&29+ MU/+/[)1%[?8>F^#@$^?TWNU?I9=$/A&^?76X1\N>ZX9+4VR?#^02ET-M-YB. MW9"X%V_LOPC1OVM83MN'V![94E2GGN1G3=?.R?)D*-BXCE_Z(NM,S"BJ]"Z! MRGUO;.EI2'R,J:Y+7KC62+_\_=9YPK<5!^'6FA- ).=;C/!:;\%D-)+'G</% MFS7YTIT)$03KH6*GL!DD[79^L9S@V";SAYY\I6F9M&W!TTTS=19V=3Z8[<C& M LPV1VNYQI;\<3&SP&\M:JWXIKMPQF/"X[[763.<TU@A9O1#-+>B*7;!7.JU M6_"YI3=H_JC_Q<QY0#45_'L^BHI21>DM*@@J39 B-:+2I2N]B*AT(KT3$0%% M( +22^B]]QYZE5Y"K]);0@F!M(W_]\X[^]_=\][NV[?G[#D,N?>&W\QOYL[, M]_,;YMX'.8__I[#$(M'HP661ELG?NT8.W3!O-P>Q5V&0M=7AC/[FI9VK;J^G M3#O&D6E4 WQ;8C\84A=P78X4G/6$76]]R9)MBZPX6W0QQXMGJ5/[AU4>QC[1 MA(IK1("^!&)D]$.1?-$04DHL)YL9OU\$6QLA,&C'?%[.&26X<?NV.ND8[AB5 M0,/#-YY+W=TU]4-'%-X!K^YV6<[;G%LF(Y3$1LPZ(<C8.5-<8M#/#UR_/E#E M+C&$>Z3YRDUR"WBLX(5_N'VLG(5<G&;,.OI8[;[Y,X9E8+[02FZ0IGNDE=?\ MYW4M<K@C1:S#& -18]YJG^.I[ODANB\'Y'LUWI3-?HG^KNYQ 9?J'CUM>VZ( MVJ>.,*WSQ:-[HGD]UC\7[!)+\I/WJW^,:O++/DI)C3\2D8:NEGSAX/ZL,>\3 M.E$V.I%'SOW:EZ=32CP:^_OKN5UQ,*BR6WCZ$]OGEM-4Q^(3:7/Q[:GKD" # MW/X>N??PD1N0\>UO8XTQJ6_*G94TG1=DVP:7.":./!NV9N>DE;+:,?5U6Q\M M<'S[I@Y%PG/M=[]?<>HY^JK=CGWM7O-IUJCGBE:1-B]%8+6!V56 U']^8^I_ MG!+$7PG2KY1]LCE!:/6_"99GOO=9SGN""'B/I<POS2U#4:-3//*-F_3!K%\J M&GLYUKDF FJW;-#PBI(X2VM&:L=UWWBN4,G+#QUZZWA>X.P(@SY$0&QXFY82 M,%?5?[+W*4L:[27S&1_U+T.02CN$ULXMB7AP#,"Z(HGB+H%A6-KV,(C4PU,D MVELH)YND&B:[?L<ANV'6D4QG'X#>*WY/9IL;![1Q7$>Y/F=IM%=15GMKO!'5 MQ2"#*9RQG_1,CM%3ARCV9&2ZDL*?S:EL\QF(6DU=@W6UET5U0ZTU)_.*^<)# MYM]6H+NR@SYYX4YG2J(,+-O/.*67S6>6%)&<2?DOK-SNUK6,$P&54^OO )TA MTA%/!MB/_ IIL&CML1)1+_OTR9Q@KY]=W%\>>US6K76\U7SV[H*"46PA)5/T MTHH:5G";/RHKL;#>ZM8UK,C:X4/)4^R70G4LW\SB$WQII\3MBNX1X]6KU^@? MZ09.KS0@1J[J.SX6WE:?E;!B'R%G0?:L[(=TT%Z?M9;R$J"23OZM(F?I7>.# ML%$K][LJ !"'\DMPNVAD? :D>U,8_3OW,"HV%&#U*U?&;4?63EIOU$'LFTQC M_'%@_!\S%MJ\>]4/&_UHR$E@^L1HU_M5P<V<:MO,2-X^*:B]WV%W8>DWT<;@ M.>Y2"U[UVL@8EI-AU7U6AH]]>0?VRXUAV9TJ4L"52'GZ@]8-0GMTGF>6"OV) M\..WMBRDF:PRWPOQ[L&\Z= DA524[6E/0)6709/[H#VA3+D7=,?)9#BBA:GV MN^_=PBWT1?,)#WHA0\]&A#ZR!VXTEJ@3I>/-,I'_2,LY= (<(J.P0@0P#;I< M"RDRLHV>:YG1FZRU+SXM>^3!\"!%?BW2G->_%W19K)BO*[&DTB./3=I/2L6U M-F*R)ND[?5BE=YB_V&F5_]5QUE>O'!W=2\@3GEB6^+#.T6F([ACQ]U#KN>4? M:SH7-=0D6*L.>C'[)]V]IP?ZG%N,SO<[VO;VK/Z1U]@B \1<WZ@M<I655N^9 ML4_[3 1X<5V"RU7[V$8HD4_5.RYN:@]/>YI=WV#2'Q?/]I92<>K/Q1:.Z*'7 MH)KII0\P;=AG)':_$>- =<LV<6*@GO^M3 'ZHVR0+Q'@AWWKN;CZ? J=Z%9 M=F9XHZ?&9=#[J6_C[5#]+*A(BT5(VKGQ!-;08#6EC@B(-K]9NN^U5M/--1[/ M^?6EM[\KI,/4$YE<8).MN?#[)<1HA]#9[58^@*\.-@*"'<&:4^&#VQ>(3G)T M$VI3GC%1$[( 1*5#[(8Y4\NW/],:).&L"5U=;KQ8.QH_>-.%%2KS-V@!;[=* MAS7%G,+7(Q(O;<</8T9)N..U-AQ_[FW]9@UO> [U=5%""PJE0>Q7AFN;.O!+ MI%((ZKXOX=6;$7-91AYX+&A-"2>V&4$$;,:FP"XV(-W0/1-S+<),!\SQX*]3 M0SZ6* 84I3\B588(2#4"_[50_NO6,E!(O2<MC @(!T[7I1=MTOBU,J\5WRO? M3#Q_TDH$U+S!3-S[T95H_]""ZPKV0SQ7/R^V7U/UHO#5Q)U)_O2&FI]J5WHY MV%WOG(AMK#ZN+AN:I-O6ZM+NW%6/G4I1-W)S3@GX3V^Y_.=T^:W.J * 9U1Q M5(W$P_'9&9]O6V?25VE=4@E0^S^$Z1"2VEZ*[^&P%6\OXXW<UJE6NG,>F\BC MGIV^9EY9]9TF:17%'9I+N$797/";C$9?;'?7BR((O^=)!/A"PCV%2,UR:6OQ M7DBW!-.(FB@<^=,T'W_\@ !\SC<.7]'"O"T@ M)5B( $0CJS:C1XLB?M#_; M*1YS;TD-7TX$+%GB;*CWF$%P* '+T$_[58Y)FPC@%($LOX+AWO#B'@E11?CW M21"N]!'$(H(1,="@EL=VMW:7Z&44W-P>+J%K:U^P?7 7DM^C=I97P4X3 6[^ M6Q?Z:;ZN2 LDJ'-!;^3YMJ4KX]$"]&[ <E@J8;+UJDR8%?NM9KY3*JI,G:#T M]/,:$63Q(>LB-7('D]DYZQ\U%F]9[RXB8QFC8 (;:MAG:B/<0KE'%\Q/:[IE M?(,X5]@"?JF0Q3#;4T4Y]31_$F<:MSF+/8NM8"YQ6/+5N=LS ;1=FI"[N]N0 M4?7$Y&5-4>\KNO9T.1WCIP<SAX93V68DE$[>PE>YFB/33M=K S9;JFIBAI;N M#P]666WBG,;2((%,E?Q6Z@A^MX<I7#%WM%Z(VF,I?0!V/)JAG/?KHB1Y&U4V MO_]0X@^]P4( YO(4S&*P9F5'B91%HDY>9-:4OY;@'$\W8>VY,ZN$OK'LX#VW M1,VV.968PU*Q:<$BO=?*B_1O.;ZF<VO:WYZ"\;;.I3PGK#I(&U80NB(,G]7] MO'GW;9MOY2ZBV,5R%?J=<7V#Z7' ^K<I[J W '*/A=/Y2\/5"E8HKDX]875Z MC_S[34-C V!N2TMIYQG.A"[-\FX1TU>@E_9*2/=#K,98N\.[,;:$# FJ\L [ M$?PKQC)DB<F^MQN-NZKJ$/QO)\2;<D:N"=Y]$1R-E"V\/+RJ_VU/R'^2>E8T M5;EZ=HOJW1UG@'EIL\T.C$E,%JQ95MY@\CQ_?6GXYINZ>K8S=CF1M(O7JJDB MTA0B'7V[Z0&KP]>7/ 6-E=W(PTR'PA_6Z@TH?E[CW34 (_B2W:[5-'U858.R M>J8>&]2SO5I_PR43OR8?9((]*W)M(\<N&'C?GFUFI2ON\RK6D(K*';:6O4($ M&+,5YO6U'W!X;9N#"7U2G;.U[?&6B4J_9C60UW[^04''6C@37P9Y",\FL'!% M#>+NT. 0B\"*LZ^..""R9HQMW?K@X(]=3GC#YP60ZOG>D=H,]U0N/$K1;+)Q M"VIJY"9F,XG<G/_/[D7[?Y&H;2W=Z-$Y$K8W8GN@_D.0(UH4#!_F <$*^- B M$5#"D!=A^-^ND".GJHF ;Q8O,)9=;'YY1F[O70W69/R0P_*8Z"P.:=/*VQDI MJ-Y<6A82JB%^S!,Z+UY(LT'H%MN+7*JZ:4]+T]P.;QIXVG:K+6B@V=B4@U]5 M/F98/X-5YW8,2%) ;-0%:224R&[:P2EU&>RTZS?>V:P(>4_5=PGM*>0X$ &1 MB<?(;Y!P(++3&XRGBH.=;4'"W9:0""* ]A>D9W]*UG_(1G/?:_GJKH<K:'\> M :G^'><2WB$8V\ .Q0ES)A !+P0V\1= DDP(<R;]VYFI)[ZT!7A,B'&'["_D M@6>Q*T>GC0U 8_?<_4JY.&#EP)+E3R(@F&L<LO6AB0B O\#9@%:^G2Q=L( A MAV,DT7"GQIKA0&;4D]-RZ/V_$O09M+ES2)H@9Z'@1(_W6!EX[QH1\$\FO#AA MFK\>R&[BL20/H'^-O/T*_F'TRQ_A#W!4&)PA FK=TQ&#TF5H+P]C=H]_<OIO M%1+G(>WJGDR$>B$,PN*O6B*) ()_"1& 9!_[J]!DDM@W2Z"3U@FL_7!QF_: M;D-9*CD^IHEW>4&'X[DV3[D7[45-8W<7$? 9467<L_X!T![0@Z&U/3XDQWDC MK2)*KZ:F%')[V'\J,PDGB>.KT]*7W\+KS !K#']6>;\EQ]6TA!2&!'/>:!"? MB+29F,S5(W_[?_-:@O_J-)53+5GP$!*".,VIY3'BZH5;"9V3>_80NOG@^-AF M/V_$,/R* TY%!--7]0/+YV.Q2EE>L2,R"(L;:Q8N\O4H@W3.J0SC/XDU>Q*. M7:*^PCW*YW7][4]+V+"@GI13!UX"CA6"AD1 MOBR(4N!AL[G23Y*TQ@L^B=J M<C-<CLM6G,=#2B-^Z4/H%._*'P[#PH%/DNVY./)L5R+@=M7<('!5XOL=^-'@ M<H.@;SGT"<3)I)=9JUEY%:[9JAMF7?+2WRGL5[;^6>#XI[F P,@@'1IGI][] M05>IPXY!._G:)[]_+CJXA<<.UO9RM#ZZ?D%GLE/1Q:\0=]?0!$]FQ;"KABK4 MA+<T$";*$XTUJQ0$TJKXV#J?.PS</@MVZJEF*'B=6U%_,U=54]]RZ,2<W,X( M78^/8?BZ9/M<SX+;BN[M[;B3X9,"A#=-II58IY.QB@MUW36;_0P!UML_)8"O M0D\+2\,O.+K3*J^[\9G?[RB*3;]IIDP7_;YP^OVFF.+:&F,2O], 1_5^4GM) MN7%'[4##Q^=UT1PQWT!!SGYVM\=XE<HS6D;;EW#2*$YH5A]$,':7M3=]^<TB MYCV_"?9=Q=VQ4Y;,@/V3W?S,!+7G+\DWS;"R^HO-(N!PQ@$W*U%*2.4^W8)) M49BX\I57J3J;->KFDRU/9Q=FYI4<P+(!4:/%:T'WE(,J8^XP@%\E9G_K],O[ M,3U&L.R#E[D)+3P8![/]MG^^*'^>-);IP$.0C%I4X_NV^:Y73UD5-S#57-D! M8L3)\J0P1M]M'E^45HJUVW[^D>=&U5?'/74K<U^MJB:D1B'_RV$I!8Z(&'29 MW/1<G'VELO^O*9[J_5ZU=-79)]UKOR,+??,C4UI2)\)@PELVV&=]5\I.9=59 M>--*545B2H8>*DIEB=\6:&KW\6*ES&OQS($>\M$D([:8]K!K7J3Y%*$^D<N] M\.C\]L&.J2<OJG1XC/9WY]M+7UPF..']+0A\Q-Z':HS.QTA#QM4=%2YJ_! ME%Z:,'SWZE5N/QJUP7TFRP6]O^3IJW+V7X&=_U6)S"A^[5[JQ%3.JQH9#[2+ M5@,X[),P$<# L$08,.O,#$4=S@P3Y%M$B(#R4-)4^*'4@EW QA1N[4**Q((% MQY7B#M6FPJL3QCQI>PYG#C2_Q:F5;.DH@4M;&U^Y.+'O'OC9;1I#9PY7.8J* M63'.*A3)C.%MYJT7^HM2->46:08#7ODF'7:V@4+\I4'F%HG'2:6S@2L;J>ML MQK<8GOYVNL6WT+;F]&ME0-WD_/='\Z!"Z7X].2T0P/_NB1Q+G2P!F44ZOB<2 M0P1\?;=F(_UM4>H",6F.G(31T)HZOB("$->( K02F$+6REP3@2&]0 C2]83 M+*=.B "R'U@)LLH\WR(Y .YE'V\'$PL7T-<UW1^ >Z&CC&QNY2T=XMN!86P/ M@_>) .$$)7P9&)E)8*U<@>.O99$DAYI #[$A:<CFTC)H;YYB-OVH G<)\S4K M<L7GLQ.T14I': ^/NNKM:;3L5'L8$5+M]X8D!X;()4*@#@S[=@+VUTG0EK 0 M'F,+F?4*P6%Q5_$I7X@ 6,@ ^3*P\\D77V&G#C#PZ?+%.&@%1KA3LX<Q6_[S M%K?:0N+XX"(,F B0SX<<=I HG5H?.4?*EL3PP;GXW'C(,+P5,C,M&$,;$])* M^\WB&2=3'<#UO.L1R;^0X)Z@ Y&6"BK6BR+_21@U$; E]M<%VGU#Y#+D]T?% M8;RP;5S"VC[8"L.$3_I<BZ*%^0*Q#SP+._5'4WP% W.40F(":/F(@ IR<+%? MP@J8=M;3^$7EV![7D8. )5UW2T>S,X$.T[=\R&Y&Z<=E$NQ3NE(+CIS;HM4V M':QC4[ERO#O5)/.1[[9AWE0XU/)J4,>(?C9?Q8=<7;T4,Z^=H/\/\.M?4E*^ MA(\68)+]:]AKF'=&4D'$J?;\]VU&S[.]31Y[F7=/AW'<^B9DL -$>6DZP_%9 MZQ+-DBW2L]M:YH5?KA".6^)%7P#7K-SAJV+O+QBN-W-$ %=P/A'@OTH$K-IY MSS>=U0^$- 3,'/384K*[ED@0;OH9$T*H=0EXDO1WDG"DG:[@F#0,W4DVO@JD M2U,RY0>.&U@@I_\H[&8)S@%%001H'G^0DHL3KC)X4U/8AU^51B1Y0CH20[X) M\@1JA$IXZKM&*;=9RN_\]F39XS-?U4MRRL2IHJB+VXX=[S9]M,G>'4;Y;"0L MX\TUR\NGJE+4-P(U)M-N)A4Z-5@GB_L?NI6.(D=??\)-G(*D.^N'FK/YZ.P6 M;TSAI*T8IM(_CF36ZVC%:@'^_'$*G/!A[3.63F"AXS\P_6/:5VWP!=0\GNW] M,0FEICRR,L[/SXC>5*Z\S5]3Z\R$??8H76580WZUJKHT@I')_0C_144@H;A] MKH?^ZOO:M[VJ5C(E9+3=WQ ED^=7ML9:*F2"JK 5O3_L/HT][G\0?J86&$PA M/*&KU[VA%4Y==*34:.$0)K(F*=^CW>6]!V,^F1O>OWYPO[E60N**\8ZVT*%] MYJ>0]=,^'1#K^R5FT1^#:J\^AA(6VQ<VCV6JVDCALPJS_Q68R:3?NP;L9;0H M//Y8@+S#&_JM='9H; I<I52GROR8[J8$1P_GE\RZ4;# 05;@0-1F_P<5GJ_" M8<)/YQK+2]]%KVF&'(C1RCW)V\9ZA$0PE\5]B'8TWD8@BV;\!;<*KXQG2<3V MYVC-OG=Z$+P?;W'?98)!9B-[59CCCHGUZ"[74#7PVJZW>#1C.L22_Z;,(.6E M^@2*H\Z(#HY= 0=!@P>,B%O*N_4,=!&HA1".J][K/=V#TE@=EBF[W1\O9.(D M?@Y$-YN*GQL<7%5;I0V/C9ORT++9%JB=%?B[WDI=8?S^3_C,9B@C#]S@2MG) MARHHMX/4_ON7C''\8QQE:8H\E@B^GF=2$^I@YR@OB%6*"6.O]3 2OS:<[=/R M Z7?X5T=,)[1T#3^)WA(,>+(FN#Y_1F+?JJ&_.9BN8P\BG/H>.4@W>VF9K6J MSKBZ3YC77M#E_B'I]Q$/#!J:^IQOGQJIB&=Y43>-SRS<'TS.63RZ5\S0">&[ MNYM\\1'^C'#9<YMP%R<V+J:2Y+8:"':!G6\UW<85'J]8'J$N\>]7VDF,N%U0 M8/71DM6)P" >PV>48O,17UVY LPTO*ZLYGB?"R@-]XV<N?V=.\P9_=+^09DJ M#>$3@"I=CTN*J&<T&4E-V@V?.10DW-CR1LBUU1<4=T0O3>AZZ&Q\9@Q]!5.5 MT+H\^O<BP(U^8<(Q[>]?J#7._OUNM('TV_'05L)'YZ^!C\Y!NO3G*FV%Q__R MZ$Q.WYUP9QL)AU9=E8:$3=^FS[*2.>?-3Y?'-E2F;WAH-V0>R^;[]DM^]M^1 MT)6 'EDO/OK'H4S;EO72OK(^D.3DX&HX23U$ZX-!;FSY2? AZV/ 6692VJU1 M;:_%&<(; ?V?_WL350*]UF5O=$YLSSO_&(:N/^ZH2F5O5\Z6):,U7W74K0&E M*.F/MTW,U#K=Q0-=PT][%G!.K^.</W!'M*MM92S7+83ML=>NOUEZK=BFO- . MBW?8-O/X@X'KO>LV!E$;UTKK@,2W:'5F6N4F)#I.4E2:433E?KSNQR\A:?0G M+TTK-MOA%*88FF&3T-/!/OBD54M89_T<VQH BS*=M8T]>LR&J\3/R.E>()(E M.AKEJ^9VI0;K@5WH*">,;@1TM5C@61E"X#1>'U:Y4PX8W&-V%=TQ,E7..3?K MR>/N7:!1*E8),+/,]GUN4'TW=^>G^@K^)?)>$Z@^&M_G#<SVF/+^F= 4=WY_ MKC%U;:K2R4G??E)%98:3%OO<?^A,3JX9?-/3:\W40DOI?E6([:O,%A*+4,*_ M^,O4)$PV"?LT&^"0:R=R,1=W"MB")3F4GMZ#016&U\R&F,1+@T-XME H277V ME^=HD!1M&YRCDER.L86;H7V?+'W8Y._[IC0]=W]_Y&2<>-+HG$SS)!DZ!5<0 MCYXDWU1<0BMMV%5BG6LMH['7XHZ!*91(JQ[5 MH@<-9LCG =A,8EM=DKO87* M<[NRL1TQY/39*0Q[6CKJEXO-/,ZT(2SCM@B+Q;@,0ELVKF?S.8X%-;8IQP1W MZV8P^ 0RHFV#<9S\I1U,T);PA+_;A5 9$>#J[^IEA847 ^<FX;_,IU_#XW%; MH&M-;HT>."ZF=2CJK2^<%)P^+.4HN8ZL1GTX#[1DX2WUQC,=#9]!C&0J\:/G MHX0R?7,J54,.H0V0%&CE%6:9.K,=,>=-/1 -U:CZ0:I 4HOF#;-'U\X#'T@R MKY&+70A7_:/<)&-L)CT$K+_018NEB,8J=7"2XV.;K%9_;.F__H$E5]?%]G$$ M1,8U!)A;>RIUN/O3C3B(ILB)10Q-7K$F]W7CG9^JUT3+RYVLF_A 'AV5>^Y, M]YGY<*;2DJE=+Z;NH3"=F+6/XK>KCW]P5BKM,*SLY;B@_KAF_HA/Q,^ZYO"^ M_YN=P5:<INW1(:O_J-D-I,F8? $F6+JPS*M\W(6_\'26VH[")1_)ES"4]1#G M7+Z[9*-Y.(9/!\'-GTCL6^68] [F8'B[6']1GWT4+[KZA, :I4&B*1EUV,6R M;4ON-Q*,0<Y%) GU+PC^D#]%%^ A*,%;:+4][N\G+_Z$;\,<8ZOBX_L$Q8L_ M)P)V_Z*8"@@<[,]-XD,NW*.6?/-S_46A$BV"QQE0W:N<"!A6)@(.TY52@+@3 M*.&"X5@()\;1@[\-N@59BB3Q9(>V"1KS8=4<2Y+^J=Q3J:7^EA,0R=SJK_DH M$> '.DQ7V23A@"P7$= 2Y#M,*E#!C0AX.= )/R.Q:+$23HP:@;\-O U92H:H MRN4:D\H/.NT'_B:L;4.EA Y+-]4VE/ GN-T-,,:6#W[!P\E+R@B$9255A+*4 M=$KRO 5R,=%"LF1:#"%9#OVU% $=YFYJ'*^Q>WTG.:'_>PDYH=_<PN09#=0D M5(O!;2F/QU<\O@L32 &"4?[;7<'OOJ-"+$J9X#]^$FA2*VYF^+OZ9<@-Y:)* M$T KN:>"2Y1-2G\7K4_SV=!I$PP>H/9#NGURV,(QM%<+62U02._D.E?QZL)C MGXYJ0P$8SCN;3@2D%IXCDG!R*->6I\CBFD+Q[QXK9Q\_V$F/ANRVE434_:GG M*''O.BZ<WO:?I,6=F@]!JU^0VDG_N,0V-",B;E^+U/AO<-O%7LPR4LENZ!+G M.OAW.)V0'.>V>YS>(C,<]62^_QW?V_JCUM/LZS[J";=AE5O>\%E2HZ9^/Q_# MEP@>"6V:/X%TO-K!@U;T,($1<F\ D$>:&)MPR]IV^$T8YCHITMB]2'$,6_.< M55-B]!.OU:Y5TL6,G?=#O@%)A C$B7873YD'I7(I]^A1>.*"U&VP)IY&+"^] MT2$EG@['@0*#A?;:.\JYIZI]'NQ.O[(S]>3B]-@:)F):,4*K9D%K=F^:1JH; M93\N85Y224#?24'[&RE-=:1#IA41)R<E7L\_828C\B9RA;[H"QUDY\4JV"^? M[.J\?\WJ1?DWS#,6T]5J^:%>E;BQJA#,K-5[)/&,G*>$,^8/L%H\WRD;QS$Y M6)6J.UC#:(&?VN$S<L4734C'Z^7O;=>C92"KY/L!^?.VM^8\5:<>"'"]DT-\ M$AE28J=578&LY+9P_UE[4RM)H -L3NO'*/Y@_2I?(UL8=%#'3G"[MV*H9N6H MN"S)[<%P0>6,$V/.?3"/0^=(T^D5:L= 20,F. T3=H-<KY:<T(PH=1K/.U2% M5S-UZO7@U(O;0.UO23'<H]YQ&8FTCFQ/(P%]S29XP]2:AZ$#^UXMQ31E:QMP ML7CPQ7*846QU7DUTH1#Z0].!H)ER:]3DJ$NY'X1B>&8Y%JE85AP*L0XC3(#H M]$L*27'3YUT,FA3"!6=@PNL>3MYA86&I-7G#!PU\:,E>[+1JY_DM6"VMO-T@ M/M,AZ_3 .FZY:<I#$RQ>?B/U+8(15:7T?FKW\YA5^? [%]V^."+@KN_TX88@ M=/;'*@B($J\U27:YC+K0*=U70+&O$7AJ.J, G,_?;X)6=,Q][X]]K%4'J4YR MN$D*_@F>GN\@ H!4-X6O$ '7698OW@B0:I+([RR[6&LO-VP[/J\8>>CZEGRA M1WO8R']8D"#O8^\\'E\!LJ7]1AKXPL861( ]8R3$5NA;"']B=6/>4_X[)K1C MA2I(V?V3;VYJQ5:]Y1&W!;HQ+MR>@+ '?S8]LM\@Y&A,MR[<%G/%R\$"7QE7 MO3X>H?<_MBE/N_61BV:JD?$.,*=+Q5<?JBJFX?-:[M7BNASZB0 O!P3NX8C_ M!(SNGL.8K?A!)NR4DL#PI[^)=D6R35NS;;]OWS1J -F4[UP8+^-X[VQ#;AS# MA%540#U"G9CJ+/"[Y<4]L@0OS%N6R/8XF2&E]#?B.O;UU)EZ4IE;:I[&\DTC M.\(.G[[S"_>/Y?I C]7OWHA77K$M,4TX/3=[9/!-SC$P+R,4I6G_[ST4^?"A MS8-+U?2([U3VG1&/C%::_%9M1#G$4L>$JFR?] H4O>N6CXFX!#[SQC^*JA>8 M_HU2^EY-K68LQ?FES4TG;6&1+GZ/2Y9&NE=)4[5^Y9!ZVM-(\FJB<$,TWN_/ MDLQQK7-/M5"PKUPJXQBAO_(<H=&M-E#D:/?=.*H3K>6ME[/0Y-2CDWL'9M[] M*SL[:._\ZYM9*4N9L5&%]V@QM1B#![CC.8"VPBN/Y[%=IOIJU5-%9OT7LVR[ M']='N]UK"S;3SQC^>&]V.S M]X0F=7#>F13,'O<ME1ORLK#D)QN'*&GOFXTR M_PX5H=\L=&787&*1N[D-9Y8!"H25\WL7-U3%ZI,?<D'//_J%>UB<?]"9;+G] M@SF;52(=Q1FX#&&W:9$9<:@VY3D5LL_%1N>U<4-N<(2[[LS]8G?;-X=!*GHZ M?RP%P>E*FMB**V>W$>-L'PUI&1%\(T1 :^$AUHNE>#+>P?Y]Z#A;2"QG[B.1 MMG<ME9H)L?K9 F+^6[GZ+%MW,D(?,/_3(F]6]L>NNP[3.60\"0YK@IL4+:=M MN.>8P$P,[[.&J=.!KMK*;[Z!'H(S*Z\]0*KS*,9:A]PV)R\WT4_3AMUC0T>< MES^[8!"#<M='K/!93?:^+JMBD;ZWLWLM1ESCV/16 GI2U^I*$A^'E4K:1_"K M*[$]%]+C%X?<A-B 3PH'"J&7<%(?\9/9+7I'>$B3IM;UTC=(\S;@%1PH6&BO M^?+D >IX88%6Q,MO@'4_YGG)97[Y9Z:1^"ZR-'-;/P43M3@D[.'KL@)0ETE[ M4?9K;F-M)H)7GOFV&CH!LID%R\7H/BA1&SZ/:#& W'TTWP<]#;^ !%WS,H8) M0U=![1D94,AY8"RP5VVC;V'N&+BBE'+OQ!VG29+%C S8D]T[ZR%'M_PR- Z< M""B27&A6@<Z&\2>0]@0%]N%_V('V:?$D[?<#(C/W14B?I&%.H.]_T)0Z1OGB M_$;0!&P)\EO'+\/\?&L-Q<! 7RI806-P\EUHEB3;J>&8&E#VY56%MD5-^X,A MD&IHJ._28KT@Y;F]E**(\/U:NM9-:'^2 GWQ8+Z3;P,I=GB5ELL=SB1<_BTU ME,;K%)TSJLOB'#DPI%I+&\&JB=W2P6=H'M:N$@%XV^#0$KO=WX(O6_KX3)3] MS86#(7.@E3?@O;<3F<*+1AT>+,Q\W-?74(-J"A3./QI^2CG%HF3LNI<J:4/$ MU#H*/557P5=V=^,B=M7?_:PD FI2A%_[WD95FB(AWXJ;F% Z"Z)X#<W8 =.0 M]9KFO:S:9W8+]#%O%6FQ"WR)F"#DL3(F::6^2MUV7DHEF@J#_T,[$SU"L9]M M)B8[6[*U7!Q2L9%1-)7KDK-SJ9P^/,[B2.(C9W6QN:@O.:JE= 7OHX4Q7KN1 MJ'G3&MXT=GJ#%O=5P,=RGN("I-G$I'5P:/ :R@^SS @".]!8P74F!422FQ_1 M?+9=;A''R)FS^TI,N=9=<S2[A8(T23(LBBF>]^X)(YI->+;[5%SO93$HU[7D MKB-F-KXH!;]^7P>E4V.C$JE ]>[++S -EM6;)X%+^ [!G/Y#+328(.\S1*R M X17R.DCP5B8"+#V$.LJW3-<$2-CC<V2=;DCACYQZ>?L4RR0XZQ1,9Z5U+7J MG]4,/]UGTI!R"\ZPK*)1O0;EKV>Y>P-;J%&-"2B=A2<Q9HHP)AP8FCWVJ*1B M1TP"D5TMMXF M-1,4M<)!:W\\"71G;RL$@'+<&NP3&3KZ?K3WE,YW:2NB\GV MF"C,E_X!;%TK?D:2[WPBRO<9BFKJMD%+_L-0"^S@:%@:,X!L2WFC)>_O,B\2 MAK]R"L1B'@#+H5_UUZ4B,F;8_#$'+II8?;)IV%Z1A\MZ(?2;&5=#TQ<OMQMR MXQ1EX6./F\HH# B7,UM0&W (90]/%L:Z"2KRM$9X^PQJOE*:(2.$?8BQ-(<9 M1JB_T-*V<9_*F^NQW6)""R$S'_#J3*ALIZPF5YI0U]#N-5FY;*K1AIGQ5MJ\ M.GOHRDK[2#SVCF_+Y<VEM%U#J;@(\*D0U6!6?\G1XJ)?P042=CJG3P'8X]L! M8MX=WB "1C2U@>@1$FI0F:^ +F[L@,Z0KY5$6[L6[L$KG:;6:T)ZC'T'ZZAH M]N>A]KH3[P-2F_2GS9%=B_2R;K)*P-.1U[%+Y7&!Z3]%XSS.;@9&LZE\]JLT M%9)MGYV:&,8";_-ZV?O.(-7:SCBE,.%9\@Y,26"PU+QIK]Q. ><U'U8\PYO9 MM$NMS"56;7!:5R' =L; B[+0,;*S&F@*H7BQ(?&<WUUB-[IA!J@?T,[/#XS_ M5:5M9K/]'ZV#WC3I^S-7J1^73IC#A'/5XGRLQ>>B1X9YK_@YF446O#<.2#YP M,@,OLYMTK+)M_IG?&8OPN^D C+%N8;02^LZA)_[']32K1'IU.*)$CMW3>4 [ MW*'69(?.0#1NAB[M)XJ7(\3[3Q5DEDO#6+JM=,;$:-AF0T5L/<RGV/>K<Z%( M[)]"V"^?T(WOF?.G.WR_BR#6I92VXF@$XU1#V-P96_S4-9XN$8!7,]-BU"8Z M'.F7+,&D?X\PU LV-MY^>U<H0?FJA>Y9/1?,N[C#<CRO5&)<#H1Q,5I"4U(K M:E;.^I5LF\FV/..GYXK=ZDSEXR2YH3F1'2HKV'W$YU7TI][A^2K_#YVH1\PI MTN4"4W$/SJ%OL[=<EHJ]8L[V658XGJC7-J6 J2IY% J>O8JL62Z(@"]:#H\U MPJ@PH<-=B\#**=%#X:)2>E%-D;T/ !PV;BI^& JW/R0'4N%>CONJO4]]OM/& M'8E(2WP2B4&96_C>145AYE8.?A0='G/752O](@+&GSU>*O8,V:_.+EYJMZ-L MNHQN""US7.:<K,72[:C[(8,7KSETSQYX]O;=(1L"25U0#"):=4N%*M./GX+G M-VX'G$2%%VKD95JN1[2<7TN)WL;MMM<*AHS19B20CK?Z3@BN@(N'"7*PH3"8 MYN:S_\5E7,<A1!7 46;;_*?] <LP,G3=5V%U=^G&[@C$QNA@1/"99NW+&T?< M?5C"C_'$N0D>K$*RCZI4;P=5R*-^[YLVLL&^AUAM6X3W("S8GW,[ZM>$C*9G MH6OAQ-S#ON$T+E",CUQX^JRGE4KE&/_=F],&+VM&7Y(OW*&!<-IU._SRS$7W M-WF]%N7D')/)IN[5LW<&/3E'U.=Q&AVI"9'+GJ^=E"0NKC\=E_G-+UG01^K( M)B%9]-H*5_^U2QLVMS[(<C>8:*S(LCN6%FZED.0F,&RZ$P%53 &.U7DG71,Y MNO=[9E::HAB-;=[S7KJ2<F/0CD+#+H&YO^CMN>%6E1YOB(Q%%J; [QV'^/I! M1+CS% ):::U(]A2X6/+N>.TL4!3/IC;YOKXA=DXGT;I8A]+*B_O]4RY'Z3>/ MWMRO(#=*]K!*US8)_H&R:_<F!.;9B2<V=%GED*'77(,E/M.DCQSEY'N^6 L) MQ-D4O,@Q,#-I\_F48VSAYX@2:(>,RT"3LFG"#4YN=>KX:1R%'AN;S_*VU38$ M5-5(94\)^G>^DO(-TC.=>\9/3G8O"HO^@11/*5@T,%E<Z$3K^J4>N5:[!S,= MQO:0Y8Z5[IP:-8<MWHOR28U3<)D%=G*0=<IQMXP4E3*:ZHQ=:?!L.^?^3EC+ M]# W\@AL\LKT/%J\\+NU4BJPYV@T9/PEB2Y'@T,7.UV4_$C)Q7,R5S;\XD%& M9-I_SV$ZT*8;6=GSNAL<2J*QQ>GU/@6\P?X3B5<:')/2?97&M7)*5Y+RUF.5 M+YKK94+/-,EWIV;129;YLW*[QAB%]MH)/=[P*H/3I2N8P%<)3'WUY7'L5FG< M^N18WMU;.\"KKJ#'"9QM&Q72$9K]/< 8M[E9BU)<;A)P?M4+$G^V]S;4[;%5 MJ#-"RD-Y3W4P@N/1PZPW;-]GZ=\GK^%"XT]*!?!9,BJ@(#FZW3CWB%$3%>#/ M"L5/ W5K@4;C(551(<ZVK]&?7/:<"'+XXBI:BITX1JDW6;,G2(DXT;(R ^WF M)_,(JJ6:[LPZNI5OSU,3ZC9:[,-5'^@\U3Z/[L/;#,;HS7W^]$EYT&^2/S%4 MY3=&JKY9;S;$91N$<4A1(@3E00[Q0CCQJ6PBX/EO7L(<XAM&HBVS6W?')R?V M^MZ:_E'QKZ80?L"VOAOMUX;3:G0A0Y12_MRT:H$9+Z<EU?O26#G[4%C>,I>@ M8:9YB:675\8P*18+GIF ;^F%$ &7'VC.6>J(W%QD#KA]QVJ?83T:=Q=>CL1) M. .K=G1$/QO,*8>71?QVF4T;]Z?>O;5@HN3A9&=%W5 4K;YQX]* I76/'GG> MOMJ.H<<[N7KH@3<3*4\[M7T:=7E$QPAH3C"LT?<@F10ABW=G#LD(T#SIN5#P M8BQ'@CNU=BMLT%I*'HQG!H[ODAZ))P,?$P&40-6BI1M-JA7&'?>;FV[-,QJD M/\FS"/RR">I(A.=_6 C<C2=L5A !'?:VYB=\;41 'TF>F8"ZVE$BR5 TDK9 M0U9H0\%TY9:7-7Z/%.?.Q@WVOLUY1HZ, $EMGIK3[$BQBX_MW/0"V@BMIR__ M#+%Y>A'XAATN%%WQ/!;$P> ^G#:\7YU_AFQZBDXF K1UY+&.9K&7P92"BRN\ MY]#QQ1;KM;'$T:) JOJ+J4/>=D-K2RH$T^\E\9 MIG9XN#=3EYT-J')Z;JD= MY&,EW/GCY+14C>&\&1G7J8O17^4)R5/B:44(=]Q+[S[E91:[D"FNES]E*0W_ M7>;4KF]+J>CG;AQVL2Y0-'J?_E?U.F?=O[<W18=3\:%U&H54&KX?=I",2,3) M$@$_'2O!8\IBAI%Q"TGN=N-"7"*S_=*())OKHM!O4H.!ZY:3 E$72\#.'?&Z MBZE(C&%8R]-*M<Y4QG&<J8,5."_P?G-Q^X(2XR>J4.<G.T]F*W'JR+EGJ*#) MB8;B0DWT( @KMO*<0>;G7"OE=/ ???7HI6(NORGJX:NHB-R 9(2HQG>PJY=@ M^C(M8'IGRD@\LW20LV+T^H=J.RB/\9:'HT'VGJX,-+W$3@7C@ER593R@O8DI MH3;O;X[E4_,\"(EVN.O09F&^PF5-CI^=1\';J8U[EF[)J!Z;&,]@P%K!@^_K M9I)2^AKQNI ;IUUOD/"].?*0C?%LGSD6_P[^)&Z#1,5?'%BJ@#I^2K>S0NY& M\(H0P,[;=MMC=KPGWTZ\GY.W29>G=[Z"/4*$8I-\K+*):QD2TL(S=0JDV?*X M",YFC+F&;>P]J*1?M:(:35T/O+,]EN*"%1GT^B#^RU>>7DJVO_LL2HE&,#/2 M@P@HD T9''0C01J!=8?SQI28Z7,B0*NR'JO>).Z.-# ^5V,7MK(#%28?6=?1 M3K208]2T'<S>U\0N'NLVAEZHQ?<MT9=3W3772)%&6&;:/+:>5<\.:GPR-Q=V M@YM-Y730I(_ESG*JRJGH$[I@[;C#1(54.JR5^?W2MNKO/1(2J'LE7D_9QT&6 MP[2+MN97<K[P8<.E5*K)?YH81SB%T9V''L/GDKK5G JM.9D^Q\6.&ATLD[4W MXB?%3H;W=E=89)B0T(Y9U\SWA.>#0I;U!$O84$MHZ4%%W4CLD8?<.^AAY<,W MQO>M=FQ*.TS5XT#(!#LRPCEIZ@FRRB?1Z68A$;!6O:B8:7VH,2O+U^9=N356 M4=Y*!+173A !6RZ31 !J%K1BN ,YD=PA C#['G-*V6Q*V7>3:7%\LIJ$$%ES M(H CD\"0FDL$O$@M)0(B$'Y5WMI5WEKD9*0@<UB7"$@?UB<">JS_N<@E!\Y? MI)]+_U-1QCMJ/3@>HVZ_WK82K/5)#JQY/%<5@()P6+M8HXF &<O.V9SB?%O* M]8Y<]L=@]Q.&:4^E#@FYF\C8E)S%Q0&_1["$K#M[P])*924P[.4N,4FQ^P$* MV#3H/O/ U:%/("EU5>")WMS @]XSN:K4I.\[T.06#B!F0.C[S=JK17=DSDI= M#64Z.9LU-\T8\D0\I=&MXR7K#K&I#\8(0Q&>UUYN HW.M&AYF?<C\':Y+ 5A M<9%=7]R3HRD>9-33/GN0$7KM7_=3,UZN*>:FVV8--.6.,L(G:DK>NU*OGON) M^3#T7%<3L2=#OM)\9^NB)FD-=LED)_3GEG=XRZ#JF%[TE;P=U52OTF(1I86G M<LMTYZP;RQBK%3;33W:/,6!-J([>\2VW;Q^ V%9OQ$?.BMS,Z6/44P]]@U1# M)*S+6_-K]=(/O8:A[&M0+ENP&[N$(]<"I5+' UFG<88-3OJJR21UC'BB=)M- MH8GYCJZ12IYQ]$T][B_ZI:H7L$X@K:_0:F-GTU05I8 &ZM*;1,\V>\X>!*JP MDL1BJ:O=[N/%G;/>,>5NSZCS9-WU!AB8^ZIJ)<TH=$/5]WRAJX7JBK*@U>*6 MAO(E3!3U"\V&B8V*5\_0 2%\0)-+"$2S=PY\;<M1[C[F&AL;B-:N07:OD5_P MK?3!WB^E*(Q9H,Q;1*5$B&O-A!"I#U7N#YZ>/*=,^O*YJ1RZ;#FOYQB"W&Q/ M96V).E-%;L L/>="8/1WGI+GD5>;([@F68@ JWZI'$_-/;Q;X0NKIS]Z6.7B M<L/]_PQDSW<&KT 3G1NADF\59?D2ZL9]3;U68&&Y"O7CRR.Z.O58A_ )XQ*6 MRU^PQC7Z8B>9OO>1+^,@MF *&[B-R(W$#S_LGD1XL'L,>T]7(X<B+>T@#N < MXS:[/$:)R$>H3P9OXV0Q^;%B=N]IR1X:ZVX<AK(ZS^"XD+01OD W?*2K_?+8 ME6CQ#3LOQ=:6/[<TU/UN+&N2SWC2MDM]#+2\>=.P.].%QDQ'Y(#66657S[Q= MBCU1H"7"M1"\E_11_\LPN(].-X9KV^A/[.R3H[P5/[ZHDON#W)%++V[T:2_L MW2>A[>;?[96,_[:#/S,Z5/7-^F?91Q\RZNK![YK7KI_LHKD>U40[\F[9]4 L MDR'M.1\7ZD'5!] )ICOZ/BB[3FU/S17H]VK)#T>Q;!):/>E"[="I"M!'34IX MB!P-YN/4^Z/<!-:#-[+^[@NPJ<8)OUA6_1VO:OWJ;J6XO=1)SD^7=C4YM@L' M=&/KN3*4,N>]MLV,L<J>[N#;OKQ3 L5M-I;:C]^P\()E*$ZYQ@KGGU<^U#/M M[[ A'SEE*)9*';(%IP?9.F:Q,^D>;7 UB%K6:\CM0FX<PKQ=0 -MY C.E-U= M^#=8!6?2*O7'31TD.A,?+3;@+YVJ(/BD1@+P;I@N#="F]I\4[B9U-'-OS MY_<D[/C>MR^\30&-M/9T#%BU&Z:>M?TY+1Q0??6U3>:[$@9EBV.W';[J'VM# MQ6!;@E[,!X[=DLEFQ=G?TVT?.8:GFLD(S(6=AMR>H;W BS^>?]?I'Z(N<<-N M3D<I >ME7JNQQ/8M:NI,T3X.K?B^ 4,V5/,9H+=GU<,#/V3Q.CD<E?\.2>T9 MKU:$,>5$N!ZYVKTL[ZB=;NJ(YJK9B/8PB=UHEB8PYW:R0[H4K")'SAUZFLG1 M?(BY8!3#]ZO!].U>IQN9NX;@3Q<YEKC<!!L@4[7ZDWVGZNRF6(_:6Z:+2K?W M!8WG7>\0 8\^PE!?",.Z-7 _J447AJ+8N?O.&NW8GD&$9(_8PA:\PJRR9-"_ M?+=&ZX=:3<T[2Y XH%@>RX )>D]-!-R@_LS%Q:G=5N!95#/WW<*%;>]30T_7 MZ:3 WKHQ0_54K@I7_82S"_AV#/=+J??[>+Y$3/@J:@U\6R[]II,E.YVQ$9CY M7<'CP=H:=>\+0I?_73/("G>% 'Z-3E;J71R!N;3S?CQI4E?Z$+L.=Y^'&<6_ M.\(TYM,8O/*-X_M^W')H/A5L$1@+\$:,@I!=<G=)^A Q3,"S^H+*-6H^$ '* M*($"^87,K[%XNTJL+AG0)Z7&I:B4#?>=4PBY)%^'8NHTI]U&MO=O[$BJ1BAK M]X'[X2J3[@50^=!CVJ\D_/4%(0L6LBJI??+58.(7X!:7:6^*4PH,;H#MM/_[ MB=+T!XQ5<,ZX]P\%>OT([[9_?W_B+T W6\-)J20F,&NA?<3VPM[GL*I>?8)O MT6#NN^Y<Z(GWP$3QPMU;FQMD-F=G!2_[3-D)*07&=D9^S?@?YU.UE"WBG"EM M9V:$&(>&L.63-O(OS1"C-=X(<,C%UXOJ7R(F&/?S8Q^[FWT5+E,OS0]JG4P_ MI'0UGU:YS/17&O=*=._,T^UOG^P;]HL;45#OWW,87"]P['X2S%&_&OR1G\UI MNY9#+G=761)]$6K:LIJI:\J<S,=W*=9\]9U+ZD;R8/VS^TGD=^./,6/^DEF6 MM2SDO-7L;0,; A:8N6XCCXYA2EM60NF=T-E1#R\OMI3&1Q%[?GQ.^K^=Z]L# M8EW: TY+>3%!RWBNM9I<NQP5ALX+N3C>!(\\I;L&ZZ1P@W\$<AM2/5O;T25) M.+9,HGO8SKFQ.4 2?!GI?/]1"$?.E-OC#Y5J0<TM'T&/.N'.PCN:#!?"'^S+ MYM*TJV[*F5B2C=65!@,IJH#!#?8U#==2:_2.0?$[/2[1^(7%F"6A9U)8A+LT MP_XZ<X?U5@0[#=V(3O)9;)&K7?6S7!TA5:/CX=?_]/\7\;'19U06LVEU(;]- MW [U6.//>SBLJ\]8CN'[\LN-"VIMXOYW1],_(GR%G&M'&+#==YQW0!0G0 !F MK&-5(O $3F=3\?U>2]BMM$W+2\&Z6_(E':\KCQE5+O]Q.(]CH9+^(GN]-$[L MP2'D X3-9 ?M?FSF*XS(/79<#F-D?5_<=L==1]UMO$90,'$T<R %&;VY\&1; M:)5OZ#"7^32KX,(LWZ+41OPB(LXU#LU$P;EH#7...1P?*W)JM+Y3:[%[4BIW MD%S/#=43> V5LE!@OV!]\OI.1EBHEL@3;7?A!]F;8U$QT^VA#PJ-TB@>0KX) M>HDFT"?>U%948*&O]PG"7J5_KQVIKB"@LOV69"1!468D'42?%%+,%E)\KXHQ MU$Q6@4?A,L6#WLQ[ 4'T-#YC,4^YJ?#2^ =\\I+[\GVMP$Z1AUVJ=5H2R>]+ M9?SL!@A/?*U#5IKH;*14PRV[9R./]D2GKZ'5Y\GM_49HB^TT?A4V*D!,AVQ/ MN11<5(@ TPC0VD8Z;R>) C$N*W)1B\Y)01-B([G?'! Q85C$:(/ KT\*K-U) M BMA+QBEKG)<]>)MA08>>Y)KUD^(U1MANZ7Z)+S#UY(KK")OP>3-5L 4/<SR M[1%?&IQNJS]ZN"#8/&3";RY:6&TE^#6TF<;FQ/]77<F+)K.,M!CT^TWF*W]. M&"1LCX5F^;J8..DPVD5FL^4J"R\I=C[I>[ 4?N50><!;'V-8\,G%C\:J!UX= M$BS#E:^>,]W#TPBY,;M*=3VRF=(;0;-4@YJ+7E$D?]I7!UPQ%ZP,^LH2\810 M8984?\:%X*;"(APLD4.4I7N]0F)8!PF]%N5U5A\A@X2R:SYRDEU^/6B-6[\L MA_-1FF)=K\$_T3",(]E<NX;36?DG.7.-"3ARKH<0I$@$M 80&%:]0]I!],:[ MP[G&AF(;2X][^#7$1>U:YR'-J9-4H.LX4U%*(;196Z,=?_2C"O?YUM1KGH/Z M$R*$I>\@LYXSV6$"FRN)H/.6,#=![<'X6O&RGJ]SY42 V=/3?3-*TNC;[(1; MVD'WZBGX<WBT[RP^GO-P&'+?;);:78%]+]H_S'80[>>?Y^ZC2I]1.0R8MDJ$ M: U@_>_[^7#,HVEI"5,#*^=NO)RL7NJGH_72N>RWI%S1Q1",P]0RI/V!83GL M= W'UWW0<G/'G95BT82%>^*#GFM%[;WG\7>HI[>3QVP@UW!J'D[\^GS4WVH> MO"(X_]P9K"JX*%N[E[[\B2/ LKRG CCG6JM)<4L:* ,)DH0X=! !SS,A2RA2 MPR2&M -OS>P.YQA/)W6^.Z3N=*3XI?N%.>(KY^)JH0*RMNNV; .'1)_7@+WA MQS<R'EPE-Y9U+B+(RH4>]_#X9!+FL@0A*_1@+ '4G@+<;P;&4[4PQ/6S_ZR\ MO!3"L$*'XT>9Q.Y*H'73/LXR9)DN?#+F^$2K:Y 8&YAGC>RXCZ^*7=59>1-_ M35KC!GK8=C'5^'/AP9P.;X)E6OV<'!9CA2HDN<I@GQ6M'/\C[]F3F<& >[0F M'J7/2P>)@*_^]^/:S6^+LFWQ6#18V.^DF!JL4?D@2'#_&FA[SM]!?BH5JZGH M9V8>YMG@$35)DQ'*-R#[[#]Z'QM;U81+.P_4@OWUA!8Y,,]X.-=4&75YM&RV M7_&3; BDNUZEZ1%:XI:9I\ZIZTSR89QF,HN#(ZUO/O;K1>@I6^&;I*> Q$W! MJGJ&Z;S9Q?9\N[K$QOI^(2CWN OPF^N/YKOEOT<"18%:K;>A[5551 "+M<3H MPQ##2M#I*!K8*<ZGSIVZ= <WL.!G&S3U(]N6RFA3H3(FJ<2A>^U4S/UE=4Y@ MB8QNAO&7]U-%E\P4><C/]4S@=%5]\4K9'7[%IA)L#NGWGQQH7 .QCM0@-W[8 M+C6,%*UQ_90;HK;O88_L+@331K.YA8I1P']F](9KR#?)%F.J?WE^41AW;?<< M*S+?=#N)TJB3;2W95!IY5U'Y99'9LJ8R\,"X_7'FDNR@4<58>W+]_8OHV6JN M,,5&)=7@09VRT$9/LLLI-2D**L]I?E5I/_OR/SQ\?JTLRT(SRQ;P14$N@5 = M5&3]R=Q@WLBD-4Y<GT+/SNNUJ'WNE^MBHY93&9%R9@DY5=[62H\@C+D#$N;D M.$NDE2Y,!Z/M+N2JPES5PC3!'O/J] AJ/Q7Q'6O@::^.IF793H1^<7N#GR_T M(A-575K4[Q8V?SD_W</[6T[QE.%[B:>2)J+X%6M*4$DV)82Z\V[/[J"[$AT+ M-H9I.+^+7S3C/!\>^7N;U,-D& J>WZ]&.<:)^L.MM2]8ZV3\5BS'.QLT"5=R M,0BA//_?YM1B-YH02(=$-9PZF0A%VE(%I(.CA_!0"[)?"0D7? 5RE[/7/,JL M)?5+$H0MG3RQ 6'H86NJ+=+(JJ]74>*_3'Y>+AYSUM0X[8!T//058@=2Y/BM M@U&Y;5@^G'#PJJ1N^_>-Y[O<[U4[[,@0Q4J5':)["SV#H>JF?)SI)+RB$OXI MO[^K('MW.AU D2?^*&\K,UMZ (WG@\9P7)QR91\-.(W+;B\:RCY\R3L]%M=0 M=>6T/"'?,UIY)/.;;4-S1,K&EW?85P5!K3N*=B "(R_)RRVK,1#R(:B[P'-M MA>DK@4?=1NC[B<&IREYP[_OYUP] 0_4!)-_X><G:M3<)#6)NXZ^+Z@_=G8;> M9//VQD3.0-J[D+'[<.0O&U(<6$HB=E8PCA]ZG31/CF9!EE6)@' O= A6#L>! M LX%PU;J!%O:I(U-!-'7).F7BVTD]BJ1C:"CAR_]*R0P4P=/_?=ZDF[[W9(B M C"&G'0D.,U4)DW=,:1<02OO/5\Z^^K^:Z9.1 !R $0)W](.(1 D,./1: ., MZ0#M#?F?4BQL.%NOQ[N%0'&^BK\9&2S>6B,\"@?"+KPU43FDV]*/#'Y"XG"- MR+ U@IP^SF[8K?0SB%Q&PBU[SE:.K?;+IFY<;\UY_$'TE7U<0#$8\P$>-!^] MO.MV9_]I3)D?*A&&-@N/N_]#[;T;#%F!(R'T"PTH$1# 1Q"%(2ME@*1SO7\Y M%^N'= CB!$C5>+[TU\M1(H"J%EE+"**$8/?AW2EE"S,QY3]6E7?@*^\QTH3@ M9B[2+=;'_5VK25E>Z<'=-U(B7"G%(/C^80<G!+&98S$D21M8(E5<LYH(:)G# MV1Q98"OJRTTC)T@U&T)ZX*F-0'^-2&51@MK@)V*DW#"WX&LF=?@X?R;(2(H] M9-E!"2>"Z+BVO;RK?>I.:MO_UMAW1S7Q=>W&BH*(* @"$A61)B#2E!8;78S4 MT".@0@A50'JB(J)4 <$?-5)"D1+IG0@8JH#4"$@)O9- " %2;O!]W^]^]UOK MWG7_R<K,FGWVV?L\>Y]GGSDS8];BZ] H7ZKRDIHUA3."XFI5Q%ZXL1SS#YX) M@,F^0PB"&DB*%:M?$>:%34F_]P#'-$ C7H14@P2B:TK5L^?V(&,;F5"B>U.C M8*R5'K$XY?D,]>VAWXAK,12GY6)92@WL:NSLBR H-8SD%1S3@N3\LRA@?+$4 M/MJYZB*,YMDN7B'(?G>5)8S_&,T>T)WFXK/>\BVVH?4+;>LT[1?8%O"^H46( M=\IJ'G$#'<+!M$]$W7E\)M WSV>]2/\>(:RN ?)"T I:]G7MR$O$2[&K^Z9# MQT,?&A>@?JVQOR#G#(3I ;CT-K&CD)8R:@KA=!W<+7)3FS]5,OK10/+V_?XO MU:$R5^(D^ )4$IZIGQ!!PQXA>IR#([\.4#YZK".LSRVT%A9R)==]%IF;"4&U M;1?WM$W?LVC*,5 *A>7!S\L5RD'_O A"WVYB N![D,:@!_08UVU7(_@DQ_)] M?8NQH$KCPPY_ HNEHJ&_\:VJ]]*L#$3*[,J@OD)=;&8<HTZ]H8DV$;E*^<O1 M;)I47&#V:(>#:%S#VX&'Z[$EISG2]A-JB7=XP8^I&?YYP1G9%7?Z+=M@.R.E M!9>"V])K>)>0Q%9;62;@2VL:$Q!4 ?P_CF2+G]$[]XI!)3CE-GW4VJ&O3("] M%:>%P^9YPLFF*C&O!\8YNAN/%[$7BLDV,OI."@5^Z[/)$#Y)_;1^I4=>@Q!6 MA)UZ-KVQQ[$TN=/U&.D Y)/GII?D'G-!<GB&:U1]WA%;KEYO.\>"6>D\*^N0 MX<'JH]HO[2Z[Z,R>=PN<%5;Q>@#EYRQ_=X(LY>1=>H'Q4]31_38J4#?^=^S M1*TT'P5"NE:GN#RV'. '5PWA6#>;:X ;@!QD^24/T3&YCHN#C16OUA]Z4)>@ M]]_V:<A#%RD[2DS $T-7_^O]G?:?"O.>/O'(K93;&W!%R/8>+SE&;XT_]OL= M?K6]5*?[RO0=0I7O[<-UA'T!OWHFX"?T$2M8+&.H#B!6"/SK #5<RI@KU% M MZ5J9Y+\\?+83;J59BA=[7;1>P>M0>6*DZ3)?AD-T<)EU%8[K@FRTFC7^H^S> ML4(I=_92!P3@^%W:RB"2$$FSF30;B*D4R ZAR),>1&H,%)EK"OO_CGPDF1'9 MM=25=M/9SK-"I+-O%LE)UJ7=)7&T4,X7) FL7;W.IGGJ)$B/+FYZV200\HEV MB<J6&21I5F<62'=^<A0_$#F+]&$CAF^'[P9U\0F9/I@NUQZ<J[8@Y._O?T-G MAI-ZK?]_/A?P3$DG47,>G9->#O_%;@1;[$14""S!PG]E1MW)HB<F7'\)%_1L M*KB=G2/ !91\K6^(\*[+=Y9Y"E)XGM5](4>H/9[U9WQ-.VGM3DWL-:=N;>QH M%&,P).GL\\C!0'I>]Z&?'^190CS+['VK&N'/83?5G7Z=%,\ID@9P/G2O,S)2 M'O]RHG+0I28?RP[OK]AYD*^P'MY[47MVJ%=V-&DN.2AO8/1*ROUN80/KT6#Q MW\'B<S'WO!/G0&7K6:NY XI>L%S)U#WCTO-C/(V=R!KM$?".)Z3RU^/I*$ & MQ?+!V]T(<D&= <CQTKZ104[HU51+-8>I4U(4S'LD1:X;U=_@V#%+>"%O"R$> M\\H+N@?<ENNFA0;R?;8RHZYZ_2J+1@/+$AGLX+(UAI#I\'T#'U4#^X1*E:N9 M";WGJ'.G-R[2Q&9R*MN8@,L5@>>LUC^F.F*V,%>HLUB2[<'6FF\C3$"?J^VO M@B80=,'<Z,6\HX\3QO%X[23Q&;@,M6[D+[9?X07+LB,71Y2%XR>-<D=B=B0T MNLPH?55JW(9?&L9&?Q9_(WCJSM*&'-UNY4J2^@N2R%()9*E==4GSF9%N_8$* M2;KXO%UGJW]@33ZO.$W<^B7/#I^4U>5!(P=%T2-G$\.C4N9QEY429S\-'RHQ M$"/EQ*"%L_!?UAK)KCM9Q&R:9'#??O/:3I9[@QA!6_A38/9^2^6 U88L06OU M9?95^=/JXO7N=BL.'ZA>3 "P\<"D+):Q-JWR,6@/)N T:&8'!Z3P(&>EJKC6 M3$5Y-%675U6=LEP5TE40Y2D-6,L8GX3*&4JXTH!R(*+<<6P[]XL-.T1]V3*$ M2(>]&"2?MK?N'U2-0:OKXM0/SRSF1&N*\W^Q[_N_W( +0XN>\LA)JGX'V'O^ M2C0STX(#(R2 !=)Y11?=.%I=8A?TD<%3#7>H!D/-')3'VU8#Z;XWZV<. 92 MZ!=^?^P6;CCNK?+-?$/#B-1*;;BG/^_7S\E/WX V5 _15M*JJ6D$?8ND:Z33 MR9&W1MT@(ML'A<,'H*":#4F+-&DVN"Z]NO-,8=]W<_KN[S,J+#U!GYZU<$X) MO?J1"AE^W"ZJZ-^^J[*['[)S!5&$;,:S)ME3 >X'D^S!LWK#!X>USOLI!RR% MEJGTC0GH50M\G7S^A-\5Q;8[X(!%)@#"8I?RM['# MA.1#$J?(*KC1:E F4< M$Z,.@ AP*HCQ+EB9P:)/5/P<*):/ML43G*@XI57,E^C!(I-T6S1M%32LAVV/ M&4)2K82Y6'PBQ8 )P*YHTZ1CCA\PK5SDY/:!]KQ]->O7IVG(LP.(+@ZON4/; MW<!E&B@IANZ03\NCF[I'-'*:B3#.1LF3:G@*2,BF8)HQ.F8_ $K"=*)*VR)/ M[&]?Q'+I0<LD2X0M%^CK$HW"85LW0<,J!ZJA5"L&.TMU 8M^?<_^R\@\_,2P MX60LC1W,:@!S3?3J$_G365<1)@1WX-5B]:_(H3WD3QRCU)1A@LAG>6J*J$WG M#/AK]@$["6D"DI5@R -^#$U .L:PS77D[,+2'X>N=G4;$9;=UV[BSQZ(%B"; MIXD@.F?M7\D#E\\<'%I"&,=8K'P./#+#6 ,^B]DO1Q;\8CQA LR7D9(@LRO4 MNJF.6>ZV:1O%/V1<,XLRNB^-SD47UZT63]49TLPVPXZLA-/"]H5N]R;*KW2[ M4\%MPI>),NB+DV$5@2F";Q>>O'#0^)D;8C[8?C:*(&T \^3X5*28L8<7#!E- MJZV7I7C0,^RH35D=SX(KQWZ\=#Y%G.*ZC6S,JKJ-<?L0\Q-\OWT/TCF,ECSG M$3>XMZKNA,]=.W?-TB7J-4[PJYA]_?;>L$K#6:7Y&$^+\-F/?KSQ!7YU6GVS M$L$%%J,WMRIA0U:;W4$)^[J(8<O0QB(?@OO1\>L2+A.FPX75#EAJ%O@>J $J M#H7:+.//_G'F^ZR\U3Z6K)^D7S4/7[SAKZCW:R&E5,/A0GKSV]3+@K_IK DO MM&R*"=B[0)[<9V!G'H+XU 3C616/UN=_$=5=H^'*&>JY+86YBI@C.P[;& L/ M&G#4,9D:E[E_@FX*C10^>03% [/X-\6'4JUMV2X&&:.14Y;(*(0)_QED%VCX M]='@Z=X9[;T&KGD[1HG)9 +PZR2QFG8:- _K1Q*E0:VI*+YZ/OEC,3_VK.16 M93XR 98'B(5N=6UG.UT&;G9M9Q#IBKFJU=KOG=4MM5<JDS#FSJ2DZ[*7&J%6 M_D=B^LO/@V]\$UI;^8V?Q80&P3#4\TON"A=M5PS\>N@E-1+4_"G\!!-0!EWC M0?%?=QRH,$_L^D&1RZ]^ZW#N\M(5>F#TT/3,"]9%"C[:-6^Z\Z?+$R-WG+D" MG*NL!^5M3F3"+E2V'I]>>,5S*BY8JB6F 2Z\BI)TC&7T8C?/4$.8 <>)J"_ M(:[>G>(J]KA?#5)\"9>37_RGVW527- MN.D2ONS8=&41*94:?$DI26ROS$A1 MKM%%MNAYU!RQ#(=00;;O$E&,%D<F0%,Q\!Z]=VO%5F)?2ZZ_ AR6O/I6.A%5 MW'K-:^>Q2NEL>LM52-G=&_\$-9Q<&<-O%@<$Z/Y9+RJ2A'ECYQ].^M(DZ@L< MU0(.Z8H0=(\"LJZF)Q#;UN3VGRQ# G ;;VD<+UREBZZ.^!1< LISU;]WAD]? M#HM1Z.HBFI9L4;Q->\L50><752Y(L>BKDINJ@<=7Y/5A[8,JY:@LD/AIR6*G M]BX=OFFT-ST#22KVX<BOX$AD A(_W^0#Y7]-?R )<!I,)HFEZJ]FK6<TZTW6 M%VXL(FJ46V,.8]APM3J@;3)J1ILF@SW,M9OBC?J;&MHWRG[4N])A#\4+ZIYK M#Y<QAO,2V[';6HF,/E0QD%BGQC:)8]78_TX+5=^A9*6EOV4S-)9QST/OB8#: M^VB/++3LV@?*/2; !(;L;4548UI1AQ\VG</5&CK\XD"S,+E(QIXQAY_9352F M[.335UAX:>.E#G[[T86Z?E8E?(*(C*9I3@G.8HF,(A^'F]7N5W4>@J-QX*," MPQ<J)ALC)8GAAB]RC4W_T-]O'9YRO.[LO+M#L:-G?:$.97;9Y866DC22 ;55 M4R<_,P+$JBH"5PRJ(I\WOODT9)[_@"HY*/GXZY*!BV[M/]W1!2CT@Q[$<[9< MY]T02AZ]0)3J*$:[,L$O)?8^%SII/76C8N:6R&!X\A"O^)9.O<SY8AE$SR>W MWJQM,#=L5)(/V_BF4XYFW%Y Z[9#-D\0[>4XI]-D__H5&M]XB22#F>YJJ\<K MZA<]6KZ?N#5G7]![1_X[I1!S3?K'^R'D>#OFT/PR)5QC/>9$_OWDPC69MI6Z MH"=$*)U3Q9P)J#H(7S#56ICC()7K@R@'S<9J/#!X7>:[H#<<*P'X48VFL^:P M3P-TPUS:*MT;Q*_&\R5^.NTZU]X>E)2#;)XG*K.2L?;?[#OK/E+$!%2S_1(P M?:=$,-:8G?Y,Z6+<90+RR4Q &JJ8DY3RG0GX3YJ_0^V8@O%S4?45,B*5$,-I M\MN8=B9 0IT)4-&,4N8]XC4CZ.L9N5"DUV.ST0E<CE*U2D/E31RAHJ>Z!+'< M%^I-T9D=>0KMD\[@))T]O E6H/YD.1)GDXW:9U7VF([CT;?ONKA9N_*K(LK? MC/.<^G*A2#2UBJ)Y^DQ._,[(WKR&@A\7XQU=C%0+)F4Q^$"OF(!%=Q;D#E8_ ML")!_S !-<EJV:L)4K>"PV-._M*W[ Z*P<M2;80/LWR%U?ZO:<_;CX/5#*O. M/QQ/@V_*=X%W%[0_H;9Z8M;":.AB[BSI E UG54^A0Y-R>X)EB,/@B 7V;Q( MY*-SCFH?X!P_"QV99JS)QO/M:$(H]=A/H"$!?88MMIH>,,"0] .9H;K*24KQ MJHZ'C)9>($_AC3F;N_G]_NB$K9=N<DU+D7P[P9]>5WR:58GC#^8,V&E"C7KA M4"<J DW@(Q48+C<F0.];M>O/V!WQMMCHB@JAH4?6969J?Z <@UD&@UD:<&^0 MT:?4%R=R11P5>_S$6BU]H^ME<U>2U9LGEO"Q'ZXD!',YK',!0]W79T)Z W8& MC"#:33TR9^<"XRJ4%5HN;V<\/:5U^F[68WR)J$J2?OR=T_]C!?6PA+GK O\. MYCSU VGSHA3.K)&;N#H,49G1$5B'=[WF.6]XI&=K_/WBL<"'$=4.>>KP[XTB MC%XY:[^.(#M"MRRXOJ'6)\9TP/VSMZ_GD1T\R ?G_9ABW3LJY!=J@5Z-,8R9 M=@^=>2<G]IY<=LFP)K1S*IV^C*1:3/"RABGBX;_7BW 14]#75T,%P"=@GB6/ M]?PO3>WPBM'$40#DK]P<Y.1KO<&P?49.!A5% ._QEV-I)UD(B@"YN@O?G^X5 M7JP4\)D->(=R='G67?[ZHPYX@JP&P6.)&0Q@L1=!_083,'8(>HTQ"CJQ6L^5 M!Q-@A*!;<A<WM2E6,651&4\[1-1?M05LWVS3NO6I5U IRM\N:0M:E0OM^9@N M>/%.M[AQ\QOKEV[9?9TE9OS '_(]4F1_]YS/()6(E_B,0:I^2ZW!<,0T9Z U MG]%2\LT?!@TIDATBM]O,I@ WD>PKBN!7$/8F<I%]WY<&J*I^18U1F35G2OC! M:\C7_8JY6H1E!NM%%38<9Q]^EGN_+KV>=593_.+-W($]LX1>'.C<A"WZ3VVT M&W>V][.[^Y7>OW'!&K: 1:G>?/8>VQ75I9[DF'IG72+"3WBFER2<X%PIHI)D M_].;LHJ)SHY3,>O)(,JX*M\?R*T9E/;NN S3F Q6>GC==RW,28BP*9>\@"1X M^:7^T9:ZJ!Z>$6T*U[RRA%RJ LKMY$U1FZ;;GSZ/HPC.!KU[LWZ&E)K*RA!/ MZ9,/3?:%M#THGT"?)DJI1PJ*?G([0RK/XS/2#7-543>=3"LWC&ZMF/BXA^P, M!\2--&8XN'XU4()H=RGT->MR7';[9VKX73QI?0=,G,]P]W$77?@@DY 5\SC! MY+V#=/574FSWD_ND")R'_T,9:8/!F[L17E</H>U2=]W&!\]Z2%B=^S- 1Y7D MSG"%LGUG<-?5#\K8I^^O5?:-=1]!K!4]6V&%>+</BMBCY.G7.=UN^W "* : MDY[_?MU-::&]]^$LW=/6<QH9KG&%%)IEN>SUG8+KOROD">#)Z'3X;<)*+-5J MYB92SA:&MZO9^=B%<IJ1&[%M#1+WSS!^:?D%KIRSG)QZGBNS>+P*W9H8)I!R MV&I?O9)O="(;@X:-TDX:/NE&%EA:MEX._,==1#2T.;03H.JHV/$GR)ID,)Y7 M%;?) Y;(\+_RVG3^V,OUCS/S+I[QC\*F=\+M],T9>(XF^,FJ<*6W9QPDJCC) M*U1VO?0KH^U&?L\W'"RY7JN@FVM<'0WN/T57W."P[V6W/K[=&3U1\6)KRO1G ML\3U;76-7]8RUPDR/R8TFJG0AZ_@*=74JNF4 E!I2IUW5*;3\Z=OCZ?>3+AV M_\_4E(E1$)@D*/U!F;L,-N-:_/N[I!(/*+K?O\#PA_:##GK; PL2N'F_E]V) M*\\@WV*\]VA)D^\S@)UH0>VZ8-F@0W]U)YGK LT\#*=QLN279B3*9:M_>O]Q MD%M2[,M7'BH.P_6,6J=]F^",;HN[8R-?LA<^@H4_K96G>L7Q 2=F0'HK'SI$ M77N8 J29))^DMI V"?_<__40' R 74YJ&PYN( ,TQ#S>QR"XEY*%0JJ.N"Z MN_MR-&56>HXGF>%DBH[UQ.>$>/HVO$B-/":V,MJX$3$%?G7Q/O#DTM.]" ]5 M_,)N2X8D$S"+>!U__5Y6U00<V=Q#3-XF74O[]QIOD FUX<L2Z'3]?=\<>*4R MW\KSE5.>/86X]]^_LTU4@@@/@C2$6$6+2 YPWU[J7"NJC D(490]N3R<C'Q7 MZ+*!KHQ]DLS_IK1QH(IM)9RTV';JJ^9*S;J9'\91NA(D/ZQ[E;Z5-B GH^_A MFV[-T*@8"5(F&GR.EJW@+W9/O^S*WL794*RV7YAZ\77U=_**=4Z&@U>6,R0Y MF.S*.1>9<R%AX! 8W*981H">[R; <OW6I+?%%S@:)U9Y9X7"(-8W8U<]H3G7 MT'<#Y3<7M[0*&[ZJ6,4<];.?;$%<&10T&;I6W2\S//#4[&N!E"X# X@DT:!H MIV74D=XP]^MCQH//5#P'-,9?4A;5?C\%(*8DEMO4(+)B/\:=I[>,:FO.[YR% M3N+R.@NS+\5I\ ! 8<,52$* 7Z:AU^F,ZRH-"3]*=8BV$NX)K0(W L77EJS= M^-,CUR.)&]XN..*+[TO)K9EE*WQ*%'N@S/@EG071P?AJ97YKGXMP+MSD:?(: MVW?BRLN (MSJ)DZHL_6,-,/>2U#XZ\Q$!#8R.3H7YN48F+VT,WRV4/]B^6M\ M!W>D^*G<JP[XAL=#&M><!3"AZ^1SSY[!80'Y%P<3E^^K7!8]KK$HHNX9)^D@ M=&\\7N+Q8NAPX\4_2WOK:3 X):5.ZA]7=.*:0V?+PID;GDO=LC^ A]JF?$HD M O!86+)?Z1V _U.NWN3>037?@F5+-)I<=2K&E4?NNIR<3I)]ZWBG"CD+AU > MK(=1[!#?,L?J:M]#A$JZ@',V)O1<Q6P[T+.NS-N;N9Z28WJ;&A5_@KA(#E2Q MZ;9WVP\27&?@F-*?/3\D(+?LVP9V(6=^V+6[97&T(9H;[E-<J2\GSS9*F5OI MNU2IF(9M;/P(D13<?^O;#8_VB!:P_64N>AL24ZJ]*(W'@4^86^T.4.,-HI06 M&!H\J':!+:YS0?>PU#'>ME#:L8O-2Q!@W6"]X?7GJGY98O,Z95TE0I ,"QHW M4;3H>X*:!-H_*TNQMFH1_JV\?VW5=>;-A$+5.XWSMSY*OEYEX]U]-E4),BF? M3>C3;];@*R'ZAJTJN"J!KG3V<// 8AYE[\=;.2OE7>AMD-/Z!<B-3HCW]54. MGS,[96SAS[-W3UZGJ,=AFNW-JEHPX2+X[N#GX(15 T%E;W73MNI;H%"_G;<( M66<H&RV&/<C@G95)Y6$.KG.2B>4-D1YUO<1;%[UPP6P*5GBJ;H_6>L*C?>T0 MX]=%&U?>K0\UDHVUA)1+V"H>?'8(\/&>2_Y%VHB""JF!GA'#?BC7RC3DCD]4 M9%WEX&P__;,%D+>2#M^ZHMXM;%VV_CPAH9&RU>$ S4.> SUG MBH$4VC:XT) MA&Z-+DAUA4]5.O\;WH^'(2R:\U,P18(\UE4GF. D(VTQDW1-T.+"HQN(QHJM M"ZF.KB]!V@3+3Y\5G.ITR!S0=\F2-(U*DN($)F"9=,$1SG_TV]C-5/YL==-> M>[^B+O<WH^?+9M+$6D;=BO+6:@9:<[U\O=BGQ9->A . @5=/^Q5+CDUK9;D2 M M/."JJ>2)\?6#V[##LO%O<G=?=I<+_V\];@Y4Z:%4FTP+HAJA-696S1E)M2 MS7>S4"YXZ.C>CN+"OIZ4'TI3TKS#]B=^@,&E"4?GXV4PA"&W8AG7->E":=JO M]$=W_;5MLF,("[QH3R)8OR3E;D7]T,9UE-&;V\E[S^ZZ<!P.^J9!=/AUKJWH MF39IX0<0%K<<:* 1^%W?:MQ%2K3NT^AZM5KBLM>*R3RU(=A?!N7CD[FD+!"5 M#><:?1KYS:_U!5JW[79/0(C!8":^^0',P;U M)8*=9ODEE93/#8W5P\YW_]H MTOW]]5\)9I>$@@I/3YS(I69-D6N%(R[.O=U:KM):OI78SRN89L'Q%*%5YLZ0 M<MX1%O\V/%U541FL,53D*FVHK_7Z]=$XQ/,ILEAXA"4U%P,?EAO5O6+Q547O M6L6QJQ!3J4W4PW,6MA&+/I+FZ?/=V*:%035>]Z^6$QUTK,(].S0_-J2;N[K7 MNG@*_HF4'@(C('EM%RNKD*,<3AWGNK_3Y_]\$VZN] 9&V%XB3F1DV(X8 $>] M_:Z]&4?/ZHCNX^B/_(LU9GSF?I8^T@<K1%V-IIO'I\886PS.>NYPBAMCUHK4 MO55[1U9PO5.3D0R^P?.>KBX#*8%9=<[7'4O$BA"ILC@0&VHWJ;P'N32';,7> MPCY#O1.;SL4U: C6&?IDPMK=W/I>;Y:J7!8I$*"?@([L$/#TDWL0.I67G!0D MV<IG!4PCG6ON.AO?@+>?SR!Y-2O5!H\W^\48_-,:V61& %_RN,&),/%KL:XF M02*VNVU)$[H;,G,OGR]#/#FH#KQ[$9[[ZC25..6[A(O2%U[?:3XC%XM#. 8] M)JKWML2\#U@(<[OL9%"_<=7JW9"3;OLSC9!;.*VG7S>O452JK7X'PK12G,V6 M7Z3*'!-SZ6NP$HK<]]*OBGR)23#2W42A]5.2Q+!>@4T:%R)PR3.C!OX4*=5 M?YGU'(Z:X:LVW>6^+M[%7V5#P-."ZB!S8B7F(CX,0["X4C-D?O]*2?#7E, X M'4#X-$U^6K_WQ(JA<X!'Y,^\OGHOSHXK-UI$N.Z=Y.T;#[(>6JC0%Y=V*2QO M#T)7E;Y3R^80_, +4:\ZA7=11YGY5V2%S^]<4 WB)EF[\IS3=CS^99-7Q6M< M/,VA1^T/TG>R'W.?"#*K_K61+3\Z;MUV'?F\IO)C<)R3^;/9"63=)*_EQDSN M>YGM$SX2T@KXX2NJ6MF_YKVXC-ER6B;B9*,G+I=M$DK+!U;)BPD.$>#HZ\VQ MK()D#311,)_CT!7)^.<C[21)\\><2,K#3;0A1?5=S6&I9HCO>DJ6I^$*\MAV MBOALHF)52:6)L9#O9\EK]1^_/)?+6S[N7YS2C 1*%\Z*_+#TEK]K%]:OL']+ M.]:9H!2532YVWII!U'R]7[K_L'_C(7A^I$--,"IEC:-6;N#J::]'@X%)7C,1 M7D'<@V04%UREI^0Z\FF806"=KBO_S8XKW)]<R%/1J8/<0=Q#F/(TI7V#P?*N MMW6E5L/A,%KE>WG7$UZ#B5,FC&O4W6E97B=? =-N]-OSG[D5C-Z+7"*\.J7] MQ..8?0O)RJ*,B*O\<-2LO9*4+3?A\K-5X<5B-ID0[8ST^5/=)@A/[D?T-MZ( M,2L?&'>)T\][^'[";U3H3,X59/U)8)IY-1VU75U$WA49\JZ*,[>%YXUZY'!B MRMS5=5V,BY@ )\Q9J^7^98EG]OBSK9E@>7^SCV>"?CJ&Q(Z6^<A&!3!*<CO@ MGNY/HT0N;K6^O0V]H</'V.-!S'P]&VW7CVO'.F+Y#?(T82<'BLT+_+?N>Y]Z MN8IM9NQ*[0Y IH ?IL\$%[MJ]*7A7^B^4"X,K"Q/45GKX(%AA>NU<Z17GZO" M7#>*KZ:OG\D^Z?M*+CV+GVW%HH@4:!TWLR9L@TFB:)7NMH#6=\)L=7ON\L1G M(7#(2LP'3.SKZ;4C#&X0CW. E TN4/13ZSF%"Z.K*J\W+'ASIPT"H&=7\,G9 MWUK<%<?<O=_:W=^Q6X?+A\\FU*15JCL'_8E(&G\'&T,LL:5GQKM7B-R(!LE% M<^NR":4G]4@&% B,VBC8!'.5(9],A@L@/A"" ^\.^UBY:DQ,3.F[4O+? H! MDC5KL:C6Q@)H..*,$+)9%YW/!�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end </TEXT> </DOCUMENT> </SEC-DOCUMENT>